PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Donnan, PT; Wei, L; Steinke, DT; Phillips, G; Clarke, R; Noone, A; Sullivan, FM; MacDonald, TM; Davey, PG				Donnan, PT; Wei, L; Steinke, DT; Phillips, G; Clarke, R; Noone, A; Sullivan, FM; MacDonald, TM; Davey, PG			Presence of bacteriuria caused by trimethoprim resistant bacteria in patients prescribed antibiotics: multilevel model with practice and individual patient data	BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTION; ANTIMICROBIAL RESISTANCE; ESCHERICHIA-COLI; RISK-FACTORS; PERSISTENCE; CONSUMPTION; PROPHYLAXIS	Objective To look for evidence of a relation between antibiotic resistance and prescribing by general practitioners by analysis of prescribing at both practice and individual patient level. Design Repeated cross-sectional study in 1995 and 1996. Setting 28 general practices in the Ninewells Hospital laboratory catchment area, Tayside, Scotland. Subjects reviewed 8833 patients registered with the 28 practices who submitted urine samples for analysis. Main outcome measures Resistance to trimethoprim in bacteria isolated from urine samples at practice and individual level simultaneously in a multilevel model. Results Practices showed considerable variation in both the prevalence of trimethoprim resistance (26-50% of bacteria isolated) and trimethoprim prescribing (67-357 prescriptions per 100 practice patients). Although variation in prescribing showed no association with resistance at the practice level after adjustment for other factors (P = 0.101), in the multilevel model resistance to trimethoprim was significantly associated with age, sex, and individual-level exposure to trimethoprim (P < 0.001) or to other antibiotics (P = 0.002). The association with trimethoprim resistance was strongest for people recently exposed to trimethoprim, and there was no association for people with trimethoprim exposure more than six months before the date of the urine sample. Discussion Analysis of practice level data obscured important associations between antibiotic prescribing and resistance. The results support efforts to reduce unnecessary prescribing of antibiotics in the community and show the added value of individual patient data for research on the outcomes of prescribing.	Univ Dundee, Tayside Ctr Gen Practice Community Hlth Sci, Dundee DD2 4BF, Scotland; Univ Dundee, Med Monitoring Unit MEMO, Dundee DD2 4BF, Scotland; Informat & Stat Div, Primary Care Informat Unit, Edinburgh, Midlothian, Scotland; Ninewells Hosp, Dept Med Microbiol, Dundee DD1 9SY, Scotland; Scottish Ctr Infect & Environm Hlth, Glasgow, Lanark, Scotland	University of Dundee; University of Dundee; University of Dundee	Donnan, PT (corresponding author), Univ Dundee, Tayside Ctr Gen Practice Community Hlth Sci, Dundee DD2 4BF, Scotland.	p.t.donnan@dundee.ac.uk	Sullivan, Frank/L-8286-2019; Sullivan, Frank m/A-7767-2009	Sullivan, Frank/0000-0002-6623-4964; MacDonald, Thomas/0000-0001-5189-6669; Donnan, Peter/0000-0001-7828-0610				Aarestrup FM, 2000, J CLIN MICROBIOL, V38, P2774, DOI 10.1128/JCM.38.7.2774-2777.2000; Al-Shahi R, 2000, BMJ-BRIT MED J, V321, P1031, DOI 10.1136/bmj.321.7268.1031; Austin DJ, 1997, P ROY SOC B-BIOL SCI, V264, P1629, DOI 10.1098/rspb.1997.0227; Barbosa TM, 2000, DRUG RESIST UPDATE, V3, P303, DOI 10.1054/drup.2000.0167; *BRIT MED ASS, 1996, 32 BMA RPS; Bronzwaer SLAM, 2002, EMERG INFECT DIS, V8, P278, DOI 10.3201/eid0803.010192; Chiew YF, 1998, J ANTIMICROB CHEMOTH, V41, P247, DOI 10.1093/jac/41.2.247; COHEN P S, 1985, Recombinant DNA Technical Bulletin, V8, P51; D'Agata EMC, 1999, CRIT CARE MED, V27, P1090, DOI 10.1097/00003246-199906000-00026; Department of Health and Social Care (DHSC), 2000, UK ANT RES STRAT ACT; Enne VI, 2001, LANCET, V357, P1325, DOI 10.1016/S0140-6736(00)04519-0; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; Hall AJ, 2001, LANCET, V358, P1197, DOI 10.1016/S0140-6736(01)06337-1; Harbarth S, 2001, CLIN INFECT DIS, V33, P1462, DOI 10.1086/322677; Harbarth S, 2000, CIRCULATION, V101, P2916, DOI 10.1161/01.CIR.101.25.2916; HARTLEY CL, 1975, BRIT MED J, V4, P71, DOI 10.1136/bmj.4.5988.71; Hillier SL, 2002, J ANTIMICROB CHEMOTH, V50, P241, DOI 10.1093/jac/dkf121; Holman CDJ, 2001, AUST NZ J PUBL HEAL, V25, P421, DOI 10.1111/j.1467-842X.2001.tb00285.x; Horsfield P, 2002, INFORM PRIM CARE, V10, P227; LANGLOIS BE, 1983, APPL ENVIRON MICROB, V46, P1433, DOI 10.1128/AEM.46.6.1433-1434.1983; Leibovici L, 2001, J ANTIMICROB CHEMOTH, V48, P535, DOI 10.1093/jac/48.4.535; Magee JT, 1999, BMJ-BRIT MED J, V319, P1239, DOI 10.1136/bmj.319.7219.1239; Marshall EG, 1998, BRIT MED J, V316, P1701, DOI 10.1136/bmj.316.7146.1701; MCCLOONE P, 1991, CARSTAIRS CODES SCOT; MCLOONE P, 1991, CARSTAIRS CODES SCOT; Mercer BM, 1999, AM J OBSTET GYNECOL, V181, P816, DOI 10.1016/S0002-9378(99)70307-8; Pauker SG, 1999, BRIT MED J, V318, P1616; Powsner SM, 1998, LANCET, V352, P1617, DOI 10.1016/S0140-6736(98)08309-3; Priest P, 2001, BMJ-BRIT MED J, V323, P1037, DOI 10.1136/bmj.323.7320.1037; ROSDAHL VK, 1998, INV EU C MICR THREAT, P1; Standing Medical Advisory Committee: Sub-group on Antimicrobial Resistance, 1998, PATH LEAST RES; Steinke D, 2002, J ANTIMICROB CHEMOTH, V50, P1085, DOI 10.1093/jac/dkf223; Steinke D, 2001, CLIN INFECT DIS, V33, pS193, DOI 10.1086/321848; Steinke DT, 2001, J ANTIMICROB CHEMOTH, V47, P781, DOI 10.1093/jac/47.6.781; Towers CV, 1998, AM J OBSTET GYNECOL, V179, P879, DOI 10.1016/S0002-9378(98)70182-6; Woods GM, 1997, J PEDIAT HEMATOL ONC, V19, P327, DOI 10.1097/00043426-199707000-00011; Young AF, 2001, AUST NZ J PUBL HEAL, V25, P417, DOI 10.1111/j.1467-842X.2001.tb00284.x	37	65	65	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 29	2004	328	7451					1297	1300		10.1136/bmj.328.7451.1297	http://dx.doi.org/10.1136/bmj.328.7451.1297			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826PN	15166067	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000221841100022
J	de Hoog, CL; Foster, LJ; Mann, M				de Hoog, CL; Foster, LJ; Mann, M			RNA and RNA binding proteins participate in early stages of cell spreading through spreading initiation centers	CELL			English	Article							ACTIN MESSENGER-RNA; QUANTITATIVE PROTEOMICS; KINASE-C; FOCAL ADHESIONS; BETA-SUBUNIT; AMINO-ACIDS; HNRNP-K; DYNAMICS; PHOSPHORYLATION; LOCALIZATION	Focal adhesions are specialized attachment and signaling centers that form at sites of cell-matrix contacts. We employed a quantitative mass spectrometry-based method called SILAC to identify and quantify proteins interacting in an attachment-dependent manner with focal adhesion proteins. Subsequent confocal microscopy revealed a previously undescribed structure, which we have termed a spreading initiation center (SIC), existing only in early stages of cell spreading. SICs contain focal adhesion markers, appear to be surrounded by an actin sheath, and, surprisingly, contain numerous RNA binding proteins, ribosomal RNA, and perhaps other RNAs. Interfering with the function of FUS/TLS, hnRNP K, and hnRNP E1 results in increased spreading. Spreading initiation centers are ribonucleoprotein complexes distinct from focal adhesions and demonstrate a role for RNA and RNA binding proteins in the initiation of cell spreading.	Univ So Denmark, Ctr Expt Bioinformat, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	University of Southern Denmark	Mann, M (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense M, Denmark.	mann@bmb.sdu.dk	Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799				Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Buensuceso CS, 2001, J CELL SCI, V114, P1691; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kaverina I, 2002, INT J BIOCHEM CELL B, V34, P746, DOI 10.1016/S1357-2725(01)00171-6; Kislauskis EH, 1997, J CELL BIOL, V136, P1263, DOI 10.1083/jcb.136.6.1263; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Latham VM, 2001, CURR BIOL, V11, P1010, DOI 10.1016/S0960-9822(01)00291-3; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Meli Marc, 2001, International Microbiology, V4, P5; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Ong SE, 2003, METHODS, V29, P124, DOI 10.1016/S1046-2023(02)00303-1; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Ong SE, 2003, J PROTEOME RES, V2, P173, DOI 10.1021/pr0255708; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; Pickford AS, 2003, CELL MOL LIFE SCI, V60, P871, DOI 10.1007/s00018-003-2245-2; Pruijn GJM, 1997, J AUTOIMMUN, V10, P127, DOI 10.1006/jaut.1996.0123; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Shestakova EA, 2001, P NATL ACAD SCI USA, V98, P7045, DOI 10.1073/pnas.121146098; Small JV, 2003, CURR OPIN CELL BIOL, V15, P40, DOI 10.1016/S0955-0674(02)00008-X; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Turner CE, 2000, J CELL SCI, V113, P4139; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Woods AJ, 2002, J BIOL CHEM, V277, P6428, DOI 10.1074/jbc.M109446200; Zamir E, 2001, J CELL SCI, V114, P3583	36	216	220	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					649	662		10.1016/S0092-8674(04)00456-8	http://dx.doi.org/10.1016/S0092-8674(04)00456-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163412	Bronze			2022-12-28	WOS:000221857900011
J	Youngman, EM; Brunelle, JL; Kochaniak, AB; Green, R				Youngman, EM; Brunelle, JL; Kochaniak, AB; Green, R			The active site of the ribosome is composed of two layers of conserved nucleotides with distinct roles in peptide bond formation and peptide release	CELL			English	Article							TRANSFER-RNA HYDROLYSIS; STOP CODON RECOGNITION; TRANSFERASE CENTER; FACTOR RF2; GGQ MOTIF; STRUCTURAL BASIS; MUTATIONS; COLI; CATALYSIS; PURIFICATION	Peptide bond formation and peptide release are catalyzed in the active site of the large subunit of the ribosome where universally conserved nucleotides surround the CCA ends of the peptidyl- and aminoacyl-tRNA substrates. Here, we describe the use of an affinity-tagging system for the purification of mutant ribosomes and analysis of four universally conserved nucleotides in the innermost layer of the active site: A2451, U2506, U2585, and A2602. While pre-steady-state kinetic analysis of the peptidyl transferase activity of the mutant ribosomes reveals substantially reduced rates of peptide bond formation using the minimal substrate puromycin, their rates of peptide bond formation are unaffected when the substrates are intact aminoacyl-tRNAs. These mutant ribosomes do, however, display substantial defects in peptide release. These results reveal a view of the catalytic center in which an inner shell of conserved nucleotides is pivotal for peptide release, while an outer shell is responsible for promoting peptide bond formation.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Green, R (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	ragreen@jhmi.edu	Youngman, Elaine/O-7449-2019; Youngman, Elaine/E-7072-2013	Loveland, Anna B./0000-0001-9172-7747				Asai T, 1999, P NATL ACAD SCI USA, V96, P1971, DOI 10.1073/pnas.96.5.1971; Bayfield MA, 2001, P NATL ACAD SCI USA, V98, P10096, DOI 10.1073/pnas.171319598; Beringer M, 2003, RNA, V9, P919, DOI 10.1261/rna.5600503; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DAMMEL CS, 1993, GENE DEV, V7, P660, DOI 10.1101/gad.7.4.660; Das R, 2000, MOL CELL, V5, P779, DOI 10.1016/S1097-2765(00)80318-4; DOUTHWAITE S, 1989, J MOL BIOL, V209, P655, DOI 10.1016/0022-2836(89)93000-3; Engelhardt MA, 2000, BIOCHEMISTRY-US, V39, P2639, DOI 10.1021/bi992313g; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Green R, 2002, CELL, V110, P665, DOI 10.1016/S0092-8674(02)00965-0; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; Jurica MS, 2002, RNA, V8, P426, DOI 10.1017/S1355838202021088; Khvorova A, 2003, NAT STRUCT BIOL, V10, P708, DOI 10.1038/nsb959; Kim DF, 1999, MOL CELL, V4, P859, DOI 10.1016/S1097-2765(00)80395-0; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; KUTUNIN VI, 2002, MOL CELL, V10, P1; LECUYER KA, 1995, BIOCHEMISTRY-US, V34, P10600, DOI 10.1021/bi00033a035; Leonov AA, 2003, J BIOL CHEM, V278, P25664, DOI 10.1074/jbc.M302873200; LIEBERMAN KR, 1995, PROG NUCLEIC ACID RE, V50, P1, DOI 10.1016/S0079-6603(08)60809-0; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MISKIN R, 1968, BIOCHEM BIOPH RES CO, V33, P551, DOI 10.1016/0006-291X(68)90330-6; Misra VK, 1998, BIOPOLYMERS, V48, P113, DOI 10.1002/(SICI)1097-0282(1998)48:2<113::AID-BIP3>3.0.CO;2-Y; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; Moore PB, 2003, ANNU REV BIOCHEM, V72, P813, DOI 10.1146/annurev.biochem.72.110601.135450; Moore PB, 2003, RNA, V9, P155, DOI 10.1261/rna.2127103; Mora L, 2003, MOL MICROBIOL, V47, P267, DOI 10.1046/j.1365-2958.2003.03301.x; Muth GW, 2001, RNA, V7, P1403; O'Connor M, 2001, NUCLEIC ACIDS RES, V29, P710, DOI 10.1093/nar/29.3.710; Pape T, 1999, EMBO J, V18, P3800, DOI 10.1093/emboj/18.13.3800; PAWLIK RT, 1981, BIOCHEM INT, V2, P421; PEDERSEN S, 1984, EMBO J, V3, P2895, DOI 10.1002/j.1460-2075.1984.tb02227.x; Peracchi A, 1998, BIOCHEMISTRY-US, V37, P14765, DOI 10.1021/bi980867y; Polacek N, 2003, MOL CELL, V11, P103, DOI 10.1016/S1097-2765(02)00825-0; Polacek N, 2001, NATURE, V411, P498, DOI 10.1038/35078113; POWERS T, 1990, P NATL ACAD SCI USA, V87, P1042, DOI 10.1073/pnas.87.3.1042; Rajagopalan PTR, 2002, CHEM REC, V2, P24, DOI 10.1002/tcr.10009; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; Rodnina MV, 2003, CURR OPIN STRUC BIOL, V13, P334, DOI 10.1016/S0959-440X(03)00065-4; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; Scarlett DJG, 2003, J BIOL CHEM, V278, P15095, DOI 10.1074/jbc.M211024200; Seit-Nebi A, 2001, NUCLEIC ACIDS RES, V29, P3982, DOI 10.1093/nar/29.19.3982; Semenkov YP, 2000, NAT STRUCT BIOL, V7, P1027; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; SIGMUND CD, 1988, METHOD ENZYMOL, V164, P673; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Spahn CMT, 1999, STRUCT FOLD DES, V7, P1567, DOI 10.1016/S0969-2126(00)88347-1; Staley JP, 1999, MOL CELL, V3, P55, DOI 10.1016/S1097-2765(00)80174-4; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; Vestergaard B, 2001, MOL CELL, V8, P1375, DOI 10.1016/S1097-2765(01)00415-4; WEBER AL, 1979, J MOL EVOL, V13, P185, DOI 10.1007/BF01739478; Wilson KS, 2000, NAT STRUCT BIOL, V7, P866, DOI 10.1038/82818; Xiong LQ, 2001, RNA, V7, P1365; Zavialov AV, 2002, MOL CELL, V10, P789, DOI 10.1016/S1097-2765(02)00691-3	57	276	281	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					589	599		10.1016/S0092-8674(04)00411-8	http://dx.doi.org/10.1016/S0092-8674(04)00411-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163407	Bronze			2022-12-28	WOS:000221857900006
J	Ohmoto, H; Watanabe, Y; Kumazawa, K				Ohmoto, H; Watanabe, Y; Kumazawa, K			Evidence from massive siderite beds for a CO2-rich atmosphere before, 1.8 billion years ago	NATURE			English	Article							CARBON-DIOXIDE CONCENTRATIONS; IRON-FORMATION; STABLE-ISOTOPE; OXYGEN; ORIGIN; RICH; GEOCHEMISTRY; SUPERGROUP; PALEOSOLS; EVOLUTION	It is generally thought that, in order to compensate for lower solar flux and maintain liquid oceans on the early Earth, methane must have been an important greenhouse gas before similar to2.2 billion years (Gyr) ago(1-5). This is based upon a simple thermodynamic calculation that relates the absence of siderite (FeCO3) in some pre-2.2-Gyr palaeosols to atmospheric CO2 concentrations that would have been too low to have provided the necessary greenhouse effect(1). Using multi-dimensional thermodynamic analyses and geological evidence, we show here that the absence of siderite in palaeosols does not constrain atmospheric CO2 concentrations. Siderite is absent in many palaeosols (both pre- and post-2.2-Gyr in age) because the O-2 concentrations and pH conditions in well-aerated soils have favoured the formation of ferric (Fe3+)-rich minerals, such as goethite, rather than siderite. Siderite, however, has formed throughout geological history in subsurface environments, such as euxinic seas, where anaerobic organisms created H-2-rich conditions. The abundance of large, massive siderite-rich beds in pre-1.8-Gyr sedimentary sequences and their carbon isotope ratios indicate that the atmospheric CO2 concentration was more than 100 times greater than today, causing the rain and ocean waters to be more acidic than today. We therefore conclude that CO2 alone ( without a significant contribution from methane) could have provided the necessary greenhouse effect to maintain liquid oceans on the early Earth.	Penn State Univ, Astrobiol Res Ctr, NASA, Astrobiol Inst, University Pk, PA 16802 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Oyo Corp, Miyazaki Branch, Miyazaki 099561, Japan	National Aeronautics & Space Administration (NASA); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; OYO Corporation	Ohmoto, H (corresponding author), Penn State Univ, Astrobiol Res Ctr, NASA, Astrobiol Inst, University Pk, PA 16802 USA.	ohmoto@geosc.psu.edu		Ohmoto, Hiroshi/0000-0001-7605-0862				BAUR ME, 1985, ECON GEOL, V80, P270, DOI 10.2113/gsecongeo.80.2.270; BECKER RH, 1972, GEOCHIM COSMOCHIM AC, V36, P577, DOI 10.1016/0016-7037(72)90077-4; Beukes NJ, 2002, GEOLOGY, V30, P491, DOI 10.1130/0091-7613(2002)030<0491:TLLOLA>2.0.CO;2; BEUKES NJ, 1990, ECON GEOL BULL SOC, V85, P663, DOI 10.2113/gsecongeo.85.4.663; CARRIGAN WJ, 1991, PRECAMBRIAN RES, V52, P347, DOI 10.1016/0301-9268(91)90088-R; Catling DC, 2001, SCIENCE, V293, P839, DOI 10.1126/science.1061976; GOODWIN AM, 1985, CAN J EARTH SCI, V22, P72, DOI 10.1139/e85-006; Hayes J. M., 1994, EARLY LIFE EARTH, P220; KASTING JF, 1987, PRECAMBRIAN RES, V34, P205, DOI 10.1016/0301-9268(87)90001-5; Kimberley M.M., 1989, ORE GEOL REV, V5, P13, DOI [DOI 10.1016/0169-1368(89)90003-6, https://doi.org/10.1016/0169-1368(89)90003-6]; Knauth LP, 2003, GEOL SOC AM BULL, V115, P566, DOI 10.1130/0016-7606(2003)115<0566:HACTIF>2.0.CO;2; Langmuir D., 1997, AQUEOUS ENV, P600; Marmo J.S., 1992, EARLY ORGANIC EVOLUT, P41; MOORE SE, 1992, J SEDIMENT PETROL, V62, P357; MOZLEY PS, 1992, GEOLOGY, V20, P817, DOI 10.1130/0091-7613(1992)020<0817:ICOSAA>2.3.CO;2; Ohmoto H, 1999, GEOLOGY, V27, P1151, DOI 10.1130/0091-7613(1999)027<1151:RSOTAA>2.3.CO;2; Ohmoto H, 1996, GEOLOGY, V24, P1135, DOI 10.1130/0091-7613(1996)024<1135:EIPGPF>2.3.CO;2; Ohmoto H., 1997, GEOCHEM NEWS, V93, P26; OHMOTO H, 1997, GEOCHEM NEWS, V93, P12; Panahi A, 2000, GEOCHIM COSMOCHIM AC, V64, P2199, DOI 10.1016/S0016-7037(99)00420-2; Pavlov AA, 2003, GEOLOGY, V31, P87, DOI 10.1130/0091-7613(2003)031<0087:MRPA>2.0.CO;2; Pavlov AA, 2001, GEOLOGY, V29, P1003, DOI 10.1130/0091-7613(2001)029<1003:OHIESE>2.0.CO;2; Pavlov AA, 2001, J GEOPHYS RES-PLANET, V106, P23267, DOI 10.1029/2000JE001448; *ROCKWARE INC, 2002, GEOCH WORKB VERS 4; RYE R, 1995, NATURE, V378, P603, DOI 10.1038/378603a0; Rye R, 1998, AM J SCI, V298, P621, DOI 10.2475/ajs.298.8.621; Schidlowski M., 1992, EARLY ORGANIC EVOLUT, P147; Shields G, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000266; Stumm W., 1996, AQUATIC CHEM CHEM EQ, V3rd ed., DOI [10.5860/choice.33-6312, DOI 10.5860/CHOICE.33-6312]; Watanabe Y, 2004, GEOCHIM COSMOCHIM AC, V68, P2129, DOI 10.1016/j.gca.2003.10.036; WINTER BL, 1992, PRECAMBRIAN RES, V59, P283, DOI 10.1016/0301-9268(92)90061-R	31	164	176	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					395	399		10.1038/nature02573	http://dx.doi.org/10.1038/nature02573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164058				2022-12-28	WOS:000221644600034
J	Prockop, DJ				Prockop, DJ			Targeting gene therapy for osteogenesis imperfecta	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							STEM-CELLS		Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70118 USA	Tulane University	Prockop, DJ (corresponding author), Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70118 USA.							Chamberlain JR, 2004, SCIENCE, V303, P1198, DOI 10.1126/science.1088757; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; McCormack MP, 2004, NEW ENGL J MED, V350, P913, DOI 10.1056/NEJMra032207; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016	5	15	17	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2302	2304		10.1056/NEJMcibr040806	http://dx.doi.org/10.1056/NEJMcibr040806			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163783				2022-12-28	WOS:000221641900015
J	McLeod, AA; Jokhi, PP				McLeod, AA; Jokhi, PP			Lesson of the week - Pacemaker induced ventricular fibrillation in coronary care units	BMJ-BRITISH MEDICAL JOURNAL			English	Review							STIMULATION; INFARCTION		Poole Hosp NHS Trust, Dept Cardiac, Poole BH15 2JB, Dorset, England		McLeod, AA (corresponding author), Poole Hosp NHS Trust, Dept Cardiac, Poole BH15 2JB, Dorset, England.	heartdoc@tcp.co.uk						CHARDACK WM, 1969, ANN NY ACAD SCI, V167, P919, DOI 10.1111/j.1749-6632.1969.tb34154.x; Darpo B, 2001, EUR HEART J SUPPL, V3, pK70, DOI 10.1016/S1520-765X(01)90009-4; LANGENDORF R, 1955, CIRCULATION, V11, P422, DOI 10.1161/01.CIR.11.3.422; MITTAL SR, 1992, INT J CARDIOL, V34, P100, DOI 10.1016/0167-5273(92)90088-K; MOOSS AN, 1982, CATHETER CARDIO DIAG, V8, P253, DOI 10.1002/ccd.1810080307; Oupadia P, 1998, NEW ENGL J MED, V338, P1812, DOI 10.1056/NEJM199806183382505; PALMER DG, 1962, AM HEART J, V63, P367, DOI 10.1016/0002-8703(62)90281-8; Preisman S, 1999, ANESTHESIOLOGY, V91, P880, DOI 10.1097/00000542-199909000-00046; PRESTON TA, 1973, AM HEART J, V86, P366, DOI 10.1016/0002-8703(73)90046-X; SALLAM IA, 1973, J CARDIOVASC SURG, V14, P443; SEIPEL L, 1976, AM HEART J, V92, P810, DOI 10.1016/S0002-8703(76)80024-5; TAVEL ME, 1964, CIRCULATION, V30, P493, DOI 10.1161/01.CIR.30.4.493; WOOD M, 1996, CARDIAC PACING; Zipes D., 2001, HEART DIS TXB CARDIO	14	17	17	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	2004	328	7450					1249	1250		10.1136/bmj.328.7450.1249	http://dx.doi.org/10.1136/bmj.328.7450.1249			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824HL	15155506	Green Published			2022-12-28	WOS:000221677200030
J	Gillick, MR				Gillick, MR			Medicare coverage for technological innovations - Time for new criteria?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COST-EFFECTIVENESS; REDUCTION SURGERY; SEVERE EMPHYSEMA; LUNG-VOLUME; DEFIBRILLATOR; HEALTH		Harvard Vanguard Med Associates, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA	Harvard Vanguard Medical Associates; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Gillick, MR (corresponding author), Harvard Vanguard Med Associates, Boston, MA USA.							*ADM AG, 2002, PROF OLD AM 2002, P3; AGOVINO T, 2003, BOSTON GLOBE    0902, pA10; Bodenheimer T, 1997, NEW ENGL J MED, V337, P651, DOI 10.1056/NEJM199708283370923; BROWN D, 2003, WASHINGTON POST 1009, pA4; Daniels N, 2002, SETTING LIMITS FAIRL; Fishman A, 2003, NEW ENGL J MED, V348, P2059; Foote SB, 2003, HEALTH AFFAIR, V22, P137, DOI 10.1377/hlthaff.22.4.137; Foote SB, 2002, J HEALTH POLIT POLIC, V27, P707, DOI 10.1215/03616878-27-5-707; GRADY D, 2003, NY TIMES        0225, pA22; Lynd LD, 2003, J CARDIOVASC ELECTR, V14, pS99, DOI 10.1046/j.1540-8167.14.s9.3.x; Medicare Program, 2003, FED REGISTER, V68, P55634; MENZEL P, BROADER VIEW VALUES; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Phurrough S., 2003, DECISION MEMORANDUM; PHURROUGH SE, 2003, COVERAGE DECISION ME; Ramsey SD, 2003, NEW ENGL J MED, V348, P2092; Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Samson David, 2004, Technol Eval Cent Assess Program Exec Summ, V19, P1; WOODWARD K, 2003, F HUTCHINSON CAN MAY; 2002, FED REG, V67, P79109	21	70	70	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2199	2203		10.1056/NEJMsb032612	http://dx.doi.org/10.1056/NEJMsb032612			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152067				2022-12-28	WOS:000221496700016
J	Glines, ME				Glines, ME			The effect of work hour regulations on personal development during residency	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							YOUNG DOCTORS HEALTH		Sutter Med Ctr Santa Rosa, Santa Rosa, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Glines, ME (corresponding author), Family Practice Ctr, 3324 Chanate Rd, Santa Rosa, CA 95404 USA.	glinesm@sutterhealth.org						Baldwin PJ, 1997, SOC SCI MED, V45, P41, DOI 10.1016/S0277-9536(96)00307-3; Baldwin PJ, 1997, SOC SCI MED, V45, P35, DOI 10.1016/S0277-9536(96)00306-1; DaRosa DA, 2003, SURGERY, V133, P13, DOI 10.1067/msy.2003.67; DOLAN KL, 1990, J NATL MED ASSOC, V82, P629; Lowenstein J, 2003, PERSPECT BIOL MED, V46, P273, DOI 10.1353/pbm.2003.0026; Monk TH, 2003, SLEEP, V26, P208, DOI 10.1093/sleep/26.2.208; REUBEN DB, 1985, ARCH INTERN MED, V145, P286, DOI 10.1001/archinte.145.2.286; Suskin N, 1998, J Cardiopulm Rehabil, V18, P216, DOI 10.1097/00008483-199805000-00005; Yu J N, 1994, Fam Med, V26, P163	9	9	9	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					818	819		10.7326/0003-4819-140-10-200405180-00013	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148070				2022-12-28	WOS:000221520900008
J	Salpeter, SR; Ormiston, TM; Salpeter, EE				Salpeter, SR; Ormiston, TM; Salpeter, EE			Meta-analysis: Respiratory tolerance to regular beta(2)-agonist use in patients with asthma	ANNALS OF INTERNAL MEDICINE			English	Review							LONG-ACTING BETA(2)-AGONISTS; PLACEBO-CONTROLLED TRIAL; FORMOTEROL DRY POWDER; QUALITY-OF-LIFE; INHALED SALBUTAMOL; DOUBLE-BLIND; AIRWAY RESPONSIVENESS; BETA-AGONISTS; BRONCHODILATOR SUBSENSITIVITY; BRONCHIAL RESPONSIVENESS	Background: The regular administration of beta(2)-agonists may be associated with the development of tolerance to their effects. Purpose: To assess the effect of regular beta(2)-agonist use on respiratory function and beta(2)-receptor function in asthmatic patients. Data Sources: Comprehensive searches of the EMBASE, MEDLINE, and CINAHL databases from 1966 to June 2003 and references of identified articles and reviews. Study Selection: Randomized, placebo-controlled trials that studied at least 1 week of regular beta(2)-agonist administration in patients with asthma and did not allow "as-needed" beta(2)-agonist use in the placebo group. Data Extraction: Outcomes measured in the active treatment and placebo groups were the change in FEV, in response to treatment and subsequent beta(2)-agonist administration, the provocative concentration of bronchoconstrictive agents causing a 20% reduction in FEV1 (PC20), and in vitro variables of leukocyte beta(2)-receptor function. Data Synthesis: Pooled results of 22 trials showed that regular beta(2)-agonist use, compared with placebo, did not change the mean FEV, after treatment or the net FEV, treatment effect but substantially reduced the following: the peak FEV, response to subsequent beta(2)-agonist administration (change, -17.8% [95% CI, -27.2% to -8.5%]); the FEV, dose response to subsequent beta(2)agonists (-34.8% [CI, -45.7% to -24%]); the PC20 to combined bronchoconstrictive stimuli (-26% [CI, -37% to -11%]); and leukocyte beta(2)-receptor density (-18.3% [CI, -31.6% to -5.1%]), binding affinity (-23.1% [CI, -39.4% to -6.8%]), and in vitro response to isoproterenol (-32.7% [CI, -56.5% to -9.0%]). Conclusion: Regular beta(2)-agonist use for at least 1 week in patients with asthma results in tolerance to the drug's bronchodilator and nonbronchodilator effects and may be associated with poorer disease control compared with placebo.	Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Cornell Univ, Ithaca, NY USA	Santa Clara Valley Medical Center; Stanford University; Cornell University	Salpeter, SR (corresponding author), Santa Clara Valley Med Ctr, 751 S Bascom Ave, San Jose, CA 95128 USA.	salpeter@stanford.edu						Adams BK, 2003, EMERG MED CLIN N AM, V21, P315, DOI 10.1016/S0733-8627(03)00015-4; ALDREY OE, 1995, J ASTHMA, V32, P21, DOI 10.3109/02770909509089496; Aldridge RE, 2000, AM J RESP CRIT CARE, V161, P1459, DOI 10.1164/ajrccm.161.5.9906052; Anstead MI, 2001, J ASTHMA, V38, P59, DOI 10.1081/JAS-100000022; Apter AJ, 1996, J ALLERGY CLIN IMMUN, V98, P295, DOI 10.1016/S0091-6749(96)70153-7; Arledge TE, 1996, J ALLERGY CLIN IMMUN, V98, P1116, DOI 10.1016/S0091-6749(96)80200-4; Aziz I, 1998, J ALLERGY CLIN IMMUN, V101, P337, DOI 10.1016/S0091-6749(98)70245-3; Aziz I, 1998, EUR RESPIR J, V12, P580, DOI 10.1183/09031936.98.12030580; Baki A, 1998, ACTA PAEDIATR JAPON, V40, P247; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Bensch G, 2002, ANN ALLERG ASTHMA IM, V89, P180, DOI 10.1016/S1081-1206(10)61935-7; Bensch G, 2001, ANN ALLERG ASTHMA IM, V86, P19, DOI 10.1016/S1081-1206(10)62351-4; Bhagat R, 1996, J ALLERGY CLIN IMMUN, V97, P47, DOI 10.1016/S0091-6749(96)70282-8; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; Bijl-Hofland ID, 2001, AM J RESP CRIT CARE, V164, P764, DOI 10.1164/ajrccm.164.5.9910103; Booth H, 1996, THORAX, V51, P1100, DOI 10.1136/thx.51.11.1100; Boulet LP, 1998, EUR RESPIR J, V11, P1091, DOI 10.1183/09031936.98.11051091; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Boulet LP, 2001, CLIN EXP ALLERGY, V31, P430, DOI 10.1046/j.1365-2222.2001.01014.x; Bousquet J, 1996, ANN ALLERG ASTHMA IM, V76, P189, DOI 10.1016/S1081-1206(10)63421-7; BOYD G, 1995, EUR RESPIR J, V8, P1494; Brophy JM, 2001, ANN INTERN MED, V134, P550, DOI 10.7326/0003-4819-134-7-200104030-00008; BUSSE WW, 1985, AM REV RESPIR DIS, V132, P1194; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Busse WW, 1998, AM J MANAG CARE, V4, P1579; Chatterjee K, 2003, MED CLIN N AM, V87, P391, DOI 10.1016/S0025-7125(02)00185-2; Chavasse RJ, 2000, ARCH DIS CHILD, V82, P370, DOI 10.1136/adc.82.5.370; Chervinsky P, 1999, CHEST, V115, P642, DOI 10.1378/chest.115.3.642; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; Cheung D, 1998, AM J RESP CRIT CARE, V158, P792, DOI 10.1164/ajrccm.158.3.9801036; Cloosterman SGM, 2001, CHEST, V119, P1306, DOI 10.1378/chest.119.5.1306; COCKCROFT DW, 1995, J ALLERGY CLIN IMMUN, V96, P44, DOI 10.1016/S0091-6749(95)70031-5; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; Creticos PS, 1999, INT ARCH ALLERGY IMM, V118, P345, DOI 10.1159/000024129; D'Urzo AD, 2001, CHEST, V119, P714, DOI 10.1378/chest.119.3.714; DAHL R, 1991, EUR RESPIR J, V4, P1178; deJong JW, 1996, AM J RESP CRIT CARE, V153, P70, DOI 10.1164/ajrccm.153.1.8542165; Dennis SM, 2000, LANCET, V355, P1675, DOI 10.1016/S0140-6736(00)02238-8; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ekstrom T, 1998, RESP MED, V92, P1040, DOI 10.1016/S0954-6111(98)90352-3; Ekstrom T, 1998, ANN ALLERG ASTHMA IM, V81, P225, DOI 10.1016/S1081-1206(10)62816-5; FAURSCHOU P, 1994, ALLERGY, V49, P827, DOI 10.1111/j.1398-9995.1994.tb00782.x; FITZPATRICK MF, 1990, BRIT MED J, V301, P1365, DOI 10.1136/bmj.301.6765.1365; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Ganassini A, 1997, J ASTHMA, V34, P61, DOI 10.3109/02770909709071204; Garcia R, 2001, J INVEST ALLERG CLIN, V11, P176; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Giannini D, 1996, CHEST, V110, P1452, DOI 10.1378/chest.110.6.1452; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; GRENDER JM, 1992, STAT MED, V11, P727, DOI 10.1002/sim.4780110604; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; Hancox RJ, 1999, EUR RESPIR J, V14, P283, DOI 10.1034/j.1399-3003.1999.14b08.x; Hancox RJ, 1999, THORAX, V54, P482, DOI 10.1136/thx.54.6.482; Hancox RJ, 2002, AM J RESP CRIT CARE, V165, P1068, DOI 10.1164/ajrccm.165.8.200111-091bc; Harrison TW, 1999, THORAX, V54, P98, DOI 10.1136/thx.54.2.98; HASANI A, 1993, THORAX, V48, P287, DOI 10.1136/thx.48.3.287; HYLAND ME, 1994, QUAL LIFE RES, V3, P121, DOI 10.1007/BF00435255; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; Jokic R, 2001, CHEST, V119, P370, DOI 10.1378/chest.119.2.370; JONES KP, 1994, THORAX, V49, P971, DOI 10.1136/thx.49.10.971; Jones SL, 2001, EUR RESPIR J, V17, P368, DOI 10.1183/09031936.01.17303680; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; Kraft M, 1997, CHEST, V111, P1249, DOI 10.1378/chest.111.5.1249; Lanes SF, 2002, THORAX, V57, P683, DOI 10.1136/thorax.57.8.683; Langley SJ, 1998, EUR RESPIR J, V11, P1081, DOI 10.1183/09031936.98.11051081; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Leblanc P, 1996, AM J RESP CRIT CARE, V154, P324, DOI 10.1164/ajrccm.154.2.8756801; Li X, 1999, AM J RESP CRIT CARE, V160, P1493, DOI 10.1164/ajrccm.160.5.9811052; LIPWORTH BJ, 1989, AM REV RESPIR DIS, V140, P586, DOI 10.1164/ajrccm/140.3.586; Lipworth BJ, 1999, J ALLERGY CLIN IMMUN, V103, P88, DOI 10.1016/S0091-6749(99)70530-0; Lockey RF, 1999, CHEST, V115, P666, DOI 10.1378/chest.115.3.666; MANOLITSAS ND, 1995, AM J RESP CRIT CARE, V151, P1925, DOI 10.1164/ajrccm.151.6.7767541; McGraw DW, 2003, J CLIN INVEST, V112, P619, DOI 10.1172/JCI200318193; Milgrom H, 2001, J ALLERGY CLIN IMMUN, V108, P938, DOI 10.1067/mai.2001.120134; Nathan RA, 1999, ANN ALLERG ASTHMA IM, V82, P521, DOI 10.1016/S1081-1206(10)63159-6; NATHAN RA, 1995, ANN ALLERG ASTHMA IM, V75, P243; Nelson HS, 1999, AM J RESP CRIT CARE, V159, P1556, DOI 10.1164/ajrccm.159.5.9807128; Nelson JA, 1998, NEW ENGL J MED, V339, P141, DOI 10.1056/NEJM199807163390301; NEWNHAM DM, 1995, THORAX, V50, P497, DOI 10.1136/thx.50.5.497; NEWNHAM DM, 1994, AM J MED, V97, P29, DOI 10.1016/0002-9343(94)90045-0; Nielsen LP, 1999, RESP MED, V93, P863, DOI 10.1016/S0954-6111(99)90051-3; Nishikawa M, 1996, EUR J PHARMACOL, V318, P123, DOI 10.1016/S0014-2999(96)00769-8; Norhaya M R, 1999, Respirology, V4, P77, DOI 10.1046/j.1440-1843.1999.00153.x; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; PANSEGROUW DF, 1991, S AFR MED J, V80, P229; Pearlman DS, 1999, ANN ALLERG ASTHMA IM, V82, P257, DOI 10.1016/S1081-1206(10)62606-3; Price D, 2002, THORAX, V57, P791, DOI 10.1136/thorax.57.9.791; Prieto L, 2002, CHEST, V122, P798, DOI 10.1378/chest.122.3.798; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; RAMAGE L, 1994, INT ARCH ALLERGY IMM, V105, P181, DOI 10.1159/000236822; Richter B, 2000, J INTERN MED, V247, P657, DOI 10.1046/j.1365-2796.2000.00677.x; Roberts JA, 1999, EUR RESPIR J, V14, P275, DOI 10.1034/j.1399-3003.1999.14b07.x; Rodrigo GJ, 2002, CHEST, V122, P160, DOI 10.1378/chest.122.1.160; Rosenthal RR, 1999, CHEST, V116, P595, DOI 10.1378/chest.116.3.595; Salpeter SR, 2002, ANN INTERN MED, V137, P715, DOI 10.7326/0003-4819-137-9-200211050-00035; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SIEGEL SC, 1985, J ALLERGY CLIN IMMUN, V75, P698, DOI 10.1016/0091-6749(85)90096-X; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; SITAR DS, 1993, CHEST, V103, P771, DOI 10.1378/chest.103.3.771; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STEFFENSEN I, 1995, ALLERGY, V50, P657, DOI 10.1111/j.1398-9995.1995.tb02582.x; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; Stelmach I, 2002, ANN ALLERG ASTHMA IM, V89, P67, DOI 10.1016/S1081-1206(10)61913-8; Tan KS, 1998, CHEST, V113, P34, DOI 10.1378/chest.113.1.34; Tan KS, 1997, AM J RESP CRIT CARE, V156, P28, DOI 10.1164/ajrccm.156.1.9610113; Taylor DR, 1996, MED CLIN N AM, V80, P719, DOI 10.1016/S0025-7125(05)70465-X; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; *US FDA, 2003, STUD ASTHM DRUG HALT; van Schayck CP, 2002, EUR RESPIR J, V19, P240, DOI 10.1183/09031936.02.00203602; van Schayck CP, 2002, RESP MED, V96, P155, DOI 10.1053/rmed.2001.1243; vanderMolen T, 1997, THORAX, V52, P535, DOI 10.1136/thx.52.6.535; VANGANSE E, 1995, EUR RESPIR J, V8, P1856, DOI 10.1183/09031936.95.08111856; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; Wallin A, 1999, AM J RESP CRIT CARE, V159, P79, DOI 10.1164/ajrccm.159.1.9801007; WESTERMANN CJJ, 1986, ALLERGY, V41, P308, DOI 10.1111/j.1398-9995.1986.tb02034.x; Wilding P, 1997, BRIT MED J, V314, P1441, DOI 10.1136/bmj.314.7092.1441; Wilding PJ, 1996, THORAX, V51, P989, DOI 10.1136/thx.51.10.989; Williams C, 1998, THORAX, V53, P7, DOI 10.1136/thx.53.1.7; Yates DH, 1996, AM J RESP CRIT CARE, V154, P1603, DOI 10.1164/ajrccm.154.6.8970342; YATES DH, 1995, AM J RESP CRIT CARE, V152, P1170, DOI 10.1164/ajrccm.152.4.7551366; Yates DH, 1997, AM J RESP CRIT CARE, V156, P988, DOI 10.1164/ajrccm.156.3.9610051	127	96	101	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					802	813		10.7326/0003-4819-140-10-200405180-00010	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148067				2022-12-28	WOS:000221520900005
J	Vernick, KD				Vernick, KD			Gamete interruptus: A novel calcium-dependent kinase is essential for malaria sexual reproduction	CELL			English	Editorial Material							XANTHURENIC ACID; PLASMODIUM-FALCIPARUM; ANOPHELES-STEPHENSI; MOSQUITO; GAMETOGENESIS; INFECTIVITY; BERGHEI	Malaria parasites undergo sexual fertilization minutes after the bloodmeal enters the mosquito midgut. In this issue of Cell, Billker et al. (2004) describe a new Plasmodium calcium-dependent protein kinase essential for gamete formation, and show that it is required for parasite transmission.	Univ Minnesota, Ctr Microbial & Plant Genom, St Paul, MN 55108 USA; Univ Minnesota, Dept Microbiol, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Vernick, KD (corresponding author), Univ Minnesota, Ctr Microbial & Plant Genom, 1500 Gortner Ave, St Paul, MN 55108 USA.							Alavi Y, 2003, INT J PARASITOL, V33, P933, DOI 10.1016/S0020-7519(03)00112-7; Arai M, 2001, MOL BIOCHEM PARASIT, V116, P17, DOI 10.1016/S0166-6851(01)00299-7; Bhattacharyya MK, 2001, INT J PARASITOL, V31, P1129, DOI 10.1016/S0020-7519(01)00222-3; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; Billker O, 1997, PARASITOLOGY, V115, P1, DOI 10.1017/S0031182097008895; Cao Ya-Ming, 1998, Parasitology International, V47, P157, DOI 10.1016/S1383-5769(98)00014-2; Fang J, 2002, NATURE, V418, P742, DOI 10.1038/418742a; Garcia GE, 1998, J BIOL CHEM, V273, P12003, DOI 10.1074/jbc.273.20.12003; Li JL, 2000, BBA-GENE STRUCT EXPR, V1491, P341, DOI 10.1016/S0167-4781(00)00032-4	10	1	1	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	2004	117	4					419	420		10.1016/S0092-8674(04)00455-6	http://dx.doi.org/10.1016/S0092-8674(04)00455-6			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137935	Bronze			2022-12-28	WOS:000221458000002
J	Mitchell, MW; Lundeen, JS; Steinberg, AM				Mitchell, MW; Lundeen, JS; Steinberg, AM			Super-resolving phase measurements with a multiphoton entangled state	NATURE			English	Article							QUANTUM-DOT; INTERFEROMETER; INTERFERENCE; LIMIT	Interference phenomena are ubiquitous in physics, often forming the basis of demanding measurements. Examples include Ramsey interferometry in atomic spectroscopy, X-ray diffraction in crystallography and optical interferometry in gravitational-wave studies(1,2). It has been known for some time that the quantum property of entanglement can be exploited to perform super-sensitive measurements, for example in optical interferometry or atomic spectroscopy(3-7). The idea has been demonstrated for an entangled state of two photons(8), but for larger numbers of particles it is difficult to create the necessary multiparticle entangled states(9-11). Here we demonstrate experimentally a technique for producing a maximally entangled three-photon state from initially non-entangled photons. The method can in principle be applied to generate states of arbitrary photon number, giving arbitrarily large improvement in measurement resolution(12-15). The method of state construction requires nonunitary operations, which we performusing post-selected linear-optics techniques similar to those used for linear-optics quantum computing(16-20).	Univ Toronto, Dept Phys, Toronto, ON M5S 1A7, Canada	University of Toronto	Mitchell, MW (corresponding author), Univ Toronto, Dept Phys, 60 St George St, Toronto, ON M5S 1A7, Canada.	mitchell@physics.utoronto.ca	Steinberg, Aephraim M/C-3226-2008; Mitchell, Morgan W/I-9027-2012; Lundeen, Jeffrey S./E-8512-2012	Steinberg, Aephraim M/0000-0002-7737-8971; Mitchell, Morgan W/0000-0001-8949-9407; Lundeen, Jeffrey S./0000-0002-0978-2913				Barish BC, 1999, PHYS TODAY, V52, P44, DOI 10.1063/1.882861; Bollinger JJ, 1996, PHYS REV A, V54, pR4649, DOI 10.1103/PhysRevA.54.R4649; Campos RA, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.023810; Caron B, 1997, CLASSICAL QUANT GRAV, V14, P1461, DOI 10.1088/0264-9381/14/6/011; D'Angelo M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.013602; Dowling JP, 1998, PHYS REV A, V57, P4736, DOI 10.1103/PhysRevA.57.4736; Fiurasek J, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.053818; Franson JD, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.137901; HOFMANN HF, 2003, GENERATION HIGHLY NO; HOLLAND MJ, 1993, PHYS REV LETT, V71, P1355, DOI 10.1103/PhysRevLett.71.1355; Huelga SF, 1997, PHYS REV LETT, V79, P3865, DOI 10.1103/PhysRevLett.79.3865; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Kok P, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.052104; Meyer V, 2001, PHYS REV LETT, V86, P5870, DOI 10.1103/PhysRevLett.86.5870; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Mitchell MW, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.120402; O'Brien JL, 2003, NATURE, V426, P264, DOI 10.1038/nature02054; OU ZY, 1990, PHYS REV A, V42, P2957, DOI 10.1103/PhysRevA.42.2957; Ou ZY, 1997, PHYS REV A, V55, P2598, DOI 10.1103/PhysRevA.55.2598; Pryde GJ, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.052315; Rarity JG, 1999, PHYS REV A, V59, pR35, DOI 10.1103/PhysRevA.59.R35; RARITY JG, 1990, PHYS REV LETT, V65, P1348, DOI 10.1103/PhysRevLett.65.1348; RARITY JG, 1997, NONCLASSICAL INTERFE; Rauschenbeutel A, 2000, SCIENCE, V288, P2024, DOI 10.1126/science.288.5473.2024; Resch KJ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.037904; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Sanders BC, 1997, J MOD OPTIC, V44, P1309; Solomon GS, 2001, PHYS REV LETT, V86, P3903, DOI 10.1103/PhysRevLett.86.3903; Takeuchi S, 2001, OPT LETT, V26, P843, DOI 10.1364/OL.26.000843; Zhao Z, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.180401	30	592	597	5	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988					161	164		10.1038/nature02493	http://dx.doi.org/10.1038/nature02493			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141206	Green Submitted			2022-12-28	WOS:000221356300035
J	Aboelella, NW; Reynolds, AM; Tolman, WB				Aboelella, NW; Reynolds, AM; Tolman, WB			Catching copper in the act	SCIENCE			English	Editorial Material							NITRIC-OXIDE; COMPLEXES; ACTIVATION; DIOXYGEN; MONOOXYGENASE; PROTEINS		Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Met Biocatalysis, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Aboelella, NW (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	tol-man@chem.umn.edu						Aboelella NW, 2002, J AM CHEM SOC, V124, P10660, DOI 10.1021/ja027164v; Andrews L, 2002, CHEM REV, V102, P885, DOI 10.1021/cr0000729; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Chen P, 2004, J AM CHEM SOC, V126, P4991, DOI 10.1021/ja031564g; Coppens P, 2002, CHEM REV, V102, P861, DOI 10.1021/cr000031c; Evans JP, 2003, J BIOL CHEM, V278, P49691, DOI 10.1074/jbc.M300797200; Francisco WA, 2002, J AM CHEM SOC, V124, P8194, DOI 10.1021/ja025758s; FUJISAWA K, 1994, J AM CHEM SOC, V116, P12079, DOI 10.1021/ja00105a069; Halfen JA, 1996, J AM CHEM SOC, V118, P763, DOI 10.1021/ja952691i; MCCLEVERTY JA, 2004, COMPREHENSIVE COOR 2, V8; Murphy MEP, 1997, J BIOL CHEM, V272, P28455, DOI 10.1074/jbc.272.45.28455; Prigge ST, 2004, SCIENCE, V304, P864, DOI 10.1126/science.1094583; RUGGIERO CE, 1993, J AM CHEM SOC, V115, P11285, DOI 10.1021/ja00077a030; Tocheva EI, 2004, SCIENCE, V304, P867, DOI 10.1126/science.1095109; Wasser IM, 2002, CHEM REV, V102, P1201, DOI 10.1021/cr0006627; Wilmot CM, 1999, SCIENCE, V286, P1724, DOI 10.1126/science.286.5445.1724	16	18	18	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					836	837		10.1126/science.1098301	http://dx.doi.org/10.1126/science.1098301			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131298				2022-12-28	WOS:000221243000032
J	Redfield, MM				Redfield, MM			Understanding "diastolic" heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mayo Clin, Coll Med, Dept Internal Med, Cardiovasc Div,Mayo Heart Failure Program, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Internal Med, Cardiovasc Div,Mayo Cardiorenal Res Lab, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Redfield, MM (corresponding author), Mayo Clin, Coll Med, Dept Internal Med, Cardiovasc Div,Mayo Heart Failure Program, Rochester, MN 55905 USA.								0	70	74	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1930	1931		10.1056/NEJMp048064	http://dx.doi.org/10.1056/NEJMp048064			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128890				2022-12-28	WOS:000221218800002
J	Kirke, PN; Mills, JI; Molloy, AM; Brody, LC; O'Leary, VB; Daly, L; Murray, S; Conley, M; Mayne, PD; Smith, O; Scott, JM				Kirke, PN; Mills, JI; Molloy, AM; Brody, LC; O'Leary, VB; Daly, L; Murray, S; Conley, M; Mayne, PD; Smith, O; Scott, JM			Impact of the MHFR C677T polymorphism on risk of neural tube defects: case-control study	BRITISH MEDICAL JOURNAL			English	Article							5,10-METHYLENETETRAHYDROFOLATE REDUCTASE; HOMOCYSTEINE		Hlth Res Board, Child Hlth Epidemiol Div, Dublin 2, Ireland; NICHHD, Div Epidemiol Stat & Prevent Res, NIH, Epidemiol Sect, Bethesda, MD 20892 USA; Univ Ireland Trinity Coll, St James Hosp, Dept Clin Med, Dublin 8, Ireland; NHGRI, Mol Pathogenesis Sect, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Natl Univ Ireland Univ Coll Dublin, Dept Epidemiol & Publ Hlth Med, Dublin 2, Ireland; Childrens Univ Hosp, Dublin 1, Ireland; Natl Ctr Hereditary Coagulat Disorders, Dublin 8, Ireland	Health Research Board - Ireland; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Trinity College Dublin; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Trinity College Dublin; University College Dublin; Childrens University Hospital - Temple Street	Kirke, PN (corresponding author), Hlth Res Board, Child Hlth Epidemiol Div, Dublin 2, Ireland.	pkirke@hrb.ie	Smith, Owen/AAU-8929-2020	Mills, James/0000-0003-4496-332X; O'Leary, Valerie/0000-0003-1171-9830; Molloy, Anne/0000-0002-1688-9049	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD002502, N01HD023163] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000167] Funding Source: NIH RePORTER; NICHD NIH HHS [N0IHD 23163] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Botto LD, 2000, AM J EPIDEMIOL, V151, P862; Johanning GL, 2000, J MED GENET, V37, P949, DOI 10.1136/jmg.37.12.949; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Shields DC, 1999, AM J HUM GENET, V64, P1045, DOI 10.1086/302310; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202	5	99	104	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 26	2004	328	7455					1535	1536		10.1136/bmj.38036.646030.EE	http://dx.doi.org/10.1136/bmj.38036.646030.EE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DV	15155469	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000222392700019
J	Craft, AW; Hall, DMB				Craft, AW; Hall, DMB			Munchausen syndrome by proxy and sudden infant death	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILD-ABUSE; POSTNATAL DEPRESSION; QT INTERVAL; SUFFOCATION; IDENTIFICATION; PROTECTION; COMPLAINTS; PATTERNS; APNEA; RISK	Media vilification of paediatricians acting in cases of alleged child abuse has resulted in widespread confusion about research data and threatens the systems to protect vulnerable children. How should we move forward?	Royal Victoria Infirm, Sir James Spence Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; No Gen Hosp, Inst Gen Practice, Sheffield S6 6GY, S Yorkshire, England	Newcastle University - UK; Northern General Hospital; University of Sheffield	Hall, DMB (corresponding author), Royal Victoria Infirm, Sir James Spence Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	d.hall@sheffield.ac.uk						Adshead G, 2000, CHILD ABUSE NEGLECT, V24, P1175, DOI 10.1016/S0145-2134(00)00174-5; ASCH SS, 1974, AM J PSYCHIAT, V131, P870; ASCH SS, 1968, J MT SINAI HOSP, V35, P214; ASHER R, 1951, LANCET, V260, P339; Becroft DMO, 1997, PATHOLOGY, V29, P60, DOI 10.1080/00313029700169554; BOOLS C, 1994, CHILD ABUSE NEGLECT, V18, P773, DOI 10.1016/0145-2134(94)00044-1; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CARPENTER RG, 1979, LANCET, V2, P343; Chapman AH, 1996, ARQ NEURO-PSIQUIAT, V54, P127, DOI 10.1590/S0004-282X1996000100022; DIMAIO DJ, 1989, FORENSIC PATHOLOGY, P291; DIMAIO VJM, 1974, J FORENSIC SCI, V19, P744; EMERY J L, 1988, Pediatric Pathology, V8, P171; EMERY JL, 1988, LANCET, V2, P29; EMERY JL, 1993, AM J DIS CHILD, V147, P1097, DOI 10.1001/archpedi.1993.02160340083019; EMINSON DM, 2000, MUNCHAUSEN SYNDROME; FIRSTMAN R, 1998, DEATH INNOCENTS; FISHER GC, 1995, ARCH DIS CHILD, V72, P530, DOI 10.1136/adc.72.6.530; Fleming P., 2000, SUDDEN UNEXPECTED DE; Fleming PJ, 2004, BMJ-BRIT MED J, V328, P331, DOI 10.1136/bmj.328.7435.331; Golden MH, 2003, ARCH DIS CHILD, V88, P105, DOI 10.1136/adc.88.2.105; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; Kmietowicz Z, 2004, BRIT MED J, V328, P601, DOI 10.1136/bmj.328.7440.601; LEFANU J, 2004, SUNDAY TELEGRAP 0125; Levene S, 2004, ARCH DIS CHILD, V89, P443, DOI 10.1136/adc.2003.036202; Marcovitch H, 2002, BRIT MED J, V324, P167; MARKS MN, 1993, MED SCI LAW, V33, P329, DOI 10.1177/002580249303300411; MARKS N., 2003, BMJ-BRIT MED J, V327, P110; McClure RJ, 1996, ARCH DIS CHILD, V75, P57, DOI 10.1136/adc.75.1.57; Meadow R, 1999, ARCH DIS CHILD, V80, P7, DOI 10.1136/adc.80.1.7; MEADOW R, 1990, J PEDIATR-US, V117, P351, DOI 10.1016/S0022-3476(05)81072-8; MEADOW R, 1977, LANCET, V2, P343; MEADOW R, 1995, ARCH DIS CHILD, V72, P534, DOI 10.1136/adc.72.6.534; Milroy CM, 1999, INT J LEGAL MED, V112, P309, DOI 10.1007/s004140050255; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS13, DOI 10.1111/j.1440-1754.1992.tb02724.x; Money J, 1976, Bull Am Acad Psychiatry Law, V4, P351; PITT SE, 1995, B AM ACAD PSYCH LAW, V23, P375; ROGERS D, 1976, BRIT MED J, V1, P793, DOI 10.1136/bmj.1.6013.793; *ROYAL COLL PAED C, 2002, FABR IND ILLN CAR; Sanderson CA, 2002, BRIT J GEN PRACT, V52, P636; SCOTT D, 1992, CHILD ABUSE NEGLECT, V16, P345, DOI 10.1016/0145-2134(92)90044-R; SOUTHALL DP, 1979, ARCH DIS CHILD, V54, P776, DOI 10.1136/adc.54.10.776; SOUTHALL DP, 1986, ARCH DIS CHILD, V61, P327, DOI 10.1136/adc.61.4.327; Southall DP, 2003, ARCH DIS CHILD, V88, P101, DOI 10.1136/adc.88.2.101; Southall DP, 1997, PEDIATRICS, V100, P735, DOI 10.1542/peds.100.5.735; SOUTHALL DP, 1987, ARCH DIS CHILD, V62, P721, DOI 10.1136/adc.62.7.721; SOUTHALL DP, 1987, BRIT MED J, V294, P1637, DOI 10.1136/bmj.294.6588.1637; Stanton J, 2001, ARCH DIS CHILD, V85, P454, DOI 10.1136/adc.85.6.454; STEBBENS VA, 1987, BIOL NEONATE, V51, P129; STEINSCHNEIDER A, 1977, PEDIATRICS, V59, P962; TAYLOR EM, 1990, ARCH DIS CHILD, V65, P535, DOI 10.1136/adc.65.5.535; TAYLOR EM, 1982, ARCH DIS CHILD, V57, P668, DOI 10.1136/adc.57.9.668; Truman Thomas L, 2002, Child Maltreat, V7, P138; Weightman H, 1998, PSYCHOPATHOLOGY, V31, P246, DOI 10.1159/000029046; WILSON AJ, 1988, ANN NY ACAD SCI, V533, P390, DOI 10.1111/j.1749-6632.1988.tb37267.x; WILSON AJ, 1985, BRIT MED J, V290, P497, DOI 10.1136/bmj.290.6467.497; WOLKIND S, 1993, ACTA PAEDIATR, V82, P873, DOI 10.1111/j.1651-2227.1993.tb12583.x	56	17	18	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	2004	328	7451					1309	1312		10.1136/bmj.328.7451.1309	http://dx.doi.org/10.1136/bmj.328.7451.1309			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826PN	15166071	Green Published			2022-12-28	WOS:000221841100028
J	Mitchell, H				Mitchell, H			ABC of sexually transmitted infections - Vaginal discharge - causes, diagnosis, and treatment	BRITISH MEDICAL JOURNAL			English	Review							BACTERIAL VAGINOSIS; CANDIDIASIS	Vaginal discharge is a common presenting symptom seen by doctors in many services (primary care, gynaecology, family planning, and departments of genitourinary medicine). Vaginal discharge may be physiological or pathological. Although abnormal vaginal discharge often prompts women to seek screening for sexually transmitted infections (STIs), vaginal discharge is poorly predictive of the presence of an STI. This article focuses on the causes and diagnosis of vaginal discharge and treatment of the most common infective causes.	Camden Primary Care Trust, Mortimer Market Ctr, London, England		Mitchell, H (corresponding author), Camden Primary Care Trust, Mortimer Market Ctr, London, England.	hmitchell@gum.ucl.ac.uk						DENNING DW, 1995, BRIT MED J, V310, P1241, DOI 10.1136/bmj.310.6989.1241; Hay PE, 1996, INT J STD AIDS, V7, P233, DOI 10.1258/0956462961917898; Hook Er., 1999, SEX TRANSM DIS; Irving G, 1998, SEX TRANSM INFECT, V74, P334, DOI 10.1136/sti.74.5.334; Ison CA, 1997, INT J STD AIDS, V8, P1; Rodgers CA, 1999, INT J STD AIDS, V10, P435, DOI 10.1258/0956462991914429	6	50	60	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 29	2004	328	7451					1306	1308		10.1136/bmj.328.7451.1306	http://dx.doi.org/10.1136/bmj.328.7451.1306			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826PN	15166070	Green Published			2022-12-28	WOS:000221841100027
J	Deloukas, P; Earthrowl, ME; Grafham, DV; Rubenfield, M; French, L; Steward, CA; Sims, SK; Jones, MC; Searle, S; Scott, C; Howe, K; Hunt, SE; Andrews, TD; Gilbert, JGR; Swarbreck, D; Ashurst, JL; Taylor, A; Battles, J; Bird, CP; Ainscough, R; Almeida, JP; Ashwell, RIS; Ambrose, KD; Babbage, AK; Bagguley, CL; Bailey, J; Banerjee, R; Bates, K; Beasley, H; Bray-Allen, S; Brown, AJ; Brown, JY; Burford, DC; Burrill, W; Burton, J; Cahill, P; Camire, D; Carter, NP; Chapman, JC; Clark, SY; Clarke, G; Clee, CM; Clegg, S; Corby, N; Coulson, A; Dhami, P; Dutta, I; Dunn, M; Faulkner, L; Frankish, A; Frankland, JA; Garner, P; Garnett, J; Gribble, S; Griffiths, C; Grocock, R; Gustafson, E; Hammond, S; Harley, JL; Hart, E; Heath, PD; Ho, TP; Hopkins, B; Horne, J; Howden, PJ; Huckle, E; Hynds, C; Johnson, C; Johnson, D; Kana, A; Kay, M; Kimberley, AM; Kershaw, JK; Kokkinaki, M; Laird, GK; Lawlor, S; Lee, HM; Leongamornlert, DA; Laird, G; Lloyd, C; Lloyd, DM; Loveland, J; Lovell, J; McLaren, S; McLay, KE; McMurray, A; Mashreghi-Mohammadi, M; Matthews, L; Milne, S; Nickerson, T; Nguyen, M; Oveton-Larty, E; Palmer, SA; Pearce, AV; Peck, AI; Pelan, S; Phillimore, B; Porter, K; Rice, CM; Rogosin, A; Ross, MT; Sarafidou, T; Sehra, HK; Shownkeen, R; Skuce, CD; Smith, M; Standring, L; Sycamore, N; Tester, J; Thorpe, A; Torcasso, W; Tracey, A; Tromans, A; Tsolas, J; Wall, M; Walsh, J; Wang, H; Weinstock, K; West, AP; Willey, DL; Whitehead, SL; Wilming, L; Wray, PW; Young, L; Chen, Y; Lovering, RC; Moschonas, NK; Siebert, R; Fechtel, K; Bentley, D; Durbin, R; Hubbard, T; Doucette-Stamm, L; Beck, S; Smith, DR; Rogers, J				Deloukas, P; Earthrowl, ME; Grafham, DV; Rubenfield, M; French, L; Steward, CA; Sims, SK; Jones, MC; Searle, S; Scott, C; Howe, K; Hunt, SE; Andrews, TD; Gilbert, JGR; Swarbreck, D; Ashurst, JL; Taylor, A; Battles, J; Bird, CP; Ainscough, R; Almeida, JP; Ashwell, RIS; Ambrose, KD; Babbage, AK; Bagguley, CL; Bailey, J; Banerjee, R; Bates, K; Beasley, H; Bray-Allen, S; Brown, AJ; Brown, JY; Burford, DC; Burrill, W; Burton, J; Cahill, P; Camire, D; Carter, NP; Chapman, JC; Clark, SY; Clarke, G; Clee, CM; Clegg, S; Corby, N; Coulson, A; Dhami, P; Dutta, I; Dunn, M; Faulkner, L; Frankish, A; Frankland, JA; Garner, P; Garnett, J; Gribble, S; Griffiths, C; Grocock, R; Gustafson, E; Hammond, S; Harley, JL; Hart, E; Heath, PD; Ho, TP; Hopkins, B; Horne, J; Howden, PJ; Huckle, E; Hynds, C; Johnson, C; Johnson, D; Kana, A; Kay, M; Kimberley, AM; Kershaw, JK; Kokkinaki, M; Laird, GK; Lawlor, S; Lee, HM; Leongamornlert, DA; Laird, G; Lloyd, C; Lloyd, DM; Loveland, J; Lovell, J; McLaren, S; McLay, KE; McMurray, A; Mashreghi-Mohammadi, M; Matthews, L; Milne, S; Nickerson, T; Nguyen, M; Oveton-Larty, E; Palmer, SA; Pearce, AV; Peck, AI; Pelan, S; Phillimore, B; Porter, K; Rice, CM; Rogosin, A; Ross, MT; Sarafidou, T; Sehra, HK; Shownkeen, R; Skuce, CD; Smith, M; Standring, L; Sycamore, N; Tester, J; Thorpe, A; Torcasso, W; Tracey, A; Tromans, A; Tsolas, J; Wall, M; Walsh, J; Wang, H; Weinstock, K; West, AP; Willey, DL; Whitehead, SL; Wilming, L; Wray, PW; Young, L; Chen, Y; Lovering, RC; Moschonas, NK; Siebert, R; Fechtel, K; Bentley, D; Durbin, R; Hubbard, T; Doucette-Stamm, L; Beck, S; Smith, DR; Rogers, J			The DNA sequence and comparative analysis of human chromosome 10	NATURE			English	Article							HUMAN GENOME SEQUENCE; PERICENTROMERIC SATELLITES; TRANSCRIPTIONAL PROFILE; SEGMENTAL DUPLICATIONS; GENE; MAP; PTEN; MUTATIONS; BOUNDARY; NUMBER	The finished sequence of human chromosome 10 comprises a total of 131,666,441 base pairs. It represents 99.4% of the euchromatic DNA and includes one megabase of heterochromatic sequence within the pericentromeric region of the short and long arm of the chromosome. Sequence annotation revealed 1,357 genes, of which 816 are protein coding, and 430 are pseudogenes. We observed widespread occurrence of overlapping coding genes ( either strand) and identified 67 antisense transcripts. Our analysis suggests that both inter- and intrachromosomal segmental duplications have impacted on the gene count on chromosome 10. Multispecies comparative analysis indicated that we can readily annotate the protein-coding genes with current resources. We estimate that over 95% of all coding exons were identified in this study. Assessment of single base changes between the human chromosome 10 and chimpanzee sequence revealed nonsense mutations in only 21 coding genes with respect to the human sequence.	Genome Therapeut Corp, Waltham, MA 02453 USA; Agencourt Biosci Corp, Beverly, MA 01915 USA; Univ Crete, Dept Biol, Iraklion 71409, Crete, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion 71409, Crete, Greece; UCL, Dept Biol, HUGO Gene Nomenclature Comm, London NW1 2HE, England; Univ Hosp Schleswig Holstein, Inst Human Genet, D-24105 Kiel, Germany	University of Crete; Foundation for Research & Technology - Hellas (FORTH); University of London; University College London; University of Kiel; Schleswig Holstein University Hospital		panos@sanger.ac.uk	Hubbard, Tim J.P./AAT-4571-2020; Deloukas, Panos/B-2922-2013; Hubbard, Tim J/C-2567-2008; Frankish, Adam/G-6545-2011; Andrews, Dan/ABG-4815-2020; Johnson, David/A-3907-2011; Siebert, Reiner/A-8049-2010; Durbin, Richard/AAE-7178-2019	Hubbard, Tim J.P./0000-0002-1767-9318; Deloukas, Panos/0000-0001-9251-070X; Hubbard, Tim J/0000-0002-1767-9318; Johnson, David/0000-0003-0887-3343; Durbin, Richard/0000-0002-9130-1006; Moschonas, Nicholas/0000-0002-2556-537X; Swarbreck, David/0000-0002-5453-1013; Steward, Charles/0000-0001-8829-5349; Fosker, Christine/0000-0002-3799-9474; Wilming, Laurens/0000-0002-4154-7358; Wass, Elizabeth/0000-0002-8605-9921; Hunt, Sarah/0000-0002-8350-1235; Lovering, Ruth/0000-0002-9791-0064; Gilbert, James/0000-0001-8079-3159; Kay, Mike/0000-0002-3282-0834; Howe, Kevin/0000-0002-1751-9226; Frankish, Adam/0000-0002-4333-628X; Loveland, Jane/0000-0002-7669-2934; Leongamornlert, Daniel/0000-0002-3486-3168; Taylor, Amy/0000-0001-9811-330X; Andrews, Dan/0000-0003-3922-6376; Davidson, Claire/0000-0002-4910-8202				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Boutin P, 2003, PLOS BIOL, V1, P361, DOI 10.1371/journal.pbio.0000068; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; BRYCE SD, 1994, GENOMICS, V24, P568, DOI 10.1006/geno.1994.1667; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r25; Crosier M, 2002, GENOME RES, V12, P67, DOI 10.1101/gr.213702; Davuluri RV, 2001, NAT GENET, V29, P412, DOI 10.1038/ng780; Deloukas P., 2000, Cytogenetics and Cell Genetics, V90, P1, DOI 10.1159/000015653; DELOUKAS P, 1993, GENOMICS, V17, P676, DOI 10.1006/geno.1993.1389; Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Down TA, 2002, GENOME RES, V12, P458, DOI 10.1101/gr.216102; DUNHAM I, GENOME MAPPING SEQUE; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Felsenfeld A, 1999, GENOME RES, V9, P1; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Guy J, 2003, GENOME RES, V13, P159, DOI 10.1101/gr.644503; Guy J, 2000, HUM MOL GENET, V9, P2029, DOI 10.1093/hmg/9.13.2029; Jackson MS, 1996, GENOMICS, V33, P258, DOI 10.1006/geno.1996.0190; Kiyosawa H, 2003, GENOME RES, V13, P1324, DOI 10.1101/gr.982903; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Morante-Redolat JM, 2002, HUM MOL GENET, V11, P1119, DOI 10.1093/hmg/11.9.1119; MOSCHONAS NK, 2003, ENCY HUMAN GENOME, V1, P618; Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Roest Crollius H, 2000, NAT GENET, V25, P235, DOI 10.1038/76118; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; SARAFIDOU T, IN PRESS GENOMICS; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Vanaja DK, 2003, CANCER RES, V63, P3877; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; Wain HM, 2002, NUCLEIC ACIDS RES, V30, P169, DOI 10.1093/nar/30.1.169; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185	41	54	751	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					375	381		10.1038/nature02462	http://dx.doi.org/10.1038/nature02462			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164054	Bronze			2022-12-28	WOS:000221644600030
J	Pengo, V; Lensing, AWA; Prins, MH; Marchiori, A; Davidson, BL; Tiozzo, F; Albanese, P; Biasiolo, A; Pegoraro, C; Iliceto, S; Prandoni, P; Razzolini, R; Ramondo, A; Bellotto, F; Noventa, F; Villanova, C; Barbero, F; Casara, D; Nante, G; Tormene, D; Gerosa, G; Testolin, L; Bottio, T; Piovella, F; Vigano, M; D'Armini, A				Pengo, V; Lensing, AWA; Prins, MH; Marchiori, A; Davidson, BL; Tiozzo, F; Albanese, P; Biasiolo, A; Pegoraro, C; Iliceto, S; Prandoni, P; Razzolini, R; Ramondo, A; Bellotto, F; Noventa, F; Villanova, C; Barbero, F; Casara, D; Nante, G; Tormene, D; Gerosa, G; Testolin, L; Bottio, T; Piovella, F; Vigano, M; D'Armini, A		Thromboembolic Pulmonary Hypertens	Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOSIS; CLINICAL COURSE; ANTICOAGULANT; ANGIOGRAPHY; OBSTRUCTION	BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTPH) is associated with considerable morbidity and mortality. Its incidence after pulmonary embolism and associated risk factors are not well documented. METHODS: We conducted a prospective, long-term, follow-up study to assess the incidence of symptomatic CTPH in consecutive patients with an acute episode of pulmonary embolism but without prior venous thromboembolism. Patients with unexplained persistent dyspnea during follow-up underwent transthoracic echocardiography and, if supportive findings were present, ventilation-perfusion lung scanning and pulmonary angiography. CTPH was considered to be present if systolic and mean pulmonary-artery pressures exceeded 40 mm Hg and 25 mm Hg, respectively; pulmonary-capillary wedge pressure was normal; and there was angiographic evidence of disease. RESULTS: The cumulative incidence of symptomatic CTPH was 1.0 percent (95 percent confidence interval, 0.0 to 2.4) at six months, 3.1 percent (95 percent confidence interval, 0.7 to 5.5) at one year, and 3.8 percent (95 percent confidence interval, 1.1 to 6.5) at two years. No cases occurred after two years among the patients with more than two years of follow-up data. The following increased the risk of CTPH: a previous pulmonary embolism (odds ratio, 19.0), younger age (odds ratio, 1.79 per decade), a larger perfusion defect (odds ratio, 2.22 per decile decrement in perfusion), and idiopathic pulmonary embolism at presentation (odds ratio, 5.70). CONCLUSIONS: CTPH is a relatively common, serious complication of pulmonary embolism. Diagnostic and therapeutic strategies for the early identification and prevention of CTPH are needed.	Univ Amsterdam, Acad Med Ctr F4 211, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Univ Hosp Padua, Dept Clin & Expt Med, Div Clin Cardiol, Padua, Italy; Univ Hosp Padua, Dept Med & Surg Sci, Med Clin 2, Padua, Italy; Univ Hosp Padua, Div Geriatr Med, Padua, Italy; Univ Maastricht, Acad Hosp, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands; Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA; Swedish Med Ctr, Seattle, WA USA	University of Amsterdam; Academic Medical Center Amsterdam; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; Azienda Ospedaliera - Universita di Padova; Maastricht University; Maastricht University Medical Centre (MUMC); University of Washington; University of Washington Seattle; Swedish Medical Center	Lensing, AWA (corresponding author), Univ Amsterdam, Acad Med Ctr F4 211, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	awalensing@planet.nl	Noventa, Franco/C-1202-2008; Gerosa, Gino/M-8106-2014; Pengo, Vittorio/GSE-5972-2022; Bottio, Tomaso/AAQ-9040-2020; Bottio, Tomaso/AAC-4207-2021; Piovella, Franco/AAM-8305-2020; Pengo, Vittorio/AAV-9491-2020	Noventa, Franco/0000-0003-4622-5523; Gerosa, Gino/0000-0002-6261-699X; Pengo, Vittorio/0000-0003-2064-6071; Bottio, Tomaso/0000-0001-7299-2983; Pengo, Vittorio/0000-0003-2064-6071				AUGER WR, 1995, AM J MED, V99, P392, DOI 10.1016/S0002-9343(99)80187-9; AUGER WR, 1992, RADIOLOGY, V182, P393, DOI 10.1148/radiology.182.2.1732955; Badorff C, 2000, CIRCULATION, V102, P2276; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; Egermayer P, 2000, EUR RESPIR J, V15, P440, DOI 10.1034/j.1399-3003.2000.15.03.x; Fedullo PF, 2001, NEW ENGL J MED, V345, P1465, DOI 10.1056/NEJMra010902; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; Goldhaber SZ, 1998, NEW ENGL J MED, V339, P93, DOI 10.1056/NEJM199807093390207; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Koopman MMW, 1997, NEW ENGL J MED, V337, P1251; Lensing AWA, 1999, LANCET, V353, P479, DOI 10.1016/S0140-6736(98)04298-6; MEYER G, 1990, EUR J NUCL MED, V17, P315, DOI 10.1007/BF01268022; MILLER GAH, 1971, BRIT MED J, V2, P681, DOI 10.1136/bmj.2.5763.681; Otto CM, 2000, TXB CLIN ECHOCARDIOG, P123; Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Torbicki A, 2000, EUR HEART J, V21, P1301; vanBeek EJR, 1997, ARCH INTERN MED, V157, P2593, DOI 10.1001/archinte.157.22.2593; Wolf M, 2000, EUR RESPIR J, V15, P395, DOI 10.1034/j.1399-3003.2000.15b28.x	20	1216	1282	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2257	2264		10.1056/NEJMoa032274	http://dx.doi.org/10.1056/NEJMoa032274			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163775				2022-12-28	WOS:000221641900006
J	Luman, ET; Fiore, AE; Strine, TW; Barker, LE				Luman, ET; Fiore, AE; Strine, TW; Barker, LE			Impact of thimerosal-related changes in hepatitis B vaccine birth-dose recommendations on childhood vaccination coverage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; IMMUNIZATION; CHILDREN; MERCURY; AGE	Context In July 1999, the longstanding preference to begin hepatitis B vaccination of all US infants at birth was temporarily suspended because of concerns about exposure to mercury contained in the vaccine preservative thimerosal. The suspension was lifted in September 1999 when preservative-free hepatitis B vaccine became available. Objective To determine the effects of changes in recommendations regarding administration of a hepatitis B birth dose on vaccination coverage. Design, Setting, and Participants Cohort analysis of vaccination status of 41589 US children born before, during, and after the recommendation to suspend the birth dose. Main Outcome Measures Association between birth cohort and age at receipt of hepatitis B vaccine dose 1, and receipt by 19 months of age of all recommended vaccines. Results The proportion of US infants who received dose 1 of hepatitis B vaccine at birth declined from 47% among those born 7 to 12 months before the suspension to 11% among those born during the suspension. Birth-dose coverage remained significantly lower in the year after the suspension was lifted (23% in the first 6 months and 33% in months 7-12). Coverage with 3 doses of hepatitis B vaccine by 19 months of age declined from 88% among those born 7 to 12 months before the suspension to 81% among those born during the suspension and 85% among those born in the 6 months after the suspension, but returned to baseline levels for those born 7 to 12 months after the suspension was lifted. These reductions represent 750000 fewer newborns vaccinated during 2000 compared with 1998, and an excess 182000 children undervaccinated for hepatitis B at 19 months of age compared with 1998 coverage levels. Coverage with other recommended vaccinations did not decline over this time. Conclusions' Reductions in hepatitis B vaccine birth-dose coverage persisted after recommendations were made to resume previous newborn vaccination practices. Although the recommendation to complete the series by 19 months of age was never changed, infants born between July and December 1999 were less likely to have completed the series by 19 months, compared with infants born during the previous year. The lack of impact on other vaccinations suggests that public confidence in immunization remained strong.	Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Emory Univ, Sch Publ Hlth, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University	Luman, ET (corresponding author), Ctr Dis Control & Prevent, Natl Immunizat Program, 1600 Clifton Rd NE,Mail Stop E-62, Atlanta, GA 30333 USA.	ECL7@cdc.gov	Fiore, Anthony/AAO-8956-2020					[Anonymous], 2002, CENS 2000 BAS; [Anonymous], 1991, MMWR-MORBID MORTAL W, V40, P1; [Anonymous], [No title captured]; Armstrong GL, 2001, PEDIATRICS, V108, P1123, DOI 10.1542/peds.108.5.1123; Ball LK, 2001, PEDIATRICS, V107, P1147, DOI 10.1542/peds.107.5.1147; Barker L, 2002, MMWR Morb Mortal Wkly Rep, V51, P664; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; Biroscak BJ, 2003, PEDIATRICS, V111, pE645, DOI 10.1542/peds.111.6.e645; Brayden RM, 2001, J PEDIATR-US, V138, P752, DOI 10.1067/mpd.2001.112896; Cabana MD, 2002, AMBUL PEDIATR, V2, P367, DOI 10.1367/1539-4409(2002)002<0367:EOSVFS>2.0.CO;2; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P94; *CDCP, 2002, GUID VIR HEP SURV CA; *CDCP, 1996, MMWR-MORBID MORTAL W, V44, P940; *CDCP, 2001, VIT STAT US 1999, V1; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P563; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P19; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P1007; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P829; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P963; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P996; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P780; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P203; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P637; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P585; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P547; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P176; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P893; Clark SJ, 2001, ARCH PEDIAT ADOL MED, V155, P915, DOI 10.1001/archpedi.155.8.915; Clarkson TW, 2003, NEW ENGL J MED, V349, P1731, DOI 10.1056/NEJMra022471; Cooper A, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e98; DALAKER J., 1998, CURRENT POPULATION R, VP60-201; DeStefano Frank, 2004, Expert Rev Vaccines, V3, P19, DOI 10.1586/14760584.3.1.19; EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197, DOI 10.1098/rspb.1993.0102; Ehresman K., 1999, Morbidity and Mortality Weekly Report, V48, P577; Frankel MR, 2003, STAT MED, V22, P1611, DOI 10.1002/sim.1515; Freed GL, 2002, PEDIATRICS, V109, P1153, DOI 10.1542/peds.109.6.1153; Hurie MB, 2001, PEDIATRICS, V107, P755, DOI 10.1542/peds.107.4.755; Lauderdale DS, 1999, JAMA-J AM MED ASSOC, V282, P1725, DOI 10.1001/jama.282.18.1725; Madsen KM, 2003, PEDIATRICS, V112, P604, DOI 10.1542/peds.112.3.604; MARGOLIS HS, 1995, JAMA-J AM MED ASSOC, V274, P1201, DOI 10.1001/jama.274.15.1201; Martin Joyce A, 2002, Natl Vital Stat Rep, V50, P1; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; Oram RJ, 2001, JAMA-J AM MED ASSOC, V285, P1874, DOI 10.1001/jama.285.14.1874; Pichichero ME, 2002, LANCET, V360, P1737, DOI 10.1016/S0140-6736(02)11682-5; Research Triangle Institute, 2001, SUDAAN US MAN REL 8; Smith PJ, 2001, AM J PREV MED, V20, P17, DOI 10.1016/S0749-3797(01)00285-9; SMITH PJ, 2001, VITAL HLTH STAT SERI, V2; Stokley S, 2001, AM J PREV MED, V20, P55, DOI 10.1016/S0749-3797(01)00280-X; Stratton K, 2001, IMMUNIZATION SAFETY; Ventura S J, 2001, Natl Vital Stat Rep, V49, P1; Verstraeten T, 2003, PEDIATRICS, V112, P1039, DOI 10.1542/peds.112.2.e98; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Yusuf HR, 2000, JAMA-J AM MED ASSOC, V284, P978, DOI 10.1001/jama.284.8.978; Zell ER, 2000, PUBLIC HEALTH REP, V115, P65, DOI 10.1093/phr/115.1.65; 1995, MMWR MORB MORTAL WKL, V44, P613; 1995, MMWR MORB MORTAL WKL, V44, P621; 1995, MMWR MORB MORTAL WKL, V44, P619	57	24	25	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2004	291	19					2351	2358		10.1001/jama.291.19.2351	http://dx.doi.org/10.1001/jama.291.19.2351			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821JD	15150207	Bronze			2022-12-28	WOS:000221455400023
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Services Task Force	Screening for suicide risk: Recommendation and rationale	ANNALS OF INTERNAL MEDICINE			English	Article								This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendations on screening for suicide risk and the supporting scientific evidence and updates the 1996 recommendations on this topic. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the systematic evidence review on this topic, which is available through the USPSTF Web site (www.preventiveservices.ahrq.gov) and through the National Guideline Clearinghouse (www.guideline.gov). The complete recommendation statement and the summary of the evidence are also available from the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov).	Univ Washington, Seattle, WA 98195 USA; Univ Maryland, Baltimore, MD 21201 USA; Tri Cty Family Med, Cohocton, NY USA; Natl Initiat Childrens Healthcare Qual, Boston, MA USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Univ Rochester, Sch Med, Rochester, NY 14627 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Robert Wood Johnson Fdn, Princeton, NJ USA; Women & Infants Hosp Rhode Isl, Providence, RI USA; Univ Michigan, Ann Arbor, MI 48109 USA; Mt Sinai Med Ctr, New York, NY 10029 USA; Merck & Co Inc, West Point, PA USA; Columbia Univ, New York, NY USA; Virginia Commonwealth Univ, Fairfax, VA USA	University of Washington; University of Washington Seattle; University System of Maryland; University of Maryland Baltimore; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Rochester; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Robert Wood Johnson Foundation (RWJF); Women & Infants Hospital Rhode Island; University of Michigan System; University of Michigan; Icahn School of Medicine at Mount Sinai; Merck & Company; Columbia University; Virginia Commonwealth University	Berg, AO (corresponding author), Univ Washington, Seattle, WA 98195 USA.							American Medical Association, 1997, GUIDELINES ADOLESCEN; MCNAMEE JE, 1994, CANADIAN GUIDE CLIN, P456; Shaffer D, 2001, J AM ACAD CHILD PSY, V40, p24S, DOI 10.1097/00004583-200107001-00003; 2000, PEDIATRICS 1, V105, P871	4	31	31	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					820	821		10.7326/0003-4819-140-10-200405180-00014	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	822EX	15148071				2022-12-28	WOS:000221520900009
J	Cyranoski, D; Chou, IH				Cyranoski, D; Chou, IH			Winds of change blow away the cobwebs on campus	NATURE			English	Article																			0	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	2004	429	6988					210	214		10.1038/429210a	http://dx.doi.org/10.1038/429210a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141219				2022-12-28	WOS:000221356300049
J	Miller, WC; Ford, CA; Morris, M; Handcock, MS; Schmitz, JL; Hobbs, MM; Cohen, MS; Harris, KM; Udry, JR				Miller, WC; Ford, CA; Morris, M; Handcock, MS; Schmitz, JL; Hobbs, MM; Cohen, MS; Harris, KM; Udry, JR			Prevalence of chlamydial and gonococcal infections among young adults in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRACHOMATIS INFECTION; RISK BEHAVIORS; CARE; EPIDEMIOLOGY; ADOLESCENTS; POLICY; WOMEN; BLACK; CITY	Context Chlamydial and gonococcal infections are important causes of pelvic inflammatory disease, ectopic pregnancy, and infertility. Although screening for Chlamydia trachomatis is widely recommended among young adult women, little information is available regarding the prevalence of chlamydial and gonococcal infections in the general young adult population. Objective To determine the prevalence of chlamydial and gonoccoccal infections in a nationally representative sample of young adults living in the United States. Design, Setting, and Participants Cross-sectional analyses of a prospective cohort study of a nationally representative sample of 14322 young adults aged 18 to 26 years. In-home interviews were conducted across the United States for Wave III of The National Longitudinal Study of Adolescent Health (Add Health) from April 2, 2001, to May 9, 2002. This study sample represented 66.3% of the original 18924 participants in Wave I of Add Health. First-void urine specimens using ligase chain reaction assay were available for 12548 (87.6%) of the Wave III participants. Main Outcome Measures Prevalences of chlamydial and gonococcal infections in the general young adult population, and by age, self-reported race/ethnicity, and geographic region of current residence. Results Overall prevalence of chlamydial infection was 4.19% (95% confidence interval [CI], 3.48%-4.90%). Women (4.74%; 95% CI, 3.93%-5.71%) were more likely to be infected than men (3.67%; 95% CI, 2.93%-4.58%; prevalence ratio, 1.29; 95% CI 1.03-1.63). The prevalence of chlamydial infection was highest among black women (13.95%; 95% CI, 11.25%-17.18%) and black men (11.12%; 95% CI, 8.51%14.42%); lowest prevalences were among Asian men (1.14%; 95% CI, 0.40%-3.21%), white men (1.38%; 95% CI, 0.93%-2.03%), and white women (2.52%; 95% CI, 1.90%-3.34%). Prevalence of chlamydial infection was highest in the south (5.39%; 95% CI, 4.24%-6.83%) and lowest in the northeast (2.39%; 95% CI, 1.56%-3.65%). Overall prevalence of gonorrhea was 0.43% (95% CI, 0.29%-0.63%). Among black men and women, the prevalence was 2.13% (95% CI, 1.46%-3.10%) and among white young adults, 0.10% (95% CI, 0.03%-0.27%). Prevalence of coinfection with both chlamydial and gonococcal infections was 0.030% (95% CI, 0.18%-0.49%). Conclusions The prevalence of chlamydial infection is high among young adults in the United States. Substantial racial/ethnic disparities are present in the prevalence of both chlamydial and gonococcal infections.	Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC USA; Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC USA; Univ N Carolina, Dept Sociol, Chapel Hill, NC USA; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA; Univ Washington, Dept Sociol, Seattle, WA 98195 USA; Univ Washington, Dept Stat, Seattle, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Miller, WC (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, CB 7435,2105F Mcgavran Greenburg, Chapel Hill, NC 27599 USA.	bill_miller@unc.edu	Handcock, Mark S./AAY-3318-2021; Miller, William C/H-4800-2014; Schmitz, John/AAF-9053-2019; Schmitz, John/HHS-0634-2022	Handcock, Mark S./0000-0002-9985-2785; Miller, William C/0000-0002-1934-7827; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD042828, P01HD031921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041877, R01HD038210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012831] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		*ADD HLTH BIOM TEA, BIOM WAV 3 ADD HLTH; *AM AC FAM PHYS, SUMM POL REC PER HLT; American Academy of Pediatrics, 2000, PEDIATRICS, V105, P645; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BEARMAN PS, NATL LONGITUDINAL ST; Brookmeyer R., 1994, AIDS EPIDEMIOLOGY QU; BRUNHAM RC, 1990, MED CLIN N AM, V74, P1339, DOI 10.1016/S0025-7125(16)30484-9; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; *CDCP, 2002, SEX TRANSM DIS SURV; Centers of Disease Control and Prevention, 2000, SEX TRANSM DIS SURV; Childs James E., 1993, Morbidity and Mortality Weekly Report, V42, P1; Cook RL, 2001, J ADOLESCENT HEALTH, V28, P204, DOI 10.1016/S1054-139X(00)00152-X; Fang J, 2000, J URBAN HEALTH, V77, P735, DOI 10.1007/BF02344034; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Hollblad-Fadiman K, 2003, AM J PREV MED, V24, P287, DOI 10.1016/S0749-3797(02)00636-0; Hook E. W., 1999, SEXU LLY TRANSMITTED, P451; Johnson Robert E, 2002, MMWR Recomm Rep, V51, P1; Klausner JD, 2001, J INFECT DIS, V183, P1087, DOI 10.1086/319276; Ku L, 2002, AM J PUBLIC HEALTH, V92, P1140, DOI 10.2105/AJPH.92.7.1140; Mangione-Smith R, 2000, ARCH PEDIAT ADOL MED, V154, P1108, DOI 10.1001/archpedi.154.11.1108; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Miller WC, 2000, AM J PREV MED, V18, P115, DOI 10.1016/S0749-3797(99)00146-4; *NAT COMM QUAL ASS, 2001, STAT MAN CAR QUAL; Nelson HD, 2001, AM J PREV MED, V20, P95, DOI 10.1016/S0749-3797(01)00253-7; ODONNELL L, 1994, SEX TRANSM DIS, V21, P137, DOI 10.1097/00007435-199405000-00003; QUINN K, THEIR OWN YOUNG ADUL; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Resnick MD, 1997, JAMA-J AM MED ASSOC, V278, P823, DOI 10.1001/jama.278.10.823; Sandman D, OUT TOUCH AM MEN HLT; Saraiya M, 1999, AM J EPIDEMIOL, V149, P1025; St Lawrence JS, 2002, AM J PUBLIC HEALTH, V92, P1784, DOI 10.2105/AJPH.92.11.1784; TILSON EC, 2001, PREV MED 2001 SCI SY; Torkko KC, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e32; Turner CF, 2002, JAMA-J AM MED ASSOC, V287, P726, DOI 10.1001/jama.287.6.726; Udry JR, 2003, SOC SCI RES, V32, P294, DOI 10.1016/S0049-089X(02)00060-1; Wallin KL, 2002, INT J CANCER, V101, P371, DOI 10.1002/ijc.10639; Watson EJ, 2002, J MED MICROBIOL, V51, P1021, DOI 10.1099/0022-1317-51-12-1021; WESTROM L, 1999, SEXUALLY TRANSMITTED, P783	38	429	442	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2004	291	18					2229	2236		10.1001/jama.291.18.2229	http://dx.doi.org/10.1001/jama.291.18.2229			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GR	15138245	Green Submitted			2022-12-28	WOS:000221303500025
J	Ryan, J; Piercy, J; James, P				Ryan, J; Piercy, J; James, P			Assessment of NICE guidance on two surgical procedures	LANCET			English	Article								The National Institute of Excellence (NICE) released its first guidance in 2000 on clinical procedures and technologies in England and Wales. Using hospital activity data, we looked at the effect of NICE guidance on wisdom tooth extraction and primary total hip replacement in the UK National Health Service. We selected hospitals that submitted their activity continuously between 1997 and 2002. Analysis of wisdom tooth extraction showed that NICE guidance was not the primary reason for the downward trend in extractions (p=0.8287); this trend was more likely to be attributable to previous guidance. For total hip replacement there was no significant change in behaviour away from use of non-cemented hip prostheses. Therefore, NICE guidance has had little effect on behaviour for these two procedures.	Mapi Values Ltd, Bollington SK10 5JB, Cheshire, England; Thames Valley Univ, London, England; CHKS Ltd, Alcester, Warwick, England; Univ York, York YO10 5DD, N Yorkshire, England	University of West London; University of York - UK	Ryan, J (corresponding author), Mapi Values Ltd, Bollington SK10 5JB, Cheshire, England.	james.ryan@mapivalues.com						*FAC DENT SURG, 1997, NAT CLIN GUID 1997; Maddala GS, 2001, INTRO ECONOMETRICS; *NAT I CLIN EXC, 2000, 2 NAT I CLIN EXC; *NAT I CLIN EXC, 2000, 1 NAT I CLINE XC; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Thwaites R, 2004, ACTA PAEDIATR, V93, P23, DOI 10.1080/08035320310021011	6	24	24	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	2004	363	9420					1525	1526		10.1016/S0140-6736(04)16180-1	http://dx.doi.org/10.1016/S0140-6736(04)16180-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135602				2022-12-28	WOS:000221302700014
J	Scofield, RH				Scofield, RH			Autoantibodies as predictors of disease	LANCET			English	Review							STEROID 21-HYDROXYLASE AUTOANTIBODIES; CLINICAL ADDISONS-DISEASE; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASES; ADRENOCORTICAL AUTOANTIBODIES; ADRENAL AUTOANTIBODIES; LUPUS-ERYTHEMATOSUS; ADULT PATIENTS; HEART-BLOCK; FOLLOW-UP		Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA; Dept Vet Affairs Med Ctr, Oklahoma City, OK USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Scofield, RH (corresponding author), Oklahoma Med Res Fdn, Arthrit & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	hal-scofield@omrf.ouhsc.edu	Scofield, Robert Hal/AEJ-8314-2022					Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Betterle C, 1997, J CLIN ENDOCR METAB, V82, P939, DOI 10.1210/jc.82.3.939; Betterle C, 1997, J CLIN ENDOCR METAB, V82, P932, DOI 10.1210/jc.82.3.932; Betterle C, 2002, ENDOCR REV, V23, P327, DOI 10.1210/er.23.3.327; BETTERLE C, 1983, LANCET, V1, P1238; De Bellis A, 2001, J CLIN ENDOCR METAB, V86, P675, DOI 10.1210/jc.86.2.675; DEBELLIS A, 1993, J CLIN ENDOCR METAB, V76, P1002, DOI 10.1210/jc.76.4.1002; Ferber KM, 1999, J CLIN ENDOCR METAB, V84, P2342, DOI 10.1210/jc.84.7.2342; Hahl J, 1998, DIABETOLOGIA, V41, P79, DOI 10.1007/s001250050870; Iijima T, 1998, ANN RHEUM DIS, V57, P460, DOI 10.1136/ard.57.8.460; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Julkunen H, 2001, ARTHRITIS RHEUM, V44, P647, DOI 10.1002/1529-0131(200103)44:3<647::AID-ANR113>3.3.CO;2-9; KETCHUM CH, 1984, J CLIN ENDOCR METAB, V58, P1166, DOI 10.1210/jcem-58-6-1166; Kisand KE, 2001, J GASTROENTEROL, V36, P248, DOI 10.1007/s005350170111; Kita M, 2002, J ENDOCRINOL INVEST, V25, P513, DOI 10.1007/BF03345493; Kuijpens JL, 1998, J CLIN ENDOCR METAB, V83, P1959, DOI 10.1210/jc.83.6.1959; Kupila A, 2001, DIABETOLOGIA, V44, P290, DOI 10.1007/s001250051616; LaGasse JM, 2002, DIABETES CARE, V25, P505, DOI 10.2337/diacare.25.3.505; Laureti S, 1998, J CLIN ENDOCR METAB, V83, P3507, DOI 10.1210/jc.83.10.3507; MCCUNE AB, 1987, ANN INTERN MED, V106, P518, DOI 10.7326/0003-4819-106-4-518; Nielen MMJ, 2004, ARTHRITIS RHEUM-US, V50, P380, DOI 10.1002/art.20018; Notkins AL, 2001, J CLIN INVEST, V108, P1247, DOI 10.1172/JCI200114257; Rantapaa-Dahlqvist S, 2003, ARTHRITIS RHEUM, V48, P2741, DOI 10.1002/art.11223; Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295; WALTUCK J, 1994, ANN INTERN MED, V120, P544, DOI 10.7326/0003-4819-120-7-199404010-00003	25	172	187	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	2004	363	9420					1544	1546		10.1016/S0140-6736(04)16154-0	http://dx.doi.org/10.1016/S0140-6736(04)16154-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135604				2022-12-28	WOS:000221302700024
J	Cartigny, P; Chinn, I; Viljoen, KS; Robinson, D				Cartigny, P; Chinn, I; Viljoen, KS; Robinson, D			Early proterozoic ultrahigh pressure metamorphism: Evidence from microdiamonds	SCIENCE			English	Article							NITROGEN AGGREGATION; PERIDOTITIC DIAMONDS; KOKCHETAV MASSIF; ISOTOPE RATIOS; ROCKS; CARBON; INCLUSIONS; GARNET; KINETICS; COESITE	Microdiamonds from the Akluilak minette dykes (Nunavut, Canada) are similar to diamonds formed in subducted metamorphic rocks. High concentrations of unaggregated nitrogen and positive delta(15)N suggest that the microdiamonds formed within rocks subducted to ultrahigh pressures before being sampled by the minette magma 1.8 billion years ago. This ultrahigh pressure metamorphism in North America, probably related to the Trans-Hudson orogen ( about 2 billion years ago), extends the occurrence of ultrahigh pressure metamorphism from 0.6 billion years to before 1.8 billion years ago and suggests that Phanerozoic-type subductions were active by the Early Proterozoic.	Inst Phys Globe, Lab Geochim Isotopes Stables, UMR 7047, F-75251 Paris 05, France; De Beers Consolidated Mines Ltd, Geosci Ctr, ZA-2135 Johannesburg, South Africa	UDICE-French Research Universities; Universite Paris Cite	Cartigny, P (corresponding author), Inst Phys Globe, Lab Geochim Isotopes Stables, UMR 7047, 2 Pl Jussieu, F-75251 Paris 05, France.	cartigny@ipgp.jussieu.fr	Cartigny, Pierre/A-6251-2011; Chinn, Ingrid/ABE-9561-2021	Chinn, Ingrid/0000-0002-5796-6194				BARDET MG, 1977, MEMOIRES BRGM, P166; Beaumont V, 1999, PRECAMBRIAN RES, V96, P63, DOI 10.1016/S0301-9268(99)00005-4; BOYD SR, 1992, EARTH PLANET SC LETT, V109, P633, DOI 10.1016/0012-821X(92)90121-B; BOYD SR, 1995, MEAS SCI TECHNOL, V6, P297, DOI 10.1088/0957-0233/6/3/007; BOYD SR, 1994, CHEM GEOL, V116, P29, DOI 10.1016/0009-2541(94)90156-2; BOYD SR, 1987, EARTH PLANET SC LETT, V86, P341, DOI 10.1016/0012-821X(87)90231-7; Brueckner HK, 2002, EARTH PLANET SC LETT, V203, P805, DOI 10.1016/S0012-821X(02)00919-6; Cartigny P, 2003, GEOCHIM COSMOCHIM AC, V67, P1571, DOI 10.1016/S0016-7037(03)00028-0; Cartigny P, 2001, CHEM GEOL, V176, P265, DOI 10.1016/S0009-2541(00)00407-1; Cartigny P, 1997, TERRA NOVA, V9, P175, DOI 10.1046/j.1365-3121.1997.d01-26.x; CARTIGNY P, UNPUB; CHINN I, UNPUB; CHOPIN C, 1984, CONTRIB MINERAL PETR, V86, P107, DOI 10.1007/BF00381838; Chopin C, 2003, EARTH PLANET SC LETT, V212, P1, DOI 10.1016/S0012-821X(03)00261-9; Davies R., 1999, P 7 INT KIMB C, P148; DAVIES R, 2003, 8 INT KIMB C VICT CA; De Corte K, 1998, GEOCHIM COSMOCHIM AC, V62, P3765, DOI 10.1016/S0016-7037(98)00266-X; De Corte K., 1999, P 7 INT KIMB C APR 1, P174; Deines P, 1997, GEOCHIM COSMOCHIM AC, V61, P3993, DOI 10.1016/S0016-7037(97)00199-3; DOBRZHINETSKAYA LF, 1995, GEOLOGY, V23, P597, DOI 10.1130/0091-7613(1995)023<0597:MIHGMR>2.3.CO;2; DYER HB, 1965, PHILOS MAG, V11, P763, DOI 10.1080/14786436508230081; EVANS T, 1982, PROC R SOC LON SER-A, V381, P159, DOI 10.1098/rspa.1982.0063; FINNIE KS, 1994, GEOCHIM COSMOCHIM AC, V58, P5173, DOI 10.1016/0016-7037(94)90302-6; Galimov E. M., 1985, GEOCHEM INT, V22, P18; Harris J.W., 1992, PROPERTIES NATURAL S, P345; Jahn B, 2001, CHEM GEOL, V178, P143, DOI 10.1016/S0009-2541(01)00264-9; KAMINSKY FV, 2000, IZVESTYA ES, V4, P85; MacRae N.D., 1995, INT GEOL REV, V37, P212; Maruyama S, 1998, ISL ARC, V7, P6; Massonne H.-J., 1999, P 7 INT KIMB C CAP T, P533; MCCALLUM ME, 1991, CPRM SPECIAL PUBLICA, P32; McCandless T.E., 1991, CPRM SPECIAL PUBLICA, V2, P78; Mingram B, 2001, GEOCHIM COSMOCHIM AC, V65, P273, DOI 10.1016/S0016-7037(00)00517-2; NAVON O, 1988, NATURE, V335, P784, DOI 10.1038/335784a0; Parkinson CD, 1999, GEOLOGY, V27, P979, DOI 10.1130/0091-7613(1999)027<0979:PDUPCO>2.3.CO;2; RICHARDSON SH, 1984, NATURE, V310, P198, DOI 10.1038/310198a0; ROBINSON DH, 1989, KIMBERLITES RELATED, V2, P991; ROBINSON DN, 1979, MANTLE SAMPLE INCLUS, P50; SCHRAUDER M, 1997, THESIS U WIEN AUSTRI; Shelkov DA, 1998, METEORIT PLANET SCI, V33, P985, DOI 10.1111/j.1945-5100.1998.tb01705.x; SOBOLEV NV, 1990, NATURE, V343, P742, DOI 10.1038/343742a0; Stachel T, 2003, LITHOS, V71, P489, DOI 10.1016/S0024-4937(03)00127-0; Stockhert B, 2001, GEOLOGY, V29, P391, DOI 10.1130/0091-7613(2001)029<0391:MDCPFS>2.0.CO;2; Taylor WR, 1996, GEOCHIM COSMOCHIM AC, V60, P4725, DOI 10.1016/S0016-7037(96)00302-X; TRAUTMAN RL, 1997, RUSS GEOL GEOPHYS, V38, P341; van Roermund HLM, 2002, GEOLOGY, V30, P959, DOI 10.1130/0091-7613(2002)030<0959:MIAMGW>2.0.CO;2; WOODS GS, 1983, J PHYS CHEM SOLIDS, V44, P471, DOI 10.1016/0022-3697(83)90078-1; XU ST, 1992, SCIENCE, V256, P80, DOI 10.1126/science.256.5053.80; Zhao GC, 2002, EARTH-SCI REV, V59, P125, DOI 10.1016/S0012-8252(02)00073-9	49	33	35	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					853	855		10.1126/science.1094668	http://dx.doi.org/10.1126/science.1094668			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131301				2022-12-28	WOS:000221243000038
J	Cooper, JS; Pajak, TF; Forastiere, AA; Jacobs, J; Campbell, BH; Saxman, SB; Kish, JA; Kim, HE; Cmelak, AJ; Rotman, M; Machtay, M; Ensley, JF; Chao, KSC; Schultz, CJ; Lee, N; Fu, KK				Cooper, JS; Pajak, TF; Forastiere, AA; Jacobs, J; Campbell, BH; Saxman, SB; Kish, JA; Kim, HE; Cmelak, AJ; Rotman, M; Machtay, M; Ensley, JF; Chao, KSC; Schultz, CJ; Lee, N; Fu, KK		Rad Therapy Oncology Grp 9501	Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOCALLY ADVANCED HEAD; RADIATION-THERAPY; RANDOMIZED-TRIAL; CONCOMITANT CHEMOTHERAPY; EUROPEAN-ORGANIZATION; CANCER; CHEMORADIOTHERAPY; RTOG; PRESERVATION; IRRADIATION	BACKGROUND Despite the use of resection and postoperative radiotherapy, high-risk squamous-cell carcinoma of the head and neck frequently recurs in the original tumor bed. We tested the hypothesis that concurrent postoperative administration of cisplatin and radiotherapy would improve the rate of local and regional control. METHODS Between September 9, 1995, and April 28, 2000, 459 patients were enrolled. After undergoing total resection of all visible and palpable disease, 231 patients were randomly assigned to receive radiotherapy alone ( 60 to 66 Gy in 30 to 33 fractions over a period of 6 to 6.6 weeks) and 228 patients to receive the identical treatment plus concurrent cisplatin (100 mg per square meter of body-surface area intravenously on days 1, 22, and 43). RESULTS After a median follow-up of 45.9 months, the rate of local and regional control was significantly higher in the combined-therapy group than in the group given radiotherapy alone ( hazard ratio for local or regional recurrence, 0.61; 95 percent confidence interval, 0.41 to 0.91; P = 0.01). The estimated two-year rate of local and regional control was 82 percent in the combined-therapy group, as compared with 72 percent in the radiotherapy group. Disease-free survival was significantly longer in the combined-therapy group than in the radiotherapy group ( hazard ratio for disease or death, 0.78; 95 percent confidence interval, 0.61 to 0.99; P= 0.04), but overall survival was not ( hazard ratio for death, 0.84; 95 percent confidence interval, 0.65 to 1.09; P= 0.19). The incidence of acute adverse effects of grade 3 or greater was 34 percent in the radiotherapy group and 77 percent in the combined-therapy group ( P< 0.001). Four patients who received combined therapy died as a direct result of the treatment. CONCLUSIONS Among high-risk patients with resected head and neck cancer, concurrent postoperative chemotherapy and radiotherapy significantly improve the rates of local and regional control and disease-free survival. However, the combined treatment is associated with a substantial increase in adverse effects.	NYU Med Ctr, New York, NY 10016 USA; Radiat Therapy Oncol Grp Headquarters, Philadelphia, PA USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA; Wayne State Univ, Sch Med, Detroit, MI USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; NCI, Bethesda, MD 20892 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; Vanderbilt Canc Ctr, Nashville, TN USA; SUNY Hlth Ctr Brooklyn, Brooklyn, NY USA; Univ Penn Hlth Syst, Philadelphia, PA USA; Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	New York University; Radiation Therapy Oncology Group (RTOG); Johns Hopkins University; Johns Hopkins Medicine; Wayne State University; Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Vanderbilt University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Pennsylvania; Washington University (WUSTL); University of California System; University of California San Francisco	Cooper, JS (corresponding author), NYU Med Ctr, New York, NY 10016 USA.			Campbell, Bruce/0000-0001-9485-5728	NATIONAL CANCER INSTITUTE [U10CA021661, U10CA032115] Funding Source: NIH RePORTER; NCI NIH HHS [CA32115, CA21661] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelstein DJ, 2000, CANCER, V88, P876, DOI 10.1002/(SICI)1097-0142(20000215)88:4<876::AID-CNCR19>3.0.CO;2-Y; Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Bernier J., 2001, International Journal of Radiation Oncology Biology Physics, V51, P1, DOI 10.1016/S0360-3016(01)01825-9; Bernier J, 2004, NEW ENGL J MED, V350, P1945, DOI 10.1056/NEJMoa032641; Brizel DM, 1998, NEW ENGL J MED, V338, P1798, DOI 10.1056/NEJM199806183382503; Calais G, 1999, J NATL CANCER I, V91, P2081, DOI 10.1093/jnci/91.24.2081; Cooper JS, 1999, JAMA-J AM MED ASSOC, V281, P1623, DOI 10.1001/jama.281.17.1623; Cooper JS, 1998, HEAD NECK-J SCI SPEC, V20, P588, DOI 10.1002/(SICI)1097-0347(199810)20:7<588::AID-HED2>3.3.CO;2-6; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705, DOI 10.1016/0360-3016(92)90642-U; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	19	2132	2186	0	61	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1937	1944		10.1056/NEJMoa032646	http://dx.doi.org/10.1056/NEJMoa032646			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128893				2022-12-28	WOS:000221218800005
J	Fu, Q; Johanson, CM; Warren, SG; Seidel, DJ				Fu, Q; Johanson, CM; Warren, SG; Seidel, DJ			Contribution of stratospheric cooling to satellite-inferred tropospheric temperature trends	NATURE			English	Article							SURFACE	From 1979 to 2001, temperatures observed globally by the mid-tropospheric channel of the satellite-borne Microwave Sounding Unit (MSU channel 2), as well as the inferred temperatures in the lower troposphere, show only small warming trends of less than 0.1 K per decade (refs 1 - 3). Surface temperatures based on in situ observations however, exhibit a larger warming of similar to0.17 K per decade ( refs 4, 5), and global climate models forced by combined anthropogenic and natural factors project an increase in tropospheric temperatures that is somewhat larger than the surface temperature increase(6-8). Here we show that trends in MSU channel 2 temperatures are weak because the instrument partly records stratospheric temperatures whose large cooling trend(9) offsets the contributions of tropospheric warming. We quantify the stratospheric contribution to MSU channel 2 temperatures using MSU channel 4, which records only stratospheric temperatures. The resulting trend of reconstructed tropospheric temperatures from satellite data is physically consistent with the observed surface temperature trend. For the tropics, the tropospheric warming is similar to1.6 times the surface warming, as expected for a moist adiabatic lapse rate.	Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA; NOAA, Air Resources Lab, Silver Spring, MD 20910 USA	University of Washington; University of Washington Seattle; National Oceanic Atmospheric Admin (NOAA) - USA	Fu, Q (corresponding author), Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA.	qfu@atmos.washington.edu	Fu, Qiang/W-5836-2019					Bengtsson L, 1999, J GEOPHYS RES-ATMOS, V104, P3865, DOI 10.1029/1998JD200046; Christy JR, 2000, J ATMOS OCEAN TECH, V17, P1153, DOI 10.1175/1520-0426(2000)017<1153:MTTDCA>2.0.CO;2; CHRISTY JR, 1995, J CLIMATE, V8, P888, DOI 10.1175/1520-0442(1995)008<0888:RNITMD>2.0.CO;2; Christy JR, 2003, J ATMOS OCEAN TECH, V20, P613, DOI 10.1175/1520-0426(2003)20<613:EEOVOM>2.0.CO;2; Christy JR, 1998, J CLIMATE, V11, P2016, DOI 10.1175/1520-0442-11.8.2016; Gaffen DJ, 2000, J CLIMATE, V13, P1776, DOI 10.1175/1520-0442(2000)013<1776:SOTAST>2.0.CO;2; HANSEN J, 1995, CLIMATIC CHANGE, V30, P103, DOI 10.1007/BF01093228; Hansen J, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001143; Hegerl GC, 2002, J CLIMATE, V15, P2412, DOI 10.1175/1520-0442(2002)015<2412:IOPOCV>2.0.CO;2; Houghton J. T., 2001, CLIMATE CHANGE 2001; Hurrell JW, 1997, NATURE, V386, P164, DOI 10.1038/386164a0; Hurrell JW, 1998, J CLIMATE, V11, P945, DOI 10.1175/1520-0442(1998)011<0945:DIORTT>2.0.CO;2; Jones PD, 2003, J CLIMATE, V16, P206, DOI 10.1175/1520-0442(2003)016<0206:HALSSA>2.0.CO;2; Lanzante JR, 2003, J CLIMATE, V16, P224, DOI 10.1175/1520-0442(2003)016<0224:THOMRT>2.0.CO;2; Mears CA, 2003, J CLIMATE, V16, P3650, DOI 10.1175/1520-0442(2003)016<3650:AROTMC>2.0.CO;2; Mo T, 2001, J GEOPHYS RES-ATMOS, V106, P10145, DOI 10.1029/2001JD900027; Prabhakara C, 2000, GEOPHYS RES LETT, V27, P3517, DOI 10.1029/2000GL011719; Ramaswamy V, 2001, REV GEOPHYS, V39, P71, DOI 10.1029/1999RG000065; Santer BD, 2003, SCIENCE, V300, P1280, DOI 10.1126/science.1082393; Santer BD, 2000, SCIENCE, V287, P1227, DOI 10.1126/science.287.5456.1227; SEIDEL DJ, IN PRESS J CLIM; Singer SF, 2001, NATURE, V409, P281, DOI 10.1038/35053324; SPENCER RW, 1992, J CLIMATE, V5, P858, DOI 10.1175/1520-0442(1992)005<0858:PARVOS>2.0.CO;2; SPENCER RW, 1990, SCIENCE, V247, P1558, DOI 10.1126/science.247.4950.1558; STONE PH, 1979, J ATMOS SCI, V36, P415, DOI 10.1175/1520-0469(1979)036<0415:ALRRAT>2.0.CO;2; Trenberth KE, 1997, NATURE, V389, P342, DOI 10.1038/38640-c1; Vinnikov KY, 2003, SCIENCE, V302, P269, DOI 10.1126/science.1087910; WALLACE JM, 2000, RECONCILING OBSERVAT; Wentz FJ, 2000, NATURE, V403, P414, DOI 10.1038/35000184; Wentz FJ, 1998, NATURE, V394, P661, DOI 10.1038/29267	30	153	159	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 6	2004	429	6987					55	58		10.1038/nature02524	http://dx.doi.org/10.1038/nature02524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129277				2022-12-28	WOS:000221222100041
J	Shorter, J; Lindquist, S				Shorter, J; Lindquist, S			Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers	SCIENCE			English	Article							TERMINAL ATPASE DOMAIN; PROPAGATION; CHAPERONE; COMMUNICATION; DETERMINANT; INHERITANCE; MECHANISM; FIBERS; SYSTEM; PSI+	The protein-remodeling factor Hsp104 governs inheritance of [PSI+], a yeast prion formed by self-perpetuating amyloid conformers of the translation termination factor Sup35. Perplexingly, either excess or insufficient Hsp104 eliminates [PSI+]. In vitro, at low concentrations, Hsp104 catalyzed the formation of oligomeric intermediates that proved critical for the nucleation of Sup35 fibrillization de novo and displayed a conformation common among amyloidogenic polypeptides. At higher Hsp104 concentrations, amyloidogenic oligomerization and contingent fibrillization were abolished. Hsp104 also disassembled mature fibers in a manner that initially exposed new surfaces for conformational replication but eventually exterminated prion conformers. These Hsp104 activities differed in their reaction mechanism and can explain [PSI+] inheritance patterns.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Lindquist, S (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lindquist_admin@wi.mit.edu	Shorter, James/ABE-7307-2020; Shorter, James/E-8207-2011	Shorter, James/0000-0001-5269-8533; 	NIGMS NIH HHS [GM25874] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025874, R01GM025874] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Hattendorf DA, 2002, P NATL ACAD SCI USA, V99, P2732, DOI 10.1073/pnas.261693199; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Huff ME, 2003, CURR OPIN STRUC BIOL, V13, P674, DOI 10.1016/j.sbi.2003.10.010; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kimura Y, 2003, CELL STRUCT FUNCT, V28, P187; Kryndushkin DS, 2003, J BIOL CHEM, V278, P49636, DOI 10.1074/jbc.M307996200; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Liu JJ, 2002, P NATL ACAD SCI USA, V99, P16446, DOI 10.1073/pnas.252652099; Narayanan S, 2003, P NATL ACAD SCI USA, V100, P9286, DOI 10.1073/pnas.1233535100; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Scheibel T, 2004, P NATL ACAD SCI USA, V101, P2287, DOI 10.1073/pnas.0308754101; Scheibel T, 2001, NAT STRUCT BIOL, V8, P958, DOI 10.1038/nsb1101-958; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Serio TR, 2002, ADV PROTEIN CHEM, V59, P391; SHORTER J, UNPUB; Si K, 2003, CELL, V115, P879, DOI 10.1016/S0092-8674(03)01020-1; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Wegrzyn RD, 2001, MOL CELL BIOL, V21, P4656, DOI 10.1128/MCB.21.14.4656-4669.2001	27	376	382	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1793	1797		10.1126/science.1098007	http://dx.doi.org/10.1126/science.1098007			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15155912				2022-12-28	WOS:000222089500043
J	Wright, P				Wright, P			Sarwar Jehan Zuberi - Obituary	LANCET			English	Biographical-Item												xeq87@dial.pipex.com							0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	2004	363	9422					1739	1739		10.1016/S0140-6736(04)16277-6	http://dx.doi.org/10.1016/S0140-6736(04)16277-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15160726				2022-12-28	WOS:000221546300040
J	Lybarger, SR; Sandkvist, M				Lybarger, SR; Sandkvist, M			A hitchhiker's guide to type IV secretion	SCIENCE			English	Editorial Material							AGROBACTERIUM-TUMEFACIENS; SYSTEMS; PLANT		Amer Red Cross, Jerome H Holland Lab, Dept Biochem, Rockville, MD 20855 USA	American Red Cross	Lybarger, SR (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Biochem, Rockville, MD 20855 USA.	sandkvis@usa.redcross.org						Burns DL, 2003, CURR OPIN MICROBIOL, V6, P29, DOI 10.1016/S1369-5274(02)00006-1; Cascales E, 2004, SCIENCE, V304, P1170, DOI 10.1126/science.1095211; Cascales E, 2003, NAT REV MICROBIOL, V1, P137, DOI 10.1038/nrmicro753; Ding ZY, 2003, TRENDS MICROBIOL, V11, P527, DOI 10.1016/j.tim.2003.09.004; Escobar MA, 2003, TRENDS PLANT SCI, V8, P380, DOI 10.1016/S1360-1385(03)00162-6; Mason HS, 2002, TRENDS MOL MED, V8, P324, DOI 10.1016/S1471-4914(02)02360-2; Nagai H, 2003, CELL MICROBIOL, V5, P373, DOI 10.1046/j.1462-5822.2003.00285.x; Valentine L, 2003, PLANT PHYSIOL, V133, P948, DOI 10.1104/pp.103.032243; Yeo HJ, 2004, J BACTERIOL, V186, P1919, DOI 10.1128/JB.186.7.1919-1926.2004; 2002, 194 WHO	10	8	9	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1122	1123		10.1126/science.1098806	http://dx.doi.org/10.1126/science.1098806			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155939				2022-12-28	WOS:000221524500030
J	Lanzetti, L; Palamidessi, A; Areces, L; Scita, G; Di Fiore, PP				Lanzetti, L; Palamidessi, A; Areces, L; Scita, G; Di Fiore, PP			Rab5 is a signalling GTPase involved in actin remodelling by receptor tyrosine kinases	NATURE			English	Article							EPIDERMAL-GROWTH-FACTOR; ALPHA-ACTININ; NUCLEOTIDE EXCHANGE; STIMULATED CELLS; RHO GTPASES; RAS; MACROPINOCYTOSIS; ACTIVATION; BINDING; EPS8	Rab5 is a small GTPase involved in the control of intracellular trafficking, both at the level of receptor endocytosis and endosomal dynamics(1). The finding that Rab5 can be activated by receptor tyrosine kinases (RTK)(2) raised the question of whether it also participates in effector pathways emanating from these receptors. Here we show that Rab5 is indispensable for a form of RTK-induced actin remodelling, called circular ruffling. Three independent signals, originating from Rab5, phosphatidylinositol-3-OH kinase and Rac, respectively, are simultaneously required for the induction of circular ruffles. Rab5 signals to the actin cytoskeleton through RN-tre, a previously identified Rab5-specific GTPase-activating protein (GAP)(3). Here we demonstrate that RN-tre has the dual function of Rab(5)-GAP and Rab5 effector. We also show that RN-tre is critical for macropinocytosis, a process previously connected to the formation of circular ruffles(4,5). Finally, RN-tre interacts with both F-actin and actinin-4, an F-actin bundling protein. We propose that RN-tre establishes a three-pronged connection with Rab5, F-actin and actinin-4. This may aid crosslinking of actin fibres into actin networks at the plasma membrane. Thus, we have shown that Rab5 is a signalling GTPase and have elucidated the major molecular elements of its downstream pathway.	Ist Europeo Oncol, I-20141 Milan, Italy; Ist FIRC Oncol Mol, IFOM, I-20139 Milan, Italy; Univ Milan, Dipartimento Med Chirurg & Odontoiatria, I-20122 Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; University of Milan	Di Fiore, PP (corresponding author), Ist Europeo Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	difiore@ifom-firc.it	Palamidessi, Andrea/F-1203-2018; Scita, Giorgio/J-9670-2012; Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; palamidessi, andrea/0000-0002-7134-7023; Scita, Giorgio/0000-0001-7984-1889; LANZETTI, Letizia/0000-0001-7541-5524				Araki N, 2000, J CELL SCI, V113, P3329; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Benmerah A, 1999, J CELL SCI, V112, P1303; Corgan AM, 2004, BIOCHEM J, V378, P1067, DOI 10.1042/BJ20031124; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Fraley TS, 2003, J BIOL CHEM, V278, P24039, DOI 10.1074/jbc.M213288200; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schafer DA, 2002, CURR BIOL, V12, P1852, DOI 10.1016/S0960-9822(02)01228-9; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Seastone DJ, 2001, J CELL SCI, V114, P2673; Spaargaren M, 1999, MOL BIOL CELL, V10, P3239, DOI 10.1091/mbc.10.10.3239; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	29	219	233	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					309	314		10.1038/nature02542	http://dx.doi.org/10.1038/nature02542			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152255				2022-12-28	WOS:000221505900046
J	Serwer, BA; Barold, HS				Serwer, BA; Barold, HS			Pericardial cyst	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									USN, Med Ctr, Bethesda, MD 20889 USA	United States Department of Defense; United States Navy	Serwer, BA (corresponding author), USN, Med Ctr, Bethesda, MD 20889 USA.								0	2	2	1	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					E19	E19		10.1056/ENEJMicm030196	http://dx.doi.org/10.1056/ENEJMicm030196			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152075				2022-12-28	WOS:000221496700011
J	Barnes, KI; Mwenechanya, J; Tembo, M; Mcilleron, H; Folb, PI; Ribeiro, I; Little, F; Gomes, M; Molyneux, ME				Barnes, KI; Mwenechanya, J; Tembo, M; Mcilleron, H; Folb, PI; Ribeiro, I; Little, F; Gomes, M; Molyneux, ME			Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised study	LANCET			English	Article							PLASMODIUM-FALCIPARUM MALARIA; ARTEMISININ DERIVATIVES; MALAWIAN CHILDREN; CEREBRAL MALARIA; IN-VIVO; MEFLOQUINE; ARTEMETHER; TRIAL; DIHYDROARTEMISININ; SUPPOSITORY	Background Many patients with malaria of increasing severity cannot take medicines orally, and delay in injectable treatment can be fatal. We aimed to assess the reliability of absorption, antimalarial efficacy, and tolerability of a single rectal dose of artesunate in the initial management of moderately severe falciparum malaria. Methods 109 children and 35 adults were randomly assigned to rectal artesunate (single dose of about 10 mg/kg) or parenteral quinine treatment (10 mg/kg at 0, 4, and 12 h). The primary endpoint was the proportion of patients with peripheral asexual parasitaemia of less than 60% of that at baseline after 12 h. Secondary endpoints were clinical response and concentrations of drug in plasma. Analysis was by intention-to-treat. Findings All artesunate-treated patients had pharmacodynamic or pharmacokinetic evidence of adequate drug absorption. 80 (92%) of 87 artesunate-treated children had a 12 h parasite density lower than 60% of baseline, compared with three of 22 (14%) receiving quinine (relative risk 0.09 [95% CI 0.04-0.19]; p<0.0001). In adults, parasitaemia at 12 h was lower than 60% of baseline in 26 (96%) of 27 receiving artesunate, compared with three (38%) of eight receiving quinine (relative risk 0.06 [0.01-0.44]; p=0.0009). These differences were greater at 24 h. Clinical response was equivalent with rectal artesunate and parenteral quinine. Interpretation A single rectal dose of artesunate is associated with rapid reduction in parasite density in adults and children with moderately severe malaria, within the initial 24 h of treatment. This option is useful for initiation of treatment in patients unable to take oral medication, particularly where parenteral treatment is unavailable.	Univ Cape Town, Div Pharmacol, ZA-7700 Rondebosch, South Africa; Univ Cape Town, Dept Stat Sci, ZA-7700 Rondebosch, South Africa; Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi; Coll Med, Malaria Project, Blantyre, Malawi; Univ Malawi, Coll Med, Dept Paediat, Zomba, Malawi; Univ Liverpool, UNDP World Bank WHO Special Program Res & Trainin, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Sch Trop Med, Liverpool L69 3BX, Merseyside, England	University of Cape Town; University of Cape Town; University of Malawi; University of Malawi; University of Malawi; University of Liverpool; Liverpool School of Tropical Medicine; University of Liverpool	Molyneux, ME (corresponding author), Box 30096, Blantyre 3, Malawi.	mmolyneux@malawi.net		McIlleron, Helen/0000-0002-0982-6226; Little, Francesca/0000-0002-5917-9928				Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Awad MI, 2003, AM J TROP MED HYG, V68, P153, DOI 10.4269/ajtmh.2003.68.153; BARRADELL LB, 1995, DRUGS, V50, P714, DOI 10.2165/00003495-199550040-00009; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; Bhatia M, 1996, EXP HEMATOL, V24, P59; Bredenkamp BLF, 2001, SAMJ S AFR MED J, V91, P970; Brewer T G, 1998, Med Trop (Mars), V58, P22; BREWER TG, 1994, T ROY SOC TROP MED H, V88, P33, DOI 10.1016/0035-9203(94)90469-3; BREWER TG, 1994, AM J TROP MED HYG, V51, P251, DOI 10.4269/ajtmh.1994.51.251; Brockman A, 2000, T ROY SOC TROP MED H, V94, P537, DOI 10.1016/S0035-9203(00)90080-4; BUNNAG D, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P534; Day NPJ, 2000, CRIT CARE MED, V28, P1833, DOI 10.1097/00003246-200006000-00025; EDUARDO A, 1996, JPN J TROP MED HYG, V24, P17; Genovese RF, 1998, BRAIN RES BULL, V45, P199, DOI 10.1016/S0361-9230(97)00339-0; Gogtay NJ, 2000, ANN TROP MED PARASIT, V94, P519, DOI 10.1080/00034983.2000.11813571; GU HM, 1984, T ROY SOC TROP MED H, V78, P265, DOI 10.1016/0035-9203(84)90296-7; Halpaap B, 1998, AM J TROP MED HYG, V58, P365, DOI 10.4269/ajtmh.1998.58.365; JANSE CJ, 1994, INT J PARASITOL, V24, P589, DOI 10.1016/0020-7519(94)90150-3; Johann-Liang R, 2003, CLIN INFECT DIS, V36, P1626; Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0; Kissinger E, 2000, AM J TROP MED HYG, V63, P48, DOI 10.4269/ajtmh.2000.63.48; LOOAREESUWAN S, 1995, ANN TROP MED PARASIT, V89, P469, DOI 10.1080/00034983.1995.11812979; Looareesuwan S, 1997, AM J TROP MED HYG, V57, P348, DOI 10.4269/ajtmh.1997.57.348; LOOAREESUWAN S, 1992, AM J TROP MED HYG, V47, P794, DOI 10.4269/ajtmh.1992.47.794; Luxemburger C, 1998, T ROY SOC TROP MED H, V92, P668, DOI 10.1016/S0035-9203(98)90807-0; LUXEMBURGER C, 1995, AM J TROP MED HYG, V53, P522, DOI 10.4269/ajtmh.1995.53.522; MANSOR SM, 1990, T ROY SOC TROP MED H, V84, P482, DOI 10.1016/0035-9203(90)90007-2; MOLYNEUX ME, 1989, Q J MED, V71, P441; Murphy S, 1996, T ROY SOC TROP MED H, V90, P298, DOI 10.1016/S0035-9203(96)90260-6; Navaratnam V, 1997, J CHROMATOGR B, V692, P157, DOI 10.1016/S0378-4347(96)00505-1; NOSTEN F, 1994, J INFECT DIS, V170, P971, DOI 10.1093/infdis/170.4.971; PLOWE CV, 2004, BMJ; Price R, 1999, AM J TROP MED HYG, V60, P547, DOI 10.4269/ajtmh.1999.60.547; Ranford-Cartwright LC, 1997, T ROY SOC TROP MED H, V91, P719, DOI 10.1016/S0035-9203(97)90539-3; Ribeiro I R, 1998, Med Trop (Mars), V58, P50; RINGWALD P, 1995, ANN SOC BELG MED TR, V75, P141; SHWE T, 1988, T ROY SOC TROP MED H, V82, P665, DOI 10.1016/0035-9203(88)90187-3; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8; Stepniewska K, 2001, T ROY SOC TROP MED H, V95, P637, DOI 10.1016/S0035-9203(01)90104-X; Taylor TE, 1998, TROP MED INT HEALTH, V3, P3, DOI 10.1046/j.1365-3156.1998.00166.x; Thwe Y, 1996, JPN J TROP MED HYG, V24, P25; Van Vugt M, 2000, AM J TROP MED HYG, V62, P65, DOI 10.4269/ajtmh.2000.62.65; WHITE DR, 1992, MEAS SCI TECHNOL, V3, P1, DOI 10.1088/0957-0233/3/1/001; White N, 1999, TROP MED INT HEALTH, V4, P469, DOI 10.1046/j.1365-3156.1999.00435.x; WHITE NJ, 1994, T ROY SOC TROP MED H, V88, P1, DOI 10.1016/0035-9203(94)90458-8	45	64	65	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	2004	363	9421					1598	1605		10.1016/S0140-6736(04)16203-X	http://dx.doi.org/10.1016/S0140-6736(04)16203-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145633				2022-12-28	WOS:000221408800010
J	Russell, J; Greenhalgh, T; Boynton, P; Rigby, M				Russell, J; Greenhalgh, T; Boynton, P; Rigby, M			Soft networks for bridging the gap between research and practice: illuminative evaluation of CHAIN	BRITISH MEDICAL JOURNAL			English	Article							KNOWLEDGE; CARE; ORGANIZATION; MANAGEMENT	Objectives To explore the process of knowledge exchange in an informal email network for evidence based health care, to illuminate the value of the service and its critical success factors, and to identify areas for improvement. Design Illuminative evaluation Setting Targeted email and networking service for UK healthcare practitioners and researchers. Participants 2800 members of a networking service. Main outcome measures Tracking of email messages, interviews with core staff, and a qualitative analysis of messages, postings from focus groups, and invited and unsolicited feedback to the service. Results The informal email network helped to bridge the gap between research and practice by serving as a rich source of information, providing access to members' experiences, suggestions, and ideas, facilitating cross boundary collaboration, and enabling participation in networking at a variety of levels. Ad hoc groupings and communities of practice emerged spontaneously as members discovered common areas of interest. Conclusion This study illuminated how knowledge for evidence based health care can be targeted, personalised, and made meaningful through informal social processes. Critical success factors include a broad based membership from both the research and service communities; a loose and fluid network structure; fight targeting of messages based on members' interests; the presence of a strong network identity and culture of reciprocity; and the opportunity for new members to learn through passive participation.	UCL, Dept Primary Hlth Care, London N19 5LW, England	University of London; University College London	Russell, J (corresponding author), UCL, Dept Primary Hlth Care, London N19 5LW, England.	j.russell@pcps.ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Boynton, Petra/0000-0001-6699-2266				[Anonymous], 1995, KNOWLEDGE CREATION C; Bate SP, 2002, PUBLIC ADMIN, V80, P643, DOI 10.1111/1467-9299.00322; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; BROWN JS, 2000, SOCIAL LIFE INFORMAT; Cuba E.G., 1989, 4 GENERATION EVALUAT; Dopson S, 2001, J Health Serv Res Policy, V6, P23, DOI 10.1258/1355819011927161; Dunning M., 1999, EXPERIENCE EVIDENCE; Edwards N, 2001, CLIN NETWORKS DISCUS; ERAUT M, 1999, INFORMAL LEARNING; Evans D., 2000, IMPLEMENTING CHANGES; Fenton E, 2001, FAM PRACT, V18, P540, DOI 10.1093/fampra/18.5.540; Ferlie E., 2001, ORG BEHAV ORG STUDIE; GARVIN DA, 1993, HARVARD BUS REV, V71, P78; GRANOVETTER MS, 1973, AM J SOCIOL, V78, P1360, DOI 10.1086/225469; Grol R, 2001, JAMA-J AM MED ASSOC, V286, P2578, DOI 10.1001/jama.286.20.2578; Guba E., 1989, 4 GENERATION EVALUAT; HIPPEL EV, 1991, MANAGE SCI, V44, P429; Kushner S., 1996, EVALUATION-US, V2, P189, DOI [10.1177/135638909600200205, DOI 10.1177/135638909600200205]; Lave J., 1988, COGNITION PRACTICE, DOI DOI 10.1017/CBO9780511609268; Lomas J, 1997, IMPROVING RES DISSEM; NEEDHAM G, 2000, USING EVIDENCE HLTH; NONAKA I, 1994, ORGAN SCI, V5, P14, DOI 10.1287/orsc.5.1.14; NONNECKE B, 2002, USENET COWEBS INTERA; PARLETT M, 1972, NUMBERS GAME READER; Patton MQ., 1997, UTILIZATION FOCUSED; Polanyi M., 1962, TACIT DIMENSION; RUSSELL J, 2003, CHAIN EVALUATION REP; SAFFRON I, 2000, FUTURE CHAIN EVALUAT; Spencer L, 2003, QUALITY QUALITATIVE; URQUHART C, 2002, COMMUNITIES PRACTICE; Urquhart C, 2002, NELH COMMUNITIES PRA; WELLMAN B., 1997, CULTURE INTERNET; Wenger Etienne, 1996, COMMUNITIES PRACTICE; West E, 1999, SOC SCI MED, V48, P633, DOI 10.1016/S0277-9536(98)00361-X; Wyatt JC, 2001, J ROY SOC MED, V94, P6, DOI 10.1177/014107680109400102	35	53	54	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 15	2004	328	7449					1174	1177		10.1136/bmj.328.7449.1174	http://dx.doi.org/10.1136/bmj.328.7449.1174			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142924	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000221497500025
J	Palme, H				Palme, H			The giant impact formation of the Moon	SCIENCE			English	Editorial Material							ORIGIN; HYPOTHESIS		Univ Cologne, Inst Geol & Mineral, D-50674 Cologne, Germany	University of Cologne	Palme, H (corresponding author), Univ Cologne, Inst Geol & Mineral, D-50674 Cologne, Germany.	palme@gwp-min.min.uni-koeln.de						BENZ W, 1986, ICARUS, V66, P515, DOI 10.1016/0019-1035(86)90088-6; BENZ W, 1987, ICARUS, V71, P30, DOI 10.1016/0019-1035(87)90160-6; Canup RM, 2004, ICARUS, V168, P433, DOI 10.1016/j.icarus.2003.09.028; Jones J. H., 2000, ORIGIN EARTH MOON, P197, DOI DOI 10.1016/0016-7037(83)90024-8.; Melosh H. J, COMMUNICATION; Melosh HJ., 2000, LUNAR PLANETARY SCI, P1903; Munker C, 2003, SCIENCE, V301, P84, DOI 10.1126/science.1084662; Palme H, 2001, PHILOS T ROY SOC A, V359, P2061, DOI 10.1098/rsta.2001.0897; WANKE H, 1986, ORIGIN MOON, P649; Weyer S, 2002, CHEM GEOL, V187, P295, DOI 10.1016/S0009-2541(02)00129-8; [No title captured]	12	9	9	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	2004	304	5673					977	979		10.1126/science.1097059	http://dx.doi.org/10.1126/science.1097059			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143271				2022-12-28	WOS:000221383300036
J	Markel, H				Markel, H			Becoming a physician - "I swear by Apollo" - On taking the Hippocratic Oath	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Markel, H (corresponding author), Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA.							Carey EJ, 1928, BULL ASSOC AM MED CO, V3, P159; Edelstein L, 1967, ANCIENT MED SELECTED; Nutton V, 1995, J ROY COLL PHYS LOND, V29, P518; Orr RD, 1997, J CLIN ETHIC, V8, P377; Smith DC, 1996, J HIST MED ALL SCI, V51, P484	5	48	49	2	21	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2026	2029		10.1056/NEJMp048092	http://dx.doi.org/10.1056/NEJMp048092			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141039				2022-12-28	WOS:000221354000002
J	Ritz, T; Thalau, P; Phillips, JB; Wiltschko, R; Wiltschko, W				Ritz, T; Thalau, P; Phillips, JB; Wiltschko, R; Wiltschko, W			Resonance effects indicate a radical-pair mechanism for avian magnetic compass	NATURE			English	Article							EUROPEAN ROBINS; MIGRATORY BIRDS; FIELD DETECTION; HOMING PIGEONS; ORIENTATION; MODEL; ANIMALS; RECOMBINATION; LIGHT	Migratory birds are known to use the geomagnetic field as a source of compass information(1,2). There are two competing hypotheses for the primary process underlying the avian magnetic compass, one involving magnetite(3-5), the other a magnetically sensitive chemical reaction(6-8). Here we show that oscillating magnetic fields disrupt the magnetic orientation behaviour of migratory birds. Robins were disoriented when exposed to a vertically aligned broadband (0.1 - 10 MHz) or a single-frequency (7-MHz) field in addition to the geomagnetic field. Moreover, in the 7-MHz oscillating field, this effect depended on the angle between the oscillating and the geomagnetic fields. The birds exhibited seasonally appropriate migratory orientation when the oscillating field was parallel to the geomagnetic field, but were disoriented when it was presented at a 24degrees or 48degrees angle. These results are consistent with a resonance effect on singlet - triplet transitions and suggest a magnetic compass based on a radical-pair mechanism(7,8).	Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA; Univ Frankfurt, Inst Zool, Fachbereich Biol & Informat, D-60054 Frankfurt, Germany; Virginia Tech, Dept Biol, Blacksburg, VA 24061 USA	University of California System; University of California Irvine; Goethe University Frankfurt; Virginia Polytechnic Institute & State University	Ritz, T (corresponding author), Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA.	tritz@uci.edu	Ritz, Thorsten/B-5260-2008	Ritz, Thorsten/0000-0002-2713-539X				Batschelet E., 1981, CIRCULAR STAT BIOL; Beason R.C., 1991, P1813; BEASON RC, 1984, NATURE, V309, P151, DOI 10.1038/309151a0; Beason RC, 1996, J EXP BIOL, V199, P1241; CANFIELD JM, 1994, CHEM PHYS, V182, P1, DOI 10.1016/0301-0104(93)E0442-X; Cintolesi F, 2003, CHEM PHYS, V294, P385, DOI 10.1016/S0301-0104(03)00320-3; Edmonds DT, 1996, P ROY SOC B-BIOL SCI, V263, P295, DOI 10.1098/rspb.1996.0045; Fleissner G, 2003, J COMP NEUROL, V458, P350, DOI 10.1002/cne.10579; KIRSCHVINK JL, 1981, BIOSYSTEMS, V13, P181, DOI 10.1016/0303-2647(81)90060-5; KIRSCHVINK JL, 1992, SOC GEN PHY, V47, P225; Kirschvink JL, 1996, BIOELECTROMAGNETICS, V17, P187, DOI 10.1002/(SICI)1521-186X(1996)17:3<187::AID-BEM4>3.0.CO;2-#; Kobayashi A, 1995, ADV CHEM SER, V250, P367; LEASK MJM, 1977, NATURE, V267, P144, DOI 10.1038/267144a0; Munro U, 1997, NATURWISSENSCHAFTEN, V84, P26, DOI 10.1007/s001140050343; Ritz T, 2000, BIOPHYS J, V78, P707, DOI 10.1016/S0006-3495(00)76629-X; SCHULTEN K, 1982, FESTKOR-ADV SOLID ST, V22, P61, DOI 10.1007/BFb0107935; SEMM P, 1990, BRAIN RES BULL, V25, P735, DOI 10.1016/0361-9230(90)90051-Z; Shcherbakov VP, 1999, EUR BIOPHYS J BIOPHY, V28, P380, DOI 10.1007/s002490050222; Timmel CR, 2001, CHEM PHYS LETT, V334, P387, DOI 10.1016/S0009-2614(00)01436-6; Weaver JC, 2000, NATURE, V405, P707, DOI 10.1038/35015128; WILTSCHK.W, 1972, SCIENCE, V176, P62, DOI 10.1126/science.176.4030.62; Wiltschko R., 1995, TIEROSYCHOL; WILTSCHKO W, 1993, NATURE, V364, P525, DOI 10.1038/364525a0; Wiltschko W, 1998, J EXP BIOL, V201, P3257; Wiltschko W, 2002, NATURWISSENSCHAFTEN, V89, P445, DOI 10.1007/s00114-002-0356-5; Wiltschko W, 2002, NATURE, V419, P467, DOI 10.1038/nature00958; Wiltschko W, 1999, J COMP PHYSIOL A, V184, P295, DOI 10.1007/s003590050327; Wiltschko W, 2001, NATURWISSENSCHAFTEN, V88, P387, DOI 10.1007/s001140100248; Wiltschko W., 1978, ANIMAL MIGRATION NAV, P302, DOI [10.1007/978-3-662-11147-5_29, DOI 10.1007/978-3-662-11147-5_29]	29	392	405	4	155	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	2004	429	6988					177	180		10.1038/nature02534	http://dx.doi.org/10.1038/nature02534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141211				2022-12-28	WOS:000221356300040
J	Speed, C				Speed, C			ABC of rheumatology - Low back pain	BRITISH MEDICAL JOURNAL			English	Review									Addenbrookes Hosp, Cambridge, England	Addenbrooke's Hospital; University of Cambridge	Speed, C (corresponding author), Addenbrookes Hosp, Cambridge, England.								0	47	53	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 8	2004	328	7448					1119	1121		10.1136/bmj.328.7448.1119	http://dx.doi.org/10.1136/bmj.328.7448.1119			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130982	Green Published			2022-12-28	WOS:000221281000025
J	Izquierdo, I; Cammarota, M				Izquierdo, I; Cammarota, M			Zif and the survival of memory	SCIENCE			English	Editorial Material							RECONSOLIDATION		Univ Fed Rio Grande do Sul, Dept Bioquim, Ctr Memoria, BR-90035003 Porto Alegre, RS, Brazil	Universidade Federal do Rio Grande do Sul	Izquierdo, I (corresponding author), Univ Fed Rio Grande do Sul, Dept Bioquim, Ctr Memoria, Ramiro Barcelos 2600 Anexo, BR-90035003 Porto Alegre, RS, Brazil.	izquier@terra.com.br	Cammarota, Martin/AAC-7478-2021	Cammarota, Martin/0000-0001-9741-5074; Izquierdo, Ivan/0000-0002-7208-0869				Anderson MC, 2004, SCIENCE, V303, P232, DOI 10.1126/science.1089504; Barros DM, 2003, CNS NEUROL DISORD-DR, V2, P81, DOI 10.2174/1568007033482931; BORGES JL, 1989, OBRAS COMPLETAS, V1, P485; Debiec J, 2002, NEURON, V36, P527, DOI 10.1016/S0896-6273(02)01001-2; Frankland PW, 2004, SCIENCE, V304, P881, DOI 10.1126/science.1094804; Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799; Lee JLC, 2004, SCIENCE, V304, P839, DOI 10.1126/science.1095760; Moser EI, 1998, SCIENCE, V281, P2038, DOI 10.1126/science.281.5385.2038; Myers KM, 2002, NEURON, V36, P567, DOI 10.1016/S0896-6273(02)01064-4; Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052; Rescorla RA, 2001, J EXP PSYCHOL-ANIM B, V27, P115, DOI 10.1037//0097-7403.27.2.115; Vianna MR, 2004, CURR NEUROVASC RES, V1, P55, DOI 10.2174/1567202043480170	12	28	29	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					829	830		10.1126/science.1098139	http://dx.doi.org/10.1126/science.1098139			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131293				2022-12-28	WOS:000221243000027
J	Fedorka, KM; Mousseau, TA				Fedorka, KM; Mousseau, TA			Female mating bias results in conflicting sex-specific offspring fitness	NATURE			English	Article							MATE CHOICE; GIFTS	Indirect-benefit models of sexual selection assert that females gain heritable offspring advantages through a mating bias for males of superior genetic quality. This has generally been tested by associating a simple morphological quality indicator ( for example, bird tail length) with offspring viability(1). However, selection acts simultaneously on many characters, limiting the ability to detect significant associations, especially if the simple indicator is weakly correlated to male fitness(2,3). Furthermore, recent conceptual developments suggest that the benefits gained from such mating biases may be sex-specific because of sexually antagonistic genes that differentially influence male and female reproductive ability(4). A more suitable test of the indirect-benefit model would examine associations between an aggregate quality indicator(1,3) (such as male mating success) and gender-specific adult fitness components, under the expectation that these components may trade off(1). Here, we show that a father's mating success in the cricket, Allonemobius socius, is positively genetically correlated with his son's mating success but negatively with his daughter's reproductive success. This provides empirical evidence that a female mating bias can result in sexually antagonistic offspring fitness.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Fedorka, KM (corresponding author), Univ Georgia, Dept Genet, Athens, GA 30602 USA.	fedorka@uga.edu	Mousseau, Timothy A/A-1253-2011	Mousseau, Timothy/0000-0002-2235-4868				BOAKE CRB, 1985, SCIENCE, V227, P1061, DOI 10.1126/science.227.4690.1061; Chapman T, 2003, TRENDS ECOL EVOL, V18, P41, DOI 10.1016/S0169-5347(02)00004-6; Chippindale AK, 2001, P NATL ACAD SCI USA, V98, P1671, DOI 10.1073/pnas.041378098; Fedorka KM, 2002, FLA ENTOMOL, V85, P317, DOI 10.1653/0015-4040(2002)085[0317:TSFIGC]2.0.CO;2; Fedorka KM, 2002, EVOLUTION, V56, P590, DOI 10.1111/j.0014-3820.2002.tb01369.x; HEISLER IL, 1985, HEREDITY, V55, P187, DOI 10.1038/hdy.1985.91; Kokko H, 2001, ECOL LETT, V4, P322, DOI 10.1046/j.1461-0248.2001.00224.x; LYNCH M, 1998, GENETICS ANAL QUANTI, P632; MONTALVO AM, 1994, EVOLUTION, V48, P828, DOI 10.1111/j.1558-5646.1994.tb01365.x; MOUSSEAU TA, 1991, ANNU REV ENTOMOL, V36, P511, DOI 10.1146/annurev.en.36.010191.002455; MOUSSEAU TA, 1991, UNITY EVOLUTIONARY B, V0002, P00745; Rice WR, 2000, P NATL ACAD SCI USA, V97, P12953, DOI 10.1073/pnas.97.24.12953; ROFF DA, 1997, EVOLUTIONARY GENETIC; Wedell N, 1999, EVOLUTION, V53, P620, DOI 10.1111/j.1558-5646.1999.tb03797.x; Zar JH., 1999, BIOSTAT ANAL	15	143	143	1	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	2004	429	6987					65	67		10.1038/nature02492	http://dx.doi.org/10.1038/nature02492			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129280				2022-12-28	WOS:000221222100044
J	Lindenauer, PK; Pekow, P; Wang, KJ; Gutierrez, B; Benjamin, EM				Lindenauer, PK; Pekow, P; Wang, KJ; Gutierrez, B; Benjamin, EM			Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPROVES ENDOTHELIAL FUNCTION; VASCULAR-SURGERY; MYOCARDIAL-INFARCTION; CARDIAC RISK; PERIOPERATIVE MORTALITY; REDUCTION; EVENTS; INDEX; PREDICTORS; MORBIDITY	Context Cardiovascular complications following major noncardiac surgery are an important source of perioperative morbidity and mortality. Although lipid-lowering medications are considered a key component in the primary and secondary prevention of cardiovascular disease, their potential benefit during the perioperative period is uncertain. Objective To examine the association between treatment with lipid-lowering medications and in-hospital mortality following major noncardiac surgery. Design, Setting, and Patients A retrospective cohort study based on hospital discharge and pharmacy records of 780591 patients aged 18 years or older who underwent major noncardiac surgery from January 1, 2000, to December 31, 2001, at any 1 of 329 hospitals throughout the United States. Only patients who survived through at least the second hospital day were included. Lipid-lowering therapy was defined as use during the first 2 hospital days. Propensity matching was used to adjust for numerous baseline differences. Main Outcome Measure In-hospital mortality. Results Of the 780 591 patients, 77 082 patients (9.9%) received lipid-lowering therapy perioperatively and 23 100 (2.96%) died during the hospitalization. Treatment with lipid-lowering agents was associated with lower crude mortality (2.13% vs 3.05%, P<.001). In an analysis using matching by propensity score, 1595 patients (2.18%) treated with lipid-lowering medications died compared with 4158 patients (3.15%) who did not receive therapy or in whom treatment was initiated after the second day (P<.001). After adjusting for residual differences in the propensity matched groups using conditional logistic regression, risk of mortality remained lower among treated patients (adjusted odds ratio [OR], 0.62; 95% confidence interval [CI], 0.58-0.67). Based on this adjusted OR, the number needed to treat to prevent a postoperative death in the propensity matched cohort was 85 (95% Cl, 77-98) and varied from 186 among patients at lowest risk to 30 among those with a revised cardiac risk index score of 4 or more. in a further analysis using the entire study cohort and adjusting for quintile of propensity, a significant effect of treatment persisted (adjusted OR, 0.71; 95% Cl, 0.67-0.75). Conclusions Treatment with lipid-lowering agents may reduce risk of death following major noncardiac surgery. Clinical trials are required to confirm this observation.	Baystate Med Ctr, Div Healthcare Qual, Springfield, MA 01199 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA; Premier Corp, Premier Healthcare Informat, Charlotte, NC USA	Baystate Medical Center; Tufts University; University of Massachusetts System; University of Massachusetts Amherst	Lindenauer, PK (corresponding author), Baystate Med Ctr, Div Healthcare Qual, 759 Chestnut St,P-5931, Springfield, MA 01199 USA.	peter.lindenauer@bhs.org						Auerbach AD, 2002, JAMA-J AM MED ASSOC, V287, P1435, DOI 10.1001/jama.287.11.1435; Best WR, 2002, J AM COLL SURGEONS, V194, P257, DOI 10.1016/S1072-7515(01)01183-8; Boersma E, 2001, JAMA-J AM MED ASSOC, V285, P1865, DOI 10.1001/jama.285.14.1865; Dawood MM, 1996, INT J CARDIOL, V57, P37, DOI 10.1016/S0167-5273(96)02769-6; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; Dupuis J, 1999, CIRCULATION, V99, P3227, DOI 10.1161/01.CIR.99.25.3227; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; Farmer J A, 2000, Curr Atheroscler Rep, V2, P208, DOI 10.1007/s11883-000-0022-3; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HALL MJ, 2002, 2000 NATL HOSP DISCH; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Huggins GS, 1998, CIRCULATION, V98, P1291, DOI 10.1161/01.CIR.98.13.1291; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Lindenauer PK, 2004, ARCH INTERN MED, V164, P762, DOI 10.1001/archinte.164.7.762; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Nettleman MD, 1997, AM J MED, V103, P357, DOI 10.1016/S0002-9343(97)00162-9; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126; Osamah H, 1997, BRIT J CLIN PHARMACO, V44, P77, DOI 10.1046/j.1365-2125.1997.00625.x; Poldermans D, 2003, CIRCULATION, V107, P1848, DOI 10.1161/01.CIR.0000066286.15621.98; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Ridker PM, 2001, CIRCULATION, V103, P1191; SHOJANIA K, 2001, AHRQ PUBLICATION; Sonksen J, 1998, BMJ-BRIT MED J, V317, P1400, DOI 10.1136/bmj.317.7170.1400	25	303	314	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2004	291	17					2092	2099		10.1001/jama.291.17.2092	http://dx.doi.org/10.1001/jama.291.17.2092			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JR	15126437	Bronze			2022-12-28	WOS:000221174300026
J	Van Petegem, F; Clark, KA; Chatelain, FC; Minor, DL				Van Petegem, F; Clark, KA; Chatelain, FC; Minor, DL			Structure of a complex between a voltage-gated calcium channel beta-subunit and an alpha-subunit domain	NATURE			English	Article							G-PROTEIN MODULATION; I-II LINKER; MOLECULAR DETERMINANTS; CA2+ CHANNELS; INACTIVATION; BINDING; GAMMA; INHIBITION; CONTAINS; LOOP	Voltage-gated calcium channels (CaVs) govern muscle contraction, hormone and neurotransmitter release, neuronal migration, activation of calcium-dependent signalling cascades, and synaptic input integration(1). An essential Ca-V intracellular protein, the beta-subunit (Ca(V)beta)(1,2), binds a conserved domain ( the alpha-interaction domain, AID) between transmembrane domains I and II of the pore-forming alpha(1) subunit(3) and profoundly affects multiple channel properties such as voltage-dependent activation(2), inactivation rates(2), G-protein modulation(4), drug sensitivity(5) and cell surface expression(6,7). Here, we report the high-resolution crystal structures of the Ca(V)beta(2a) conserved core, alone and in complex with the AID. Previous work suggested that a conserved region, the beta-interaction domain (BID), formed the AID-binding site(3,8); however, this region is largely buried in the Ca(V)beta core and is unavailable for protein - protein interactions. The structure of the AID - Ca(V)beta(2a) complex shows instead that Ca(V)beta(2a) engages the AID through an extensive, conserved hydrophobic cleft ( named the alpha-binding pocket, ABP). The ABP - AID interaction positions one end of the Ca(V)beta near the intracellular end of a pore-lining segment, called IS6, that has a critical role in Ca-V inactivation(9,10). Together, these data suggest that Ca(V)betas influence Ca-V gating by direct modulation of IS6 movement within the channel pore.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Minor, DL (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, 513 Parnassus Ave,Box 0130, San Francisco, CA 94143 USA.	minor@itsa.ucsf.edu	Tuluc, Petronel/C-2527-2011; Van Petegem, Filip/M-6061-2016	Van Petegem, Filip/0000-0003-2728-8537; CHATELAIN, Franck C./0000-0002-8426-8893	NHLBI NIH HHS [R01 HL080050, R01 HL080050-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Berrou L, 2002, BIOPHYS J, V83, P1429, DOI 10.1016/S0006-3495(02)73914-3; Berrou L, 2001, BIOPHYS J, V80, P215, DOI 10.1016/S0006-3495(01)76008-0; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Dolphin AC, 2003, PHARMACOL REV, V55, P607, DOI 10.1124/pr.55.4.3; Hering S, 2002, TRENDS PHARMACOL SCI, V23, P509, DOI 10.1016/S0165-6147(02)02104-1; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kochegarov AA, 2003, CELL CALCIUM, V33, P145, DOI 10.1016/S0143-4160(02)00239-7; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Opatowsky Y, 2003, J BIOL CHEM, V278, P52323, DOI 10.1074/jbc.M303564200; Paarmann I, 2002, J BIOL CHEM, V277, P40832, DOI 10.1074/jbc.M205618200; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Restituito S, 2000, J NEUROSCI, V20, P9046; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Walker D, 1999, J BIOL CHEM, V274, P12383, DOI 10.1074/jbc.274.18.12383; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	30	317	324	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	2004	429	6992					671	675		10.1038/nature02588	http://dx.doi.org/10.1038/nature02588			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15141227	Green Accepted			2022-12-28	WOS:000221912600044
J	Gross, E; Kastner, DB; Kaiser, CA; Fass, D				Gross, E; Kastner, DB; Kaiser, CA; Fass, D			Structure of Ero1p, source of disulfide bonds for oxidative protein folding in the cell	CELL			English	Article							WHITE SULFHYDRYL OXIDASE; MECHANISM; PATHWAY; YEAST; MOTIF; GENE; DSBB; THIOREDOXIN; STABILITY; CYSTEINES	The flavoenzyme Ero1p produces disulficle bonds for oxidative protein folding in the endoplasmic reticulum. Disulfides generated de novo within Ero1p are transferred to protein disulfide isomerase and then to substrate proteins by dithiol-disulfide exchange reactions. Despite this key role of Ero1p, little is known about the mechanism by which this enzyme catalyzes thiol oxidation. Here, we present the X-ray crystallographic structure of Ero1p, which reveals the molecular details of the catalytic center, the role of a CXXCXXC motif, and the spatial relationship between functionally significant cysteines and the bound cofactor. Remarkably, the Ero1p active site closely resembles that of the versatile thiol oxidase module of Erv2p, a protein with no sequence homology to Ero1p. Furthermore, both Ero1p and Erv2p display essential dicysteine motifs on mobile polypeptide segments, suggesting that shuttling electrons to a rigid active site using a flexible strand is a fundamental feature of disulfide-generating flavoenzymes.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; MIT, Dept Biol, Cambridge, MA 02139 USA	Weizmann Institute of Science; Massachusetts Institute of Technology (MIT)	Fass, D (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	deborah.fass@weizmann.ac.il	Gross, Einav/AAS-7417-2021					Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Becher D, 1999, YEAST, V15, P1171, DOI 10.1002/(SICI)1097-0061(19990915)15:12<1171::AID-YEA443>3.0.CO;2-T; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Frand AR, 2000, MOL BIOL CELL, V11, P2833, DOI 10.1091/mbc.11.9.2833; Gerber J, 2001, J BIOL CHEM, V276, P23486, DOI 10.1074/jbc.M100134200; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Grauschopf U, 2003, EMBO J, V22, P3503, DOI 10.1093/emboj/cdg356; Grossman SD, 2002, NEUROMOL MED, V2, P61, DOI 10.1385/NMM:2:1:61; Hofhaus G, 2003, EUR J BIOCHEM, V270, P1528, DOI 10.1046/j.1432-1033.2003.03519.x; Holm L, 1998, PROTEINS, V33, P88, DOI 10.1002/(SICI)1097-0134(19981001)33:1<88::AID-PROT8>3.0.CO;2-H; Hoober KL, 1999, BIOCHEMISTRY-US, V38, P3211, DOI 10.1021/bi9820816; Hoober KL, 1999, J BIOL CHEM, V274, P31759, DOI 10.1074/jbc.274.45.31759; Hoober KL, 1996, J BIOL CHEM, V271, P30510, DOI 10.1074/jbc.271.48.30510; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung YS, 2000, J BIOL CHEM, V275, P36974, DOI 10.1074/jbc.M004947200; Kadokura H, 2002, EMBO J, V21, P2354, DOI 10.1093/emboj/21.10.2354; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lario PI, 2003, J MOL BIOL, V326, P1635, DOI 10.1016/S0022-2836(03)00054-8; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Linke K, 2003, ANTIOXID REDOX SIGN, V5, P425, DOI 10.1089/152308603768295168; Niimura Y, 2000, J BACTERIOL, V182, P5046, DOI 10.1128/JB.182.18.5046-5051.2000; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1988, J BIOL CHEM, V263, P11820; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Raje S, 2003, BIOCHEMISTRY-US, V42, P4560, DOI 10.1021/bi030003z; Raje S, 2002, ANAL BIOCHEM, V307, P266, DOI 10.1016/S0003-2697(02)00050-7; Regeimbal J, 2003, P NATL ACAD SCI USA, V100, P13779, DOI 10.1073/pnas.1935988100; SALAMOV AA, 1995, J MOL BIOL, V247, P11, DOI 10.1006/jmbi.1994.0116; Senkevich TG, 2000, P NATL ACAD SCI USA, V97, P12068, DOI 10.1073/pnas.210397997; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012	48	194	199	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					601	610		10.1016/S0092-8674(04)00418-0	http://dx.doi.org/10.1016/S0092-8674(04)00418-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163408	Bronze			2022-12-28	WOS:000221857900007
J	Lupardus, PJ; Cimprich, KA				Lupardus, PJ; Cimprich, KA			Checkpoint adaptation: Molecular mechanisms uncovered	CELL			English	Editorial Material							RECOVERY; ARREST	Adaptation to the DNA damage checkpoint is a phenomenon long thought to be confined to the unicellular world. A new report in this issue of Cell by Yoo and colleagues (2004) suggests the presence of a check-point adaptation pathway in Xenopus egg extracts that displays interesting molecular parallels to adaptation in yeast.	Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Lupardus, PJ (corresponding author), Stanford Univ, Dept Mol Pharmacol, 318 Campus Dr, Stanford, CA 94305 USA.							Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Galgoczy DJ, 2001, MOL CELL BIOL, V21, P1710, DOI 10.1128/MCB.21.5.1710-1718.2001; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lee SE, 2000, COLD SPRING HARB SYM, V65, P303, DOI 10.1101/sqb.2000.65.303; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9	10	15	15	1	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					555	556		10.1016/j.cell.2004.05.005	http://dx.doi.org/10.1016/j.cell.2004.05.005			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163402	Bronze			2022-12-28	WOS:000221857900001
J	Turgeon, JL; McDonnell, DP; Martin, KA; Wise, PM				Turgeon, JL; McDonnell, DP; Martin, KA; Wise, PM			Hormone therapy: Physiological complexity belies therapeutic simplicity	SCIENCE			English	Review							ESTROGEN-RECEPTOR-ALPHA; RANDOMIZED CONTROLLED-TRIAL; C-REACTIVE PROTEIN; PROGESTERONE-RECEPTOR; REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; BREAST-CANCER; MEDROXYPROGESTERONE ACETATE; CARDIOVASCULAR-DISEASE; TISSUE-SPECIFICITY	The results of the Women's Health Initiative, a study anticipated to provide definitive answers about health benefits and risks of postmenopausal hormone therapy, have generated debate and confusion among clinicians, researchers, and the lay public. The ovarian hormones estrogen and progesterone, which decline at menopause, normally elicit complex tissue-specific responses throughout the body. Major advances are providing a detailed molecular definition of how that differential action is achieved. Here we review estrogen and progestin actions, discuss how effectively knowledge of steroid hormone endocrinology has been incorporated into clinical studies, and consider the impact on modern hormone therapy protocols and pharmaceutical development.	Univ Calif Davis, Dept Internal Med, Div Endocrinol Clin Nutr & Vasc Med, Davis, CA 95616 USA; Univ Calif Davis, Dept Neurobiol Physiol & Behav, Div Biol Sci, Davis, CA 95616 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit, Boston, MA 02114 USA	University of California System; University of California Davis; University of California System; University of California Davis; Duke University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Turgeon, JL (corresponding author), Univ Calif Davis, Dept Internal Med, Div Endocrinol Clin Nutr & Vasc Med, Davis, CA 95616 USA.	jlturgeon@ucdavis.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050495, R01DK048807, R21DK066606, R37DK048807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002224, P01AG017164, R37AG002224] Funding Source: NIH RePORTER; NIA NIH HHS [AG17164, AG02224] Funding Source: Medline; NICHD NIH HHS [HD12137] Funding Source: Medline; NIDDK NIH HHS [DK50495, DK66606, DK48807] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Bamberger CM, 1999, J CLIN ENDOCR METAB, V84, P4055, DOI 10.1210/jc.84.11.4055; Bhavnani BR, 2003, J STEROID BIOCHEM, V85, P473, DOI 10.1016/S0960-0760(03)00220-6; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; Dhandapani KM, 2002, BIOL REPROD, V67, P1379, DOI 10.1095/biolreprod.102.003848; Gao JG, 2000, MOL ENDOCRINOL, V14, P1954, DOI 10.1210/me.14.12.1954; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291; Godsland IF, 2001, FERTIL STERIL, V75, P898, DOI 10.1016/S0015-0282(01)01699-5; Gregory CW, 2002, J CLIN ENDOCR METAB, V87, P2960, DOI 10.1210/jc.87.6.2960; Gustaftson JA, 2003, TRENDS PHARMACOL SCI, V24, P479, DOI 10.1016/S0165-6147(03)00229-3; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Harris HA, 2003, ENDOCRINOLOGY, V144, P4241, DOI 10.1210/en.2003-0550; Herrington DM, 2002, CIRCULATION, V105, P1879, DOI 10.1161/01.CIR.0000016173.98826.88; Ke HZ, 2004, ENDOCRINOLOGY, V145, P1996, DOI 10.1210/en.2003-1481; Key TJ, 2003, J NATL CANCER I, V95, P1218, DOI 10.1093/jnci/djg022; Labrie F, 2003, ENDOCRINOLOGY, V144, P4700, DOI 10.1210/en.2003-0269; Leonhardt SA, 2003, STEROIDS, V68, P761, DOI 10.1016/S0039-128X(03)00129-6; Li XT, 2003, J BIOL CHEM, V278, P39261, DOI 10.1074/jbc.R300024200; Liu XM, 2002, CHEM RES TOXICOL, V15, P512, DOI 10.1021/tx0101649; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Manson JE, 2001, NEW ENGL J MED, V345, P34, DOI 10.1056/NEJM200107053450106; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; McDonnell DP, 2002, RECENT PROG HORM RES, V57, P295, DOI 10.1210/rp.57.1.295; Mendelsohn ME, 2002, AM J CARDIOL, V90, p3F, DOI 10.1016/S0002-9149(02)02418-9; Mikkola TS, 2002, CARDIOVASC RES, V53, P605, DOI 10.1016/S0008-6363(01)00466-7; Miller AP, 2003, HYPERTENSION, V42, P657, DOI 10.1161/01.HYP.0000085560.02979.0C; Miyagawa K, 1997, NAT MED, V3, P324, DOI 10.1038/nm0397-324; Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Oger E, 2003, ARTERIOSCL THROM VAS, V23, P1671, DOI 10.1161/01.ATV.0000087141.05044.1F; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Otsuki M, 2001, ARTERIOSCL THROM VAS, V21, P243, DOI 10.1161/01.ATV.21.2.243; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shearman AM, 2003, JAMA-J AM MED ASSOC, V290, P2263, DOI 10.1001/jama.290.17.2263; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sun J, 2002, ENDOCRINOLOGY, V143, P941, DOI 10.1210/en.143.3.941; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Vongpatanasin W, 2003, J AM COLL CARDIOL, V41, P1358, DOI 10.1016/S0735-1097(03)00156-6; Webb P, 2003, J BIOL CHEM, V278, P6912, DOI 10.1074/jbc.M208501200; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Zhi L, 2003, J MED CHEM, V46, P4104, DOI 10.1021/jm020477g	49	223	234	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	2004	304	5675					1269	1273		10.1126/science.1096725	http://dx.doi.org/10.1126/science.1096725			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166356				2022-12-28	WOS:000221669600030
J	Stoffle, NN; Cohen, PR				Stoffle, NN; Cohen, PR			Sarcoptes scabiei infestation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Houston, Houston, TX 77204 USA	University of Houston System; University of Houston	Stoffle, NN (corresponding author), Univ Houston, Houston, TX 77204 USA.			Stoffle, Nicholas N./0000-0002-6520-7358					0	4	4	2	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					E20	E20		10.1056/NEJMicm030276	http://dx.doi.org/10.1056/NEJMicm030276			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163791				2022-12-28	WOS:000221641900010
J	Buchbinder, R				Buchbinder, R			Plantar fasciitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SHOCK-WAVE THERAPY; RANDOMIZED CONTROLLED-TRIAL; PAINFUL HEEL SYNDROME; CORTICOSTEROID INJECTION; CONSERVATIVE TREATMENT; CALCANEAL SPUR; INJURIES; ULTRASOUND; MANAGEMENT; DIAGNOSIS		Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; Cabrini Hosp, Dept Clin Epidemiol, Melbourne, Vic, Australia	Monash University; Cabrini Health	Buchbinder, R (corresponding author), Cabrini Med Ctr, Suite 41,183 Wattletree Rd, Malvern, Vic 3144, Australia.	rachelle.buchbinder@med.monash.edu.au	Rothbart, Brian/AAA-8452-2021; Buchbinder, Rachelle/G-2952-2011	Buchbinder, Rachelle/0000-0002-0597-0933				Acevedo JI, 1998, FOOT ANKLE INT, V19, P91, DOI 10.1177/107110079801900207; *AM AC ORTH SURG, 1998, ORTH KNOWL UPD FOOT, P175; Ballas MT, 1997, AM FAM PHYSICIAN, V55, P2473; Barrett SL, 1999, AM FAM PHYSICIAN, V59, P2200; BERKOWITZ JF, 1991, RADIOLOGY, V179, P665, DOI 10.1148/radiology.179.3.2027971; Buch M, 2002, ORTHOPADE, V31, P637, DOI 10.1007/s00132-002-0323-z; Buchbinder R, 2002, JAMA-J AM MED ASSOC, V288, P1364, DOI 10.1001/jama.288.11.1364; Caselli MA, 1997, J AM PODIAT MED ASSN, V87, P11, DOI 10.7547/87507315-87-1-11; Chigwanda P. C. K., 1997, Central African Journal of Medicine, V43, P23; Clement D B, 1981, Phys Sportsmed, V9, P47, DOI 10.1080/00913847.1981.11711077; Crawford F, 2003, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD000416; Davies MS, 1999, FOOT ANKLE INT, V20, P803, DOI 10.1177/107110079902001209; DAVIS PF, 1994, FOOT ANKLE INT, V15, P531, DOI 10.1177/107110079401501002; DEMAIO M, 1993, ORTHOPEDICS, V16, P1153; DiGiovanni BF, 2003, J BONE JOINT SURG AM, V85A, P1270, DOI 10.2106/00004623-200307000-00013; FUREY JG, 1975, J BONE JOINT SURG AM, V57, P672, DOI 10.2106/00004623-197557050-00016; Gibbon WW, 1999, SKELETAL RADIOL, V28, P21, DOI 10.1007/s002560050467; Gill LH, 1996, FOOT ANKLE INT, V17, P722; Gill LH, 1996, FOOT ANKLE INT, V17, P527, DOI 10.1177/107110079601700903; Groshar D, 2000, FOOT, V10, P164; Haake M, 2003, BRIT MED J, V327, P75, DOI 10.1136/bmj.327.7406.75; Jarde Olivier, 2003, Acta Orthop Belg, V69, P267; Kane D, 2001, RHEUMATOLOGY, V40, P1002, DOI 10.1093/rheumatology/40.9.1002; Kinley S, 1993, J Foot Ankle Surg, V32, P595; LAPIDUS PAUL W, 1965, CLIN ORTHOP RELAT RES, V39, P178; LEACH RE, 1986, FOOT ANKLE, V7, P156, DOI 10.1177/107110078600700305; Lemont H, 2003, J AM PODIAT MED ASSN, V93, P234, DOI 10.7547/87507315-93-3-234; Lynch DM, 1998, J AM PODIAT MED ASSN, V88, P375, DOI 10.7547/87507315-88-8-375; Martin JE, 2001, J AM PODIAT MED ASSN, V91, P55, DOI 10.7547/87507315-91-2-55; Martin RL, 1998, FOOT ANKLE INT, V19, P803, DOI 10.1177/107110079801901203; McBryde A M Jr, 1984, Instr Course Lect, V33, P278; MCCARTHY DJ, 1979, J AM POD ASSOC, V69, P527, DOI 10.7547/87507315-69-9-527; McGonagle D, 2002, ARTHRITIS RHEUM-US, V46, P489, DOI 10.1002/art.10125; MILGROM C, 1992, CLIN ORTHOP RELAT R, V281, P189; Ogden JA, 2001, CLIN ORTHOP RELAT R, P47, DOI 10.1097/00003086-200106000-00007; ONUBA O, 1986, Italian Journal of Orthopaedics and Traumatology, V12, P533; Pfeffer G, 1999, FOOT ANKLE INT, V20, P214, DOI 10.1177/107110079902000402; Powell M, 1998, FOOT ANKLE INT, V19, P10, DOI 10.1177/107110079801900103; PRICHASUK S, 1994, CLIN ORTHOP RELAT R, V306, P192; Probe RA, 1999, CLIN ORTHOP RELAT R, P190; RANO JA, 2001, FOOT ANKLE SURG, V40, P351; Riddle D, 2003, J BONE JOINT SURG AM, V85A, P1338; Riddle D, 2003, J BONE JOINT SURG AM, V85A, P872, DOI 10.2106/00004623-200305000-00015; Rome K, 1997, PHYS THER REV, V2, P123, DOI DOI 10.1179/PTR.1997.2.3.123; Rompe JD, 2003, AM J SPORT MED, V31, P268, DOI 10.1177/03635465030310021901; Sadat-Ali M, 1998, MIL MED, V163, P56, DOI 10.1093/milmed/163.1.56; Sammarco GJ, 1996, FOOT ANKLE INT, V17, P520, DOI 10.1177/107110079601700902; SELLMAN JR, 1994, FOOT ANKLE INT, V15, P376, DOI 10.1177/107110079401500706; Singh D, 1997, BMJ-BRIT MED J, V315, P172, DOI 10.1136/bmj.315.7101.172; Speed CA, 2003, J ORTHOPAED RES, V21, P937, DOI 10.1016/S0736-0266(03)00048-2; Taunton JE, 2002, BRIT J SPORT MED, V36, P95, DOI 10.1136/bjsm.36.2.95; Tisdel CL, 1996, FOOT ANKLE INT, V17, P41, DOI 10.1177/107110079601700109; Winemiller MH, 2003, JAMA-J AM MED ASSOC, V290, P1474, DOI 10.1001/jama.290.11.1474; WINEMILLER MH, 2004, JAMA-J AM MED ASSOC, V291, P46; WOLGIN M, 1994, FOOT ANKLE INT, V15, P97, DOI 10.1177/107110079401500303; Yeung EW, 2001, BRIT J SPORT MED, V35, P383, DOI 10.1136/bjsm.35.6.383; Young CC, 2001, AM FAM PHYSICIAN, V64, P570; 2001, J FOOT ANKLE SURG, V40, P329	58	277	286	0	65	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2159	2166		10.1056/NEJMcp032745	http://dx.doi.org/10.1056/NEJMcp032745			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152061				2022-12-28	WOS:000221496700008
J	Olsen, NJ; Stein, CM				Olsen, NJ; Stein, CM			Drug therapy - New drugs for rheumatoid arthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; ALPHA MONOCLONAL-ANTIBODY; LONG-TERM SAFETY; DOUBLE-BLIND; TNF-ALPHA; ADALIMUMAB D2E7; CONCOMITANT METHOTREXATE; COMBINATION THERAPY; ETANERCEPT THERAPY		Vanderbilt Univ, Sch Med, Div Rheumatol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Olsen, NJ (corresponding author), Vanderbilt Univ, Sch Med, Div Rheumatol, Nashville, TN 37212 USA.		Messori, Andrea/U-6903-2019		AHRQ HHS [HS1-0384] Funding Source: Medline; NHLBI NIH HHS [HL 67964, HL 65082] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010384] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065082, R01HL067964] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*ABB LAB, 2003, HUM AD; *AM COLL RHEUM, FDA M MARCH 2003 U 3; *AM COLL RHEUM, REP LEFL HEP PAT RHE; [Anonymous], 1999, Neurology, V53, P457; Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Auer J, 2000, ACTA MED AUST, V27, P131, DOI 10.1046/j.1563-2571.2000.00034.x; Baecklund E, 1998, BRIT MED J, V317, P180, DOI 10.1136/bmj.317.7152.180; Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Bathon JM, 2001, NEW ENGL J MED, V344, P240; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Beaman JM, 2002, ANN PHARMACOTHER, V36, P75, DOI 10.1345/aph.1A127; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bozkurt B, 2001, CIRCULATION, V103, P1044, DOI 10.1161/01.CIR.103.8.1044; Breedveld FC, 2000, ANN RHEUM DIS, V59, P841, DOI 10.1136/ard.59.11.841; Brent RL, 2001, TERATOLOGY, V63, P106; Bresnihan B, 1998, RHEUM DIS CLIN N AM, V24, P615, DOI 10.1016/S0889-857X(05)70029-6; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; Brown SL, 2002, ARTHRITIS RHEUM-US, V46, P3151, DOI 10.1002/art.10679; Bukhari M, 2002, ARTHRITIS RHEUM-US, V46, P906, DOI 10.1002/art.10167; Burger D, 2003, RHEUMATOLOGY, V42, P89, DOI 10.1093/rheumatology/keg038; Campion GV, 1996, ARTHRITIS RHEUM, V39, P1092, DOI 10.1002/art.1780390704; Charles PJ, 2000, ARTHRITIS RHEUM, V43, P2383, DOI 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.3.CO;2-4; Choy EHS, 2002, ARTHRITIS RHEUM-US, V46, P3143, DOI 10.1002/art.10623; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908; Chung ES, 2003, CIRCULATION, V107, P3133, DOI 10.1161/01.CIR.0000077913.60364.D2; Clair EWS, 2002, ARTHRITIS RHEUM, V46, P1451, DOI 10.1002/art.10302; Coblyn JS, 2001, ARTHRITIS RHEUM, V44, P1048, DOI 10.1002/1529-0131(200105)44:5<1048::AID-ANR184>3.3.CO;2-M; Cohen S, 2001, ARTHRITIS RHEUM-US, V44, P1984, DOI 10.1002/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B; Cohen S, 2002, ARTHRITIS RHEUM, V46, P614, DOI 10.1002/art.10141; Colombel JF, 2004, GASTROENTEROLOGY, V126, P19, DOI 10.1053/j.gastro.2003.10.047; Day R, 2002, LANCET, V359, P540, DOI 10.1016/S0140-6736(02)07718-8; den Broeder A, 2002, J RHEUMATOL, V29, P2288; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524; Ekstrom K, 2003, ARTHRITIS RHEUM-US, V48, P963, DOI 10.1002/art.10939; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1564, DOI 10.1002/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M; Fichtlscherer S, 2001, CIRCULATION, V104, P3023, DOI 10.1161/hc5001.101749; FIRESTEIN GS, 1994, ARTHRITIS RHEUM, V37, P644, DOI 10.1002/art.1780370507; Fleischmann RM, 2003, J RHEUMATOL, V30, P691; Fleischmann RM, 2003, ARTHRITIS RHEUM-US, V48, P927, DOI 10.1002/art.10870; *FOOD DRUG ADM, AD US TREATM RHEUM A; *FOOD DRUG ADM, 2003, SAF UPD M TNF BLOCK; *FOOD DRUG ADM CTR, 2003, ARTHR ADV COMM M WED; Francis GS, 1999, CIRCULATION, V99, P3213, DOI 10.1161/01.CIR.99.25.3213; Furst DE, 2002, ANN RHEUM DIS, V61, P62; Gorman JD, 2002, NEW ENGL J MED, V346, P1349, DOI 10.1056/NEJMoa012664; Helbling D, 2002, EUR J GASTROEN HEPAT, V14, P1393, DOI 10.1097/00042737-200212000-00018; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Husni ME, 2002, ARTHRITIS RHEUM, V46, P1171, DOI 10.1002/art.10231; Jiang YB, 2000, ARTHRITIS RHEUM, V43, P1001, DOI 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P; Kamath BM, 2002, J PEDIATR GASTR NUTR, V34, P410, DOI 10.1097/00005176-200204000-00018; Kashyap AS, 2002, LANCET, V359, P1252, DOI 10.1016/S0140-6736(02)08241-7; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Keystone EC, 2004, ARTHRITIS RHEUM, V50, P353, DOI 10.1002/art.20019; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; Korth-Bradley JM, 2000, ANN PHARMACOTHER, V34, P161; Kremer JM, 2002, ANN INTERN MED, V137, P726, DOI 10.7326/0003-4819-137-9-200211050-00007; Kremer JM, 1999, SEMIN ARTHRITIS RHEU, V29, P14, DOI 10.1016/S0049-0172(99)80034-1; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Kroesen S, 2003, RHEUMATOLOGY, V42, P617, DOI 10.1093/rheumatology/keg263; Kwoh CK, 2002, ARTHRITIS RHEUM-US, V46, P328; Lee H, 2003, CLIN PHARMACOL THER, V73, P348, DOI 10.1016/S0009-9236(02)17635-1; Lee JH, 2002, ARTHRITIS RHEUM-US, V46, P2565, DOI 10.1002/art.10583; Lim V, 2002, BRIT MED J, V325, P1333, DOI 10.1136/bmj.325.7376.1333; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; Manna SK, 2000, J IMMUNOL, V165, P5962, DOI 10.4049/jimmunol.165.10.5962; Marchesoni A, 2003, RHEUMATOLOGY, V42, P193, DOI 10.1093/rheumatology/key051; McCain ME, 2002, RHEUMATOLOGY, V41, P116, DOI 10.1093/rheumatology/41.1.116; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; MLADENOVIC V, 1995, ARTHRITIS RHEUM-US, V38, P1595, DOI 10.1002/art.1780381111; Mohan AK, 2002, LANCET, V360, P646, DOI 10.1016/S0140-6736(02)09800-8; Mohan N, 2001, ARTHRITIS RHEUM-US, V44, P2862, DOI 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W; Mohan VP, 2001, INFECT IMMUN, V69, P1847, DOI 10.1128/IAI.69.3.1847-1855.2001; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Moreland LW, 2001, J RHEUMATOL, V28, P1238; Nakelchik M, 2002, AM J MED, V112, P78, DOI 10.1016/S0002-9343(01)00945-7; NEIDEL J, 1995, INFLAMM RES, V44, P217, DOI 10.1007/BF01782262; NEWTON RC, 2001, ANN RHEUM DIS     S3, V60, P25; Nuki G, 2002, ARTHRITIS RHEUM, V46, P2838, DOI 10.1002/art.10578; Perez-Ruiz F, 2003, JCR-J CLIN RHEUMATOL, V9, P215, DOI 10.1097/01.rhu.0000081470.31167.8b; Pincus T, 1999, ARTHRITIS RHEUM, V42, P1572, DOI 10.1002/1529-0131(199908)42:8<1572::AID-ANR2>3.0.CO;2-G; Reiff A, 2001, ARTHRITIS RHEUM, V44, P1411, DOI 10.1002/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O; Rozman B, 2002, CLIN PHARMACOKINET, V41, P421, DOI 10.2165/00003088-200241060-00003; Rozman B, 2002, ANN RHEUM DIS, V61, P567, DOI 10.1136/ard.61.6.567; SAXNE T, 1988, ARTHRITIS RHEUM, V31, P1041, DOI 10.1002/art.1780310816; SCALLON BJ, 1995, CYTOKINE, V7, P251, DOI 10.1006/cyto.1995.0029; Schiff M, 2001, ARTHRITIS RHEUM, V44, pS79; Schuna AA, 2000, AM J HEALTH-SYST PH, V57, P225, DOI 10.1093/ajhp/57.3.225; Shakoor N, 2002, LANCET, V359, P579, DOI 10.1016/S0140-6736(02)07714-0; Sharp JT, 2000, ARTHRITIS RHEUM, V43, P1345; Sharp JT, 2000, ARTHRITIS RHEUM-US, V43, P495, DOI 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U; Siemasko K, 1998, J IMMUNOL, V160, P1581; Silverman GJ, 2003, ARTHRITIS RHEUM-US, V48, P1484, DOI 10.1002/art.10947; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3; Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109; Sokka T, 2002, J RHEUMATOL, V29, P2521; Stone JH, 2001, ARTHRITIS RHEUM, V44, P1149, DOI 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.3.CO;2-6; Strand V, 1999, ARCH INTERN MED, V159, P2542, DOI 10.1001/archinte.159.21.2542; Taylor PC, 2000, ARTHRITIS RHEUM-US, V43, P38, DOI 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L; van de Putte LBA, 2002, ARTHRITIS RHEUM-US, V46, pS205; Velagapudi RB, 2002, ARTHRITIS RHEUM-US, V46, pS133; Warris A, 2001, NEW ENGL J MED, V344, P1099, DOI 10.1056/NEJM200104053441415; Weinblatt ME, 2000, ARTHRITIS RHEUM, V43, P2609, DOI 10.1002/1529-0131(200011)43:11<2609::AID-ANR32>3.0.CO;2-R; Weinblatt ME, 1999, ARTHRITIS RHEUM-US, V42, P1322, DOI 10.1002/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; Xu XL, 1999, BIOCHEM PHARMACOL, V58, P1405, DOI 10.1016/S0006-2952(99)00228-2; Yang BB, 2003, CLIN PHARMACOL THER, V74, P85, DOI 10.1016/S0009-9236(03)00094-8; Yocum DE, 2003, ARTHRITIS RHEUM-US, V48, P3328, DOI 10.1002/art.11363	122	465	507	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2167	2179		10.1056/NEJMra032906	http://dx.doi.org/10.1056/NEJMra032906			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152062				2022-12-28	WOS:000221496700009
J	Eysenbach, G; Powell, J; Englesakis, M; Rizo, C; Stern, A				Eysenbach, G; Powell, J; Englesakis, M; Rizo, C; Stern, A			Health related virtual communities and electronic support groups: systematic review of the effects of online peer to peer interactions	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTERNET; NETWORK; COMMUNICATION; INTERVENTION; INFORMATION; QUALITY; IMPACT; TRIAL	Objective To compile and evaluate the evidence on the effects on health and social outcomes of computer based peer to peer communities and electronic self support groups, used by people to discuss health related issues remotely. Design and data sources Analysis of studies identified from Medline, Embase, CINAHL, PsycINFO, Evidence Based Medicine Reviews, Electronics and Communications Abstracts, Computer and Information Systems Abstracts, ERIC, LISA, ProQuest Digital Dissertations, Web of Science. Selection of studies We searched for before and after studies, interrupted time series, cohort studies, or studies with control groups; evaluating health or social outcomes of virtual peer to peer communities, either as stand alone interventions or in the context of more complex systems with peer to peer components. Main outcome measures Peer to peer interventions and co-interventions studied, general characteristics of studies, outcome measures used, and study results. Results 45 publications describing 38 distinct studies met our inclusion criteria: 20 randomised trials, three meta-analyses of n of 1 trials, three non-randomised controlled trials, one cohort study, and 11 before and after studies. Only six of these evaluated "pure" peer to peer communities, and one had a factorial design with a "peer to peer only" arm, whereas 31 studies evaluated complex interventions, which often included psychoeducational programmes or one to one communication with healthcare professionals, making it impossible to attribute intervention effects to the peer to peer community component. The outcomes measured most often were depression and social support; most studies did not show an effect. We found no evidence to support concerns over virtual communities harming people. Conclusions No robust evidence exists on the effects of consumer led peer to peer communities, partly because most peer to peer communities have been evaluated only in conjunction with more complex interventions or involvement with health professionals. Given the abundance of unmoderated peer to peer groups on the internet, research is required to evaluate under which conditions and for whom electronic support groups are effective and how effectiveness in delivering social support electronically can be maximised.	Univ Toronto, Ctr Global eHealth Innovat,Univ Hlth Network, Dept Hlth Policy Management & Evaluat, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada; Univ Southampton, Wessex Inst Hlth Res & Dev, Southampton SO16 7PX, Hants, England; Toronto Gen Hosp, Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Southampton; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Eysenbach, G (corresponding author), Univ Toronto, Ctr Global eHealth Innovat,Univ Hlth Network, Dept Hlth Policy Management & Evaluat, Toronto Gen Hosp, Fraser Elliott Bldg,190 Elizabeth St, Toronto, ON M5G 2C4, Canada.	geysenba@uhnres.utoronto.ca	Gutowski, Emily/N-1491-2015; Englesakis, Marina/B-4162-2008; Eysenbach, Gunther/AAJ-7158-2020	Englesakis, Marina/0000-0002-2199-1056; Eysenbach, Gunther/0000-0001-6479-5330; Powell, John/0000-0002-1456-4857				Alemi F, 1996, MED CARE, V34, pOS32; Bass DM, 1998, J AGING HEALTH, V10, P20, DOI 10.1177/089826439801000102; Culver JD, 1997, J GEN INTERN MED, V12, P466, DOI 10.1046/j.1525-1497.1997.00084.x; Cummings JN, 2002, COMMUN ACM, V45, P103, DOI 10.1145/514236.514242; Dunham PJ, 1998, AM J COMMUN PSYCHOL, V26, P281, DOI 10.1023/A:1022132720104; EBBINGHOUSE C, 1998, SEARCHER, V6, P50; Eysenbach G, 2003, CA-CANCER J CLIN, V53, P356, DOI 10.3322/canjclin.53.6.356; Eysenbach G, 2001, BRIT MED J, V323, P1103, DOI 10.1136/bmj.323.7321.1103; FEARON B, 2003, NOTICEBOARD, V11; Ferguson T, 2002, BMJ-BRIT MED J, V324, P555, DOI 10.1136/bmj.324.7337.555; Flatley-Brennan P, 1998, COMPUT BIOL MED, V28, P489, DOI 10.1016/S0010-4825(98)00029-8; Gary TL, 2003, DIABETES EDUCATOR, V29, P488, DOI 10.1177/014572170302900313; Golant M, 2003, PSYCHO-ONCOL, V12, pS96; Gustafson DH, 1999, AM J PREV MED, V16, P1, DOI 10.1016/S0749-3797(98)00108-1; HAMMAN CJ, 2000, THESIS TEXAS TU, P1; Harvey-Berino J, 2002, INT J OBESITY, V26, P1254, DOI 10.1038/sj.ijo.0802051; HOUGHTON AR, 2001, BR J CARDIOL, V8, P165; Houston TK, 2002, AM J PSYCHIAT, V159, P2062, DOI 10.1176/appi.ajp.159.12.2062; Iafusco D, 2000, DIABETES CARE, V23, P1853, DOI 10.2337/diacare.23.12.1853b; JOHSARTISENSI JL, 2002, THESIS U N TEXAS, P1; Kayany JM, 1998, J AM SOC INFORM SCI, V49, P1135, DOI 10.1002/(SICI)1097-4571(1998)49:12<1135::AID-ASI8>3.0.CO;2-W; KELLY W, 2002, PRACTICAL DIABETES I, V19, P108, DOI DOI 10.1002/PDI.340; KIM MS, 1991, VERBAL AGGRESSION SE, P1; Kraut R, 1998, AM PSYCHOL, V53, P1017, DOI 10.1037/0003-066X.53.9.1017; Landro L, 1999, Oncologist, V4, P59; Lieberman MA, 2003, CANCER, V97, P920, DOI 10.1002/cncr.11145; McKay HG, 2001, DIABETES CARE, V24, P1328, DOI 10.2337/diacare.24.8.1328; QUICK BG, 1999, THESIS U PACIFIC, P1; SCHNEIDER SJ, 1990, COMPUT HUM BEHAV, V6, P141, DOI 10.1016/0747-5632(90)90002-X; WELLMAN B, 1997, CULTURES INTERNET, P170; Winzelberg AJ, 1998, INT J EAT DISORDER, V24, P339, DOI 10.1002/(SICI)1098-108X(199812)24:4&lt;339::AID-EAT1&gt;3.0.CO;2-J	31	689	694	11	176	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2004	328	7449					1166	1170A		10.1136/bmj.328.7449.1166	http://dx.doi.org/10.1136/bmj.328.7449.1166			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	821XU	15142921	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000221497500021
J	Ramos, JD; Rai-Chaudhuri, A; Neill, RW				Ramos, JD; Rai-Chaudhuri, A; Neill, RW			International online discussion lists on chronic myelogenous leukaemia	BRITISH MEDICAL JOURNAL			English	Article									Canc Resources & Advocacy, Seattle, WA 98115 USA		Ramos, JD (corresponding author), Canc Resources & Advocacy, 7303 23rd Ave NE, Seattle, WA 98115 USA.	jdramos3@comcast.net						BOUDREAU D, PATIENT POWER; HOU CH, 2003, COMPUTER TIMES  0108; *PEW INT AM LIF PR, 2002, VIT DEC INT US DEC W; STROM S, 2003, NY TIMES A      0605, V1, pC11	4	8	9	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 15	2004	328	7449					1177	1178		10.1136/bmj.328.7449.1177	http://dx.doi.org/10.1136/bmj.328.7449.1177			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142925	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000221497500026
J	Bieganowski, P; Brenner, C				Bieganowski, P; Brenner, C			Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD(+) in fungi and humans	CELL			English	Article							BIOCHEMICAL GENOMICS APPROACH; COLONY-ENHANCING FACTOR; BINDING-PROTEIN MIBP; LIFE-SPAN EXTENSION; SACCHAROMYCES-CEREVISIAE; NMN ADENYLYLTRANSFERASE; HAEMOPHILUS-INFLUENZAE; CALORIE RESTRICTION; DIPHOSPHOPYRIDINE NUCLEOTIDE; HETEROLOGOUS EXPRESSION	NAD(+) is essential for life in all organisms, both as a coenzyme for oxidoreductases and as a source of ADPribosyl groups used in various reactions, including those that retard aging in experimental systems. Nicotinic acid and nicotinamide were defined as the vitamin precursors of NAD(+) in Elvehjem's classic discoveries of the 1930s. The accepted view of eukaryotic NAD(+) biosynthesis, that all anabolism flows through nicotinic acid mononucleotide, was challenged experimentally and revealed that nicotinamide riboside is an unanticipated NAD(+) precursor in yeast. Nicotinamide riboside kinases from yeast and humans essential for this pathway were identified and found to be highly specific for phosphorylation of nicotinamide riboside and the cancer drug tiazofurin. Nicotinamide riboside was discovered as a nutrient in milk, suggesting that nicotinamide riboside is a useful compound for elevation of NAD(+) levels in humans.	Dartmouth Coll Sch Med, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Biochem, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Brenner, C (corresponding author), Dartmouth Coll Sch Med, Dept Genet, Rubin 733-HB7937, Lebanon, NH 03756 USA.	charles.brenner@dartmouth.edu	Brenner, Charles/D-6339-2014; Bieganowski, Pawel/ABC-8554-2021	Brenner, Charles/0000-0002-4955-3226; Bieganowski, Pawel/0000-0002-1169-4517	NCI NIH HHS [CA77738, P01 CA077738-040003, P01 CA077738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL R, 1955, ARCH BIOCHEM BIOPHYS, V54, P558, DOI 10.1016/0003-9861(55)90070-9; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Bieganowski P, 2003, J BIOL CHEM, V278, P33049, DOI 10.1074/jbc.M302257200; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Brachmann CB, 1998, YEAST, V14, P115; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Capuzzi D M, 2000, Curr Atheroscler Rep, V2, P64, DOI 10.1007/s11883-000-0096-y; COONEY DA, 1983, ADV ENZYME REGUL, V21, P271, DOI 10.1016/0065-2571(83)90019-5; Elvehjem CA, 1938, J BIOL CHEM, V123, P137; Emanuelli M, 1999, FEBS LETT, V455, P13, DOI 10.1016/S0014-5793(99)00852-2; Emanuelli M, 2003, PROTEIN EXPRES PURIF, V27, P357, DOI 10.1016/S1046-5928(02)00645-9; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRIDLAND A, 1986, CANCER RES, V46, P532; Gallo CA, 2004, MOL CELL BIOL, V24, P1301, DOI 10.1128/MCB.24.3.1301-1312.2004; Garavaglia S, 2002, J BIOL CHEM, V277, P8524, DOI 10.1074/jbc.M111589200; Ghislain M, 2002, YEAST, V19, P215, DOI 10.1002/yea.810; Ghosh S, 1996, GENE, V176, P249, DOI 10.1016/0378-1119(96)00260-0; Gingrich W, 1944, J BACTERIOL, V47, P535, DOI 10.1128/JB.47.6.535-550.1944; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; KERN L, 1990, NUCLEIC ACIDS RES, V18, P5279, DOI 10.1093/nar/18.17.5279; KORNBERG A, 1950, J BIOL CHEM, V182, P779; KREHL WA, 1945, SCIENCE, V101, P489, DOI 10.1126/science.101.2628.489; KROHN K, 1992, J MED CHEM, V35, P511, DOI 10.1021/jm00081a012; KUMASOV OV, 2002, J BACTERIOL, V184, P6906; Kurtz JE, 1999, CURR GENET, V36, P130, DOI 10.1007/s002940050482; Lecoq K, 2001, YEAST, V18, P335, DOI 10.1002/1097-0061(20010315)18:4<335::AID-YEA674>3.0.CO;2-X; LEDER IG, 1951, J BIOL CHEM, V189, P889; Li J, 2003, DEV BIOL, V261, P209, DOI 10.1016/S0012-1606(03)00304-X; Li J, 1999, J CELL BIOL, V147, P1391, DOI 10.1083/jcb.147.7.1391; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; MAAYAN ML, 1964, NATURE, V204, P1169, DOI 10.1038/2041169a0; Magni G, 2004, CELL MOL LIFE SCI, V61, P19, DOI 10.1007/s00018-003-3161-1; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; MUNSON M, 1994, GENE, V144, P59, DOI 10.1016/0378-1119(94)90203-8; Panozzo C, 2002, FEBS LETT, V517, P97, DOI 10.1016/S0014-5793(02)02585-1; Pasternak RC, 1996, ANN INTERN MED, V125, P529, DOI 10.7326/0003-4819-125-7-199610010-00001; PETRACK B, 1965, J BIOL CHEM, V240, P1725; Phizicky EM, 2002, METHOD ENZYMOL, V350, P546; PREISS J, 1958, J BIOL CHEM, V233, P488; PREISS J, 1958, J BIOL CHEM, V233, P493; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431; Sandmeier JJ, 2002, GENETICS, V160, P877; Sasiak K, 1996, ARCH BIOCHEM BIOPHYS, V333, P414, DOI 10.1006/abbi.1996.0409; SAUNDERS PP, 1990, CANCER RES, V50, P5269; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; SCHUTZ G, 1972, J BIOL CHEM, V247, P5327; SHIFRINE M, 1960, NATURE, V187, P623, DOI 10.1038/187623a0; Singh SK, 2002, J BIOL CHEM, V277, P33291, DOI 10.1074/jbc.M204368200; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; Yun M, 2000, J BIOL CHEM, V275, P28093; Zhou TJ, 2002, J BIOL CHEM, V277, P13148, DOI 10.1074/jbc.M111469200; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	58	459	500	8	95	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	2004	117	4					495	502		10.1016/S0092-8674(04)00416-7	http://dx.doi.org/10.1016/S0092-8674(04)00416-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137942	Bronze			2022-12-28	WOS:000221458000009
J	Eisenbarth, GS; Gottlieb, PA				Eisenbarth, GS; Gottlieb, PA			Medical progress - Autoimmune polyendocrine syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTERFERON-ALPHA THERAPY; DIABETES-MELLITUS; T-CELLS; BB RAT; 21-HYDROXYLASE AUTOANTIBODIES; PANCREAS TRANSPLANTATION; ISLET TRANSPLANTATION; SUSCEPTIBILITY LOCUS; MONOCLONAL-ANTIBODY; ADDISONS-DISEASE		Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Eisenbarth, GS (corresponding author), Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, 4200 E 9th Ave,Box B140, Denver, CO 80262 USA.	george.eisenbarth@uchsc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR000069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI046374, R01AI039213, N01AI095380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059097, R21DK063518, R01DK032493, R01DK055969, R37DK032083, P30DK057516, R01DK062718, R01DK032083, U01DK061926, R37DK032493] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00069, M01 RR00051] Funding Source: Medline; NIAID NIH HHS [AI95380, AI046374, AI15416, AI46374, AI39213] Funding Source: Medline; NIDDK NIH HHS [DK32493, DK32083, DK55969, P30 DK57516, DK63518, DK62718, DK61926, DK59097] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Achenbach P, 2004, DIABETES, V53, P384, DOI 10.2337/diabetes.53.2.384; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; Alkhateeb A, 2002, HUM MOL GENET, V11, P661, DOI 10.1093/hmg/11.6.661; Alleva DG, 2002, DIABETES, V51, P2126, DOI 10.2337/diabetes.51.7.2126; ALVAREZMARFANY M, 1994, J CLIN ENDOCR METAB, V79, P10, DOI 10.1210/jc.79.1.10; Amrani A, 2000, NATURE, V406, P739, DOI 10.1038/35021081; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; [Anonymous], 1991, Diabetes Care, V14, P49; Avcin T, 2002, ANN RHEUM DIS, V61, P608, DOI 10.1136/ard.61.7.608; AWATA T, 1995, ENDOCRINOLOGY, V136, P5731, DOI 10.1210/en.136.12.5731; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bao F, 1999, J AUTOIMMUN, V13, P143, DOI 10.1006/jaut.1999.0303; BARKER JM, 2003, TYPE 1 DIABETES MOL; Barton GM, 2002, CURR OPIN IMMUNOL, V14, P380, DOI 10.1016/S0952-7915(02)00343-6; Betterle C, 2002, ENDOCR REV, V23, P579; Betterle C, 2002, ENDOCR REV, V23, P327, DOI 10.1210/er.23.3.327; Bingley PJ, 1997, DIABETES, V46, P1701, DOI 10.2337/diabetes.46.11.1701; Bosi E, 2001, DIABETIC MED, V18, P329, DOI 10.1046/j.1464-5491.2001.00492.x; Bosi E, 2001, DIABETES, V50, P2464, DOI 10.2337/diabetes.50.11.2464; Brix TH, 1998, CLIN ENDOCRINOL, V48, P397; Chase HP, 2001, J PEDIATR-US, V138, P244, DOI 10.1067/mpd.2001.111274; Clark LB, 1999, J IMMUNOL, V162, P2546; Coles AJ, 1999, LANCET, V354, P1691, DOI 10.1016/S0140-6736(99)02429-0; Collin P, 2002, ENDOCR REV, V23, P464, DOI 10.1210/er.2001-0035; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; Corazza GR, 1996, BONE, V18, P525, DOI 10.1016/8756-3282(96)00071-3; Cox NJ, 2001, AM J HUM GENET, V69, P820, DOI 10.1086/323501; De Block CEM, 2001, J CLIN ENDOCR METAB, V86, P4358, DOI 10.1210/jc.86.9.4358; Durelli L, 2001, J CLIN ENDOCR METAB, V86, P3525, DOI 10.1210/jc.86.8.3525; Eisenbarth GS, 2003, WILLIAMS TXB ENDOCRI, P1763; Falorni A, 1997, CLIN EXP IMMUNOL, V107, P341, DOI 10.1111/j.1365-2249.1997.262-ce1153.x; Falorni A, 2002, ENDOCRIN METAB CLIN, V31, P369, DOI 10.1016/S0889-8529(01)00010-X; Farrell RJ, 2002, NEW ENGL J MED, V346, P180, DOI 10.1056/NEJMra010852; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Furmaniak J, 1999, CONT ENDOCRINOL, V15, P183; Gambelunghe G, 1999, J CLIN ENDOCR METAB, V84, P3701, DOI 10.1210/jc.84.10.3701; GOTTLIEB PA, 2002, CURR OPIN ENDOCRINOL, V9, P237; Halonen M, 2002, J CLIN ENDOCR METAB, V87, P2568, DOI 10.1210/jc.87.6.2568; Hanahan D, 1998, CURR OPIN IMMUNOL, V10, P656, DOI 10.1016/S0952-7915(98)80085-X; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Hoffenberg EJ, 2000, J PEDIATR-US, V137, P356, DOI 10.1067/mpd.2000.107582; Hogan WJ, 2001, BONE MARROW TRANSPL, V28, P305, DOI 10.1038/sj.bmt.1703108; Hogenauer C, 2001, NEW ENGL J MED, V344, P270, DOI 10.1056/NEJM200101253440405; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hornum L, 2002, DIABETES, V51, P1972, DOI 10.2337/diabetes.51.6.1972; Hutton JC, 2003, P NATL ACAD SCI USA, V100, P8626, DOI 10.1073/pnas.1633447100; Karges W, 2002, DIABETES, V51, P3237, DOI 10.2337/diabetes.51.11.3237; Kawasaki E, 2000, FRONT BIOSCI, V5, pE181, DOI 10.2741/kawasaki; Kemp EH, 1998, CLIN ENDOCRINOL, V49, P609; Kumar PG, 2002, ENDOCRIN METAB CLIN, V31, P321, DOI 10.1016/S0889-8529(01)00011-1; Lieberman SM, 2003, P NATL ACAD SCI USA, V100, P8384, DOI 10.1073/pnas.0932778100; Lyons PA, 2001, DIABETES, V50, P2633, DOI 10.2337/diabetes.50.11.2633; MacMurray AJ, 2002, GENOME RES, V12, P1029, DOI 10.1101/gr.412702; Martin AM, 1999, DIABETES, V48, P2138, DOI 10.2337/diabetes.48.11.2138; Moriyama H, 2002, P NATL ACAD SCI USA, V99, P5539, DOI 10.1073/pnas.082120099; MUIR A, 1995, ENDOCRINOLOGY, V3, P3013; Myhre AG, 2002, J CLIN ENDOCR METAB, V87, P618, DOI 10.1210/jc.87.2.618; Nepom GT, 2002, ARTHRITIS RHEUM, V46, P5, DOI 10.1002/1529-0131(200201)46:1<5::AID-ART10063>3.0.CO;2-S; NEUFELD M, 1981, MEDICINE, V60, P355, DOI 10.1097/00005792-198109000-00003; Park YS, 2002, TISSUE ANTIGENS, V60, P155, DOI 10.1034/j.1399-0039.2002.600206.x; Patel DD, 2001, J CLIN INVEST, V107, P155, DOI 10.1172/JCI11966; Pearce SHS, 1998, AM J HUM GENET, V63, P1675, DOI 10.1086/302145; Perheentupa J, 2002, ENDOCRIN METAB CLIN, V31, P295, DOI 10.1016/S0889-8529(01)00013-5; Perniola R, 2000, EUR J ENDOCRINOL, V143, P497, DOI 10.1530/eje.0.1430497; Pugliese A, 2002, DIABETES-METAB RES, V18, P13, DOI 10.1002/dmrr.261; Ramanathan S, 2002, DIABETES, V51, P2975, DOI 10.2337/diabetes.51.10.2975; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Redondo MJ, 2001, DIABETOLOGIA, V44, P927; Redondo MJ, 2001, DIABETOLOGIA, V44, P354, DOI 10.1007/s001250051626; Robles DT, 2003, DIABETES, V52, P882, DOI 10.2337/diabetes.52.3.882; Roep BO, 1999, J AUTOIMMUN, V13, P267, DOI 10.1006/jaut.1999.0312; Rovira M, 2001, BRIT J HAEMATOL, V115, P373, DOI 10.1046/j.1365-2141.2001.03040.x; Ryan EA, 2002, DIABETES, V51, P2148, DOI 10.2337/diabetes.51.7.2148; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; SARTOR G, 1995, DIABETIC MED, V12, P607, DOI 10.1111/j.1464-5491.1995.tb00550.x; Schatz DA, 2002, ENDOCRIN METAB CLIN, V31, P339, DOI 10.1016/S0889-8529(01)00012-3; Schenker M, 1999, DIABETOLOGIA, V42, P671, DOI 10.1007/s001250051214; Schey S, 1996, BLOOD REV, V10, P75, DOI 10.1016/S0268-960X(96)90035-1; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Scott HS, 1998, MOL ENDOCRINOL, V12, P1112, DOI 10.1210/me.12.8.1112; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Skyler JS, 2002, NEW ENGL J MED, V346, P1685; Soderbergh A, 1996, CLIN ENDOCRINOL, V45, P453, DOI 10.1046/j.1365-2265.1996.8040813.x; SUTHERLAND DER, 1984, T ASSOC AM PHYSICIAN, V97, P80; Thomas HE, 2000, DIABETES-METAB RES, V16, P251, DOI 10.1002/1520-7560(200007/08)16:4<251::AID-DMRR126>3.3.CO;2-3; UCHIGATA Y, 1999, MED INTELL UNIT, V13, P133; Venstrom JM, 2003, JAMA-J AM MED ASSOC, V290, P2817, DOI 10.1001/jama.290.21.2817; Verge CF, 1998, J CLIN INVEST, V102, P1569, DOI 10.1172/JCI3379; Verge CF, 1996, DIABETES, V45, P926, DOI 10.2337/diabetes.45.7.926; Vincent C, 2002, ARTHRITIS RHEUM, V46, P2051, DOI 10.1002/art.10436; Wesche B, 2001, GUT, V48, P378, DOI 10.1136/gut.48.3.378; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Winter William E, 2002, Diabetes Technol Ther, V4, P817, DOI 10.1089/152091502321118838; YU L, 2002, TYPE 1 DIABETES MOL; Yu LP, 2000, P NATL ACAD SCI USA, V97, P1701, DOI 10.1073/pnas.040556697; Yu LP, 1999, J CLIN ENDOCR METAB, V84, P328, DOI 10.1210/jc.84.1.328	99	361	389	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2068	2079		10.1056/NEJMra030158	http://dx.doi.org/10.1056/NEJMra030158			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141045				2022-12-28	WOS:000221354000008
J	Flannery, B; Schrag, S; Bennett, NA; Lynfield, R; Harrison, LH; Reingold, A; Cieslak, PR; Hadler, J; Farley, MM; Facklam, RR; Zell, ER; Whitney, CG				Flannery, B; Schrag, S; Bennett, NA; Lynfield, R; Harrison, LH; Reingold, A; Cieslak, PR; Hadler, J; Farley, MM; Facklam, RR; Zell, ER; Whitney, CG		Active Bacterial Core Surveillance	Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCOCCAL DISEASE; NASOPHARYNGEAL CARRIAGE; CONJUGATE VACCINE	Context Historically, incidence of pneumococcal disease in the United States has been higher among blacks than among whites. Following recommendation of a new 7-valent pneumococcal conjugate vaccine for children in October 2000, the incidence of invasive pneumococcal disease has declined dramatically, but the impact of vaccination on racial disparities in incidence of pneumococcal disease is unknown. Objective To assess the effect of conjugate vaccine introduction on rates of pneumococcal disease among whites and blacks in the United States. Design, Setting, and Patients Analysis of data from the Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network, an active, population-based surveillance system in 7 states. Patients were 15923 persons with invasive pneumococcal disease occurring between January 1, 1998, and December 31, 2002, Main Outcome Measures Age- and race-specific pneumococcal disease incidence rates (cases per 100000 persons), rate ratios, and rate differences. Results Between 1998 and 2002, annual incidence rates for invasive pneumococcal disease decreased from 19.0 to 12.1 cases per 100000 among whites and from 54.9 to 26.5 among blacks. Due to these declines, 14730 fewer cases occurred among whites and 8780 fewer cases occurred among blacks in the United States in 2002, compared with 2 prevaccine years, 1998 and 1999. Before vaccine introduction, incidence among blacks was 2.9 times higher than among whites (95% confidence interval [CI], 2.73.0); in 2002, the black-white rate ratio had been reduced to 2.2 (95% CI, 2.0-2.4). Incidence among black children younger than 2 years went from being 3.3 times higher (95% CI, 3.0-3.7) than among white children in the prevaccine period to 1.6 times higher (95% CI, 1.1-2.2) in 2002. By 2002, 74% of white children and 68% of black children aged 19 to 35 months in the 7 states had received at least 1 dose of pneumococcal conjugate vaccine; 43% of white and 39% of black children received 3 or more doses. Conclusion Although blacks remain at higher risk of invasive pneumococcal disease, introduction of childhood pneumococcal vaccination has reduced the racial disparity in incidence of pneumococcal disease.	CDCP, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Monroe Cty Dept Hlth, Rochester, NY USA; Univ Rochester, Rochester, NY USA; Minnesota Dept Hlth, Minneapolis, MN USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Oregon Dept Human Serv, Off Dis Prevent & Epidemiol, Portland, OR USA; Connecticut Dept Publ Hlth, Hartford, CT USA; Emory Univ, Sch Med, Atlanta, GA USA; Vet Affairs Med Ctr, Atlanta, GA 30033 USA	Centers for Disease Control & Prevention - USA; University of Rochester; Minnesota Department of Health (MHD); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California Berkeley; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Flannery, B (corresponding author), CDCP, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, MS C-23,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	bflannery@cdc.gov						[Anonymous], 2000, MMWR Recomm Rep, V49, P1; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; Black SB, 2001, PEDIATR INFECT DIS J, V20, P1105, DOI 10.1097/00006454-200112000-00002; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P783; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P987; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P1140; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P446; Dagan R, 2002, J INFECT DIS, V185, P927, DOI 10.1086/339525; Harrison LH, 2000, ARCH INTERN MED, V160, P89, DOI 10.1001/archinte.160.1.89; Ingram DD., 2003, VITAL HLTH STAT SERI, V2; Levine OS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e28; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; Research Triangle Institute, 2001, SUDAAN US MAN REL 8; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Sisk JE, 2003, ANN INTERN MED, V138, P960, DOI 10.7326/0003-4819-138-12-200306170-00007; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; *US DEP HHS, 2002, 2001 NAT IMM SURV; *US DEP HHS, 2003, 2002 NAT IMM SURV; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823	21	136	142	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2004	291	18					2197	2203		10.1001/jama.291.18.2197	http://dx.doi.org/10.1001/jama.291.18.2197			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GR	15138241	Bronze			2022-12-28	WOS:000221303500021
J	Clarke, HF; Dalley, JW; Crofts, HS; Robbins, TW; Roberts, AC				Clarke, HF; Dalley, JW; Crofts, HS; Robbins, TW; Roberts, AC			Cognitive inflexibility after prefrontal serotonin depletion	SCIENCE			English	Article							OBSESSIVE-COMPULSIVE DISORDER; ORBITOFRONTAL CORTEX; TRYPTOPHAN DEPLETION; FRONTAL-CORTEX; EXCITOTOXIC LESIONS; DECISION-MAKING; BASAL FOREBRAIN; REWARD; REVERSAL; METHYLPHENIDATE	Serotonergic dysregulation within the prefrontal cortex (PFC) is implicated in many neuropsychiatric disorders, but the precise role of serotonin within the PFC is poorly understood. Using a serial discrimination reversal paradigm, we showed that upon reversal, selective serotonin depletion of the marmoset PFC produced perseverative responding to the previously rewarded stimulus without any significant effects on either retention of a discrimination learned preoperatively or acquisition of a novel discrimination postoperatively. These results highlight the importance of prefrontal serotonin in behavioral flexibility and are highly relevant to obsessive-compulsive disorder, schizophrenia, and the cognitive sequelae of drug abuse in which perseveration is prominent.	Univ Cambridge, Dept Anat, Cambridge, England; Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England	University of Cambridge; University of Cambridge	Roberts, AC (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge, England.	acr4@cam.ac.uk	Robbins, Trevor W/A-7551-2008; Roberts, Angela C/C-1313-2012	Roberts, Angela C/0000-0003-2873-157X; Robbins, Trevor/0000-0003-0642-5977; Dalley, Jeffrey/0000-0002-2282-3660				Baare WFC, 1999, BIOL PSYCHIAT, V45, P1597, DOI 10.1016/S0006-3223(98)00266-2; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Crofts HS, 2001, CEREB CORTEX, V11, P1015, DOI 10.1093/cercor/11.11.1015; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; Fellows LK, 2003, BRAIN, V126, P1830, DOI 10.1093/brain/awg180; Freedman M, 1998, CEREB CORTEX, V8, P18, DOI 10.1093/cercor/8.1.18; HANDLEY GW, 1978, PSYCHOPHARMACOLOGY, V57, P115, DOI 10.1007/BF00426967; HARDIN H, 1994, MOL BRAIN RES, V26, P1, DOI 10.1016/0169-328X(94)90067-1; Hermesh H, 2003, EUR NEUROPSYCHOPHARM, V13, P87, DOI 10.1016/S0924-977X(02)00128-1; HIRANO H, 1995, J NEUROCHEM, V65, P1139; INSEL TR, 1992, PSYCHIAT CLIN N AM, V15, P813; Jentsch JD, 2002, NEUROPSYCHOPHARMACOL, V26, P183, DOI 10.1016/S0893-133X(01)00355-4; JONES B, 1972, EXP NEUROL, V36, P362, DOI 10.1016/0014-4886(72)90030-1; Mayberg HS, 1997, NEUROREPORT, V8, P1057, DOI 10.1097/00001756-199703030-00048; McCann UD, 2000, NEUROPSYCHOBIOLOGY, V42, P11, DOI 10.1159/000026665; Mobini S, 2000, PSYCHOPHARMACOLOGY, V152, P390, DOI 10.1007/s002130000542; O'Doherty J, 2001, NAT NEUROSCI, V4, P95, DOI 10.1038/82959; Pantelis C, 1999, SCHIZOPHR RES, V37, P251, DOI 10.1016/S0920-9964(98)00156-X; PARK SB, 1994, NEUROPHARMACOLOGY, V33, P575, DOI 10.1016/0028-3908(94)90089-2; RIDLEY RM, 1981, PHARMACOL BIOCHEM BE, V14, P849, DOI 10.1016/0091-3057(81)90373-7; ROBERTS AC, 1992, NEUROSCIENCE, V47, P251, DOI 10.1016/0306-4522(92)90241-S; ROBERTS AC, 1990, NEUROSCIENCE, V34, P311, DOI 10.1016/0306-4522(90)90142-Q; Rogers RD, 1999, PSYCHOPHARMACOLOGY, V146, P482, DOI 10.1007/PL00005494; Rogers RD, 2003, NEUROPSYCHOPHARMACOL, V28, P153, DOI 10.1038/sj.npp.1300001; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Schoenbaum G, 1999, J NEUROSCI, V19, P1876; Wilson JM, 1996, NAT MED, V2, P699, DOI 10.1038/nm0696-699; Zohar J, 1996, BRIT J PSYCHIAT, V169, P468, DOI 10.1192/bjp.169.4.468	28	463	469	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					878	880		10.1126/science.1094987	http://dx.doi.org/10.1126/science.1094987			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131308				2022-12-28	WOS:000221243000046
J	Kers, JA; Wach, MJ; Krasnoff, SB; Widom, J; Cameron, KD; Bukhalid, RA; Gibson, DM; Crane, BR; Loria, R				Kers, JA; Wach, MJ; Krasnoff, SB; Widom, J; Cameron, KD; Bukhalid, RA; Gibson, DM; Crane, BR; Loria, R			Nitration of a peptide phytotoxin by bacterial nitric oxide synthase	NATURE			English	Article							PROTEIN; THAXTOMIN; BIOSYNTHESIS; EXPRESSION; GENES	Nitric oxide ( NO) is a potent intercellular signal in mammals that mediates key aspects of blood pressure, hormone release, nerve transmission and the immune response of higher organisms(1-4). Proteins homologous to full-length mammalian nitric oxide synthases (NOSs) are found in lower multicellular organisms(5). Recently, genome sequencing has shown that some bacteria contain genes coding for truncated NOS proteins; this is consistent with reports of NOS-like activities in bacterial extracts(6,7). Biological functions for bacterial NOSs are unknown, but have been presumed to be analogous to their role in mammals. Here we describe a gene in the plant pathogen Streptomyces turgidiscabies that encodes a NOS homologue, and we reveal its role in nitrating a dipeptide phytotoxin required for plant pathogenicity(8). High similarity between bacterial NOSs indicates a general function in biosynthetic nitration; thus, bacterial NOSs constitute a new class of enzymes(9-11). Here we show that the primary function of Streptomyces NOS is radically different from that of mammalian NOS. Surprisingly, mammalian NO signalling and bacterial biosynthetic nitration share an evolutionary origin.	Cornell Univ, Dept Plant Pathol, Ithaca, NY 14853 USA; ARS, USDA, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; United States Department of Agriculture (USDA); Cornell University	Loria, R (corresponding author), Cornell Univ, Dept Plant Pathol, Ithaca, NY 14853 USA.	rl21@cornell.edu						Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; CARTER GT, 1989, J CHEM SOC CHEM COMM, P1271, DOI 10.1039/c39890001271; CHEN YJ, 1995, J BACTERIOL, V177, P5122, DOI 10.1128/jb.177.17.5122-5128.1995; Choi WS, 1997, BIOCHEM BIOPH RES CO, V237, P554, DOI 10.1006/bbrc.1997.7189; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Goyer C, 1998, PHYTOPATHOLOGY, V88, P442, DOI 10.1094/PHYTO.1998.88.5.442; Healy FG, 2000, MOL MICROBIOL, V38, P794, DOI 10.1046/j.1365-2958.2000.02170.x; Healy FG, 2002, J BACTERIOL, V184, P2019, DOI 10.1128/JB.184.7.2019-2029.2002; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; ISCHIROPOULOS H, 2002, FREE RADICAL BIOL ME, V33; JALAL MAF, 1986, ACTA CRYSTALLOGR C, V42, P733, DOI 10.1107/S010827018609474X; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; Lipton SA, 2001, NATURE, V413, P118, DOI 10.1038/35093186; MACNEIL DJ, 1992, GENE, V111, P61, DOI 10.1016/0378-1119(92)90603-M; Martin GE, 2000, J NAT PROD, V63, P543, DOI 10.1021/np9903191; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; OHBA K, 1987, J ANTIBIOT, V40, P709, DOI 10.7164/antibiotics.40.709; Packer L., 1996, METHODS ENZYMOL, P268; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; Pfeiffer S, 1999, ANGEW CHEM INT EDIT, V38, P1715, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1714::AID-ANIE1714>3.0.CO;2-3; Ridd JH, 1998, ACTA CHEM SCAND, V52, P11, DOI 10.3891/acta.chem.scand.52-0011; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Sun JH, 1999, MICROBIOL-UK, V145, P2221, DOI 10.1099/00221287-145-9-2221; Torreilles J, 2001, FRONT BIOSCI-LANDMRK, V6, pD1161, DOI 10.2741/Torreill	30	202	209	4	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 6	2004	429	6987					79	82		10.1038/nature02504	http://dx.doi.org/10.1038/nature02504			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129284				2022-12-28	WOS:000221222100048
J	Lee, MS; Makkar, RR				Lee, MS; Makkar, RR			Stem-cell transplantation in myocardial infarction: A status report	ANNALS OF INTERNAL MEDICINE			English	Review							ENDOTHELIAL PROGENITOR CELLS; BONE-MARROW-CELLS; IMPROVES CARDIAC-FUNCTION; LEFT-VENTRICULAR FUNCTION; CORONARY-ARTERY DISEASE; HEART FUNCTION; TENASCIN-C; CARDIOMYOCYTE TRANSPLANTATION; MYOBLAST TRANSPLANTATION; FETAL CARDIOMYOCYTES	Myocardial infarction is the leading cause of congestive heart failure and death in the industrialized world. Current therapy is limited in preventing the progression of ventricular remodeling and congestive heart failure. Recent interest has focused on stem cells, which are undifferentiated and pluripotent cells that can proliferate, potentially self-renew, and differentiate into cardiomyocytes. Myocardial regeneration with stem-cell transplantation is a possible treatment option to reverse the deleterious hemodynamic and neurohormonal effects that occur after myocardial infarction and can lead to congestive heart failure. Various preclinical animal studies show the potential to regenerate myocardium and improve perfusion to the infarct area to improve cardiac function but also suggest that stem cells may have proarrhythmic effects. Early phase I clinical studies indicate that stem-cell transplantation is feasible and may have beneficial effects on ventricular remodeling after myocardial infarction. Future randomized clinical trials will establish the magnitude of the benefit and the effects on arrhythmias after stem-cell therapy.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Cardiac Catheterizat Lab, Div Cardiol,Sch Med, Los Angeles, CA 90048 USA; Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, New York, NY 10032 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Makkar, RR (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Cardiac Catheterizat Lab, Div Cardiol,Sch Med, 8631 W 3rd St 415E, Los Angeles, CA 90048 USA.	raj.makkar@cshs.org						Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Badorff C, 2003, CIRCULATION, V107, P1024, DOI 10.1161/01.CIR.0000051460.85800.BB; Becker W, 2001, Lancet Infect Dis, V1, P326, DOI 10.1016/S1473-3099(01)00146-3; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Bishop AE, 2002, J PATHOL, V197, P424, DOI 10.1002/path.1154; Cao JM, 2000, CIRC RES, V86, P816, DOI 10.1161/01.RES.86.7.816; Cao JM, 2000, CIRCULATION, V101, P1960, DOI 10.1161/01.CIR.101.16.1960; Caplice NM, 2003, CIRC RES, V92, P6, DOI 10.1161/01.RES.0000052826.35667.40; Cohn JN, 1997, CIRCULATION, V95, P766; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; Dengler TJ, 2002, HERZ, V27, P598, DOI 10.1007/s00059-002-2412-5; Etzion S, 2001, J MOL CELL CARDIOL, V33, P1321, DOI 10.1006/jmcc.2000.1391; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Fuchs S, 2001, J AM COLL CARDIOL, V37, P1726, DOI 10.1016/S0735-1097(01)01200-1; Garot J, 2003, J AM COLL CARDIOL, V41, P1841, DOI 10.1016/S0735-1097(03)00414-5; Gassler N, 1999, HISTOL HISTOPATHOL, V14, P81, DOI 10.14670/HH-14.81; Ghostine S, 2002, CIRCULATION, V106, pI131, DOI 10.1161/01.cir.0000032889.55215.f1; Hagege AA, 2003, LANCET, V361, P491, DOI 10.1016/S0140-6736(03)12458-0; Hamano K, 2001, JPN CIRC J, V65, P845, DOI 10.1253/jcj.65.845; HARDY CL, 1995, AM J MED SCI, V309, P260; Hescheler J, 2001, J CLIN INVEST, V108, P363, DOI 10.1172/JCI200113634; Hughes S, 2002, J PATHOL, V197, P468, DOI 10.1002/path.1159; Jain M, 2001, CIRCULATION, V103, P1920; Joester A, 2001, MATRIX BIOL, V20, P13, DOI 10.1016/S0945-053X(00)00136-0; Kawamoto A, 2001, CIRCULATION, V103, P634; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Kocher AA, 2003, WIEN KLIN WOCHENSCHR, V115, P77, DOI 10.1007/BF03040281; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kraitchman DL, 2003, CIRCULATION, V107, P2290, DOI 10.1161/01.CIR.0000070931.62772.4E; Lai AC, 2000, J CARDIOVASC ELECTR, V11, P1345, DOI 10.1046/j.1540-8167.2000.01345.x; Lederman RJ, 2002, CIRCULATION, V105, P1282, DOI 10.1161/circ.105.11.1282; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Leor J, 1997, CARDIOVASC RES, V35, P431, DOI 10.1016/S0008-6363(97)00159-4; Li RK, 1996, ANN THORAC SURG, V62, P654; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Makkar RR, 2002, CIRCULATION, V106, P34; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; Min JY, 2002, ANN THORAC SURG, V74, P1568, DOI 10.1016/S0003-4975(02)03952-8; Min JY, 2002, J APPL PHYSIOL, V92, P288, DOI 10.1152/jappl.2002.92.1.288; NelissenVrancken HJMG, 1996, CIRCULATION, V93, P349; O'Shea KS, 1999, ANAT RECORD, V257, P32, DOI 10.1002/(SICI)1097-0185(19990215)257:1<32::AID-AR6>3.0.CO;2-2; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pagani FD, 2003, J AM COLL CARDIOL, V41, P879, DOI 10.1016/S0735-1097(03)00081-0; Pak HN, 2003, J CARDIOVASC ELECTR, V14, P841, DOI 10.1046/j.1540-8167.2003.03124.x; Perin EC, 2003, CIRCULATION, V107, P935, DOI 10.1161/01.CIR.0000057526.10455.BD; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Perin EC, 2002, CIRCULATION, V106, P957, DOI 10.1161/01.CIR.0000026394.01888.18; Pouzet B, 2000, CIRCULATION, V102, P210; Probstmeier R, 2001, J NEUROSCI RES, V64, P70, DOI 10.1002/jnr.1055; Qayyum MS, 2002, J AM COLL CARDIOL, V39, p169A; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rangappa S, 2003, ANN THORAC SURG, V75, P775, DOI 10.1016/S0003-4975(02)04568-X; Robinson SW, 1996, CELL TRANSPLANT, V5, P77, DOI 10.1016/0963-6897(95)02016-0; Scorsin M, 1996, CIRCULATION, V94, P337; Semsarian C, 2002, INTERN MED J, V32, P259, DOI 10.1046/j.1445-5994.2002.00206.x; Shake JG, 2002, ANN THORAC SURG, V73, P1919, DOI 10.1016/S0003-4975(02)03517-8; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Szilvassy SJ, 1999, BLOOD, V93, P1557, DOI 10.1182/blood.V93.5.1557; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; VANMETER CH, 1995, J THORAC CARDIOV SUR, V110, P1442, DOI 10.1016/S0022-5223(95)70067-6; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; Wallner K, 1999, CIRCULATION, V99, P1284, DOI 10.1161/01.CIR.99.10.1284; Wallner K, 2001, J AM COLL CARDIOL, V37, P655, DOI 10.1016/S0735-1097(00)01117-7; Wang JS, 2000, J THORAC CARDIOV SUR, V120, P999, DOI 10.1067/mtc.2000.110250; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75; Wolf T, 2001, J AM COLL CARDIOL, V37, P1590, DOI 10.1016/S0735-1097(01)01209-8; WOLLERT KC, 2003, CIRCULATION, V108, P2723; Yamamoto K, 1999, J BIOL CHEM, V274, P21840, DOI 10.1074/jbc.274.31.21840; Zhang YM, 2002, CIRCULATION, V106, P1294, DOI 10.1161/01.CIR.0000027585.05868.67	80	69	85	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	2004	140	9					729	737		10.7326/0003-4819-140-9-200405040-00013	http://dx.doi.org/10.7326/0003-4819-140-9-200405040-00013			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816XR	15126257				2022-12-28	WOS:000221143100007
J	Collins, FS				Collins, FS			The case for a US prospective cohort study of genes and environment	NATURE			English	Editorial Material							ASSOCIATION; DISEASE	Information from the Human Genome Project will be vital for defining the genetic and environmental factors that contribute to health and disease. Well-designed case-control studies of people with and without a particular disease are essential for this, but rigorous and unbiased conclusions about the causes of diseases and their population-wide impact will require a representative population to be monitored over time ( a prospective cohort study). The time is right for the United States to consider such a project.	NHGRI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Collins, FS (corresponding author), NHGRI, NIH, Bldg 31,Room 4B09,MSC 2152,31 Ctr Dr, Bethesda, MD 20892 USA.	fc23a@nih.gov						Chakravarti A, 2003, NATURE, V421, P412, DOI 10.1038/nature01401; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; FEINSTEIN AR, 1985, J CHRON DIS, V38, P127, DOI 10.1016/0021-9681(85)90085-2; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Gordis L., 2000, EPIDEMIOLOGY, V2; Guo SW, 1998, AM J HUM GENET, V63, P252, DOI 10.1086/301928; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Shi Michael M, 2002, Am J Pharmacogenomics, V2, P197, DOI 10.2165/00129785-200202030-00005; Silberberg JS, 1998, AM J EPIDEMIOL, V147, P1123; van den Oord EJCG, 1999, AM J EPIDEMIOL, V150, P1179; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Weaver VM, 1998, ENVIRON HEALTH PERSP, V106, P827, DOI 10.2307/3434197	14	177	184	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					475	477		10.1038/nature02628	http://dx.doi.org/10.1038/nature02628			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164074				2022-12-28	WOS:000221644600051
J	Goldhaber, SZ; Nadel, ES; King, ME; Sharma, A; Noble, VE; Harris, NL; Rice, P; Brown, D				Goldhaber, SZ; Nadel, ES; King, ME; Sharma, A; Noble, VE; Harris, NL; Rice, P; Brown, D			A 42-year-old woman with cardiac arrest several weeks after an ankle fracture - Cardiac arrest due to a pulmonary embolus.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TISSUE-PLASMINOGEN ACTIVATOR; ORAL ANTICOAGULANT-THERAPY; VENOUS THROMBOEMBOLISM; CARDIOPULMONARY-RESUSCITATION; THROMBOLYTIC THERAPY; RISK STRATIFICATION; LONG-TERM; XIMELAGATRAN; PREVENTION; WARFARIN		Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Emergency Med, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Cardiol, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Noble, VE (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, Boston, MA 02115 USA.							Abu-Laban RB, 2002, NEW ENGL J MED, V346, P1522, DOI 10.1056/NEJMoa012885; AbuLaban RB, 2003, NEW ENGL J MED, V349, P1487; Aklog L, 2002, CIRCULATION, V105, P1416, DOI 10.1161/01.CIR.0000012526.21603.25; Albers GW, 2003, LANCET, V362, P1691; *AM HEART ASS, 2002, ACLS PROV MAN; Beer JH, 2003, J THROMB HAEMOST, V1, P186, DOI 10.1046/j.1538-7836.2003.00005.x; Bottiger BW, 2001, LANCET, V357, P1583, DOI 10.1016/S0140-6736(00)04726-7; Cohn LH, 2003, CIRCULATION, V107, P2168, DOI 10.1161/01.CIR.0000071746.50876.E2; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; Eriksson H, 2003, J THROMB HAEMOST, V1, P41, DOI 10.1046/j.1538-7836.2003.00034.x; Francis CW, 2003, NEW ENGL J MED, V349, P1703, DOI 10.1056/NEJMoa035162; Goldhaber SZ, 2002, ANN INTERN MED, V136, P691, DOI 10.7326/0003-4819-136-9-200205070-00012; Goldhaber SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; Goldhaber SZ, 1998, CHEST, V114, P1237, DOI 10.1378/chest.114.5.1237; Kearon C, 1999, NEW ENGL J MED, V341, P298; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Konstantinides S, 2002, CIRCULATION, V106, P1263, DOI 10.1161/01.CIR.0000028422.51668.A2; Konstantinides S, 2002, NEW ENGL J MED, V347, P1143, DOI 10.1056/NEJMoa021274; Kucher N, 2003, CIRCULATION, V108, P2191, DOI 10.1161/01.CIR.0000100687.99687.CE; Lederer W, 2001, RESUSCITATION, V50, P71, DOI 10.1016/S0300-9572(01)00317-3; Levine JS, 2002, NEW ENGL J MED, V346, P752, DOI 10.1056/NEJMra002974; McConnell MV, 1996, AM J CARDIOL, V78, P469, DOI 10.1016/S0002-9149(96)00339-6; Newman DH, 2000, ANN EMERG MED, V35, P472, DOI 10.1067/mem.2000.105600; Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Sharma GVRK, 2000, VASC MED, V5, P91, DOI 10.1191/135886300666830773; STUEVEN HA, 1989, RESUSCITATION, V17, P173, DOI 10.1016/0300-9572(89)90069-5; Wicki J, 2000, THROMB HAEMOSTASIS, V84, P548, DOI 10.1055/s-0037-1614065	30	8	8	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2281	2290		10.1056/NEJMcpc049008	http://dx.doi.org/10.1056/NEJMcpc049008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163779				2022-12-28	WOS:000221641900011
J	Lang, IM				Lang, IM			Chronic thromboembolic pulmonary hypertension - Not so rare after all	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Med Univ Vienna, Div Cardiol, Vienna, Austria	Medical University of Vienna	Lang, IM (corresponding author), Med Univ Vienna, Div Cardiol, Vienna, Austria.			Lang, Irene/0000-0003-0485-2692				Bonderman D, 2003, THROMB HAEMOSTASIS, V90, P372, DOI 10.1160/TH03-02-0067; Fedullo PF, 2001, NEW ENGL J MED, V345, P1465, DOI 10.1056/NEJMra010902; Jamieson SW, 2003, ANN THORAC SURG, V76, P1457, DOI 10.1016/S0003-4975(03)00828-2; LANG IM, 1994, CIRCULATION, V89, P2715, DOI 10.1161/01.CIR.89.6.2715; MOSER KM, 1965, CIRCULATION, V32, P377, DOI 10.1161/01.CIR.32.3.377	5	165	181	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2236	2238		10.1056/NEJMp048088	http://dx.doi.org/10.1056/NEJMp048088			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163772				2022-12-28	WOS:000221641900003
J	Mitchell, JF; Stoner, GR; Reynolds, JH				Mitchell, JF; Stoner, GR; Reynolds, JH			Object-based attention determines dominance in binocular rivalry	NATURE			English	Article							SELECTIVE ATTENTION; SURFACES; MOTION; SYNCHRONY; FEATURES	A question of long-standing interest to philosophers, psychologists and neuroscientists is how the brain selects which signals enter consciousness(1,2). Binocular rivalry and attention both involve selection of visual stimuli, but affect perception quite differently. During binocular rivalry, awareness alternates between two different stimuli presented to the two eyes. In contrast, attending to one of two different stimuli impairs discrimination of the ignored stimulus, but without causing it to disappear from consciousness. Here we show that despite this difference, attention and rivalry rely on shared object-based selection mechanisms. We cued attention to one of two superimposed transparent surfaces and then deleted the image of one surface from each eye, resulting in rivalry. Observers usually reported seeing only the cued surface. They were also less accurate in judging unpredictable changes in the features of the uncued surface. Our design ensured that selection of the cued surface could not have resulted from spatial, ocular or feature-based mechanisms. Rather, attention was drawn to one surface, and this caused the other surface to be perceptually suppressed during rivalry. These results raise the question of how object representations compete during these two forms of perceptual selection, even as the features of those objects change unpredictably over time.	Salk Inst Biol Studies, Syst Neurobiol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Vis Ctr Lab, La Jolla, CA 92037 USA	Salk Institute; Salk Institute	Reynolds, JH (corresponding author), Salk Inst Biol Studies, Syst Neurobiol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reynolds@salk.edu		Mitchell, Jude/0000-0003-0197-7545				Alais D, 1999, VISION RES, V39, P4341, DOI 10.1016/S0042-6989(99)00146-7; Alais D, 1998, VISION RES, V38, P637, DOI 10.1016/S0042-6989(97)00190-9; Blake R, 2002, NAT REV NEUROSCI, V3, P13, DOI 10.1038/nrn701; Blaser E, 2000, NATURE, V408, P196, DOI 10.1038/35041567; Castelo-Branco M, 2000, NATURE, V405, P685, DOI 10.1038/35015079; Diaz-Caneja E, 1928, ANN OCUL, V165, P721; DUNCAN J, 1984, J EXP PSYCHOL GEN, V113, P501, DOI 10.1037/0096-3445.113.4.501; James W, 1890, PRINCIPLES PSYCHOL, V1; Kovacs I, 1996, P NATL ACAD SCI USA, V93, P15508, DOI 10.1073/pnas.93.26.15508; KULIKOWSKI JJ, 1992, OPHTHAL PHYSL OPT, V12, P168, DOI 10.1111/j.1475-1313.1992.tb00283.x; Lack L.C., 1978, SELECTIVE ATTENTION; Lee SH, 1999, VISION RES, V39, P1447, DOI 10.1016/S0042-6989(98)00269-7; Leopold DA, 1996, NATURE, V379, P549, DOI 10.1038/379549a0; Leopold DA, 1999, TRENDS COGN SCI, V3, P254, DOI 10.1016/S1364-6613(99)01332-7; Logothetis NK, 1996, NATURE, V380, P621, DOI 10.1038/380621a0; Mitchell JF, 2003, VISION RES, V43, P1323, DOI 10.1016/S0042-6989(03)00123-8; Ooi TL, 1999, PERCEPTION, V28, P551, DOI 10.1068/p2923; Ooi TL, 2003, PERCEPTION, V32, P155, DOI 10.1068/p3467; Pinilla T, 2001, VISION RES, V41, P1619, DOI 10.1016/S0042-6989(01)00039-6; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Reynolds JH, 2003, VISION RES, V43, P59, DOI 10.1016/S0042-6989(02)00403-0; Sasaki H, 2002, PERCEPTION, V31, P409, DOI 10.1068/p3255; Schoenfeld MA, 2003, P NATL ACAD SCI USA, V100, P11806, DOI 10.1073/pnas.1932820100; Shenberg DL, 1997, P NATL ACAD SCI USA, V94, P3408, DOI 10.1073/pnas.94.7.3408; Sobel KV, 2002, PERCEPTION, V31, P813, DOI 10.1068/p3279; Thiele A, 2003, NATURE, V421, P366, DOI 10.1038/nature01285; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Valdes-Sosa M, 2000, J EXP PSYCHOL HUMAN, V26, P488, DOI 10.1037/0096-1523.26.2.488; VONNHELMHOLTZ H, 1909, HDB PHYSL OPTIK; WHITTLE P, 1968, PERCEPT PSYCHOPHYS, V4, P183, DOI 10.3758/BF03210465	30	182	184	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					410	413		10.1038/nature02584	http://dx.doi.org/10.1038/nature02584			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164062	Green Accepted			2022-12-28	WOS:000221644600038
J	Bogaty, P; Brophy, JM				Bogaty, P; Brophy, JM			Primary angioplasty or thrombolysis? a topical parable	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION		Univ Laval, Quebec Heart Inst, St Foy, PQ G1V 4G5, Canada; McGill Univ, Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada	Laval University; McGill University; Royal Victoria Hospital	Bogaty, P (corresponding author), Univ Laval, Quebec Heart Inst, St Foy, PQ G1V 4G5, Canada.	peter.bogaty@med.ulaval.ca	brophy, james/H-6673-2019	brophy, james/0000-0001-8049-6875				Bonnefoy E, 2002, LANCET, V360, P825, DOI 10.1016/S0140-6736(02)09963-4; BROPHY J, IN PRESS ANN INTERN; Feldman LJ, 2003, CIRCULATION, V107, P2684, DOI 10.1161/01.CIR.0000070423.91346.45; Henriques JPS, 2003, J AM COLL CARDIOL, V41, P2138, DOI 10.1016/S0735-1097(03)00461-3; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7	5	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 22	2004	328	7450					1257	1258		10.1136/bmj.328.7450.1257	http://dx.doi.org/10.1136/bmj.328.7450.1257			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824HL	15155510	Green Published			2022-12-28	WOS:000221677200034
J	Erwin, DH; Krakauer, DC				Erwin, DH; Krakauer, DC			Insights into innovation	SCIENCE			English	Editorial Material									Smithsonian Inst, Dept Paleobiol, Washington, DC 20560 USA; Santa Fe Inst, Santa Fe, NM 87501 USA	Smithsonian Institution; Smithsonian National Museum of Natural History; The Santa Fe Institute	Erwin, DH (corresponding author), Smithsonian Inst, Dept Paleobiol, Washington, DC 20560 USA.	erwin@santafe.edu; krakauer@santafe.edu	Erwin, Douglas H/A-9668-2009	Erwin, Douglas/0000-0003-2518-5614				Gould SJ, 2002, STRUCTURE EVOLUTIONA; Odling-Smee John, 2003, NICHE CONSTRUCTION; Pellmyr O, 2002, P NATL ACAD SCI USA, V99, P5498, DOI 10.1073/pnas.072588699; *SANT FE I, 2004, INN NAT EXP APPL EV; Schumpeter Joseph A., 1926, THEORY EC DEV; Szathmary E, 1995, MAJOR TRANSITIONS EV	6	54	54	3	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	2004	304	5674					1117	1119		10.1126/science.1099385	http://dx.doi.org/10.1126/science.1099385			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155937				2022-12-28	WOS:000221524500027
J	Hadigan, C; Yawetz, S; Thomas, A; Havers, F; Sax, PE; Grinspoon, S				Hadigan, C; Yawetz, S; Thomas, A; Havers, F; Sax, PE; Grinspoon, S			Metabolic effects of rosiglitazone in HIV lipodystrophy - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS-INFECTION; PROTEASE INHIBITOR THERAPY; NUCLEOSIDE ANALOG THERAPY; INSULIN-RESISTANCE; BODY-COMPOSITION; FAT REDISTRIBUTION; ADIPOSE-TISSUE; MYOCARDIAL-INFARCTION; MEN	Background: Patients with HIV infection who are treated with antiretroviral agents often lose subcutaneous fat and have metabolic abnormalities, including insulin resistance and reduced adiponectin levels, which may be related to disrupted subcutaneous adipogenesis and altered peroxisome proliferator-activated receptor-gamma signaling. Objective: To investigate the effects of rosiglitazone (4 mg/d), a peroxisome proliferator-activated receptor-gamma agonist, in HIV-infected men and women with hyperinsulinemia and lipoatrophy. Design: A randomized, double-blind, placebo-controlled, 3-month study. Setting: University hospital. Patients: 28 HIV-infected men and women with hyperinsulinemia and lipoatrophy. Measurements: Insulin sensitivity measured by euglycemic hyperinsulinemic clamp testing; subcutaneous leg fat area measured by computed tomography; adiponectin, free fatty acid, and lipid levels; and safety variables. Results: Rosiglitazone, when compared with placebo, improved insulin sensitivity (mean [+/-SD] change, 1.5 +/- 2.1 mg of glucose/kg of lean body mass per minute vs. -0.4 +/- 1.6 mg/kg per minute; P = 0.02), increased adiponectin levels (mean [+/-SD], 2.2 +/- 2.2 mug/mL vs. 0.1 +/- 1.1 mug/mL; P = 0.006), and reduced free fatty acid levels (mean [+/-SD], -0.09 +/- 0.1 mmol/L vs. 0.01 +/- 0.1 mmol/L; P = 0.02). Mean percentage (+/-SD) of body fat (1.38% +/- 3.03% vs. -0.83% +/- 2.76%; P = 0.03) and subcubaneous leg fat area (2.3 +/- 8.4 cm(2) VS. -0.9 +/- 1.9 cm(2); P = 0.02) increased significantly with rosiglitazone compared with placebo. Mean total cholesterol levels (+/-SD) also increased with rosiglitazone compared with placebo (0.6 +/- 1.0 mmol/L [25 +/- 37 mg/dL] vs. -0.4 +/- 0.6 mmol/L [-15 +/- 25 mg/dL]; P = 0.007). Limitations: The study was relatively small and of short duration. Conclusions: The authors demonstrated positive effects of rosiglitazone on lipoatrophy; insulin sensitivity; and metabolic indices, including adiponectin levels, in HIV-infected patients with lipoatrophy and insulin resistance. Peroxisome proliferator-activated receptor-gamma agonists may correct the metabolic abnormalities associated with disrupted adipogenesis in this population. Further studies must determine the clinical utility of such agents in HIV-infected patients.	Massachusetts Gen Hosp, Program Nutr Metab, Boston, MA 02114 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Hadigan, C (corresponding author), Massachusetts Gen Hosp, Program Nutr Metab, 55 Fruit St LON207, Boston, MA 02114 USA.	chadigan@partners.org			NCRR NIH HHS [M01-RR02635, M01-RR300088] Funding Source: Medline; NIDDK NIH HHS [R01 DK 59535, K23 DK 02844] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059535, K23DK002844] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Addy CL, 2003, J CLIN ENDOCR METAB, V88, P627, DOI 10.1210/jc.2002-020795; Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Bastard JP, 2002, LANCET, V359, P1026, DOI 10.1016/S0140-6736(02)08094-7; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; BORKAN GA, 1982, AM J CLIN NUTR, V36, P172, DOI 10.1093/ajcn/36.1.172; Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048; Carr A, 2002, JAMA-J AM MED ASSOC, V288, P207, DOI 10.1001/jama.288.2.207; Carr A, 2000, AIDS, V14, pF25, DOI 10.1097/00002030-200002180-00001; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; DAS S, 2003, 10 C RETR OPP INF BO; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Dube MP, 2002, ANTIVIR THER, V7, pL18; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Gelato MC, 2002, JAIDS-J ACQ IMM DEF, V31, P163, DOI 10.1097/00126334-200210010-00006; Hadigaan C, 2003, AM J CLIN NUTR, V77, P490, DOI 10.1093/ajcn/77.2.490; Hadigan C, 2001, CLIN INFECT DIS, V32, P130, DOI 10.1086/317541; Hadigan C, 2000, JAMA-J AM MED ASSOC, V284, P472, DOI 10.1001/jama.284.4.472; Hadigan C, 2002, METABOLISM, V51, P1143, DOI 10.1053/meta.2002.34704; HAMMOND E, 2003, 10 C RETR OPP INF BO; Heath KV, 2001, AIDS, V15, P231, DOI 10.1097/00002030-200101260-00013; HOY JF, 2003, 10 C RETR OPP INF BO; John M, 2003, JAIDS-J ACQ IMM DEF, V33, P29, DOI 10.1097/00126334-200305010-00005; Klein D, 2002, J ACQ IMMUN DEF SYND, V30, P471, DOI 10.1097/00126334-200208150-00002; Kosmiski L, 2003, ANTIVIR THER, V8, P9; Kosmiski LA, 2001, AIDS, V15, P1993, DOI 10.1097/00002030-200110190-00012; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lichtenstein KA, 2001, AIDS, V15, P1389, DOI 10.1097/00002030-200107270-00008; Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010; Meininger G, 2002, AM J CLIN NUTR, V76, P460, DOI 10.1093/ajcn/76.2.460; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Morris AD, 1997, CLIN EXP PHARMACOL P, V24, P513, DOI 10.1111/j.1440-1681.1997.tb01237.x; Moyle GJ, 2003, JAIDS-J ACQ IMM DEF, V33, P22, DOI 10.1097/00126334-200305010-00004; Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005; Mulligan K, 1997, J ACQ IMMUN DEF SYND, V15, P43, DOI 10.1097/00042560-199705010-00007; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Mynarcik DC, 2002, JAIDS-J ACQ IMM DEF, V31, P514, DOI 10.1097/00126334-200212150-00009; MYNARCIK DC, 2002, J ACQ IMMUN DEF SYND, V25, P312; Noor MA, 2002, AIDS, V16, pF1, DOI 10.1097/00002030-200203290-00002; Noor MA, 2001, AIDS, V15, pF11, DOI 10.1097/00002030-200105040-00001; Ohsuzu F, 1998, Radiat Med, V16, P99; Paradisi G, 2003, J CLIN ENDOCR METAB, V88, P576, DOI 10.1210/jc.2002-020386; Raskin P, 2000, DIABETOLOGIA, V43, P278, DOI 10.1007/s001250050045; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; Sekhar RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE332, DOI 10.1152/ajpendo.00058.2002; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Sutinen J, 2003, J CLIN ENDOCR METAB, V88, P1907, DOI 10.1210/jc.2002-021922; Tong Q, 2003, J CLIN ENDOCR METAB, V88, P1559, DOI 10.1210/jc.2002-021600; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Vigouroux C, 1999, DIABETES METAB, V25, P225; Vigouroux C, 2003, AIDS, V17, P1503, DOI 10.1097/00002030-200307040-00011; Visnegarwala F, 2003, ANTIVIR THER, V8, pL52; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yki-Jarvinen H, 2003, ARTERIOSCL THROM VAS, V23, P688, DOI 10.1161/01.ATV.0000062885.61917.A5	58	156	162	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					786	794		10.7326/0003-4819-140-10-200405180-00008	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148065				2022-12-28	WOS:000221520900003
J	Amsen, D; Blander, JM; Lee, GR; Tanigaki, K; Honjo, T; Flavell, RA				Amsen, D; Blander, JM; Lee, GR; Tanigaki, K; Honjo, T; Flavell, RA			Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells	CELL			English	Article							NF-KAPPA-B; DENDRITIC CELLS; IN-VIVO; GENE-EXPRESSION; FUNCTIONAL DIVERSITY; PHYSICAL INTERACTION; NEURAL DEVELOPMENT; CUTTING EDGE; TH2 CELLS; ACTIVATION	Antigen-presenting cells (APC) tailor immune responses to microbial encounters by stimulating differentiation of CD4 T cells into the Th1 and Th2 lineages. We demonstrate that APC use the Notch pathway to instruct T cell differentiation. Strikingly, of the two Notch ligand families, Delta induces Th1, while Jagged induces the alternate Th2 fate. Expression of these different Notch ligands on APC is induced by Th1- or Th2-promoting stimuli. Th2 differentiation has been considered a default process as APC-derived instructive signals are unknown. We demonstrate that Jagged constitutes an instructive signal for Th2 differentiation, which is independent of IL4/STAT6. Th2 differentiation induced by APC is abrogated in T cells lacking the Notch effector RBPJkappa. Notch directs Th2 differentiation by inducing GATA3 and by directly regulating il4 gene transcription through RBPJkappa sites in a 3' enhancer.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan	Yale University; Kyoto University	Amsen, D (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA.	richard.flavell@yale.edu	Honjo, Tasuku/N-4470-2016	Blander, Julie Magarian/0000-0001-9207-1700				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Adler SH, 2003, J IMMUNOL, V171, P2896, DOI 10.4049/jimmunol.171.6.2896; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Anastasi E, 2003, J IMMUNOL, V171, P4504, DOI 10.4049/jimmunol.171.9.4504; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Asnagli H, 2002, J IMMUNOL, V168, P4268, DOI 10.4049/jimmunol.168.9.4268; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Beatus P, 1999, DEVELOPMENT, V126, P3925; Bray S, 1998, SEMIN CELL DEV BIOL, V9, P591, DOI 10.1006/scdb.1998.0262; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; d'Ostiani CF, 2000, J EXP MED, V191, P1661, DOI 10.1084/jem.191.10.1661; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; de Jong EC, 2002, J IMMUNOL, V168, P1704, DOI 10.4049/jimmunol.168.4.1704; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Finkelman FD, 2000, J IMMUNOL, V164, P2303, DOI 10.4049/jimmunol.164.5.2303; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Gagliardi MC, 2000, EUR J IMMUNOL, V30, P2394, DOI 10.1002/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO;2-Y; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; Hicks C, 2002, J NEUROSCI RES, V68, P655, DOI 10.1002/jnr.10263; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hoyne GF, 2000, INT IMMUNOL, V12, P177, DOI 10.1093/intimm/12.2.177; Huppert SS, 1997, DEVELOPMENT, V124, P3283; Iwasaki A, 1999, J EXP MED, V190, P229, DOI 10.1084/jem.190.2.229; Jaleco AC, 2001, J EXP MED, V194, P991, DOI 10.1084/jem.194.7.991; Jankovic D, 2000, J IMMUNOL, V164, P3047, DOI 10.4049/jimmunol.164.6.3047; Jankovic D, 2002, IMMUNITY, V16, P429, DOI 10.1016/S1074-7613(02)00278-9; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Justice NJ, 2002, CURR OPIN NEUROBIOL, V12, P64, DOI 10.1016/S0959-4388(02)00291-X; Kaisho T, 2002, INT IMMUNOL, V14, P695, DOI 10.1093/intimm/dxf039; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Kato H, 1996, FEBS LETT, V395, P221, DOI 10.1016/0014-5793(96)01046-0; Krebs LT, 2003, GENE DEV, V17, P1207, DOI 10.1101/gad.1084703; Lane P, 2000, J EXP MED, V191, P201, DOI 10.1084/jem.191.2.201; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lee CY, 2001, J SCHED, V4, P3, DOI 10.1002/1099-1425(200101/02)4:1<3::AID-JOS57>3.0.CO;2-D; Lee GR, 2003, IMMUNITY, V19, P145, DOI 10.1016/S1074-7613(03)00179-1; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; Lu BF, 2004, P NATL ACAD SCI USA, V101, P3023, DOI 10.1073/pnas.0307743100; Maekawa Y, 2003, IMMUNITY, V19, P549, DOI 10.1016/S1074-7613(03)00270-X; Maillard I, 2003, IMMUNITY, V19, P781, DOI 10.1016/S1074-7613(03)00325-X; Mohrs M, 2001, NAT IMMUNOL, V2, P842, DOI 10.1038/ni0901-842; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murphy KM, 1998, CURR OPIN IMMUNOL, V10, P226, DOI 10.1016/S0952-7915(98)80253-7; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nakamura T, 1997, J IMMUNOL, V158, P1085; Newberry RD, 2001, J IMMUNOL, V166, P4465, DOI 10.4049/jimmunol.166.7.4465; NobenTrauth N, 1997, P NATL ACAD SCI USA, V94, P10838, DOI 10.1073/pnas.94.20.10838; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; OKA C, 1995, DEVELOPMENT, V121, P3291; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Palaga T, 2003, J IMMUNOL, V171, P3019, DOI 10.4049/jimmunol.171.6.3019; Palmieri M, 1999, NUCLEIC ACIDS RES, V27, P2785, DOI 10.1093/nar/27.13.2785; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Ramsdell F, 2003, IMMUNITY, V19, P165, DOI 10.1016/S1074-7613(03)00207-3; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; SCHMITZ J, 1994, J EXP MED, V179, P1349, DOI 10.1084/jem.179.4.1349; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528; Shimizu K, 2000, BIOCHEM BIOPH RES CO, V276, P385, DOI 10.1006/bbrc.2000.3469; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Solymar DC, 2002, IMMUNITY, V17, P41, DOI 10.1016/S1074-7613(02)00334-5; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; Vigouroux S, 2003, J VIROL, V77, P10872, DOI 10.1128/JVI.77.20.10872-10880.2003; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Yamaguchi E, 2002, IMMUNOL LETT, V81, P59, DOI 10.1016/S0165-2478(01)00326-1; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	79	702	741	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	2004	117	4					515	526		10.1016/S0092-8674(04)00451-9	http://dx.doi.org/10.1016/S0092-8674(04)00451-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137944	Bronze			2022-12-28	WOS:000221458000011
J	D'Amours, D; Stegmeier, F; Amon, A				D'Amours, D; Stegmeier, F; Amon, A			Cdc14 and condensin control the dissolution of cohesin-independent chromosome linkages at repeated DNA	CELL			English	Article							SISTER-CHROMATID SEPARATION; MITOTIC CHROMOSOME; BUDDING YEAST; POLO KINASE; S-PHASE; ANAPHASE; CHECKPOINT; PROTEIN; MITOSIS; SMT4	Chromosome segregation is triggered by the cleavage of cohesins by separase. Here we show that in budding yeast separation of the ribosomal DNA (rDNA) and telomeres also requires Cdc14, a protein phosphatase known for its role in mitotic exit. Cdc14 shares this role with the FEAR network, which activates Cdc14 during early anaphase, but not the mitotic exit network, which promotes Cdc14 activity during late anaphase. We further show that CDC14 is necessary and sufficient to promote condensin enrichment at the rDNA locus and to trigger rDNA segregation in a condensin-dependent manner. We propose that Cdc14 released by the FEAR network mediates the partitioning of rDNA by facilitating the localization of condensin thereto. This dual role of the FEAR network in initiating mitotic exit and promoting chromosome segregation ensures that exit from mitosis is coupled to the completion of chromosome segregation.	MIT, Howard Hughes Med Inst, Canc Res Ctr, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Amon, A (corresponding author), MIT, Howard Hughes Med Inst, Canc Res Ctr, E17-233,40 Ames St, Cambridge, MA 02139 USA.	angelika@mit.edu		Amon, Angelika/0000-0001-9837-0314	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056800, R29GM056800] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56800] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal R, 2002, GENE DEV, V16, P1371, DOI 10.1101/gad.971402; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Amon A, 2002, METHOD ENZYMOL, V351, P457; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Bhalla N, 2002, MOL BIOL CELL, V13, P632, DOI 10.1091/mbc.01-05-0264; Buonomo SBC, 2003, DEV CELL, V4, P727, DOI 10.1016/S1534-5807(03)00129-1; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; Gardner RD, 2000, TRENDS CELL BIOL, V10, P154, DOI 10.1016/S0962-8924(00)01727-X; Geymonat M, 2002, CURR BIOL, V12, pR482, DOI 10.1016/S0960-9822(02)00963-6; GONZALEZ C, 1991, EXP CELL RES, V192, P10, DOI 10.1016/0014-4827(91)90150-S; GRANOT D, 1991, CELL MOTIL CYTOSKEL, V20, P47, DOI 10.1002/cm.970200106; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Guillermond A., 1917, ANN I PASTEUR, V3, P107; Haering CH, 2003, BIOESSAYS, V25, P1178, DOI 10.1002/bies.10361; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; HARTWELL LH, 1985, GENETICS, V110, P381; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Lavoie BD, 2004, GENE DEV, V18, P76, DOI 10.1101/gad.1150404; Lavoie BD, 2002, J CELL BIOL, V156, P805, DOI 10.1083/jcb.200109056; Lavoie BD, 2000, MOL BIOL CELL, V11, P1293, DOI 10.1091/mbc.11.4.1293; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Ouspenski II, 2000, MOL BIOL CELL, V11, P1305, DOI 10.1091/mbc.11.4.1305; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shou WY, 2001, MOL CELL, V8, P45, DOI 10.1016/S1097-2765(01)00291-X; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Steffensen S, 2001, CURR BIOL, V11, P295, DOI 10.1016/S0960-9822(01)00096-3; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Strunnikov AV, 2001, GENETICS, V158, P95; Sullivan M, 2004, CELL, V117, P471, DOI 10.1016/S0092-8674(04)00415-5; Sullivan M, 2003, NAT CELL BIOL, V5, P249, DOI 10.1038/ncb940; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; van Heemst D, 1999, CELL, V98, P261, DOI 10.1016/S0092-8674(00)81020-X; VIG BK, 1987, MUTAGENESIS, V2, P155, DOI 10.1093/mutage/2.3.155; Visintin R, 2003, MOL BIOL CELL, V14, P4486, DOI 10.1091/mbc.E03-02-0095; Wai HH, 2000, NUCLEIC ACIDS RES, V28, P3524, DOI 10.1093/nar/28.18.3524; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99	44	236	238	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	2004	117	4					455	469		10.1016/S0092-8674(04)00413-1	http://dx.doi.org/10.1016/S0092-8674(04)00413-1			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137939	Bronze			2022-12-28	WOS:000221458000006
J	Sullivan, M; Higuchi, T; Katis, VL; Uhlmann, F				Sullivan, M; Higuchi, T; Katis, VL; Uhlmann, F			Cdc14 phosphatase induces rDNA condensation and resolves cohesin-independent cohesion during budding yeast anaphase	CELL			English	Article							DNA TOPOISOMERASE-II; SISTER-CHROMATID SEPARATION; CHROMOSOME CONDENSATION; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; MITOTIC EXIT; MAMMALIAN-CELLS; FISSION YEAST; EGG EXTRACTS; MITOSIS	At anaphase onset, the protease separase triggers chromosome segregation by cleaving the chromosomal cohesin complex. Here, we show that cohesin destruction in metaphase is sufficient for segregation of much of the budding yeast genome, but not of the long arm of chromosome XII that contains the rDNA repeats. rDNA in metaphase, unlike most other sequences, remains in an undercondensed and topologically entangled state. Separase, concomitantly with cleaving cohesin, activates the phosphatase Cdc14. We find that Cdc14 exerts two effects on rDNA, both mediated by the condensin complex. Lengthwise condensation of rDNA shortens the chromosome XII arm sufficiently for segregation. This condensation depends on the aurora B kinase complex. Independently of condensation, Cdc14 induces condensin-dependent resolution of cohesin-independent rDNA linkage. Cdc14-dependent sister chromatid resolution at the rDNA could introduce a temporal order to chromosome segregation.	Canc Res UK London Res Inst, Chromosome Segregat Lab, London WC2A 3PX, England; Res Inst Mol Pathol, A-1030 Vienna, Austria	Cancer Research UK; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Uhlmann, F (corresponding author), Canc Res UK London Res Inst, Chromosome Segregat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	frank.uhlmann@cancer.org.uk		Uhlmann, Frank/0000-0002-3527-6619				Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Bhalla N, 2002, MOL BIOL CELL, V13, P632, DOI 10.1091/mbc.01-05-0264; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Buonomo SBC, 2003, DEV CELL, V4, P727, DOI 10.1016/S1534-5807(03)00129-1; Buvelot S, 2003, J CELL BIOL, V160, P329, DOI 10.1083/jcb.200209018; Coelho PA, 2003, J CELL SCI, V116, P4763, DOI 10.1242/jcs.00799; D'Amours D, 2004, CELL, V117, P455, DOI 10.1016/S0092-8674(04)00413-1; DOWNES CS, 1991, P NATL ACAD SCI USA, V88, P8895, DOI 10.1073/pnas.88.20.8895; ELLIOTT SG, 1979, MOL GEN GENET, V169, P237, DOI 10.1007/BF00382269; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; Gerlich D, 2003, CELL, V112, P751, DOI 10.1016/S0092-8674(03)00189-2; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRANOT D, 1991, CELL MOTIL CYTOSKEL, V20, P47, DOI 10.1002/cm.970200106; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; JANNATIPOUR M, 1993, J BIOL CHEM, V268, P18586; Jaspersen SL, 2000, CURR BIOL, V10, P615, DOI 10.1016/S0960-9822(00)00491-7; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; Laloraya S, 2000, J CELL BIOL, V151, P1047, DOI 10.1083/jcb.151.5.1047; Lavoie BD, 2004, GENE DEV, V18, P76, DOI 10.1101/gad.1150404; Lavoie BD, 2002, J CELL BIOL, V156, P805, DOI 10.1083/jcb.200109056; Lavoie BD, 2000, MOL BIOL CELL, V11, P1293, DOI 10.1091/mbc.11.4.1293; Losada A, 2001, BIOESSAYS, V23, P924, DOI 10.1002/bies.1133; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Ouspenski II, 2000, MOL BIOL CELL, V11, P1305, DOI 10.1091/mbc.11.4.1305; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Sullivan M, 2003, NAT CELL BIOL, V5, P249, DOI 10.1038/ncb940; Sullivan M, 2001, NAT CELL BIOL, V3, P771, DOI 10.1038/ncb0901-771; Sumner AT., 2003, CHROMOSOMES ORG FUNC; TAKAO O, 2003, CELL, V115, P109; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; VIG BK, 1981, HUM GENET, V57, P247; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wignall SM, 2003, J CELL BIOL, V161, P1041, DOI 10.1083/jcb.200303185; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	53	208	209	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	2004	117	4					471	482		10.1016/S0092-8674(04)00415-5	http://dx.doi.org/10.1016/S0092-8674(04)00415-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137940	Bronze			2022-12-28	WOS:000221458000007
J	Christensen, UR; Tilgner, A				Christensen, UR; Tilgner, A			Power requirement of the geodynamo from ohmic losses in numerical and laboratory dynamos	NATURE			English	Article							EARTHS CORE; 2-SCALE DYNAMO; MAGNETIC-FIELD; POTASSIUM; EVOLUTION; MODEL; HEAT	In the Earth's fluid outer core, a dynamo process converts thermal and gravitational energy into magnetic energy. The power needed to sustain the geomagnetic field is set by the ohmic losses (dissipation due to electrical resistance)(1). Recent estimates of ohmic losses cover a wide range, from 0.1 to 3.5 TW, or roughly 0.3 - 10% of the Earth's surface heat flow(1-4). The energy requirement of the dynamo puts constraints on the thermal budget and evolution of the core through Earth's history(1-5). Here we use a set of numerical dynamo models to derive scaling relations between the core's characteristic dissipation time and the core's magnetic and hydrodynamic Reynolds numbers dimensionless numbers that measure the ratio of advective transport to magnetic and viscous diffusion, respectively. The ohmic dissipation of the Karlsruhe dynamo experiment(6) supports a simple dependence on the magnetic Reynolds number alone, indicating that flow turbulence in the experiment and in the Earth's core has little influence on its characteristic dissipation time. We use these results to predict moderate ohmic dissipation in the range of 0.2-0.5 TW, which removes the need for strong radioactive heating in the core(7) and allows the age of the solid inner core to exceed 2.5 billion years.	Max Planck Inst Aeron, D-37191 Katlenburg Lindau, Germany; Univ Gottingen, Inst Geophys, D-37075 Gottingen, Germany	Max Planck Society; University of Gottingen	Christensen, UR (corresponding author), Max Planck Inst Aeron, Max Planck Str 2, D-37191 Katlenburg Lindau, Germany.	Christensen@linmpi.mpg.de		Tilgner, Andreas/0000-0002-7671-5008				BLOXHAM J, 1989, PHILOS T R SOC A, V329, P415, DOI 10.1098/rsta.1989.0087; BLOXHAM J, 1992, J GEOPHYS RES-SOL EA, V97, P19537, DOI 10.1029/92JB01591; Buffett BA, 2003, SCIENCE, V299, P1675, DOI 10.1126/science.1081518; BUFFETT BA, 2002, GEOPHYS RES LETT, V29, DOI DOI 10.1029/2001GL014649; Christensen U, 1999, GEOPHYS J INT, V138, P393, DOI 10.1046/j.1365-246X.1999.00886.x; Gessmann CK, 2002, EARTH PLANET SC LETT, V200, P63, DOI 10.1016/S0012-821X(02)00593-9; Gubbins D, 2003, GEOPHYS J INT, V155, P609, DOI 10.1046/j.1365-246X.2003.02064.x; HULOT G, 1994, PHYS EARTH PLANET IN, V82, P167, DOI 10.1016/0031-9201(94)90070-1; Kuang WL, 1997, NATURE, V389, P371, DOI 10.1038/38712; Kutzner C, 2002, PHYS EARTH PLANET IN, V131, P29, DOI 10.1016/S0031-9201(02)00016-X; Labrosse S, 2003, PHYS EARTH PLANET IN, V140, P127, DOI 10.1016/j.pepi.2003.07.006; LANGEL RA, 1982, GEOPHYS RES LETT, V9, P250, DOI 10.1029/GL009i004p00250; MCELHINNY MW, 1980, J GEOPHYS RES, V85, P3523, DOI 10.1029/JB085iB07p03523; Muller U, 2002, NONLINEAR PROC GEOPH, V9, P165; Murthy VM, 2003, NATURE, V423, P163, DOI 10.1038/nature01560; Nimmo F, 2004, GEOPHYS J INT, V156, P363, DOI 10.1111/j.1365-246X.2003.02157.x; Roberts PH, 2003, FL MEC ASTR, V11, P100; Roberts PH, 2000, PHILOS T ROY SOC A, V358, P1109, DOI 10.1098/rsta.2000.0576; SECCO RA, 1989, J GEOPHYS RES-SOLID, V94, P5887, DOI 10.1029/JB094iB05p05887; Stieglitz R, 2001, PHYS FLUIDS, V13, P561, DOI 10.1063/1.1331315; Tilgner A, 2002, PHYS FLUIDS, V14, P4092, DOI 10.1063/1.1513156	21	155	156	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	2004	429	6988					169	171		10.1038/nature02508	http://dx.doi.org/10.1038/nature02508			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141208				2022-12-28	WOS:000221356300037
J	Singh, S; Dhikav, V; Agarwal, N; Anand, KS				Singh, S; Dhikav, V; Agarwal, N; Anand, KS			An unusual cause of psychosis	LANCET			English	Editorial Material							NEUROCYSTICERCOSIS		All India Inst Med Sci, Dept Radiotherapy, New Delhi, India; All India Inst Med Sci, Dept Pharmacol, New Delhi, India; Lady Harding Med Coll, Dept Psychiat, New Delhi, India; Dr Ram Manohar Lohlya Hosp, New Delhi, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; Lady Hardinge Medical College & Hospital	Singh, S (corresponding author), All India Inst Med Sci, Dept Radiotherapy, New Delhi, India.	singhsindhu@hotmail.com						Forlenza OV, 1997, J NEUROL NEUROSUR PS, V62, P612, DOI 10.1136/jnnp.62.6.612; Garcia HH, 2003, LANCET, V362, P547, DOI 10.1016/S0140-6736(03)14117-7; SCHANTZ PM, 1992, NEW ENGL J MED, V327, P692, DOI 10.1056/NEJM199209033271004; SHRIQUI CL, 1992, CAN J PSYCHIAT, V37, P121, DOI 10.1177/070674379203700209; TAVARES AR, 1993, BRIT J PSYCHIAT, V163, P869	5	7	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	2004	363	9420					1522	1522		10.1016/S0140-6736(04)16152-7	http://dx.doi.org/10.1016/S0140-6736(04)16152-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135600				2022-12-28	WOS:000221302700012
J	Reynolds, TA; Tierney, LM				Reynolds, TA; Tierney, LM			Medical education in modern China	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMUM ESSENTIAL REQUIREMENTS; 21ST-CENTURY		Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Reynolds, TA (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.							Armstrong EG, 2002, MED TEACH, V24, P130, DOI 10.1080/01421590220120731; FOX S, 1984, JAMA-J AM MED ASSOC, V251, P490; Gao TQ, 1999, MED EDUC, V33, P768, DOI 10.1046/j.1365-2923.1999.00313.x; KAUFMAN A, 1988, MED EDUC, V22, P253, DOI 10.1111/j.1365-2923.1988.tb00750.x; Lee SH, 1997, MED EDUC, V31, P468, DOI 10.1046/j.1365-2923.1997.00706.x; Schwarz MR, 2002, MED TEACH, V24, P125, DOI 10.1080/01421590220120740; WEN CP, 1975, NEW ENGL J MED, V292, P998, DOI 10.1056/NEJM197505082921904	7	10	10	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2004	291	17					2141	2141		10.1001/jama.291.17.2141	http://dx.doi.org/10.1001/jama.291.17.2141			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JR	15126446				2022-12-28	WOS:000221174300035
J	Bejerano, G; Pheasant, M; Makunin, I; Stephen, S; Kent, WJ; Mattick, JS; Haussler, D				Bejerano, G; Pheasant, M; Makunin, I; Stephen, S; Kent, WJ; Mattick, JS; Haussler, D			Ultraconserved elements in the human genome	SCIENCE			English	Article							CONSERVED SEQUENCES; REGULATORY ELEMENTS; NONCODING SEQUENCES; GENE; MOUSE; HUMAN-CHROMOSOME-21; IDENTIFICATION; EVOLUTION; RNA; INTRONS	There are 481 segments longer than 200 base pairs (bp) that are absolutely conserved (100% identity with no insertions or deletions) between orthologous regions of the human, rat, and mouse genomes. Nearly all of these segments are also conserved in the chicken and dog genomes, with an average of 95 and 99% identity, respectively. Many are also significantly conserved in fish. These ultraconserved elements of the human genome are most often located either overlapping exons in genes involved in RNA processing or in introns or nearby genes involved in the regulation of transcription and development. Along with more than 5000 sequences of over 100 bp that are absolutely conserved among the three sequenced mammals, these represent a class of genetic elements whose functions and evolutionary origins are yet to be determined, but which are more highly conserved between these species than are proteins and appear to be essential for the ontogeny of mammals and other vertebrates.	Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA; Univ Queensland, Inst Mol Biosci, ARC Special Res Ctr Funct & Appl Genom, Brisbane, Qld 4072, Australia	University of California System; University of California Santa Cruz; Howard Hughes Medical Institute; University of California System; University of California Santa Cruz; University of Queensland	Bejerano, G (corresponding author), Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA.	jill@soe.ucsc.edu; haussler@soe.ucsc.edu	Stuart, Stephen/I-3380-2012; Mattick, John/ABH-6130-2020; Mattick, John S/I-7789-2012; Makunin, Igor V/A-1306-2008; Pheasant, Michael/A-7564-2008	Stuart, Stephen/0000-0001-5141-640X; Mattick, John/0000-0002-7680-7527; Mattick, John S/0000-0002-7680-7527; Pheasant, Michael/0000-0001-9781-7655	NHGRI NIH HHS [1P41HG02371] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P41HG002371] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Aruscavage PJ, 2000, RNA, V6, P257, DOI 10.1017/S1355838200991921; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BEJERANO G, IN PRESS BIOINFORM S; BOFFELI D, IN PRESS NATURE REV; Chiaromonte F, 2003, COLD SPRING HARB SYM, V68, P245, DOI 10.1101/sqb.2003.68.245; Chuang JH, 2004, PLOS BIOL, V2, P253, DOI 10.1371/journal.pbio.0020029; Cooper GM, 2004, GENOME RES, V14, P539, DOI 10.1101/gr.2034704; Dermitzakis ET, 2004, GENOME RES, V14, P852, DOI 10.1101/gr.1934904; Dermitzakis ET, 2003, SCIENCE, V302, P1033, DOI 10.1126/science.1087047; Dermitzakis ET, 2002, NATURE, V420, P578, DOI 10.1038/nature01251; DeSilva U, 2002, GENOME RES, V12, P3, DOI 10.1101/gr.214802; Frazer KA, 2004, GENOME RES, V14, P367, DOI 10.1101/gr.1961204; Frazer KA, 2001, GENOME RES, V11, P1651, DOI 10.1101/gr.198201; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Hardison RC, 2000, TRENDS GENET, V16, P369, DOI 10.1016/S0168-9525(00)02081-3; Hardison RC, 2003, GENOME RES, V13, P13, DOI 10.1101/gr.844103; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Margulies EH, 2003, GENOME RES, V13, P2507, DOI 10.1101/gr.1602203; Mattick JS, 2001, MOL BIOL EVOL, V18, P1611, DOI 10.1093/oxfordjournals.molbev.a003951; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; PLAZA S, 1995, MOL CELL BIOL, V15, P892; Rahman L, 2004, GENOMICS, V83, P76, DOI 10.1016/S0888-7543(03)00207-6; ROSKIN KM, 2003, P 7 ANN INT C RES CO, P257, DOI DOI 10.1145/640075.640109; SABARINADH C, 2003, GENOME BIOL, V4; Sherr EH, 2003, CURR OPIN PEDIATR, V15, P567, DOI 10.1097/00008480-200312000-00004; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0	37	1170	1263	2	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1321	1325		10.1126/science.1098119	http://dx.doi.org/10.1126/science.1098119			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15131266	Green Submitted			2022-12-28	WOS:000221669600054
J	Downward, J				Downward, J			Science, medicine, and the future - RNA interference	BRITISH MEDICAL JOURNAL			English	Review							GENE-EXPRESSION; HUMAN-CELLS; APOPTOSIS; VIRUS; MICE; SUPPRESSION; INHIBITION; HEPATITIS; PETUNIA; SCREEN		Canc Res UK London Res Inst, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Canc Res UK London Res Inst, 44 Lincolns Inn Fields, London WC2A 3PX, England.	downward@cancer.org.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002; Damm-Welk C, 2003, SEMIN CANCER BIOL, V13, P283, DOI 10.1016/S1044-579X(03)00042-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Ge Q, 2003, P NATL ACAD SCI USA, V100, P2718, DOI 10.1073/pnas.0437841100; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Tewari M, 2003, DEV CELL, V5, P534, DOI 10.1016/S1534-5807(03)00303-4; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291	17	67	115	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 22	2004	328	7450					1245	1248		10.1136/bmj.328.7450.1245	http://dx.doi.org/10.1136/bmj.328.7450.1245			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824HL	15155505	Green Published			2022-12-28	WOS:000221677200029
J	Ingelfinger, JR				Ingelfinger, JR			Pediatric antecedents of adult cardiovascular disease - Awareness and intervention	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		[Anonymous], 1987, PEDIATRICS, V79, P1; BLUMENTHAL S, 1977, PEDIATRICS, V59, P797; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Falkner B, 1996, PEDIATRICS, V98, P649	4	51	54	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2123	2126		10.1056/NEJMp048069	http://dx.doi.org/10.1056/NEJMp048069			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152057				2022-12-28	WOS:000221496700003
J	Heymann, DL; Aylward, RB; Wolff, C				Heymann, DL; Aylward, RB; Wolff, C			Dangerous pathogens in the laboratory: from smallpox to today's SARS setbacks and tomorrow's polio-free world	LANCET			English	Editorial Material							CERTIFICATION		WHO, Polio Eradicat Initiat, CH-1211 Geneva, Switzerland	World Health Organization	Heymann, DL (corresponding author), WHO, Polio Eradicat Initiat, CH-1211 Geneva, Switzerland.	heymannd@who.int						DOWDLE W, 2003, B WORLD HEALTH ORGAN, V82, P59; Fine PEM, 2004, B WORLD HEALTH ORGAN, V82, P47; Jezek Z, 1988, HUMAN MONKEYPOX; Mulders MN, 1997, J INFECT DIS, V176, P617, DOI 10.1086/514081; *SARS, 2003, SARS SING UPD, V2; Sutter RW, 2004, B WORLD HEALTH ORGAN, V82, P31; *WHO, 2003, SEV AC RESP SYNDR TA; *WHO, WHOVB0311; *WHO, 2004, SARS CHIN UPD, V6; *WHO, 2003, REP INF CONS ID MAN; *WHO, CHIN CONF SARS INF P; World Health Organization, 2003, WHO POST BIOS GUID H; World Health Organization, 2003, WHO BIOS GUID HANDL; World Health Organization, 2003, GUID SAF PROD QUAL C	14	28	28	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	2004	363	9421					1566	1568		10.1016/S0140-6736(04)16234-X	http://dx.doi.org/10.1016/S0140-6736(04)16234-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145625	Green Published, Bronze			2022-12-28	WOS:000221408800002
J	Ferguson, NM; Fraser, C; Donnelly, CA; Ghani, AC; Anderson, RM				Ferguson, NM; Fraser, C; Donnelly, CA; Ghani, AC; Anderson, RM			Public health risk from the avian H5N1 influenza epidemic	SCIENCE			English	Editorial Material							EMERGENCE		Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London W2 1PG, England	Imperial College London	Ferguson, NM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	neil.ferguson@imperial.ac.uk	Ghani, Azra/B-8560-2009; Fraser, Christophe/A-8109-2008; Ferguson, Neil/B-8578-2008	Fraser, Christophe/0000-0003-2399-9657; Ferguson, Neil/0000-0002-1154-8093; Donnelly, Christl/0000-0002-0195-2463; Ghani, Azra/0000-0002-0007-4910; Anderson, Roy/0000-0002-9528-3175				Abbott A, 2004, NATURE, V427, P472, DOI 10.1038/427472a; ANDERSON R M, 1991; [Anonymous], 2002, Wkly Epidemiol Rec, V77, P350; Antia R, 2003, NATURE, V426, P658, DOI 10.1038/nature02104; Cox NJ, 2003, VACCINE, V21, P1801, DOI 10.1016/S0264-410X(03)00076-8; De Serres G, 2000, AM J EPIDEMIOL, V151, P1039, DOI 10.1093/oxfordjournals.aje.a010145; Farrington CP, 2003, BIOSTATISTICS, V4, P279, DOI 10.1093/biostatistics/4.2.279; Ferguson NM, 2003, NATURE, V422, P428, DOI 10.1038/nature01509; Jansen VAA, 2003, SCIENCE, V301, P804, DOI 10.1126/science.1086726; Katz JM, 1999, J INFECT DIS, V180, P1763, DOI 10.1086/315137; Koopmans M, 2004, LANCET, V363, P587, DOI 10.1016/S0140-6736(04)15589-X; MONTO AS, 1975, AM J EPIDEMIOL, V102, P553, DOI 10.1093/oxfordjournals.aje.a112193; Nicholson KG, 2003, LANCET, V362, P1733, DOI 10.1016/S0140-6736(03)14854-4; Webby RJ, 2001, PHILOS T R SOC B, V356, P1817, DOI 10.1098/rstb.2001.0997	14	122	130	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					968	969		10.1126/science.1096898	http://dx.doi.org/10.1126/science.1096898			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143265				2022-12-28	WOS:000221383300030
J	Palmisano, DJ; Emmons, DW; Wozniak, GD				Palmisano, DJ; Emmons, DW; Wozniak, GD			Expanding insurance coverage through tax credits, consumer choice, and market enhancements - The American Medical Association proposal for health insurance reform	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED-CARE PLANS; COSTS	Recent reports showing an increase in the number of uninsured individuals in the United States have given heightened attention to increasing health insurance coverage. The American Medical Association (AMA) has proposed a system of tax credits for the purchase of individually owned health insurance and enhancements to individual and group health insurance markets as a means of expanding coverage. Individually owned insurance would enable people to maintain coverage without disruption to existing patient-physician relationships, regardless of changes in employers or in work status. The AMA's plan would empower individuals to choose their health plan and give patients and their physicians more control over health care choices. Employers could continue to offer employment-based coverage, but employees would not be limited to the health plans offered by their employer. With a tax credit large enough to make coverage affordable and the ability to choose their own coverage, consumers would dramatically transform the individual and group health insurance markets. Health insurers would respond to the demands of individual consumers and be more cautious about increasing premiums. insurers would also tailor benefit packages and develop new forms of coverage to better match the preferences of individuals and families. The AMA supports the development of new health insurance markets through legislative and regulatory changes to foster a wider array of high-quality, affordable plans.	Amer Med Assoc, Ctr Hlth Policy Res, Chicago, IL 60610 USA	American Medical Association	Wozniak, GD (corresponding author), Amer Med Assoc, Ctr Hlth Policy Res, 515 N State St, Chicago, IL 60610 USA.	gregory_wozniak@ama-assn.org						Addington W., 1999, NO HLTH INSURANCE IT, P65; *AM MED ASS, 2003, 7 CMS AM MED ASS; *AM MED ASS, 2000, 4 CMS AM MED ASS; *AM MED ASS, EXP HLTH INS AMA PRO; *AM MED ASS COUNC, 1998, 9 CMS AM MED ASS; ARMEY D, 1999, WASHINGTON POST 0618, pA41; Ayanian JZ, 2000, JAMA-J AM MED ASSOC, V284, P2061, DOI 10.1001/jama.284.16.2061; Baumol W. J., 1982, CONTESTABLE MARKETS; Christianson JB, 2002, HEALTH AFFAIR, V21, P49, DOI 10.1377/hlthaff.21.1.49; COLLINS R, 2003, HLTH CARE REFORM RET; CUNNINGHAM R, 2002, HLTH AFFAIRS    0918, pW290; DAVIS K, 1997, MANAGED CARE CHOICE; DOHERTY B, ACP ASIM OBSERVER; Ellwood P M, 1992, Health Econ, V1, P149, DOI 10.1002/hec.4730010303; *FED EMPL HLTH BEN, 2003, 2003 PLAN GUID; FEDER J, 1999, DIFFERENCE DIFFERENT; Fein R, 2003, JAMA-J AM MED ASSOC, V290, P818, DOI 10.1001/jama.290.6.818; FRANCIS W, 2003, FEHBP MODEL MEDICARE; Franks Peter, 2003, Ann Fam Med, V1, P156, DOI 10.1370/afm.24; FRONSTIN P, 2001, DEFINED CONTRIBUTION; GABEL JR, 2002, HLTH AFF MILLWOOD S, pW395; Glied S, 2002, MILBANK Q, V80, P603, DOI 10.1111/1468-0009.00026; GLIED S, 2003, GROWING SHARE UNINSU; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; Gruber J, 2000, HEALTH AFFAIR, V19, P72, DOI 10.1377/hlthaff.19.1.72; HADLEY J, 2003, HLTH AFF MILLWOO FEB; Hadley J, 2002, SICKER POORER CONSEQ; Hall MA, 2002, HLTH AFF MILLWOO OCT, pW353; Harrington Scott E., 2003, RISK MANAGEMENT INSU; *HLTH POL CONS GRO, 2000, TAX CRED STAT PRINC; HUNTER D, 2003, HLTH CARE CHOICE PAT; *I MED, 2002, CAR COV TOO LITT TOO; *I MED, 2003, HIDD COSTS VAL LOST; *I MED, 2004, INS AM HLTH; *INT REV SERV, YOUR 2003 ADV CHILD; *INTERSTUDY, 1994, COMP EDGE HMO IND RE; *KAIS FAM FDN HLTH, EMPL HLTH BEN 2003 A; LAY J, 2001, TAX CRED IND BUY HLT; LEMIEUX J, 1999, COMMUNICATION   0217; *LEW GROUP, 2000, HLTH COV 2000 COST C; Long SH, 1999, HEALTH AFFAIR, V18, P105, DOI 10.1377/hlthaff.18.4.105; Long SH, 2001, HEALTH AFFAIR, V20, P154, DOI 10.1377/hlthaff.20.1.154; MAYS G, HLTH PLANS USE QUALI; MEYER J, 2003, HLTH AFF MILLWOO AUG; MILLER M, 2000, ATLANTIC MONTHLY OCT; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Miller Tom, 2002, HLTH AFF MILLWOO OCT, pW359; Mills RAJ, 2003, CURRENT POPULATION R, P60; *NAT COMM QUAL ASS, NCQAS HLTH PLAN REP; NICHOLS L, 2002, CAN DEFINED CONTRIBU; OBRIEN E, 1998, WELL DOES EMPLOYMENT; Patel V, 2002, HEALTH AFFAIR, V21, pW280; PATEL V, 2002, HLTH AFF MILLWOO OCT, pW367; Pauly M, 1999, HEALTH AFFAIR, V18, P28, DOI 10.1377/hlthaff.18.6.28; Pauly M, 2001, HEALTH AFFAIR, V20, P9, DOI 10.1377/hlthaff.20.1.9; PAULY M, 2002, FRONTIERS HLTH POLIC, V5, P102; Pauly MV, 2000, J HEALTH POLIT POLIC, V25, P9, DOI 10.1215/03616878-25-1-9; Remler DK, 1997, INQUIRY-J HEALTH CAR, V34, P196; RESCHOVSKY J, 2004, HLTH AFF MILLWOO FEB; Rice T, 2002, HEALTH AFFAIR, V21, P182, DOI 10.1377/hlthaff.21.1.182; Schone BS, 2001, HEALTH AFFAIR, V20, P267, DOI 10.1377/hlthaff.20.1.267; Schur CL, 1998, HEALTH CARE FINANC R, V20, P29; SHEILS J, 2004, HLTH AFF MILLWOO FEB; SHEILS J, 2003, COVERING AM COST COV; Short PF, 2003, HEALTH AFFAIR, V22, P244, DOI 10.1377/hlthaff.22.6.244; SILLIVAN T, PRESIDENTS MESSAGE L; Sloan FA, 1998, INQUIRY-J HEALTH CAR, V35, P280; SWARTZ K, 2002, HLTH AFF MILLWOO OCT, pW380; Thompson JW, 1998, HEALTH AFFAIR, V17, P152, DOI 10.1377/hlthaff.17.1.152; Ullman R, 1997, HEALTH AFFAIR, V16, P209, DOI 10.1377/hlthaff.16.3.209; Weiss LJ, 1996, AM J PUBLIC HEALTH, V86, P1742, DOI 10.2105/AJPH.86.12.1742; WHOLEY D, 1995, J HEALTH ECON, V14, P81, DOI 10.1016/0167-6296(94)00039-7; WOZNIAK G, 001 AMA CTR HLTH POL; ZUKERMAN S, 1999, INQUIRY, V36, P44	74	24	24	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2004	291	18					2237	2242		10.1001/jama.291.18.2237	http://dx.doi.org/10.1001/jama.291.18.2237			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	819GR	15138246				2022-12-28	WOS:000221303500026
J	Stone, R; McCloy, R				Stone, R; McCloy, R			Ergonomics in medicine and surgery	BMJ-BRITISH MEDICAL JOURNAL			English	Review							VIRTUAL-REALITY		Univ Birmingham, Human Interface Technol Team, Dept Elect Elect & Comp Engn, Birmingham B15 2TT, W Midlands, England; Univ Manchester, Clin Res Div 1, Manchester M13 9WL, Lancs, England; Univ Manchester, Clin Res Div 2, Manchester M13 9WL, Lancs, England	University of Birmingham; University of Manchester; University of Manchester	Stone, R (corresponding author), Univ Birmingham, Human Interface Technol Team, Dept Elect Elect & Comp Engn, Birmingham B15 2TT, W Midlands, England.	r.j.stone@bham.ac.uk						Berguer Ramon, 1997, Reviews on Environmental Health, V12, P99; BLEVINS NH, 1997, TEMPORAL BONE DISSEC; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; *CTR INT MED INN T, OP ROOM FUT PROJ; DELANO KT, 2003, P HIMMS HEALTHC INF; Diaper D., 2003, HDB TASK ANAL HUMAN, DOI DOI 10.1201/B12470; *FOOD DRUG ADM, WHY IS HUM FACT ENG; Grantcharov TP, 2001, SURG ENDOSC-ULTRAS, V15, P242, DOI 10.1007/s004640090008; Johnston CI, 2000, BLOOD PRESSURE, V9, P9, DOI 10.1080/080370500439155; Kaye R, 2000, MED DEVICE USE SAFET; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; *KOMM ARB NORM, 7 KOMM ARB NORM; LEAPE L, 1994, JAMA-J AM MED ASSOC, V21, P272; McCloy R, 2001, BRIT MED J, V323, P912, DOI 10.1136/bmj.323.7318.912; Sawyer D, 1996, DO IT DESIGN INTRO H; Stone R. J., 1999, P SURG COMP CHALL AS, P109; STONE RJ, 2001, INFORMATION TECHNOLO, V2; SUTTON C, 1997, P MED MEETS VIRTUAL, P5; *U PITTSB MED CTR, 2000, U PITTS MED CTR OP O	19	59	64	3	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	2004	328	7448					1115	1118		10.1136/bmj.328.7448.1115	http://dx.doi.org/10.1136/bmj.328.7448.1115			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130981	Green Published			2022-12-28	WOS:000221281000024
J	Prigge, ST; Eipper, BA; Mains, RE; Amzel, LM				Prigge, ST; Eipper, BA; Mains, RE; Amzel, LM			Dioxygen binds end-on to mononuclear copper in a precatalytic enzyme complex	SCIENCE			English	Article							ALPHA-HYDROXYLATING MONOOXYGENASE; ACTIVE-SITE COPPER; PEPTIDYLGLYCINE MONOOXYGENASE; PEPTIDE AMIDATION; ELECTRON-TRANSFER; OXYGEN ACTIVATION; MECHANISM; REACTIVITY; SUBSTRATE; BIOACTIVITY	Copper active sites play a major role in enzymatic activation of dioxygen. We trapped the copper-dioxygen complex in the enzyme peptidylglycine-alpha-hydroxylating monooxygenase (PHM) by freezing protein crystals that had been soaked with a slow substrate and ascorbate in the presence of oxygen. The x-ray crystal structure of this precatalytic complex, determined to 1.85-angstrom resolution, shows that oxygen binds to one of the coppers in the enzyme with an end-on geometry. Given this structure, it is likely that dioxygen is directly involved in the electron transfer and hydrogen abstraction steps of the PHM reaction. These insights may apply to other copper oxygen-activating enzymes, such as dopamine beta-monooxygenase, and to the design of biomimetic complexes.	Johns Hopkins Univ, Johns Hopkins Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA; Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Connecticut	Amzel, LM (corresponding author), Johns Hopkins Univ, Johns Hopkins Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21218 USA.	Mario@neruda.med.jhmi.edu	Prigge, Sean/GVS-9197-2022	Prigge, Sean/0000-0001-9684-1733; Amzel, L. Mario/0000-0002-0129-9572	NIDDK NIH HHS [DK32949] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032949, R01DK032949, R37DK032949] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aboelella NW, 2002, J AM CHEM SOC, V124, P10660, DOI 10.1021/ja027164v; Bell J, 2003, BIOCHEMISTRY-US, V42, P7133, DOI 10.1021/bi034247v; Berreau LM, 1996, INORG CHEM, V35, P6339, DOI 10.1021/ic960340e; Blackburn NJ, 2000, J BIOL INORG CHEM, V5, P341, DOI 10.1007/PL00010663; Boswell JS, 1996, BIOCHEMISTRY-US, V35, P12241, DOI 10.1021/bi960742y; BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; Chaudhuri P, 1999, ANGEW CHEM INT EDIT, V38, P1095, DOI 10.1002/(SICI)1521-3773(19990419)38:8<1095::AID-ANIE1095>3.0.CO;2-I; Chen P, 2003, J AM CHEM SOC, V125, P466, DOI 10.1021/ja020969i; Croft AK, 2003, J AM CHEM SOC, V125, P4119, DOI 10.1021/ja029674v; CUTTITTA F, 1993, ANAT REC, V236, P87, DOI 10.1002/ar.1092360112; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Evans JP, 2003, J BIOL CHEM, V278, P49691, DOI 10.1074/jbc.M300797200; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Francisco WA, 2002, J AM CHEM SOC, V124, P8194, DOI 10.1021/ja025758s; Francisco WA, 1998, BIOCHEMISTRY-US, V37, P8244, DOI 10.1021/bi973004y; Francisco WA, 2003, BIOCHEMISTRY-US, V42, P1813, DOI 10.1021/bi020592t; FREEMAN JC, 1993, J AM CHEM SOC, V115, P4923, DOI 10.1021/ja00064a077; FUJISAWA K, 1994, J AM CHEM SOC, V116, P12079, DOI 10.1021/ja00105a069; GUBELMANN MH, 1983, STRUCT BOND, V55, P1; HARATA M, 1994, J AM CHEM SOC, V116, P10817, DOI 10.1021/ja00102a070; Jaron S, 2001, BIOCHEMISTRY-US, V40, P6867, DOI 10.1021/bi002849y; Jaron S, 1999, BIOCHEMISTRY-US, V38, P15086, DOI 10.1021/bi991341w; Karlin KD, 1997, ACCOUNTS CHEM RES, V30, P139, DOI 10.1021/ar950257f; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; LANDYMORELIM AEN, 1983, BIOCHEM BIOPH RES CO, V117, P289, DOI 10.1016/0006-291X(83)91573-5; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; Ponce A, 2000, J AM CHEM SOC, V122, P8187, DOI 10.1021/ja000017h; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; Prigge ST, 1999, NAT STRUCT BIOL, V6, P976; Prigge ST, 1997, SCIENCE, V278, P1300, DOI 10.1126/science.278.5341.1300; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; PRIGGE ST, UNPUB; Solomon EI, 2001, ANGEW CHEM INT EDIT, V40, P4570, DOI 10.1002/1521-3773(20011217)40:24<4570::AID-ANIE4570>3.0.CO;2-4; Takahashi K, 1998, BIOCHEM J, V336, P131, DOI 10.1042/bj3360131; Tezcan FA, 2001, P NATL ACAD SCI USA, V98, P5002, DOI 10.1073/pnas.081072898; Tolman WB, 2001, CURR OPIN CHEM BIOL, V5, P188, DOI 10.1016/S1367-5931(00)00189-7; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Wilmot CM, 1999, SCIENCE, V286, P1724, DOI 10.1126/science.286.5445.1724; Wilmot CM, 2003, BIOCHEM SOC T, V31, P493, DOI 10.1042/bst0310493	41	335	336	2	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					864	867		10.1126/science.1094583	http://dx.doi.org/10.1126/science.1094583			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131304				2022-12-28	WOS:000221243000042
J	Smith, WCS; Anderson, AM; Withington, SG; van Brakel, WH; Croft, RP; Nicholls, PG; Richardus, JH				Smith, WCS; Anderson, AM; Withington, SG; van Brakel, WH; Croft, RP; Nicholls, PG; Richardus, JH			Steroid prophylaxis for prevention of nerve function impairment in leprosy: trial (TRIPOD 1)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORTICOSTEROIDS	Objective To determine whether addition of low dose prednisolone to multidrug treatment can prevent reaction and nerve function impairment in leprosy. Design Multicentre, double blind, randomised, placebo controlled, parallel group trial: Setting Six centres in Bangladesh and Nepal. Participants 636 people with newly diagnosed multibacillary leprosy. Intervention Prednisolone 20 mg/day for three months, with tapering dose in month 4, plus multidrug treatment, compared with multidrug treatment alone. Main outcome measures Signs of reaction, impairment of sensory and motor nerve function, and nerve tenderness needing full dose prednisolone at four months and one year. Results Prednisolone had a significant effect in the prevention of reaction and nerve function impairment at four months (relative risk 3.9, 95% confidence interval 2.1 to 7.3), but this was not maintained at one year (relative risk 1.3, 0.9 to 1.8). Fewer events occurred in the prednisolone group at all time points up to 12 months, but the difference at 12 months was small. Subgroup analysis showed a difference in response between people with and without impairment of nerve function at diagnosis. Conclusions The use of low dose prophylactic prednisolone during the first four months of multidrug treatment for leprosy reduces the incidence of new reactions and nerve function impairment in the short term, but the effect is not sustained at one year. The presence of nerve function impairment at diagnosis may influence the response to low dose prednisolone.	Univ Aberdeen, Dept Publ Hlth, Aberdeen AB25 2ZD, Scotland; RELEASE, Pokhara, Nepal; Leprosy Mission Bangladesh, Dhaka 1206, Bangladesh; Royal Trop Inst KIT, Leprosy Unit, NL-1097 DN Amsterdam, Netherlands; Univ Med Ctr, Erasmus MC, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	University of Aberdeen; Erasmus University Rotterdam; Erasmus MC	Smith, WCS (corresponding author), Univ Aberdeen, Dept Publ Hlth, Aberdeen AB25 2ZD, Scotland.	w.c.s.smith@abdn.ac.uk	Richardus, Jan Hendrik/AAE-1278-2021	Richardus, Jan Hendrik/0000-0003-0564-6313				Anderson A, 1998, INT J LEPROSY, V66, p69A; Anderson AM, 1999, LEPROSY REV, V70, P305; BRANDSMA W, 1981, LEPROSY REV, V52, P161; Croft RP, 2000, LANCET, V355, P1603, DOI 10.1016/S0140-6736(00)02216-9; Croft RP, 2000, LEPROSY REV, V71, P18; Croft RP, 1999, INT J LEPROSY, V67, P75; DEAN AG, 1996, EPI INFO WORD PROCES; Girdhar B K, 1985, Indian J Lepr, V57, P491; Lockwood DNJ, 2000, LEPROSY REV, V71, pS111; Meima A, 2001, LEPROSY REV, V72, P158; NAAFS B, 1980, THESIS U AMSTERDAM; Richardus JH, 2003, LEPROSY REV, V74, P319; Richardus JH, 2003, LEPROSY REV, V74, P311; Van Brakel WH, 2003, LEPROSY REV, V74, P300; Van Brakel WH, 2000, LEPROSY REV, V71, pS146; VANBRAKEL WH, 1994, LEPROSY REV, V65, P106; VanBrakel WH, 1996, LEPROSY REV, V67, P104; *WHO, 1998, WHO TECH REP SER, V874; *WHO, 2002, WKLY EPIDEMIOL REC, V77, P1	19	63	63	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	2004	328	7454					1459	1462A		10.1136/bmj.38107.645926.AE	http://dx.doi.org/10.1136/bmj.38107.645926.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15159285	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000222244600013
J	Terrak, M; Kerff, F; Langsetmo, K; Tao, T; Dominguez, R				Terrak, M; Kerff, F; Langsetmo, K; Tao, T; Dominguez, R			Structural basis of protein phosphatase 1 regulation	NATURE			English	Article							MUSCLE MYOSIN PHOSPHATASE; LIGHT-CHAIN-PHOSPHATASE; CATALYTIC SUBUNIT; SMOOTH-MUSCLE; CRYSTAL-STRUCTURE; PHOSPHORYLATION; COMPLEX; P53; INHIBITION; ANKYRIN	The coordinated and reciprocal action of serine/threonine (Ser/Thr) protein kinases and phosphatases produces transient phosphorylation, a fundamental regulatory mechanism for many biological processes. The human genome encodes a far greater number of Ser/Thr protein kinases than of phosphatases. Protein phosphatase 1 (PP1), in particular, is ubiquitously distributed and regulates a broad range of cellular functions, including glycogen metabolism, cell-cycle progression and muscle relaxation(1,2). PP1 has evolved effective catalytic machinery but lacks substrate specificity. Substrate specificity is conferred upon PP1 through interactions with a large number of regulatory subunits. The regulatory subunits are generally unrelated, but most possess the RVxF motif, a canonical PP1-binding sequence. Here we reveal the crystal structure at 2.7 Angstrom resolution of the complex between PP1 and a 34-kDa N-terminal domain of the myosin phosphatase targeting subunit MYPT1. MYPT1 is the protein that regulates PP1 function in smooth muscle relaxation(3). Structural elements amino- and carboxy-terminal to the RVxF motif of MYPT1 are positioned in a way that leads to a pronounced reshaping of the catalytic cleft of PP1, contributing to the increased myosin specificity of this complex. The structure has general implications for the control of PP1 activity by other regulatory subunits.	Boston Biomed Res Inst, Watertown, MA 02472 USA	Boston Biomedical Research Institute	Dominguez, R (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	dominguez@bbri.org			NIAMS NIH HHS [R01 AR046524, P01 AR041637] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637, R01AR046524] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Gailly P, 1996, EUR J BIOCHEM, V239, P326, DOI 10.1111/j.1432-1033.1996.0326u.x; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; Ichikawa K, 1996, BIOCHEMISTRY-US, V35, P6313, DOI 10.1021/bi960208q; Johnson K P, 1996, Mult Scler, V1, P325; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Kita A, 2002, STRUCTURE, V10, P715, DOI 10.1016/S0969-2126(02)00764-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Long X, 2002, APOPTOSIS, V7, P31, DOI 10.1023/A:1013508811252; Maynes JT, 2001, J BIOL CHEM, V276, P44078, DOI 10.1074/jbc.M107656200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Tanaka J, 1998, BIOCHEMISTRY-US, V37, P16697, DOI 10.1021/bi980782x; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Toth A, 2000, EUR J BIOCHEM, V267, P1687, DOI 10.1046/j.1432-1327.2000.01158.x; Velasco G, 2002, FEBS LETT, V527, P101, DOI 10.1016/S0014-5793(02)03175-7	30	286	300	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					780	784		10.1038/nature02582	http://dx.doi.org/10.1038/nature02582			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15164081	Bronze			2022-12-28	WOS:000222059900043
J	Ploegh, HL				Ploegh, HL			Nothing 'gainst time's scythe can make defense...	SCIENCE			English	Editorial Material							MHC CLASS-I; CROSS-PRESENTATION; ANTIGEN; CELLS		Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.	ploegh@hms.harvard.edu						Guermonprez P, 2003, NATURE, V425, P397, DOI 10.1038/nature01911; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Norbury CC, 2004, SCIENCE, V304, P1318, DOI 10.1126/science.1096378; Reits E, 2003, IMMUNITY, V18, P97, DOI 10.1016/S1074-7613(02)00511-3; Rock KL, 2003, NAT IMMUNOL, V4, P941, DOI 10.1038/ni1003-941; Shen LJ, 2004, P NATL ACAD SCI USA, V101, P3035, DOI 10.1073/pnas.0308345101; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; Wolkers MC, 2004, SCIENCE, V304, P1314, DOI 10.1126/science.1096268	8	5	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	2004	304	5675					1262	1263		10.1126/science.1098965	http://dx.doi.org/10.1126/science.1098965			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166355				2022-12-28	WOS:000221669600029
J	Nesic, D; Hsu, Y; Stebbins, CE				Nesic, D; Hsu, Y; Stebbins, CE			Assembly and function of a bacterial genotoxin	NATURE			English	Article							CYTOLETHAL DISTENDING TOXIN; CELL-CYCLE ARREST; DNA-DAMAGE; HELA-CELLS; CDTB; COMPLEX; CHECKPOINT; INVOLVEMENT; ACTIVATION; RESIDUES	The tripartite cytolethal distending toxin (CDT) induces cell cycle arrest and apoptosis in eukaryotic cells(1,2). The subunits CdtA and CdtC associate with the nuclease CdtB to form a holotoxin that translocates CdtB into the host cell, where it acts as a genotoxin by creating DNA lesions(3-7). Here we show that the crystal structure of the holotoxin from Haemophilus ducreyi reveals that CDT consists of an enzyme of the DNase-I family, bound to two ricin-like lectin domains. CdtA, CdtB and CdtC form a ternary complex with three interdependent molecular interfaces, characterized by globular, as well as extensive non-globular, interactions. The lectin subunits form a deeply grooved, highly aromatic surface that we show to be critical for toxicity. The holotoxin possesses a steric block of the CdtB active site by means of a non-globular extension of the CdtC subunit, and we identify putative DNA binding residues in CdtB that are essential for toxin activity.	Rockefeller Univ, Lab Stuct Microbiol, New York, NY 10021 USA	Rockefeller University	Stebbins, CE (corresponding author), Rockefeller Univ, Lab Stuct Microbiol, 1230 York Ave, New York, NY 10021 USA.	stebbins@rockefeller.edu	Stebbins, Erec/N-2565-2018	Stebbins, Erec/0000-0001-6229-5308				Alby F, 2001, FEBS LETT, V491, P261, DOI 10.1016/S0014-5793(01)02205-0; Comayras C, 1997, INFECT IMMUN, V65, P5088, DOI 10.1128/IAI.65.12.5088-5095.1997; Cortes-Bratti X, 2001, TOXICON, V39, P1729, DOI 10.1016/S0041-0101(01)00159-3; Cortes-Bratti X, 2001, J BIOL CHEM, V276, P5296, DOI 10.1074/jbc.M008527200; Cortes-Bratti X, 2000, INFECT IMMUN, V68, P6903, DOI 10.1128/IAI.68.12.6903-6911.2000; De Rycke J, 2001, FEMS MICROBIOL LETT, V203, P141, DOI 10.1016/S0378-1097(01)00344-5; Deng KP, 2003, INFECT IMMUN, V71, P6633, DOI 10.1128/IAI.71.11.6633-6640.2003; Deng KP, 2001, BIOCHEM BIOPH RES CO, V285, P609, DOI 10.1006/bbrc.2001.5223; Elwell C, 2001, INFECT IMMUN, V69, P3418, DOI 10.1128/IAI.69.5.3418-3422.2001; Elwell CA, 2000, MOL MICROBIOL, V37, P952, DOI 10.1046/j.1365-2958.2000.02070.x; Escalas N, 2000, EXP CELL RES, V257, P206, DOI 10.1006/excr.2000.4878; Frisan T, 2003, CELL MICROBIOL, V5, P695, DOI 10.1046/j.1462-5822.2003.00311.x; Frisan T, 2002, INT J MED MICROBIOL, V291, P495; Hassane DC, 2001, INFECT IMMUN, V69, P5752, DOI 10.1128/IAI.69.9.5752-5759.2001; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JOHNSON WM, 1988, MICROB PATHOGENESIS, V4, P115, DOI 10.1016/0882-4010(88)90053-8; Jones SJ, 1996, J MOL BIOL, V264, P1154, DOI 10.1006/jmbi.1996.0703; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Lara-Tejero M, 2002, TRENDS MICROBIOL, V10, P147, DOI 10.1016/S0966-842X(02)02316-8; Lara-Tejero M, 2001, INFECT IMMUN, V69, P4358, DOI 10.1128/IAI.69.7.4358-4365.2001; Lee RB, 2003, INFECT IMMUN, V71, P4883, DOI 10.1128/IAI.71.9.4883-4890.2003; Lewis DA, 2001, INFECT IMMUN, V69, P5626, DOI 10.1128/IAI.69.9.5626-5634.2001; Mao XQ, 2002, CELL MICROBIOL, V4, P245, DOI 10.1046/j.1462-5822.2002.00186.x; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; Nishikubo S, 2003, J BIOL CHEM, V278, P50671, DOI 10.1074/jbc.M305062200; Pan CQ, 1998, PROTEIN SCI, V7, P628, DOI 10.1002/pro.5560070312; Pickett CL, 1999, TRENDS MICROBIOL, V7, P292, DOI 10.1016/S0966-842X(99)01537-1; Shenker BJ, 2004, J IMMUNOL, V172, P410, DOI 10.4049/jimmunol.172.1.410; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V	30	228	239	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					429	433		10.1038/nature02532	http://dx.doi.org/10.1038/nature02532			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164065				2022-12-28	WOS:000221644600042
J	Evans, R; Elwyn, G; Edwards, A				Evans, R; Elwyn, G; Edwards, A			Review of instruments for peer assessment of physicians	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTERNAL-MEDICINE; RATINGS; PERFORMANCE; NURSES; EVALUATE; PATIENT; SELF; RESIDENTS; FEEDBACK; FACULTY	Objectives To identify existing instruments for rating peers (professional colleagues) in medical practice and to evaluate them in terms of how they have been developed, their validity and reliability, and their appropriateness for use in clinical settings, including primary care. Design Systematic literature review. Data sources Electronic search techniques, snowball sampling, and correspondence with specialists. Study selection The peer assessment instruments identified were evaluated in terms of how they were developed and to what extent, if relevant, their psychometric properties had been determined. Results A search of six electronic databases identified 4566 possible articles. After appraisal of the abstracts and in depth assessment of 42 articles, three rating scales fulfilled the inclusion criteria and were fully appraised. The three instruments did not meet established standards of instrument development, as no reference was made to a theoretical framework and the published psychometric data omitted essential work on construct and criterion validity. Rater training was absent, and guidance consisted of short written instructions. Two instruments were developed for a hospital setting in the United States and one for a primary care setting in Canada. Conclusions The instruments developed to date for physicians to evaluate characteristics of colleagues need further assessment of validity before their widespread use is merited.	Univ Coll Swansea, Swansea Clin Sch, Primary Care Grp, Swansea SA2 8PP, W Glam, Wales	Swansea University	Evans, R (corresponding author), Univ Coll Swansea, Swansea Clin Sch, Primary Care Grp, Swansea SA2 8PP, W Glam, Wales.	richevansg@msn.com	Elwyn, Glyn/B-4798-2009; Elwyn, G./L-4292-2015	Elwyn, Glyn/0000-0002-0917-6286; 				*AM BOARD INT MED, REC PROGR CONT PROF, P243; Atwater LE, 1998, PERS PSYCHOL, V51, P577, DOI 10.1111/j.1744-6570.1998.tb00252.x; Beehr TA, 2001, J ORGAN BEHAV, V22, P775, DOI 10.1002/job.113; Church AH, 1997, J APPL SOC PSYCHOL, V27, P983, DOI 10.1111/j.1559-1816.1997.tb00283.x; Dancer S, 1997, Nurs Manage, V28, P57; Davis JD, 2002, OBSTET GYNECOL, V99, P647, DOI 10.1016/S0029-7844(02)01658-7; Festinger L, 1954, HUM RELAT, V7, P117, DOI 10.1177/001872675400700202; Fidler M, 1999, ACAD MED, V74, P702, DOI 10.1097/00001888-199906000-00019; Fletcher C, 2001, J OCCUP ORGAN PSYCH, V74, P473, DOI 10.1348/096317901167488; FOX S, 1989, J APPL PSYCHOL, V74, P781, DOI 10.1037/0021-9010.74.5.781; GOLDMAN RL, 1994, EVAL HEALTH PROF, V17, P3, DOI 10.1177/016327879401700101; Gombeski W R Jr, 1992, J Health Care Mark, V12, P52; Hall W, 1999, CAN MED ASSOC J, V161, P52; KAPLAN CB, 1990, J GEN INTERN MED, V5, P410, DOI 10.1007/BF02599428; Lipner RS, 2002, ACAD MED, V77, pS64, DOI 10.1097/00001888-200210001-00021; MCLEOD PJ, 1994, J GEN INTERN MED, V9, P321, DOI 10.1007/BF02599179; Morris J, 2001, Nurse Educ Today, V21, P507, DOI 10.1054/nedt.2001.0661; MUMFORD MD, 1983, PERS PSYCHOL, V36, P867, DOI 10.1111/j.1744-6570.1983.tb00516.x; Norcini JJ, 2003, MED EDUC, V37, P539, DOI 10.1046/j.1365-2923.2003.01536.x; O'Neill O., 2002, REITH LECT QUESTION, V3; Peirperl M., 1999, INT J HUM RESOUR MAN, V10, P429; Ramsey PG, 1999, ADV HEALTH SCI EDUC, V4, P27, DOI 10.1023/A:1009845802726; RAMSEY PG, 1993, JAMA-J AM MED ASSOC, V269, P1655, DOI 10.1001/jama.269.13.1655; RAMSEY PG, 1989, ANN INTERN MED, V110, P719, DOI 10.7326/0003-4819-110-9-719; Ramsey PG, 1999, J GEN INTERN MED, V14, P581, DOI 10.1046/j.1525-1497.1999.07019.x; Ramsey PG, 1996, ACAD MED, V71, P364, DOI 10.1097/00001888-199604000-00014; Saturno PJ, 1999, INT J QUAL HEALTH C, V11, P487, DOI 10.1093/intqhc/11.6.487; STREINER DL, 1995, HLTH MEAS SCAL PRACT; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.; Thomas PA, 1999, J GEN INTERN MED, V14, P551, DOI 10.1046/j.1525-1497.1999.10148.x; vandenBos K, 1997, J PERS SOC PSYCHOL, V72, P95, DOI 10.1037/0022-3514.72.1.95; Violato C, 2003, BMJ-BRIT MED J, V326, P546, DOI 10.1136/bmj.326.7388.546; Violato C, 1997, ACAD MED, V72, pS82, DOI 10.1097/00001888-199710001-00028; Vuorinen R, 2000, J CLIN NURS, V9, P273, DOI 10.1046/j.1365-2702.2000.00353.x; WENRICH MD, 1993, ACAD MED, V68, P680, DOI 10.1097/00001888-199309000-00014; WOOLLISCROFT JO, 1994, ACAD MED, V69, P216, DOI 10.1097/00001888-199403000-00017	36	95	97	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	2004	328	7450					1240	1243		10.1136/bmj.328.7450.1240	http://dx.doi.org/10.1136/bmj.328.7450.1240			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	824HL	15155502	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000221677200026
J	Vandenbroucke, JP				Vandenbroucke, JP			When are observational studies as credible as randomised trials?	LANCET			English	Editorial Material							MENDELIAN RANDOMIZATION; MORTALITY		Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Vandenbroucke, JP (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, Bldg 1 C9-P, NL-2300 RC Leiden, Netherlands.	J.P.Vandenbroucke@lumc.nl	Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				Abbott S, 2002, BJOG-INT J OBSTET GY, V109, P1319; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Breslow NE, 1987, STAT METHODS CANC RE, VII, P17; Chalmers I, 1999, BRIT MED J, V319, P1372, DOI 10.1136/bmj.319.7221.1372; Darby S, 2003, BRIT MED J, V326, P256, DOI 10.1136/bmj.326.7383.256; Fisher R., 1971, DESIGN EXPT; Goldthorpe JH, 2001, EUR SOCIOL REV, V17, P1, DOI 10.1093/esr/17.1.1; JICK H, 1978, AM J EPIDEMIOL, V107, P1; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; Little J, 2003, LANCET, V362, P930, DOI 10.1016/S0140-6736(03)14396-6; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; MIETTININ OS, 1985, THEORETICAL EPIDEMIO, P44; Rosenbaum P. R., 2002, OBSERVATIONAL STUDIE; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; RUBIN DB, 1978, ANN STAT, V6, P34, DOI 10.1214/aos/1176344064; Schulz KF, 2002, LANCET, V359, P614, DOI 10.1016/S0140-6736(02)07750-4; Smets YFC, 1999, LANCET, V353, P1915, DOI 10.1016/S0140-6736(98)07513-8; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070	20	385	395	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	2004	363	9422					1728	1731		10.1016/S0140-6736(04)16261-2	http://dx.doi.org/10.1016/S0140-6736(04)16261-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158638				2022-12-28	WOS:000221546300024
J	Wang, ZH; Shen, D; Parsons, DW; Bardelli, A; Sager, J; Szabo, S; Ptak, J; Silliman, N; Peters, BA; van der Heijden, MS; Parmigiani, G; Yan, H; Wang, TL; Riggins, G; Powell, SM; Willson, JKV; Markowitz, S; Kinzler, KW; Vogelstein, B; Velculescu, VE				Wang, ZH; Shen, D; Parsons, DW; Bardelli, A; Sager, J; Szabo, S; Ptak, J; Silliman, N; Peters, BA; van der Heijden, MS; Parmigiani, G; Yan, H; Wang, TL; Riggins, G; Powell, SM; Willson, JKV; Markowitz, S; Kinzler, KW; Vogelstein, B; Velculescu, VE			Mutational analysis of the tyrosine phosphatome in colorectal cancers	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENE; BREAST-CANCER; BETA-CATENIN; PHOSPHORYLATION; GROWTH; CELLS; IDENTIFICATION; DISEASE; KINASES; PTPRG	Tyrosine phosphorylation, regulated by protein tyrosine phosphatases (PTPs) and kinases (PTKs), is important in signaling pathways underlying tumorigenesis. A mutational analysis of the tyrosine phosphatase gene superfamily in human cancers identified 83 somatic mutations in six PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14), affecting 26% of colorectal cancers and a smaller fraction of lung, breast, and gastric cancers. Fifteen mutations were nonsense, frameshift, or splice-site alterations predicted to result in truncated proteins lacking phosphatase activity. Five missense mutations in the most commonly altered PTP ( PTPRT) were biochemically examined and found to reduce phosphatase activity. Expression of wild-type but not a mutant PTPRT in human cancer cells inhibited cell growth. These observations suggest that the mutated tyrosine phosphatases are tumor suppressor genes, regulating cellular pathways that may be amenable to therapeutic intervention.	Johns Hopkins Univ Med Inst, Howard Hughes Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; UVA Hlth Syst, Div Gastroenterol Hepatol, Charlottesville, VA 22908 USA; Univ Hosp Cleveland, Howard Hughes Med Inst, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Duke University; Howard Hughes Medical Institute; University Hospitals of Cleveland; University Hospitals of Cleveland; University Hospitals of Cleveland; Case Western Reserve University	Velculescu, VE (corresponding author), Johns Hopkins Univ Med Inst, Howard Hughes Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.	velculescu@jhmi.edu	Velculescu, Victor/ABF-4846-2020; Jin, Ning/B-7956-2011; BARDELLI, Alberto/J-9721-2018	Velculescu, Victor/0000-0003-1195-438X; BARDELLI, Alberto/0000-0003-1647-5070; Parsons, Donald/0000-0002-8775-3501; Peters, Brock/0000-0002-5137-3902	NATIONAL CANCER INSTITUTE [P50CA062924, R37CA043460, R01CA057345, R01CA043460, R37CA057345] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43460, CA 57345, CA 62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Ayalon O, 1997, J CELL SCI, V110, P547; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bompard G, 2002, J BIOL CHEM, V277, P47861, DOI 10.1074/jbc.M208950200; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DRUCK T, 1995, CANCER RES, V55, P5348; Fodde R, 2002, SCIENCE, V298, P761, DOI 10.1126/science.1077707; Forrest ARR, 2003, GENOME RES, V13, P1443, DOI 10.1101/gr.954803; Freiss G, 1998, MOL ENDOCRINOL, V12, P568, DOI 10.1210/me.12.4.568; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Kastury K, 1996, GENOMICS, V32, P225, DOI 10.1006/geno.1996.0109; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; McAndrew PE, 1998, J COMP NEUROL, V391, P444, DOI 10.1002/(SICI)1096-9861(19980222)391:4<444::AID-CNE3>3.0.CO;2-0; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Oganesian A, 2003, P NATL ACAD SCI USA, V100, P7563, DOI 10.1073/pnas.1336511100; Panagopoulos I, 1996, CANCER RES, V56, P4871; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Wang TL, 2002, P NATL ACAD SCI USA, V99, P3076, DOI 10.1073/pnas.261714699; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806	28	421	444	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1164	1166		10.1126/science.1096096	http://dx.doi.org/10.1126/science.1096096			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155950				2022-12-28	WOS:000221524500045
J	Takio, Y; Pasqualetti, M; Kuraku, S; Hirano, S; Rijli, FM; Kuratani, S				Takio, Y; Pasqualetti, M; Kuraku, S; Hirano, S; Rijli, FM; Kuratani, S			Lamprey Hox genes and the evolution of jaws	NATURE			English	Editorial Material							NEURAL CREST; PETROMYZON-MARINUS; BRANCHIAL REGION; EXPRESSION; ORGANIZATION; CLUSTERS; MURINE; HEAD		RIKEN, Ctr Dev Biol, Lab Evolutionary Morphol, Kobe, Hyogo 6500047, Japan; Kobe Univ, Grad Sch Sci & Technol, Kobe, Hyogo 6578501, Japan; ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM,CU Strasbourg, F-67404 Illkirch Graffenstaden, France; Univ Pisa, Lab Biol Cellulare & Sviluppo, I-56010 Pisa, Italy; Niigata Univ, Fac Med, Sch Hlth Sci, Dept Med Technol, Niigata 9518518, Japan	RIKEN; Kobe University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Pisa; Niigata University	Takio, Y (corresponding author), RIKEN, Ctr Dev Biol, Lab Evolutionary Morphol, 2-2-3 Minatojima Minami, Kobe, Hyogo 6500047, Japan.	saizo@cdb.riken.go.jp	Kuraku, Shigehiro/B-2801-2009; Kuratani, Shigeru/J-4146-2014; Pasqualetti, Massimo/F-8682-2012; RIJLI, Filippo/AAP-2516-2020	Kuraku, Shigehiro/0000-0003-1464-8388; Kuratani, Shigeru/0000-0001-9717-7221; RIJLI, Filippo/0000-0003-0515-0182; Pasqualetti, Massimo/0000-0002-0844-8139				Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Cohn MJ, 2002, NATURE, V416, P386, DOI 10.1038/416386a; Couly G, 1998, DEVELOPMENT, V125, P3445; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Force A, 2002, J EXP ZOOL, V294, P30, DOI 10.1002/jez.10091; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; Irvine SQ, 2002, J EXP ZOOL, V294, P47, DOI 10.1002/jez.10090; Murakami Y, 2004, DEVELOPMENT, V131, P983, DOI 10.1242/dev.00986; Pasqualetti M, 2000, DEVELOPMENT, V127, P5367; PRINCE V, 1994, DEVELOPMENT, V120, P911; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; Shigetani Y, 2002, SCIENCE, V296, P1316, DOI 10.1126/science.1068310; Trainor PA, 2002, SCIENCE, V295, P1288, DOI 10.1126/science.1064540; Wada H, 1999, DEV BIOL, V213, P131, DOI 10.1006/dbio.1999.9369	15	84	87	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989								10.1038/nature02616	http://dx.doi.org/10.1038/nature02616			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15154395	Bronze			2022-12-28	WOS:000221505900033
J	Vendrasco, MJ; Wood, TE; Runnegar, BN				Vendrasco, MJ; Wood, TE; Runnegar, BN			Articulated Palaeozoic fossil with 17 plates greatly expands disparity of early chitons	NATURE			English	Article							NORTH GREENLAND; HALKIERIIDS; AFFINITIES; SCLERITES; GROWTH	Modern chitons (Mollusca: Polyplacophora) possess a highly conserved skeleton of eight shell plates ( valves) surrounded by spicules or scales, and fossil evidence suggests that the chiton skeleton has changed little since the first appearance of the class in the Late Cambrian period ( about 500 million years before present, Myr BP). However, the Palaeozoic problematic taxon Multiplacophora(1-5), in spite of having a more complex skeleton, shares several derived characters with chitons. The enigmatic status of the Multiplacophora is due in part to the fact that its members had an exoskeleton of numerous calcium carbonate valves that usually separated after death. A new articulated specimen from the Carboniferous period (about 335 Myr BP) of Indiana reveals that multiplacophorans had a dorsal protective surface composed of head and tail valves, left and right columns of overlapping valves (five on each side), and a central zone of five smaller valves, all surrounded by an annulus of large spines. Here we describe and name the articulated specimen and present evidence that multiplacophorans were chitons. Thus the highly conserved body plan of living chitons belies the broad disparity of this clade during the Palaeozoic era.	Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Indiana Univ, Dept Biol, JH 142, Bloomington, IN 47405 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Indiana University System; Indiana University Bloomington	Vendrasco, MJ (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.	mikev@ess.ucla.edu	Wood, Troy/F-7302-2010					ADRAIN JM, 1992, ALCHERINGA, V16, P15, DOI 10.1080/03115519208619031; Aurivillius CWS, 1892, KUNGLIGA SVENSKA VET, V18, P1; BAXTER JM, 1981, J MAR BIOL ASSOC UK, V61, P65, DOI 10.1017/S0025315400045914; Cohen BL, 2003, PALAEONTOLOGY, V46, P59, DOI 10.1111/1475-4983.00287; DZIK J, 1986, PROBLEMATIC FOSSIL T, P116; EERNISSE DJ, 1994, MICROSCOPIC ANATOMY, V5, P55; HALL J, 1888, GEOLOGICAL SURVEY ST, V7, P1; Haszprunar G, 2000, AM MALACOL BULL, V15, P115; HOARE R D, 1976, Ohio Journal of Science, V76, P116; Hoare RD, 2000, J PALEONTOL, V74, P976, DOI 10.1666/0022-3360(2000)074<0976:NDOTGD>2.0.CO;2; Hoare RD, 1996, J PALEONTOL, V70, P341, DOI 10.1017/S0022336000038282; Hoare Richard D., 1995, Acta Palaeontologica Polonica, V40, P111; KNIPRATH E, 1980, ROUX ARCH DEV BIOL, V189, P97, DOI 10.1007/BF00848498; MORRIS SC, 1995, PHILOS T ROY SOC B, V347, P305, DOI 10.1098/rstb.1995.0029; MORRIS SC, 1990, NATURE, V345, P802, DOI 10.1038/345802a0; Pojeta J, 2003, J PALEONTOL, V77, P646, DOI 10.1666/0022-3360(2003)077<0646:EDANSO>2.0.CO;2; RUNNEGAR B, 1979, J PALEONTOL, V53, P1374; Scheltema AH, 2002, INVERTEBR BIOL, V121, P1; Sutton MD, 2001, NATURE, V410, P461, DOI 10.1038/35068549; SUTTON MD, IN PRESS PALAEONTOLO; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; Van Name W. G., 1925, American Museum Novitates, Vno. 197, P1; VAN NAME WILLARD G., 1926, AMER MUS NOVITATES, V227, P1; Williams A, 2002, PALAEONTOLOGY, V45, P845, DOI 10.1111/1475-4983.00264; WITHERS TH, 1915, GEOLOGICAL MAGAZINE, V6, P112	25	54	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					288	291		10.1038/nature02548	http://dx.doi.org/10.1038/nature02548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152250				2022-12-28	WOS:000221505900040
J	Isabel, G; Pascual, A; Preat, T				Isabel, G; Pascual, A; Preat, T			Exclusive consolidated memory phases in Drosophila	SCIENCE			English	Article							MUSHROOM BODIES; OLFACTORY MEMORY; TERM-MEMORY; BRAIN; LOCALIZATION; ACQUISITION; DISSECTION; EXPRESSION; RETENTION	Two types of consolidated memory have been described in Drosophila, anesthesia-resistant memory (ARM), a shorter-lived form, and stabilized long-term memory (LTM). Until now, it has been thought that ARM and LTM coexist. On the contrary, we show that LTM formation leads to the extinction of ARM. Flies devoid of mushroom body vertical lobes cannot form LTM, but spaced conditioning can still erase their ARM, resulting in a remarkable situation: The more these flies are trained, the less they remember. We propose that ARM acts as a gating mechanism that ensures that LTM is formed only after repetitive and spaced training.	CNRS, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Preat, T (corresponding author), CNRS, 1 Ave Terrasse, F-91190 Gif Sur Yvette, France.	preat@iaf.cnrs-gif.fr	IBIS, NEURONAL/O-9910-2015; Isabel, Guillaume/U-7405-2017; Pascual, Alberto/L-2014-2019; Pascual, Alberto P/E-9609-2015	Pascual, Alberto/0000-0001-5459-6207; Pascual, Alberto P/0000-0001-5459-6207; Preat, Thomas/0000-0001-9976-1763				Armstrong JD, 1998, LEARN MEMORY, V5, P102; Boquet I, 2000, J NEUROBIOL, V42, P33; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; DEZAZZO J, 1995, TRENDS NEUROSCI, V18, P212, DOI 10.1016/0166-2236(95)93905-D; Drier EA, 2002, NAT NEUROSCI, V5, P316, DOI 10.1038/nn820; Dubnau J, 2001, NATURE, V411, P476, DOI 10.1038/35078077; DUDAI Y, 1988, J COMP PHYSIOL A, V162, P101, DOI 10.1007/BF01342707; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; FOLKERS E, 1993, P NATL ACAD SCI USA, V90, P8123, DOI 10.1073/pnas.90.17.8123; Kim JJ, 2001, TRENDS NEUROSCI, V24, P324, DOI 10.1016/S0166-2236(00)01818-X; Kitamoto T, 2001, J NEUROBIOL, V47, P81, DOI 10.1002/neu.1018; McGuire SE, 2001, SCIENCE, V293, P1330, DOI 10.1126/science.1062622; Menzel R, 2001, LEARN MEMORY, V8, P53, DOI 10.1101/lm.38801; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Pascual A, 2001, SCIENCE, V294, P1115, DOI 10.1126/science.1064200; Schwaerzel M, 2002, NEURON, V35, P951, DOI 10.1016/S0896-6273(02)00832-2; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; TULLY T, 1990, COLD SPRING HARB SYM, V55, P203; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; Zars T, 2000, SCIENCE, V288, P672, DOI 10.1126/science.288.5466.672	26	215	221	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					1024	1027		10.1126/science.1094932	http://dx.doi.org/10.1126/science.1094932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143285				2022-12-28	WOS:000221383300053
J	Horsburgh, CR				Horsburgh, CR			Priorities for the treatment of latent tuberculosis infection in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; ISONIAZID PREVENTIVE THERAPY; CONTROLLED TRIAL; GOLD MINERS; DRUG-USERS; RISK; EPIDEMIOLOGY; MORBIDITY; SILICOSIS; DISEASE	BACKGROUND: The prevention of active tuberculosis through the treatment of latent tuberculosis infection is a major element of the national strategy for eliminating tuberculosis in the United States. Targeted treatment for persons who are at the highest risk for reactivation tuberculosis will be needed to achieve this goal. A more precise assessment of the lifetime risk of reactivation tuberculosis, usually estimated at 5 to 10 percent, could help to identify patients who are at the highest risk and motivate them to complete treatment. Currently, the rate of completion of treatment is low. METHODS: Published reports were reviewed to obtain estimates of the risk of tuberculosis among persons with a positive tuberculin skin test. Using these data, I constructed a model to estimate the lifetime risk of tuberculosis among persons with specific medical conditions. RESULTS: The lifetime risk of reactivation tuberculosis is 20 percent or more among most persons with induration of 10 mm or more on a tuberculin skin test and either human immunodeficiency virus infection or evidence of old, healed tuberculosis. The lifetime risk is 10 to 20 percent among persons with recent conversion of a tuberculin skin test and among most persons younger than 35 years of age who are receiving infliximab therapy and have induration of 15 mm or more on a tuberculin skin test. The risk is also 10 to 20 percent among children five years of age or younger who have induration of 10 mm or more on a tuberculin skin test. CONCLUSIONS: Persons with these characteristics should be targeted for intensive efforts to ensure full treatment of latent tuberculosis. Improved rates of completion of treatment among such persons could help to eliminate tuberculosis in the United States.	Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA	Boston University	Horsburgh, CR (corresponding author), Boston Univ, Sch Publ Hlth, Dept Epidemiol, 715 Albany St,T-3E, Boston, MA 02118 USA.	rhorsbu@bu.edu		Horsburgh, C./0000-0001-6838-7895				[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1999, EPIDEMIOLOGIC BASIS; [Anonymous], 2000, AM J RESP CRIT CARE, V161, pS221; ARIAS E, 2000, NATL VITAL STAT REPO, V51; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Bock NM, 1999, AM J RESP CRIT CARE, V159, P295, DOI 10.1164/ajrccm.159.1.9807020; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P269; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; COMSTOCK GW, 1966, AM REV RESPIR DIS, V93, P171; COMSTOCK GW, 1975, AM J EPIDEMIOL, V101, P363, DOI 10.1093/oxfordjournals.aje.a112105; COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8; Corbett EL, 2000, AIDS, V14, P2759, DOI 10.1097/00002030-200012010-00016; COWIE RL, 1994, AM J RESP CRIT CARE, V150, P1460, DOI 10.1164/ajrccm.150.5.7952577; EDWARDS LB, 1971, ARCH ENVIRON HEALTH, V22, P106, DOI 10.1080/00039896.1971.10665820; FEREBEE SH, 1963, AM REV RESPIR DIS, V88, P161; FEREBEE SH, 1962, AM REV RESPIR DIS, V85, P490; FEREBEE SH, 1970, BIBL TUBERC MED THOR, V17, P28; GEITER L, 2000, ENDING NEGLECT ELMIN; Gilroy SA, 2000, CLIN INFECT DIS, V31, P826, DOI 10.1086/314037; Gourevitch MN, 1998, INT J TUBERC LUNG D, V2, P531; Horsburgh CR, 2004, TUBERCULOSIS, P31; Jones JL, 2000, INT J TUBERC LUNG D, V4, P1026; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Kleinschmidt I, 1997, OCCUP ENVIRON MED, V54, P636, DOI 10.1136/oem.54.9.636; Kohn MR, 1996, ARCH PEDIAT ADOL MED, V150, P727, DOI 10.1001/archpedi.1996.02170320073012; LOWELL AM, 1969, TUBERCULOSIS; Miller FJW, 1963, TUBERCULOSIS CHILDRE; Moss AR, 2000, AM J RESP CRIT CARE, V162, P460, DOI 10.1164/ajrccm.162.2.9910055; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Nolan CM, 1997, AM J RESP CRIT CARE, V155, P583, DOI 10.1164/ajrccm.155.2.9032198; PablosMendez A, 1997, AM J PUBLIC HEALTH, V87, P574, DOI 10.2105/AJPH.87.4.574; PALMER CE, 1957, AM REV TUBERC PULM, V76, P517; Poss J E, 2000, Nurs Res, V49, P20, DOI 10.1097/00006199-200001000-00004; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; STEIGER Z, 1976, AM J SURG, V131, P668, DOI 10.1016/0002-9610(76)90174-4; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; THORN PA, 1956, BMJ-BRIT MED J, V4967, P603; Tulsky JP, 1998, AM J PUBLIC HEALTH, V88, P223, DOI 10.2105/AJPH.88.2.223; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Ziv E, 2001, AM J EPIDEMIOL, V153, P381, DOI 10.1093/aje/153.4.381	40	451	463	2	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2060	2067		10.1056/NEJMsa031667	http://dx.doi.org/10.1056/NEJMsa031667			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141044				2022-12-28	WOS:000221354000007
J	Little, MP; Breitling, LP; Basanez, MG; Alley, ES; Boatin, BA				Little, MP; Breitling, LP; Basanez, MG; Alley, ES; Boatin, BA			Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study	LANCET			English	Article							RIVER-BLINDNESS; WEST-AFRICA; PATHOGENESIS; EPILEPSY; VOLVULUS; INFECTION; INTENSITY; SAVANNA; GROWTH	Background Infection with the parasitic filarial nematode Onchocerca volvulus can lead to severe visual impairment and ultimately blindness. Excess mortality has been noted among people with onchocerciasis, but it is not clear whether this effect is entirely due to blindness, or mediated by some more direct effects of the infection. Methods We assessed the relations between infection with O volvulus, visual acuity, and host mortality with data obtained by the Onchocerciasis Control Programme in West Africa from 2315 villages in 11 countries. Findings 297 756 people were eligible for follow-up, and accumulated 2579449 person-years of follow-up from 1971 through 2001. 24517 people died during this period; 1283 (5.2%) of these deaths were due to onchocerciasis. Mortality of the human host was significantly and positively associated with increasing microfilarial burden (p<0.00001), but not with blindness after adjustment for microfilarial load and other variables. Overall, after adjustment for microfilarial load and other variables, female individuals had a risk of death about 7.5% lower than males (p<0.00001). Rates of mortality peaked in the mid 1980s but generally decreased thereafter. Interpretation We have shown a direct relation between O volvulus microfilarial load and host mortality in a comprehensive dataset and in both sexes.	Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, London, England; Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England; WHO, Reg Off Africa, Brazzaville, Rep Congo; WHO, Onchocerciasis Control Programme, Ouagadougou, Burkina Faso	Imperial College London; Imperial College London; World Health Organization; World Health Organization	Little, MP (corresponding author), Imperial Coll Fac Med, Dept Epidemiol & Publ Hlth, St Marys Campus,Norfolk Pl, London W2 1PG, England.	mark.little@imperial.ac.uk	Breitling, Lutz/C-7377-2008	Basanez, Maria-Gloria/0000-0001-5031-3361; Little, Mark/0000-0003-0980-7567				[Anonymous], 1995, World Health Organ Tech Rep Ser, V852, P1; Basanez MG, 2001, TRENDS PARASITOL, V17, P430, DOI 10.1016/S1471-4922(01)02013-X; Borsboom GJJM, 2003, FILARIA J, V2, P1; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BURNHAM GM, 1991, T ROY SOC TROP MED H, V85, P497, DOI 10.1016/0035-9203(91)90234-P; Cooper PJ, 1998, J INFECT DIS, V178, P1133, DOI 10.1086/515661; Dietz K., 1982, P209; Doetze A, 2000, INT IMMUNOL, V12, P623, DOI 10.1093/intimm/12.5.623; Duerr HP, 2003, PARASITOLOGY, V126, P87, DOI 10.1017/S0031182002002561; Duke BOL, 1998, T ROY SOC TROP MED H, V92, P236, DOI 10.1016/S0035-9203(98)90763-5; EVANS TG, 1995, B WORLD HEALTH ORGAN, V73, P495; HABBEMA JDF, 1996, PUBLICATIONS NEWTON, P360; Hall LR, 1999, CLIN MICROBIOL REV, V12, P445, DOI 10.1128/CMR.12.3.445; Hoerauf A, 2002, TRENDS PARASITOL, V18, P25, DOI 10.1016/S1471-4922(01)02173-0; Hougard JM, 2001, J INFECT DIS, V184, P497, DOI 10.1086/322789; KIPP W, 1994, LANCET, V343, P183, DOI 10.1016/S0140-6736(94)90980-6; KIRKWOOD B, 1983, T ROY SOC TROP MED H, V77, P862, DOI 10.1016/0035-9203(83)90308-5; LITTLE MP, IN PRESS J INFECT DI; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MOLYNEUX DH, 1995, PARASITOL TODAY, V11, P399, DOI 10.1016/0169-4758(95)80016-6; Molyneux DH, 1997, PARASITOL TODAY, V13, P418, DOI 10.1016/S0169-4758(97)00142-7; Moreau J.-P., 1978, Medecine Tropicale, V38, P43; Newell ED, 1997, T ROY SOC TROP MED H, V91, P525, DOI 10.1016/S0035-9203(97)90009-2; OTTESEN EA, 1995, J INFECT DIS, V171, P659, DOI 10.1093/infdis/171.3.659; Pearlman E, 2000, PARASITE IMMUNOL, V22, P625, DOI 10.1046/j.1365-3024.2000.00345.x; Pion SDS, 2002, ANN TROP MED PARASIT, V96, P181, DOI 10.1179/000349802125000718; PRESTON SH, 1985, POP B UN, V18, P34; Prost A., 1978, Medecine Tropicale, V38, P519; PROST A, 1981, B WORLD HEALTH ORGAN, V59, P773; PROST A, 1986, T ROY SOC TROP MED H, V80, P525, DOI 10.1016/0035-9203(86)90129-X; PROST A, 1979, TROPENMED PARASITOL, V30, P477; Prost A, 1975, ONCHOWP7514 WHO; REMME J, 1989, TROP MED PARASITOL, V40, P340; Richards FO, 2001, TRENDS PARASITOL, V17, P558, DOI 10.1016/S1471-4922(01)02112-2; *S PLUS, 2001, S PLUS 6 0 PROF REL; Saint Andre AV, 2002, SCIENCE, V295, P1892, DOI 10.1126/science.1068732; Satoguina J, 2002, MICROBES INFECT, V4, P1291, DOI 10.1016/S1286-4579(02)00014-X; STEEL C, 1993, J IMMUNOL, V150, P5511; THYLEFORS B, 1977, WHO, V55, P115	39	78	82	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2004	363	9420					1514	1521		10.1016/S0140-6736(04)16151-5	http://dx.doi.org/10.1016/S0140-6736(04)16151-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135599				2022-12-28	WOS:000221302700011
J	Pimm, SL; Brown, JH				Pimm, SL; Brown, JH			Domains of diversity	SCIENCE			English	Editorial Material							SPECIES RICHNESS PATTERNS; LATITUDINAL GRADIENTS		Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27713 USA; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA	Duke University; University of New Mexico	Pimm, SL (corresponding author), Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27713 USA.	stuartpimm@aol.com; jhbrown@unm.edu	pimm, stuart/ABF-1082-2020					[Anonymous], 1878, TROPICAL NATURE OTHE; Bokma F, 2001, ECOGRAPHY, V24, P43, DOI 10.1034/j.1600-0587.2001.240106.x; Colwell RK, 2004, AM NAT, V163, pE1, DOI 10.1086/382056; GOTELLI NJ, 1966, NULL MODELS ECOLOGY; Keynes RichardD., 1979, BEAGLE RECORD SELECT; KINEMAN J, 1992, GLOBAL ECOSYSTEMS DA; LEWIN R, 1983, SCIENCE, V221, P636, DOI 10.1126/science.221.4611.636; Manne LL, 1999, NATURE, V399, P258, DOI 10.1038/20436; PIANKA ER, 1966, AM NAT, V100, P33, DOI 10.1086/282398; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; ROY K, 2003, GEOL SOC AM ABST, V34, P84; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Willig MR, 2003, ANNU REV ECOL EVOL S, V34, P273, DOI 10.1146/annurev.ecolsys.34.012103.144032; Zapata FA, 2003, J ANIM ECOL, V72, P677, DOI 10.1046/j.1365-2656.2003.00741.x	14	76	85	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					831	833		10.1126/science.1095332	http://dx.doi.org/10.1126/science.1095332			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131295				2022-12-28	WOS:000221243000029
J	Dor, Y; Brown, J; Martinez, OI; Melton, DA				Dor, Y; Brown, J; Martinez, OI; Melton, DA			Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation	NATURE			English	Article							LIVER-REGENERATION; ISLET VOLUME; IN-VIVO; MICE; RATS; NEOGENESIS; MOUSE; MASS; ENDOCRINE; EXOCRINE	How tissues generate and maintain the correct number of cells is a fundamental problem in biology. In principle, tissue turnover can occur by the differentiation of stem cells, as is well documented for blood, skin and intestine, or by the duplication of existing differentiated cells. Recent work on adult stem cells has highlighted their potential contribution to organ maintenance and repair. However, the extent to which stem cells actually participate in these processes in vivo is not clear. Here we introduce a method for genetic lineage tracing to determine the contribution of stem cells to a tissue of interest. We focus on pancreatic beta-cells, whose postnatal origins remain controversial. Our analysis shows that pre-existing beta-cells, rather than pluripotent stem cells, are the major source of new beta-cells during adult life and after pancreatectomy in mice. These results suggest that terminally differentiated beta-cells retain a significant proliferative capacity in vivo and cast doubt on the idea that adult stem cells have a significant role in beta-cell replenishment.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Harvard University; Howard Hughes Medical Institute	Melton, DA (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	dmelton@mcb.harvard.edu	Young, Richard A/F-6495-2012; Dor, Yuval/C-2405-2011	Young, Richard A/0000-0001-8855-8647; 				Alison MR, 2002, SEMIN CELL DEV BIOL, V13, P385, DOI 10.1016/S1084952102001246; ARKLE S, 1986, Q J EXP PHYSIOL CMS, V71, P249, DOI 10.1113/expphysiol.1986.sp002982; Bock T, 2003, DIABETES, V52, P1716, DOI 10.2337/diabetes.52.7.1716; Bonner-Weir S, 2000, TRENDS ENDOCRIN MET, V11, P375, DOI 10.1016/S1043-2760(00)00305-2; Bonner-Weir S, 2002, J PATHOL, V197, P519, DOI 10.1002/path.1158; BONNERWEIR S, 1993, DIABETES, V42, P1715, DOI 10.2337/diabetes.42.12.1715; BUNNAG SC, 1966, DIABETES, V15, P480, DOI 10.2337/diab.15.7.480; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; Fausto N, 2003, MECH DEVELOP, V120, P117, DOI 10.1016/S0925-4773(02)00338-6; Finegood DT, 1999, AM J PHYSIOL-ENDOC M, V276, pE822, DOI 10.1152/ajpendo.1999.276.5.E822; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; FONG I, 1992, PANCREAS, V7, P453, DOI 10.1097/00006676-199207000-00006; Freshney R.I, 2010, CULTURE ANIMAL CELLS, Vsixth, P732; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Guz Y, 2001, ENDOCRINOLOGY, V142, P4956, DOI 10.1210/en.142.11.4956; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hardikar AA, 1999, J ENDOCRINOL, V162, P189, DOI 10.1677/joe.0.1620189; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Kodama S, 2003, SCIENCE, V302, P1223, DOI 10.1126/science.1088949; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; LEBLOND C. P., 1964, NAT CANCER INST MONOGR, V14, P119; Lin YQ, 2001, DIABETOLOGIA, V44, P1026, DOI 10.1007/s001250100597; Lipsett M, 2002, DIABETES, V51, P1834, DOI 10.2337/diabetes.51.6.1834; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; MESSIER B, 1960, AM J ANAT, V106, P247, DOI 10.1002/aja.1001060305; Oh SH, 2002, SEMIN CELL DEV BIOL, V13, P405, DOI 10.1016/S1084952102001271; Paris M, 2003, ENDOCRINOLOGY, V144, P2717, DOI 10.1210/en.2002-221112; Rooman I, 2002, DIABETES, V51, P686, DOI 10.2337/diabetes.51.3.686; Skau M, 2001, DIABETES, V50, P1763, DOI 10.2337/diabetes.50.8.1763; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; TSUBOUCHI S, 1987, ANAT REC, V218, P111, DOI 10.1002/ar.1092180203; Waguri M, 1997, DIABETES, V46, P1281, DOI 10.2337/diabetes.46.8.1281; WANG RN, 1995, DIABETOLOGIA, V38, P1405, DOI 10.1007/BF00400600; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Yamamoto K, 2000, DIABETES, V49, P2021, DOI 10.2337/diabetes.49.12.2021; ZAJICEK G, 1990, DIABETES RES CLIN EX, V13, P121; Zulewski H, 2001, DIABETES, V50, P521, DOI 10.2337/diabetes.50.3.521	38	1731	1839	0	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 6	2004	429	6987					41	46		10.1038/nature02520	http://dx.doi.org/10.1038/nature02520			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129273	Bronze			2022-12-28	WOS:000221222100037
J	Dyer, O				Dyer, O			US societies to defy ban on editing articles from embargoed countries	BRITISH MEDICAL JOURNAL			English	News Item																			0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 6	2004	328	7439					543	543		10.1136/bmj.328.7439.543	http://dx.doi.org/10.1136/bmj.328.7439.543			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JI	15132124	Green Published			2022-12-28	WOS:000220091800012
J	van Hilten, JA; de Watering, LMGV; van Bockel, JH; van de Velde, JH; Kievit, J; Brand, R; van den Hout, WB; Geelkerken, RH; Roumen, RMH; Wesslink, RMJ; Koopman-van Gemert, WMM; Koning, J; Brand, A				van Hilten, JA; de Watering, LMGV; van Bockel, JH; van de Velde, JH; Kievit, J; Brand, R; van den Hout, WB; Geelkerken, RH; Roumen, RMH; Wesslink, RMJ; Koopman-van Gemert, WMM; Koning, J; Brand, A		Tactics	Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OUTCOMES FOLLOWING INSTITUTION; BLOOD-TRANSFUSION; CARDIAC-SURGERY; UNIVERSAL LEUKOREDUCTION; INFECTIOUS COMPLICATIONS; POSTOPERATIVE INFECTION; DEPLETION; COMPONENTS; RISK	Objective To compare postoperative complications in patients undergoing major surgery who received non-filtered or filtered red blood cell transfusions. Design Prospective, randomised, double blinded trial. Setting 19 hospitals throughout the Netherlands (three university; 10 clinical; six general). Participants 1051 evaluable patients: 79 patients with ruptured aneurysm, 412 patients undergoing elective surgery for aneurysm, and 560 undergoing gastrointestinal surgery. Interventions The non-filtered products had the buffy coat removed and were plasma reduced. The filtered products had the huffy coat removed, were plasma reduced, and filtered before storage to remove leucocytes. Main outcome measures Mortality and duration of stay in intensive care. Secondary end points were occurrence of multiorgan failure, infections, and length of hospital stay. Results No significant differences were found in mortality (odds ratio for filtered v non-filtered 0.80, 95% confidence interval 0.53 to 1.21) and in mean stay in intensive care (- 0.4 day, - 1.6 to 0.6 day). In the filtered group the mean length of hospital stay was 2.4 days shorter (- 4.8 to 0.0 day; P = 0.050) and the incidence of multiorgan failure was 30% lower (odds ratio 0.70, 0.49 to 1.00; P = 0.050). There were no differences in rates of infection (0.98 (0.73 to 1.32). Conclusion The use of filtered transfusions in some types of major surgery may reduce the length of hospital stay and the incidence of postoperative multiorgan failure.	Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, NL-2300 RC Leiden, Netherlands; Sanquin Blood Supply, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands; Leiden Univ, Dept Med Stat, NL-2300 RC Leiden, Netherlands; Med Spectrum Twente, NL-7500 KA Enschede, Netherlands; St Joseph Hosp, NL-5500 MB Veldhoven, Netherlands; St Antonius Hosp, NL-3430 EM Nieuwegein, Netherlands; Albert Schweitzer Locatie Dordwijk, NL-3300 AH Dordrecht, Netherlands; Reinier de Graaf Grp, NL-2600 GA Delft, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Medical Spectrum Twente; St. Antonius Hospital Utrecht; Reinier de Graaf Hospital	van Hilten, JA (corresponding author), Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, POB 9600, NL-2300 RC Leiden, Netherlands.	J.A.van_Hilten@lumc.nl	Kievit, Job/A-3924-2008; Geelkerken, R. H./AAF-7404-2019	van den Hout, Wilbert B./0000-0002-6425-0135				Asimakopoulos G, 1999, PERFUSION-UK, V14, P269, DOI 10.1177/026765919901400406; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Bilgin YM, 2001, BLOOD, V98, p828A; Blumberg N, 2002, AM J CLIN PATHOL, V118, P376; Collier AC, 2001, JAMA-J AM MED ASSOC, V285, P1592, DOI 10.1001/jama.285.12.1592; Desgagne A, 1998, PHARMACOECONOMICS, V13, P487, DOI 10.2165/00019053-199813050-00002; Duffy G, 1996, TRANSFUSION MED, V6, P325, DOI 10.1111/j.1365-3148.1996.tb00091.x; Dzik WH, 2002, TRANSFUSION, V42, P1114, DOI 10.1046/j.1537-2995.2002.00182.x; Fergusson D, 2003, JAMA-J AM MED ASSOC, V289, P1950, DOI 10.1001/jama.289.15.1950; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; Groeneveld ABJ, 1997, EUR J VASC ENDOVASC, V14, P351, DOI 10.1016/S1078-5884(97)80284-5; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hebert PC, 2003, JAMA-J AM MED ASSOC, V289, P1941, DOI 10.1001/jama.289.15.1941; HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; Jensen LS, 1996, LANCET, V348, P841, DOI 10.1016/S0140-6736(96)06168-5; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Nathens AB, 1996, WORLD J SURG, V20, P386, DOI 10.1007/s002689900061; PINTO V, 1991, TRANSFUSION, V31, P114, DOI 10.1046/j.1537-2995.1991.31291142940.x; RAPAPORT FT, 1983, TRANSPLANT P, V15, P952; Sharma AD, 2000, ANESTH ANALG, V90, P1315, DOI 10.1097/00000539-200006000-00010; Spark JI, 1997, EUR J VASC ENDOVASC, V14, P482, DOI 10.1016/S1078-5884(97)80128-1; Tartter PI, 1998, AM J SURG, V176, P462, DOI 10.1016/S0002-9610(98)00245-1; Titlestad IL, 2001, INT J COLORECTAL DIS, V16, P147, DOI 10.1007/s003840100298; Vamvakas EC, 2000, TRANSFUS MED REV, V14, P137, DOI 10.1016/S0887-7963(00)80004-8; van de Watering LMG, 1998, CIRCULATION, V97, P562; VANWAKAS EC, 2000, BLOOD, V97, P1180; WARE LB, 2000, NEW ENGL J MED, V342, P1334, DOI [DOI 10.1056/NEJM200005043421806, 10.1056/NEJM200005043421806]; WOBBES T, 1990, SURG GYNECOL OBSTET, V171, P59	31	84	85	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	2004	328	7451					1281	1284B		10.1136/bmj.38103.735266.55	http://dx.doi.org/10.1136/bmj.38103.735266.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826PN	15142885	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000221841100014
J	Marques, CJ; Carvalho, F; Sousa, M; Barros, A				Marques, CJ; Carvalho, F; Sousa, M; Barros, A			Genomic imprinting in disruptive spermatogenesis	LANCET			English	Article							HUMAN H19; GENES	The possibility of imprinting disease transmission by assisted reproductive technologies has been raised after births of children with Angelman's and Beckwith-Wiedemann's syndromes. To investigate whether imprinting defects were associated with disturbed spermatogenesis, we studied two oppositely imprinted genes in spermatozoan DNA from normozoospermic and oligozoospermic patients. In the mesodermal specific transcript gene (MEST), bisulphite genomic sequencing showed that maternal imprinting was correctly erased in all 123 patients. However, methylation of the H19 gene did not change in any of 27 normozoospermic individuals (0%, 95% CI 0-13%), compared with methylation changes in eight moderate (17%, 8-31%, p=0.026) and 15 severe (30%, 18-45%, p=0.002) oligozoospermic patients. Our data suggest an association between abnormal genomic imprinting and hypospermatogenesis, and that spermatozoa from oligozoospermic patients carry a raised risk of transmitting imprinting errors.	Univ Porto, Inst Biomed Sci Abel Salazar, Cell Biol Lab, P-4099003 Oporto, Portugal; Univ Porto, Fac Med, Dept Genet, P-4100 Oporto, Portugal; Ctr Reprod Genet A Barros, Oporto, Portugal	Universidade do Porto; Universidade do Porto	Sousa, M (corresponding author), Univ Porto, Inst Biomed Sci Abel Salazar, Cell Biol Lab, P-4099003 Oporto, Portugal.	msousa@icbas.up.pt	Barros, Alberto/L-3094-2013; Sousa, Mário/A-7340-2019; Carvalho, Filipa/L-2566-2013; Marques, Joana/B-5564-2008	Barros, Alberto/0000-0002-8700-3698; Sousa, Mário/0000-0002-3009-3290; Carvalho, Filipa/0000-0001-9546-4614; Marques, Joana/0000-0002-5658-3773				Frevel MAE, 1999, TRENDS GENET, V15, P216, DOI 10.1016/S0168-9525(99)01752-7; Gosden R, 2003, LANCET, V361, P1975, DOI 10.1016/S0140-6736(03)13592-1; Kerjean A, 2000, HUM MOL GENET, V9, P2183, DOI 10.1093/hmg/9.14.2183; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619	5	247	263	1	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	2004	363	9422					1700	1702		10.1016/S0140-6736(04)16256-9	http://dx.doi.org/10.1016/S0140-6736(04)16256-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158633				2022-12-28	WOS:000221546300012
J	Smith, D; Channer, K				Smith, D; Channer, K			For and against - Primary angioplasty should be first line treatment for acute myocardial infarction	BMJ-BRITISH MEDICAL JOURNAL			English	Article							THROMBOLYTIC THERAPY; MORTALITY		Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England	University of Exeter	Smith, D (corresponding author), Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England.	dagobert@eurobell.co.uk; kevin.channer@sth.nhs.uk						APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; *DEP HLTH, 2000, NAT SERV FRAM COR HE; FathOrdoubadi F, 1997, AM HEART J, V134, P62, DOI 10.1016/S0002-8703(97)70107-8; French JK, 1999, J AM COLL CARDIOL, V34, P62, DOI 10.1016/S0735-1097(99)00166-7; Garcia E, 1999, J AM COLL CARDIOL, V33, P605, DOI 10.1016/S0735-1097(98)00644-5; Gibson CM, 2000, CIRCULATION, V101, P125, DOI 10.1161/01.CIR.101.2.125; Grines CL, 1998, J AM COLL CARDIOL, V31, P967, DOI 10.1016/S0735-1097(98)00031-X; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SMITH LDR, 1997, HEART, V77, P46	11	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	2004	328	7450					1254	1255		10.1136/bmj.328.7450.1254	http://dx.doi.org/10.1136/bmj.328.7450.1254			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824HL	15155508	Green Published			2022-12-28	WOS:000221677200032
J	Clutton-Brock, TH; Coulson, T; Milner, JM				Clutton-Brock, TH; Coulson, T; Milner, JM			Red deer stocks in the Highlands of Scotland	NATURE			English	Editorial Material									Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ascot SL5 7PY, Berks, England; Hedmark Univ Coll, N-2480 Evenstad, Koppand, Norway	University of Cambridge; Imperial College London; Inland Norway University of Applied Sciences	Clutton-Brock, TH (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	thcb@cam.ac.uk	Milner, Jos M./G-7722-2012; Coulson, Tim/AAL-8148-2021	Milner, Jos M./0000-0003-0229-3655; Coulson, Tim/0000-0001-9371-9003				[Anonymous], 1977, ECOLOGY RED DEER RES; [Anonymous], IMPACT VERTEBRATE HE; BEAUMONT D, 1994, OUR PINEWOOD HERITAG, P73; Caughley G., 1981, P7; CAUGHLEY G, 1986, RANGELANDS RESOURCE, P135; Clutton-Brock T. H., 1989, RED DEER HIGHLANDS; Clutton-Brock TH, 2002, HIGHLAND DEER HERD I, P237; CLUTTONBROCK TH, 1992, NATURE, V358, P11; Darling FR., 1963, HERD RED DEER STUDY; HARTDAVIS D, 1978, MONARCH GLEN; HESTER AI, 1998, VEGETATION SURVEY AB; HUNT JF, 2003, IMPACTS WILD DEER SC; MILNER JM, 2002, HIGHLAND DEER HERD I, P109	13	61	62	1	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					261	262		10.1038/429261a	http://dx.doi.org/10.1038/429261a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152241				2022-12-28	WOS:000221505900030
J	Dalakas, MC				Dalakas, MC			Intravenous immunoglobulin in autoimmune neuromuscular diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INFLAMMATORY DEMYELINATING POLYNEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; GUILLAIN-BARRE-SYNDROME; INCLUSION-BODY MYOSITIS; DOUBLE-BLIND; IMMUNE GLOBULIN; PLASMA-EXCHANGE; BLOCKING ANTIBODIES; CLINICAL SPECTRUM	Context Intravenous immunoglobulin (IVIG) enhances immune homeostasis by modulating expression and function of Fc receptors, interfering with activation of complement and production of cytokines, providing anti-idiotypic antibodies, and affecting the activation and effector functions of T and B cells. These mechanisms may explain the effectiveness of IVIG in autoimmune neuromuscular disorders. Objective To systematically review the current status of the treatment of autoimmune neuromuscular diseases with IVIG, with emphasis on controlled trials. Data Sources Peer-reviewed publications identified through MEDLINE (1966-2003), EMBASE (1974-2003), and references from bibliographies of pertinent articles. Each autoimmune neuromuscular disease term was searched in combination with the term intravenous immunoglobulin. Study Selection and Data Extraction Criteria for selection of studies included controlled study design, English language, and clinical pertinence. Data quality was based on venue of publication and relevance to clinical care. Data Synthesis Outcomes of controlled trials indicate that IVIG at a total dose of 2 g/kg is effective as first-line therapy in Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy and as second-line therapy in stiff-person syndrome, dermatomyositis, myasthenia gravis, and Lambert-Eaton myasthenic syndrome. in other controlled studies, IVIG produced a modest, variable, and transient but not statistically significant benefit in patients with inclusion body myositis and paraproteinemic anti-myelin-associated glycoprotein antibody demyelinating polyneuropathy. Intravenous immunoglobulin is not effective in patients with multiple sclerosis who have established weakness or optic neuritis. In myasthenia gravis, it should be reserved for difficult cases or before thymectomy in lieu of plasma exchange. Conclusion intravenous immunoglobulin is effective in many autoimmune neurologic diseases, but its spectrum of efficacy, especially as first-line therapy, and the appropriate dose for long-term maintenance therapy are not fully established. Further controlled studies of IVIG, combined with a dose-finding effect, pharmacoeconomics, and quality-of-life assessments, are warranted to improve the evidence base for clinical practice.	NINDS, NIH, Neuromuscular Dis Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Dalakas, MC (corresponding author), NINDS, NIH, Neuromuscular Dis Sect, Bldg 10,Room 4N248, Bethesda, MD 20892 USA.	dalakasm@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002038] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amemiya K, 2000, CLIN IMMUNOL, V94, P99, DOI 10.1006/clim.1999.4823; AZULAY JP, 1994, NEUROLOGY, V44, P429, DOI 10.1212/WNL.44.3_Part_1.429; Bain PG, 1996, NEUROLOGY, V47, P678, DOI 10.1212/WNL.47.3.678; Basta M, 1996, J NEUROIMMUNOL, V71, P227, DOI 10.1016/S0165-5728(96)00133-6; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; Bayry J, 2003, ARTHRITIS RHEUM-US, V48, P3497, DOI 10.1002/art.11346; Bayry J, 2003, BLOOD, V101, P758, DOI 10.1182/blood-2002-05-1447; Buchwald B, 2002, ANN NEUROL, V51, P673, DOI 10.1002/ana.10205; CHERIN P, 1991, AM J MED, V91, P162, DOI 10.1016/0002-9343(91)90009-M; Cherin P, 2002, NEUROLOGY, V58, P326, DOI 10.1212/WNL.58.2.326; CHESTER KA, 1988, J NEUROIMMUNOL, V18, P97, DOI 10.1016/0165-5728(88)90058-6; Comi G, 2002, J NEUROL, V249, P1370, DOI 10.1007/s00415-002-0808-z; Dalakas, 1995, ANN NEUROL S, V37, P2; Dalakas Marinos C., 2001, Current Opinion in Pharmacology, V1, P300, DOI 10.1016/S1471-4892(01)00053-4; Dalakas MC, 2000, NEUROLOGY, V55, P1531, DOI 10.1212/WNL.55.10.1531; Dalakas MC, 1998, ARCH NEUROL-CHICAGO, V55, P1509, DOI 10.1001/archneur.55.12.1509; Dalakas MC, 2003, LANCET, V362, P971, DOI 10.1016/S0140-6736(03)14368-1; DALAKAS MC, 1994, NEUROLOGY, V44, P223, DOI 10.1212/WNL.44.2.223; Dalakas MC, 2003, NEUROLOGY, V60, P1736, DOI 10.1212/01.WNL.0000074394.15882.83; DALAKAS MC, 1994, ARCH NEUROL-CHICAGO, V51, P861, DOI 10.1001/archneur.1994.00540210031010; Dalakas MC, 1996, ANN NEUROL, V40, P792, DOI 10.1002/ana.410400516; Dalakas MC, 1999, MUSCLE NERVE, V22, P1479, DOI 10.1002/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B; Dalakas MC, 2002, NEUROLOGY, V59, pS13, DOI 10.1212/WNL.59.12_suppl_6.S13; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; Dalakas MC, 2001, NEW ENGL J MED, V345, P1870, DOI 10.1056/NEJMoa01167; Dalakas MC, 2002, ANN NEUROL, V51, P667, DOI 10.1002/ana.10259; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; Dalakas MC, 2001, NEUROLOGY, V56, P323, DOI 10.1212/WNL.56.3.323; Dalakas MC, 1997, NEUROLOGY, V48, P712, DOI 10.1212/WNL.48.3.712; Dalakas MC, 1999, CURR OPIN NEUROL, V12, P403, DOI 10.1097/00019052-199908000-00006; Dalakas MC, 1997, ANN INTERN MED, V126, P721, DOI 10.7326/0003-4819-126-9-199705010-00008; Delves PJ, 2000, NEW ENGL J MED, V343, P108, DOI 10.1056/NEJM200007133430207; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; Duse M, 1996, CLIN EXP IMMUNOL, V104, P71, DOI 10.1111/cei.1996.104.s1.71; DYCK PJ, 1994, ANN NEUROL, V36, P838, DOI 10.1002/ana.410360607; Farcas P, 1997, LANCET, V350, P1747, DOI 10.1016/S0140-6736(97)24050-X; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; Federico P, 2000, NEUROLOGY, V55, P1256, DOI 10.1212/WNL.55.9.1256; Gajdos P, 1997, ANN NEUROL, V41, P789, DOI 10.1002/ana.410410615; Gajdos P, 2004, INTRAVENOUS IMMUNOGLOBULINS IN THE THIRD MILLENNIUM, P203; Gold R, 2003, LANCET NEUROL, V2, P22, DOI 10.1016/S1474-4422(03)00264-3; HaferMacko C, 1996, ANN NEUROL, V40, P635, DOI 10.1002/ana.410400414; HaferMacko CE, 1996, ANN NEUROL, V39, P627, DOI 10.1002/ana.410390512; Hahn AF, 1998, LANCET, V352, P635, DOI 10.1016/S0140-6736(97)12308-X; Hahn AF, 1996, BRAIN, V119, P1067, DOI 10.1093/brain/119.4.1067; Ho TW, 1997, NEUROLOGY, V48, P695, DOI 10.1212/WNL.48.3.695; Hoch W, 2001, NAT MED, V7, P365, DOI 10.1038/85520; Hohlfeld Reinhard, 1997, Current Opinion in Rheumatology, V9, P520, DOI 10.1097/00002281-199711000-00007; Hughes R, 2001, ANN NEUROL, V50, P195, DOI 10.1002/ana.1088; Hughes RAC, 1997, LANCET, V349, P225; Hughes RAC, 1999, J NEUROIMMUNOL, V100, P74, DOI 10.1016/S0165-5728(99)00195-2; ISHII A, 1994, J NEUROL NEUROSUR PS, V57, P840, DOI 10.1136/jnnp.57.7.840; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Karlsen AE, 1998, SEMIN IMMUNOL, V10, P25, DOI 10.1006/smim.1997.0102; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Kieseier BC, 2002, NEUROLOGY, V59, pS7, DOI 10.1212/WNL.59.12_suppl_6.S7; KORNBERG AJ, 1994, ANN NEUROL, V35, P234, DOI 10.1002/ana.410350217; LANG BA, 1991, AM J MED, V91, P169, DOI 10.1016/0002-9343(91)90010-U; Malik U, 1996, ANN NEUROL, V39, P136, DOI 10.1002/ana.410390121; Marchioni E, 2002, J NEUROL, V249, P100, DOI 10.1007/PL00007836; Mendell JR, 2001, NEUROLOGY, V56, P445, DOI 10.1212/WNL.56.4.445; Nobile-Orazio E, 2001, J NEUROIMMUNOL, V115, P4, DOI 10.1016/S0165-5728(01)00266-1; NOBILEORAZIO E, 1994, ANN NEUROL, V36, P416, DOI 10.1002/ana.410360313; Noseworthy JH, 2000, NEUROLOGY, V55, P1135, DOI 10.1212/WNL.55.8.1135; Noseworthy JH, 2001, NEUROLOGY, V56, P1514, DOI 10.1212/WNL.56.11.1514; Raphael JC, 2001, J NEUROL NEUROSUR PS, V71, P235, DOI 10.1136/jnnp.71.2.235; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Saperstein DS, 2001, MUSCLE NERVE, V24, P311, DOI 10.1002/1097-4598(200103)24:3<311::AID-MUS1001>3.3.CO;2-1; SEKUL EA, 1994, ANN INTERN MED, V121, P259, DOI 10.7326/0003-4819-121-4-199408150-00004; Sharma KR, 2002, ARCH NEUROL-CHICAGO, V59, P758, DOI 10.1001/archneur.59.5.758; Sheikh KA, 1999, BRAIN, V122, P449, DOI 10.1093/brain/122.3.449; Sorensen PS, 1998, NEUROLOGY, V50, P1273, DOI 10.1212/WNL.50.5.1273; Takamori M, 2000, NEUROSCI RES, V36, P183, DOI 10.1016/S0168-0102(99)00135-2; Van den Berg-Vos RA, 2002, BRAIN, V125, P1875, DOI 10.1093/brain/awf193; van Koningsveld R, 2004, LANCET, V363, P192, DOI 10.1016/S0140-6736(03)15324-X; VANDENBERG LH, 1995, J NEUROL NEUROSUR PS, V59, P248, DOI 10.1136/jnnp.59.3.248; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; VANENGELEN BGM, 1994, EUR J PEDIATR, V153, P762, DOI 10.1007/BF01954498; Villani F, 2001, NEUROLOGY, V56, P248, DOI 10.1212/WNL.56.2.248; Walter MC, 2000, J NEUROL, V247, P22, DOI 10.1007/s004150050005; Weiss MD, 1998, NEUROLOGY, V51, P1738, DOI 10.1212/WNL.51.6.1738; Willison HJ, 2001, J NEUROL SCI, V185, P1, DOI 10.1016/S0022-510X(01)00465-8; Yuki N, 2001, Lancet Infect Dis, V1, P29	83	211	237	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2004	291	19					2367	2375		10.1001/jama.291.19.2367	http://dx.doi.org/10.1001/jama.291.19.2367			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821JD	15150209				2022-12-28	WOS:000221455400025
J	Li, JB; Gerdes, JM; Haycraft, CJ; Fan, YL; Teslovich, TM; May-Simera, H; Li, HT; Blacque, OE; Li, LY; Leitch, CC; Lewis, RA; Green, JS; Parfrey, PS; Leroux, MR; Davidson, WS; Beales, PL; Guay-Woodford, LM; Yoder, BK; Stormo, GD; Katsanis, N; Dutcher, SK				Li, JB; Gerdes, JM; Haycraft, CJ; Fan, YL; Teslovich, TM; May-Simera, H; Li, HT; Blacque, OE; Li, LY; Leitch, CC; Lewis, RA; Green, JS; Parfrey, PS; Leroux, MR; Davidson, WS; Beales, PL; Guay-Woodford, LM; Yoder, BK; Stormo, GD; Katsanis, N; Dutcher, SK			Comparative and basal genomics identifies a flagellar and basal body proteome that includes the BBS5 human disease gene	CELL			English	Article							BARDET-BIEDL-SYNDROME; POLYCYSTIC KIDNEY-DISEASE; CELL-CYCLE PROGRESSION; HUMAN OBESITY SYNDROME; CHLAMYDOMONAS-REINHARDTII; INTRAFLAGELLAR TRANSPORT; CAENORHABDITIS-ELEGANS; C-ELEGANS; TRIALLELIC INHERITANCE; SENSORY CILIA	Cilia and flagella are microtubule-based structures nucleated by modified centrioles termed basal bodies. These biochemically complex organelles have more than 250 and 150 polypeptides, respectively. To identify the proteins involved in ciliary and basal body biogenesis and function, we undertook a comparative genomics approach that subtracted the nonflagellated proteome of Arabidopsis from the shared proteome of the ciliated/flagellated organisms Chlamydomonas and human. We identified 688 genes that are present exclusively in organisms with flagella and basal bodies and validated these data through a series of in silico, in vitro, and in vivo studies. We then applied this resource to the study of human ciliation disorders and have identified BBS5, a novel gene for Bardet-Biedl syndrome. We show that this novel protein localizes to basal bodies in mouse and C. elegans, is under the regulatory control of daf-19, and is necessary for the generation of both cilia and flagella.	Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21205 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; UCL, Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; Univ Alabama, Dept Med, Div Genet & Translat Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Pediat, Div Genet & Translat Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Genet, Div Genet & Translat Med, Birmingham, AL 35294 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Mem Univ Newfoundland, Dept Med Genet, St John, NF, Canada; Mem Univ Newfoundland, Dept Clin Epidemiol, St John, NF, Canada	Washington University (WUSTL); Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of Alabama System; University of Alabama Birmingham; Simon Fraser University; University of London; University College London; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Memorial University Newfoundland; Memorial University Newfoundland	Dutcher, SK (corresponding author), Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.	dutcher@genetics.wustl.edu	Gerdes, Jantje Mareike/M-9868-2014; Blacque, Oliver/AAL-8860-2021; Katsanis, Nicholas/E-1837-2012; Beales, Philip L/C-7367-2009; Stormo, Gary D/C-5367-2013	Gerdes, Jantje Mareike/0000-0001-6885-5441; Stormo, Gary D/0000-0001-6896-1850; May-Simera, Helen/0000-0002-9477-4036; Blacque, Oliver/0000-0003-1598-2695; Katsanis, Nicholas/0000-0002-2480-0171	NICHD NIH HHS [HD04260] Funding Source: Medline; NIDDK NIH HHS [DK065655, DK-62758, DK055534, P30 DK074038] Funding Source: Medline; NIGMS NIH HHS [GM-32843, GM28755] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK074038, R01DK055534, R01DK065655, R01DK062758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028755, R01GM032843] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANHOLT RRH, 1990, BIOCHEMISTRY-US, V29, P4049, DOI 10.1021/bi00469a004; Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Badano JL, 2003, HUM MOL GENET, V12, P1651, DOI 10.1093/hmg/ddg188; Badano JL, 2003, AM J HUM GENET, V72, P650, DOI 10.1086/368204; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Beales PL, 2003, AM J HUM GENET, V72, P1187, DOI 10.1086/375178; Beales PL, 2001, AM J HUM GENET, V68, P606, DOI 10.1086/318794; Bobinnec Y, 1999, EUR J CELL BIOL, V78, P671, DOI 10.1016/S0171-9335(99)80053-3; BRENNER S, 1974, GENETICS, V77, P71; Cole DG, 2003, TRAFFIC, V4, P435, DOI 10.1034/j.1600-0854.2003.t01-1-00103.x; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Davy BE, 2003, HUM MOL GENET, V12, P1163, DOI 10.1093/hmg/ddg122; DUTCHER S, 2004, DISSECTION BASAL BOD; Dutcher SK, 2003, CURR OPIN MICROBIOL, V6, P634, DOI 10.1016/j.mib.2003.10.016; DUTCHER SK, 1995, TRENDS GENET, V11, P398, DOI 10.1016/S0168-9525(00)89123-4; DUTCHER SK, 1995, METHOD CELL BIOL, V47, P323, DOI 10.1016/S0091-679X(08)60826-2; Dutcher SK, 2003, TRAFFIC, V4, P443, DOI 10.1034/j.1600-0854.2003.00104.x; EHLER LL, 1995, GENETICS, V141, P945; Essner JJ, 2002, NATURE, V418, P37, DOI 10.1038/418037a; Fuhrmann M, 1999, PLANT J, V19, P353, DOI 10.1046/j.1365-313X.1999.00526.x; Fujiwara M, 1999, DEVELOPMENT, V126, P4839; Handel M, 1999, NEUROSCIENCE, V89, P909, DOI 10.1016/S0306-4522(98)00354-6; Haycraft CJ, 2001, DEVELOPMENT, V128, P1493; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Huang KY, 2003, P NATL ACAD SCI USA, V100, P6269, DOI 10.1073/pnas.0931459100; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; Katsanis N, 2002, AM J HUM GENET, V71, P22, DOI 10.1086/341031; Katsanis N, 2000, NAT GENET, V26, P67, DOI 10.1038/79201; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; LEFEBVRE PA, 1980, CELL, V20, P469, DOI 10.1016/0092-8674(80)90633-9; Li JB, 2003, J EUKARYOT MICROBIOL, V50, P145, DOI 10.1111/j.1550-7408.2003.tb00109.x; Li QZ, 2001, GENE, V273, P275, DOI 10.1016/S0378-1119(01)00582-0; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lopez R, 2003, NUCLEIC ACIDS RES, V31, P3795, DOI 10.1093/nar/gkg573; Marszalek JR, 2000, BBA-MOL CELL RES, V1496, P142, DOI 10.1016/S0167-4889(00)00015-X; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Meraldi P, 2001, J CELL SCI, V114, P3749; Mollet G, 2002, NAT GENET, V32, P300, DOI 10.1038/ng996; Mykytyn K, 2002, NAT GENET, V31, P435, DOI 10.1038/ng935; Mykytyn K, 2001, NAT GENET, V28, P188, DOI 10.1038/88925; Nishimura DY, 2001, HUM MOL GENET, V10, P865, DOI 10.1093/hmg/10.8.865; PASQUALE SM, 1987, J CELL BIOL, V105, P2279, DOI 10.1083/jcb.105.5.2279; Pazour GJ, 2003, CURR OPIN CELL BIOL, V15, P105, DOI 10.1016/S0955-0674(02)00012-1; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pazour GJ, 2002, TRENDS CELL BIOL, V12, P551, DOI 10.1016/S0962-8924(02)02410-8; Pazour GJ, 2002, CURR BIOL, V12, pR378, DOI 10.1016/S0960-9822(02)00877-1; Perrone CA, 2003, MOL BIOL CELL, V14, P2041, DOI 10.1091/mbc.e02-10-0682; Pfannenschmid F, 2003, J CELL SCI, V116, P1449, DOI 10.1242/jcs.00337; PICKETTHEAPS J, 1971, CYTOBIOS, V3, P205; PIPERNO G, 1977, P NATL ACAD SCI USA, V74, P1600, DOI 10.1073/pnas.74.4.1600; Piperno G, 1997, P NATL ACAD SCI USA, V94, P4457, DOI 10.1073/pnas.94.9.4457; Schafer JC, 2003, MOL BIOL CELL, V14, P2057, DOI 10.1091/mbc.E02-10-0677; Sineshchekov OA, 2002, P NATL ACAD SCI USA, V99, P8689, DOI 10.1073/pnas.122243399; Sizova I, 2001, GENE, V277, P221, DOI 10.1016/S0378-1119(01)00616-3; Slavotinek AM, 2000, NAT GENET, V26, P15, DOI 10.1038/79116; Stanton BA, 1997, WIEN KLIN WOCHENSCHR, V109, P457; Swoboda P, 2000, MOL CELL, V5, P411, DOI 10.1016/S1097-2765(00)80436-0; Tabin CJ, 2003, GENE DEV, V17, P1, DOI 10.1101/gad.1053803; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Taulman PD, 2001, MOL BIOL CELL, V12, P589, DOI 10.1091/mbc.12.3.589; Wang SX, 2004, J AM SOC NEPHROL, V15, P592, DOI 10.1097/01.ASN.0000113793.12558.1D; Ward CJ, 2002, NAT GENET, V30, P259, DOI 10.1038/ng833; WARD S, 1975, J COMP NEUROL, V160, P71; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Wicks SR, 2000, DEV BIOL, V221, P295, DOI 10.1006/dbio.2000.9686; WITMAN GB, 1972, J CELL BIOL, V54, P507, DOI 10.1083/jcb.54.3.507; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; Wu-Scharf D, 2000, SCIENCE, V290, P1159, DOI 10.1126/science.290.5494.1159; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Young TL, 1998, AM J MED GENET, V78, P461, DOI 10.1002/(SICI)1096-8628(19980806)78:5<461::AID-AJMG12>3.0.CO;2-D	72	573	594	1	34	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 14	2004	117	4					541	552		10.1016/S0092-8674(04)00450-7	http://dx.doi.org/10.1016/S0092-8674(04)00450-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137946	Bronze			2022-12-28	WOS:000221458000013
J	Halliday, A; Mansfield, A; Marro, J; Peto, C; Peto, R; Potter, J; Thomas, D				Halliday, A; Mansfield, A; Marro, J; Peto, C; Peto, R; Potter, J; Thomas, D		ACST Collaborative Grp	Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial	LANCET			English	Article							ARTERY STENOSIS; SURGERY-TRIAL; MODERATE; DISEASE; DESIGN; RISK	Background Among patients with substantial carotid artery narrowing but no recent neurological symptom (stroke or transient ischaemia), the balance of surgical risks and long-term benefits from carotid endarterectomy (CEA) was unclear. Methods During 1993-2003, 3120 asymptomatic patients with substantial carotid narrowing were randomised equally between immediate CEA (half got CEA by 1 month, 88% by 1 year) and indefinite deferral of any CEA (only 4% per year got CEA) and were followed for up to 5 years (mean 3.4 years). Kaplan-Meier analyses of 5-year risks are by allocated treatment. Findings The risk of stroke or death within 30 days of CEA was 3.1% (95% CI 2.3-4.1). Comparing all patients allocated immediate CEA versus all allocated deferral, but excluding such perioperative events, the 5-year stroke risks were 3.8% versus 11% (gain 7.2% [95% CI 5.0-9.4], p<0.0001). This gain chiefly involved carotid territory ischaemic strokes (2.7% vs 9.5%; gain 6.8% [4.8-8.8], p<0.0001), of which half were disabling or fatal (1.6% vs 5.3%; gain 3.7% [2.1-5.2], p<0.0001), as were half the perioperative strokes. Combining the perioperative events and the non-perioperative strokes, net 5-year risks were 6.4% versus 11.8% for all strokes (net gain 5.4% [3.0-7.8], p<0.0001), 3.5% versus 6.1% for fatal or disabling strokes (net gain 2.5% [0.8-4.3], p=0.004), and 2.1% versus 4.2% just for fatal strokes (net gain 2.1% [0.6-3.6], p = 0.006). Subgroup-specific analyses found no significant heterogeneity in the perioperative hazards or (apart from the importance of cholesterol) in the long-term postoperative benefits. These benefits were separately significant for males and females; for those with about 70%, 80%, and 90% carotid artery narrowing on ultrasound; and for those younger than 65 and 65-74 years of age (though not for older patients, half of whom die within 5 years from unrelated causes). Full compliance with allocation to immediate CEA or deferral would, in expectation, have produced slightly bigger differences in the numbers operated on, and hence in the net 5-year benefits. The 10-year benefits are not yet known. Interpretation In asymptomatic patients younger than 75 years of age with carotid diameter reduction about 70% or more on ultrasound (many of whom were on aspirin, antihypertensive, and, in recent years, statin therapy), immediate CEA halved the net 5-year stroke risk from about 12% to about 6% (including the 3% perioperative hazard). Half this 5-year benefit involved disabling or fatal strokes. But, outside trials, inappropriate selection of patients or poor surgery could obviate such benefits.	St George Hosp, Sch Med, ACST Off, London SW17 0RE, England	St Georges University London	Halliday, A (corresponding author), St George Hosp, Sch Med, ACST Off, London SW17 0RE, England.	acst@sghms.ac.uk	Chuen, Jason/H-2224-2017; Halliday, Alison/AAA-2230-2022	Chuen, Jason/0000-0002-0955-5446; Halliday, Alison/0000-0001-9828-3579				Alamowitch S, 2001, LANCET, V357, P1154, DOI 10.1016/S0140-6736(00)04332-4; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Barnett HJM, 2002, CAN MED ASSOC J, V166, P1169; Collins R, 2004, LANCET, V363, P757; COLLINS R, 2003, OXFORD TXB MED, P24; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; HALLIDAY AW, 1994, EUR J VASCULAR SURG, V8, P703; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; Nederkoorn PJ, 2003, STROKE, V34, P1324, DOI 10.1161/01.STR.0000068367.08991.A2; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; Yusuf S, 2002, LANCET, V360, P2, DOI 10.1016/S0140-6736(02)09358-3	18	1751	1837	0	34	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2004	363	9420					1491	1502						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135594				2022-12-28	WOS:000221302700006
J	Zampieri, N; Chao, MV				Zampieri, N; Chao, MV			The p75 NGF receptor exposed	SCIENCE			English	Editorial Material							NERVE GROWTH-FACTOR; CRYSTAL-STRUCTURE; COMPLEX; NEUROTROPHINS; TNF		NYU, Sch Med, Mol Neurobiol Program,Skirball Inst Biomol Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Mol Neurobiol Program,Skirball Inst Biomol Med, Dept Physiol, New York, NY 10016 USA; NYU, Sch Med, Mol Neurobiol Program,Skirball Inst Biomol Med, Dept Neurosci, New York, NY 10016 USA	New York University; New York University; New York University	Zampieri, N (corresponding author), NYU, Sch Med, Mol Neurobiol Program,Skirball Inst Biomol Med, Dept Cell Biol, New York, NY 10016 USA.	chao@saturn.med.nyu.edu		Chao, Moses/0000-0002-6969-3744; Zampieri, Niccolo/0000-0002-2228-9453				BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705	12	17	19	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					833	834		10.1126/science.1098110	http://dx.doi.org/10.1126/science.1098110			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131296				2022-12-28	WOS:000221243000030
J	Carroll, S				Carroll, S			Insignificance	NATURE			English	Editorial Material									Univ Chicago, Dept Phys, Chicago, IL 60637 USA	University of Chicago	Carroll, S (corresponding author), Univ Chicago, Dept Phys, 5640 S Ellis Ave, Chicago, IL 60637 USA.		Carroll, Sean/C-5972-2015	Carroll, Sean/0000-0002-4226-5758				KRAUSS L, 2001, QUINTESSENCE MYSTERY; PEEBLES PJE, PRECISION COSMOLOGY; REES M, 2003, OUR COSMIC HABITAT	3	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	2004	429	6987					27	27		10.1038/429027a	http://dx.doi.org/10.1038/429027a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129262				2022-12-28	WOS:000221222100026
J	Muntner, P; He, J; Cutler, JA; Wildman, RP; Whelton, PK				Muntner, P; He, J; Cutler, JA; Wildman, RP; Whelton, PK			Trends in blood pressure among children and adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NUTRITION EXAMINATION SURVEY; CORONARY RISK-FACTORS; NATIONAL-HEALTH; SECULAR TRENDS; UNITED-STATES; US CHILDREN; BODY-SIZE; HYPERTENSION; PREVALENCE; POPULATION	Context The prevalence of overweight among children and adolescents increased between 1988 and 2000. The change in blood pressure among children and adolescents over that time and the role of overweight is unknown. Objective To examine trends in systolic and diastolic blood pressure among children and adolescents between 1988 and 2000. Design, Setting, and Population Two serially conducted cross-sectional studies using nationally representative samples of children and adolescents, aged 8 to 17 years, from the third National Health and Nutrition Examination Survey (NHANES 111) conducted in 1988-1994 (n=3496) and NHANES 1999-2000 (n=2086). Main Outcome Measures Systolic and diastolic blood pressure levels. Results In 1999-2000, the mean (SE) systolic blood pressure was 106.0 (0.3) mm Hg and diastolic blood pressure was 61.7 (0.5) mm Hg. After adjustment for age, mean systolic blood pressure was 1.6 mm Hg higher among non-Hispanic black girls (P=.11) and 2.9 mm Hg higher among non-Hispanic black boys (P<.001) compared with non-Hispanic whites. Among Mexican Americans, girls' systolic blood pressure was 1.0 mm Hg higher (P=.21) and boys' was 2.7 mm Hg higher (P<.001) compared with non-Hispanic whites (P<.001). With further adjustment for body mass index, these differences were attenuated. After age, race/ethnicity, and sex standardization, systolic blood pressure was 1.4 (95% confidence interval [CI], 0.6-2.2) mm Hg higher (P<.001) and diastolic blood pressure was 3.3 (95% Cl, 2.1-4.5) mm Hg higher in 1999-2000 (P<.001) compared with 1988-1994. With further adjustment for differences in the body mass index distribution in 1988-1994 and 1999-2000, the increase in systolic blood pressure was reduced by 29% and diastolic blood pressure was reduced by 12%. Conclusions Blood pressure has increased over the past decade among children and adolescents. This increase is partially attributable to an increased prevalence of overweight.	Tulane Univ, Sch Med, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Sch Publ Hlth & Trop Med, Dept Med, New Orleans, LA 70112 USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA	Tulane University; Tulane University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Muntner, P (corresponding author), Tulane Univ, Sch Med, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1430 Tulane Ave,SL-18, New Orleans, LA 70112 USA.	pmuntner@tulane.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017659] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068057] Funding Source: NIH RePORTER; NCRR NIH HHS [P2 0 RR017659] Funding Source: Medline; NHLBI NIH HHS [R01 HL68057] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAO WH, 1995, AM J HYPERTENS, V8, P657, DOI 10.1016/0895-7061(95)00116-7; Berenson GS, 1996, PUBLIC HEALTH REP, V111, P3; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Daniels SR, 1998, HYPERTENSION, V31, P97, DOI 10.1161/01.HYP.31.1.97; Daniels SR, 1996, J PEDIATR-US, V129, P208, DOI 10.1016/S0022-3476(96)70244-5; Falkner B, 1996, PEDIATRICS, V98, P649; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; GIDDING SS, 1995, J PEDIATR-US, V127, P868, DOI 10.1016/S0022-3476(95)70020-X; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Hunt KJ, 2003, AM J EPIDEMIOL, V158, P1048, DOI 10.1093/aje/kwg249; Luepker RV, 1999, J PEDIATR-US, V134, P668, DOI 10.1016/S0022-3476(99)70279-9; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Mahoney LT, 1996, J AM COLL CARDIOL, V27, P277, DOI 10.1016/0735-1097(95)00461-0; *NAT CTR HLTH STAT, 1994, PUBL US DEP HHS; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Ostchega Y, 2003, J CLIN EPIDEMIOL, V56, P768, DOI 10.1016/S0895-4356(03)00085-4; PERLOFF D, 1993, CIRCULATION, V88, P2460, DOI 10.1161/01.CIR.88.5.2460; Raitakari OT, 2003, JAMA-J AM MED ASSOC, V290, P2277, DOI 10.1001/jama.290.17.2277; Rosner B, 2000, AM J EPIDEMIOL, V151, P1007, DOI 10.1093/oxfordjournals.aje.a010129; ROWLAND M, 1982, BLOOD PRESSURE LEVEL; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Stary HC, 1989, ARTERIOSCLERIOSIS, V9, P119; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Vasan RS, 2001, NEW ENGL J MED, V345, P1291, DOI 10.1056/NEJMoa003417	24	560	576	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2004	291	17					2107	2113		10.1001/jama.291.17.2107	http://dx.doi.org/10.1001/jama.291.17.2107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JR	15126439	Bronze			2022-12-28	WOS:000221174300028
J	Walter, LC; Lindquist, K; Covinsky, KE				Walter, LC; Lindquist, K; Covinsky, KE			Relationship between health status and use of screening mammography and Papanicolaou smears among women older than 70 years of age	ANNALS OF INTERNAL MEDICINE			English	Article						relationship between health status and use of screening; mammography and Papanicolaou smears among women older than; 70 years of age	SERVICES TASK-FORCE; PREVENTIVE SERVICES; BREAST-CANCER; DECISION-MAKING; UNITED-STATES; RISK-FACTORS; MORTALITY; ADULTS; HYSTERECTOMY; COMORBIDITY	Background: Older women whose life expectancy is less than 5 years are unlikely to benefit from screening mammography or Papanicolaou (Pap) smears. Since life expectancy is better predicted by health status than by age alone, guidelines recommend considering an older woman's general health when making screening decisions. Objective: To determine whether screening mammography and Pap smears are targeted to healthy older women and are avoided in women with limited life expectancies. Design: Cross-sectional population-based study. Setting: California. Patients: 4792 women 70 years of age or older who participated in the California Health Interview Survey between November 2000 and October 2001. Measurements: Predictor variables included age and health status. Health status was measured by using the Medical Outcomes Study 12-item Short Form Physical Summary Scale. The main outcome was self-reported receipt of screening mammography within the previous 2 years and a screening Pap smear within 3 years. Results: Seventy-eight percent of women reported recent screening mammography, and 77% reported a recent Pap smear. Screening rates decreased with advancing age. However, within each age group, the percentage of women reporting screening did not significantly decrease with worsening health status (P > 0.1 for all comparisons). More than half of women 80 years of age or older in the worst health quartile reported recent screening, representing approximately 81 000 mammograms and 35 000 Pap smears. Limitations: This study relied on self-report, and the interview response rate was 63.7%. Conclusions: Rates of recent screening mammography and Pap smears are high among older women in California. Although screening rates drop with advancing age, women in poor health do not avoid screening. Screening should be better targeted to healthy older women and should be avoided in women with limited life expectancies for whom risks of screening outweigh potential benefits.	Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Walter, LC (corresponding author), Vet Affairs Med Ctr, Div Geriatr, 4150 Clement St, San Francisco, CA 94121 USA.	louisew@itsa.ucsf.edu		Lindquist, Karla/0000-0002-1971-2273	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K02HS000006] Funding Source: NIH RePORTER; AHRQ HHS [K02HS000006-02] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Ahluwalia Indu B, 2003, MMWR Surveill Summ, V52, P1; Amer Geriatrics Soc, 2001, J AM GERIATR SOC, V49, P655; [Anonymous], 2003, CALIFORNIA HLTH INTE; [Anonymous], 2003, J AM GERIATR SOC, V51, P270; Arias E., 2000, US LIFE TABLES; Bernard SL, 1997, J GERONTOL B-PSYCHOL, V52, pS155, DOI 10.1093/geronb/52B.3.S155; Blustein J, 1998, J AM GERIATR SOC, V46, P941, DOI 10.1111/j.1532-5415.1998.tb02746.x; Breen N, 2001, J NATL CANCER I, V93, P1704, DOI 10.1093/jnci/93.22.1704; Burack RC, 1998, J GEN INTERN MED, V13, P366, DOI 10.1046/j.1525-1497.1998.00116.x; Burdine JN, 2000, HEALTH SERV RES, V35, P885; *CAL HLTH INT SURV, CHIS 2001 METH SER; COHEN HJ, 1992, J GERONTOL, P47; COLEMAN EA, 1992, ANN INTERN MED, V117, P961, DOI 10.7326/0003-4819-117-11-961; DEGNAN D, 1992, AM J PUBLIC HEALTH, V82, P1386, DOI 10.2105/AJPH.82.10.1386; Farquhar CM, 2002, OBSTET GYNECOL, V99, P229, DOI 10.1016/S0029-7844(01)01723-9; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; GURALNIK JM, 1989, NATL CTR HLTH STAT, V170; Heflin MT, 2002, J AM GERIATR SOC, V50, P1651, DOI 10.1046/j.1532-5415.2002.50456.x; Humphrey LL, 2002, ANN INTERN MED, V137, P347, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00012; Kiefe CI, 1998, J GEN INTERN MED, V13, P357, DOI 10.1046/j.1525-1497.1998.00115.x; KING ES, 1990, AM J PUBLIC HEALTH, V80, P1386, DOI 10.2105/AJPH.80.11.1386; Mandelblatt J, 2003, ANN INTERN MED, V139, P835, DOI 10.7326/0003-4819-139-10-200311180-00011; MOR V, 1992, J GERONTOL, V47, P43; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; Nelson DE, 2002, JAMA-J AM MED ASSOC, V287, P2659, DOI 10.1001/jama.287.20.2659; Pearce KF, 1996, NEW ENGL J MED, V335, P1559, DOI 10.1056/NEJM199611213352103; Rich JS, 2000, HOSP PRACT, V35, P45, DOI 10.3810/hp.2000.10.215; Riddle DL, 2001, MED CARE, V39, P867, DOI 10.1097/00005650-200108000-00012; Saraiya M, 2002, J WOMEN HEALTH GEN-B, V11, P103, DOI 10.1089/152460902753645245; Saslow D, 2002, CA-CANCER J CLIN, V52, P342, DOI 10.3322/canjclin.52.6.342; Satariano WA, 2003, CRIT REV ONCOL HEMAT, V48, P239, DOI 10.1016/j.critrevonc.2003.08.002; SATARIANO WA, 1992, J GERONTOL, V47, P24; Sawaya GF, 2001, NEW ENGL J MED, V344, P1603, DOI 10.1056/NEJM200105243442107; Sawaya GF, 2000, ANN INTERN MED, V133, P942, DOI 10.7326/0003-4819-133-12-200012190-00009; Scinto JD, 2001, J AM GERIATR SOC, V49, P1101, DOI 10.1046/j.1532-5415.2001.49216.x; Smith RA, 2003, CA-CANCER J CLIN, V53, P141, DOI 10.3322/canjclin.53.3.141; Towle A, 1999, BRIT MED J, V319, P766, DOI 10.1136/bmj.319.7212.766; U.S. Preventive Services Task Force, 2003, GUID CLIN PREV SERV; *UCLA CTR HLTH POL, 2003, 1 UCLA CTR HLTH POL; Walter LC, 2001, J GEN INTERN MED, V16, P779, DOI 10.1046/j.1525-1497.2001.10113.x; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2750, DOI 10.1001/jama.285.21.2750; Ware J.E., 1995, SF 12 SCORE SF 12 PH; Ware J.E, 1994, PHYS MENTAL HLTH SUM; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Welch HG, 1996, ANN INTERN MED, V124, P577, DOI 10.7326/0003-4819-124-6-199603150-00007; Wright PJ, 2000, J AM GERIATR SOC, V48, P124, DOI 10.1111/j.1532-5415.2000.tb03902.x; Zapka JG, 1996, AM J PUBLIC HEALTH, V86, P1016, DOI 10.2105/AJPH.86.7.1016	47	68	68	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	2004	140	9					681	688		10.7326/0003-4819-140-9-200405040-00007	http://dx.doi.org/10.7326/0003-4819-140-9-200405040-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	816XR	15126251				2022-12-28	WOS:000221143100001
J	Muto, A; Tashiro, S; Nakajima, O; Hoshino, H; Takahashi, S; Sakoda, E; Ikebe, D; Yamamoto, M; Igarashi, K				Muto, A; Tashiro, S; Nakajima, O; Hoshino, H; Takahashi, S; Sakoda, E; Ikebe, D; Yamamoto, M; Igarashi, K			The transcriptional programme of antibody class switching involves the repressor Bach2	NATURE			English	Article							PLASMA-CELL DIFFERENTIATION; GERMINAL-CENTER FORMATION; SMALL MAF PROTEINS; SOMATIC HYPERMUTATION; MATURE B; RECOMBINATION; MECHANISM; BLIMP-1; EXPRESSION; ACTIVATION	Activated B cells differentiate to plasma cells to secrete IgM or, after undergoing class switch recombination (CSR), to secrete other classes of immunoglobulins(1-4). Diversification of antibody function by CSR is important for humoral immunity. However, it remains unclear how the decision for the bifurcation is made. Bach2 is a B-cell-specific transcription repressor interacting with the small Maf proteins whose expression is high only before the plasma cell stage(5-7). Here we show that Bach2 is critical for CSR and somatic hypermutation (SHM)(2,4,8) of immunoglobulin genes. Genetic ablation of Bach2 in mice revealed that Bach2 was required for both T-cell-independent and T-cell-dependent IgG responses and SHM. When stimulated in vitro, Bach2-deficient B cells produced IgM, as did wild-type cells, and abundantly expressed Blimp-1 (refs 9, 10) and XBP-1 (ref. 11), critical regulators of the plasmacytic differentiation(12), indicating that Bach2 was not required for the plasmacytic differentiation itself. However, they failed to undergo efficient CSR. These findings define Bach2 as a key regulator of antibody response and provide an insight into the orchestration of CSR and SHM during plasma cell differentiation.	Hiroshima Univ, Dept Biomed Chem, Grad Sch Biomed Sci, Hiroshima 7348551, Japan; Hiroshima Univ, Leukemia Program Project, Grad Sch Biomed Sci, Hiroshima 7348551, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Environm Response Project, Tsukuba, Ibaraki 3058577, Japan	Hiroshima University; Hiroshima University; University of Tsukuba; University of Tsukuba	Igarashi, K (corresponding author), Hiroshima Univ, Dept Biomed Chem, Grad Sch Biomed Sci, Hiroshima 7348551, Japan.	igarak@hiroshima-u.ac.jp	Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Igarashi, Kazuhiko/0000-0002-2470-2475				ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; Brand M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/nsmb713; Calame KL, 2003, ANNU REV IMMUNOL, V21, P205, DOI 10.1146/annurev.immunol.21.120601.141138; Durandy A, 2001, CURR OPIN IMMUNOL, V13, P543, DOI 10.1016/S0952-7915(00)00256-9; Hasbold J, 1998, EUR J IMMUNOL, V28, P1040, DOI 10.1002/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.3.CO;2-0; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; MONROE JG, 1988, J IMMUNOL, V140, P1454; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Muto A, 2002, J BIOL CHEM, V277, P20724, DOI 10.1074/jbc.M112003200; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6; Sun BW, 2001, CHEM LETT, P2, DOI 10.1246/cl.2001.2; Sun JY, 2001, J BIOCHEM, V130, P385, DOI 10.1093/oxfordjournals.jbchem.a002997; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161	28	216	222	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					566	571		10.1038/nature02596	http://dx.doi.org/10.1038/nature02596			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15152264	Green Submitted			2022-12-28	WOS:000221767700041
J	Altshuler, JS; Altshuler, D				Altshuler, JS; Altshuler, D			Organizational challenges in clinical genomic research	NATURE			English	Editorial Material								Genome sequence data are enabling clinical genomic investigation, in which the characteristics of human patients are explored using comprehensive inventories of biomolecules. Successful investigators must navigate rapid technological change, collect and analyse large volumes of data, and engage systems of clinical care. Such projects will increasingly rely on fully integrated multidisciplinary teams, demanding new organizational models in academic biomedical research.	Altshuler Gray LLC, Brookline, MA 02445 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Broad Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Altshuler, JS (corresponding author), Altshuler Gray LLC, 61 Dean Rd, Brookline, MA 02445 USA.	jill@altshulergray.com; altshuler@molbio.mgh.harvard.edu	Altshuler, David M/A-4476-2009	Altshuler, David M/0000-0002-7250-4107				[Anonymous], 2003, NATURE, V424, P1; GALAMBOS L, 1998, CONFRONTING AIDS SCI; Goldstein JL, 1997, J CLIN INVEST, V99, P2803, DOI 10.1172/JCI119470; Gray ML, 2002, NAT MED, V8, P433, DOI 10.1038/nm0502-433; Kennedy D, 2003, SCIENCE, V301, P733, DOI 10.1126/science.301.5634.733	5	6	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					478	481		10.1038/nature02629	http://dx.doi.org/10.1038/nature02629			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164075				2022-12-28	WOS:000221644600052
J	Finfer, S; Bellomo, R; Boyce, N; French, J; Myburgh, J; Norton, R; Norton, R; French, J; Bellomo, R; Finfer, S; Myburgh, J; Doig, M; Hayek, M; O'Donnell, S; Finfer, S; Bell, A; Bellomo, R; Boyce, N; Blythe, D; Cade, J; Chapman, M; Cole, L; Cooper, J; Davies, A; French, C; French, J; Joyce, C; McArthur, C; MacMahon, S; Myburgh, J; Neal, B; Norton, R; Presneill, J; Saul, P; Seppelt, I; Stephens, D; Turner, A; Williams, A; Woolfe, C; Peto, R; Sandercock, P; Sprung, C; Young, D; Lo, SK; Sivarajasingham, S; Francis, L; Woodward, M; Charlton, J; Cooper, J; Davies, A; Harry, C; Higgins, L; Moulden, K; Vallance, S; Chadderton, J; Newby, L; McArthur, C; Bates, S; Bellomo, R; Goldsmith, D; Voss, A; Boyce, N; Blythe, D; Palermo, A; Francis, L; French, J; Hayek, M; Jayne, K; MacMahon, S; Merai, M; Neal, B; Norton, B; Pandey, S; O'Donnell, S; Schmidt, M; Sivarajasingham, S; Woodward, M; Carroll, R; McFadyen, B; Saul, P; Clarke, J; Powell, J; Williams, A; Tai, J; Cole, L; Hynesova, I; Seppelt, I; Weisbrodt, L; Bradley, L; Joyce, C; Kelly, T; Limpus, A; Moore, R; Chapman, M; Creed, S; Kaplan, S; Rivett, J; Stephens, D; Thomas, J; Bell, A; Marsden, K; Turner, A; Boyce, C; Cade, J; Howe, B; Presneill, J; Robertson, M; Doig, G; Finfer, S; O'Connor, A; Potter, J; Ramakrishnan, N; Powell, C; Rajbhandari, D; Woolfe, C; Girling, K; Hodgetts, M; Jovanovska, A; Myburgh, J; French, C; Little, L				Finfer, S; Bellomo, R; Boyce, N; French, J; Myburgh, J; Norton, R; Norton, R; French, J; Bellomo, R; Finfer, S; Myburgh, J; Doig, M; Hayek, M; O'Donnell, S; Finfer, S; Bell, A; Bellomo, R; Boyce, N; Blythe, D; Cade, J; Chapman, M; Cole, L; Cooper, J; Davies, A; French, C; French, J; Joyce, C; McArthur, C; MacMahon, S; Myburgh, J; Neal, B; Norton, R; Presneill, J; Saul, P; Seppelt, I; Stephens, D; Turner, A; Williams, A; Woolfe, C; Peto, R; Sandercock, P; Sprung, C; Young, D; Lo, SK; Sivarajasingham, S; Francis, L; Woodward, M; Charlton, J; Cooper, J; Davies, A; Harry, C; Higgins, L; Moulden, K; Vallance, S; Chadderton, J; Newby, L; McArthur, C; Bates, S; Bellomo, R; Goldsmith, D; Voss, A; Boyce, N; Blythe, D; Palermo, A; Francis, L; French, J; Hayek, M; Jayne, K; MacMahon, S; Merai, M; Neal, B; Norton, B; Pandey, S; O'Donnell, S; Schmidt, M; Sivarajasingham, S; Woodward, M; Carroll, R; McFadyen, B; Saul, P; Clarke, J; Powell, J; Williams, A; Tai, J; Cole, L; Hynesova, I; Seppelt, I; Weisbrodt, L; Bradley, L; Joyce, C; Kelly, T; Limpus, A; Moore, R; Chapman, M; Creed, S; Kaplan, S; Rivett, J; Stephens, D; Thomas, J; Bell, A; Marsden, K; Turner, A; Boyce, C; Cade, J; Howe, B; Presneill, J; Robertson, M; Doig, G; Finfer, S; O'Connor, A; Potter, J; Ramakrishnan, N; Powell, C; Rajbhandari, D; Woolfe, C; Girling, K; Hodgetts, M; Jovanovska, A; Myburgh, J; French, C; Little, L		SAFE Study Investigators	A comparison of albumin and saline for fluid resuscitation in the intensive care unit	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED-TRIALS; CLINICAL-TRIALS; MULTICENTER; DEFINITIONS	BACKGROUND: It remains uncertain whether the choice of resuscitation fluid for patients in intensive care units (ICUs) affects survival. We conducted a multicenter, randomized, double-blind trial to compare the effect of fluid resuscitation with albumin or saline on mortality in a heterogeneous population of patients in the ICU. METHODS: We randomly assigned patients who had been admitted to the ICU to receive either 4 percent albumin or normal saline for intravascular-fluid resuscitation during the next 28 days. The primary outcome measure was death from any cause during the 28-day period after randomization. RESULTS: Of the 6997 patients who underwent randomization, 3497 were assigned to receive albumin and 3500 to receive saline; the two groups had similar baseline characteristics. There were 726 deaths in the albumin group, as compared with 729 deaths in the saline group (relative risk of death, 0.99; 95 percent confidence interval, 0.91 to 1.09; P=0.87). The proportion of patients with new single-organ and multiple-organ failure was similar in the two groups (P=0.85). There were no significant differences between the groups in the mean (+/-SD) numbers of days spent in the ICU (6.5+/-6.6 in the albumin group and 6.2+/-6.2 in the saline group, P=0.44), days spent in the hospital (15.3+/-9.6 and 15.6+/-9.6, respectively; P=0.30), days of mechanical ventilation (4.5+/-6.1 and 4.3+/-5.7, respectively; P=0.74), or days of renal-replacement therapy (0.5+/-2.3 and 0.4+/-2.0, respectively; P=0.41). CONCLUSIONS: In patients in the ICU, use of either 4 percent albumin or normal saline for fluid resuscitation results in similar outcomes at 28 days.	ANZICS CTG, Melbourne, Vic 3053, Australia		Finfer, S (corresponding author), ANZICS CTG, Level 3,10 Levers St, Melbourne, Vic 3053, Australia.	ctg@anzics.com.au	French, Craig/ABF-5087-2020; Cooper, D. James/G-7961-2013; Woodward, Mark/D-8492-2015; Presneill, Jeffrey J/B-4894-2012; FRENCH, CRAIG/HGA-5299-2022; ODonnell, Jane/GEX-9181-2022; Goldsmith, David J A/H-6965-2018; Carroll, Rosemary/W-5427-2018; Woodward, Mark/L-6817-2017; Joyce, Christopher/B-7437-2013; Norton, Brian/O-9170-2017	French, Craig/0000-0003-1363-9711; Cooper, D. James/0000-0002-5872-9051; Presneill, Jeffrey J/0000-0001-7177-7667; ODonnell, Jane/0000-0002-9554-5497; Goldsmith, David J A/0000-0002-4349-9193; Carroll, Rosemary/0000-0002-2162-2744; Norton, Brian/0000-0001-9123-0845; NOIRI, Eisei/0000-0002-9515-7582; MacMahon, Stephen/0000-0003-2064-7699; Neal, Bruce/0000-0002-0490-7465; Bates, Samantha Jean/0000-0002-8613-1946; Young, John Duncan/0000-0002-6838-4835; Bellomo, Rinaldo/0000-0002-1650-8939; Stephens, Dianne/0000-0002-3785-6828; Myburgh, John/0000-0003-4088-7016; Finfer, Simon/0000-0002-2785-5864				*ANZICS CLIN TRIAL, 2004, SAL VS ALB FLUID EV; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Boldt J, 2003, ANESTH ANALG, V97, P1595, DOI 10.1213/01.ANE.0000089961.15975.78; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BUNN F, 2003, COCHRANE DB SYST REV, V1, P1319; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Cook D, 2001, ANN INTERN MED, V135, P205, DOI 10.7326/0003-4819-135-3-200108070-00013; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; TEASDALE G, 1974, LANCET, V2, P81; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; Woodward M., 2014, EPIDEMIOLOGY STUDY D	17	1613	1742	1	66	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2247	2256						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163774				2022-12-28	WOS:000221641900005
J	Trifunovic, A; Wredenberg, A; Falkenberg, M; Spelbrink, JN; Rovio, AT; Bruder, CE; Bohlooly-Y, M; Gidlof, S; Oldfors, A; Wibom, R; Tornell, J; Jacobs, HT; Larsson, NG				Trifunovic, A; Wredenberg, A; Falkenberg, M; Spelbrink, JN; Rovio, AT; Bruder, CE; Bohlooly-Y, M; Gidlof, S; Oldfors, A; Wibom, R; Tornell, J; Jacobs, HT; Larsson, NG			Premature ageing in mice expressing defective mitochondrial DNA polymerase	NATURE			English	Article							POINT MUTATIONS; AGE; DELETIONS; MUSCLE; MOUSE; CELLS	Point mutations and deletions of mitochondrial DNA (mtDNA) accumulate in a variety of tissues during ageing in humans(1), monkeys(2) and rodents(3). These mutations are unevenly distributed and can accumulate clonally in certain cells, causing a mosaic pattern of respiratory chain deficiency in tissues such as heart(4), skeletal muscle(5) and brain(6). In terms of the ageing process, their possible causative effects have been intensely debated because of their low abundance and purely correlative connection with ageing(7,8). We have now addressed this question experimentally by creating homozygous knock-in mice that express a proof-reading-deficient version of PolgA, the nucleus-encoded catalytic subunit of mtDNA polymerase. Here we show that the knock-in mice develop an mtDNA mutator phenotype with a threefold to fivefold increase in the levels of point mutations, as well as increased amounts of deleted mtDNA. This increase in somatic mtDNA mutations is associated with reduced lifespan and premature onset of ageing-related phenotypes such as weight loss, reduced subcutaneous fat, alopecia ( hair loss), kyphosis (curvature of the spine), osteoporosis, anaemia, reduced fertility and heart enlargement. Our results thus provide a causative link between mtDNA mutations and ageing phenotypes in mammals.	Karolinska Inst, Novum, Karolinska Univ Hosp, Dept Med Nutr, S-14186 Huddinge, Sweden; Karolinska Inst, Novum, Karolinska Univ Hosp, Dept Biosci, S-14186 Huddinge, Sweden; Tampere Univ, Tampere Univ Hosp, FIN-33014 Tampere, Finland; Astra Zeneca R&D, S-43183 Molndal, Sweden; Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden; Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Tampere University; Tampere University Hospital; AstraZeneca; Sahlgrenska University Hospital; Karolinska Institutet; Karolinska University Hospital	Larsson, NG (corresponding author), Karolinska Inst, Novum, Karolinska Univ Hosp, Dept Med Nutr, S-14186 Huddinge, Sweden.	nils-goran.larsson@mednut.ki.se	Jacobs, Howard T/G-2434-2011; Gidlöf, Sebastian/L-5039-2013; Larsson, Nils-Göran/GVS-5578-2022; Spelbrink, Johannes N/L-4661-2015	Larsson, Nils-Göran/0000-0001-5100-996X; Spelbrink, Johannes N/0000-0002-9756-2602; Wredenberg, Anna/0000-0002-2500-6121; Gidlof, Sebastian/0000-0002-1432-8344; Jacobs, Howard/0000-0003-1895-6003; Oldfors, Anders/0000-0002-5758-7397				ARKING R, 1998, BIOL AGING; Balducci L, 2003, J AM GERIATR SOC, V51, pS2; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; Braunwald E., 1997, HEART DIS TXB CARDIO, V5th; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; Cottrell D A, 2000, Curr Opin Clin Nutr Metab Care, V3, P473, DOI 10.1097/00075197-200011000-00009; Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7; Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; Haines DC, 2001, TOXICOL PATHOL, V29, P653, DOI 10.1080/019262301753385988; Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100; KALU DN, 1995, HDB PHYSL 11; Khaidakov M, 2003, MUTAT RES-FUND MOL M, V526, P1, DOI 10.1016/S0027-5107(03)00010-1; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MUELLER-HOECKER J, 1989, American Journal of Pathology, V134, P1167; Pal L, 2003, ENDOCRIN METAB CLIN, V32, P669, DOI 10.1016/S0889-8529(03)00046-X; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Sorensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001; Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200; TANEMURA K, 1993, J VET MED SCI, V55, P703, DOI 10.1292/jvms.55.703; Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690; Wallace D C, 2001, Novartis Found Symp, V235, P247; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; WEISS A, 1991, BONE, V12, P165, DOI 10.1016/8756-3282(91)90039-L; Wibom R, 2002, ANAL BIOCHEM, V311, P139, DOI 10.1016/S0003-2697(02)00424-4; Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499	30	1851	1927	3	145	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					417	423		10.1038/nature02517	http://dx.doi.org/10.1038/nature02517			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164064				2022-12-28	WOS:000221644600040
J	Naylor, CD; Chantler, C; Griffiths, S				Naylor, CD; Chantler, C; Griffiths, S			Learning from SARS in Hong Kong and Toronto	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE RESPIRATORY SYNDROME; INFECTION		Univ Toronto, Fac Med, Toronto, ON M5S 1A8, Canada; Kings Fund, London, England; Univ Oxford, Dept Publ Hlth, Oxford, England	University of Toronto; University of Oxford	Naylor, CD (corresponding author), Univ Toronto, Fac Med, MSB2109,1 Kings Coll Cir, Toronto, ON M5S 1A8, Canada.	david.naylor@utoronto.ca						Detsky AS, 2003, NEW ENGL J MED, V349, P804, DOI 10.1056/NEJMhpr035304; *HL SEL COMM SCI T, 2003, FIGHT INF; LANARD J, SARS COMMUNICATION W; Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a; *NAT ADV COMM SARS, LEARN SARS REN PUBL; *ONT EXP PAN SARS, 2004, PUBL HLTH PLAN ACT; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; *SARS EXP COMM, SARS HONG KONG EXP A; Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6; World Health Organization, SUMM PROB SARS CAS O; Zoutman DE, 2003, AM J INFECT CONTROL, V31, P266, DOI 10.1067/mic.2003.88	11	34	34	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2004	291	20					2483	2487		10.1001/jama.291.20.2483	http://dx.doi.org/10.1001/jama.291.20.2483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823HB	15161900				2022-12-28	WOS:000221599700032
J	Bodamer, OA; Ratschmann, R; Paschke, E; Voigtlander, T; Stockler-Ipsiroglu, S				Bodamer, OA; Ratschmann, R; Paschke, E; Voigtlander, T; Stockler-Ipsiroglu, S			Recurrent acroparaesthesia during febrile infections	LANCET			English	Editorial Material							ANDERSON-FABRY-DISEASE		Univ Childrens Hosp, Dept Gen Pediat, A-1090 Vienna, Austria; Univ Childrens Hosp, Metab Unit, A-1090 Vienna, Austria; Univ Hosp Vienna, Inst Neurol, A-1090 Vienna, Austria	University Hospital Vienna	Bodamer, OA (corresponding author), Univ Childrens Hosp, Dept Gen Pediat, A-1090 Vienna, Austria.	olaf.bodamer@univie.ac.at						DESNICK JR, 2001, METABOLIC MOL BASES, P3733; Garman SC, 2002, STRUCTURE, V10, P425, DOI 10.1016/S0969-2126(02)00726-8; Hopkin RJ, 2003, GENET MED, V5, P144, DOI 10.1097/01.GIM.0000069509.57929.CD; MacDermot J, 2001, EUR J PHARMACOL, V429, P121, DOI 10.1016/S0014-2999(01)01312-7; MacDermot KD, 2001, J MED GENET, V38, P769, DOI 10.1136/jmg.38.11.769	5	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	2004	363	9422					1698	1698		10.1016/S0140-6736(04)16254-5	http://dx.doi.org/10.1016/S0140-6736(04)16254-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158631				2022-12-28	WOS:000221546300010
J	Hlatky, MA				Hlatky, MA			Evidence-based use of cardiac procedure and devices	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Sch Med, Donald W Reynolds Cardiovasc Clin Res Ctr, Stanford, CA 94305 USA	Stanford University	Hlatky, MA (corresponding author), Stanford Univ, Sch Med, Donald W Reynolds Cardiovasc Clin Res Ctr, Stanford, CA 94305 USA.			Hlatky, Mark/0000-0003-4686-9441				BRAUNWALD E, 1977, NEW ENGL J MED, V297, P661, DOI 10.1056/NEJM197709222971209; Ezekowitz JA, 2003, ANN INTERN MED, V138, P445, DOI 10.7326/0003-4819-138-6-200303180-00007; Yusuf, 1994, LANCET, V344, P1446	3	34	34	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2126	2128		10.1056/NEJMp048071	http://dx.doi.org/10.1056/NEJMp048071			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152058				2022-12-28	WOS:000221496700004
J	Thomas, SG; Franklin-Tong, VE				Thomas, SG; Franklin-Tong, VE			Self-incompatibility triggers programmed cell death in Papaver pollen	NATURE			English	Article							CASPASE INHIBITORS; DNA FRAGMENTATION; ARABIDOPSIS; ACTIVATION; PROTEIN; RHOEAS; ACTIN; TUBES	Sexual reproduction in many angiosperm plants involves self-incompatibility ( SI), which is one of the most important mechanisms to prevent inbreeding. SI is genetically controlled by the S-locus, and involves highly specific interactions during pollination between pollen and the pistil on which it lands. This results in the rejection of incompatible ('self') pollen, whereas compatible ('non-self') pollen is allowed to fertilize the plant(1). In Papaver rhoeas, S-proteins encoded by the stigma component of the S-locus interact with incompatible pollen, triggering a Ca2+-dependent signalling network(2-7), resulting in the inhibition of pollen-tube growth. Programmed cell death (PCD) is a mechanism used by many organisms to destroy unwanted cells in a precisely regulated manner(8-10). Here we show that PCD is triggered by SI in an S-specific manner in incompatible pollen. This provides a demonstration of a SI system using PCD, revealing a novel mechanism to prevent self-fertilization. Furthermore, our data reveal that the response is biphasic; rapid inhibition of pollen-tube growth is followed by PCD, which is involved in a later 'decision-making' phase, making inhibition irreversible.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Franklin-Tong, VE (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	v.e.franklin-tong@bham.ac.uk	Franklin-Tong, Vernonica E/D-1287-2012	Franklin-Tong, Noni/0000-0003-1782-8413; Thomas, Steven/0000-0001-8733-7842				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Babiychuk E, 1998, PLANT J, V15, P635, DOI 10.1046/j.1365-313x.1998.00240.x; Balk J, 1999, FEBS LETT, V463, P151, DOI 10.1016/S0014-5793(99)01611-7; Danon A, 2004, J BIOL CHEM, V279, P779, DOI 10.1074/jbc.M304468200; DICKINSON H, 1994, NATURE, V367, P517, DOI 10.1038/367517a0; Franklin-Tong N, 2003, TRENDS PLANT SCI, V8, P598, DOI 10.1016/j.tplants.2003.10.008; Franklin-Tong VE, 2002, PLANT J, V29, P333, DOI 10.1046/j.1365-313X.2002.01219.x; FRANKLINTONG VE, 1993, PLANT J, V4, P163, DOI 10.1046/j.1365-313X.1993.04010163.x; FranklinTong VE, 1996, PLANT CELL, V8, P1305, DOI 10.1105/tpc.8.8.1305; Fukuda H, 2000, PLANT MOL BIOL, V44, P245, DOI 10.1023/A:1026532223173; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Geitmann A, 2000, PLANT CELL, V12, P1239, DOI 10.1105/tpc.12.7.1239; HODGKIN T, 1988, NEW PHYTOL, V110, P557, DOI 10.1111/j.1469-8137.1988.tb00296.x; Jordan ND, 2000, PLANT J, V23, P471, DOI 10.1046/j.1365-313x.2000.00811.x; Kakeda K, 1998, PLANT CELL, V10, P1723, DOI 10.1105/tpc.10.10.1723; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPINIEC L, 1995, FEBS LETT, V364, P103, DOI 10.1016/0014-5793(95)00335-7; Mittler R, 1996, TRENDS MICROBIOL, V4, P10, DOI 10.1016/0966-842X(96)81499-5; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Richael C, 2001, PHYSIOL MOL PLANT P, V59, P213, DOI 10.1006/pmpp.2001.0359; Rudd JJ, 1996, PLANT CELL, V8, P713, DOI 10.1105/tpc.8.4.713; Rudd JJ, 2003, FEBS LETT, V547, P223, DOI 10.1016/S0014-5793(03)00710-5; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scovassi AI, 1999, MOL CELL BIOCHEM, V199, P125; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Snowman BN, 2002, PLANT CELL, V14, P2613, DOI 10.1105/tpc.002998; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woltering EJ, 2002, PLANT PHYSIOL, V130, P1764, DOI 10.1104/pp.006338	30	187	205	0	47	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					305	309		10.1038/nature02540	http://dx.doi.org/10.1038/nature02540			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152254				2022-12-28	WOS:000221505900045
J	Ferner, RE				Ferner, RE			Commentary: Computer aided prescribing leaves holes in the safety net	BRITISH MEDICAL JOURNAL			English	Editorial Material									City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Ferner, RE (corresponding author), City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England.	r.e.ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				Anderson JG, 2002, J AM MED INFORM ASSN, V9, P479, DOI 10.1197/jamia.M1099; *AUSTR DEP HLTH AG, 2002, BETT MED MAN SYST DR; Fernando B, 2004, BMJ-BRIT MED J, V328, P1171, DOI 10.1136/bmj.328.7449.1171; Nightingale PG, 2000, BMJ-BRIT MED J, V320, P750, DOI 10.1136/bmj.320.7237.750; Smith J., 2004, BUILDING SAFER NHS P; Weingart SN, 2003, ARCH INTERN MED, V163, P2625, DOI 10.1001/archinte.163.21.2625	6	18	19	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 15	2004	328	7449					1172	1173		10.1136/bmj.328.7449.1172	http://dx.doi.org/10.1136/bmj.328.7449.1172			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142923	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000221497500024
J	Casolari, JM; Brown, CR; Komili, S; West, J; Hieronymus, H; Silver, PA				Casolari, JM; Brown, CR; Komili, S; West, J; Hieronymus, H; Silver, PA			Genome-wide localization of the nuclear transport machinery couples transcriptional status and nuclear organization	CELL			English	Article							PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; NUCLEOCYTOPLASMIC TRANSPORT; DISTINCT DOMAINS; MESSENGER-RNAS; GENE RCC1; YEAST; PROTEIN; BINDING; TELOMERES	The association of genes with the nuclear pore complex (NPC) and nuclear transport factors has been implicated in transcriptional regulation. We therefore examined the association of components of the nuclear transport machinery including karyopherins, nucleoporins, and the Ran guanine-nucleotide exchange factor (RanGEF) with the Saccharomyces cerevisiae genome. We find that most nucleoporins and karyopherins preferentially associate with a subset of highly transcribed genes and with genes that possess Rap1 binding sites whereas the RanGEF preferentially associates with transcriptionally inactive genes. Consistent with coupling of transcription to the nuclear pore, we show that transcriptional activation of the GAL genes results in their association with nuclear pore proteins, relocation to the nuclear periphery, and loss of RanGEF association. Taken together, these results indicate that the organization of the genome is coupled via transcriptional state to the nuclear transport machinery.	Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Silver, PA (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.	pamela_silver@dfci.harvard.edu	West, Jason/I-4445-2014	West, Jason/0000-0002-7252-8651; Brown, Christopher/0000-0001-6076-4035				AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; AMATI B, 1990, EMBO J, V9, P4007, DOI 10.1002/j.1460-2075.1990.tb07622.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; Andrulis ED, 2002, MOL CELL BIOL, V22, P8292, DOI 10.1128/MCB.22.23.8292-8301.2002; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Azuma Y, 2000, CURR OPIN CELL BIOL, V12, P302, DOI 10.1016/S0955-0674(00)00093-4; Becskei A, 2003, P NATL ACAD SCI USA, V100, P1717, DOI 10.1073/pnas.252766999; Berriz GF, 2003, BIOINFORMATICS, V19, P2502, DOI 10.1093/bioinformatics/btg363; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CLARK KL, 1991, CELL REGUL, V2, P781, DOI 10.1091/mbc.2.10.781; Damelin M, 2002, MOL CELL, V9, P563, DOI 10.1016/S1097-2765(02)00475-6; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; Emtage JLT, 1997, J CELL SCI, V110, P911; Fahrenkrog B, 1998, J CELL BIOL, V143, P577, DOI 10.1083/jcb.143.3.577; Feuerbach F, 2002, NAT CELL BIOL, V4, P214, DOI 10.1038/ncb756; Fontoura BMA, 2000, J BIOL CHEM, V275, P31289, DOI 10.1074/jbc.M004651200; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; FREEMAN KB, 1992, MOL CELL BIOL, V12, P5455, DOI 10.1128/MCB.12.12.5455; Galy V, 2004, CELL, V116, P63, DOI 10.1016/S0092-8674(03)01026-2; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Gotta M, 1999, METHOD ENZYMOL, V304, P663; Gotta M, 1996, EXPERIENTIA, V52, P1136, DOI 10.1007/BF01952113; GRAHAM IR, 1994, NUCLEIC ACIDS RES, V22, P124, DOI 10.1093/nar/22.2.124; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; Green DM, 2003, P NATL ACAD SCI USA, V100, P1010, DOI 10.1073/pnas.0336594100; Hediger F, 2002, CURR BIOL, V12, P2076, DOI 10.1016/S0960-9822(02)01338-6; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hood JK, 2000, J CELL SCI, V113, P1471; Huang L, 2002, MOL CELL PROTEOMICS, V1, P434, DOI 10.1074/mcp.M200027-MCP200; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Idrissi FZ, 1999, BIOCHEM J, V341, P477, DOI 10.1042/0264-6021:3410477; Ishii K, 2002, CELL, V109, P551, DOI 10.1016/S0092-8674(02)00756-0; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kosova B, 2000, J BIOL CHEM, V275, P343, DOI 10.1074/jbc.275.1.343; Krebber H, 1999, GENE DEV, V13, P1994, DOI 10.1101/gad.13.15.1994; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Lascaris RF, 1999, BIOINFORMATICS, V15, P267, DOI 10.1093/bioinformatics/15.4.267; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; SCHNEITER S, 1994, J CELL BIOL, V126, P649; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; STAVENHAGEN JB, 1994, GENE DEV, V8, P1411, DOI 10.1101/gad.8.12.1411; Strambio-de-Castillia C, 1999, J CELL BIOL, V144, P839, DOI 10.1083/jcb.144.5.839; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Teixeira MT, 1999, J BIOL CHEM, V274, P32439, DOI 10.1074/jbc.274.45.32439; Teixeira MT, 1997, EMBO J, V16, P5086, DOI 10.1093/emboj/16.16.5086; THOMPSON JS, 1994, MOL CELL BIOL, V14, P446, DOI 10.1128/MCB.14.1.446; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Yu Q, 2003, NUCLEIC ACIDS RES, V31, P1224, DOI 10.1093/nar/gkg200	64	470	480	0	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	2004	117	4					427	439		10.1016/S0092-8674(04)00448-9	http://dx.doi.org/10.1016/S0092-8674(04)00448-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137937	Bronze			2022-12-28	WOS:000221458000004
J	Kobayashi, T; Horiuchi, T; Tongaonkar, P; Vu, L; Nomura, M				Kobayashi, T; Horiuchi, T; Tongaonkar, P; Vu, L; Nomura, M			SIR2 regulates recombination between different rDNA repeats, but not recombination within individual rRNA genes in yeast	CELL			English	Article							REPLICATION FORK BLOCKING; SISTER-CHROMATID COHESION; TRANSCRIPTION FACTOR UAF; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; POLYMERASE-I; LIFE-SPAN; DEACETYLASE ACTIVITY; SHUTTLE VECTORS; PROTEIN FAMILY	It is known that mutations in gene SIR2 increase and those in FOB1 decrease recombination within rDNA repeats as assayed by marker loss or extrachromosomal rDNA circle formation. SIR2-dependent chromatin structures have been thought to inhibit access and/or function of recombination machinery in rDNA. We measured the frequency of FOB1-dependent arrest of replication forks, consequent DNA double-strand breaks, and formation of DNA molecules with Holliday junction structures, and found no significant difference between sir2Delta and SIR2 strains. Formal genetic experiments measuring mitotic recombination rates within individual rRNA genes also showed no significant difference between these two strains. Instead, we found a significant decrease in the association of cohesin subunit Mcd1p (Scc1p) to rDNA in sir2Delta relative to SIR2 strains. From these and other experiments, we conclude that SIR2 prevents unequal sister-chromatid recombination, probably by forming special cohesin structures, without significant effects on re-combinational events within individual rRNA genes.	Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Adv Studies, Hayama 2400193, Japan; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan; Graduate University for Advanced Studies - Japan; University of California System; University of California Irvine	Kobayashi, T (corresponding author), Natl Inst Basic Biol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.	koba@nibb.ac.jp; mnomura@uci.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035949, R01GM035949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; Buck SW, 2002, CELL, V111, P1003, DOI 10.1016/S0092-8674(02)01193-5; Cioci F, 2003, MOL CELL, V12, P135, DOI 10.1016/S1097-2765(03)00262-4; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Donze D, 1999, GENE DEV, V13, P698, DOI 10.1101/gad.13.6.698; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Gangloff S, 1996, EMBO J, V15, P1715, DOI 10.1002/j.1460-2075.1996.tb00517.x; Gerber JK, 1997, CELL, V90, P559, DOI 10.1016/S0092-8674(00)80515-2; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; HAWLEY RS, 1989, ANNU REV GENET, V23, P87, DOI 10.1146/annurev.genet.23.1.87; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ivanov D, 2002, CURR BIOL, V12, P323, DOI 10.1016/S0960-9822(02)00681-4; Johzuka K, 2002, GENES CELLS, V7, P99, DOI 10.1046/j.1356-9597.2001.00508.x; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaiser C., 1994, METHODS YEAST GENETI; Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097; Kobayashi T, 2003, MOL CELL BIOL, V23, P9178, DOI 10.1128/MCB.23.24.9178-9188.2003; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; Kobayashi T, 1998, GENE DEV, V12, P3821, DOI 10.1101/gad.12.24.3821; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Laloraya S, 2000, J CELL BIOL, V151, P1047, DOI 10.1083/jcb.151.5.1047; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; Meluh PB, 2002, EUR J BIOCHEM, V269, P2300, DOI 10.1046/j.1432-1033.2002.02886.x; Merker RJ, 2002, MOL CELL BIOL, V22, P421, DOI 10.1128/MCB.22.2.421-429.2002; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Mohanty BK, 2004, J BIOL CHEM, V279, P1932, DOI 10.1074/jbc.M309078200; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; Nomura M, 2001, COLD SPRING HARB SYM, V66, P555, DOI 10.1101/sqb.2001.66.555; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Oakes M, 1999, MOL CELL BIOL, V19, P8559; Park PU, 1999, MOL CELL BIOL, V19, P3848; Pasero P, 2002, GENE DEV, V16, P2479, DOI 10.1101/gad.232902; Rothstein R, 2000, GENE DEV, V14, P1; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Vu L, 1999, P NATL ACAD SCI USA, V96, P4390, DOI 10.1073/pnas.96.8.4390; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	54	197	200	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	2004	117	4					441	453		10.1016/S0092-8674(04)00414-3	http://dx.doi.org/10.1016/S0092-8674(04)00414-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137938	Bronze			2022-12-28	WOS:000221458000005
J	Kraytsberg, Y; Schwartz, M; Brown, TA; Ebralidse, K; Kunz, WS; Clayton, DA; Vissing, J; Khrapko, K				Kraytsberg, Y; Schwartz, M; Brown, TA; Ebralidse, K; Kunz, WS; Clayton, DA; Vissing, J; Khrapko, K			Recombination of human mitochondrial DNA	SCIENCE			English	Article							INHERITANCE		Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Natl Univ Hosp Rigshosp, Dept Clin Genet, Copenhagen, Denmark; Natl Univ Hosp Rigshosp, Dept Neurol, Copenhagen, Denmark; Natl Univ Hosp Rigshosp, Copenhagen Muscle Res Ctr, Copenhagen, Denmark; Howard Hughes Med Inst, Chevy Chase, MD USA; Univ Bonn, Med Ctr, Dept Epileptol, D-5300 Bonn, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Howard Hughes Medical Institute; University of Bonn	Khrapko, K (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.	khrapko@hms.harvard.edu	Khrapko, Konstantin/A-3244-2009; Kunz, Wolfram/K-1232-2019	Kunz, Wolfram/0000-0003-1113-3493; Brown, Timothy/0000-0001-8941-7678	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018388, R01AG019787] Funding Source: NIH RePORTER; NIA NIH HHS [AG18388, AG19787] Funding Source: Medline; NIEHS NIH HHS [ES11343] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BROWN TB, UNPUB; Hagelberg E, 2003, TRENDS GENET, V19, P84, DOI 10.1016/S0168-9525(02)00048-3; Jacobs HT, 2000, BIOESSAYS, V22, P564, DOI 10.1002/(SICI)1521-1878(200006)22:6<564::AID-BIES9>3.0.CO;2-4; Rokas A, 2003, TRENDS ECOL EVOL, V18, P411, DOI 10.1016/S0169-5347(03)00125-3; Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350; Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536; Yauk CL, 2003, EMBO J, V22, P1389, DOI 10.1093/emboj/cdg136	7	206	217	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					981	981		10.1126/science.1096342	http://dx.doi.org/10.1126/science.1096342			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143273				2022-12-28	WOS:000221383300038
J	Felis, T; Lohmann, G; Kuhnert, H; Lorenz, SJ; Scholz, D; Patzold, J; Al-Rousan, SA; Al-Moghrabi, SM				Felis, T; Lohmann, G; Kuhnert, H; Lorenz, SJ; Scholz, D; Patzold, J; Al-Rousan, SA; Al-Moghrabi, SM			Increased seasonality in Middle East temperatures during the last interglacial period	NATURE			English	Article							NORTH-ATLANTIC OSCILLATION; CLIMATE; VARIABILITY; TELECONNECTIONS; RECONSTRUCTION; SIMULATION; EVOLUTION; CORALS; TRENDS; ENSO	The last interglacial period ( about 125,000 years ago) is thought to have been at least as warm as the present climate(1). Owing to changes in the Earth's orbit around the Sun, it is thought that insolation in the Northern Hemisphere varied more strongly than today on seasonal timescales(2), which would have led to corresponding changes in the seasonal temperature cycle(3). Here we present seasonally resolved proxy records using corals from the northernmost Red Sea, which record climate during the last interglacial period, the late Holocene epoch and the present. We find an increased seasonality in the temperature recorded in the last interglacial coral. Today, climate in the northern Red Sea is sensitive to the North Atlantic Oscillation(4,5), a climate oscillation that strongly influences winter temperatures and precipitation in the North Atlantic region. From our coral records and simulations with a coupled atmosphere - ocean circulation model, we conclude that a tendency towards the high-index state of the North Atlantic Oscillation during the last interglacial period, which is consistent with European proxy records(6-8), contributed to the larger amplitude of the seasonal cycle in the Middle East.	Univ Bremen, DFG Forschszentrum Ozeanrander, D-28359 Bremen, Germany; Univ Bremen, Fachbereich Geowissensch, D-28359 Bremen, Germany; Max Planck Inst Meteorol, D-20146 Hamburg, Germany; Heidelberger Akad Wissensch, D-69120 Heidelberg, Germany; Univ Jordan, Marine Sci Stn, Aqaba 77110, Jordan; Yarmouk Univ, Aqaba 77110, Jordan	University of Bremen; University of Bremen; Max Planck Society; Ruprecht Karls University Heidelberg; University of Jordan; Yarmouk University	Felis, T (corresponding author), Univ Bremen, DFG Forschszentrum Ozeanrander, D-28359 Bremen, Germany.	tfelis@allgeo.uni-bremen.de	Felis, Thomas/G-6670-2011; Al-Rousan, Saber/K-9031-2015; Lohmann, Gerrit/M-7453-2016; Scholz, Denis/G-1861-2016; Patzold, Jurgen/D-5111-2017	Felis, Thomas/0000-0003-1417-9657; Al-Rousan, Saber/0000-0001-8773-2113; Lohmann, Gerrit/0000-0003-2089-733X; Scholz, Denis/0000-0002-0055-8915; Patzold, Jurgen/0000-0001-8074-4103; Kuhnert, Henning/0000-0001-5242-4495				Aalbersberg G, 1998, J QUATERNARY SCI, V13, P367, DOI 10.1002/(SICI)1099-1417(1998090)13:5<367::AID-JQS400>3.3.CO;2-9; Bar-Matthews M, 2000, CHEM GEOL, V169, P145, DOI 10.1016/S0009-2541(99)00232-6; BARNSTON AG, 1987, MON WEATHER REV, V115, P1083, DOI 10.1175/1520-0493(1987)115<1083:CSAPOL>2.0.CO;2; BERGER AL, 1978, J ATMOS SCI, V35, P2362, DOI 10.1016/0033-5894(78)90064-9; Eshel G, 2000, J CLIMATE, V13, P339, DOI 10.1175/1520-0442(2000)013<0339:TPBLIA>2.0.CO;2; Felis T, 2003, CORAL REEFS, V22, P328, DOI 10.1007/s00338-003-0324-3; Felis T, 2000, PALEOCEANOGRAPHY, V15, P679, DOI 10.1029/1999PA000477; Fyfe JC, 1999, GEOPHYS RES LETT, V26, P1601, DOI 10.1029/1999GL900317; GENIN A, 1995, NATURE, V377, P507, DOI 10.1038/377507a0; Ghil M, 2002, REV GEOPHYS, V40, DOI 10.1029/2000RG000092; Held IM, 2002, J CLIMATE, V15, P2125, DOI 10.1175/1520-0442(2002)015<2125:NWSWTA>2.0.CO;2; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Keigwin LD, 1999, SCIENCE, V286, P520, DOI 10.1126/science.286.5439.520; Klotz S, 2003, GLOBAL PLANET CHANGE, V36, P277, DOI 10.1016/S0921-8181(02)00222-9; Kukla GJ, 2002, QUATERNARY RES, V58, P2, DOI 10.1006/qres.2001.2316; Legutke S., 1999, 21 DTSCH KLIM; LORENZ SJ, UNPUB CLIM DYN; Marshall JF, 2002, GEOCHIM COSMOCHIM AC, V66, P3263, DOI 10.1016/S0016-7037(02)00926-2; Montoya M, 2000, J CLIMATE, V13, P1057, DOI 10.1175/1520-0442(2000)013<1057:CSFKBW>2.0.CO;2; Noren AJ, 2002, NATURE, V419, P821, DOI 10.1038/nature01132; Rimbu N, 2003, J CLIMATE, V16, P1414, DOI 10.1175/1520-0442-16.9.1414; Rimbu N, 2001, GEOPHYS RES LETT, V28, P2959, DOI 10.1029/2001GL013083; Rogers JC, 2002, CLIM DYNAM, V19, P599, DOI 10.1007/s00382-002-0247-7; Scholz D, 2004, EARTH PLANET SC LETT, V218, P163, DOI 10.1016/S0012-821X(03)00647-2; Shindell DT, 1999, NATURE, V399, P452, DOI 10.1038/20905; Stirling CH, 1998, EARTH PLANET SC LETT, V160, P745, DOI 10.1016/S0012-821X(98)00125-3; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Thompson DWJ, 2001, SCIENCE, V293, P85, DOI 10.1126/science.1058958; Walter RC, 2000, NATURE, V405, P65, DOI 10.1038/35011048; Zagwijn WH, 1996, QUATERNARY SCI REV, V15, P451, DOI 10.1016/0277-3791(96)00011-X	30	203	212	2	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988					164	168		10.1038/nature02546	http://dx.doi.org/10.1038/nature02546			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141207	Green Published			2022-12-28	WOS:000221356300036
J	Aronson, NE; Santosham, M; Comstock, GW; Howard, RS; Moulton, LH; Rhoades, ER; Harrison, LH				Aronson, NE; Santosham, M; Comstock, GW; Howard, RS; Moulton, LH; Rhoades, ER; Harrison, LH			Long-term efficacy of BCG vaccine in American Indians and Alaska natives - A 60-year follow-up study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CALMETTE-GUERIN VACCINATION; PUBLISHED LITERATURE; 20-YEAR EVALUATION; MUSCOGEE COUNTY; TUBERCULOSIS; PREVENTION; METAANALYSIS; STRAINS; DECLINE; GEORGIA	Context The duration of protection from tuberculosis of BCG vaccines is not known. Objective To determine the long-term duration of protection of a BCG vaccine that was previously found to be efficacious. Design Retrospective record review using Indian Health Service records, tuberculosis registries, death certificates, and supplemental interviews with trial participants. Setting and Participants Follow-up for the period 1948-1998 among American Indians and Alaska Natives who participated in a placebo-controlled BCG vaccine trial during 1935-1938 and who were still at risk of developing tuberculosis. Data from 1483 participants in the BCG vaccine group and 1309 in the placebo group were analyzed. Main Outcome Measures Efficacy of BCG vaccine, calculated for each 10-year interval using a Cox regression model with time-dependent variables based on tuberculosis events occurring after December 31, 1947 (end of prospective case finding). Results The overall incidence of tuberculosis was 66 and 138 cases per 100000 person-years in the BCG vaccine and placebo groups, respectively, for an estimate of vaccine efficacy of 52 % (95% confidence interval, 27%-69%). Adjustments for age at vaccination, tribe, subsequent BCG vaccination, chronic medical illness, isoniazid use, and bacille Calmette-Guerin strain did not substantially affect vaccine efficacy. There was slight but not statistically significant waning of the efficacy of BCG vaccination over time, greater among men than women. Conclusion In this trial, BCG vaccine efficacy persisted for 50 to 60 years, suggesting that a single dose of an effective BCG vaccine can have a long duration of protection.	Uniformed Serv Univ Hlth Sci, Dept Med, Div Infect Dis, Bethesda, MD 20814 USA; Walter Reed Army Med Ctr, Dept Med, Infect Dis Serv, Washington, DC 20307 USA; Walter Reed Army Med Ctr, Dept Clin Invest, Washington, DC 20307 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Amer Indian & Alaska Native Hlth, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Univ Oklahoma, Coll Publ Hlth, Native Amer Prevent Res Ctr, Oklahoma City, OK USA; Univ Pittsburgh, Infect Dis Epidemiol Res Unit, Pittsburgh, PA USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Oklahoma System; University of Oklahoma Health Sciences Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Aronson, NE (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Med, Div Infect Dis, Room A3058,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	naronson@usuhs.mil		Moulton, Lawrence/0000-0001-7041-7387	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI052788] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21670] Funding Source: Medline; NIAID NIH HHS [K24 AI52788] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARONSON JD, 1958, ARCH INTERN MED, V101, P881, DOI 10.1001/archinte.1958.00260170037006; ARONSON JD, 1948, AM REV TUBERC PULM, V58, P255; ARONSON JD, 1948, AM REV TUBERC PULM, V57, P96; ARONSON JD, 1952, JAMA-J AM MED ASSOC, V149, P334, DOI 10.1001/jama.1952.02930210018006; ARONSON JD, 1946, PUBLIC HEALTH REP, V61, P802, DOI 10.2307/4585699; ARONSON JOSEPH D., 1940, AMER REV TUBERC, V42, P651; Baik SH, 1999, DIABETES RES CLIN PR, V46, P91, DOI 10.1016/S0168-8227(99)00079-0; Baily G V, 1980, Indian J Med Res, V72 Suppl, P1; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Behr MA, 1999, VACCINE, V17, P915, DOI 10.1016/S0264-410X(98)00277-1; Behr MA, 2002, LANCET INFECT DIS, V2, P86, DOI 10.1016/S1473-3099(02)00182-2; Classen JB, 1999, AUTOIMMUNITY, V31, P43, DOI 10.3109/08916939908993858; COLDITZ GA, 1995, PEDIATRICS, V96, P29; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; COMSTOCK GW, 1969, AM REV RESPIR DIS, V100, P839; COMSTOCK GW, 1976, PUBLIC HEALTH REP, V91, P276; COMSTOCK GW, 1974, AM J PUBLIC HEALTH, V64, P283, DOI 10.2105/AJPH.64.3.283; COMSTOCK GW, 1994, CONTROL CLIN TRIALS, V15, P247, DOI 10.1016/0197-2456(94)90042-6; DAHLQUIST G, 1995, DIABETOLOGIA, V38, P873, DOI 10.1007/BF03035306; Datta M, 1999, INDIAN J MED RES, V110, P56; FERGUSON R. G., 1949, TUBERCLE, V30, P5, DOI 10.1016/S0041-3879(49)80055-9; FINE PEM, 2001, TUBERCULOSIS COMPREH, P503; Frimodt-Moller J, 1973, Bull Int Union Tuberc, V48, P40; FRIMODT-MOLLER J., 1964, BULL WORLD HEALTH ORGAN, V30, P545; HART PD, 1977, BRIT MED J, V2, P293, DOI 10.1136/bmj.2.6082.293; LAKEY JRT, 1994, TRANSPLANTATION, V57, P1213, DOI 10.1097/00007890-199404270-00013; *MASS CYT, 2001, STATX 5; *MED RES COUNC, 1972, B WORLD HEALTH ORGAN, V46, P371; Meinert CL, 1986, CLIN TRIALS DESIGN C, P214; MORI MA, 1992, ARCH INTERN MED, V152, P547, DOI 10.1001/archinte.152.3.547; Parent ME, 1997, DIABETES CARE, V20, P767, DOI 10.2337/diacare.20.5.767; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; ROSENTHAL S, 1961, AM REV RESPIR DIS, V84, P690; ROSENTHAL S, 1961, PEDIATRICS, V28, P622; SHEHADEH N, 1994, LANCET, V343, P706, DOI 10.1016/S0140-6736(94)91583-0; Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915; STEIN SC, 1953, AM REV TUBERC PULM, V68, P695; Sterne JAC, 1998, INT J TUBERC LUNG D, V2, P200; SUTHERLAND I, 1979, TUBERCLE, V60, P225, DOI 10.1016/0041-3879(79)90003-5; TOWNSEND J. G., 1942, AMER REV TUBERC, V45, P41	40	230	241	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2004	291	17					2086	2091		10.1001/jama.291.17.2086	http://dx.doi.org/10.1001/jama.291.17.2086			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JR	15126436	Bronze			2022-12-28	WOS:000221174300025
J	Humphray, SJ; Oliver, K; Hunt, AR; Plumb, RW; Loveland, JE; Howe, KL; Andrews, TD; Searle, S; Hunt, SE; Scott, CE; Jones, MC; Ainscough, R; Almeida, JP; Ambrose, KD; Ashwell, RIS; Babbage, AK; Babbage, S; Bagguley, CL; Bailey, J; Banerjee, R; Barker, DJ; Barlow, KF; Bates, K; Beasley, H; Beasley, O; Bird, CP; Bray-Allen, S; Brown, AJ; Brown, JY; Burford, D; Burrill, W; Burton, J; Carder, C; Carter, NP; Chapman, JC; Chen, Y; Clarke, G; Clark, SY; Clee, CM; Clegg, S; Collier, RE; Corby, N; Crosier, M; Cummings, AT; Davies, J; Dhami, P; Dunn, M; Dutta, I; Dyer, LW; Earthrowl, ME; Faulkner, L; Fleming, CJ; Frankish, A; Frankland, JA; French, L; Fricker, DG; Garner, P; Garnett, J; Ghori, J; Gilbert, JGR; Glison, C; Grafham, DV; Gribble, S; Griffiths, C; Jones, SG; Grocock, R; Guy, J; Hall, RE; Hammond, S; Harley, JL; Harrison, ESI; Hart, EA; Heath, PD; Henderson, CD; Hopkins, BL; Howard, PJ; Howden, PJ; Huckle, E; Johnson, C; Johnson, D; Joy, AA; Kay, M; Keenan, S; Kershaw, JK; Kimberley, AM; King, A; Knights, A; Laird, GK; Langford, C; Lawlor, S; Leongamornlert, DA; Leversha, M; Lloyd, C; Lloyd, DM; Lovell, J; Martin, S; Mashreghi-Mohammadi, M; Matthews, L; McLaren, S; McLay, KE; McMurray, A; Milne, S; Nickerson, T; Nisbett, J; Nordsiek, G; Pearce, AV; Peck, AI; Porter, KM; Pandian, R; Pelan, S; Phillimore, B; Povey, S; Ramsey, Y; Rand, V; Scharfe, M; Sehra, HK; Shownkeen, R; Sims, SK; Skuce, CD; Smith, M; Steward, CA; Swarbreck, D; Sycamore, N; Tester, J; Thorpe, A; Tracey, A; Tromans, A; Thomas, DW; Wall, M; Wallis, JM; West, AP; Whitehead, SL; Willey, DL; Williams, SA; Wilming, L; Wray, PW; Young, L; Ashurst, JL; Coulson, A; Blocker, H; Durbin, R; Sulston, JE; Hubbard, T; Jackson, MJ; Bentley, DR; Beck, S; Rogers, J; Dunham, I				Humphray, SJ; Oliver, K; Hunt, AR; Plumb, RW; Loveland, JE; Howe, KL; Andrews, TD; Searle, S; Hunt, SE; Scott, CE; Jones, MC; Ainscough, R; Almeida, JP; Ambrose, KD; Ashwell, RIS; Babbage, AK; Babbage, S; Bagguley, CL; Bailey, J; Banerjee, R; Barker, DJ; Barlow, KF; Bates, K; Beasley, H; Beasley, O; Bird, CP; Bray-Allen, S; Brown, AJ; Brown, JY; Burford, D; Burrill, W; Burton, J; Carder, C; Carter, NP; Chapman, JC; Chen, Y; Clarke, G; Clark, SY; Clee, CM; Clegg, S; Collier, RE; Corby, N; Crosier, M; Cummings, AT; Davies, J; Dhami, P; Dunn, M; Dutta, I; Dyer, LW; Earthrowl, ME; Faulkner, L; Fleming, CJ; Frankish, A; Frankland, JA; French, L; Fricker, DG; Garner, P; Garnett, J; Ghori, J; Gilbert, JGR; Glison, C; Grafham, DV; Gribble, S; Griffiths, C; Jones, SG; Grocock, R; Guy, J; Hall, RE; Hammond, S; Harley, JL; Harrison, ESI; Hart, EA; Heath, PD; Henderson, CD; Hopkins, BL; Howard, PJ; Howden, PJ; Huckle, E; Johnson, C; Johnson, D; Joy, AA; Kay, M; Keenan, S; Kershaw, JK; Kimberley, AM; King, A; Knights, A; Laird, GK; Langford, C; Lawlor, S; Leongamornlert, DA; Leversha, M; Lloyd, C; Lloyd, DM; Lovell, J; Martin, S; Mashreghi-Mohammadi, M; Matthews, L; McLaren, S; McLay, KE; McMurray, A; Milne, S; Nickerson, T; Nisbett, J; Nordsiek, G; Pearce, AV; Peck, AI; Porter, KM; Pandian, R; Pelan, S; Phillimore, B; Povey, S; Ramsey, Y; Rand, V; Scharfe, M; Sehra, HK; Shownkeen, R; Sims, SK; Skuce, CD; Smith, M; Steward, CA; Swarbreck, D; Sycamore, N; Tester, J; Thorpe, A; Tracey, A; Tromans, A; Thomas, DW; Wall, M; Wallis, JM; West, AP; Whitehead, SL; Willey, DL; Williams, SA; Wilming, L; Wray, PW; Young, L; Ashurst, JL; Coulson, A; Blocker, H; Durbin, R; Sulston, JE; Hubbard, T; Jackson, MJ; Bentley, DR; Beck, S; Rogers, J; Dunham, I			DNA sequence and analysis of human chromosome 9	NATURE			English	Article							HUMAN GENOME SEQUENCE; BCR-ABL; SEGMENTAL DUPLICATIONS; GENE; EVOLUTION; REGION; MAP; CONSERVATION; BOUNDARY; RECEPTOR	Chromosome 9 is highly structurally polymorphic. It contains the largest autosomal block of heterochromatin, which is heteromorphic in 6-8% of humans, whereas pericentric inversions occur in more than 1% of the population. The finished euchromatic sequence of chromosome 9 comprises 109,044,351 base pairs and represents >99.6% of the region. Analysis of the sequence reveals many intra- and interchromosomal duplications, including segmental duplications adjacent to both the centromere and the large heterochromatic block. We have annotated 1,149 genes, including genes implicated in male-to-female sex reversal, cancer and neurodegenerative disease, and 426 pseudogenes. The chromosome contains the largest interferon gene cluster in the human genome. There is also a region of exceptionally high gene and G + C content including genes paralogous to those in the major histocompatibility complex. We have also detected recently duplicated genes that exhibit different rates of sequence divergence, presumably reflecting natural selection.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; European Bioinformat Inst, Cambridge CB10 1SD, England; Newcastle Univ, Int Ctr Life, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; German Res Ctr Biotechnol GBF, Dept Genome Anal, D-38124 Braunschweig, Germany; UCL, Dept Biol, HUGO Gene Nomenclature Comm, London NW1 2HE, England	Wellcome Trust Sanger Institute; European Molecular Biology Laboratory (EMBL); Newcastle University - UK; Helmholtz Association; Helmholtz-Center for Infection Research; University of London; University College London	Humphray, SJ (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	sjh@sanger.ac.uk	Andrews, Dan/ABG-4815-2020; Frankish, Adam/G-6545-2011; Hubbard, Tim J.P./AAT-4571-2020; Durbin, Richard/AAE-7178-2019; Johnson, David/A-3907-2011; Hubbard, Tim J/C-2567-2008; Barker, David JP/A-5671-2013; Griffiths-Jones, Sam/H-2998-2014	Hubbard, Tim J.P./0000-0002-1767-9318; Durbin, Richard/0000-0002-9130-1006; Johnson, David/0000-0003-0887-3343; Hubbard, Tim J/0000-0002-1767-9318; Davidson, Claire/0000-0002-4910-8202; Rand, Vikki/0000-0002-2198-8949; Fosker, Christine/0000-0002-3799-9474; Martin, Sancha/0000-0001-6213-5259; Frankish, Adam/0000-0002-4333-628X; Swarbreck, David/0000-0002-5453-1013; Keenan, Stephen/0000-0002-9141-7690; Kay, Mike/0000-0002-3282-0834; Dunham, Ian/0000-0003-2525-5598; Loveland, Jane/0000-0002-7669-2934; Hunt, Adrienne/0000-0002-1227-0310; Griffiths-Jones, Sam/0000-0001-6043-807X; Andrews, Dan/0000-0003-3922-6376; Gilbert, James/0000-0001-8079-3159; Jackson, Michael/0000-0001-7179-1354; Wass, Elizabeth/0000-0002-8605-9921; Howe, Kevin/0000-0002-1751-9226; Steward, Charles/0000-0001-8829-5349; Hunt, Sarah/0000-0002-8350-1235; Wilming, Laurens/0000-0002-4154-7358; Leongamornlert, Daniel/0000-0002-3486-3168				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bathgate RAD, 2003, TRENDS ENDOCRIN MET, V14, P207, DOI 10.1016/S1043-2760(03)00081-X; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Brun ME, 2003, GENE, V312, P41, DOI 10.1016/S0378-1119(03)00530-4; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r25; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; CRAWFORD RJ, 1989, J MOL ENDOCRINOL, V3, P169, DOI 10.1677/jme.0.0030169; Della Torre G, 2001, BRIT J CANCER, V85, P836; Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718; Fan YX, 2002, GENOME RES, V12, P1663, DOI 10.1101/gr.338402; Felsenfeld A, 1999, GENOME RES, V9, P1; Flajnik MF, 2001, IMMUNITY, V15, P351, DOI 10.1016/S1074-7613(01)00198-4; Guy J, 2003, GENOME RES, V13, P159, DOI 10.1101/gr.644503; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348; Hillier LW, 2003, NATURE, V424, P157, DOI 10.1038/nature01782; Horvath JE, 2001, HUM MOL GENET, V10, P2215, DOI 10.1093/hmg/10.20.2215; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; Humphray SJ, 2001, METH MOL B, V175, P69; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MADAN K, 1974, ANN GENET-PARIS, V17, P81; Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055; Nanda I, 2000, CYTOGENET CELL GENET, V89, P67, DOI 10.1159/000015567; NEI M, 1986, MOL BIOL EVOL, V3, P418; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; OHNO S, 1968, HEREDITAS-GENETISK A, V59, P169; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; Park JP, 1998, CYTOGENET CELL GENET, V82, P192, DOI 10.1159/000015097; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; Rampoldi L, 2001, NAT GENET, V28, P119, DOI 10.1038/88821; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Schmid M, 2000, CYTOGENET CELL GENET, V90, P169, DOI 10.1159/000056772; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Shan ZH, 2000, EUR J HUM GENET, V8, P167, DOI 10.1038/sj.ejhg.5200431; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Smith CA, 1999, NATURE, V402, P601, DOI 10.1038/45130; Soderlund C, 2000, GENOME RES, V10, P1772, DOI 10.1101/gr.GR-1375R; Uetani N, 2000, EMBO J, V19, P2775, DOI 10.1093/emboj/19.12.2775; Warder DE, 2003, J BIOMED SCI, V10, P406, DOI 10.1159/000071160; Wong S, 2003, P NATL ACAD SCI USA, V100, P11630, DOI 10.1073/pnas.2035020100; Yang ZH, 2000, GENETICS, V155, P431; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185	50	88	872	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					369	374		10.1038/nature02465	http://dx.doi.org/10.1038/nature02465			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164053	Green Accepted, Bronze			2022-12-28	WOS:000221644600029
J	Brooks, WA; Yunus, M; Santosham, M; Wahed, MA; Nahar, K; Yeasmin, S; Black, RE				Brooks, WA; Yunus, M; Santosham, M; Wahed, MA; Nahar, K; Yeasmin, S; Black, RE			Zinc for severe pneumonia in very young children: double-blind placebo-controlled trial	LANCET			English	Article							ACUTE-PHASE RESPONSE; RANDOMIZED CONTROLLED-TRIALS; HEPATIC PROTEIN-SYNTHESIS; ACUTE DIARRHEA; RECOMBINANT INTERLEUKIN-1; RESPIRATORY-INFECTIONS; BANGLADESHI CHILDREN; DEVELOPING-COUNTRIES; POOLED ANALYSIS; IMMUNE FUNCTION	Background Pneumonia is a leading cause of morbidity and mortality in young children. Early reversal of severity signs-chest indrawing, hypoxia, and tachypnoea-improves outcome. We postulated that zinc, an acute phase reactant, would shorten duration of severe pneumonia and time in hospital. Methods In a double-blind placebo-controlled clinical trial in Matlab Hospital, Bangladesh, 270 children aged 2-23 months were randomised to receive elemental zinc (20 mg per day) or placebo, plus the hospital's standard antimicrobial management, until discharge. The outcomes were time to cessation of severe pneumonia (no chest indrawing, respiratory rate 50 per min or less, oxygen saturation at least 95% on room air) and discharge from hospital. Discharge was allowed when respiratory rate was 40 per minute or less for 24 consecutive hours while patients were maintained only on oral antibiotics. Findings The group receiving zinc had reduced duration of severe pneumonia (relative hazard [RH]=0.70, 95% CI 0.51-0.98), including duration of chest indrawing (0.80, 0.61-1.05), respiratory rate more than 50 per min (0.74, 0.57-0.98), and hypoxia (0.79, 0.61-1.04), and overall hospital duration (0.75, 0.57-0.99). The mean reduction is equivalent to 1 hospital day for both severe pneumonia and time in hospital. All effects were greater when children with wheezing were omitted from the analysis. Interpretation Adjuvant treatment with 20 mg zinc per day accelerates recovery from severe pneumonia in children, and could help reduce antimicrobial resistance by decreasing multiple antibiotic exposures, and lessen complications and deaths where second line drugs are unavailable.	Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Hlth Syst Infect Dis Div, Programme Infect Dis & Vaccine Sci, Dhaka 1000, Bangladesh; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA	International Centre for Diarrhoeal Disease Research (ICDDR); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Brooks, WA (corresponding author), Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Hlth Syst Infect Dis Div, Programme Infect Dis & Vaccine Sci, GPO Box 128, Dhaka 1000, Bangladesh.	abrooks@icddrb.org	Brooks, W. Abdullah/AAD-3876-2021	Brooks, W. Abdullah/0000-0001-9871-5546; Black, Robert/0000-0001-9926-7984; Nahar, Dr.Kamrun/0000-0003-3867-9920				Baqui AH, 2002, BRIT MED J, V325, P1059, DOI 10.1136/bmj.325.7372.1059; Bhandari N, 2002, BRIT MED J, V324, P1358, DOI 10.1136/bmj.324.7350.1358; Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7; Bhutta ZA, 2000, AM J CLIN NUTR, V72, P1516; Braunschweig CL, 1997, J NUTR, V127, P70, DOI 10.1093/jn/127.1.70; Casal J, 2002, J ANTIMICROB CHEMOTH, V50, P83, DOI 10.1093/jac/dkf502; Cho YH, 2002, INT J ANTIMICROB AG, V19, P576, DOI 10.1016/S0924-8579(02)00115-2; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; Duff M, 2002, CELLS TISSUES ORGANS, V172, P21, DOI 10.1159/000064383; Fontaine O, 2001, J HEALTH POPUL NUTR, V19, P339; FOSMIRE GJ, 1990, AM J CLIN NUTR, V51, P225, DOI 10.1093/ajcn/51.2.225; Gaetke LM, 1997, AM J PHYSIOL-ENDOC M, V272, pE952, DOI 10.1152/ajpendo.1997.272.6.E952; GOLDBLUM SE, 1987, AM J PHYSIOL, V252, P27; Groeneveld ABJ, 2001, CLIN DIAGN LAB IMMUN, V8, P1189, DOI 10.1128/CDLI.8.6.1189-1195.2001; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; Iwata M, 1999, HISTOCHEM CELL BIOL, V112, P283, DOI 10.1007/s004180050449; JIANG SL, 1992, FOLIA HISTOCHEM CYTO, V30, P133; Ling PR, 1996, AM J PHYSIOL-ENDOC M, V270, pE305, DOI 10.1152/ajpendo.1996.270.2.E305; Luk HH, 2002, EUR J PHARMACOL, V443, P197, DOI 10.1016/S0014-2999(02)01592-3; Ninh NX, 1996, AM J CLIN NUTR, V63, P514, DOI 10.1093/ajcn/63.4.514; Noursadeghi M, 2002, J IMMUNOL, V169, P913, DOI 10.4049/jimmunol.169.2.913; Osendarp SJM, 2002, AM J CLIN NUTR, V76, P1401, DOI 10.1093/ajcn/76.6.1401; Osendarp SJM, 2001, LANCET, V357, P1080, DOI 10.1016/S0140-6736(00)04260-4; Peters M, 1996, HEPATOLOGY, V23, P909, DOI 10.1053/jhep.1996.v23.ajhep0230909; Rahman MM, 2002, AM J CLIN NUTR, V75, P92, DOI 10.1093/ajcn/75.1.92; RAMADORI G, 1985, J EXP MED, V162, P930, DOI 10.1084/jem.162.3.930; Ramadori G, 1999, SEMIN LIVER DIS, V19, P141, DOI 10.1055/s-2007-1007106; RAMADORI G, 1988, EUR J IMMUNOL, V18, P1259, DOI 10.1002/eji.1830180817; Roberts RM, 1995, CRIT REV EUKAR GENE, V5, P385, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.80; Roy SK, 1997, ARCH DIS CHILD, V77, P196, DOI 10.1136/adc.77.3.196; Sazawal S, 1997, Indian Pediatr, V34, P589; Sazawal S, 1998, PEDIATRICS, V102, P1, DOI 10.1542/peds.102.1.1; SAZAWAL S, 1995, NEW ENGL J MED, V333, P839, DOI 10.1056/NEJM199509283331304; Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S; SIMMER K, 1988, AM J CLIN NUTR, V47, P1036, DOI 10.1093/ajcn/47.6.1036; STRATOWA C, 1995, IMMUNOBIOLOGY, V193, P293, DOI 10.1016/S0171-2985(11)80558-9; Szalai AJ, 2000, J IMMUNOL, V165, P1030, DOI 10.4049/jimmunol.165.2.1030; Thurnham DI, 1997, J CLIN PATHOL, V50, P887, DOI 10.1136/jcp.50.11.887; Truong-Tran AQ, 2002, AM J RESP CELL MOL, V27, P286, DOI 10.1165/rcmb.2001-0014OC; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0	40	154	158	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	2004	363	9422					1683	1688		10.1016/S0140-6736(04)16252-1	http://dx.doi.org/10.1016/S0140-6736(04)16252-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158629				2022-12-28	WOS:000221546300008
J	Lawlor, DA; Smith, GD; Bruckdorfer, KR; Kundu, D; Ebrahim, S				Lawlor, DA; Smith, GD; Bruckdorfer, KR; Kundu, D; Ebrahim, S			Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?	LANCET			English	Editorial Material							BETA-CAROTENE; CARDIOVASCULAR-DISEASE; PROSPECTIVE POPULATION; HEART-DISEASE; E CONSUMPTION; LUNG-CANCER; RISK; MEN; SUPPLEMENTATION; EPIDEMIOLOGY		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ London, Royal Free Hosp, Sch Med, Dept Biochem & Mol Biochem, London WC1E 7HU, England	University of Bristol; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Lawlor, DA (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall,Whiteladies Rd, Bristol BS8 2PR, Avon, England.	d.a.lawlor@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Venkatasubramanian, Siddharth/0000-0002-5860-0768; Lawlor, Debbie A/0000-0002-6793-2262; s, hema/0000-0002-3440-9475				Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Greenland S, 1996, INT J EPIDEMIOL, V25, P1107, DOI 10.1093/ije/25.6.1107-a; Gunnell D, 2002, INT J EPIDEMIOL, V31, P390, DOI 10.1093/ije/31.2.390; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Holick CN, 2002, AM J EPIDEMIOL, V156, P536, DOI 10.1093/aje/kwf072; Khaw KT, 2001, LANCET, V357, P657, DOI 10.1016/S0140-6736(00)04128-3; Lawlor DA, 2002, DIABETOLOGIA, V45, P1097, DOI 10.1007/s00125-002-0887-5; Nyyssonen K, 1997, BRIT MED J, V314, P634, DOI 10.1136/bmj.314.7081.634; PETITTI DB, 1986, NEW ENGL J MED, V315, P131; PHILLIPS AN, 1993, J CLIN EPIDEMIOL, V46, P1203, DOI 10.1016/0895-4356(93)90120-P; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P25; Smith GD, 2002, AM J PUBLIC HEALTH, V92, P1295, DOI 10.2105/AJPH.92.8.1295; Smith GD, 2001, J CLIN EPIDEMIOL, V54, P325, DOI 10.1016/S0895-4356(00)00334-6; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Weiss NS, 2002, EPIDEMIOLOGY, V13, P6, DOI 10.1097/00001648-200201000-00003	21	308	313	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	2004	363	9422					1724	1727		10.1016/S0140-6736(04)16260-0	http://dx.doi.org/10.1016/S0140-6736(04)16260-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158637				2022-12-28	WOS:000221546300023
J	Cascales, E; Christie, PJ				Cascales, E; Christie, PJ			Definition of a bacterial type IV secretion pathway for a DNA substrate	SCIENCE			English	Article							AGROBACTERIUM-TUMEFACIENS VIRB7; COMPLEX TRANSPORT APPARATUS; PLANT-CELLS; PROTEIN; CONJUGATION; SYSTEM; ATPASE; TRWB	Bacteria use conjugation systems, a subfamily of the type IV secretion systems, to transfer DNA to recipient cells. Despite 50 years of research, the architecture and mechanism of action of the channel mediating DNA transfer across the bacterial cell envelope remains obscure. By use of a sensitive, quanti. able assay termed transfer DNA immunoprecipitation (TrIP), we identify contacts between a DNA substrate (T-DNA) and 6 of 12 components of the VirB/D4 conjugation system of the phytopathogen Agrobacterium tumefaciens. Our results de. ne the translocation pathway for a DNA substrate through a bacterial conjugation machine, specifying the contributions of each subunit of the secretory apparatus to substrate passage.	Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System	Christie, PJ (corresponding author), Univ Texas, Sch Med, Dept Microbiol & Mol Genet, 6431 Fannin,JFB1-765, Houston, TX 77030 USA.	peter.j.christie@uth.tmc.edu	CASCALES, ERIC/G-7420-2011	CASCALES, ERIC/0000-0003-0611-9179	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048746, R01GM048746] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM048746, GM48746] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson LB, 1996, P NATL ACAD SCI USA, V93, P8889, DOI 10.1073/pnas.93.17.8889; Atmakuri K, 2003, MOL MICROBIOL, V49, P1699, DOI 10.1046/j.1365-2958.2003.03669.x; Beaupre CE, 1997, J BACTERIOL, V179, P78, DOI 10.1128/jb.179.1.78-89.1997; BERGER BR, 1994, J BACTERIOL, V176, P3646, DOI 10.1128/JB.176.12.3646-3660.1994; Cascales E, 2003, NAT REV MICROBIOL, V1, P137, DOI 10.1038/nrmicro753; Dang TA, 1999, MOL MICROBIOL, V32, P1239, DOI 10.1046/j.1365-2958.1999.01436.x; Ding ZY, 2003, TRENDS MICROBIOL, V11, P527, DOI 10.1016/j.tim.2003.09.004; Fernandez D, 1996, J BACTERIOL, V178, P3168, DOI 10.1128/jb.178.11.3168-3176.1996; Gelvin SB, 2003, MICROBIOL MOL BIOL R, V67, P16, DOI 10.1128/MMBR.67.1.16-37.2003; Gilmour MW, 2003, MOL MICROBIOL, V49, P105, DOI 10.1046/j.1365-2958.2003.03551.x; Gomis-Ruth FX, 2001, NATURE, V409, P637, DOI 10.1038/35054586; Hacker J, 2003, SCIENCE, V301, P790, DOI 10.1126/science.1086802; Hormaeche I, 2002, J BIOL CHEM, V277, P46456, DOI 10.1074/jbc.M207250200; Jakubowski SJ, 2003, J BACTERIOL, V185, P2867, DOI 10.1128/JB.185.9.2867-2878.2003; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lawley TD, 2003, FEMS MICROBIOL LETT, V224, P1, DOI 10.1016/S0378-1097(03)00430-0; LESSL M, 1994, CELL, V77, P321, DOI 10.1016/0092-8674(94)90146-5; Llosa M, 2002, MOL MICROBIOL, V45, P1, DOI 10.1046/j.1365-2958.2002.03014.x; Llosa M, 2003, P NATL ACAD SCI USA, V100, P10465, DOI 10.1073/pnas.1830264100; Pantoja M, 2002, MOL MICROBIOL, V45, P1325, DOI 10.1046/j.1365-2958.2002.03098.x; Savvides SN, 2003, EMBO J, V22, P1969, DOI 10.1093/emboj/cdg223; Spudich GM, 1996, P NATL ACAD SCI USA, V93, P7512, DOI 10.1073/pnas.93.15.7512; Vergunst AC, 2000, SCIENCE, V290, P979, DOI 10.1126/science.290.5493.979; Ward DV, 2002, P NATL ACAD SCI USA, V99, P11493, DOI 10.1073/pnas.172390299; Yeo HJ, 2000, MOL CELL, V6, P1461, DOI 10.1016/S1097-2765(00)00142-8	25	268	280	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1170	1173		10.1126/science.1095211	http://dx.doi.org/10.1126/science.1095211			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155952	Green Accepted			2022-12-28	WOS:000221524500047
J	Cordaux, R; Deepa, E; Vishwanathan, H; Stoneking, M				Cordaux, R; Deepa, E; Vishwanathan, H; Stoneking, M			Genetic evidence for the demic diffusion of agriculture to India	SCIENCE			English	Article									Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany; Louisiana State Univ, Baton Rouge, LA 70803 USA; Bharathiar Univ, Dept Environm Sci, Coimbatore 641046, Tamil Nadu, India	Max Planck Society; Louisiana State University System; Louisiana State University; Bharathiar University	Cordaux, R (corresponding author), Max Planck Inst Evolutionary Anthropol, Deutsch Pl 6, D-04103 Leipzig, Germany.	cordaux@lsu.edu	Hucthagowder, Vishwanathan/C-9831-2009					AMMERMAN AJ, 1984, NEOLITHIC TRANSITION; Misra VN, 2001, J BIOSCIENCES, V26, P491, DOI 10.1007/BF02704749; SINGH KS, 1998, PEOPLE INDIA INDIA C; Whittle A., 1996, EUROPE NEOLITHIC	4	29	32	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	2004	304	5674					1125	1125		10.1126/science.1095819	http://dx.doi.org/10.1126/science.1095819			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155941				2022-12-28	WOS:000221524500032
J	Munoz, J; Felicisimo, AM; Cabezas, F; Burgaz, AR; Martinez, I				Munoz, J; Felicisimo, AM; Cabezas, F; Burgaz, AR; Martinez, I			Wind as a long-distance dispersal vehicle in the Southern Hemisphere	SCIENCE			English	Article							NEW-ZEALAND; BIOGEOGRAPHY; ENVIRONMENT	Anisotropic (direction-dependent) long-distance dispersal (LDD) by wind has been invoked to explain the strong floristic affinities shared among landmasses in the Southern Hemisphere. Its contribution has not yet been systematically tested because of the previous lack of global data on winds. We used global winds coverage from the National Aeronautics and Space Administration SeaWinds scatterometer to test whether floristic similarities of Southern Hemisphere moss, liverwort, lichen, and pteridophyte floras conform better with (i) the anisotropic LDD hypothesis, which predicts that connection by "wind highways" increases floristic similarities, or (ii) a direction-independent LDD hypothesis, which predicts that floristic similarities among sites increase with geographic proximity. We found a stronger correlation of floristic similarities with wind connectivity than with geographic proximities, which supports the idea that wind is a dispersal vehicle for many organisms in the Southern Hemisphere.	Real Jardin Bot, Madrid 28014, Spain; Univ Extremadura, Escuela Politecn, Caceres 10071, Spain; Univ Complutense, Dept Biol Vegetal 1, E-28040 Madrid, Spain; Univ Rey Juan Carlos, Mostoles 28933, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Real Jardin Botanico de Madrid; Universidad de Extremadura; Complutense University of Madrid; Universidad Rey Juan Carlos	Munoz, J (corresponding author), Real Jardin Bot, Plaza Murillo 2, Madrid 28014, Spain.	jmunoz@ma-rjb.csic.es	Felicisimo, Angel/B-4138-2008; Cabezas, Francisco José/A-8859-2016; Munoz, Jesus/B-7809-2008; Cabezas, Francisco J./ABG-2629-2020; Martinez, Isabel/K-8800-2014; Cabezas, Francisco J./ABG-3403-2020	Felicisimo, Angel/0000-0002-9953-8614; Cabezas, Francisco J./0000-0003-0614-0445; Martinez, Isabel/0000-0002-5924-1648; Cabezas, Francisco J./0000-0003-0614-0445; Munoz, Jesus/0000-0002-9266-2268				Brodo I. M., 2001, LICHENS N AM; CLOSE RC, 1978, INT J BIOMETEOROL, V22, P1, DOI 10.1007/BF01553136; FREEMAN JA, 1945, J ANIM ECOL, V14, P128, DOI 10.2307/1389; Greenslade P, 1999, J BIOGEOGR, V26, P1161, DOI 10.1046/j.1365-2699.1999.00356.x; Hooker JD., 1845, BOT ANTARCTIC VOYAGE, V1; Hubbell Stephen P., 2001, V32, pi; Humphries C.J., 1999, CLADISTIC BIOGEOGRAP; JACKSON DA, 1995, ECOSCIENCE, V2, P297, DOI 10.1080/11956860.1995.11682297; Jet Propulsion Laboratory, 2001, SEAWINDS QUIKSCAT LE; Legendre P., 2012, NUMERICAL ECOLOGY; Marshall WA, 1996, NATURE, V383, P680, DOI 10.1038/383680a0; MILLER N. G., 1985, MONOGRAPHS SYSTEMATI, V11, P71; MILLER NG, 1976, BRYOLOGIST, V79, P55, DOI 10.2307/3241866; MORRONE JJ, 1995, ANNU REV ECOL SYST, V26, P373, DOI 10.1146/annurev.es.26.110195.002105; Oliver WRB, 1925, J LINN SOC LOND BOT, V47, P99, DOI DOI 10.1111/J.1095-8339.1925.TB01794.X; RAVEN P H, 1973, New Zealand Journal of Botany, V11, P177; Sassen K, 2003, J ATMOS SCI, V60, P873, DOI 10.1175/1520-0469(2003)060<0873:MCCDFH>2.0.CO;2; Shigesada N, 2002, DISPERSAL ECOLOGY, P350; TRYON R, 1986, BOT REV, V52, P117, DOI 10.1007/BF02860999; Tuomisto H, 2003, SCIENCE, V299, P241, DOI 10.1126/science.1078037; van Zanten B. O., 1976, J HATTORI BOT LAB, V41, P133; van Zanten BO, 1981, ADV BRYOLOGY, V1, P479; van Zanten BO., 1978, J HATTORI BOT LAB, V44, P455, DOI DOI 10.1639/0007-2745(1997)100[380:OMDBIG]2.0.CO;2; Winkworth RC, 2002, TRENDS ECOL EVOL, V17, P514, DOI 10.1016/S0169-5347(02)02590-9	24	407	424	0	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1144	1147		10.1126/science.1095210	http://dx.doi.org/10.1126/science.1095210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155945				2022-12-28	WOS:000221524500039
J	Zaric, S; Ostojic, GN; Kono, J; Shaver, J; Moore, VC; Strano, MS; Hauge, RH; Smalley, RE; Wei, X				Zaric, S; Ostojic, GN; Kono, J; Shaver, J; Moore, VC; Strano, MS; Hauge, RH; Smalley, RE; Wei, X			Optical signatures of the Aharonov-Bohm phase in single-walled carbon nanotubes	SCIENCE			English	Article							DISORDERED CONDUCTORS; MAGNETIC-PROPERTIES; OSCILLATIONS; TUBULES	We report interband magneto-optical spectra for single-walled carbon nanotubes in high magnetic fields up to 45 tesla, confirming theoretical predictions that the band structure of a single-walled carbon nanotube is dependent on the magnetic flux phi threading the tube. We have observed field-induced optical anisotropy as well as red shifts and splittings of absorption and photoluminescence peaks. The amounts of shifts and splittings depend on the value of phi/phi(0) and are quantitatively consistent with theories based on the Aharonov-Bohm effect. These results represent evidence of the influence of the Aharonov-Bohm phase on the band gap of a solid.	Rice Univ, Dept Elect & Comp Engn, Houston, TX 77005 USA; Rice Univ, Dept Phys & Astron, Houston, TX 77005 USA; Rice Univ, Dept Chem, Houston, TX 77005 USA; Rice Univ, Rice Quantum Inst, Houston, TX 77005 USA; Rice Univ, Ctr Nanoscale Sci & Technol, Houston, TX 77005 USA; Rice Univ, Ctr Biol & Environm Nanotechnol, Houston, TX 77005 USA; Florida State Univ, Znatl High Magnet Field Lab, Tallahassee, FL 32310 USA	Rice University; Rice University; Rice University; Rice University; Rice University; Rice University; State University System of Florida; Florida State University	Kono, J (corresponding author), Rice Univ, Dept Elect & Comp Engn, Houston, TX 77005 USA.	kono@rice.edu	Hauge, Robert H/A-7008-2011	Hauge, Robert H/0000-0002-3656-0152; Shaver, Jonah/0000-0002-9602-7798				AHARONOV Y, 1959, PHYS REV, V115, P485, DOI 10.1103/PhysRev.115.485; AJIKI H, 1993, J PHYS SOC JPN, V62, P1255, DOI 10.1143/JPSJ.62.1255; AJIKI H, 1993, J PHYS SOC JPN, V62, P2470, DOI 10.1143/JPSJ.62.2470; AJIKI H, 1994, PHYSICA B, V201, P349, DOI 10.1016/0921-4526(94)91112-6; ALTSHULER BL, 1981, JETP LETT+, V33, P94; ARONOV AG, 1987, REV MOD PHYS, V59, P755, DOI 10.1103/RevModPhys.59.755; Bachilo SM, 2002, SCIENCE, V298, P2361, DOI 10.1126/science.1078727; Bachtold A, 1999, NATURE, V397, P673, DOI 10.1038/17755; LINCHUNG PJ, 1994, PHYS REV B, V49, P8454, DOI 10.1103/PhysRevB.49.8454; Lorke A, 2000, PHYS REV LETT, V84, P2223, DOI 10.1103/PhysRevLett.84.2223; LU JP, 1995, PHYS REV LETT, V74, P1123, DOI 10.1103/PhysRevLett.74.1123; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Ostojic GN, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.117402; Roche S, 2000, PHYS REV B, V62, P16092, DOI 10.1103/PhysRevB.62.16092; Shyu FL, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.045405; TIAN WD, 1994, PHYS REV B, V49, P5097, DOI 10.1103/PhysRevB.49.5097; Walters DA, 2001, CHEM PHYS LETT, V338, P14, DOI 10.1016/S0009-2614(01)00072-0	17	266	269	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1129	1131		10.1126/science.1096524	http://dx.doi.org/10.1126/science.1096524			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155942				2022-12-28	WOS:000221524500034
J	Amato, AA; Oaklander, AL; Harris, NL; Hayward, LJ				Amato, AA; Oaklander, AL; Harris, NL; Hayward, LJ			A 76-year-old woman with numbness and pain in the feet and legs - Small-fiber neuropathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IMPAIRED GLUCOSE-TOLERANCE; PERIPHERAL DIABETIC-NEUROPATHY; RANDOMIZED CONTROLLED-TRIAL; EPIDERMAL NERVE-FIBERS; DOUBLE-BLIND; IDIOPATHIC POLYNEUROPATHY; SYMPTOMATIC TREATMENT; SENSORY NEUROPATHY; AMITRIPTYLINE; DEGENERATION		Brigham & Womens Hosp, Dept Neurol, Div Neuromuscular Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Anesthesia, Nerve Injury Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Crit Care, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neuropathol, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Amato, AA (corresponding author), Brigham & Womens Hosp, Dept Neurol, Div Neuromuscular Med, 75 Francis St, Boston, MA 02115 USA.							Amato AA, 2001, NEW ENGL J MED, V345, P1758, DOI 10.1056/NEJMcpc402001; Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001/jama.280.21.1831; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; BARBANO RL, 2003, 6 ANN INT C MECH TRE, P2; Dahlin LB, 1997, DIABETIC MED, V14, P353, DOI 10.1002/(SICI)1096-9136(199705)14:5<353::AID-DIA343>3.0.CO;2-E; DALSGAARD CJ, 1989, HISTOCHEMISTRY, V92, P385, DOI 10.1007/BF00492495; Davis JL, 1999, DIABETES CARE, V22, P1909, DOI 10.2337/diacare.22.11.1909; Dyck PJ, 1999, MUSCLE NERVE, V22, P659, DOI 10.1002/(SICI)1097-4598(199906)22:6<659::AID-MUS1>3.0.CO;2-X; Freeman R, 2003, NEUROLOGY, V60, P465, DOI 10.1212/WNL.60.3.465; GORSON KC, 1995, ACTA NEUROL SCAND, V92, P376; Grant IA, 1997, NEUROLOGY, V48, P855, DOI 10.1212/WNL.48.4.855; Harati Y, 1998, NEUROLOGY, V50, P1842, DOI 10.1212/WNL.50.6.1842; Herrmann DN, 1999, NEUROLOGY, V53, P1634, DOI 10.1212/WNL.53.8.1634; HILLIGES M, 1995, J INVEST DERMATOL, V104, P134, DOI 10.1111/1523-1747.ep12613631; Holland NR, 1998, ANN NEUROL, V44, P47, DOI 10.1002/ana.410440111; KELLY JJ, 1979, ANN NEUROL, V6, P1, DOI 10.1002/ana.410060102; Kennedy WR, 1996, NEUROLOGY, V47, P1042, DOI 10.1212/WNL.47.4.1042; Lacomis D, 1997, ARTHRITIS RHEUM, V40, P1173, DOI 10.1002/art.1780400624; Lauria G, 2003, NEUROLOGY, V61, P631, DOI 10.1212/01.WNL.0000070781.92512.A4; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; Mendell JR, 2003, NEW ENGL J MED, V348, P1243, DOI 10.1056/NEJMcp022282; NASCIMENTO O, 2003, 22 APS ANN SCI M CHI; NOTERMANS NC, 1993, J NEUROL NEUROSUR PS, V56, P1066, DOI 10.1136/jnnp.56.10.1066; Novak V, 2001, NEUROLOGY, V56, P861, DOI 10.1212/WNL.56.7.861; Novella SP, 2001, MUSCLE NERVE, V24, P1229, DOI 10.1002/mus.1137; RULL JA, 1969, DIABETOLOGIA, V5, P215, DOI 10.1007/BF01212087; Russell JW, 2001, MUSCLE NERVE, V24, P1109, DOI 10.1002/mus.1122; Semenchuk MR, 2001, NEUROLOGY, V57, P1583, DOI 10.1212/WNL.57.9.1583; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shlay JC, 1998, JAMA-J AM MED ASSOC, V280, P1590, DOI 10.1001/jama.280.18.1590; Simone DA, 1998, J NEUROSCI, V18, P8947; Simpson DM, 2000, NEUROLOGY, V54, P2115, DOI 10.1212/WNL.54.11.2115; Sindrup SH, 1999, PAIN, V83, P389, DOI 10.1016/S0304-3959(99)00154-2; Singleton JR, 2001, MUSCLE NERVE, V24, P1225, DOI 10.1002/mus.1136; STEWART JD, 1992, MUSCLE NERVE, V15, P661, DOI 10.1002/mus.880150605; Sumner CJ, 2003, NEUROLOGY, V60, P108, DOI 10.1212/WNL.60.1.108; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Tobin K, 1999, CLIN NEUROPHYSIOL, V110, P1909, DOI 10.1016/S1388-2457(99)00164-9; Wolfe GI, 1997, MUSCLE NERVE, V20, P1275, DOI 10.1002/(SICI)1097-4598(199710)20:10<1275::AID-MUS10>3.0.CO;2-2	39	20	20	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2181	2189		10.1056/NEJMcpc049005	http://dx.doi.org/10.1056/NEJMcpc049005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152064				2022-12-28	WOS:000221496700012
J	Steinmetz, OK; Palerme, LP				Steinmetz, OK; Palerme, LP			Acquired arteriovenous fistula	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									McGill Univ, Ctr Hlth, Montreal, PQ H3A 1A1, Canada	McGill University	Steinmetz, OK (corresponding author), McGill Univ, Ctr Hlth, Montreal, PQ H3A 1A1, Canada.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2180	2180		10.1056/NEJMicm990557	http://dx.doi.org/10.1056/NEJMicm990557			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152063				2022-12-28	WOS:000221496700010
J	Merten, GJ; Burgess, WP; Gray, LV; Holleman, JH; Roush, TS; Kowalchuk, GJ; Bersin, RM; Van Moore, A; Simonton, CA; Rittase, RA; Norton, HJ; Kennedy, TP				Merten, GJ; Burgess, WP; Gray, LV; Holleman, JH; Roush, TS; Kowalchuk, GJ; Bersin, RM; Van Moore, A; Simonton, CA; Rittase, RA; Norton, HJ; Kennedy, TP			Prevention of contrast-induced nephropathy with sodium bicarbonate - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE-RENAL-FAILURE; NITRIC-OXIDE; N-ACETYLCYSTEINE; FREE-RADICALS; RADIOCONTRAST; EXCRETION; HYPOXIA; NEPHROTOXICITY; INTERVENTION; INVOLVEMENT	Context Contrast-induced nephropathy remains a common complication of radiographic procedures. Pretreatment with sodium bicarbonate is more protective than sodium chloride in animal models of acute ischemic renal failure. Acute renal failure from both ischemia and contrast are postulated to occur from free-radical injury. However, no studies in humans or animals have evaluated the efficacy of sodium bicarbonate for prophylaxis against contrast-induced nephropathy. Objective To examine the efficacy of sodium bicarbonate compared with sodium chloride for preventive hydration before and after radiographic contrast. Design, Setting, and Patients A prospective, single-center, randomized trial conducted from September 16, 2002, to June 17, 2003, of 119 patients with stable serum creatinine levels of at least 1.1 mg/dL (greater than or equal to97.2 mumol/L) who were randomized to receive a 154-mEq/L infusion of either sodium chloride (n = 59) or sodium bicarbonate (n = 60) before and after iopamidol administration (370 mg iodine/mL). Serum creatinine levels were measured at baseline and 1 and 2 days after contrast. Interventions Patients received 154 mEq/L of either sodium chloride or sodium bicarbonate, as a bolus of 3 mL/kg per hour for 1 hour before iopamidol contrast, followed by an infusion of 1 mL/kg per hour for 6 hours after the procedure. Main Outcome Measure Contrast-induced nephropathy, defined as an increase of 25% or more in serum creatinine within 2 days of contrast. Results There were no significant group differences in age, sex, incidence of diabetes mellitus, ethnicity, or contrast volume. Baseline serum creatinine was slightly higher but not statistically different in patients receiving sodium bicarbonate treatment (mean [SD], 1.71 [0.42] mg/dL [151.2 {37.1} mumol/L] for sodium chloride and 1.89 [0.69] mg/dL [167.1 {61.0} mumol/L] for sodium bicarbonate; P = .09). The primary end point of contrast-induced nephropathy occurred in 8 patients (13.6%) infused with sodium chloride but in only 1 (1.7%) of those receiving sodium bicarbonate (mean difference, 11.9%; 95% confidence interval [Cl], 2.6%-21.2%; P = .02). A follow-up registry of 191 consecutive patients receiving prophylactic sodium bicarbonate and meeting the same inclusion criteria as the study resulted in 3 cases of contrast-induced nephropathy (1.6%; 95% Cl, 0%-3.4%). Conclusion Hydration with sodium bicarbonate before contrast exposure is more effective than hydration with sodium chloride for prophylaxis of contrast-induced renal failure.	Carolinas Med Ctr, Dept Internal Med, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Radiol, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Clin Pharm, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Biostat, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Sanger Cardiol, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Sanger Cardiovasc Surg, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Metrolina Nephrol, Charlotte, NC 28232 USA	Carolinas Medical Center; Carolinas Medical Center; Carolinas Medical Center; Carolinas Medical Center; Carolinas Medical Center; Carolinas Medical Center; Carolinas Medical Center	Kennedy, TP (corresponding author), Carolinas Med Ctr, Dept Internal Med, MEB 507,POB 38162, Charlotte, NC 28232 USA.	tkennedy@carolinas.org						AGMON Y, 1994, J CLIN INVEST, V94, P1069, DOI 10.1172/JCI117421; Allaqaband S, 2002, CATHETER CARDIO INTE, V57, P279, DOI 10.1002/ccd.10323; Alpern RJ, 2000, KIDNEY, P455; Aspelin P, 2003, NEW ENGL J MED, V348, P491, DOI 10.1056/NEJMoa021833; ATKINS JL, 1986, NEPHRON, V44, P70, DOI 10.1159/000183915; Baker CSR, 2003, J AM COLL CARDIOL, V41, P2114, DOI 10.1016/S0735-1097(03)00487-X; Baker CSR, 2001, HEART, V85, P361, DOI 10.1136/heart.85.4.361; BAKRIS GL, 1990, AM J PHYSIOL, V258, pF115, DOI 10.1152/ajprenal.1990.258.1.F115; BAKRIS GL, 1990, RADIOLOGY, V175, P57, DOI 10.1148/radiology.175.1.2315505; Baroni EA, 1999, AM J KIDNEY DIS, V34, P328, DOI 10.1016/S0272-6386(99)70363-X; Birck R, 2003, LANCET, V362, P598, DOI 10.1016/S0140-6736(03)14189-X; Boccalandro F, 2003, CATHETER CARDIO INTE, V58, P336, DOI 10.1002/ccd.10389; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; Briguori C, 2003, PROG CARDIOVASC DIS, V45, P493, DOI 10.1053/pcad.2003.YPCAD16; Caulfield JL, 1996, J BIOL CHEM, V271, P25859, DOI 10.1074/jbc.271.42.25859; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Cohen G., 1985, CRC HDB METHODS OXYG, P55; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Durham JD, 2002, KIDNEY INT, V62, P2202, DOI 10.1046/j.1523-1755.2002.00673.x; Gonzalez NC, 2001, ADV EXP MED BIOL, V502, P39; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HEYMAN SN, 1991, KIDNEY INT, V40, P632, DOI 10.1038/ki.1991.255; JULIAN BA, 1982, J LAB CLIN MED, V100, P261; Katholi RE, 1998, AM J KIDNEY DIS, V32, P64, DOI 10.1053/ajkd.1998.v32.pm9669426; Kay J, 2003, JAMA-J AM MED ASSOC, V289, P553, DOI 10.1001/jama.289.5.553; KOTCHEN TA, 1983, ANN INTERN MED, V98, P817, DOI 10.7326/0003-4819-98-5-817; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lindinger MI, 2000, J APPL PHYSIOL, V88, P540, DOI 10.1152/jappl.2000.88.2.540; Loitsch SM, 2000, BIOCHEM BIOPH RES CO, V276, P571, DOI 10.1006/bbrc.2000.3504; Marenzi G, 2003, NEW ENGL J MED, V349, P1333, DOI 10.1056/NEJMoa023204; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; Murphy ME, 1998, INVEST RADIOL, V33, P356, DOI 10.1097/00004424-199806000-00007; Novikov M, 2003, J AM SOC NEPHROL, V14, p354A; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Qin SF, 1999, BIOCHEM BIOPH RES CO, V262, P231, DOI 10.1006/bbrc.1999.1079; RUDNICK MR, 1995, KIDNEY INT, V47, P254, DOI 10.1038/ki.1995.32; Safirstein R, 2000, NEW ENGL J MED, V343, P210, DOI 10.1056/NEJM200007203430311; Shyu KG, 2002, J AM COLL CARDIOL, V40, P1383, DOI 10.1016/S0735-1097(02)02308-2; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; SPORER H, 1981, EUR J CLIN INVEST, V11, P311, DOI 10.1111/j.1365-2362.1981.tb02122.x; Stone GW, 2003, JAMA-J AM MED ASSOC, V290, P2284, DOI 10.1001/jama.290.17.2284; Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304; TERUEL JL, 1989, NEPHRON, V51, P282, DOI 10.1159/000185304; Vallero A, 2002, G Ital Nefrol, V19, P529	44	719	769	0	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2004	291	19					2328	2334		10.1001/jama.291.19.2328	http://dx.doi.org/10.1001/jama.291.19.2328			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821JD	15150204	Bronze			2022-12-28	WOS:000221455400020
J	Coiera, E				Coiera, E			Four rules for the reinvention of health care	BRITISH MEDICAL JOURNAL			English	Article							COMMUNICATION		Univ New S Wales, Ctr Hlth Informat, Sydney, NSW 2055, Australia	University of New South Wales Sydney	Coiera, E (corresponding author), Univ New S Wales, Ctr Hlth Informat, Sydney, NSW 2055, Australia.	e.coiera@unsw.edu.au		Coiera, Enrico/0000-0002-6444-6584				BOOTH N, 2001, PHCSG ANN C P, P90; Bostrom R. P., 1977, MIS QUART, V1, P11, DOI [10.2307/249019, DOI 10.2307/249019]; Coiera E, 1999, MED J AUSTRALIA, V171, P508, DOI 10.5694/j.1326-5377.1999.tb123776.x; Coiera E, 2003, INT J MED INFORM, V69, P205, DOI 10.1016/S1386-5056(02)00106-5; Coiera E, 2003, GUIDE HLTH INFORM, V2nd; COSTELLO P, 2002, 5 COMM AUSTR; Gosling AS, 2003, INT J MED INFORM, V69, P1, DOI 10.1016/S1386-5056(02)00046-1; GREATBATCH D, 1993, INTERACT COMPUT, V5, P193, DOI 10.1016/0953-5438(93)90018-O; Kaplan B, 2001, J AM MED INFORM ASSN, V8, P235, DOI 10.1136/jamia.2001.0080235; MARKUS ML, 1994, ORGAN SCI, V5, P502, DOI 10.1287/orsc.5.4.502; Parker J, 2000, J AM MED INFORM ASSN, V7, P453, DOI 10.1136/jamia.2000.0070453; Reeves B, 1996, MEDIA EQUATION PEOPL; Rotich JK, 2003, J AM MED INFORM ASSN, V10, P295, DOI 10.1197/jamia.M1301; Trist E., 1981, PERSPECTIVES ORG DES, P19	14	122	125	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 15	2004	328	7449					1197	1199		10.1136/bmj.328.7449.1197	http://dx.doi.org/10.1136/bmj.328.7449.1197			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	821XU	15142933	Green Published			2022-12-28	WOS:000221497500034
J	McAlearney, AS; Schweikhart, SB; Medow, MA				McAlearney, AS; Schweikhart, SB; Medow, MA			Doctors' experience with handheld computers in clinical practice: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							INFORMATION	Objective To examine doctors' perspectives about their experiences with handheld computers in clinical practice. Design Qualitative study of eight focus groups consisting of doctors with diverse training and practice patterns. Setting Six practice settings across the United States an two additional focus group sessions held at a national meeting of general internists. Participants 54 doctors who did or did not use handheld computers. Results Doctors who used handheld computers in clinical practice seemed generally satisfied with them and reported diverse patterns of use. Users perceived that the devices helped them increase productivity and improve patient care. Barriers to use concerned the device itself and personal and perceptual constraints, with perceptual factors such as comfort with technology, preference for paper, and the impression that the devices are not easy to use somewhat difficult to overcome. Participants suggested that organisations can help promote handheld computers by providing advice about purchase and usage, training, and user support. Participants expressed concern about reliability and security of the device but were particularly concerned about dependency and over-reliance as a substitute for clinical thinking. Conclusions Doctors expect handheld computers to become more useful, and most seem interested in leveraging (getting the most value from) their use. Key opportunities with handheld computers included their use as a stepping stone to build doctors' comfort with other information technology and ehealth initiatives and providing point of care support to doctors that helps improve patient care.	Ohio State Univ, Sch Publ Hlth, Div Hlth Serv Management & Policy, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Div Gen Internal Med, Columbus, OH 43210 USA	Ohio State University; Ohio State University	McAlearney, AS (corresponding author), Ohio State Univ, Sch Publ Hlth, Div Hlth Serv Management & Policy, 1583 Perry St,Atwell 246, Columbus, OH 43210 USA.	mcalearney.1@osu.edu	McAlearney, Ann/J-3008-2013; Greiver, Michelle/N-8764-2015	McAlearney, Ann/0000-0001-9107-5419; Greiver, Michelle/0000-0001-8957-0285				ALUBAYDLI M, 2003, HANDHELD COMPUTERS D; Chen ES, 2004, J AM MED INFORM ASSN, V11, P19, DOI 10.1197/jamia.M1387; Doolan DF, 2003, J AM MED INFORM ASSN, V10, P94, DOI 10.1197/jamia.M1127; Embi PJ, 2001, CLEV CLIN J MED, V68, P840, DOI 10.3949/ccjm.68.10.840; Fischer S, 2003, J AM MED INFORM ASSN, V10, P139, DOI 10.1197/jamia.M1180; Glaser B.G., 1965, AWARENESS DYING; *HARR INT, DOCT US HANDH PERS C; Maxwell J.A., 2005, QUALITATIVE RES DESI; Miles M., 2013, QUALITATIVE DATA ANA; Rothschild JM, 2002, J AM MED INFORM ASSN, V9, P223, DOI 10.1197/jamia.M1001; Schneider S, 2001, Fam Pract Manag, V8, P50; WILDERMAN, 2003, CAN FAM DOCTOR, V49, P1510; WILDERMAN, 2003, CAN FAM DOCTOR, V49, P1507; Wright P, 2000, ERGONOMICS, V43, P702, DOI 10.1080/001401300404689	14	109	110	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 15	2004	328	7449					1162	1165		10.1136/bmj.328.7449.1162	http://dx.doi.org/10.1136/bmj.328.7449.1162			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142920	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000221497500020
J	Polman, CH; Killestein, J				Polman, CH; Killestein, J			Statins for the treatment of multiple sclerosis: cautious hope	LANCET			English	Editorial Material							LOVASTATIN		VU Med Ctr Amsterdam, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Polman, CH (corresponding author), VU Med Ctr Amsterdam, NL-1007 MB Amsterdam, Netherlands.	ch.polman@vumc.nl		Killestein, Joep/0000-0002-6347-5957				Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02-1014fje; Neuhaus O, 2002, NEUROLOGY, V59, P990, DOI 10.1212/WNL.59.7.990; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	5	10	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	2004	363	9421					1570	1570		10.1016/S0140-6736(04)16237-5	http://dx.doi.org/10.1016/S0140-6736(04)16237-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145628				2022-12-28	WOS:000221408800005
J	Liu, LD; Wong, TP; Pozza, MF; Lingenhoehl, K; Wang, YS; Sheng, M; Auberson, YP; Wang, YT				Liu, LD; Wong, TP; Pozza, MF; Lingenhoehl, K; Wang, YS; Sheng, M; Auberson, YP; Wang, YT			Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity	SCIENCE			English	Article							LONG-TERM DEPRESSION; SUBUNIT COMPOSITION; RAT-BRAIN; FUNCTIONAL-PROPERTIES; CRITICAL PERIOD; VISUAL-CORTEX; IN-VITRO; LTP; POTENTIATION; DEPENDENCE	Activation of N-methyl-D-aspartate subtype glutamate receptors (NMDARs) is required for long-term potentiation (LTP) and long-term depression (LTD) of excitatory synaptic transmission at hippocampal CA1 synapses, the proposed cellular substrates of learning and memory. However, little is known about how activation of NMDARs leads to these two opposing forms of synaptic plasticity. Using hippocampal slice preparations, we showed that selectively blocking NMDARs that contain the NR2B subunit abolishes the induction of LTD but not LTP. In contrast, preferential inhibition of NR2A-containing NMDARs prevents the induction of LTP without affecting LTD production. These results demonstrate that distinct NMDAR subunits are critical factors that determine the polarity of synaptic plasticity.	Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 2B5, Canada; Novartis Pharma AG, Novartis Inst Biomed Res, CH-4002 Basel, Switzerland; MIT, Picower Ctr Learning & Memory, RIKE MIT Neurosci Res Ctr, Howard Hughes Med Inst, Cambridge, MA 02139 USA	University of British Columbia; Novartis; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Wang, YT (corresponding author), Univ British Columbia, Brain Res Ctr, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.	ytwang@interchange.ubc.ca	Wang, Yu Tian/A-4729-2008; Wang, Yu Tian/J-8255-2015; Auberson, Yves/AAF-6538-2019	Auberson, Yves/0000-0001-5800-4811; Wong, Tak Pan/0000-0001-8611-4911; Liu, Lidong/0000-0002-7026-690X				Barth AL, 2001, NAT NEUROSCI, V4, P235, DOI 10.1038/85070; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BULLER AL, 1994, J NEUROSCI, V14, P5471; Chen NS, 1999, J NEUROSCI, V19, P6844, DOI 10.1523/JNEUROSCI.19-16-06844.1999; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; Emptage NJ, 2003, NEURON, V38, P797, DOI 10.1016/S0896-6273(03)00325-8; Erisir A, 2003, J NEUROSCI, V23, P5208; ERRINGTON ML, 1995, J NEUROPHYSIOL, V74, P1793, DOI 10.1152/jn.1995.74.4.1793; Hendricson AW, 2002, J PHARMACOL EXP THER, V301, P938, DOI 10.1124/jpet.301.3.938; Hrabetova S, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-12-j0002.2000; Kemp N, 2000, EUR J NEUROSCI, V12, P360, DOI 10.1046/j.1460-9568.2000.00903.x; Kirson ED, 1996, J PHYSIOL-LONDON, V497, P437, DOI 10.1113/jphysiol.1996.sp021779; Kohr G, 2003, J NEUROSCI, V23, P10791; Laurie DJ, 1997, MOL BRAIN RES, V51, P23, DOI 10.1016/S0169-328X(97)00206-4; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Mizuno T, 2001, EUR J NEUROSCI, V14, P701, DOI 10.1046/j.0953-816x.2001.01679.x; Mockett B, 2002, EUR J NEUROSCI, V15, P1819, DOI 10.1046/j.1460-9568.2002.02008.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Mutel V, 1998, J NEUROCHEM, V70, P2147; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; Philpot BD, 2001, NEURON, V29, P157, DOI 10.1016/S0896-6273(01)00187-8; Ritter LM, 2002, DEV BRAIN RES, V139, P227, DOI 10.1016/S0165-3806(02)00572-2; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Tovar KR, 1999, J NEUROSCI, V19, P4180; Wenzel A, 1997, J NEUROCHEM, V68, P469; Williams K, 2001, CURR DRUG TARGETS, V2, P285, DOI 10.2174/1389450013348489; Yoshimura Y, 2003, J NEUROSCI, V23, P6557; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	36	862	907	0	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					1021	1024		10.1126/science.1096615	http://dx.doi.org/10.1126/science.1096615			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143284				2022-12-28	WOS:000221383300052
J	Brown, EJ				Brown, EJ			The molecular basis of streptococcal toxic shock syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FIBRINOGEN		Univ Calif San Francisco, Program Microbial Pathogenesis & Host Def, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Brown, EJ (corresponding author), Univ Calif San Francisco, Program Microbial Pathogenesis & Host Def, San Francisco, CA 94143 USA.							Harlan JM, 2002, CRIT CARE MED, V30, pS214, DOI 10.1097/00003246-200205001-00007; Herwald H, 2004, CELL, V116, P367, DOI 10.1016/S0092-8674(04)00057-1; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; Lolis E, 2003, NAT REV DRUG DISCOV, V2, P635, DOI 10.1038/nrd1153	4	19	21	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2093	2094		10.1056/NEJMcibr040657	http://dx.doi.org/10.1056/NEJMcibr040657			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141050				2022-12-28	WOS:000221354000014
J	Berwick, DM				Berwick, DM			Lessons from developing nations on improving health care	BRITISH MEDICAL JOURNAL			English	Article							TUBERCULOSIS		Inst Healthcare Improvement, Boston, MA 02215 USA	Institute for Healthcare Improvement	Berwick, DM (corresponding author), Inst Healthcare Improvement, 375 Longwood Ave, Boston, MA 02215 USA.	dberwick@ihi.org						ABDALLAH H, IN PRESS EVIDENCE BA; Berwick DM, 1998, ANN INTERN MED, V128, P289, DOI 10.7326/0003-4819-128-4-199802150-00008; Deming WE, 1994, NEW EC IND GOVT ED; Deming WE, 2000, OUT CRISIS; EDCIER TT, 2000, BRIT MED J, V321, P797; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; Langley Gj., 1996, IMPROVEMENT GUIDE PR; Pruitt S., 2002, INNOVATIVE CARE CHRO; Rotich JK, 2003, J AM MED INFORM ASSN, V10, P295, DOI 10.1197/jamia.M1301; Smits HL, 2002, INT J QUAL HEALTH C, V14, P439, DOI 10.1093/intqhc/14.6.439; Wagner E H, 1998, Eff Clin Pract, V1, P2	12	79	80	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 8	2004	328	7448					1124	1129		10.1136/bmj.328.7448.1124	http://dx.doi.org/10.1136/bmj.328.7448.1124			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	818YS	15130984	Green Published, Green Submitted			2022-12-28	WOS:000221281000027
J	Bottle, A; Jarman, B; Aylin, P; Taylor, R				Bottle, A; Jarman, B; Aylin, P; Taylor, R			Dr Foster's case notes - Some way to go for consistent implementation of guidance on hip fracture	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England	Imperial College London	Bottle, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England.		Aylin, Paul/A-1073-2014	Bottle, Alex/0000-0001-9978-2011; Aylin, Paul/0000-0003-4589-1743					0	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 8	2004	328	7448					1097	1097		10.1136/bmj.328.7448.1097	http://dx.doi.org/10.1136/bmj.328.7448.1097			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130976	Green Published			2022-12-28	WOS:000221281000014
J	Gaur, L; Skochelak, S				Gaur, L; Skochelak, S			Evaluating competence in medical students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERFORMANCE		Univ Wisconsin, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Gaur, L (corresponding author), Univ Wisconsin, Sch Med, Madison, WI 53706 USA.				NIDDK NIH HHS [T35 DK062709] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T35DK062709] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayers WR, 2001, TEACH LEARN MED, V13, P214, DOI 10.1207/S15328015TLM1304_01; Barzansky B, 2003, JAMA-J AM MED ASSOC, V290, P1190, DOI 10.1001/jama.290.9.1190; Campos-Outcalt D, 1999, Fam Med, V31, P90; HARDEN RM, 1975, BRIT MED J, V1, P447, DOI 10.1136/bmj.1.5955.447; Hatala R, 2002, JAMA-J AM MED ASSOC, V288, P1110, DOI 10.1001/jama.288.9.1110; Kahn MJ, 2001, TEACH LEARN MED, V13, P9, DOI 10.1207/S15328015TLM1301_3; Prislin M D, 1998, Fam Med, V30, P338; Simon SR, 2002, MED TEACH, V24, P535, DOI 10.1080/0142159021000012586	8	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2004	291	17					2143	2143		10.1001/jama.291.17.2143	http://dx.doi.org/10.1001/jama.291.17.2143			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JR	15126448				2022-12-28	WOS:000221174300037
J	Fagerlin, A; Rovner, D; Stableford, S; Jentoft, C; Wei, JT; Holmes-Rovner, M				Fagerlin, A; Rovner, D; Stableford, S; Jentoft, C; Wei, JT; Holmes-Rovner, M			Patient education materials about the treatment of early-stage prostate cancer: A critical review	ANNALS OF INTERNAL MEDICINE			English	Review							NUMERACY; INFORMATION; DECISIONS; CHOICE	Background: To ensure that patients make informed medical decisions, patient education materials must communicate treatment risks and benefits. Objective: To survey publicly available patient education materials and assess their suitability to support informed decision making in early-stage prostate cancer. Design: Cross-sectional review of Internet, print, and multimedia sources. Setting: University data analysis laboratory. Measurements: The content of 44 materials that described all standard treatment options was reviewed. Top-rated documents underwent plain-language review. Total score on 54 content items and accuracy, balance, and plain-language evaluation was measured. Results: 502 of 546 patient education materials did not describe all standard treatments (watchful waiting, surgery, radiation, and hormone therapy). Eighty percent of the 44 materials that addressed standard treatments and underwent content review described anatomy, physiology, stage, and grade of cancer. Half of the materials fully described radical prostatectomy and radiation therapy. One third of the materials included risks and benefits of each treatment; none explicitly compared outcomes of all treatments in a single summary. Information was accurate and balanced but did not include key content for informed consent. Limitations: The search was restricted to publicly available materials and did not include books or materials written in languages other than English. The accuracy, balance, and plain-language reviews were evaluated by 1 reviewer. The criteria reflect the authors' focus on informed decision making. Other aspects of health education may require a different evaluation template. Conclusions: Currently available patient education materials on early-stage prostate cancer treatment do not contain comprehensive information about the risks and benefits of each treatment. To assist patients and physicians in choosing among prostate cancer treatment options, a new generation of materials is needed.	Univ Michigan, Div Gen Med, Ann Arbor, MI 48109 USA; Vet Adm Ctr Practice Management & Outcomes Res, Vet Adm Healthcare Syst, Program Improving Hlth Care Decis, Ann Arbor, MI 48109 USA; Michigan State Univ, E Lansing, MI 48824 USA; Univ New England, Maine Area Hlth Educ Ctr, Hlth Literacy Ctr, Biddeford, ME USA	University of Michigan System; University of Michigan; Michigan State University; University of New England - Maine	Fagerlin, A (corresponding author), Univ Michigan, Div Gen Med, 300 N Ingalls Bldg,Room 7C27, Ann Arbor, MI 48109 USA.	fagerlin@umich.edu	lei, cao/ABA-7520-2021; Wei, John T/E-8967-2012					Adelsward V, 1996, SOC SCI MED, V43, P1179, DOI 10.1016/0277-9536(95)00366-5; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; Centers for Disease Control and Prevention, 1999, SCI TECHN INF SIMPL; COULTER A, 1998, INFORMING PATIENTS A; Doak CC, 1996, TEACHING PATIENTS LO; Feldman-Stewart D, 2000, MED DECIS MAKING, V20, P228, DOI 10.1177/0272989X0002000208; Fischhoff Baruch, 1999, Journal of the National Cancer Institute Monographs, P7; Fowler FJ, 2000, JAMA-J AM MED ASSOC, V283, P3217, DOI 10.1001/jama.283.24.3217; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; Holmes-Rovner M, 1999, MED CARE, V37, P270, DOI 10.1097/00005650-199903000-00007; Holmes-Rovner M, 2000, J EVAL CLIN PRACT, V6, P263, DOI 10.1046/j.1365-2753.2000.00258.x; Holmes-Rovner M, 2001, BMJ-BRIT MED J, V322, P664, DOI 10.1136/bmj.322.7287.664; Kirsch I. S., 1993, 93275 NCES US DEP ED; Lipkus IM, 2001, MED DECIS MAKING, V21, P37, DOI 10.1177/0272989X0102100105; MAZUR DJ, 1993, MED DECIS MAKING, V13, P59, DOI 10.1177/0272989X9301300108; McBean A M, 1994, Health Care Financ Rev, V15, P77; O'Connor A M, 1999, J Natl Cancer Inst Monogr, P67; O'Connor AM, 1998, PATIENT EDUC COUNS, V33, P267, DOI 10.1016/S0738-3991(98)00026-3; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; O'Connor AM, 2003, COCHRANE LIB, P2; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; SELDEN CR, 2000, HLTH LIT CURRENT BIB; TAUB D, 2002, N CENTR SECT M AM UR	23	81	82	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	2004	140	9					721	728		10.7326/0003-4819-140-9-200405040-00012	http://dx.doi.org/10.7326/0003-4819-140-9-200405040-00012			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816XR	15126256				2022-12-28	WOS:000221143100006
J	Kogan, A; Amasha, S; Kastner, MA				Kogan, A; Amasha, S; Kastner, MA			Photon-induced Kondo satellites in a single-electron transistor	SCIENCE			English	Article							QUANTUM-DOT; EQUILIBRIUM; SUPPRESSION; MODEL	We measure the differential conductance of a single-electron transistor ( SET) irradiated with microwaves. The spin-entangled many-electron Kondo state produces a zero-bias peakin the dc differential conductance if the quantum dot in the SET contains an unpaired electron. When the photon energy hf is comparable to the energy width of the Kondo peak and to e ( the charge on the electron) times the microwave voltage across the dot, satellites appear in the differential conductance shifted in voltage by +/-hf/e from the zero-bias resonance. We also observe an overall suppression of the Kondo features with increasing microwave voltage.	MIT, Dept Phys, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Kogan, A (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.	akogan@mit.edu		Kogan, Andrei/0000-0002-3859-1497; Kastner, Marc/0000-0001-7641-5438				Coleman P, 2002, J PHYS-CONDENS MAT, V14, pL205, DOI 10.1088/0953-8984/14/8/105; Cronenwett SM, 1998, SCIENCE, V281, P540, DOI 10.1126/science.281.5376.540; Elzerman JM, 2000, J LOW TEMP PHYS, V118, P375, DOI 10.1023/A:1004694017738; GLAZMAN LI, 1988, JETP LETT+, V47, P452; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; Goldin Y, 1998, PHYS REV LETT, V81, P5394, DOI 10.1103/PhysRevLett.81.5394; HETTLER MH, 1995, PHYS REV LETT, V74, P4907, DOI 10.1103/PhysRevLett.74.4907; HEWSON AC, 1993, CAMBRIDGE STUDIES MA, V2; Kaminski A, 1999, PHYS REV LETT, V83, P384, DOI 10.1103/PhysRevLett.83.384; Kaminski A, 2000, PHYS REV B, V62, P8154, DOI 10.1103/PhysRevB.62.8154; Kogan A, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.113309; Kouwenhoven L, 2001, PHYS WORLD, V14, P33; KOUWENHOVEN LP, 1994, PHYS REV LETT, V73, P3443, DOI 10.1103/PhysRevLett.73.3443; Lopez R, 1998, PHYS REV LETT, V81, P4688, DOI 10.1103/PhysRevLett.81.4688; Lopez R, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.075319; Ng TK, 1996, PHYS REV LETT, V76, P487, DOI 10.1103/PhysRevLett.76.487; NG TK, 1988, PHYS REV LETT, V61, P1768, DOI 10.1103/PhysRevLett.61.1768; Nordlander P, 2000, PHYS REV B, V61, P2146, DOI 10.1103/PhysRevB.61.2146	18	43	44	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	2004	304	5675					1293	1295		10.1126/science.1096377	http://dx.doi.org/10.1126/science.1096377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166371				2022-12-28	WOS:000221669600045
J	Bell, J				Bell, J			Predicting disease using genomics	NATURE			English	Review							GENE; ASSOCIATION; CLASSIFICATION; SUSCEPTIBILITY; PROGRESSION; MECHANISMS; GENOTYPE; PATTERNS; THERAPY; LESSONS	Information from the human genome sequence will eventually alter many aspects of clinical practice. It will increase through our understanding of disease mechanisms, and guide the development of new drugs and therapeutic procedures. In the short term, however, knowledge of the genome will have a profound clinical impact on the diagnostic capability of clinical genetics laboratories. Molecular phenotyping using genetic and genomic information will allow early and more accurate prediction and diagnosis of disease and of disease progression. Medicine will become oriented towards disease prevention rather than efforts to cure people at late stages of illness.	Univ Oxford, John Radcliffe Hosp, Acad Ctr, Oxford OX3 9DU, England	University of Oxford	Bell, J (corresponding author), Univ Oxford, John Radcliffe Hosp, Acad Ctr, Oxford OX3 9DU, England.	regius@medsci.ox.ac.uk						Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Bohen SP, 2003, P NATL ACAD SCI USA, V100, P1926, DOI 10.1073/pnas.0437875100; Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Collins R, 2003, LANCET, V361, P2005; de Leon MP, 2004, BRIT J CANCER, V90, P882, DOI 10.1038/sj.bjc.6601529; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; EVANS DAP, 1960, BRIT MED J, V2, P485, DOI 10.1136/bmj.2.5197.485; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Fornier M, 2002, ONCOLOGY-NY, V16, P1340; Gloyn AL, 2003, DIABETES, V52, P568, DOI 10.2337/diabetes.52.2.568; Grody WW, 2003, ANNU REV MED, V54, P473, DOI 10.1146/annurev.med.54.101601.152127; HARRIS BE, 1991, CANCER, V68, P499, DOI 10.1002/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F; Hartge P, 2003, NEW ENGL J MED, V348, P2352, DOI 10.1056/NEJMe030065; JOHNSTONE EC, IN PRESS PHARMACOGEN; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KRYNETSKI EY, 1995, P NATL ACAD SCI USA, V92, P949, DOI 10.1073/pnas.92.4.949; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mira MT, 2004, NATURE, V427, P636, DOI 10.1038/nature02326; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Paul Sindy M, 2003, N J Med, V100, P44; Pearson ER, 2003, LANCET, V362, P1275, DOI 10.1016/S0140-6736(03)14571-0; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Seligsohn U, 2001, NEW ENGL J MED, V344, P1222, DOI 10.1056/NEJM200104193441607; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Watkins H, 2000, NEW ENGL J MED, V342, P422, DOI 10.1056/NEJM200002103420609; Weatherall DJ, 2001, NAT REV GENET, V2, P245, DOI 10.1038/35066048; WEBER WW, 1979, PHARMACOGENETICS; Weedon MN, 2003, AM J HUM GENET, V73, P1208, DOI 10.1086/379285; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; Wexler NS, 2004, P NATL ACAD SCI USA, V101, P3498, DOI 10.1073/pnas.0308479101; Wong YF, 2003, CLIN CANCER RES, V9, P5486; Young J, 2004, BRIT MED J, V328, P15, DOI 10.1136/bmj.328.7430.15	46	140	150	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					453	456		10.1038/nature02624	http://dx.doi.org/10.1038/nature02624			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164070				2022-12-28	WOS:000221644600047
J	Ravelo, AC; Andreasen, DH; Lyle, M; Lyle, AO; Wara, MW				Ravelo, AC; Andreasen, DH; Lyle, M; Lyle, AO; Wara, MW			Regional climate shifts caused by gradual global cooling in the Pliocene epoch	NATURE			English	Article							WATER CIRCULATION; PLIOPLEISTOCENE; VARIABILITY; GLACIATION; DELTA-O-18; TROPICS; SEAWAY	The Earth's climate has undergone a global transition over the past four million years, from warm conditions with global surface temperatures about 3degreesC warmer than today, smaller ice sheets and higher sea levels to the current cooler conditions. Tectonic changes and their influence on ocean heat transport have been suggested as forcing factors for that transition, including the onset of significant Northern Hemisphere glaciation similar to2.75 million years ago, but the ultimate causes for the climatic changes are still under debate. Here we compare climate records from high latitudes, subtropical regions and the tropics, indicating that the onset of large glacial/interglacial cycles did not coincide with a specific climate reorganization event at lower latitudes. The regional differences in the timing of cooling imply that global cooling was a gradual process, rather than the response to a single threshold or episodic event as previously suggested. We also find that high-latitude climate sensitivity to variations in solar heating increased gradually, culminating after cool tropical and subtropical upwelling conditions were established two million years ago. Our results suggest that mean low-latitude climate conditions can significantly influence global climate feedbacks.	Univ Calif Santa Cruz, Ocean Sci Dept, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Boise State Univ, Ctr Geophys Invest Shallow Subsurface, Boise, ID 83725 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; Idaho; Boise State University	Ravelo, AC (corresponding author), Univ Calif Santa Cruz, Ocean Sci Dept, Santa Cruz, CA 95064 USA.	acr@es.ucsc.edu		Ravelo, Ana Christina/0000-0003-3929-677X				ANDREASEN DH, 2001, THESIS U CALIFORNIA; BERGER WH, 1993, P OCEAN DRILLING PRO, V0130; Billups K, 1999, GEOLOGY, V27, P319, DOI 10.1130/0091-7613(1999)027<0319:LBOHTT>2.3.CO;2; Billups K, 1998, PALEOCEANOGRAPHY, V13, P459, DOI 10.1029/98PA02262; BJERKNES J, 1969, MON WEATHER REV, V97, P163, DOI 10.1175/1520-0493(1969)097<0163:ATFTEP>2.3.CO;2; Cane MA, 2000, SCIENCE, V290, P1107, DOI 10.1126/science.290.5494.1107; Cane MA, 2001, NATURE, V411, P157, DOI 10.1038/35075500; Cannariato KG, 1997, PALEOCEANOGRAPHY, V12, P805, DOI 10.1029/97PA02514; Chaisson W.P., 1997, Proceedings of the Ocean Drilling Program Scientific Results, V154, P255; Chaisson WP, 2000, PALEOCEANOGRAPHY, V15, P497, DOI 10.1029/1999PA000442; Clark PU, 1999, SCIENCE, V286, P1104, DOI 10.1126/science.286.5442.1104; Clemens SC, 1996, SCIENCE, V274, P943, DOI 10.1126/science.274.5289.943; DeConto RM, 2003, NATURE, V421, P245, DOI 10.1038/nature01290; DEMENOCAL PB, 1995, SCIENCE, V270, P53, DOI 10.1126/science.270.5233.53; Dowsett H, 1996, MAR MICROPALEONTOL, V27, P13, DOI 10.1016/0377-8398(95)00050-X; Driscoll NW, 1998, SCIENCE, V282, P436, DOI 10.1126/science.282.5388.436; Gu DF, 1997, SCIENCE, V275, P805, DOI 10.1126/science.275.5301.805; Harper S, 2000, TELLUS A, V52, P330, DOI 10.1034/j.1600-0870.2000.d01-7.x; Haug GH, 1999, NATURE, V401, P779, DOI 10.1038/44550; Haug GH, 2001, GEOLOGY, V29, P207, DOI 10.1130/0091-7613(2001)029<0207:ROPUOO>2.0.CO;2; Haywood AM, 2000, GLOBAL PLANET CHANGE, V25, P239, DOI 10.1016/S0921-8181(00)00028-X; Jansen E., 1993, PROC OCEAN DRILL SCI, V130, P349; Kwiek PB, 1999, PALAEOGEOGR PALAEOCL, V154, P191, DOI 10.1016/S0031-0182(99)00111-X; LASKAR J, 1993, ASTRON ASTROPHYS, V270, P522; Lear CH, 2003, EARTH PLANET SC LETT, V210, P425, DOI [10.1016/S0012-821X(03)00164-X, 10.1016/S0012-821X(03)-00164-X]; Lyle M., 1997, P ODP INIT REPTS, V167, P175, DOI [10. 2973/odp. proc. ir. 167. 1997, DOI 10.2973/ODP.PROC.IR.167.1997]; Lyle M., 2000, P OCEAN DRILL PROGRA, V167, P163, DOI DOI 10.2973/ODP.PROC.SR.167.214.2000; Marlow JR, 2000, SCIENCE, V290, P2288; Molnar P, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2001PA000663; Norris Richard D., 1998, Proceedings of the Ocean Drilling Program Scientific Results, V159, P539; OKADA H, 1973, DEEP-SEA RES, V20, P355, DOI 10.1016/0011-7471(73)90059-4; Philander SG, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000837; Ravelo AC, 1997, PALEOCEANOGRAPHY, V12, P729, DOI 10.1029/97PA02525; Ravelo AC, 2000, GEOPHYS RES LETT, V27, P1001, DOI 10.1029/1999GL007000; Raymo ME, 1990, PALEOCEANOGRAPHY, V5, P367, DOI 10.1029/PA005i003p00367; Raymo ME, 1992, PALEOCEANOGRAPHY, V7, P645, DOI 10.1029/92PA01609; Raymo ME, 1996, MAR MICROPALEONTOL, V27, P313, DOI 10.1016/0377-8398(95)00048-8; Raymo ME, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000791; Raymo ME, 1998, SCIENCE, V281, P1467, DOI 10.1126/science.281.5382.1467; Rind D, 2000, QUATERNARY SCI REV, V19, P381, DOI 10.1016/S0277-3791(99)00070-0; RUDDIMAN WF, 1988, PHILOS T ROY SOC B, V318, P411, DOI 10.1098/rstb.1988.0017; SALTZMAN B, 1993, CLIM DYNAM, V9, P1, DOI 10.1007/BF00208010; Sautter LR, 1991, PALEOCEANOGRAPHY, V6, P307, DOI 10.1029/91PA00385; Shackleton N.J., 1995, P ODP SCI RESULTS, V138, P73, DOI DOI 10.2973/0DP.PR0C.SR.138.106.1995; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; VANDERBURGH J, 1993, SCIENCE, V260, P1788, DOI 10.1126/science.260.5115.1788; WARA MW, 2003, THESIS U CALIFORNIA; Yin JH, 2001, J CLIMATE, V14, P565, DOI 10.1175/1520-0442(2001)014<0565:TIOTSS>2.0.CO;2	48	489	518	6	128	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					263	267		10.1038/nature02567	http://dx.doi.org/10.1038/nature02567			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152244				2022-12-28	WOS:000221505900034
J	Daumke, O; Weyand, M; Chakrabarti, PP; Vetter, IR; Wittinghofer, A				Daumke, O; Weyand, M; Chakrabarti, PP; Vetter, IR; Wittinghofer, A			The GTPase-activating protein Rap1GAP uses a catalytic asparagine	NATURE			English	Article							TUBEROUS-SCLEROSIS; MUTATIONAL ANALYSIS; MOLECULAR-CLONING; ARGININE-FINGER; TSC2 GENE; GAP; HYDROLYSIS; BINDING; COMPLEX; DOMAIN	Rap1 is a Ras-like guanine-nucleotide-binding protein ( GNBP) that is involved in a variety of signal-transduction processes(1,2). It regulates integrin-mediated cell adhesion and might activate extracellular signal-regulated kinase. Like other Ras-like GNBPs, Rap1 is regulated by guanine-nucleotide-exchange factors ( GEFs) and GTPase-activating proteins ( GAPs). These GAPs increase the slow intrinsic GTPase reaction of Ras-like GNBPs by many orders of magnitude and allow tight regulation of signalling. The activation mechanism involves stabilization of the catalytic glutamine of the GNBP and, in most cases, the insertion of a catalytic arginine of GAP into the active site(3). Rap1 is a close homologue of Ras but does not possess the catalytic glutamine essential for GTP hydrolysis in all other Ras-like and Galpha proteins. Furthermore, RapGAPs are not related to other GAPs and apparently do not use a catalytic arginine residue(4). Here we present the crystal structure of the catalytic domain of the Rap1-specific Rap1GAP at 2.9 Angstrom. By mutational analysis, fluorescence titration and stopped-flow kinetic assay, we demonstrate that Rap1GAP provides a catalytic asparagine to stimulate GTP hydrolysis. Implications for the disease tuberous sclerosis are discussed.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Otto Hahnstr 11, D-44227 Dortmund, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.de						Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; Au KS, 1998, AM J HUM GENET, V62, P286, DOI 10.1086/301705; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brinkmann T, 2002, J BIOL CHEM, V277, P12525, DOI 10.1074/jbc.M109176200; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; Daumke O, 2004, ACTA CRYSTALLOGR D, V60, P752, DOI 10.1107/S0907444904002392; De Antoni A, 2002, J BIOL CHEM, V277, P41023, DOI 10.1074/jbc.M205783200; Gao QS, 2001, J VIROL, V75, P4459, DOI 10.1128/JVI.75.9.4459-4466.2001; Gao QS, 1999, MOL CELL BIOL, V19, P733; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Graham DL, 1999, BIOCHEMISTRY-US, V38, P14981, DOI 10.1021/bi991358e; HATTORI M, 1995, MOL CELL BIOL, V15, P552, DOI 10.1128/MCB.15.1.552; Hattori M, 2003, J BIOCHEM, V134, P479, DOI 10.1093/jb/mvg180; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; Jones AC, 1999, AM J HUM GENET, V64, P1305, DOI 10.1086/302381; Klose A, 1998, HUM MOL GENET, V7, P1261, DOI 10.1093/hmg/7.8.1261; Kraemer A, 2002, J MOL BIOL, V324, P763, DOI 10.1016/S0022-2836(02)01136-1; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h	30	110	114	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988					197	201		10.1038/nature02505	http://dx.doi.org/10.1038/nature02505			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141215				2022-12-28	WOS:000221356300045
J	Bagshawe, KD				Bagshawe, KD			I never did become a cardiologist	LANCET			English	Editorial Material									Imperial Coll Sch Med, Dept Med Oncol, London W6 8RF, England	Imperial College London	Bagshawe, KD (corresponding author), Imperial Coll Sch Med, Dept Med Oncol, Charing Cross Campus, London W6 8RF, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	2004	363	9420					1502	1502		10.1016/S0140-6736(04)16147-3	http://dx.doi.org/10.1016/S0140-6736(04)16147-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135595				2022-12-28	WOS:000221302700007
J	Koestner, SC; Kappeler, A; Schaffner, T; Carrel, TP; Nydegger, UE; Mohacsi, P				Koestner, SC; Kappeler, A; Schaffner, T; Carrel, TP; Nydegger, UE; Mohacsi, P			Histo-blood group type change of the graft from B to O after ABO mismatched heart transplantation	LANCET			English	Article								A patient with blood group type O accidentally received a blood group B cardiac allograft. He died almost 5 years after transplantation because of transplant vasculopathy. We monitored the expression of ABO-type antigens on the vascular endothelial cells of the cardiac allograft for 44 months, using monoclonal antibodies for immunohistology. The antigenic profile of the graft endothelial cells changed progressively from B to O. This change was first detectable 14 months after transplantation and it was most prominent at the end of the observation period. Thus, we have shown that the allograft blood type of the endothelium of this patient's heart began to change from type B to his own, 1 year after transplantation. By 44 months post-transplantation, it had changed to O type.	Univ Hosp Bern, Dept Cardiol, Bern, Switzerland; Univ Hosp Bern, Dept Cardiovasc Surg, Bern, Switzerland; Univ Hosp Bern, Inst Pathol, Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Mohacsi, P (corresponding author), Univ Hosp Bern, Inselspital, Swiss Cardiovasc Ctr Bern, CH-3010 Bern, Switzerland.	paul.mohacsi@insel.ch	Carrel, Thierry/AAI-5910-2021					CARUANA RJ, 1988, TRANSPLANTATION, V46, P472, DOI 10.1097/00007890-198809000-00034; COOPER DKC, 1990, J HEART TRANSPLANT, V9, P376; Mohacsi P, 2001, TRANSPLANTATION, V72, P1328, DOI 10.1097/00007890-200110150-00026; ULFVIN A, 1993, KIDNEY INT, V44, P1289, DOI 10.1038/ki.1993.381; West L. J., 2001, Journal of Heart and Lung Transplantation, V20, P222, DOI 10.1016/S1053-2498(00)00488-5	5	30	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2004	363	9420					1523	1525		10.1016/S0140-6736(04)16179-5	http://dx.doi.org/10.1016/S0140-6736(04)16179-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135601				2022-12-28	WOS:000221302700013
J	Weiss, KM				Weiss, KM			The unkindest cup	LANCET			English	Editorial Material							LACTASE PERSISTENCE		Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Weiss, KM (corresponding author), Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA.	kmw4@psu.edu						Beja-Pereira A, 2003, NAT GENET, V35, P311, DOI 10.1038/ng1263; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; Durham WH., 1991, COEVOLUTION GENES CU; Enattah NS, 2002, NAT GENET, V30, P233, DOI 10.1038/ng826; Hollox EJ, 2001, AM J HUM GENET, V68, P160, DOI 10.1086/316924; Kittles RA, 2003, ANNU REV GENOM HUM G, V4, P33, DOI 10.1146/annurev.genom.4.070802.110356; Olds LC, 2003, HUM MOL GENET, V12, P2333, DOI 10.1093/hmg/ddg244; Risch N., 2002, GENOME BIOL, V3, pcomm, DOI [10.1186/gb-2002-3-7-comment2007, 10.1186/GB-2002-3-7-COMMENT2007]; Swallow DM, 2003, ANNU REV GENET, V37, P197, DOI 10.1146/annurev.genet.37.110801.143820; Troelsen JT, 2003, GASTROENTEROLOGY, V125, P1686, DOI 10.1053/j.gastro.2003.09.031	10	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	2004	363	9420					1489	1490		10.1016/S0140-6736(04)16195-3	http://dx.doi.org/10.1016/S0140-6736(04)16195-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135593				2022-12-28	WOS:000221302700005
J	Muenzer, J; Fisher, A				Muenzer, J; Fisher, A			Advances in the treatment of mucopolysaccharidosis type I	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ N Carolina, Dept Pediat, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill	Muenzer, J (corresponding author), Univ N Carolina, Dept Pediat, Chapel Hill, NC 27514 USA.							FRATANTONI JC, 1968, SCIENCE, V162, P570, DOI 10.1126/science.162.3853.570; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165	3	46	60	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1932	1934		10.1056/NEJMp048084	http://dx.doi.org/10.1056/NEJMp048084			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128891				2022-12-28	WOS:000221218800003
J	Beck, AH				Beck, AH			The flexner report and the standardization of American medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FLEXNER,ABRAHAM; PHYSICIANS		Brown Med Sch, Providence, RI 02912 USA	Brown University	Beck, AH (corresponding author), Brown Med Sch, Providence, RI 02912 USA.							BILLINGS JS, 1891, SCIENCE, V18, P1; Bonner TN, 1998, ACAD MED, V73, P160, DOI 10.1097/00001888-199802000-00014; *COUNC MED ED AM M, 1905, JAMA-J AM MED ASSOC, V44, P1470; Flexner A., 1910, FLEXNER REPORT; FOX DM, 1980, B HIST MED, V54, P475; Hotez PJ, 2003, AM J MED SCI, V325, P10, DOI 10.1097/00000441-200301000-00003; Hudson R P, 1972, Bull Hist Med, V46, P545; KING LS, 1984, JAMA-J AM MED ASSOC, V251, P1079, DOI 10.1001/jama.251.8.1079; Kuttner R, 1999, NEW ENGL J MED, V341, P1092, DOI 10.1056/NEJM199909303411421; Ludmerer KM, 1999, TIME HEAL; LUDMERER KM, 1985, LEARNINGS HEAL; Markowitz G.E., 1973, AM Q, V25, P83, DOI DOI 10.2307/2711558; Mechanic R, 1998, JAMA-J AM MED ASSOC, V280, P1015, DOI 10.1001/jama.280.11.1015; Rabinowitz HK, 1999, JAMA-J AM MED ASSOC, V281, P255, DOI 10.1001/jama.281.3.255; Reede JY, 2003, HEALTH AFFAIR, V22, P91, DOI 10.1377/hlthaff.22.4.91; Rothstein William G., 1972, AM PHYS 19 CENTURY S; Savitt Todd, 1992, FLEXNER MED ED 20 CE, P65; SHRYOCK RH, 1963, MED LICENSING AM 165; Starr P, 1982, SOCIAL TRANSFORMATIO; Wheatly S.C., 1988, POLITICS PHILANTHROP; 1901, JAMA, V37, P775	21	128	132	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2004	291	17					2139	2140		10.1001/jama.291.17.2139	http://dx.doi.org/10.1001/jama.291.17.2139			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JR	15126445				2022-12-28	WOS:000221174300034
J	Compton, WM; Grant, BF; Colliver, JD; Glantz, MD; Stinson, FS				Compton, WM; Grant, BF; Colliver, JD; Glantz, MD; Stinson, FS			Prevalence of marijuana use disorders in the United States - 1991-1992 and 2001-2002	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL-USE DISORDER; INTERVIEW SCHEDULE AUDADIS; DSM-III-R; DRUG-USE; PSYCHIATRIC-DISORDERS; ICD-10 ALCOHOL; SUBSTANCE USE; RELIABILITY; DISABILITIES; IV	Context Among illicit substance use disorders, marijuana use disorders are the most prevalent in the population. Yet, information about the prevalence of current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) marijuana use disorders and how prevalence has changed is lacking. Objective To examine changes in the prevalence of marijuana use, abuse, and dependence in the United States between 1991-1992 and 2001-2002. Design, Setting, and Participants Face-to-face interviews were conducted in 2 large national surveys conducted 10 years apart: the 1991-1992 National Longitudinal Alcohol Epidemiologic Survey ([NLAES] n=42862) and the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions ([NESARC] n =43 093). Main Outcome Measures Rates of past year marijuana use, abuse, and dependence. Results Among the adult US population, the prevalence of marijuana use remained stable at about 4.0% over the past decade. In contrast, the prevalence of DSM-IV marijuana abuse or dependence significantly (P=.01) increased between 1991-1992 (1.2%) and 2001-2002 (1.5%), with the greatest increases observed among young black men and women (P<.001) and young Hispanic men (P=.006). Further, marijuana use disorders among marijuana users significantly increased (P=.002) in the absence of increased frequency and quantity of marijuana use, suggesting that the concomitant increase in potency of delta-9-tetrahydrocannabinol (Delta(9)-THC) may have contributed to the rising rates. Conclusions Despite the stability in the overall prevalence of marijuana use, more adults in the United States had a marijuana use disorder in 2001-2002 than in 1991-1992. Increases in the prevalence of marijuana use disorders were most notable among young black men and women and young Hispanic men. Although rates of marijuana abuse and dependence did not increase among young white men and women, their rates have remained high. The results of this study underscore the need to develop and implement new prevention and intervention programs targeted at youth, particularly minority youth.	NIDA, Div Epidemiol Serv & Prevent Res, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; NIAAA, Lab Epidemiol & Biometry, Div Intramural Clin & Biol Res, NIH,Dept Hlth & Human Serv, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Compton, WM (corresponding author), NIDA, Div Epidemiol Serv & Prevent Res, NIH, Dept Hlth & Human Serv, 6001 Execut Blvd,MSC 9589, Bethesda, MD 20892 USA.	wcompton@nida.nih.gov	Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213	CLINICAL CENTER [ZIACL060060, Z01CL060060] Funding Source: NIH RePORTER	CLINICAL CENTER		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; American Psychiatric Association, 1991, DSM 4 OPT BOOK; ANTHONY JC, 1995, DRUG ALCOHOL DEPEN, V40, P9, DOI 10.1016/0376-8716(95)01194-3; Bachman JG, 1998, AM J PUBLIC HEALTH, V88, P887, DOI 10.2105/AJPH.88.6.887; Brook JS, 1998, J AM ACAD CHILD PSY, V37, P322, DOI 10.1097/00004583-199803000-00018; Brook JS, 2002, PSYCHOL MED, V32, P79, DOI 10.1017/S0033291701004809; Budney AJ, 1999, ADDICTION, V94, P1311, DOI 10.1046/j.1360-0443.1999.94913114.x; Budney AJ, 2001, ARCH GEN PSYCHIAT, V58, P917, DOI 10.1001/archpsyc.58.10.917; Canino G, 1999, J STUD ALCOHOL, V60, P790, DOI 10.15288/jsa.1999.60.790; Chatterji S, 1997, DRUG ALCOHOL DEPEN, V47, P171, DOI 10.1016/S0376-8716(97)00088-4; Chen CY, 2002, SOC PSYCH PSYCH EPID, V37, P199, DOI 10.1007/s00127-002-0541-z; Cottler LB, 1997, DRUG ALCOHOL DEPEN, V47, P195, DOI 10.1016/S0376-8716(97)00090-2; DiNardo J, 2001, J HEALTH ECON, V20, P991, DOI 10.1016/S0167-6296(01)00102-3; ElSohly MA, 2000, J FORENSIC SCI, V45, P24; Gledhill-Hoyt J, 2000, ADDICTION, V95, P1655, DOI 10.1046/j.1360-0443.2000.951116556.x; Grant B., 2001, ALCOHOL USE DISORDER; Grant B F, 1995, J Subst Abuse, V7, P481, DOI 10.1016/0899-3289(95)90017-9; Grant BF, 1998, J SUBST ABUSE, V10, P163, DOI 10.1016/S0899-3289(99)80131-X; Grant BF, 2003, DRUG ALCOHOL DEPEN, V71, P7, DOI 10.1016/S0376-8716(03)00070-X; Grant BF, 1996, J SUBST ABUSE, V8, P195, DOI 10.1016/S0899-3289(96)90249-7; Grant BF, 1996, ALCOHOL CLIN EXP RES, V20, P1481, DOI 10.1111/j.1530-0277.1996.tb01152.x; GRANT BF, 1995, DRUG ALCOHOL DEPEN, V39, P37, DOI 10.1016/0376-8716(95)01134-K; Grant BF, 2003, SOURCE ACCURACY STAT; Grant BF, 1992, ALCOHOL HEALTH RES W, V18, P243; Hasin D, 1997, DRUG ALCOHOL DEPEN, V47, P217, DOI 10.1016/S0376-8716(97)00092-6; Hasin D, 1997, DRUG ALCOHOL DEPEN, V44, P133, DOI 10.1016/S0376-8716(97)01332-X; Johnston L, 2003, MONITORING FUTURE NA; LEHMAN WEK, 1992, J APPL PSYCHOL, V77, P309, DOI 10.1037/0021-9010.77.3.309; Lynskey M, 2000, ADDICTION, V95, P1621, DOI 10.1046/j.1360-0443.2000.951116213.x; Lynskey MT, 2003, JAMA-J AM MED ASSOC, V289, P427, DOI 10.1001/jama.289.4.427; Mittleman MA, 2001, CIRCULATION, V103, P2805; *NAT CTR DEV NAT P, 2003, Q REP POT MON PROJ M; National Highway Traffic Safety Administration, 2001, TRAFF SAF FACTS 2001; Nelson CB, 1999, ADDICTION, V94, P843, DOI 10.1046/j.1360-0443.1999.9468438.x; Ortega AN, 2000, J NERV MENT DIS, V188, P728, DOI 10.1097/00005053-200011000-00002; POLEN MR, 1993, WESTERN J MED, V158, P596; Pull CB, 1997, DRUG ALCOHOL DEPEN, V47, P207, DOI 10.1016/S0376-8716(97)00091-4; Research Triangle Institute, 2002, SOFTW SURV DAT AN SU; *SUBST AB MENT HLT, 2002, NHSDA SER H, V17; TASHKIN DP, 1990, WESTERN J MED, V152, P525; *US DEP ED, 2001, 2001 FALL ENR COLL U; Ustun B, 1997, DRUG ALCOHOL DEPEN, V47, P161, DOI 10.1016/S0376-8716(97)00087-2; Vega WA, 1998, ARCH GEN PSYCHIAT, V55, P771, DOI 10.1001/archpsyc.55.9.771; Vrasti R, 1998, EUR ADDICT RES, V4, P144, DOI 10.1159/000018947; Zhang ZF, 1999, CANCER EPIDEM BIOMAR, V8, P1071	45	445	449	0	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2004	291	17					2114	2121		10.1001/jama.291.17.2114	http://dx.doi.org/10.1001/jama.291.17.2114			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	817JR	15126440				2022-12-28	WOS:000221174300029
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Services Task	Lung cancer screening: Recommendation statement	ANNALS OF INTERNAL MEDICINE			English	Article								This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendation on screening for lung cancer and the supporting scientific evidence and updates the 1996 recommendations on this topic. In 1996, the USPSTF recommended against screening for lung cancer (a grade D recommendation). The Task Force now uses an explicit process in which the balance of benefits and harms is determined exclusively by the quality and magnitude of the evidence. As a result, current letter grades are based on different criteria than those used in 1996. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the systematic evidence review on this topic, available through the USPSTF Web site ( www.preventiveservices.ahrq.gov) and the National Guideline Clearinghouse (www.guideline.gov). The complete USPSTF recommendation statement (which includes a brief review of the supporting evidence) and the summary of the evidence are also available in print through the Agency for Healthcare Research and Quality Publications Clearinghous (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov).	US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA	Agency for Healthcare Research & Quality	Berg, AO (corresponding author), US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA.							*AM AC FAM PHYS, REC PER HLTH EX; Smith RA, 2000, CA-CANCER J CLIN, V50, P34, DOI 10.3322/canjclin.50.1.34	2	74	74	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	2004	140	9					738	739		10.7326/0003-4819-140-9-200405040-00014	http://dx.doi.org/10.7326/0003-4819-140-9-200405040-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816XR	15126258				2022-12-28	WOS:000221143100008
J	Jang, HH; Lee, KO; Chi, YH; Jung, BG; Park, SK; Park, JH; Lee, JR; Lee, SS; Moon, JC; Yun, JW; Choi, YO; Kim, WY; Kang, JS; Cheong, GW; Yun, DJ; Rhee, SG; Cho, MJ; Lee, SY				Jang, HH; Lee, KO; Chi, YH; Jung, BG; Park, SK; Park, JH; Lee, JR; Lee, SS; Moon, JC; Yun, JW; Choi, YO; Kim, WY; Kang, JS; Cheong, GW; Yun, DJ; Rhee, SG; Cho, MJ; Lee, SY			Two enzymes in one: Two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function	CELL			English	Article							CYSTEINE-SULFINIC ACID; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; THIOL PEROXIDASE; 2-CYS PEROXIREDOXIN; PROTEIN; INACTIVATION; PROTEASES; REDUCTASE; DEFENSE	Although a great deal is known biochemically about peroxiredoxins (Prxs), little is known about their real physiological function. We show here that two cytosolic yeast Prxs, cPrxI and II, which display diversity in structure and apparent molecular weights (MW), can act alternatively as peroxidases and molecular chaperones. The peroxidase function predominates in the lower MW forms, whereas the chaperone function predominates in the higher MW complexes. Oxidative stress and heat shock exposure of yeasts causes the protein structures of cPrxI and II to shift from low MW species to high MW complexes. This triggers a peroxidase-to-chaperone functional switch. These in vivo changes are primarily guided by the active peroxidase site residue, Cys(47), which serves as an efficient "H2O2-sensor" in the cells. The chaperone function of these proteins enhances yeast resistance to heat shock.	Gyeongsang Natl Univ, Div Appl Life Sci, Chinju 660701, South Korea; Gyeongsang Natl Univ, Environm Biotechnol Natl Core Res Ctr, Chinju 660701, South Korea; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	Gyeongsang National University; Gyeongsang National University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lee, SY (corresponding author), Gyeongsang Natl Univ, Div Appl Life Sci, Chinju 660701, South Korea.	sylee@gsnu.ac.kr	Cho, Moo Je/F-1649-2010	LEE, JUNG RO/0000-0002-9596-3330; Yun, Dae-Jin/0000-0002-3638-6043				Baier M, 1999, PLANT PHYSIOL, V119, P1407, DOI 10.1104/pp.119.4.1407; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Butterfield DA, 1999, METHOD ENZYMOL, V309, P746; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Cheong NE, 1999, PLANT MOL BIOL, V40, P825, DOI 10.1023/A:1006271823973; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DURR R, 1991, ULTRAMICROSCOPY, V38, P135, DOI 10.1016/0304-3991(91)90114-L; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Georgiou G, 2003, SCIENCE, V300, P592, DOI 10.1126/science.1084976; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERGEL R, 1996, J STRUCT BIOL, V116, P30; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jaschke A, 1998, J MOL BIOL, V277, P763, DOI 10.1006/jmbi.1998.1644; KEM R, 2003, BIOCHEM J, V371, P965; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim KS, 2002, FREE RADICAL BIO MED, V32, P544, DOI 10.1016/S0891-5849(02)00741-4; Manna T, 2001, J BIOL CHEM, V276, P39742, DOI 10.1074/jbc.M104061200; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Ritz D, 2001, SCIENCE, V294, P158, DOI 10.1126/science.1063143; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Schroder E, 1998, PROTEIN SCI, V7, P2465, DOI 10.1002/pro.5560071125; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; Wang CC, 2002, METHOD ENZYMOL, V348, P66, DOI 10.1016/S0076-6879(02)48627-2; Wong CM, 2002, J BIOL CHEM, V277, P5385, DOI 10.1074/jbc.M106846200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	37	590	623	0	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					625	635		10.1016/j.cell.2004.05.002	http://dx.doi.org/10.1016/j.cell.2004.05.002			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163410	Bronze			2022-12-28	WOS:000221857900009
J	Wingreen, NS				Wingreen, NS			Quantum many-body effects in a single-electron transistor	SCIENCE			English	Editorial Material							DOT		Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Wingreen, NS (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	wingreen@molbio.princeton.edu						Cronenwett SM, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.226805; Elzerman JM, 2000, J LOW TEMP PHYS, V118, P375, DOI 10.1023/A:1004694017738; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; Kogan A, 2004, SCIENCE, V304, P1293, DOI 10.1126/science.1096377; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; Nygard J, 2000, NATURE, V408, P342, DOI 10.1038/35042545; Sasaki S, 2000, NATURE, V405, P764, DOI 10.1038/35015509; van der Wiel WG, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.126803	8	0	0	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	2004	304	5675					1258	1259		10.1126/science.1098302	http://dx.doi.org/10.1126/science.1098302			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166353				2022-12-28	WOS:000221669600027
J	Strausberg, RL; Simpson, AJG; Old, LJ; Riggins, GJ				Strausberg, RL; Simpson, AJG; Old, LJ; Riggins, GJ			Oncogenomics and the development of new cancer therapies	NATURE			English	Review							EXPRESSION-BASED CLASSIFICATION; FULL-LENGTH HUMAN; GENE-EXPRESSION; TRANSCRIPTION FACTOR; IMATINIB MESYLATE; LUNG-CANCER; PHASE-I; DISCOVERY; SEQUENCE; IDENTIFICATION	Scientists have sequenced the human genome and identified most of its genes. Now it is time to use these genomic data, and the high-throughput technology developed to generate them, to tackle major health problems such as cancer. To accelerate our understanding of this disease and to produce targeted therapies, further basic mutational and functional genomic information is required. A systematic and coordinated approach, with the results freely available, should speed up progress. This will best be accomplished through an international academic and pharmaceutical oncogenomics initiative.	Inst Genom Res, Dept Mammalian Genom, Rockville, MD 20850 USA; Ludwig Inst Canc Res, New York, NY 10158 USA; Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21224 USA	J. Craig Venter Institute; Ludwig Institute for Cancer Research; Johns Hopkins University	Strausberg, RL (corresponding author), Inst Genom Res, Dept Mammalian Genom, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	RLS@tigr.org	Simpson, Amelia/HGB-1823-2022					Albanell J, 2003, ADV EXP MED BIOL, V532, P253; Atanackovic D, 2004, J IMMUNOL, V172, P3289, DOI 10.4049/jimmunol.172.5.3289; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bera TK, 2004, P NATL ACAD SCI USA, V101, P3059, DOI 10.1073/pnas.0308746101; Beroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187; Blackledge G, 2004, BRIT J CANCER, V90, P566, DOI 10.1038/sj.bjc.6601550; Brekke OH, 2003, CURR OPIN PHARMACOL, V3, P544, DOI 10.1016/j.coph.2003.05.002; Brentani H, 2003, P NATL ACAD SCI USA, V100, P13418, DOI 10.1073/pnas.1233632100; Brizuela L, 2002, ARCH MED RES, V33, P318, DOI 10.1016/S0188-4409(02)00372-7; Buckhaults P, 2003, CANCER RES, V63, P4144; Cockerill G. Stuart, 2002, Current Topics in Medicinal Chemistry, V2, P1001, DOI 10.2174/1568026023393309; Coiffier B, 2003, SEMIN ONCOL, V30, P21, DOI 10.1053/sonc.2003.50021; Collins FS, 2003, SCIENCE, V300, P286, DOI 10.1126/science.1084564; Cottrell SE, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh008; Cowell JK, 2003, ADV CANCER RES, V90, P91, DOI 10.1016/S0065-230X(03)90003-0; Damle NK, 2003, CURR OPIN PHARMACOL, V3, P386, DOI 10.1016/S1471-4892(03)00083-3; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demetri GD, 2002, HEMATOL ONCOL CLIN N, V16, P1115, DOI 10.1016/S0889-8588(02)00052-7; Drevs J, 2003, CURR DRUG TARGETS, V4, P113, DOI 10.2174/1389450033346885; Druker BJ, 2003, EXPERT OPIN PHARMACO, V4, P963, DOI 10.1517/14656566.4.6.963; Druker BJ, 2003, SEMIN HEMATOL, V40, P50, DOI 10.1053/shem.2003.50000; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Durrant L G, 2003, Expert Opin Emerg Drugs, V8, P489, DOI 10.1517/eoed.8.2.489.21127; Duyk G, 2003, SCIENCE, V302, P603, DOI 10.1126/science.1090521; Dyrskjot L, 2003, NAT GENET, V33, P90, DOI 10.1038/ng1061; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; ENGLAND KA, 2003, P NATL ACAD SCI USA, V100, P1099; Fischer OM, 2003, CURR OPIN CHEM BIOL, V7, P490, DOI 10.1016/S1367-5931(03)00082-6; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; *GIST SU 11248 STU, 2003, P AN M AM SOC CLIN, V22, P814; Greshock J, 2004, GENOME RES, V14, P179; Hilgenfeld Eva, 2002, Methods Mol Med, V68, P29; IONGENEEL CV, 2003, P NATL ACAD SCI USA, V100, P4702; Jager D, 2001, CANCER RES, V61, P2055; Jager E, 2000, P NATL ACAD SCI USA, V97, P12198, DOI 10.1073/pnas.220413497; Jager E, 2003, INT J CANCER, V106, P817, DOI 10.1002/ijc.11292; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Joensuu H, 2002, LANCET ONCOL, V3, P655, DOI 10.1016/S1470-2045(02)00899-9; Joensuu H, 2001, ANN MED, V33, P451, DOI 10.3109/07853890109002093; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Kim JA, 2003, AM J SURG, V186, P264, DOI 10.1016/S0002-9610(03)00212-5; Koehler AN, 2003, J AM CHEM SOC, V125, P8420, DOI 10.1021/ja0352698; Kretzschmar T, 2002, CURR OPIN BIOTECH, V13, P598, DOI 10.1016/S0958-1669(02)00380-4; Kriventseva EV, 2003, TRENDS GENET, V19, P124, DOI 10.1016/S0168-9525(03)00023-4; Lal A, 1999, CANCER RES, V59, P5403; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502; Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003; McCormick F, 2003, CANCER BIOL THER, V2, pS157; McNeish IA, 2004, GENE THER, V11, P497, DOI 10.1038/sj.gt.3302238; MILENIC DE, 2004, CANC BIOL THER, V3; Moon C, 2003, CLIN CANCER RES, V9, P5055; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; Nutt CL, 2003, CANCER RES, V63, P1602; Old L J, 2001, Cancer Immun, V1, P1; Olsson P, 2003, PROSTATE, V56, P123, DOI 10.1002/pros.10185; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Popescu Nicholas C., 2000, J Cell Mol Med, V4, P151, DOI 10.1111/j.1582-4934.2000.tb00113.x; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rapisarda A, 2002, CANCER RES, V62, P4316; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; Salgaller ML, 2003, CURR OPIN MOL THER, V5, P657; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sausville EA, 2003, ANNU REV PHARMACOL, V43, P199, DOI 10.1146/annurev.pharmtox.43.100901.135813; Scanlan Matthew J, 2004, Cancer Immun, V4, P1; Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x; Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276; Schadt EE, 2003, BIOCHEM SOC T, V31, P437, DOI 10.1042/BST0310437; Scott AM, 2003, CLIN CANCER RES, V9, P1639; Scott AM, 2001, J CLIN ONCOL, V19, P3976, DOI 10.1200/JCO.2001.19.19.3976; SMITH JE, 2001, ANTICANCER DRUGS S, V4, pS3; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Strausberg R. L., 2002, Pharmacogenomics Journal, V2, P156, DOI 10.1038/sj.tpj.6500103; Strausberg RL, 2003, NAT REV GENET, V4, P409, DOI 10.1038/nrg1085; Strausberg RL, 2003, SCIENCE, V300, P294, DOI 10.1126/science.1083395; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tipping AJ, 2003, SEMIN HEMATOL, V40, P83, DOI 10.1053/shem.2003.50047; Tong A W, 2001, Clin Lung Cancer, V2, P220, DOI 10.3816/CLC.2001.n.007; Torrance CJ, 2001, NAT BIOTECHNOL, V19, P940, DOI 10.1038/nbt1001-940; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van 't Veer LJ, 2003, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vogelstein B., 2002, GENETIC BASIS HUMAN; Volik S, 2003, P NATL ACAD SCI USA, V100, P7696, DOI 10.1073/pnas.1232418100; Wang TL, 2002, P NATL ACAD SCI USA, V99, P16156, DOI 10.1073/pnas.202610899; Wang ZN, 2003, CANCER RES, V63, P655; Wannesson L, 2003, CLIN LYMPHOMA, V4, pS5, DOI 10.3816/CLM.2003.s.002; Welt S, 2003, CLIN CANCER RES, V9, P1338; Wilhelm S, 2002, CURR PHARM DESIGN, V8, P2255, DOI 10.2174/1381612023393026; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867; 王志强, 1989, Acta Mathematica Sinica. New Series, V5, P101	97	61	64	0	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					469	474		10.1038/nature02627	http://dx.doi.org/10.1038/nature02627			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164073				2022-12-28	WOS:000221644600050
J	Watanabe, H; Fujiyama, A; Hattori, M; Taylor, TD; Toyoda, A; Kuroki, Y; Noguchi, H; BenKahla, A; Lehrach, H; Sudbrak, R; Kube, M; Taenzer, S; Galgoczy, P; Platzer, M; Scharfe, M; Nordsiek, G; Blocker, HB; Hellmann, I; Khaitovich, P; Paabo, S; Reinhardt, R; Zheng, HJ; Zhang, XL; Zhu, GF; Wang, BF; Fu, G; Ren, SX; Zhao, GP; Chen, Z; Lee, YS; Cheong, JE; Choi, SH; Wu, KM; Liu, TT; Hsiao, KJ; Tsai, SF; Kim, CG; Oota, S; Kitano, T; Kohara, Y; Saitou, N; Park, HS; Wang, SY; Yaspo, ML; Sakaki, Y				Watanabe, H; Fujiyama, A; Hattori, M; Taylor, TD; Toyoda, A; Kuroki, Y; Noguchi, H; BenKahla, A; Lehrach, H; Sudbrak, R; Kube, M; Taenzer, S; Galgoczy, P; Platzer, M; Scharfe, M; Nordsiek, G; Blocker, HB; Hellmann, I; Khaitovich, P; Paabo, S; Reinhardt, R; Zheng, HJ; Zhang, XL; Zhu, GF; Wang, BF; Fu, G; Ren, SX; Zhao, GP; Chen, Z; Lee, YS; Cheong, JE; Choi, SH; Wu, KM; Liu, TT; Hsiao, KJ; Tsai, SF; Kim, CG; Oota, S; Kitano, T; Kohara, Y; Saitou, N; Park, HS; Wang, SY; Yaspo, ML; Sakaki, Y		Int Chimpanzee Chromosome 22 Consort	DNA sequence and comparative analysis of chimpanzee chromosome 22	NATURE			English	Article							HUMAN ALU REPEATS; HUMAN-EVOLUTION; HUMAN GENOME; GENES; HUMAN-CHROMOSOME-21; DIVERGENCE; HUMANS; ELEMENTS; MOUSE; SUBSTITUTION	Human-chimpanzee comparative genome research is essential for narrowing down genetic changes involved in the acquisition of unique human features, such as highly developed cognitive functions, bipedalism or the use of complex language. Here, we report the high-quality DNA sequence of 33.3 megabases of chimpanzee chromosome 22. By comparing the whole sequence with the human counterpart, chromosome 21, we found that 1.44% of the chromosome consists of single-base substitutions in addition to nearly 68,000 insertions or deletions. These differences are sufficient to generate changes in most of the proteins. Indeed, 83% of the 231 coding sequences, including functionally important genes, show differences at the amino acid sequence level. Furthermore, we demonstrate different expansion of particular subfamilies of retrotransposons between the lineages, suggesting different impacts of retrotranspositions on human and chimpanzee evolution. The genomic changes after speciation and their biological consequences seem more complex than originally hypothesized.	RIKEN, Gen Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Nara Inst Sci & Technol, Ikoma 6300101, Japan; Natl Inst Informat, Tokyo 1018430, Japan; Kitasato Univ, Sagamihara, Kanagawa 2288555, Japan; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany; German Res Ctr Biotechnol GBF, D-38124 Braunschweig, Germany; Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany; Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China; Rui Jin Hosp, State Key Lab Med Gen, Shanghai 200025, Peoples R China; Korea Res Inst Basic & Biotechnol, Genome Res Ctr, Taejon 305333, South Korea; Natl Hlth Res Inst, Taipei 115, Taiwan; Natl Yang Ming Univ, Taipei 112, Taiwan; Taipei Vet Gen Hosp, Taipei 112, Taiwan; Natl Inst Genet, Mishima, Shizuoka 4118540, Japan	RIKEN; Nara Institute of Science & Technology; Research Organization of Information & Systems (ROIS); National Institute of Informatics (NII) - Japan; Kitasato University; Max Planck Society; Helmholtz Association; Helmholtz-Center for Infection Research; Max Planck Society; National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Sakaki, Y (corresponding author), RIKEN, Gen Sci Ctr, Yokohama, Kanagawa 2300045, Japan.	sakaki@gsc.riken.jp	Hattori, Masahira/AAD-3785-2019; Taylor, Todd/A-7121-2009; Khaitovich, Philipp/HGC-8520-2022; Tsai, Shih-Feng/E-3997-2010; LEE, YONGSEOK/AAF-3965-2020; Hattori, Masahira/C-6958-2016; Sudbrak, Ralf/HHZ-8821-2022	Taylor, Todd/0000-0003-4247-6253; Hattori, Masahira/0000-0001-9467-0344; Benkahla, Alia/0000-0001-9988-3250; Lee, Yongseok/0000-0002-8687-589X				Bailey JA, 2002, AM J HUM GENET, V70, P83, DOI 10.1086/338458; BATZER MA, 1995, J MOL BIOL, V247, P418, DOI 10.1006/jmbi.1994.0150; BATZER MA, 1991, GENOMICS, V9, P481, DOI 10.1016/0888-7543(91)90414-A; Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; Britten RJ, 2002, P NATL ACAD SCI USA, V99, P13633, DOI 10.1073/pnas.172510699; Brosius J, 1999, GENE, V238, P115, DOI 10.1016/S0378-1119(99)00227-9; Chou HH, 2002, P NATL ACAD SCI USA, V99, P11736, DOI 10.1073/pnas.182257399; Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Dayhoff M.O., 1978, MODEL EVOLUTIONARY C; Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402; Ebersberger I, 2002, AM J HUM GENET, V70, P1490, DOI 10.1086/340787; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fay JC, 2000, GENETICS, V155, P1405; Frazer KA, 2003, GENOME RES, V13, P341, DOI 10.1101/gr.554603; Frazer KA, 2001, GENOME RES, V11, P1651, DOI 10.1101/gr.198201; Fujiyama A, 2002, SCIENCE, V295, P131, DOI 10.1126/science.1065199; GOJOBORI T, 1982, J MOL EVOL, V18, P360, DOI 10.1007/BF01733904; Hacia JG, 1998, NAT GENET, V18, P155, DOI 10.1038/ng0298-155; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Hellmann I, 2003, GENOME RES, V13, P831, DOI 10.1101/gr.944903; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEEFLANG EP, 1993, J MOL EVOL, V37, P566; Liu G, 2003, GENOME RES, V13, P358, DOI 10.1101/gr.923303; MCCLURE HM, 1969, SCIENCE, V165, P1010, DOI 10.1126/science.165.3897.1010; Myers JS, 2002, AM J HUM GENET, V71, P312, DOI 10.1086/341718; Nickerson E, 1998, GENOMICS, V50, P368, DOI 10.1006/geno.1998.5332; Olson MV, 2003, NAT REV GENET, V4, P20, DOI 10.1038/nrg981; Orti R, 1998, CYTOGENET CELL GENET, V83, P262, DOI 10.1159/000015201; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; Roy AM, 1999, GENETICA, V107, P149, DOI 10.1023/A:1003941704138; Roy AM, 2000, GENOME RES, V10, P1485, DOI 10.1101/gr.152300; Roy-Engel AM, 2002, J MOL BIOL, V316, P1033, DOI 10.1006/jmbi.2001.5380; SAWADA I, 1985, J MOL EVOL, V22, P316, DOI 10.1007/BF02115687; Shi JX, 2003, P NATL ACAD SCI USA, V100, P8331, DOI 10.1073/pnas.1332748100; Suzuki OT, 2002, AM J HUM GENET, V71, P1320, DOI 10.1086/344695; TAJIMA F, 1982, J MOL EVOL, V18, P115, DOI 10.1007/BF01810830; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Varki A, 2000, GENOME RES, V10, P1065, DOI 10.1101/gr.10.8.1065; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; ZIETKIEWICZ E, 1994, NUCLEIC ACIDS RES, V22, P5608, DOI 10.1093/nar/22.25.5608; 2002, NATURE, V420, P586	46	169	183	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	2004	429	6990					382	388		10.1038/nature02564	http://dx.doi.org/10.1038/nature02564			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164055	Bronze			2022-12-28	WOS:000221644600031
J	Chan, AW; Hrobjartsson, A; Haahr, MT; Gotzsche, PC; Altman, DG				Chan, AW; Hrobjartsson, A; Haahr, MT; Gotzsche, PC; Altman, DG			Empirical evidence for selective reporting of outcomes in randomized trials - Comparison of Protocols to published articles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-TRIALS; BIAS; METAANALYSIS; JOURNALS	Context Selective reporting of outcomes within published studies based on the nature or direction of their results has been widely suspected, but direct evidence of such bias is currently limited to case reports. Objective To study empirically the extent and nature of outcome reporting bias in a cohort of randomized trials. Design Cohort study using protocols and published reports of randomized trials approved by the Scientific-Ethical Committees for Copenhagen and Frederiksberg, Denmark, in 1994-1995. The number and characteristics of reported and unreported trial outcomes were recorded from protocols, journal articles, and a survey of trialists. An outcome was considered incompletely reported if insufficient data were presented in the published articles for meta-analysis. Odds ratios relating the completeness of outcome reporting to statistical significance were calculated for each trial and then pooled to provide an overall estimate of bias. Protocols an published articles were also compared to identify discrepancies in primary outcomes. Main Outcome Measures Completeness of reporting of efficacy and harm outcomes and of statistically significant vs nonsignificant outcomes; consistency between primary outcomes defined in the most recent protocols and those defined in published articles. Results One hundred two trials with 122 published journal articles and 3736 outcomes were identified. Overall, 50% of efficacy and 65% of harm outcomes per trial were incompletely reported. Statistically significant outcomes had a higher odds of being fully reported compared with nonsignificant outcomes for both efficacy (pooled odds ratio, 2.4; 95% confidence interval [CI], 1.4-4.0) and harm (pooled odds ratio, 4.7; 95% Cl,1.8-12.0) data. In comparing published articles with protocols, 62% of trials had at least 1 primary outcome that was changed, introduced, or omitted. Eighty-six percent of survey responders (42/49) denied the existence of unreported outcomes despite clear evidence to the contrary. Conclusions The reporting of trial outcomes is not only frequently incomplete but also biased and inconsistent with protocols. Published articles, as well as reviews that incorporate them, may therefore be unreliable and overestimate the benefits of an intervention. To ensure transparency, planned trials should be registered and protocols should be made publicly available prior to trial completion.	Inst Hlth Sci, Ctr Stat Med, Oxford OX3 7LF, England; Nord Cochrane Ctr, Copenhagen, Denmark; Univ Toronto, Univ Hlth Network, Toronto, ON, Canada	University of Oxford; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Chan, AW (corresponding author), Inst Hlth Sci, Ctr Stat Med, Old Rd, Oxford OX3 7LF, England.	anwen.chan@utoronto.ca						Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 1998, INT C HARM TECHN REQ; BUNN F, 2002, COCHRANE REV CD ROM; Chalmers I, 1999, LANCET, V353, P490, DOI 10.1016/S0140-6736(98)07618-1; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; Deeks J.J., 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; Dickersin K, 1997, AIDS EDUC PREV, V9, P15; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P140, DOI 10.1002/art.1780330119; FELSON DT, 1992, J CLIN EPIDEMIOL, V45, P885, DOI 10.1016/0895-4356(92)90072-U; Godlee F, 2001, BMC NEWS VIEWS, V2; Goldbeck-Wood S, 2001, BRIT MED J, V322, P1460; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Hahn S, 2002, J EVAL CLIN PRACT, V8, P353, DOI 10.1046/j.1365-2753.2002.00314.x; Hahn S, 2000, STAT MED, V19, P3325, DOI 10.1002/1097-0258(20001230)19:24<3325::AID-SIM827>3.0.CO;2-D; Hawkey CJ, 2001, BRIT MED J, V323, P1309, DOI 10.1136/bmj.323.7324.1309; HEMMINKI E, 1980, BRIT MED J, V280, P833, DOI 10.1136/bmj.280.6217.833; Higgins Julian, 2002, J Health Serv Res Policy, V7, P51, DOI 10.1258/1355819021927674; Lassere M, 2002, LANCET, V360, P1620, DOI 10.1016/S0140-6736(02)11652-7; Lynch CA, 2003, PORTAL-LIBR ACAD, V3, P327, DOI 10.1353/pla.2003.0039; MCCORMACK K, 2001, 9 INT COCHR C OCT 9; Melander H, 2003, BMJ-BRIT MED J, V326, P1171, DOI 10.1136/bmj.326.7400.1171; MILLS JL, 1993, NEW ENGL J MED, V329, P1196, DOI 10.1056/NEJM199310143291613; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Murray GD, 2001, BRIT MED J, V322, P1461; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; SIEGEL JP, 1990, NEW ENGL J MED, V323, P1355; Silagy CA, 2002, JAMA-J AM MED ASSOC, V287, P2831, DOI 10.1001/jama.287.21.2831; Smith GD, 1998, BMJ-BRIT MED J, V316, P221; Soares HP, 2004, BRIT MED J, V328, P22, DOI 10.1136/bmj.328.7430.22; Song, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/HTA4100; Tannock IF, 1996, J NATL CANCER I, V88, P206, DOI 10.1093/jnci/88.3-4.206; WEST RR, 1997, P 2 INT C SCI BAS HL; WHITEHEAD A, 2002, METAANALYSIS CONTROL, P216; Williamson PR, 2000, J EVAL CLIN PRACT, V6, P205, DOI 10.1046/j.1365-2753.2000.00236.x	34	1244	1267	0	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2004	291	20					2457	2465		10.1001/jama.291.20.2457	http://dx.doi.org/10.1001/jama.291.20.2457			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823HB	15161896	Bronze			2022-12-28	WOS:000221599700028
J	Piccirillo, JF; Tierney, RM; Costas, I; Grove, L; Spitznagel, EL				Piccirillo, JF; Tierney, RM; Costas, I; Grove, L; Spitznagel, EL			Prognostic importance of Comorbidity in a hospital-based cancer registry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CO-MORBIDITY; SURVIVAL; IMPACT; DISEASE; AGE; CLASSIFICATION; CARCINOMA; INDEX; WOMEN; RISK	Context Patients with cancer often have other medical ailments, referred to as comorbidity. Comorbidity may impact treatment decision-making, prognosis, and quality of care assessment. Objective To assess whether comorbidity information can provide important prognostic information in a hospital-based cancer registry. Design, Setting, and Participants An observational prospective cohort study using comorbidity data collected by trained hospital-based cancer registrars. Comorbidity was obtained through medical record review using the Adult Comorbidity Evaluation 27, a validated chart-based comorbidity instrument. A total of 17712 patients receiving care between January 1, 1995, and January 31, 2001, for the primary diagnosis of new cancer of the prostate, lung (nonsmall cell), breast, digestive system, gynecological, urinary system, or head and neck were included. Main Outcome Measure Duration in months of overall survival. Results A total of 19268 patients were included in the study; median duration of follow-up was 31 months. Of these patients, 1556 (8.0%) were excluded due to missing or unknown data. Severity of comorbidity strongly influenced survival in a dose-dependent fashion and the impact of comorbidity was independent of cancer stage. Compared with patients without comorbidity, the adjusted hazard ratio associated with mild comorbidity was 1.21 (95% confidence interval [Cl], 1.13-1.30), moderate comorbidity was 1.86 (95% Cl, 1.73-2.00), and severe comorbidity was 2.56 (95% Cl, 2.35-2.81). Adjusted Kaplan-Meier survival curves revealed that at any point in time the patients with more severe levels of comorbidity had worse survival (partial chi(3)(2) due to comorbidity, 523.54; P<.001). Model discrimination ranged from 0.71 for head and neck to 0.86 for prostate cancers. Conclusions Comorbidity is an important independent prognostic factor for patients with cancer. The inclusion of comorbidity in hospital-based cancer registries will increase the value and use of observational research.	Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA; Washington Univ, Barnes Jewish Hosp, Oncol Data Serv, St Louis, MO USA; Washington Univ, Siteman Canc Ctr, St Louis, MO USA; Washington Univ, Dept Math, St Louis, MO 63130 USA	Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL)	Piccirillo, JF (corresponding author), Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Campus Box 8115,660 S Euclid Ave, St Louis, MO 63110 USA.	piccirij@msnotes.wustl.edu			NCI NIH HHS [R25CA68304-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA068304] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen PC, 1996, J UROLOGY, V156, P127, DOI 10.1016/S0022-5347(01)65964-0; *CANC DAT PROJ, PIL LESS LEARN REP; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; *COMM CANC, 1999, REG OP DAT STAND ROA, V2; Committee to Advise on Tropical Medicine and Travel, 2003, SECT ON CAS EL CANC, P1; CONCATO J, 1990, T ASSOC AM PHYSICIAN, V103, P90; Desch CE, 1996, MED CARE, V34, P152, DOI 10.1097/00005650-199602000-00007; DesHarnais S, 2000, J AM COLL SURGEONS, V11, P2; DiSilvestro P, 1997, J CLIN EPIDEMIOL, V50, P501, DOI 10.1016/S0895-4356(97)00002-4; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Extermann M, 2000, CRIT REV ONCOL HEMAT, V35, P181, DOI 10.1016/S1040-8428(00)00090-1; FEINSTEIN AR, 1970, J CHRON DIS, V23, P455, DOI 10.1016/0021-9681(70)90054-8; Fleming ST, 1999, MED CARE, V37, P601, DOI 10.1097/00005650-199906000-00009; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; Hall SF, 2000, HEAD NECK-J SCI SPEC, V22, P317, DOI 10.1002/1097-0347(200007)22:4<317::AID-HED1>3.0.CO;2-0; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Iezzoni L I, 1994, Am J Med Qual, V9, P43, DOI 10.1177/0885713X9400900202; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; Iezzoni LI, 2012, RISK ADJUSTMENT MEAS, V4th; KAPLAN MH, 1974, J CHRON DIS, V27, P387, DOI 10.1016/0021-9681(74)90017-4; Kattan MW, 1997, J GEN INTERN MED, V12, P299, DOI 10.1046/j.1525-1497.1997.012005299.x; Kieszak SM, 1999, J CLIN EPIDEMIOL, V52, P137, DOI 10.1016/S0895-4356(98)00154-1; Klabunde CN, 2000, J CLIN EPIDEMIOL, V53, P1258, DOI 10.1016/S0895-4356(00)00256-0; MALENKA DJ, 1994, J CLIN EPIDEMIOL, V47, P1027, DOI 10.1016/0895-4356(94)90118-X; Miller DC, 2003, J UROLOGY, V169, P105, DOI 10.1016/S0022-5347(05)64046-3; Newschaffer CJ, 1996, ARCH INTERN MED, V156, P85, DOI 10.1001/archinte.156.1.85; PICCIRILLO J, 2001, J REGISTRY MANAGE, V28, P172; Piccirillo J F, 1995, Oncology (Williston Park), V9, P831; Piccirillo JF, 1996, CANCER, V77, P834, DOI 10.1002/(SICI)1097-0142(19960301)77:5<834::AID-CNCR5>3.3.CO;2-Z; PICCIRILLO JF, 1994, ANN OTO RHINOL LARYN, V103, P83, DOI 10.1177/000348949410300201; Piccirillo JF, 2000, LARYNGOSCOPE, V110, P593, DOI 10.1097/00005537-200004000-00011; Piccirillo JF, 2003, J REGISTRY MANAGEMEN, V30, P8; Piccirillo JF, 1999, J REGISTRY MANAGEMEN, V26, P66; *PRACT MAN INF COR, 1996, INT CLASS DIS; SATARIANO WA, 1994, ANN INTERN MED, V120, P104, DOI 10.7326/0003-4819-120-2-199401150-00002; SATARIANO WA, 2000, BAS CLIN ON, V23, P477; Schrijvers CTM, 1997, CANCER-AM CANCER SOC, V80, P1482; *STAT CORP, 2001, STAT STAT SOFTW REL, P394; van Spronsen DJ, 1999, ANN HEMATOL, V78, P315, DOI 10.1007/s002770050521; WELLS CK, 1984, ARCH INTERN MED, V144, P2004, DOI 10.1001/archinte.144.10.2004; Yancik R, 1998, CANCER, V82, P2123, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2123::AID-CNCR6>3.0.CO;2-W; Yancik R, 2001, JAMA-J AM MED ASSOC, V285, P885, DOI 10.1001/jama.285.7.885; Yancik R, 2001, J CLIN ONCOL, V19, P1147, DOI 10.1200/JCO.2001.19.4.1147; Yates JW, 2001, CA-CANCER J CLIN, V51, P329, DOI 10.3322/canjclin.51.6.329; NATL DEATH INDEX	46	862	881	1	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2004	291	20					2441	2447		10.1001/jama.291.20.2441	http://dx.doi.org/10.1001/jama.291.20.2441			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823HB	15161894				2022-12-28	WOS:000221599700026
J	Hanayama, R; Tanaka, M; Miyasaka, K; Aozasa, K; Koike, M; Uchiyama, Y; Nagata, S				Hanayama, R; Tanaka, M; Miyasaka, K; Aozasa, K; Koike, M; Uchiyama, Y; Nagata, S			Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice	SCIENCE			English	Article							GERMINAL-CENTERS; MACROPHAGES; CLEARANCE; DEATH; PHOSPHATIDYLSERINE; EXPRESSION; DEFICIENT; EXPOSURE; SURFACE	Apoptotic cells expose phosphatidylserine and are swiftly engulfed by macrophages. Milk fat globule epidermal growth factor (EGF) factor 8 (MFG-E8) is a protein that binds to apoptotic cells by recognizing phosphatidylserine and that enhances the engulfment of apoptotic cells by macrophages. We report that tingible body macrophages in the germinal centers of the spleen and lymph nodes strongly express MFG-E8. Many apoptotic lymphocytes were found on the MFG-E8(-/-) tingible body macrophages, but they were not efficiently engulfed. The MFG-E8(-/-) mice developed splenomegaly, with the formation of numerous germinal centers, and suffered from glomerulonephritis as a result of autoantibody production. These data demonstrate that MFG-E8 has a critical role in removing apoptotic B cells in the germinal centers and that its failure can lead to autoimmune diseases.	Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Pathol, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Cell Biol & Neurosci, Osaka 5650871, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Innate Cellular Immun, Kanagawa 2300045, Japan; Osaka Univ, Grad Sch Frontier Biosci, Integrated Biol Labs, Genet Lab, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; RIKEN; Osaka University; Japan Science & Technology Agency (JST)	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamada Oka, Osaka 5650871, Japan.	nagata@genetic.med.osaka-u.ac.jp	Nagata, Shigekazu/AAG-3203-2019; Hanayama, Rikinari/AAO-4959-2021; Hanayama, Rikinari/D-2940-2011; Koike, Masato/F-9584-2010	Nagata, Shigekazu/0000-0001-9758-8426; Hanayama, Rikinari/0000-0003-2102-3386; Koike, Masato/0000-0002-3174-5684				Baumann I, 2002, ARTHRITIS RHEUM-US, V46, P191, DOI 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K; FADOK VA, 1992, J IMMUNOL, V148, P2207; GAUTHIER VJ, 1992, SEMIN NEPHROL, V12, P379; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, J IMMUNOL, V172, P3876, DOI 10.4049/jimmunol.172.6.3876; HANAYAMA R, UNPUB; Hengartner MO, 2001, CELL, V104, P325, DOI 10.1016/S0092-8674(01)00219-7; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KRAAL G, 1986, IMMUNOLOGY, V58, P665; LEIJH PCJ, 1984, INFECT IMMUN, V46, P448, DOI 10.1128/IAI.46.2.448-452.1984; McKnight AJ, 1998, ADV IMMUNOL, V68, P271, DOI 10.1016/S0065-2776(08)60562-3; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Miyasaka K, 2004, EUR J IMMUNOL, V34, P1414, DOI 10.1002/eji.200424930; Oshima K, 1999, BIOCHEM BIOPH RES CO, V254, P522, DOI 10.1006/bbrc.1998.0107; Platt N, 2000, J IMMUNOL, V164, P4861, DOI 10.4049/jimmunol.164.9.4861; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; SMITH JP, 1991, ANAT REC, V229, P511, DOI 10.1002/ar.1092290412; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0	25	743	779	3	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1147	1150		10.1126/science.1094359	http://dx.doi.org/10.1126/science.1094359			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155946				2022-12-28	WOS:000221524500040
J	Bristow, MR; Saxon, LA; Boehmer, J; Krueger, S; Kass, DA; De Marco, T; Carson, P; DiCarlo, L; DeMets, D; White, BG; DeVries, DW; Feldman, AM				Bristow, MR; Saxon, LA; Boehmer, J; Krueger, S; Kass, DA; De Marco, T; Carson, P; DiCarlo, L; DeMets, D; White, BG; DeVries, DW; Feldman, AM		COMPANION Investigators	Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENTRICULAR-CONDUCTION DELAY; BUNDLE-BRANCH BLOCK; TISSUE DOPPLER; CARDIOMYOPATHY; PERFORMANCE; STIMULATION	BACKGROUND: We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays. METHODS: A total of 1520 patients who had advanced heart failure (New York Heart Association class III or IV) due to ischemic or nonischemic cardiomyopathies and a QRS interval of at least 120 msec were randomly assigned in a 1:2:2 ratio to receive optimal pharmacologic therapy (diuretics, angiotensin-converting-enzyme inhibitors, beta-blockers, and spironolactone) alone or in combination with cardiac-resynchronization therapy with either a pacemaker or a pacemaker-defibrillator. The primary composite end point was the time to death from or hospitalization for any cause. RESULTS: As compared with optimal pharmacologic therapy alone, cardiac-resynchronization therapy with a pacemaker decreased the risk of the primary end point (hazard ratio, 0.81; P=0.014), as did cardiac-resynchronization therapy with a pacemaker-defibrillator (hazard ratio, 0.80; P=0.01). The risk of the combined end point of death from or hospitalization for heart failure was reduced by 34 percent in the pacemaker group (P<0.002) and by 40 percent in the pacemaker-defibrillator group (P<0.001 for the comparison with the pharmacologic-therapy group). A pacemaker reduced the risk of the secondary end point of death from any cause by 24 percent (P=0.059), and a pacemaker-defibrillator reduced the risk by 36 percent (P=0.003). CONCLUSIONS: In patients with advanced heart failure and a prolonged QRS interval, cardiac-resynchronization therapy decreases the combined risk of death from any cause or first hospitalization and, when combined with an implantable defibrillator, significantly reduces mortality.	Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; Guidant Corp, St Paul, MN USA; Clin Cardiovasc Res, Gaithersburg, MD USA; Univ Wisconsin, Sch Med, Madison, WI USA; Pfizer Inc, Global Res & Dev, Ann Arbor, MI USA; Vet Affairs Med Ctr, Washington, DC 20422 USA; Univ Calif San Francisco, Moffitt Hosp, San Francisco, CA USA; Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; Bryan Mem Hosp, Lincoln, NE USA; Milton S Hershey Med Ctr, Hershey, PA USA; Univ So Calif, Los Angeles, CA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Jefferson University; Abbott Laboratories; University of Wisconsin System; University of Wisconsin Madison; Pfizer; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Southern California	Bristow, MR (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Cardiol, 4200 E 9th Ave, Denver, CO 80262 USA.	michael.bristow@uchsc.edu	bristow, michael r/G-7850-2011	Boehmer, John/0000-0002-8024-1589				Abraham WT, 2002, CURR OPIN CARDIOL, V17, P346, DOI 10.1097/00001573-200207000-00004; Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Auricchio A, 2002, J AM COLL CARDIOL, V39, P2026, DOI 10.1016/S0735-1097(02)01895-8; Auricchio A, 2002, J AM COLL CARDIOL, V39, p124A; Baldasseroni S, 2002, AM HEART J, V143, P398, DOI 10.1067/mhj.2002.121264; Bristow MR, 2000, J CARD FAIL, V6, P276, DOI 10.1054/jcaf.2000.9501; Higgins SL, 2003, J AM COLL CARDIOL, V42, P1454, DOI 10.1016/S0735-1097(03)01042-8; Kawaguchi M, 2002, J AM COLL CARDIOL, V39, P2052, DOI 10.1016/S0735-1097(02)01883-1; Lan K. K. G., 1983, BIOMETRIKA, V70, P649; Linde C, 2002, J AM COLL CARDIOL, V40, P111, DOI 10.1016/S0735-1097(02)01932-0; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Nelson GS, 2000, CIRCULATION, V102, P3053; Nelson GS, 2001, CIRCULATION, V103, P476; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Saxon LA, 2002, CIRCULATION, V105, P1304, DOI 10.1161/hc1102.105730; Shamim W, 1999, INT J CARDIOL, V70, P171, DOI 10.1016/S0167-5273(99)00077-7; Sogaard P, 2002, J AM COLL CARDIOL, V40, P723, DOI 10.1016/S0735-1097(02)02010-7; Sogaard P, 2001, CARDIOLOGY, V95, P173, DOI 10.1159/000047369; Sutton MGS, 2003, CIRCULATION, V107, P1985, DOI 10.1161/01.CIR.0000065226.24159.E9; Trautmann Silke Isabelle, 2002, Curr Cardiol Rep, V4, P371, DOI 10.1007/s11886-002-0036-2; Werling C, 2002, THORAC CARDIOV SURG, V50, P67, DOI 10.1055/s-2002-26702	21	3994	4181	28	349	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2140	2150		10.1056/NEJMoa032423	http://dx.doi.org/10.1056/NEJMoa032423			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152059				2022-12-28	WOS:000221496700006
J	Hirschberg, R; La Montagne, J; Fauci, AS				Hirschberg, R; La Montagne, J; Fauci, AS			Biomedical research - An integral component of national security .	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NIAID, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Hirschberg, R (corresponding author), NIAID, Dept Hlth & Human Serv, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.							Fauci AS, 2003, NATURE, V421, P787, DOI 10.1038/nature01480; Fauci AS, 2001, CLIN INFECT DIS, V32, P675, DOI 10.1086/319235; Lane HC, 2001, NAT MED, V7, P1271, DOI 10.1038/nm1201-1271; *NAT I ALL INF DIS, NIAID BIOD RES; Rotz LD, 2002, EMERG INFECT DIS, V8, P225, DOI 10.3201/eid0802.010164	5	10	11	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2119	2121		10.1056/NEJMp048123	http://dx.doi.org/10.1056/NEJMp048123			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152055				2022-12-28	WOS:000221496700001
J	Lester, J; Prady, S; Finegan, Y; Hoch, D				Lester, J; Prady, S; Finegan, Y; Hoch, D			Learning from e-patients at Massachusetts General Hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Harvard Univ, Sch Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Neurol Informat Syst Res & Dev Grp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Hoch, D (corresponding author), Harvard Univ, Sch Med, 25 Shattuck St, Boston, MA 02115 USA.	dhoch@partners.org		Hoch, Daniel/0000-0002-4294-024X	NLM NIH HHS [G03 LM06964] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [G08LM006964] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		FERGUSON T, 2002, FERGUSON REPORT  SEP; Hoch DB, 1999, SEIZURE-EUR J EPILEP, V8, P30, DOI 10.1053/seiz.1998.0217; Norris Deidre M., 1998, Epilepsia, V39, P229	3	23	24	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2004	328	7449					1188	1190		10.1136/bmj.328.7449.1188	http://dx.doi.org/10.1136/bmj.328.7449.1188			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142930	Green Published			2022-12-28	WOS:000221497500031
J	Vollmer, T; Key, L; Durkalski, V; Tyor, W; Corboy, J; Markovic-Plese, S; Preiningerova, J; Rizzo, M; Singh, L				Vollmer, T; Key, L; Durkalski, V; Tyor, W; Corboy, J; Markovic-Plese, S; Preiningerova, J; Rizzo, M; Singh, L			Oral simvastatin treatment in relapsing-remitting multiple sclerosis	LANCET			English	Article							LOVASTATIN; DISEASE; MS	Many drugs have been approved for relapsing forms of multiple sclerosis but are only partly effective, are injected, and are expensive. We aimed to investigate use of of oral simvastatin (80 mg) in 30 individuals with relapsing-remitting multiple sclerosis. The mean number of gadolinium-enhancing lesions at months 4, 5, and 6 of treatment was compared with the mean number of lesions noted on pretreatment brain MRI scans. Number and volume of Gd-enhancing lesions declined by 44%, (p<0.0001) and 41% (p=0.0018), respectively. Treatment was well tolerated. Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability.	Med Univ S Carolina, Charleston, SC 29425 USA; St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA; Clin Innovat Grp, Charleston, SC USA; Univ N Carolina, Dept Neurol, Chapel Hill, NC USA; Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Ralph H Johnson Vet Affairs Med Ctr, Neurol Serv, Charleston, SC USA; Denver Vet Affairs Med Ctr, Denver, CO USA; W Haven Vet Affairs Med Ctr, West Haven, CT USA	Medical University of South Carolina; Barrow Neurological Institute; St. Joseph's Hospital and Medical Center; University of North Carolina; University of North Carolina Chapel Hill; Yale University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Singh, L (corresponding author), Med Univ S Carolina, 316 Clin Sci Bldg,171 Ashley Ave, Charleston, SC 29425 USA.	singhi@musc.edu	Lizrova Preiningerova, Jana/F-8959-2017	Lizrova Preiningerova, Jana/0000-0003-0337-3462				Goodin DS, 2002, NEUROLOGY, V58, P169, DOI 10.1212/WNL.58.2.169; Neuhaus O, 2002, NEUROLOGY, V59, P990, DOI 10.1212/WNL.59.7.990; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	5	385	413	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	2004	363	9421					1607	1608		10.1016/S0140-6736(04)16205-3	http://dx.doi.org/10.1016/S0140-6736(04)16205-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145635				2022-12-28	WOS:000221408800012
J	Gonen, T; Sliz, P; Kistler, J; Cheng, YF; Walz, T				Gonen, T; Sliz, P; Kistler, J; Cheng, YF; Walz, T			Aquaporin-0 membrane junctions reveal the structure of a closed water pore	NATURE			English	Article							INTRINSIC PROTEIN MIP; HUMAN LENS MEMBRANE; ELECTRON CRYSTALLOGRAPHY; MAMMALIAN LENS; SELECTIVITY; TRANSPORT; BACTERIORHODOPSIN; PERMEATION; CHANNEL; AQP1	The lens-specific water pore aquaporin-0 (AQP0) is the only aquaporin known to form membrane junctions in vivo(1). We show here that AQP0 from the lens core, containing some carboxy-terminally cleaved AQP0(2,3), forms double-layered crystals that recapitulate in vivo junctions. We present the structure of the AQP0 membrane junction as determined by electron crystallography. The junction is formed by three localized interactions between AQP0 molecules in adjoining membranes, mainly mediated by proline residues conserved in AQP0s from different species but not present in most other aquaporins. Whereas all previously determined aquaporin structures show the pore in an open conformation(4-9), the water pore is closed in AQP0 junctions. The water pathway in AQP0 also contains an additional pore constriction, not seen in other known aquaporin structures(4-9), which may be responsible for pore gating.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of Auckland	Walz, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	twalz@hms.harvard.edu		Cheng, Yifan/0000-0001-9535-0369; Walz, Thomas/0000-0003-2606-2835				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Bond PJ, 2002, BIOPHYS J, V83, P763, DOI 10.1016/S0006-3495(02)75207-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chandy G, 1997, J MEMBRANE BIOL, V159, P29, DOI 10.1007/s002329900266; COSTELLO MJ, 1989, INVEST OPHTH VIS SCI, V30, P975; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Donaldson P, 2001, NEWS PHYSIOL SCI, V16, P118; Fotiadis D, 2000, J MOL BIOL, V300, P779, DOI 10.1006/jmbi.2000.3920; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Gonen T, 2000, INVEST OPHTH VIS SCI, V41, P199; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Hasler L, 1998, J MOL BIOL, V279, P855, DOI 10.1006/jmbi.1998.1796; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Mathias RT, 1997, PHYSIOL REV, V77, P21, DOI 10.1152/physrev.1997.77.1.21; Mitsuoka K, 1999, J MOL BIOL, V286, P861, DOI 10.1006/jmbi.1998.2529; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nemeth-Cahalan KL, 2000, J BIOL CHEM, V275, P6777, DOI 10.1074/jbc.275.10.6777; Ren G, 2001, P NATL ACAD SCI USA, V98, P1398, DOI 10.1073/pnas.041489198; ROY D, 1979, EXP EYE RES, V28, P353, DOI 10.1016/0014-4835(79)90097-6; Savage DF, 2003, PLOS BIOL, V1, P334, DOI 10.1371/journal.pbio.0000072; SMART OS, 1993, BIOPHYS J, V65, P2455, DOI 10.1016/S0006-3495(93)81293-1; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Tajkhorshid E, 2002, SCIENCE, V296, P525, DOI 10.1126/science.1067778; TAKEMOTO L, 1986, INVEST OPHTH VIS SCI, V27, P443; Tournaire-Roux C, 2003, NATURE, V425, P393, DOI 10.1038/nature01853; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Varadaraj K, 1999, J MEMBRANE BIOL, V170, P191, DOI 10.1007/s002329900549	29	284	294	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	2004	429	6988					193	197		10.1038/nature02503	http://dx.doi.org/10.1038/nature02503			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141214				2022-12-28	WOS:000221356300044
J	Ahmed, A				Ahmed, A			10-minute consultation - Management of diastolic heart failure in older adults	BRITISH MEDICAL JOURNAL			English	Article							GUIDELINES		Univ Alabama, Sch Med, Div Gerontol & Geriatr Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Ahmed, A (corresponding author), Univ Alabama, Sch Med, Div Gerontol & Geriatr Med, Birmingham, AL 35294 USA.	aahmed@uab.edu	Ahmed, Ali/A-2934-2008	Ahmed, Ali/0000-0002-6832-6424				Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; Paulus WJ, 1998, EUR HEART J, V19, P990; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783; Vasan RS, 2000, CIRCULATION, V101, P2118, DOI 10.1161/01.CIR.101.17.2118	4	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 8	2004	328	7448					1114	1114		10.1136/bmj.328.7448.1114	http://dx.doi.org/10.1136/bmj.328.7448.1114			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130980	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000221281000023
J	MacLennan, C; Dunn, G; Huissoon, AP; Kumararatne, DS; Martin, J; O'Leary, P; Thompson, RA; Osman, H; Wood, P; Minor, P; Wood, DJ; Pillay, D				MacLennan, C; Dunn, G; Huissoon, AP; Kumararatne, DS; Martin, J; O'Leary, P; Thompson, RA; Osman, H; Wood, P; Minor, P; Wood, DJ; Pillay, D			Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man	LANCET			English	Article							TYPE-3 POLIOVIRUS; UNITED-STATES; POLIOMYELITIS; REPLICATION; DEFICIENCY; RESISTANCE; MUTATIONS; EVOLUTION; EXCRETION	Background Individuals who chronically excrete neurovirulent poliovirus of vaccine-origin are of considerable concern to the Global Polio Eradication programme. Chronic infection with such polioviruses is a recognised complication of hypogammaglobulinaernia. Methods We did a series of in-vitro and in-vivo therapeutic studies, with a view to clearing persistent neurovirulent poliovirus infection in an individual with common variable immunodeficiency, using oral immunoglobulin, breast milk (as a source of secretory IgA), ribavirin, and the anti-picornaviral agent pleconaril. We undertook viral quantitation, antibody neutralisation and drug susceptibility assays, and viral gene sequencing. Findings Long-term asymptomatic excretion of vaccine-derived neurovirulent poliovirus 2 was identified in this hypogammaglobulinaemic man, and was estimated to have persisted for up to 22 years. Despite demonstrable in-vitro neutralising activity of immunoglobulin and breast milk, and in-vitro antiviral activity of ribavirin, no treatment was successful at clearing the virus, although in one trial breast milk significantly reduced excretion levels temporarily. During the course of study, the virus developed reduced susceptibility to pleconaril, precluding the in-vivo use of this drug. Sequence analysis revealed the emergence of a methionine to leucine mutation adjacent to the likely binding site of pleconaril in these isolates. Interpretation Chronic vaccine-associated poliovirus infection in hypogammaglobulinaemia is a difficult condition to treat. It represents a risk to the strategy to discontinue polio vaccination once global eradication has been achieved.	Univ Birmingham, Div Immun & Infect, MRC, Ctr Immune Regulat, Birmingham, W Midlands, England; Birmingham Heartlands Hosp, Dept Immunol, Birmingham B9 5ST, W Midlands, England; Natl Inst Biol Stand & Controls, Div Virol, Potters Bar EN6 3QG, Herts, England; Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England; Natl Univ Ireland Univ Coll Cork, Dept Med, Cork, Ireland; Birmingham Heartlands Hosp, Hlth Protect Agcy Lab, Birmingham, W Midlands, England; Leeds Teaching Hosp, Dept Clin Immunol, Leeds, W Yorkshire, England; WHO, CH-1211 Geneva, Switzerland; UCL, Windeyer Inst, Div Infect & Immun, Ctr Virol, London, England; Hlth Protect Agcy, Specialist & Reference Microbiol Div, Colindale, England	University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham; National Institute for Biological Standards & Control; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University College Cork; Health Protection Agency; Heart of England NHS Foundation Trust; University of Birmingham; University of Leeds; World Health Organization; University of London; University College London; Health Protection Agency	MacLennan, C (corresponding author), Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, POB 30096, Blantyre 3, Malawi.	cmaclennan@mlw.medcol.mw	MacLennan, Calman A/L-9343-2014	MacLennan, Calman A/0000-0001-9694-0846; Martin, Javier/0000-0001-5326-7081				ABO W, 1979, EUR J PEDIATR, V132, P11, DOI 10.1007/BF00443199; Alexander JP, 1997, J INFECT DIS, V175, pS176, DOI 10.1093/infdis/175.Supplement_1.S176; ANDRIES K, 1992, ANTIMICROB AGENTS CH, V36, P100, DOI 10.1128/AAC.36.1.100; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; Bellmunt A, 1999, VIROLOGY, V265, P178, DOI 10.1006/viro.1999.0003; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Dowdle WR, 1997, J INFECT DIS, V175, pS286, DOI 10.1093/infdis/175.Supplement_1.S286; FITZSIMMONS SP, 1994, J PEDIATR-US, V124, P566, DOI 10.1016/S0022-3476(05)83135-X; GRANT RA, 1994, CURR BIOL, V4, P784, DOI 10.1016/S0960-9822(00)00176-7; GUILLOT S, 1994, VACCINE, V12, P503, DOI 10.1016/0264-410X(94)90307-7; Halsey NA, 2004, B WORLD HEALTH ORGAN, V82, P3; HAMMON WM, 1953, JAMA-J AM MED ASSOC, V151, P1272; JATSYK GV, 1985, ACTA PAEDIATR SCAND, V74, P246, DOI 10.1111/j.1651-2227.1985.tb10958.x; Kew OM, 1995, SEMIN VIROL, V6, P401, DOI 10.1016/S1044-5773(05)80017-4; Kew OM, 1998, J CLIN MICROBIOL, V36, P2893, DOI 10.1128/JCM.36.10.2893-2899.1998; Lentz KN, 1997, STRUCTURE, V5, P961, DOI 10.1016/S0969-2126(97)00249-9; MacCallum F O, 1971, Spec Rep Ser Med Res Counc (G B), V310, P72; Martin J, 2000, J VIROL, V74, P3001, DOI 10.1128/JVI.74.7.3001-3010.2000; MISBAH SA, 1991, POSTGRAD MED J, V67, P301, DOI 10.1136/pgmj.67.785.301; MOSSER AG, 1994, J VIROL, V68, P8193, DOI 10.1128/JVI.68.12.8193-8201.1994; Nowak-Wegrzyn A, 2001, CLIN INFECT DIS, V32, pE13, DOI 10.1086/317523; Orenstein W, 2002, CLIN INFECT DIS, V34, P72, DOI 10.1086/338262; Pevear DC, 1999, ANTIMICROB AGENTS CH, V43, P2109, DOI 10.1128/AAC.43.9.2109; Pfeiffer JK, 2003, P NATL ACAD SCI USA, V100, P7289, DOI 10.1073/pnas.1232294100; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; Rotbart HA, 2001, CLIN INFECT DIS, V32, P228, DOI 10.1086/318452; SABIN AB, 1962, PEDIATRICS, V29, P105; SABIN AB, 1985, J INFECT DIS, V151, P420, DOI 10.1093/infdis/151.3.420; SAVILAHTI E, 1988, J CLIN IMMUNOL, V8, P89, DOI 10.1007/BF00917895; Schmugge M, 1999, EUR J PEDIATR, V158, P1010, DOI 10.1007/s004310051273; SCHONBERGER LB, 1976, AM J EPIDEMIOL, V104, P202, DOI 10.1093/oxfordjournals.aje.a112290; *WHO, 1999, WHO TECH REP SER, V904, P31; WILFERT CM, 1977, NEW ENGL J MED, V296, P1485, DOI 10.1056/NEJM197706302962601; World Health Assembly, 1988, GLOB ER POL YEAR 200; World Health Organization (WHO), 1997, MAN VIR INV POL; WYATT HV, 1973, J INFECT DIS, V128, P802, DOI 10.1093/infdis/128.6.802; YONEYAMA T, 1982, INFECT IMMUN, V37, P46, DOI 10.1128/IAI.37.1.46-53.1982; ZEICHHARDT H, 1987, VIROLOGY, V160, P281, DOI 10.1016/0042-6822(87)90075-4	38	111	113	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2004	363	9420					1509	1513		10.1016/S0140-6736(04)16150-3	http://dx.doi.org/10.1016/S0140-6736(04)16150-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135598				2022-12-28	WOS:000221302700010
J	Patel, A; Knapp, M; Evans, A; Perez, I; Kalra, L				Patel, A; Knapp, M; Evans, A; Perez, I; Kalra, L			Training care givers of stroke patients: economic evaluation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMAL CARE; PEOPLE; BURDEN; COSTS	Background. Training care givers reduces their burden and improves psychosocial outcomes in care givers and patients at one year. However, the cost effectiveness of this approach has not been investigated. Objective To evaluate the cost effectiveness of caregiver training by examining health and social care costs, informal care costs, and quality adjusted life years in care givers. Design A single, blind, randomised controlled trial. Setting Stroke rehabilitation unit. Subjects 300 stroke patients and their care givers. Interventions Caregiver training in basic nursing and facilitation of personal care techniques compared with no caregiver training. Main outcome measures Health and social care costs, informal care costs, and quality adjusted life years in care givers over one year after stroke. Results Total health and social care costs over one year for patients whose care givers received training were significantly lower (mean difference pound4043 ($7249; C6072), 95% confidence interval -pound6544 to -pound1595). Inclusion of informal care costs, which were similar between the two groups, did not alter this conclusion. The cost difference was largely due to differences in length of hospital stay. The EQ-5D did not detect changes in quality adjusted life years in care givers. Conclusion Compared with no training, caregiver training during rehabilitation of patients reduced costs of care while improving overall quality of life in care givers at one year.	Guys Kings & St Thomass Sch Med, Dept Med, London SE5 9PJ, England; Kings Coll London, Inst Psychiat, Ctr Econ Mental Hlth, London WC2R 2LS, England	University of London; King's College London; University of London; King's College London	Kalra, L (corresponding author), Guys Kings & St Thomass Sch Med, Dept Med, London SE5 9PJ, England.	lalit.kalra@kcl.ac.uk	Knapp, Martin RJ/G-3011-2011; Patel, Anita/F-9832-2010	Patel, Anita/0000-0003-0769-1732; Knapp, Martin/0000-0003-1427-0215				ANDERSON CS, 1995, STROKE, V26, P843, DOI 10.1161/01.STR.26.5.843; Bauld L., 2000, CARING OLDER PEOPLE; Beecham J., 2001, MEASURING MENTAL HLT; Bugge C, 1999, STROKE, V30, P1517, DOI 10.1161/01.STR.30.8.1517; Claesson L, 2000, STROKE, V31, P2569, DOI 10.1161/01.STR.31.11.2569; *DEP TRAD IND, 2001, DET GUID NAT MIN WAG; Department of Health (UK), 1999, CAR CAR NAT STRAT CA; Dewey HM, 2002, STROKE, V33, P1028, DOI 10.1161/01.STR.0000013067.24300.B0; DOLAN P, 1995, 138 U YORK; DONALDSON C, 1988, J HEALTH ECON, V7, P239, DOI 10.1016/0167-6296(88)90027-6; FORSTER A, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001919; Godber E, 1997, HEALTH ECON, V6, P275, DOI 10.1002/(SICI)1099-1050(199705)6:3<275::AID-HEC255>3.0.CO;2-2; Gunnell D, 2000, AGE AGEING, V29, P137, DOI 10.1093/ageing/29.2.137; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; LONGWORTH L, IN PRESS HLTH EC; McDaid D, 2001, INT J GERIATR PSYCH, V16, P400, DOI 10.1002/gps.353; NETTEN A, 2002, UNIT COSTS HLTH SOCI; Parker G, 2002, POLICY POLIT, V30, P347, DOI 10.1332/030557302760094711; Twigg J., 1998, SOCIAL POLICY OLD AG, P128; Wilkinson PR, 1997, STROKE, V28, P507, DOI 10.1161/01.STR.28.3.507; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	21	92	94	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	2004	328	7448					1102	1104A		10.1136/bmj.328.7448.1102	http://dx.doi.org/10.1136/bmj.328.7448.1102			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130978	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000221281000016
J	Mayr, G				Mayr, G			Old world fossil record of modern-type hummingbirds	SCIENCE			English	Article							BIRD	I report on tiny skeletons of stem-group hummingbirds from the early Oligocene of Germany that are of essentially modern appearance and exhibit morphological specializations toward nectarivory and hovering flight. These are the oldest fossils of modern-type hummingbirds, which had not previously been reported from the Old World. The findings demonstrate that early hummingbird evolution was not restricted to the New World. They further suggest that bird-flower coevolution dates back to the early Oligocene and open another view on the origin of ornithophily in Old World plants.	Forschungsinst Senckenberg, Div Ornithol, D-60325 Frankfurt, Germany	Senckenberg Gesellschaft fur Naturforschung (SGN)	Mayr, G (corresponding author), Forschungsinst Senckenberg, Div Ornithol, Senckenberganlage 25, D-60325 Frankfurt, Germany.	Gerald.Mayr@senckenberg.de						BERNSTEIN LOWELL, 1965, QUART FLORIDA ACAD SCI, V28, P271; Bleiweiss R, 1998, BIOL J LINN SOC, V65, P77, DOI 10.1111/j.1095-8312.1998.tb00352.x; Bleiweiss R, 1998, BIOL J LINN SOC, V65, P63, DOI 10.1006/bijl.1998.0241; Bradshaw HD, 2003, NATURE, V426, P176, DOI 10.1038/nature02106; CARPENTER FL, 1979, AM ZOOL, V19, P1105; Ericson PGP, 2003, J AVIAN BIOL, V34, P3, DOI 10.1034/j.1600-048X.2003.03121.x; GRANT V, 1994, P NATL ACAD SCI USA, V91, P10407, DOI 10.1073/pnas.91.22.10407; Johansson US, 2001, J ZOOL SYST EVOL RES, V39, P37; KARHU A. A., 1988, PALEONTOL J, V3, P78; KARHU A. A., 2001, ACHIEVEMENTS PROBLEM, P118; Karhu Alexandr A., 1999, Smithsonian Contributions to Paleobiology, V89, P207; Legendre Serge, 1997, Memoires et Travaux de l'Institut de Montpellier de l'Ecole Pratique des Hautes Etudes, V21, P461; Mayr G, 2003, AUK, V120, P145, DOI 10.1642/0004-8038(2003)120[0145:POETSA]2.0.CO;2; Mayr G, 2003, IBIS, V145, P382, DOI 10.1046/j.1474-919X.2003.00168.x; Micklich N., 1996, Publicaciones Especiales Instituto Espanol de Oceanografia, V21, P129; MOURERCHAUVIRE C, 1989, CR ACAD SCI II, V309, P843; OLSON SL, 1982, SMITHSON CONTRIB PAL, V48, P22; Schuchmann K.-L., 1999, HDB BIRDS WORLD, P468; STEGMANN B., 1963, J ORNITHOL, V104, P413, DOI 10.1007/BF01671057; STILES FG, 1981, ANN MO BOT GARD, V68, P323, DOI 10.2307/2398801; STILES FG, 1978, AM ZOOL, V18, P715; Temeles EJ, 2002, BIOTROPICA, V34, P68, DOI 10.1111/j.1744-7429.2002.tb00243.x; Trunko L., 1998, CAROLINEA, V56, P9; WESTERKAMP C, 1990, BOT ACTA, V103, P366, DOI 10.1111/j.1438-8677.1990.tb00176.x; Zusi R.L., 1984, SMITHSONIAN CONTRIBU, V395, P1; [No title captured]	26	88	95	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					861	864		10.1126/science.1096856	http://dx.doi.org/10.1126/science.1096856			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131303				2022-12-28	WOS:000221243000041
J	Moran, TG; Davila, JM				Moran, TG; Davila, JM			Three-dimensional polarimetric imaging of coronal mass ejections	SCIENCE			English	Article							SOHO MISSION; LASCO	We present three-dimensional reconstructions of coronal mass ejections (CMEs), which were obtained through polarization analysis of single-view images recorded with the use of the Large Angle and Spectrometric Coronagraph (LASCO) C2 coronagraph on board the Solar and Heliospheric Observatory (SOHO) spacecraft. Analysis of a loop-like CME shows a complex three-dimensional structure centered at 40degrees from the plane of the sky, moving radially at 250 kilometers/second. Reconstruction of two halo CMEs suggests that these events are expanding loop arcades.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20770 USA; Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Catholic University of America	Moran, TG (corresponding author), NASA, Goddard Space Flight Ctr, Code 682-3, Greenbelt, MD 20770 USA.	moran@morpheus.nascom.nasa.gov						BILLINGS B, 1966, GUIDE SOLAR CORONA, P93; Brueckner GE, 1995, SOL PHYS, V162, P357, DOI 10.1007/BF00733434; Delaboudiniere JP, 1995, SOL PHYS, V162, P291, DOI 10.1007/BF00733432; Domingo V, 1995, SOL PHYS, V162, P1, DOI 10.1007/BF00733425; KOONEN M, 1974, SOL PHYS, V34, P447; Lanzerotti LJ, 2001, GEOPHYS MONOGR SER, V125, P11; MINEART M, 1930, Z ASTROPHYS, V1, P209; SCHERRER RS, 1995, SOL PHYS, V162, P101; Turner R, 2001, GEOPH MONOG SERIES, V125, P39; van de Hulst H. C., 1950, B ASTRON I NETH, V11, P135; Vourlidas A, 2002, ESA SP PUBL, V506, P91; YASHIRO S, IN PRESS J GEOPHYS R	12	110	111	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	2004	305	5680					66	70		10.1126/science.1098937	http://dx.doi.org/10.1126/science.1098937			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15166318				2022-12-28	WOS:000222386000034
J	Hertzog, M; van Heijenoort, C; Didry, D; Gaudier, M; Coutant, J; Gigant, B; Didelot, G; Preat, T; Knossow, M; Guittet, E; Carlier, MF				Hertzog, M; van Heijenoort, C; Didry, D; Gaudier, M; Coutant, J; Gigant, B; Didelot, G; Preat, T; Knossow, M; Guittet, E; Carlier, MF			The beta-thymosin/WH2 domain: Structural basis for the switch from inhibition to promotion of actin assembly	CELL			English	Article							CYCLASE-ASSOCIATED PROTEIN; ALDRICH-SYNDROME PROTEIN; ARP2/3 COMPLEX; F-ACTIN; ATP HYDROLYSIS; SACCHAROMYCES-CEREVISIAE; ACANTHAMOEBA ACTOBINDIN; THYMOSIN BETA(4); BINDING PROTEINS; ATOMIC-STRUCTURE	The widespread beta-thymosin/WH2 actin binding domain has versatile regulatory properties in actin dynamics and motility. beta-thymosins (isolated WH2 domain) maintain monomeric actin in a "sequestered" nonpolymerizable form. In contrast, when repeated in tandem or inserted in modular proteins, the beta-thymosin/WH2 domain promotes actin assembly at filament barbed ends, like profilin. The structural basis for these opposite functions is addressed using ciboulot, a three beta-thymosin repeat protein. Only the first repeat binds actin and possesses the function of ciboulot. The region that shows the strongest interaction with actin is an amphipathic N-terminal alpha helix, present in all beta-thymosin/WH2 domains, which recognizes the ATP bound actin structure and uses the shear motion of actin linked to ATP hydrolysis to control polymerization. Crystallographic (H-1, N-15), NMR, and mutagenetic data reveal that the weaker interaction of the C-terminal region of beta-thymosin/WH2 domain with actin accounts for the switch in function from inhibition to promotion of actin assembly.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; CNRS, Inst Chim Subst Nat, F-91198 Gif Sur Yvette, France; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; CNRS, Inst Alfred Fessard, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.	carlier@lebs.cnrs-gif.fr	VAN HEIJENOORT, Carine/N-1986-2016; van Heijenoort, Carine/AAX-1041-2021	VAN HEIJENOORT, Carine/0000-0002-2839-1037; van Heijenoort, Carine/0000-0002-2839-1037; Gigant, Benoit/0000-0002-5946-6759; Guittet, Eric/0000-0002-8368-6719; Preat, Thomas/0000-0001-9976-1763				Barrero RA, 2002, PLANT CELL, V14, P149, DOI 10.1105/tpc.010301; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; Benlali A, 2000, CELL, V101, P271, DOI 10.1016/S0092-8674(00)80837-5; Boquet I, 2000, CELL, V102, P797, DOI 10.1016/S0092-8674(00)00068-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUBB MR, 1991, J BIOL CHEM, V266, P3820; Bubb MR, 1998, CELL MOTIL CYTOSKEL, V39, P134, DOI 10.1002/(SICI)1097-0169(1998)39:2<134::AID-CM4>3.0.CO;2-6; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; Crow T, 2003, J NEUROSCI, V23, P3415; CZISCH M, 1993, EUR J BIOCHEM, V218, P335, DOI 10.1111/j.1432-1033.1993.tb18382.x; De La Cruz EM, 2000, BIOPHYS J, V78, P2516, DOI 10.1016/S0006-3495(00)76797-X; DOMANSKI M, 2004, IN PRESS J BIOL CHEM; Eadie JS, 2000, J CELL BIOCHEM, V77, P277, DOI 10.1002/(SICI)1097-4644(20000501)77:2<277::AID-JCB10>3.0.CO;2-Q; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Freeman NL, 2000, CELL MOTIL CYTOSKEL, V45, P106, DOI 10.1002/(SICI)1097-0169(200002)45:2<106::AID-CM3>3.0.CO;2-3; Galkin VE, 2003, J CELL BIOL, V163, P1057, DOI 10.1083/jcb.200308144; Galkin VE, 2002, CURR BIOL, V12, P570, DOI 10.1016/S0960-9822(02)00742-X; Galkin VE, 2001, J CELL BIOL, V153, P75, DOI 10.1083/jcb.153.1.75; Gutsche-Perelroizen I, 1999, J BIOL CHEM, V274, P6234, DOI 10.1074/jbc.274.10.6234; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; Hertzog M, 2002, J BIOL CHEM, V277, P14786, DOI 10.1074/jbc.M112064200; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Hubberstey AV, 2002, FASEB J, V16, P487, DOI 10.1096/fj.01-0659rev; Hudson AM, 2002, ANNU REV GENET, V36, P455, DOI 10.1146/annurev.genet.36.052802.114101; Irobi E, 2003, FEBS LETT, V552, P86, DOI 10.1016/S0014-5793(03)00934-7; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Clainche C, 2003, P NATL ACAD SCI USA, V100, P6337, DOI 10.1073/pnas.1130513100; Le Clainche C, 2001, J BIOL CHEM, V276, P46689, DOI 10.1074/jbc.C100476200; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Otterbein LR, 2002, P NATL ACAD SCI USA, V99, P8003, DOI 10.1073/pnas.122126299; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page R, 1998, J MOL BIOL, V280, P463, DOI 10.1006/jmbi.1998.1879; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Paunola E, 2002, FEBS LETT, V513, P92, DOI 10.1016/S0014-5793(01)03242-2; ROUSSEL A, 1991, TURBO FRODO SILICON; Sablin EP, 2002, P NATL ACAD SCI USA, V99, P10945, DOI 10.1073/pnas.152329899; SAFER D, 1994, BIOESSAYS, V16, P590; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Simenel C, 2000, EUR J BIOCHEM, V267, P3530, DOI 10.1046/j.1432-1327.2000.01380.x; TIRION MM, 1993, J MOL BIOL, V230, P186, DOI 10.1006/jmbi.1993.1135; Tompa P, 2003, BIOESSAYS, V25, P847, DOI 10.1002/bies.10324; Van Troys M, 1999, BBA-MOL CELL RES, V1448, P323, DOI 10.1016/S0167-4889(98)00152-9; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; Wiesner S, 2003, J CELL BIOL, V160, P387, DOI 10.1083/jcb.200207148; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Wriggers W, 1998, J MOL BIOL, V282, P921, DOI 10.1006/jmbi.1998.2048; Yarmola EG, 2000, J BIOL CHEM, V275, P28120	65	176	186	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					611	623		10.1016/S0092-8674(04)00403-9	http://dx.doi.org/10.1016/S0092-8674(04)00403-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163409	Bronze			2022-12-28	WOS:000221857900008
J	Ofri, D				Ofri, D			Torment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU, Sch Med, Dept Med, New York, NY 10012 USA; Bellevue Hosp, New York, NY USA	New York University; Bellevue Hospital Center	Ofri, D (corresponding author), NYU, Sch Med, Dept Med, New York, NY 10012 USA.			Ofri, Danielle/0000-0001-9865-7104					0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2233	2236		10.1056/NEJMp038198	http://dx.doi.org/10.1056/NEJMp038198			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163771				2022-12-28	WOS:000221641900002
J	Greenamyre, JT; Hastings, TG				Greenamyre, JT; Hastings, TG			Parkinson's - Divergent causes, convergent mechanisms	SCIENCE			English	Editorial Material							ALPHA-SYNUCLEIN; COMPLEX-I; DISEASE; MITOCHONDRIA; PHOSPHORYLATION; RESPIRATION; MUTATIONS; CELLS; VITRO		Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA	Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Greenamyre, JT (corresponding author), Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.	jgreena@emory.edu	Greenamyre, J. Timothy/B-4049-2011	Greenamyre, J. Timothy/0000-0003-3468-7878				Beal MF, 2004, EXP NEUROL, V186, P109, DOI 10.1016/j.expneurol.2003.12.002; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; CHEN R, 2004, J BIOL CHEM; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lee I, 2002, MOL CELL BIOCHEM, V234, P63, DOI 10.1023/A:1015921513720; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Pasdois P, 2003, J BIOENERG BIOMEMBR, V35, P439, DOI 10.1023/A:1027391831382; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Schulenberg B, 2003, J BIOL CHEM, V278, P27251, DOI 10.1074/jbc.C300189200; Shamoto-Nagai M, 2003, J NEUROSCI RES, V74, P589, DOI 10.1002/jnr.10777; Sherer TB, 2002, J NEUROSCI, V22, P7006; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937	21	325	333	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1120	1122		10.1126/science.1098966	http://dx.doi.org/10.1126/science.1098966			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155938				2022-12-28	WOS:000221524500029
J	Samet, JM; DeMarini, DM; Malling, HV				Samet, JM; DeMarini, DM; Malling, HV			Do airborne particles induce heritable mutations?	SCIENCE			English	Editorial Material							AIR-POLLUTION; DNA-DAMAGE; PATTERNS; EXPOSURE; REFLECT		Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; US EPA, Res Triangle Pk, NC 27711 USA; NIEHS, Res Triangle Pk, NC 27709 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; United States Environmental Protection Agency; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Samet, JM (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.	jsamet@jhsph.edu		DeMarini, David/0000-0001-8357-7988	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065033] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bishop JB, 1997, FUND APPL TOXICOL, V40, P191, DOI 10.1006/faat.1997.2379; Dejmek J, 2000, ENVIRON HEALTH PERSP, V108, P1159, DOI 10.2307/3434828; DeMarini DM, 2001, CANCER RES, V61, P6679; DEMARINI DM, IN PRESS MUTAT RES; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Perera F, 2002, CANCER EPIDEM BIOMAR, V11, P1134; Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742; SAMET JM, 1999, AIR POLLUTION HLTH, pCH36; Selevan SG, 2000, ENVIRON HEALTH PERSP, V108, P887, DOI 10.2307/3434998; Somers CM, 2004, SCIENCE, V304, P1008, DOI 10.1126/science.1095815; Somers CM, 2002, P NATL ACAD SCI USA, V99, P15904, DOI 10.1073/pnas.252499499; Yauk CL, 2004, MUTAT RES-REV MUTAT, V566, P169, DOI 10.1016/j.mrrev.2003.08.001; Yauk CL, 1996, P NATL ACAD SCI USA, V93, P12137, DOI 10.1073/pnas.93.22.12137	13	70	76	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	2004	304	5673					971	972		10.1126/science.1097441	http://dx.doi.org/10.1126/science.1097441			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143266				2022-12-28	WOS:000221383300031
J	Ostermeier, GC; Miller, D; Huntriss, JD; Diamond, MP; Krawetz, SA				Ostermeier, GC; Miller, D; Huntriss, JD; Diamond, MP; Krawetz, SA			Reproductive biology - Delivering spermatozoan RNA to the oocyte	NATURE			English	Editorial Material							EXPRESSION; DEVELOP; EMBRYOS		Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48201 USA; Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48201 USA; Wayne State Univ, Ctr Comp Sci, Detroit, MI 48201 USA; Univ Leeds, Reprod & Early Dev Grp, Leeds LS2 9JT, W Yorkshire, England	Wayne State University; Wayne State University; Wayne State University; University of Leeds	Ostermeier, GC (corresponding author), Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48201 USA.	steve@compbio.med.wayne.edu	krawetz, stephen/GQQ-3308-2022; Ostermeier, G. Charles/Y-1172-2019	Ostermeier, G. Charles/0000-0002-3951-512X; Diamond, Michael/0000-0001-6353-4489				Geijsen N, 2004, NATURE, V427, P148, DOI 10.1038/nature02247; Hayashi S, 2003, BIOL REPROD, V69, P1170, DOI 10.1095/biolreprod.103.016832; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Kono T, 2002, DEV BIOL, V243, P294, DOI 10.1006/dbio.2001.0561; Kono T, 2004, NATURE, V428, P860, DOI 10.1038/nature02402; Kure-Bayashi S, 2000, THERIOGENOLOGY, V53, P1105, DOI 10.1016/S0093-691X(00)00256-9; OBRYAN MK, 1990, J CLIN INVEST, V85, P1477, DOI 10.1172/JCI114594; Ostermeier GC, 2002, LANCET, V360, P772, DOI 10.1016/S0140-6736(02)09899-9; Poon S, 2002, J BIOL CHEM, V277, P39532, DOI 10.1074/jbc.M204855200; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x; Ziyyat A, 2001, HUM REPROD, V16, P1449, DOI 10.1093/humrep/16.7.1449	13	411	436	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988					154	154		10.1038/429154a	http://dx.doi.org/10.1038/429154a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141202	Bronze			2022-12-28	WOS:000221356300029
J	Molyneux, DH; Nantulya, VM				Molyneux, DH; Nantulya, VM			Linking disease control programmes in rural Africa: a pro-poor strategy to reach Abuja targets and millennium development goals	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRICHURIS-TRICHIURA; PLASMODIUM-FALCIPARUM; ASCARIS-LUMBRICOIDES; WUCHERERIA-BANCROFTI; LYMPHATIC FILARIASIS; TRANSMISSION; MALARIA; INFECTIONS; PREVENTION; COUNTRIES		Univ Liverpool, Liverpool Sch Trop Med, Lymphat Filariasis Support Ctr, Liverpool L3 5QA, Merseyside, England; Global Fund Fight AIDS TB & Malaria, CH-1216 Geneva, Switzerland	Liverpool School of Tropical Medicine; University of Liverpool	Molyneux, DH (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Lymphat Filariasis Support Ctr, Liverpool L3 5QA, Merseyside, England.	fahy@liv.ac.uk						Biritwum RB, 2000, ANN TROP MED PARASIT, V94, P771, DOI 10.1080/00034980020013037; Bockarie MJ, 2002, MED VET ENTOMOL, V16, P116, DOI 10.1046/j.0269-283x.2002.00352.x; Brabin B, 2003, T ROY SOC TROP MED H, V97, P36, DOI 10.1016/S0035-9203(03)90014-9; Brabin BJ, 2001, J NUTR, V131, p604S, DOI 10.1093/jn/131.2.604S; BURKOT TR, 1990, T ROY SOC TROP MED H, V84, P773, DOI 10.1016/0035-9203(90)90073-N; Bustreo F, 2003, B WORLD HEALTH ORGAN, V81, P886; GRABOWSKY M, 2003, P ANN M AM SOC TROP; *INT FED RED CROSS, GHAN MEASL CAMP GIV; *INT FED RED CROSS, ZAMB RED CROSS TACKL; Kroeger A, 2003, AM J TROP MED HYG, V68, P307, DOI 10.4269/ajtmh.2003.68.307; Kroeger A, 2002, BMJ-BRIT MED J, V325, P810, DOI 10.1136/bmj.325.7368.810; Kwiatkowski D, 2000, CURR OPIN GENET DEV, V10, P320, DOI 10.1016/S0959-437X(00)00087-3; McCombie SC, 1996, SOC SCI MED, V43, P933, DOI 10.1016/0277-9536(95)00446-7; MIGUEL E, 2001, W8481 NBER; Molyneux DH, 1999, PARASITOL TODAY, V15, P238, DOI 10.1016/S0169-4758(99)01453-2; Molyneux DH, 2002, ANN TROP MED PARASIT, V96, pS15, DOI 10.1179/000349802125002374; Molyneux DH, 2003, TRENDS PARASITOL, V19, P516, DOI 10.1016/j.pt.2003.09.004; NOKES C, 1992, PARASITOLOGY, V104, P539, DOI 10.1017/S0031182000063800; Ottesen EA, 1999, PARASITOL TODAY, V15, P382, DOI 10.1016/S0169-4758(99)01486-6; Pedersen EM, 2002, ANN TROP MED PARASIT, V96, pS91, DOI 10.1179/000349802125002437; Roll Back Malaria Partnership, 2000, AB DECL PLAN ACT; Spiegel A, 2003, T ROY SOC TROP MED H, V97, P198, DOI 10.1016/S0035-9203(03)90117-9; STEPHENSON LS, 1993, J NUTR, V123, P656, DOI 10.1093/jn/123.4.656; STEPHENSON LS, 1993, J NUTR, V123, P1036	24	81	82	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	2004	328	7448					1129	1132		10.1136/bmj.328.7448.1129	http://dx.doi.org/10.1136/bmj.328.7448.1129			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130985	Green Published, Green Accepted			2022-12-28	WOS:000221281000028
J	Aarts, DGAL; Schmidt, M; Lekkerkerker, HNW				Aarts, DGAL; Schmidt, M; Lekkerkerker, HNW			Direct visual observation of thermal capillary waves	SCIENCE			English	Article							COLLOID-POLYMER MIXTURE; FLUID-FLUID INTERFACE; LIQUID INTERFACES; LENGTH SCALES; X-RAY; TENSION; PROFILE; SURFACE; FILMS	We studied the free fluid-fluid interface in a phase-separated colloid-polymer dispersion with laser scanning confocal microscopy and directly observed thermally induced capillary waves at the interface in real space. Experimental results for static and dynamic correlation functions validate the capillary wave model down to almost the particle level. The ultralow interfacial tension, the capillary length, and the capillary time are found to be in agreement with independent measurements. Furthermore, we show that capillary waves induce the spontaneous breakup of thin liquid films and thus are of key importance in the process of droplet coalescence.	Univ Utrecht, Debye Inst, Vant Hoff Lab, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Debye Inst, NL-3584 CC Utrecht, Netherlands	Utrecht University; Utrecht University	Aarts, DGAL (corresponding author), Univ Utrecht, Debye Inst, Vant Hoff Lab, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	d.g.a.l.aarts@chem.uu.nl	Schmidt, Matthias/A-8697-2011; Hu, Hong/A-1693-2011	Schmidt, Matthias/0000-0002-5015-2972				Aarts DGAL, 2003, J PHYS-CONDENS MAT, V15, pS245, DOI 10.1088/0953-8984/15/1/332; ASAKURA S, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740347; Bosma G, 2002, J COLLOID INTERF SCI, V245, P292, DOI 10.1006/jcis.2001.7986; Brader JM, 2000, EUROPHYS LETT, V49, P678, DOI 10.1209/epl/i2000-00204-2; Brader JM, 2002, J PHYS-CONDENS MAT, V14, pL1, DOI 10.1088/0953-8984/14/1/101; BUFF FP, 1965, PHYS REV LETT, V15, P621, DOI 10.1103/PhysRevLett.15.621; de Hoog EHA, 1999, J PHYS CHEM B, V103, P5274, DOI 10.1021/jp990061n; de Hoog EHA, 2001, J PHYS CHEM B, V105, P11636, DOI 10.1021/jp011305i; Doerr AK, 1999, PHYS REV LETT, V83, P3470, DOI 10.1103/PhysRevLett.83.3470; Eggers J, 1999, J FLUID MECH, V401, P293, DOI 10.1017/S002211209900662X; Fradin C, 2000, NATURE, V403, P871, DOI 10.1038/35002533; Jeng US, 1998, J PHYS-CONDENS MAT, V10, P4955, DOI 10.1088/0953-8984/10/23/004; LEKKERKERKER HNW, 1992, EUROPHYS LETT, V20, P559, DOI 10.1209/0295-5075/20/6/015; Mandelstam L, 1913, ANN PHYS-BERLIN, V41, P609; Mecke KR, 1999, PHYS REV E, V59, P6766, DOI 10.1103/PhysRevE.59.6766; MEUNIER J, 1988, LIQUIDS INTERFACES, P327; Milchev A, 2002, EUROPHYS LETT, V59, P81, DOI 10.1209/epl/i2002-00162-1; Poon WCK, 2002, J PHYS-CONDENS MAT, V14, pR859, DOI 10.1088/0953-8984/14/33/201; Probstein RF, 2003, PHYSICOCHEMICAL HYDR; Reynolds O., 1886, PHILOS T R SOC LONDO, V177, P157, DOI 10.1098/rstl.1886.0005; SANYAL MK, 1991, PHYS REV LETT, V66, P628, DOI 10.1103/PhysRevLett.66.628; Seydel T, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.073409; Sheludko A., 1967, ADV COLLOID INTERFAC, V1, P391, DOI DOI 10.1016/0001-8686(67)85001-2; Tolan M, 1998, PHYS REV LETT, V81, P2731, DOI 10.1103/PhysRevLett.81.2731; VINCENT B, 1990, COLLOID SURFACE, V50, P241, DOI 10.1016/0166-6622(90)80267-8; von Smoluchowski M, 1908, ANN PHYS-BERLIN, V25, P205; VRIJ A, 1966, DISCUSS FARADAY SOC, P23; Vrij A, 1997, PHYSICA A, V235, P120, DOI 10.1016/S0378-4371(96)00333-0; VRIJ A, 1976, PURE APPL CHEM, V48, P471, DOI 10.1351/pac197648040471; Vrij A., 1968, ADV COLLOID INTERFAC, V2, P39; Wilson T., 1990, CONFOCAL MICROSCOPY	31	362	363	8	169	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	2004	304	5672					847	850		10.1126/science.1097116	http://dx.doi.org/10.1126/science.1097116			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131300	Green Submitted			2022-12-28	WOS:000221243000036
J	Donley, JM; Sepulveda, CA; Konstantinidis, P; Gemballa, S; Shadwick, RE				Donley, JM; Sepulveda, CA; Konstantinidis, P; Gemballa, S; Shadwick, RE			Convergent evolution in mechanical design of lamnid sharks and tunas	NATURE			English	Article							MUSCLE DYNAMICS; HORIZONTAL SEPTUM; SCOMBRID FISHES; STEADY; LOCOMOTION; SPEED; PROPULSION	The evolution of 'thunniform' body shapes in several different groups of vertebrates, including whales, ichthyosaurs(1) and several species of large pelagic fishes(2) supports the view that physical and hydromechanical demands provided important selection pressures to optimize body design for locomotion during vertebrate evolution. Recognition of morphological similarities between lamnid sharks ( the most well known being the great white and the mako) and tunas has led to a general expectation that they also have converged in their functional design; however, no quantitative data exist on the mechanical performance of the locomotor system in lamnid sharks. Here we examine the swimming kinematics, in vivo muscle dynamics and functional morphology of the force-transmission system in a lamnid shark, and show that the evolutionary convergence in body shape and mechanical design between the distantly related lamnids and tunas is much more than skin deep; it extends to the depths of the myotendinous architecture and the mechanical basis for propulsive movements. We demonstrate that not only have lamnids and tunas converged to a much greater extent than previously known, but they have also developed morphological and functional adaptations in their locomotor systems that are unlike virtually all other fishes.	Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92093 USA; Univ Tubingen, Dept Zool, D-72076 Tubingen, Germany	University of California System; University of California San Diego; Scripps Institution of Oceanography; Eberhard Karls University of Tubingen	Donley, JM (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92093 USA.	jdonley@ucsd.edu						ALTRINGHAM JD, 2001, TUNA PHYSL ECOLOGY E, P313; Bernal D, 2001, COMP BIOCHEM PHYS A, V129, P695, DOI 10.1016/S1095-6433(01)00333-6; Carey F.G., 1985, Memoirs of the Southern California Academy of Sciences, V9, P92; CAREY FG, 1971, AM ZOOL, V11, P137; Collette B.B., 1978, P7; Compagno L. J. V., 1998, FAO IDENTIFICATION G, P1274; Coughlin DJ, 1996, J EXP BIOL, V199, P459; Donley JM, 2003, J EXP BIOL, V206, P1117, DOI 10.1242/jeb.00206; Gemballa S, 2003, J EVOLUTION BIOL, V16, P966, DOI 10.1046/j.1420-9101.2003.00588.x; Gemballa S, 2003, P ROY SOC B-BIOL SCI, V270, P1229, DOI 10.1098/rspb.2003.2345; Graham JB, 2000, ZOOL J LINN SOC-LOND, V129, P419, DOI 10.1111/j.1096-3642.2000.tb00612.x; JAYNE BC, 1995, J EXP BIOL, V198, P585; Joseph J., 1988, P1; Katz SL, 2002, J EXP BIOL, V205, P2251; Katz SL, 1999, J EXP BIOL, V202, P529; Katz SL, 2001, NATURE, V410, P770, DOI 10.1038/35071170; Knower T., 1998, THESIS U CALIFORNIA; LIGHTHILL MJ, 1969, ANNU REV FLUID MECH, V1, P413, DOI 10.1146/annurev.fl.01.010169.002213; Lindsey CC, 1978, FISH PHYSIOL, VVII, DOI DOI 10.1016/S1546-5098(08)60163-6; Magnuson J.J., 1979, FISH PHYSIOL, V7, P239, DOI DOI 10.1016/S1546-5098(08)60166-1; Motani R, 2002, NATURE, V415, P309, DOI 10.1038/415309a; Reif W.-E., 1986, Zoologische Jahrbuecher Abteilung fuer Anatomie und Ontogenie der Tiere, V114, P221; Sfakiotakis M, 1999, IEEE J OCEANIC ENG, V24, P237, DOI 10.1109/48.757275; Shadwick RE, 1998, AM ZOOL, V38, P755; Shadwick RE, 1999, J EXP BIOL, V202, P2139; Webb P.W., 1975, B FISH RES BOARD CAN, V190, P1, DOI DOI 10.1002/RRA.1371; WESTNEAT MW, 1993, J MORPHOL, V217, P183, DOI 10.1002/jmor.1052170207	27	118	124	13	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	2004	429	6987					61	65		10.1038/nature02435	http://dx.doi.org/10.1038/nature02435			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129279				2022-12-28	WOS:000221222100043
J	Garcia-Bellido, DC; Collins, DH				Garcia-Bellido, DC; Collins, DH			Moulting arthropod caught in the act	NATURE			English	Editorial Material									Royal Ontario Museum, Dept Palaeobiol, Toronto, ON M5S 2C6, Canada; Univ Complutense Madrid, Fac Ciencias Geol, Dept Paleontol, E-28040 Madrid, Spain	Royal Ontario Museum; Complutense University of Madrid	Garcia-Bellido, DC (corresponding author), Royal Ontario Museum, Dept Palaeobiol, Toronto, ON M5S 2C6, Canada.	desc@rom.on.ca	Garcia-Bellido, Diego/AAF-9043-2021	Garcia-Bellido, Diego/0000-0003-1922-9836				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Brandt DS, 2002, ALCHERINGA, V26, P399, DOI 10.1080/03115510208619264; Edgecombe GD, 1999, J PALEONTOL, V73, P263, DOI 10.1017/S0022336000027761; KUNKEL JG, 1975, BIOL BULL, V148, P259, DOI 10.2307/1540546; Matsuda H, 2003, FISHERIES SCI, V69, P124, DOI 10.1046/j.1444-2906.2003.00596.x; Nielsen C, 2003, ZOOL SCR, V32, P475, DOI 10.1046/j.1463-6409.2003.00122.x; Valentine JW, 2000, EVOL DEV, V2, P152, DOI 10.1046/j.1525-142x.2000.00043.x; Whittington H.B., 1971, Bull geol Surv Can, VNo. 209, P1; Wills MA, 1998, ARTHROPOD FOSSILS AND PHYLOGENY, P33	9	28	30	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 6	2004	429	6987					40	40		10.1038/429040a	http://dx.doi.org/10.1038/429040a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129272				2022-12-28	WOS:000221222100034
J	Reilley, B; Puertas, G; Coutin, AS				Reilley, B; Puertas, G; Coutin, AS			The battle for access - Hhealth care in Afghanistan	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Med Sans Frontieres, New York, NY 10016 USA; Med Sans Frontieres, Herat, Afghanistan; Med Sans Frontieres, Kabul, Afghanistan		Reilley, B (corresponding author), Med Sans Frontieres, New York, NY 10016 USA.								0	5	5	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1927	1929		10.1056/NEJMp038253	http://dx.doi.org/10.1056/NEJMp038253			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128889				2022-12-28	WOS:000221218800001
J	Zile, MR; Baicu, CF; Gaasch, WH				Zile, MR; Baicu, CF; Gaasch, WH			Diastolic heart failure - Abnormalities in active relaxation and passive stiffness of the left ventricle	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TWO-DIMENSIONAL ECHOCARDIOGRAPHY; PRESERVED EJECTION FRACTION; SYSTOLIC FUNCTION; 2-DIMENSIONAL ECHOCARDIOGRAPHY; MYOCARDIAL RELAXATION; THERAPEUTIC OPTIONS; DIAGNOSTIC-CRITERIA; MAGNETIC-RESONANCE; PART I; VOLUME	BACKGROUND Patients with signs and symptoms of heart failure and a normal left ventricular ejection fraction are said to have diastolic heart failure. It has traditionally been thought that the pathophysiological cause of heart failure in these patients is an abnormality in the diastolic properties of the left ventricle; however, this hypothesis remains largely unproven. METHODS We prospectively identified 47 patients who met the diagnostic criteria for definite diastolic heart failure; all the patients had signs and symptoms of heart failure, a normal ejection fraction, and an increased left ventricular end-diastolic pressure. Ten patients who had no evidence of cardiovascular disease served as controls. Left ventricular diastolic function was assessed by means of cardiac catheterization and echocardiography. RESULTS The patients with diastolic heart failure had abnormal left ventricular relaxation and increased left ventricular chamber stiffness. The mean ( +/- SD) time constant for the isovolumic-pressure decline (tau) was longer in the group with diastolic heart failure than in the control group ( 59 +/- 14 msec vs. 35 +/- 10 msec, P = 0.01). The diastolic pressure - volume relation was shifted up and to the left in the patients with diastolic heart failure as compared with the controls. The corrected left ventricular passive-stiffness constant was significantly higher in the group with diastolic heart failure than in the control group (0.03 +/- 0.01 vs. 0.01 +/- 0.01, P< 0.001). CONCLUSIONS Patients with heart failure and a normal ejection fraction have significant abnormalities in active relaxation and passive stiffness. In these patients, the pathophysiological cause of elevated diastolic pressures and heart failure is abnormal diastolic function.	Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA; Lahey Clin Fdn, Dept Cardiovasc Med, Burlington, MA USA; Univ Massachusetts, Sch Med, Div Cardiovasc Med, Worcester, MA USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Lahey Hospital & Medical Center; University of Massachusetts System; University of Massachusetts Worcester	Zile, MR (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, 135 Rutledge Ave,Suite 1201,POB 250592, Charleston, SC 29425 USA.	zilem@musc.edu		Zile, Michael/0000-0001-7076-221X				Aurigemma G P, 1995, Curr Probl Cardiol, V20, P361; Aurigemma GP, 1999, AM J CARDIOL, V83, P792, DOI 10.1016/S0002-9149(98)00996-5; BLAUSTEIN AS, 1981, CIRC RES, V49, P633, DOI 10.1161/01.RES.49.3.633; Burkhoff D, 2003, CIRCULATION, V107, P656, DOI 10.1161/01.CIR.0000053947.82595.03; BYRD BF, 1985, J AM COLL CARDIOL, V6, P1021, DOI 10.1016/S0735-1097(85)80304-1; Chen HH, 2002, J CARD FAIL, V8, P279, DOI 10.1054/jcaf.2002.128871; Dauterman KW, 2001, J CARD FAIL, V7, P221, DOI 10.1054/jcaf.2001.26896; Fraites TJ, 1997, CIRCULATION, V96, P4408; Gaasch WH, 2004, ANNU REV MED, V55, P373, DOI 10.1146/annurev.med.55.091902.104417; Gandhi SK, 2001, NEW ENGL J MED, V344, P17, DOI 10.1056/NEJM200101043440103; GORDON EP, 1983, J AM COLL CARDIOL, V2, P506, DOI 10.1016/S0735-1097(83)80278-2; Gottdiener JS, 2002, ANN INTERN MED, V137, P631, DOI 10.7326/0003-4819-137-8-200210150-00006; Grothues F, 2002, AM J CARDIOL, V90, P29, DOI 10.1016/S0002-9149(02)02381-0; HERREGODS MC, 1994, EUR HEART J, V15, P1070, DOI 10.1093/oxfordjournals.eurheartj.a060630; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; KITZMAN DW, 1991, J AM COLL CARDIOL, V17, P1065, DOI 10.1016/0735-1097(91)90832-T; Kitzman DW, 2002, JAMA-J AM MED ASSOC, V288, P2144, DOI 10.1001/jama.288.17.2144; KITZMAN DW, 1991, J AM COLL CARDIOL, V18, P1243, DOI 10.1016/0735-1097(91)90542-H; Konstam MA, 2002, CIRCULATION, V105, P2244, DOI 10.1161/01.CIR.0000017420.85607.2D; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Little W C, 2000, Heart Fail Rev, V5, P301, DOI 10.1023/A:1026503028065; Lloyd-Jones DM, 2002, CIRCULATION, V106, P3068, DOI 10.1161/01.CIR.0000039105.49749.6F; McMurray J, 2002, CIRCULATION, V105, P2223, DOI 10.1161/01.CIR.0000014771.38666.22; McMurray J, 2002, CIRCULATION, V105, P2099, DOI 10.1161/01.CIR.0000014763.63528.9D; MIRSKY I, 1990, PROG CARDIOVASC DIS, V32, P291, DOI 10.1016/0033-0620(90)90018-W; Nikitin NP, 2002, AM J CARDIOL, V90, P1174, DOI 10.1016/S0002-9149(02)02794-7; NIKOLIC S, 1988, CIRC RES, V62, P1210, DOI 10.1161/01.RES.62.6.1210; NIKOLIC S, 1988, CIRC RES, V62, P1059; Pak PH, 1996, CIRCULATION, V94, P52, DOI 10.1161/01.CIR.94.1.52; PAK RH, 1996, CIRCULATION, V94, P2668; PASIPOULARIDES A, 1986, CIRCULATION, V74, P991, DOI 10.1161/01.CIR.74.5.991; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; Smith GL, 2003, J AM COLL CARDIOL, V41, P1510, DOI 10.1016/S0735-1097(03)00185-2; Tsutsui H, 2001, AM J CARDIOL, V88, P530, DOI 10.1016/S0002-9149(01)01732-5; Vasan RS, 2000, CIRCULATION, V101, P2118, DOI 10.1161/01.CIR.101.17.2118; Vasan RS, 1999, J AM COLL CARDIOL, V33, P1948, DOI 10.1016/S0735-1097(99)00118-7; Warner JG, 1999, J AM COLL CARDIOL, V33, P1567, DOI 10.1016/S0735-1097(99)00048-0; Weisfeldt M L, 1980, Eur Heart J, VSuppl A, P119; WEISS JL, 1976, J CLIN INVEST, V58, P751, DOI 10.1172/JCI108522; YELLIN EL, 1986, AM J PHYSIOL, V250, P620; Zile MR, 2001, CIRCULATION, V104, P779, DOI 10.1161/hc3201.094226; Zile MR, 2003, J AM COLL CARDIOL, V41, P1519, DOI 10.1016/S0735-1097(03)00186-4; Zile MR, 2002, CIRCULATION, V105, P1387, DOI 10.1161/hc1102.105289	43	1020	1070	0	46	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1953	1959		10.1056/NEJMoa032566	http://dx.doi.org/10.1056/NEJMoa032566			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128895				2022-12-28	WOS:000221218800007
J	Champaneria, MC; Axtell, S				Champaneria, MC; Axtell, S			Cultural competence training in US medical schools	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STUDENTS; EDUCATION		Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Champaneria, MC (corresponding author), Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.							Beagan BL, 2003, ACAD MED, V78, P605, DOI 10.1097/00001888-200306000-00011; Betancourt JR, 2003, ACAD MED, V78, P560, DOI 10.1097/00001888-200306000-00004; Crandall SJ, 2003, ACAD MED, V78, P588, DOI 10.1097/00001888-200306000-00007; Flores G, 2000, ACAD MED, V75, P451, DOI 10.1097/00001888-200005000-00015; Flores G, 2000, J PEDIATR-US, V136, P14, DOI 10.1016/S0022-3476(00)90043-X; Genao I, 2003, AM J MED SCI, V326, P136, DOI 10.1097/00000441-200309000-00006; Godkin MA, 2001, FAM MED, V33, P178; Haq C, 2000, FAM MED, V32, P566; Kagawa-Singer M, 2003, ACAD MED, V78, P577, DOI 10.1097/00001888-200306000-00006; London RF, 1999, JAMA-J AM MED ASSOC, V282, P875, DOI 10.1001/jama.282.9.875; LUM CK, 1994, ACAD MED, V69, P239, DOI 10.1097/00001888-199403000-00021; Mutchnick IS, 2003, ACAD MED, V78, pS1, DOI 10.1097/00001888-200310001-00002	12	22	22	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2004	291	17					2142	2142		10.1001/jama.291.17.2142	http://dx.doi.org/10.1001/jama.291.17.2142			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JR	15126447				2022-12-28	WOS:000221174300036
J	Boynton, PM; Greenhalgh, T				Boynton, PM; Greenhalgh, T			Hands-on guide to questionnaire research - Selecting, designing, and developing your questionnaire	BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; VAGUE QUANTIFIERS; SELF-REPORT; INSTRUMENTS; ISSUES; SCALES		UCL, Dept Primary Care & Populat Sci, London N19 5LW, England	University of London; University College London	Boynton, PM (corresponding author), UCL, Dept Primary Care & Populat Sci, Archway Campus, London N19 5LW, England.	p.boynton@pcps.ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Boynton, Petra/0000-0001-6699-2266				Aaronson N, 2002, QUAL LIFE RES, V11, P193; Adams AS, 1999, INT J QUAL HEALTH C, V11, P187, DOI 10.1093/intqhc/11.3.187; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Anderson RT, 1996, PHARMACOECONOMICS, V10, P336, DOI 10.2165/00019053-199610040-00004; BEURSKENS AJ, 1995, SPINE, V20, P1017, DOI 10.1097/00007632-199505000-00008; Bouchard S, 1997, J ANXIETY DISORD, V11, P89, DOI 10.1016/S0887-6185(96)00037-0; Bowling A, 2000, RES METHODS HLTH INV; Bowling A., 1997, RES METHODS HLTH; BOYNTON PM, IN PRESS BMJ; BRADBURN NM, 1979, PUBLIC OPIN QUART, V43, P92, DOI 10.1086/268494; Bradley C., 1994, HDB PSYCHOL DIABETES, V1; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; *DEP HLTH, 2002, RES GOV FRAM HLTH SO; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; Drewnowski A, 2001, NUTR REV, V59, P370; Fox C, 1996, J Health Soc Policy, V8, P39, DOI 10.1300/J045v08n01_04; Gariti P, 2002, DRUG ALCOHOL DEPEN, V65, P191, DOI 10.1016/S0376-8716(01)00162-4; Garratt AN, 2002, BMJ-BRIT MED J, V324, P1417, DOI 10.1136/bmj.324.7351.1417; Gilbody SM, 2001, BRIT MED J, V322, P406, DOI 10.1136/bmj.322.7283.406; Gillham, 2000, DEV QUESTIONNAIRE RE; HOUTKOOPSTEENST.H, 2000, INTERACTION STANDARD; Howie JGR, 1998, FAM PRACT, V15, P165, DOI 10.1093/fampra/15.2.165; HOWITT D, 2000, 1 STEPS RES STAT; JOYCE CRB, 1995, PATIENT EDUC COUNS, V26, P319, DOI 10.1016/0738-3991(95)00734-H; LABAW PJ, 1980, ADV QUESTIONNAIRE DE; Little P, 1996, FAM PRACT, V13, P477, DOI 10.1093/fampra/13.5.477; McColl E., 2000, USE DESIGN QUESTIONN; Murray P, 1999, Accid Emerg Nurs, V7, P148, DOI 10.1016/S0965-2302(99)80074-5; Oppenheim A. N., 1992, QUESTIONNAIRE DESIGN; Robson C., 1993, REAL WORLD RES RESOU; Sapsford R, 1999, SURVEY RES; SCHAEFFER NC, 1991, PUBLIC OPIN QUART, V55, P395, DOI 10.1086/269270; Sudman S., 1983, ASKING QUESTIONS PRA; VanHook MP, 1996, HEALTH SOC WORK, V21, P230, DOI 10.1093/hsw/21.3.230; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WIDERSZALBAZYL M, 2000, INT J OCCUPATIONAL S, P59; Wolfe F, 1997, J RHEUMATOL, V24, P990	37	496	509	12	157	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 29	2004	328	7451					1312	1315		10.1136/bmj.328.7451.1312	http://dx.doi.org/10.1136/bmj.328.7451.1312			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	826PN	15166072	Green Submitted, Green Published			2022-12-28	WOS:000221841100029
J	Maissi, E; Marteau, TM; Hankins, M; Moss, S; Legood, R; Gray, A				Maissi, E; Marteau, TM; Hankins, M; Moss, S; Legood, R; Gray, A			Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANXIETY; INFECTION; CANCER	Objective To describe the psychological impact on women of being tested for human papillomavirus (HPV) when smear test results are borderline or mildly dyskaryotic. Design Cross sectional questionnaire study. Setting Two centres participating in an English pilot study of HPV testing in women with borderline or mildly dyskaryotic smear test results. Participants Women receiving borderline or mildly dyskaryotic smear test results tested for HPV and found to be HPV positive (n = 536) or HPV negative (n 33 1); and women not tested for HPV with borderline or mildly dyskaryotic smear results (n = 143) or normal smear results (n 366). Main outcome measures State anxiety, distress, and concern about test result, assessed within four weeks of receipt of results. Results Women with borderline or mildly dyskaryotic smear results who were HPV positive were more anxious, distressed, and concerned than the other three groups. Three variables independently predicted anxiety in HPV positive women: younger age (beta = - 0.11, P = 0.03), higher perceived risk of cervical cancer (beta = 0.17, P < 0.001), and reporting that they did not understand the meaning of test results (beta = 0.17, P < 0.001). Testing HPV negative was not reassuring: among women with abnormal smear test results, those who were HPV negative were no less anxious than those who were not tested for HPV. Conclusions Informing women more effectively about the meaning of borderline or mildly dyskaryotic smear test results and HPV status, in particular about the absolute risks of cervical cancer and the prevalence of HPV infection, may avoid some anxiety for those who are HPV positive while achieving some reassurance for those who test HPV negative.	Kings Coll London, Inst Psychiat, Dept Psychol, Hlth Psychol Sect, London SE1 9RT, England; Inst Canc Res, Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England; Univ Oxford, Dept Publ Hlth, Hlth Econ Res Ctr, Oxford OX3 7LF, England	University of London; King's College London; University of London; Institute of Cancer Research - UK; University of Oxford	Marteau, TM (corresponding author), Kings Coll London, Inst Psychiat, Dept Psychol, Hlth Psychol Sect, London SE1 9RT, England.		Legood, Rosa/GQZ-9121-2022	Legood, Rosa/0000-0003-2761-5227; Hankins, Matthew/0000-0002-1437-9117; Marteau, Theresa/0000-0003-3025-1129				BRIDGES KW, 1986, BRIT J PSYCHIAT, V148, P548, DOI 10.1192/bjp.148.5.548; Clarke P, 1996, INT J STD AIDS, V7, P197, DOI 10.1258/0956462961917618; Cohen J., 1988, STAT POWER ANAL BEHA, DOI DOI 10.1016/B978-0-12-179060-8.50006-2; Conaglen HM, 2001, INT J STD AIDS, V12, P651, DOI 10.1258/0956462011923877; Croyle R.T., 1991, MENTAL REPRESENTATIO, P85, DOI DOI 10.1007/978-1-4613-9074-9_5; CUZICK J, 1999, HEALTH TECHNOL ASSES, V3, P1; FILIBERTI A, 1993, J PSYCHOSOM OBST GYN, V14, P145, DOI 10.3109/01674829309084437; Goel V, 1996, PRENATAL DIAG, V16, P425, DOI 10.1002/(SICI)1097-0223(199605)16:5<425::AID-PD874>3.3.CO;2-U; JOHNSTON M, 1988, HDB LIFE STRESS COGN; Jorm AF, 2000, PSYCHOL MED, V30, P11, DOI 10.1017/S0033291799001452; LERMAN C, 1991, AM J OBSTET GYNECOL, V165, P658, DOI 10.1016/0002-9378(91)90304-A; MACLEOD C, 1986, J ABNORM PSYCHOL, V95, P15, DOI 10.1037/0021-843X.95.1.15; MANGIONE TW, 1995, APPL SOCIAL RES METH, V40; MARTEAU TM, 1990, BRIT J OBSTET GYNAEC, V97, P859, DOI 10.1111/j.1471-0528.1990.tb02586.x; Marteau TM, 1996, BRIT J HEALTH PSYCH, V1, P181, DOI 10.1111/j.2044-8287.1996.tb00501.x; Marteau TM, 2001, BRIT MED J, V322, P526, DOI 10.1136/bmj.322.7285.526; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Maw RD, 1998, INT J STD AIDS, V9, P571, DOI 10.1258/0956462981921143; McCaffery KJ, 2002, JAMA-J AM MED ASSOC, V288, P1350, DOI 10.1001/jama.288.11.1350; Petry KU, 2003, BRIT J CANCER, V88, P1570, DOI 10.1038/sj.bjc.6600918; Petticrew MP, 2000, HEALTH TECHNOL ASSES, V4, P1; Raffle AE, 2003, BRIT MED J, V326, P901, DOI 10.1136/bmj.326.7395.901; REED BD, 1999, J AM COLL HEALTH, V40, P227; Rogstad KE, 2002, BJOG-INT J OBSTET GY, V109, P364, DOI 10.1111/j.1471-0528.2002.99023.x; Shaw C, 1999, SOC SCI MED, V49, P1571, DOI 10.1016/S0277-9536(99)00244-0; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WILKINSON C, 1990, BRIT MED J, V300, P440, DOI 10.1136/bmj.300.6722.440	27	152	159	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	2004	328	7451					1293	1296B		10.1136/bmj.328.7451.1293	http://dx.doi.org/10.1136/bmj.328.7451.1293			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	826PN	15166066	Green Accepted, Bronze, Green Submitted, Green Published			2022-12-28	WOS:000221841100021
J	Patel, RR; Murphy, DJ				Patel, RR; Murphy, DJ			Forceps delivery in modern obstetric practice	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ASSISTED VAGINAL DELIVERY; RANDOMIZED CONTROLLED-TRIAL; OPERATIVE DELIVERY; CESAREAN-SECTION; VACUUM EXTRACTION; NEONATAL MORBIDITY; INFANT OUTCOMES; RISK-FACTORS; CHILDBIRTH; LABOR	This review discusses the specific uses and potential advantages of forceps over other modes of delivery. To enable women to make an informed choice about mode of delivery, obstetricians need to be adequately trained and supervised in the use of forceps.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Div Maternal & Child Hlth Sci, Dundee DD1 9SY, Scotland; Univ Bristol, St Michaels Hosp, Div Obstet & Gynecol, Bristol BS2 8EG, Avon, England	University of Dundee; University of Bristol	Murphy, DJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Div Maternal & Child Hlth Sci, Dundee DD1 9SY, Scotland.	D.J.Murphy@dundee.ac.uk		Murphy, Deirdre/0000-0001-6074-6718; Patel, Roshni/0000-0002-1399-3131				American College of Obstetricians and Gynecologists, 2000, EV CES DEL; [Anonymous], 2000, COCHRANE DB SYST REV; Badawi N, 1998, BMJ-BRIT MED J, V317, P1554, DOI 10.1136/bmj.317.7172.1554; Bahl R, 2004, BMJ-BRIT MED J, V328, P311, DOI 10.1136/bmj.37942.546076.44; Bewley S, 2002, BJOG-INT J OBSTET GY, V109, P593, DOI 10.1111/j.1471-0528.2002.01706.x; Bofill JA, 1996, OBSTET GYNECOL, V88, P1007; BRINK S, 2002, TOO POSH PUSH; CHISWICK ML, 1979, BRIT MED J, V1, P7, DOI 10.1136/bmj.1.6155.7; CHOW SLS, 1987, MED J AUSTRALIA, V146, P616, DOI 10.5694/j.1326-5377.1987.tb120438.x; *COLL PHYS SURG MA, GUID STAT ASS VAG DE; de Leeuw JW, 2001, BRIT J OBSTET GYNAEC, V108, P383, DOI 10.1016/S0306-5456(00)00090-5; DiMatteo MR, 1996, HEALTH PSYCHOL, V15, P303, DOI 10.1037/0278-6133.15.4.303; Eason E, 2002, CAN MED ASSOC J, V166, P326; Farrell SA, 2002, CAN MED ASSOC J, V166, P337; Fitzpatrick M, 2003, BJOG-INT J OBSTET GY, V110, P424, DOI 10.1016/S1470-0328(03)02973-2; Gardella C, 2001, AM J OBSTET GYNECOL, V185, P896, DOI 10.1067/mob.2001.117309; Gei AF, 1999, OBSTET GYN CLIN N AM, V26, P345, DOI 10.1016/S0889-8545(05)70079-6; Handa VL, 2001, OBSTET GYNECOL, V98, P225, DOI 10.1016/S0029-7844(01)01445-4; Hankins GDV, 1996, AM J OBSTET GYNECOL, V175, P275, DOI 10.1016/S0002-9378(96)70135-7; Hankins GDV, 1999, AM J PERINAT, V16, P23, DOI 10.1055/s-2007-993831; *INF STAT DIV, BIRTHS SCOTL REP 200; Johanson R, 2002, BRIT MED J, V324, P892, DOI 10.1136/bmj.324.7342.892; Johanson R., 2000, INSTRUMENTAL VAGINAL; Johanson RB, 1999, BRIT J OBSTET GYNAEC, V106, P544, DOI 10.1111/j.1471-0528.1999.tb08322.x; Jolly J, 1999, BRIT J OBSTET GYNAEC, V106, P227, DOI 10.1111/j.1471-0528.1999.tb08235.x; Kabiru WN, 2001, AM J OBSTET GYNECOL, V184, P1112, DOI 10.1067/mob.2001.115178; Kozak LJ, 2002, BIRTH-ISS PERINAT C, V29, P157; Land R, 2001, AUST NZ J OBSTET GYN, V41, P249, DOI 10.1111/j.1479-828X.2001.tb01224.x; Lavender T, 1998, BIRTH-ISS PERINAT C, V25, P215, DOI 10.1046/j.1523-536X.1998.00215.x; LIEBLING RE, 2004, IN PRESS AM J OBSTET; Liu SL, 2002, AM J OBSTET GYNECOL, V187, P681, DOI 10.1067/mob.2002.125765; Martinez J., 2002, BIRTHS FINAL DATA 20, P001; Matthews TG, 2003, BJOG-INT J OBSTET GY, V110, P346, DOI 10.1016/S1470-0328(03)02710-1; Meniru GI, 1996, BRIT J OBSTET GYNAEC, V103, P168, DOI 10.1111/j.1471-0528.1996.tb09670.x; Mesleh RA, 2002, SAUDI MED J, V23, P811; Morrell CJ, 2000, BRIT MED J, V321, P593, DOI 10.1136/bmj.321.7261.593; Murphy DJ, 2002, HUM REPROD, V17, P1914, DOI 10.1093/humrep/17.7.1914; Murphy DJ, 2001, LANCET, V358, P1203, DOI 10.1016/S0140-6736(01)06341-3; Murphy DJ, 2003, BRIT MED J, V327, P1132, DOI 10.1136/bmj.327.7424.1132; Murphy DJ, 2003, AM J OBSTET GYNECOL, V188, P542, DOI 10.1067/mob.2003.67; Okunwobi-Smith Y, 2000, BRIT J OBSTET GYNAEC, V107, P467, DOI 10.1111/j.1471-0528.2000.tb13263.x; Poma PA, 1999, AM J PERINAT, V16, P227, DOI 10.1055/s-2007-993863; RAMIN SM, 1993, OBSTET GYNECOL, V81, P307; Ransom SB, 2003, OBSTET GYNECOL, V101, P751, DOI 10.1016/S0029-7844(02)03129-0; Revah A, 1997, AM J OBSTET GYNECOL, V176, P200, DOI 10.1016/S0002-9378(97)80036-1; Roberts CL, 2002, PAEDIATR PERINAT EP, V16, P115, DOI 10.1046/j.1365-3016.2002.00409.x; Small R, 2000, BRIT MED J, V321, P1043, DOI 10.1136/bmj.321.7268.1043; Stephenson P A, 1993, Paediatr Perinat Epidemiol, V7, P45, DOI 10.1111/j.1365-3016.1993.tb00600.x; Thomas J., 2001, NATL SENTINEL CAESAR; Towner D, 1999, NEW ENGL J MED, V341, P1709, DOI 10.1056/NEJM199912023412301; Vacca A., 1999, CURRENT OBSTET GYNAE, V9, P41; Wen SW, 2001, AM J EPIDEMIOL, V153, P103, DOI 10.1093/aje/153.2.103	52	83	85	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	2004	328	7451					1302	1305		10.1136/bmj.328.7451.1302	http://dx.doi.org/10.1136/bmj.328.7451.1302			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826PN	15166069	Green Published			2022-12-28	WOS:000221841100026
J	Wilson, P				Wilson, P			Commentary: Legal issues of data anonymisation in research	BRITISH MEDICAL JOURNAL			English	Editorial Material									European Hlth Management Assoc, B-1000 Brussels, Belgium		Wilson, P (corresponding author), European Hlth Management Assoc, Rue De La Sci 4, B-1000 Brussels, Belgium.	petra.wilson@ehma.org						*RV DEP HLTH, 2000, WLR, V2, P622	1	11	11	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 29	2004	328	7451					1300	1301		10.1136/bmj.328.7451.1300	http://dx.doi.org/10.1136/bmj.328.7451.1300			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826PN	15166068	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000221841100023
J	Birchall, M				Birchall, M			Tongue transplantation	LANCET			English	Editorial Material							REPLANTATION		Univ Hosp Aintree, Head & Neck Canc Ctr, Liverpool L7AL, Merseyside, England		Birchall, M (corresponding author), Univ Hosp Aintree, Head & Neck Canc Ctr, Liverpool L7AL, Merseyside, England.	martinbirchall@btinternet.com						Buntic RF, 1998, PLAST RECONSTR SURG, V101, P1604, DOI 10.1097/00006534-199805000-00026; Day TA, 2000, MICROSURG, V20, P105, DOI 10.1002/(SICI)1098-2752(2000)20:3<105::AID-MICR2>3.0.CO;2-3; Dubernard JM, 2003, ANN SURG, V238, P128, DOI 10.1097/01.SLA.0000078945.70869.82; Hettiaratchy S, 2002, LANCET, V360, P5, DOI 10.1016/S0140-6736(02)09361-3; Klotzko AJ, 1999, NEW SCI, V162, P51; Marcen R, 2003, TRANSPL P, V35, P1714, DOI 10.1016/S0041-1345(03)00669-9; Mihalov ML, 1996, CLIN TRANSPLANT, V10, P248; Strome M, 2001, NEW ENGL J MED, V344, P1676, DOI 10.1056/NEJM200105313442204; Zuydam AC, 2000, BRIT J ORAL MAX SURG, V38, P513, DOI 10.1054/bjom.2000.0482; 2003, CDS REV, V96, P44; 2003, BBC NEWS        0722	11	30	33	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	2004	363	9422					1663	1663		10.1016/S0140-6736(04)16287-9	http://dx.doi.org/10.1016/S0140-6736(04)16287-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158625				2022-12-28	WOS:000221546300004
J	Coskun, UC; Wei, TC; Vishveshwara, S; Goldbart, PM; Bezryadin, A				Coskun, UC; Wei, TC; Vishveshwara, S; Goldbart, PM; Bezryadin, A			h/e magnetic flux modulation of the energy gap in nanotube quantum dots	SCIENCE			English	Article							CARBON NANOTUBES; ELECTRONIC-STRUCTURE; TRANSPORT; TUBULES	We report experiments on quantum dot single-electron-tunneling ( SET) transistors made from short multiwall nanotubes and threaded by magnetic flux. Such systems allow us to probe the electronic energy spectrum of the nanotube and its dependence on the magnetic field. Evidence is provided for the interconversion between gapped (semiconducting) and ungapped ( metallic) states. Our tubes exhibit h/e-period magnetic flux dependence, in agreement with simple tight-binding calculations.	Univ Illinois, Dept Phys, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Bezryadin, A (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.	bezryadi@uiuc.edu	Bezryadin, Alexey/H-1815-2016	Bezryadin, Alexey/0000-0002-4822-6960; Coskun, Ulas Cosar/0000-0003-0279-7888; Wei, Tzu-Chieh/0000-0003-4897-3410				AHARONOV Y, 1959, PHYS REV, V115, P485, DOI 10.1103/PhysRev.115.485; AJIKI H, 1993, J PHYS SOC JPN, V62, P1255, DOI 10.1143/JPSJ.62.1255; Ajiki H, 1996, J PHYS SOC JPN, V65, P505, DOI 10.1143/JPSJ.65.505; *ALF AES, MULT NAN STOCK 43197; Ando T, 2000, SEMICOND SCI TECH, V15, pR13, DOI 10.1088/0268-1242/15/6/201; Bachtold A, 1999, NATURE, V397, P673, DOI 10.1038/17755; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; Ebbesen TW, 1996, NATURE, V382, P54, DOI 10.1038/382054a0; Frank S, 1998, SCIENCE, V280, P1744, DOI 10.1126/science.280.5370.1744; Fujiwara A, 1999, PHYS REV B, V60, P13492, DOI 10.1103/PhysRevB.60.13492; GRABERT H, 1992, SINGLE CHARGE TUNNEL; IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Kane CL, 1997, PHYS REV LETT, V78, P1932, DOI 10.1103/PhysRevLett.78.1932; Kouwenhoven LP, 1997, NATO ADV SCI I E-APP, V345, P105; Lee JO, 2000, SOLID STATE COMMUN, V115, P467, DOI 10.1016/S0038-1098(00)00222-2; LITTLE WA, 1962, PHYS REV LETT, V9, P9, DOI 10.1103/PhysRevLett.9.9; LU JP, 1995, PHYS REV LETT, V74, P1123, DOI 10.1103/PhysRevLett.74.1123; MINTMIRE JW, 1992, PHYS REV LETT, V68, P631, DOI 10.1103/PhysRevLett.68.631; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; Roche S, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.121401; Roche S, 2000, PHYS REV B, V62, P16092, DOI 10.1103/PhysRevB.62.16092; SAITO R, 1992, APPL PHYS LETT, V60, P2204, DOI 10.1063/1.107080; Saito R, 1998, PHYS PROPERTIES CARB; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139	26	123	126	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	2004	304	5674					1132	1134		10.1126/science.1096647	http://dx.doi.org/10.1126/science.1096647			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155943				2022-12-28	WOS:000221524500035
J	Maugeri, L				Maugeri, L			Oil: Never cry wolf - Why the petroleum age is far from over	SCIENCE			English	Editorial Material									Eni Spa, Corp Strategies, Rome, Italy	Eni SpA	Maugeri, L (corresponding author), Eni Spa, Corp Strategies, Rome, Italy.							Adelman MA, 1995, GENIE OUT BOTTLE; ADELMAN MA, 2002, NATURAL GAS SUPPLY 2; *BRIT PETR, 2003, BPS STAT REV WORLD E; CAMPBELL C, 1989, OIL PRICE LEAP EARLY; *DTSCH BANK, 2003, GLOBAL ENERGY WI JUN; Goodstein D., 2004, OUT GAS END AGE OIL; HUBBERT KM, 1956, DRILLING PRODUCTION; *INT EN AG, 2001, WORLD EN OUTL 2001 I; KLETT TR, 2003, AAPG MEMOIR, V78, P107; USGS, 2000, WORLD PETR ASS 2000; Yergin D., 1991, PRIZE EPIC QUEST OIL, P194; 2003, WORLD OIL        AUG; 2002, OIL GAS J        DEC; 2003, ECONOMIST       1023, P11; 2004, PIW PETROL INTE 0119; 2003, ECONOMIST       1023, P61; 2003, ENI WORLD OIL GA MAY	17	61	67	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	2004	304	5674					1114	1115		10.1126/science.1096427	http://dx.doi.org/10.1126/science.1096427			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155935				2022-12-28	WOS:000221524500025
J	Yamashita, S; Miyagi, C; Fukada, T; Kagara, N; Che, YS; Hirano, T				Yamashita, S; Miyagi, C; Fukada, T; Kagara, N; Che, YS; Hirano, T			Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer	NATURE			English	Article							TRANSCRIPTION FACTOR SNAIL; BREAST-CANCER; MUTANT EMBRYOS; CELL MOVEMENTS; WILD-TYPE; EXPRESSION; STAT3; GENE; MORPHOGENESIS; INVOLVEMENT	Vertebrate gastrulation is a critical step in the establishment of body plan. During gastrulation, epithelial-mesenchymal transition (EMT) occurs(1). EMT is one of the central events of embryonic development, organ and tissue regeneration, and cancer metastasis(1,2). Signal transducers and activators of transcription (STATs) mediate biological actions such as cell proliferation, differentiation and survival in response to cytokines and growth factors, in a variety of biological processes(3-6). STATs are also important in EMT during gastrulation, organogenesis, wound healing and cancer progression(7-9). We previously showed that STAT3 is activated in the organizer during zebrafish gastrulation and its activity is essential for gastrulation movements. The requirement for STAT3 is cell-autonomous for the anterior migration of gastrula organizer cells, and non-cell-autonomous for the convergence of neighbouring cells(10). The molecular mechanisms of STAT's action in EMT, however, are unknown. Here we identify LIV1, a breast-cancer-associated zinc transporter protein(11-13), as a downstream target of STAT3 that is essential and sufficient for STAT3's cell-autonomous role in the EMT of zebrafish gastrula organizer cells. Furthermore, we demonstrate that LIV1 is essential for the nuclear localization of zinc-finger protein Snail, a master regulator of EMT1,2,14,15. These results establish a molecular link between STAT3, LIV1 and Snail in EMT.	Osaka Univ, Grad Sch Frontier Biosci, Lab Dev Immunol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Sci, Dept Mol Oncol, Suita, Osaka 5650871, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Cytokine Signaling, Kanagawa 2300045, Japan	Osaka University; Osaka University; RIKEN	Hirano, T (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Lab Dev Immunol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	hirano@molonc.med.osaka-u.ac.jp	Hirano, Toshio/C-8194-2009					Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; KAMIMURA D, 2003, SIGNAL TRANSDUCERS A, P155; Kozlowski DJ, 2000, METH MOL B, V135, P349; MANNING DL, 1994, EUR J CANCER, V30A, P675, DOI 10.1016/0959-8049(94)90543-6; MANNING DL, 1988, MOL CELL ENDOCRINOL, V59, P205, DOI 10.1016/0303-7207(88)90105-0; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; SOLNICAKREZEL L, 1995, BIOESSAYS, V17, P931, DOI 10.1002/bies.950171106; Taylor KM, 2003, BIOCHEM J, V375, P51, DOI 10.1042/BJ20030478; Taylor KM, 2003, BBA-BIOMEMBRANES, V1611, P16, DOI 10.1016/S0005-2736(03)00048-8; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; THISSE C, 1995, DEV BIOL, V172, P86, DOI 10.1006/dbio.1995.0007; THISSE C, 1993, DEVELOPMENT, V119, P1203; Van Doren M, 2003, DEVELOPMENT, V130, P2355, DOI 10.1242/dev.00454; Yamashita S, 2002, DEV CELL, V2, P363, DOI 10.1016/S1534-5807(02)00126-0; YAMASHITA S, 2003, SIGNAL TRANSDUCERS A, P595	28	291	306	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					298	302		10.1038/nature02545	http://dx.doi.org/10.1038/nature02545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15129296				2022-12-28	WOS:000221505900043
J	Kuruvilla, S; Dzenowagis, J; Pleasant, A; Dwivedi, R; Murthy, N; Samuel, R; Scholtz, M				Kuruvilla, S; Dzenowagis, J; Pleasant, A; Dwivedi, R; Murthy, N; Samuel, R; Scholtz, M			Digital bridges need concrete foundations: lessons from the Health InterNetwork India	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIVIDE		WHO, Hlth InterNetwork, CH-1211 Geneva, Switzerland; Brown Univ, Providence, RI 02912 USA; WHO, Hlth InterNetwork India, New Delhi 110011, India; Fdn Res Hlth Syst, Ahmadabad 380015, Gujarat, India; WHO, Liaison Orissa, Orissa 751009, India; WHO, EIP HIN, CH-1211 Geneva 27, Switzerland	World Health Organization; Brown University; World Health Organization; World Health Organization; World Health Organization	Dzenowagis, J (corresponding author), WHO, EIP HIN, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	dzenowagisj@who.int		Kuruvilla, Shyama/0000-0002-0327-4467				Aronson Barbara, 2002, Health Info Libr J, V19, P164, DOI 10.1046/j.1471-1842.2002.t01-1-00391.x; Gourie-Devi M, 2003, EPILEPSIA, V44, P58, DOI 10.1046/j.1528-1157.44.s.1.12.x; *HLTH INT, 2003, HLTH INT IND PIL PRO; International Telecommunication Union (ITU), 2002, WORLD TEL DEV REP; LESSIG L, 2001, FUTURE IDEAS FAITH C; *NAT FAM HLTH SURV, 2000, NAT FAM HLTH SURV 2; *NUA, 2002, MAN ONL NUA SURV WEB; Piotrow P. T., 1997, HLTH COMMUNICATION L; *REG GEN CENS COMM, 2001, CENS IND; Smith R, 2003, BRIT MED J, V326, P238, DOI 10.1136/bmj.326.7383.238; *UN DEV PROGR IND, 2001, INT STAT HLTH STAT; *UN POP DIV, 2002, WORLD POP PROSP 2002; *UNCTAD, 2004, MILL IND DAT; United Nations, 2000, WE PEOPL ROL UN 21 C; Wade RH, 2002, GLOB GOV, V8, P443, DOI 10.1163/19426720-00804005	15	11	11	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2004	328	7449					1193	1196		10.1136/bmj.328.7449.1193	http://dx.doi.org/10.1136/bmj.328.7449.1193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142932	Green Published			2022-12-28	WOS:000221497500033
J	Klausmeier, CA; Litchman, E; Daufresne, T; Levin, SA				Klausmeier, CA; Litchman, E; Daufresne, T; Levin, SA			Optimal nitrogen-to-phosphorus stoichiometry of phytoplankton	NATURE			English	Article							N-P; RATIOS; PRODUCTIVITY	Redfield noted the similarity between the average nitrogen-to-phosphorus ratio in plankton (N: P = 16 by atoms) and in deep oceanic waters (N: P = 15; refs 1, 2). He argued that this was neither a coincidence, nor the result of the plankton adapting to the oceanic stoichiometry, but rather that phytoplankton adjust the N: P stoichiometry of the ocean to meet their requirements through nitrogen fixation, an idea supported by recent modelling studies(3,4). But what determines the N: P requirements of phytoplankton? Here we use a stoichiometrically explicit model of phytoplankton physiology and resource competition to derive from first principles the optimal phytoplankton stoichiometry under diverse ecological scenarios. Competitive equilibrium favours greater allocation to P-poor resource-acquisition machinery and therefore a higher N: P ratio; exponential growth favours greater allocation to P-rich assembly machinery and therefore a lower N: P ratio. P-limited environments favour slightly less allocation to assembly than N-limited or light-limited environments. The model predicts that optimal N: P ratios will vary from 8.2 to 45.0, depending on the ecological conditions. Our results show that the canonical Redfield N: P ratio of 16 is not a universal biochemical optimum, but instead represents an average of species-specific N: P ratios.	Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Rutgers State Univ, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA	Princeton University; University System of Georgia; Georgia Institute of Technology; Rutgers State University New Brunswick	Klausmeier, CA (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	christopher.klausmeier@biology.gatech.edu	Klausmeier, Christopher A/J-9339-2012; Levin, Simon A/J-1218-2014	Levin, Simon A/0000-0002-8216-5639; Klausmeier, Christopher/0000-0002-6987-5871; Litchman, Elena/0000-0001-7736-6332				AKSNES DL, 1991, MAR ECOL PROG SER, V70, P65, DOI 10.3354/meps070065; Behrenfeld MJ, 1997, LIMNOL OCEANOGR, V42, P1479, DOI 10.4319/lo.1997.42.7.1479; Bertilsson S, 2003, LIMNOL OCEANOGR, V48, P1721, DOI 10.4319/lo.2003.48.5.1721; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P352, DOI 10.1029/98PA00920; COPINMONTEGUT C, 1983, DEEP-SEA RES, V30, P31, DOI 10.1016/0198-0149(83)90031-6; DROOP MR, 1974, J MAR BIOL ASSOC UK, V54, P825, DOI 10.1017/S002531540005760X; Elser JJ, 1996, BIOSCIENCE, V46, P674, DOI 10.2307/1312897; Falkowski PG, 2000, J PHYCOL, V36, P3, DOI 10.1046/j.1529-8817.2000.99161.x; Geider RJ, 2002, EUR J PHYCOL, V37, P1, DOI 10.1017/S0967026201003456; Heldal M, 2003, LIMNOL OCEANOGR, V48, P1732, DOI 10.4319/lo.2003.48.5.1732; HUTCHINSON G, 1961, AM NAT, V95, P137, DOI 10.1086/282171; Karl DM, 2001, DEEP-SEA RES PT II, V48, P1529, DOI 10.1016/S0967-0645(00)00152-1; KIRK JTO, 1967, PLASTIDS THEIR CHEM, P6; KLAUSMEIER CA, IN PRESS LIMNOL OCEA; Lenton TM, 2000, GLOBAL BIOGEOCHEM CY, V14, P225, DOI 10.1029/1999GB900065; Letelier RM, 1996, MAR ECOL PROG SER, V133, P263, DOI 10.3354/meps133263; Litchman E, 2001, AM NAT, V157, P170, DOI 10.1086/318628; Pahlow M, 2000, SCIENCE, V287, P831, DOI 10.1126/science.287.5454.831; Quigg A, 2003, NATURE, V425, P291, DOI 10.1038/nature01953; RAVEN JA, 1980, AD MICROB PHYSL, V21, P147; REDFIELD AC, 1958, AM SCI, V46, P205; RHEE GY, 1980, J PHYCOL, V16, P486, DOI 10.1111/j.1529-8817.1980.tb03065.x; RHEE GY, 1978, LIMNOL OCEANOGR, V23, P10, DOI 10.4319/lo.1978.23.1.0010; SaLM Kooijman, 2000, DYNAMIC ENERGY MASS, DOI 10.1017/CBO9780511565403; Schneider B, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2002GB001871; SHUTER B, 1979, J THEOR BIOL, V78, P519, DOI 10.1016/0022-5193(79)90189-9; Sterner R.W, 2002, ECOLOGICAL STOICHIOM, DOI DOI 10.1086/382444; Tilman D., 1982, Monographs in Population Biology, pi; Tilman David, 1993, P13; Tyrrell T, 1999, NATURE, V400, P525, DOI 10.1038/22941	30	639	687	14	464	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988					171	174		10.1038/nature02454	http://dx.doi.org/10.1038/nature02454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141209				2022-12-28	WOS:000221356300038
J	Dark, JH				Dark, JH			Diagnosis of lung rejection	LANCET			English	Editorial Material							TRANSPLANT RECIPIENTS		Freeman Rd Hosp, Cardiopulm Transplant Unit, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Newcastle Freeman Hospital; Newcastle University - UK	Dark, JH (corresponding author), Freeman Rd Hosp, Cardiopulm Transplant Unit, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.	j.h.dark@ncl.ac.uk						Chhajed PN, 2003, J HEART LUNG TRANSPL, V22, P195, DOI 10.1016/S1053-2498(02)00462-X; GANESH JS, UK THORACIC TRANSPLA; Hernandez-Fuentes MP, 2003, IMMUNOL REV, V196, P247, DOI 10.1046/j.1600-065X.2003.00092.x; Hopkins PM, 2002, J HEART LUNG TRANSPL, V21, P1062, DOI 10.1016/S1053-2498(02)00442-4; Hosenpud JD, 2000, J HEART LUNG TRANSPL, V19, P909, DOI 10.1016/S1053-2498(00)00138-8; Palmer SM, 2003, AM J RESP CRIT CARE, V168, P628, DOI 10.1164/rccm.200303-447OC; Valentine VG, 2002, J HEART LUNG TRANSPL, V21, P319, DOI 10.1016/S1053-2498(01)00389-8	7	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	2004	363	9420					1487	1488		10.1016/S0140-6736(04)16183-7	http://dx.doi.org/10.1016/S0140-6736(04)16183-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135591				2022-12-28	WOS:000221302700003
J	Teichgraber, UKM; Benter, T				Teichgraber, UKM; Benter, T			Air embolism after the insertion of a central venous catheter	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Virchow Klinikum, D-13353 Berlin, Germany		Teichgraber, UKM (corresponding author), Virchow Klinikum, Charite Campus, D-13353 Berlin, Germany.		Teichgräber, med. Ulf/H-8562-2019	Teichgräber, med. Ulf/0000-0002-4048-3938					0	7	7	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					E17	E17		10.1056/ENEJMicm020866	http://dx.doi.org/10.1056/ENEJMicm020866			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128909				2022-12-28	WOS:000221218800012
J	Campbell, B; Vanslembroek, K; Whitehead, E; van de Wauwer, C; Eifell, R; Wyatt, M; Campbell, J				Campbell, B; Vanslembroek, K; Whitehead, E; van de Wauwer, C; Eifell, R; Wyatt, M; Campbell, J			Views of doctors on clinical correspondence: questionnaire survey and audit of content of letters	BRITISH MEDICAL JOURNAL			English	Article							REFERRAL LETTERS; COMMUNICATION; REPLIES		Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England; Freeman Rd Hosp, Dept Surg, Newcastle Upon Tyne NE7 7ON, Tyne & Wear, England; Peninsula Med Sch, Exeter EX2 5DW, Devon, England	University of Exeter; Newcastle Freeman Hospital; University of Exeter	Campbell, B (corresponding author), Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England.	bruce.campbell@nice.nhs.uk	Campbell, John/A-5792-2011	Campbell, John/0000-0002-6752-3493; Van De Wauwer, Caroline/0000-0002-0886-4917; Wyatt, Michael G/0000-0002-9144-4437				Grol R, 2003, BRIT J GEN PRACT, V53, P217; JACOBS LGH, 1990, BRIT MED J, V301, P470, DOI 10.1136/bmj.301.6750.470; NEWTON J, 1992, BRIT MED J, V304, P821, DOI 10.1136/bmj.304.6830.821; RUTHERFORD R, 1991, BRIT MED J, V303, P968; *WORK GROUP COP LE, 2002, COP LETT PAT REP DEP	5	25	25	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 1	2004	328	7447					1060	1061		10.1136/bmj.38058.801968.47	http://dx.doi.org/10.1136/bmj.38058.801968.47			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JT	15124610	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000221174500021
J	Oransky, I				Oransky, I			Ewald W Busse - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	2004	363	9419					1479	1479		10.1016/S0140-6736(04)16123-0	http://dx.doi.org/10.1016/S0140-6736(04)16123-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816ST	15139370				2022-12-28	WOS:000221130300038
J	Hughen, KA; Eglinton, TI; Xu, L; Makou, M				Hughen, KA; Eglinton, TI; Xu, L; Makou, M			Abrupt tropical vegetation response to rapid climate changes	SCIENCE			English	Article							CARBON-ISOTOPE ANALYSES; YOUNGER DRYAS CHRON; LAST DEGLACIATION; LATE QUATERNARY; POLAR ICE; ATLANTIC; RADIOCARBON; AFRICA; EVENT; LAKE	Identifying leads and lags between high- and low-latitude abrupt climate shifts is needed to understand where and how such events were triggered. Vascular plant biomarkers preserved in Cariaco basin sediments reveal rapid vegetation changes in northern South America during the last deglaciation, 15,000 to 10,000 years ago. Comparing the biomarker records to climate proxies from the same sediment core provides a precise measure of the relative timing of changes in different regions. Abrupt deglacial climate shifts in tropical and high- latitude North Atlantic regions were synchronous, whereas changes in tropical vegetation consistently lagged climate shifts by several decades.	Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA; Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA	Woods Hole Oceanographic Institution; Woods Hole Oceanographic Institution	Hughen, KA (corresponding author), Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA.	khughen@whoi.edu		Eglinton, Timothy/0000-0001-5060-2155				ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; Bonnefille R, 1995, QUATERNARY SCI REV, V14, P917, DOI 10.1016/0277-3791(95)00071-2; BRADLEY RS, 1999, PALEOCLIMATOLOGY, P358; Broecker WS, 2003, SCIENCE, V300, P1519, DOI 10.1126/science.1083797; Brook EJ, 1996, SCIENCE, V273, P1087, DOI 10.1126/science.273.5278.1087; Conte MH, 2002, NATURE, V417, P639, DOI 10.1038/nature00777; EGLINTON G, 1967, SCIENCE, V156, P1322, DOI 10.1126/science.156.3780.1322; Finkel RC, 1997, J GEOPHYS RES-OCEANS, V102, P26699, DOI 10.1029/97JC01282; Fogel M.L., 1993, ORGANIC GEOCHEMISTRY, P73, DOI DOI 10.1007/978-1-4615-2890-6_3; Freeman KH, 2001, GEOCHIM COSMOCHIM AC, V65, P1439, DOI 10.1016/S0016-7037(00)00573-1; FRIEDRICH M, IN PRESS RADIOCARBON; HAYES JM, 1993, MAR GEOL, V113, P111, DOI 10.1016/0025-3227(93)90153-M; Huang YS, 2000, GEOCHIM COSMOCHIM AC, V64, P3505, DOI 10.1016/S0016-7037(00)00445-2; Huang YS, 1999, GEOCHIM COSMOCHIM AC, V63, P1383, DOI 10.1016/S0016-7037(99)00074-5; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; Hughen KA, 2000, SCIENCE, V290, P1951, DOI 10.1126/science.290.5498.1951; Hughen KA, 1998, NATURE, V391, P65, DOI 10.1038/34150; HUGHEN KA, IN PRESS RADIOCARBON; ISLEBE GA, 1995, PALAEOGEOGR PALAEOCL, V117, P73, DOI 10.1016/0031-0182(95)00124-5; Kennett JP, 2000, SCIENCE, V288, P128, DOI 10.1126/science.288.5463.128; Kolattukudy P.E., 1976, CHEM BIOCH NATURAL W; LEYDEN BW, 1985, ECOLOGY, V66, P1279, DOI 10.2307/1939181; Marchitto TM, 1998, NATURE, V393, P557, DOI 10.1038/31197; Meyers PA, 1997, ORG GEOCHEM, V27, P213, DOI 10.1016/S0146-6380(97)00049-1; Ohkouchi N, 1997, ORG GEOCHEM, V27, P173, DOI 10.1016/S0146-6380(97)00080-6; Ramsey CB, 2001, RADIOCARBON, V43, P381; RIELEY G, 1991, NATURE, V352, P425, DOI 10.1038/352425a0; RINALDI M, 1996, 30 INT GEOL C BEIJ 4; SALTZMAN U, 2002, QUATERNARY RES, V58, P73; Schefuss E, 2003, GEOCHIM COSMOCHIM AC, V67, P1757, DOI 10.1016/S0016-7037(02)01414-X; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Severinghaus JP, 1999, SCIENCE, V286, P930, DOI 10.1126/science.286.5441.930; Stager JC, 2002, PALAEOGEOGR PALAEOCL, V183, P169, DOI 10.1016/S0031-0182(01)00468-0; van't Veer R, 2000, QUATERNARY SCI REV, V19, P1821, DOI 10.1016/S0277-3791(00)00093-7; Yarincik KM, 2000, PALEOCEANOGRAPHY, V15, P210; Zhao MX, 2000, ORG GEOCHEM, V31, P919, DOI 10.1016/S0146-6380(00)00027-9; [No title captured]	37	194	216	4	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	2004	304	5679					1955	1959		10.1126/science.1092995	http://dx.doi.org/10.1126/science.1092995			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15155911				2022-12-28	WOS:000222241600043
J	Brawley, C; Matunis, E				Brawley, C; Matunis, E			Regeneration of male germline stem cells by spermatogonial dedifferentiation in vivo	SCIENCE			English	Article							DROSOPHILA FUSOME; SELF-RENEWAL; DIFFERENTIATION; LINE	Although the ability of engrafted stem cells to regenerate tissue has received much attention, the molecular mechanisms controlling regeneration are poorly understood. In the Drosophila male germline, local activation of the Janus kinase-signal transducer and activator of transcription (Jak-STAT) pathway maintains stem cells; germline stem cells lacking Jak-STAT signaling differentiate into spermatogonia without self-renewal. By conditionally manipulating Jak-STAT signaling, we find that spermatogonia that have initiated differentiation and are undergoing limited mitotic (transit-amplifying) divisions can repopulate the niche and revert to stem cell identity. Thus, in the appropriate microenvironment, transit-amplifying cells dedifferentiate, becoming functional stem cells during tissue regeneration.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Matunis, E (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.	matunis@jhmi.edu			NICHD NIH HHS [R01HD40307] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040307] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baksa K, 2002, DEV BIOL, V243, P166, DOI 10.1006/dbio.2001.0539; BRAWLEY C, UNPUB; de Cuevas M, 1998, DEVELOPMENT, V125, P2781; de Rooij DG, 2001, REPRODUCTION, V121, P347, DOI 10.1530/rep.0.1210347; Hime GR, 1996, J CELL SCI, V109, P2779; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; LIN HF, 1994, DEVELOPMENT, V120, P947; MCKEARIN DM, 1990, GENE DEV, V4, P2242, DOI 10.1101/gad.4.12b.2242; Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795	12	305	322	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1331	1334		10.1126/science.1097676	http://dx.doi.org/10.1126/science.1097676			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15143218				2022-12-28	WOS:000221669600057
J	Cryer, PE				Cryer, PE			Current concepts: Diverse causes of hypoglycemia-associated autonomic failure in diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BRAIN GLUCOSE-UPTAKE; DEFICIENT COUNTERREGULATION; ANTECEDENT HYPOGLYCEMIA; NOCTURNAL HYPOGLYCEMIA; COGNITIVE DYSFUNCTION; RESPONSES; TYPE-1; INSULIN; UNAWARENESS; CORTISOL		Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Gen Clin Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Diabet Res & Training, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Cryer, PE (corresponding author), Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	pcryer@wustl.edu			NCRR NIH HHS [M01 RR00036] Funding Source: Medline; NIDDK NIH HHS [T32 DK07120, R37 DK27085, P60 DK20579] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, T32DK007120, R37DK027085] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1995, Diabetes, V44, P1249; [Anonymous], 1995, DIABETES, V44, P968; [Anonymous], 1996, DIABETES; Banarer S, 2003, DIABETES, V52, P1195, DOI 10.2337/diabetes.52.5.1195; Banarer S, 2002, DIABETES, V51, P958, DOI 10.2337/diabetes.51.4.958; Bottini P, 1997, DIABETES, V46, P814, DOI 10.2337/diabetes.46.5.814; BOYLE PJ, 1994, P NATL ACAD SCI USA, V91, P9352, DOI 10.1073/pnas.91.20.9352; Boyle PJ, 1995, NEW ENGL J MED, V333, P1726, DOI 10.1056/NEJM199512283332602; CRANSTON I, 1994, LANCET, V344, P283, DOI 10.1016/S0140-6736(94)91336-6; Cranston I, 2001, DIABETES, V50, P2329, DOI 10.2337/diabetes.50.10.2329; Cryer P.E., 2001, HDB PHYSL, P1057; CRYER PE, 1992, DIABETES, V41, P255, DOI 10.2337/diabetes.41.3.255; Cryer PE, 2003, DIABETES CARE, V26, P1902, DOI 10.2337/diacare.26.6.1902; Cryer PE, 2002, DIABETOLOGIA, V45, P937, DOI 10.1007/s00125-002-0822-9; DAGOGOJACK S, 1994, DIABETES, V43, P1426, DOI 10.2337/diabetes.43.12.1426; DAGOGOJACK SE, 1993, J CLIN INVEST, V91, P819, DOI 10.1172/JCI116302; Davis SN, 1996, J CLIN INVEST, V98, P680, DOI 10.1172/JCI118839; Davis SN, 1997, J CLIN INVEST, V100, P429, DOI 10.1172/JCI119550; de Vries MG, 2003, DIABETES, V52, P2767, DOI 10.2337/diabetes.52.11.2767; DEROSA M, IN PRESS AM J PHYSL; Dunn-Meynell AA, 2002, DIABETES, V51, P2056, DOI 10.2337/diabetes.51.7.2056; Engel S, 2003, NEW ENGL J MED, V348, P2294; FANELLI C, 1995, DIABETOLOGIA, V38, P254, DOI 10.1007/BF00400106; FANELLI C, 1994, DIABETOLOGIA, V37, P1265, DOI 10.1007/BF00399801; Fanelli CG, 1998, DIABETES, V47, P1920, DOI 10.2337/diabetes.47.12.1920; FANELLI CG, 1993, DIABETES, V42, P1683, DOI 10.2337/diabetes.42.11.1683; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Galassetti P, 2001, AM J PHYSIOL-ENDOC M, V280, pE908, DOI 10.1152/ajpendo.2001.280.6.E908; HEPBURN DA, 1993, DIABETIC MED, V10, P231, DOI 10.1111/j.1464-5491.1993.tb00050.x; Holstein A, 2003, EXP CLIN ENDOCR DIAB, V111, P364, DOI 10.1055/s-2003-42728; Jones TW, 1998, NEW ENGL J MED, V338, P1657, DOI 10.1056/NEJM199806043382303; Khaw KT, 2001, BMJ-BRIT MED J, V322, P15, DOI 10.1136/bmj.322.7277.15; Leese GP, 2003, DIABETES CARE, V26, P1176, DOI 10.2337/diacare.26.4.1176; Libby P, 2002, CIRCULATION, V106, P2760, DOI 10.1161/01.CIR.0000037282.92395.AE; McGregor VP, 2002, AM J PHYSIOL-ENDOC M, V282, pE770, DOI 10.1152/ajpendo.00447.2001; McGregor VP, 2002, DIABETES, V51, P1485, DOI 10.2337/diabetes.51.5.1485; Meyer C, 1998, DIABETES CARE, V21, P1960, DOI 10.2337/diacare.21.11.1960; Ovalle F, 1998, DIABETES, V47, P1472, DOI 10.2337/diabetes.47.9.1472; Pellerin L, 2002, DIABETES NUTR METAB, V15, P268; Raju B, 2003, DIABETES, V52, P2083, DOI 10.2337/diabetes.52.8.2083; Riddle MC, 2003, DIABETES CARE, V26, P3080, DOI 10.2337/diacare.26.11.3080; Routh VH, 2003, DIABETES-METAB RES, V19, P348, DOI 10.1002/dmrr.404; Saleh TY, 1997, DIABETES CARE, V20, P1231, DOI 10.2337/diacare.20.8.1231; Segel SA, 2001, DIABETES, V50, P1911, DOI 10.2337/diabetes.50.8.1911; Segel SA, 2002, DIABETES, V51, P724, DOI 10.2337/diabetes.51.3.724; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Simpson IA, 1999, J NEUROCHEM, V72, P238, DOI 10.1046/j.1471-4159.1999.0720238.x; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; TOWLER DA, 1993, DIABETES, V42, P1791, DOI 10.2337/diabetes.42.12.1791; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *UKPDS GROUP, 1998, LANCET, V358, P837; *UKPDS GROUP, 1998, LANCET, V352, P1557; Wright A, 1998, ANN INTERN MED, V128, P165, DOI 10.7326/0003-4819-128-3-199802010-00001	54	258	269	2	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2272	2279		10.1056/NEJMra031354	http://dx.doi.org/10.1056/NEJMra031354			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163777				2022-12-28	WOS:000221641900008
J	Smith, RR; Killelea, DR; DelSesto, DF; Utz, AL				Smith, RR; Killelea, DR; DelSesto, DF; Utz, AL			Preference for vibrational over translational energy in a gas-surface reaction	SCIENCE			English	Article							ACTIVATED DISSOCIATIVE CHEMISORPTION; MOLECULAR-BEAM; CH4 DISSOCIATION; EXCITED METHANE; ASSOCIATIVE DESORPTION; METAL-SURFACES; ADSORPTION; NI(100); DYNAMICS; NI(111)	State-resolved gas-surface reactivity measurements revealed that vibrational excitation of nu(3) (the antisymmetric C-H stretch) activates methane dissociation more efficiently than does translational energy. Methane molecules in the vibrational ground state require 45 kilojoules per mole (kJ/mol) of translational energy to attain the same reactivity enhancement provided by 36 kJ/mol of nu(3) excitation. This result contradicts a key assumption underlying statistical theories of gas-surface reactivity and provides direct experimental evidence of the central role that vibrational energy can play in activating gas-surface reactions.	Tufts Univ, Dept Chem, Medford, MA 02155 USA; Tufts Univ, WM Keck Fdn Lab Mat Chem, Medford, MA 02155 USA	Tufts University; Tufts University	Smith, RR (corresponding author), Tufts Univ, Dept Chem, Medford, MA 02155 USA.			Killelea, Daniel/0000-0001-6965-5644				Beck RD, 2003, SCIENCE, V302, P98, DOI 10.1126/science.1088996; BECKERLE JD, 1990, PHYS REV LETT, V64, P2090, DOI 10.1103/PhysRevLett.64.2090; BECKERLE JD, 1989, J CHEM PHYS, V91, P5756, DOI 10.1063/1.457529; Bukoski A, 2003, J CHEM PHYS, V118, P9762, DOI 10.1063/1.1570393; CHRISTMANN K, 1974, J CHEM PHYS, V60, P4528, DOI 10.1063/1.1680935; DELSESTO DF, UNPUB; Diekhoner L, 2001, J CHEM PHYS, V115, P9028, DOI 10.1063/1.1413746; Gostein M, 1997, J CHEM PHYS, V106, P7378, DOI 10.1063/1.473699; Halonen L, 2001, J CHEM PHYS, V115, P5611, DOI 10.1063/1.1398075; Higgins J, 2001, J CHEM PHYS, V114, P5277, DOI 10.1063/1.1349895; HOLMBLAD PM, 1995, J CHEM PHYS, V102, P8255, DOI 10.1063/1.468955; Hou H, 1999, SCIENCE, V284, P1647, DOI 10.1126/science.284.5420.1647; JACOBS DC, 1995, J PHYS-CONDENS MAT, V7, P1023, DOI 10.1088/0953-8984/7/6/007; Juurlink LBF, 1999, PHYS REV LETT, V83, P868, DOI 10.1103/PhysRevLett.83.868; Juurlink LBF, 2000, FARADAY DISCUSS, V117, P147, DOI 10.1039/b003708g; Kratzer P, 1996, J CHEM PHYS, V105, P5595, DOI 10.1063/1.472399; Larsen JH, 1999, SURF SCI REP, V35, P165; LEE MB, 1987, J CHEM PHYS, V87, P2724, DOI 10.1063/1.453060; LEVINE RD, 1987, MOL REACTION DYNAMIC; Luntz AC, 2000, J CHEM PHYS, V113, P6901, DOI 10.1063/1.1311280; Luntz AC, 2003, SCIENCE, V302, P70, DOI 10.1126/science.1090172; LUNTZ AC, 1995, J CHEM PHYS, V102, P8264, DOI 10.1063/1.468956; McCabe PR, 2000, REV SCI INSTRUM, V71, P42, DOI 10.1063/1.1150158; MICHELSEN HA, 1993, J CHEM PHYS, V98, P8294, DOI 10.1063/1.464535; Milot R, 2000, PHYS REV B, V61, P15657, DOI 10.1103/PhysRevB.61.15657; Mortensen H, 2002, J CHEM PHYS, V116, P5781, DOI 10.1063/1.1456509; Murphy MJ, 1999, J CHEM PHYS, V110, P6954, DOI 10.1063/1.478601; POLANYI JC, 1972, ACCOUNTS CHEM RES, V5, P161, DOI 10.1021/ar50053a001; RETTNER CT, 1995, J CHEM PHYS, V102, P4625, DOI 10.1063/1.469511; Schmid MP, 2002, J CHEM PHYS, V117, P8603, DOI 10.1063/1.1519860; Sitz GO, 2002, REP PROG PHYS, V65, P1165, DOI 10.1088/0034-4885/65/8/202; YANG QY, 1995, J CHEM PHYS, V102, P7734, DOI 10.1063/1.469026	32	237	237	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	2004	304	5673					992	995		10.1126/science.1096309	http://dx.doi.org/10.1126/science.1096309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143277				2022-12-28	WOS:000221383300043
J	Ke, AL; Zhou, KH; Ding, F; Cate, JHD; Doudna, JA				Ke, AL; Zhou, KH; Ding, F; Cate, JHD; Doudna, JA			A conformational switch controls hepatitis delta virus ribozyme catalysis	NATURE			English	Article							GENOMIC HDV RIBOZYME; CRYSTAL-STRUCTURE; SELF-CLEAVAGE; METAL-IONS; CYTOSINE; STEP; RNA	Ribozymes enhance chemical reaction rates using many of the same catalytic strategies as protein enzymes. In the hepatitis delta virus (HDV) ribozyme, site-specific self-cleavage of the viral RNA phosphodiester backbone(1-3) requires both divalent cations and a cytidine nucleotide(4-6). General acid - base catalysis(7-12), substrate destabilization(1,13) and global and local conformational changes(14,15) have all been proposed to contribute to the ribozyme catalytic mechanism. Here we report ten crystal structures of the HDV ribozyme in its pre-cleaved state, showing that cytidine is positioned to activate the 2'-OH nucleophile in the precursor structure. This observation supports its proposed role as a general base in the reaction mechanism. Comparison of crystal structures of the ribozyme in the pre- and post-cleavage states reveals a significant conformational change in the RNA after cleavage and that a catalytically critical divalent metal ion from the active site is ejected. The HDV ribozyme has remarkable chemical similarity to protein ribonucleases and to zymogens for which conformational dynamics are integral to biological activity. This finding implies that RNA structural rearrangements control the reactivity of ribozymes and ribonucleoprotein enzymes.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94705 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94705 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94705 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Doudna, JA (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94705 USA.	doudna@uclink.berkeley.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Dunham CM, 2003, J MOL BIOL, V332, P327, DOI 10.1016/S0022-2836(03)00843-X; Ferre-D'Amare AR, 2000, J MOL BIOL, V295, P541, DOI 10.1006/jmbi.1999.3398; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Harris DA, 2002, BIOCHEMISTRY-US, V41, P12051, DOI 10.1021/bi026101m; Jeong S, 2003, BIOCHEMISTRY-US, V42, P7727, DOI 10.1021/bi034627g; Luptak A, 2001, J AM CHEM SOC, V123, P8447, DOI 10.1021/ja016091x; Moore MJ, 2000, METHOD ENZYMOL, V317, P109; Murray JB, 2002, J MOL BIOL, V315, P121, DOI 10.1006/jmbi.2001.5145; Nakano S, 2000, SCIENCE, V287, P1493, DOI 10.1126/science.287.5457.1493; Nakano S, 2001, BIOCHEMISTRY-US, V40, P12022, DOI 10.1021/bi011253n; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oyelere AK, 2002, BIOCHEMISTRY-US, V41, P3667, DOI 10.1021/bi011816v; Oyelere AK, 2001, NUCLEOS NUCLEOT NUCL, V20, P1851, DOI 10.1081/NCN-100107196; Pereira MJB, 2002, BIOCHEMISTRY-US, V41, P730, DOI 10.1021/bi011963t; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; Pyle AM, 2002, J BIOL INORG CHEM, V7, P679, DOI 10.1007/s00775-002-0387-6; Reid CE, 2000, P NATL ACAD SCI USA, V97, P424, DOI 10.1073/pnas.97.1.424; ROSENSTEIN SP, 1990, BIOCHEMISTRY-US, V29, P8011, DOI 10.1021/bi00487a002; Rupert PB, 2002, SCIENCE, V298, P1421, DOI 10.1126/science.1076093; Rupert PB, 2001, NATURE, V410, P780, DOI 10.1038/35071009; Shih I, 2001, P NATL ACAD SCI USA, V98, P1489, DOI 10.1073/pnas.98.4.1489; Shih IH, 2002, ANNU REV BIOCHEM, V71, P887, DOI 10.1146/annurev.biochem.71.110601.135349; Shih IH, 2001, EMBO J, V20, P4884, DOI 10.1093/emboj/20.17.4884; SUH YA, 1993, NUCLEIC ACIDS RES, V21, P3277, DOI 10.1093/nar/21.14.3277; TANNER NK, 1994, CURR BIOL, V4, P488, DOI 10.1016/S0960-9822(00)00109-3; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	30	215	228	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988					201	205		10.1038/nature02522	http://dx.doi.org/10.1038/nature02522			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141216				2022-12-28	WOS:000221356300046
J	Whittle, IR; Smith, C; Navoo, P; Collie, D				Whittle, IR; Smith, C; Navoo, P; Collie, D			Meningiomas	LANCET			English	Review							PROGESTERONE-RECEPTOR EXPRESSION; NERVE SHEATH MENINGIOMA; CAVERNOUS SINUS MENINGIOMAS; GAMMA-KNIFE RADIOSURGERY; TERM TUMOR-CONTROL; INTRACRANIAL MENINGIOMAS; RADIATION-THERAPY; EMBOLIZED MENINGIOMAS; RESECTED MENINGIOMAS; CLINICOPATHOLOGICAL SUBSETS	Meningiomas are by far the most common tumours; arising from the meninges. Progressive enlargement of the tumour leads to focal or generalised seizure disorders or neurological deficits caused by compression of adjacent neural tissue. Surgery remains the primary treatment of choice, although the use of fractionated radiotherapy or stereotactic single-dose radiosurgery is increasing for meningiomas that are incompletely excised, surgically inaccessible, or recurrent and either atypical or anaplastic. Although most meningiomas have good long-term prognosis after treatment, there are still controversies over management in a proportion of cases. We review various features of meningioma biology, diagnosis, and treatment and provide an overview of the current rationale and evidence base for the various therapeutic approaches.	Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Whittle, IR (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	irw@skull.dcn.ed.ac.uk	whittle, ian/AAX-7309-2021					Aguiar PH, 2003, NEUROSURG REV, V26, P221, DOI 10.1007/s10143-003-0261-1; Amatya VJ, 2001, HUM PATHOL, V32, P970, DOI 10.1053/hupa.2001.27119; Awada A, 1997, EUR J RADIOL, V25, P26, DOI 10.1016/S0720-048X(96)01148-5; Ayerbe J, 1999, ACTA NEUROCHIR, V141, P921, DOI 10.1007/s007010050398; BARBARO NM, 1987, NEUROSURGERY, V20, P525, DOI 10.1227/00006123-198704000-00003; Beaumont A, 2000, ACTA NEUROCHIR, V142, P1, DOI 10.1007/s007010050001; Becker G, 2002, INT J RADIAT ONCOL, V54, P1422, DOI 10.1016/S0360-3016(02)03753-7; Bendszus M, 2000, NEUROSURGERY, V47, P1306, DOI 10.1097/00006123-200012000-00008; Bendszus M, 2003, NEURORADIOLOGY, V45, P451, DOI 10.1007/s00234-003-1005-1; Bhatia S, 2002, BLOOD, V99, P4257, DOI 10.1182/blood.V99.12.4257; Black PM, 2001, ACTA NEUROCHIR, V143, P555, DOI 10.1007/s007010170060; Blankenstein MA, 2000, STEROIDS, V65, P795, DOI 10.1016/S0039-128X(00)00193-8; Buschges R, 2002, BRAIN PATHOL, V12, P145; Cai DX, 2001, J NEUROPATH EXP NEUR, V60, P628, DOI 10.1093/jnen/60.6.628; CAMERON EW, 1994, CLIN RADIOL, V49, P416, DOI 10.1016/S0009-9260(05)81829-X; Carvalho GA, 1997, SURG NEUROL, V47, P284, DOI 10.1016/S0090-3019(96)00361-8; Castilla EA, 2003, AM J CLIN PATHOL, V119, P123, DOI 10.1309/W0H705HAJL73T0EQ; Chozick BS, 1996, J NEUROSURG, V84, P382, DOI 10.3171/jns.1996.84.3.0382; Chun JY, 2002, NEUROSURGERY, V50, P1231, DOI 10.1097/00006123-200206000-00010; Custer BS, 2002, CANCER, V94, P1626, DOI 10.1002/cncr.10410; Das A, 2002, NEUROPATHOLOGY, V22, P194, DOI 10.1046/j.1440-1789.2002.00443.x; De Jesus O, 2001, SURG NEUROL, V55, P265, DOI 10.1016/S0090-3019(01)00440-2; Debus J, 2001, J CLIN ONCOL, V19, P3547, DOI 10.1200/JCO.2001.19.15.3547; Domingo Z, 1998, BRIT J NEUROSURG, V12, P414, DOI 10.1080/02688699844600; Dufour H, 2001, NEUROSURGERY, V48, P285, DOI 10.1097/00006123-200102000-00006; Erfurth EM, 2001, CLIN ENDOCRINOL, V55, P613, DOI 10.1046/j.1365-2265.2001.01385.x; EUGEN BH, 2000, J NEUROONCOL, V48, P151; Falleni M, 2001, VIRCHOWS ARCH, V439, P196, DOI 10.1007/s004280000387; Flickinger JC, 2003, INT J RADIAT ONCOL, V56, P801, DOI 10.1016/S0360-3016(03)00126-3; Fuller CE, 2001, HUM PATHOL, V32, P1102, DOI 10.1053/hupa.2001.28252; GOLDSMITH BJ, 1994, J NEUROSURG, V80, P195, DOI 10.3171/jns.1994.80.2.0195; Goyal LK, 2000, INT J RADIAT ONCOL, V46, P57, DOI 10.1016/S0360-3016(99)00349-1; Gruber A, 2000, MINIM INVAS NEUROSUR, V43, P18, DOI 10.1055/s-2000-8812; GRUNBERG SM, 1990, J NEURO-ONCOL, V8, P61; Gursan N, 2002, INT J NEUROSCI, V112, P463, DOI 10.1080/00207450290025581; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Hakim RH, 1998, NEUROSURGERY, V42, P446, DOI 10.1097/00006123-199803000-00002; HEICK A, 1993, ACTA NEUROL SCAND, V87, P243; Heinrich B, 2003, INT J CANCER, V103, P483, DOI 10.1002/ijc.10840; Ho DMT, 2002, CANCER, V94, P1538, DOI 10.1002/cncr.10351; Horton R, 1996, LANCET, V347, P984, DOI 10.1016/S0140-6736(96)90137-3; Hsu DW, 1997, J NEUROSURG, V86, P113, DOI 10.3171/jns.1997.86.1.0113; Hug EB, 2000, J NEURO-ONCOL, V48, P151, DOI 10.1023/A:1006434124794; JAASKELAINEN J, 1986, SURG NEUROL, V25, P233, DOI 10.1016/0090-3019(86)90233-8; Johnson MD, 2002, HUM PATHOL, V33, P1211, DOI 10.1053/hupa.2002.129200; KALLIO M, 1992, NEUROSURGERY, V31, P2, DOI 10.1227/00006123-199207000-00002; KEPES JJ, 1988, CANCER, V62, P391, DOI 10.1002/1097-0142(19880715)62:2<391::AID-CNCR2820620226>3.0.CO;2-7; Klutmann S, 1998, J NUCL MED, V39, P1913; Kokubo M, 2000, J NEURO-ONCOL, V48, P51, DOI 10.1023/A:1006430102406; KONDZIOLKA D, 1991, J NEUROSURG, V74, P552, DOI 10.3171/jns.1991.74.4.0552; Konstantinidou AE, 2003, HISTOL HISTOPATHOL, V18, P67, DOI 10.14670/HH-18.67; KONZIOLKA D, 1998, NEUROSURGERY, V43, P405; Kuratsu J, 2000, J NEUROSURG, V92, P766, DOI 10.3171/jns.2000.92.5.0766; Lang DA, 1999, J NEUROSURG, V91, P359, DOI 10.3171/jns.1999.91.3.0359; Lee JYK, 2002, J NEUROSURG, V97, P65, DOI 10.3171/jns.2002.97.1.0065; Lieu AS, 2000, EPILEPSY RES, V38, P45; Loeffler JS, 2003, NEUROSURGERY, V52, P1436, DOI 10.1227/01.NEU.0000064809.59806.E8; LONGSTRETH WT, 1993, CANCER, V72, P639, DOI 10.1002/1097-0142(19930801)72:3<639::AID-CNCR2820720304>3.0.CO;2-P; Louis DN, 2000, PATHOLOGY GENETICS T, P176; Mason WP, 2002, J NEUROSURG, V97, P341, DOI 10.3171/jns.2002.97.2.0341; Meewes C, 2001, J NUCL MED, V42, P1338; MIRIMANOFF RO, 1985, J NEUROSURG, V62, P18, DOI 10.3171/jns.1985.62.1.0018; Muhr C, 2001, CLIN CANCER RES, V7, P2269; Murakami M, 2003, CANCER GENET CYTOGEN, V140, P99, DOI 10.1016/S0165-4608(02)00653-2; Nagashima G, 2001, Brain Tumor Pathol, V18, P1; Nakamura M, 2003, NEUROSURGERY, V53, P62, DOI 10.1227/01.NEU.0000068730.76856.58; NAKASU S, 1987, SURG NEUROL, V27, P319, DOI 10.1016/0090-3019(87)90005-X; Narayan S, 2003, INT J RADIAT ONCOL, V56, P537, DOI 10.1016/S0360-3016(03)00005-1; Newton HB, 2000, J NEURO-ONCOL, V49, P165, DOI 10.1023/A:1026770624783; Ng HK, 1996, AM J SURG PATHOL, V20, P1224, DOI 10.1097/00000478-199610000-00008; OLIVERO WC, 1995, J NEUROSURG, V83, P222, DOI 10.3171/jns.1995.83.2.0222; OSullivan MG, 1997, NEUROSURGERY, V40, P238, DOI 10.1097/00006123-199702000-00003; Palma L, 1997, J NEUROSURG, V86, P793, DOI 10.3171/jns.1997.86.5.0793; Perry A, 1998, AM J SURG PATHOL, V22, P1482, DOI 10.1097/00000478-199812000-00005; Perry A, 1997, AM J SURG PATHOL, V21, P1455, DOI 10.1097/00000478-199712000-00008; Perry A, 2002, BRAIN PATHOL, V12, P183; Perry A, 2001, CANCER, V92, P701, DOI 10.1002/1097-0142(20010801)92:3<701::AID-CNCR1373>3.0.CO;2-7; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Phillips LE, 2002, NEUROLOGY, V58, P1849, DOI 10.1212/WNL.58.12.1849; Pieper DR, 1999, NEUROSURGERY, V44, P742, DOI 10.1097/00006123-199904000-00028; Pistolesi S, 2002, J NEURO-ONCOL, V60, P159, DOI 10.1023/A:1020624119944; Pollock BE, 2000, NEUROSURG CLIN N AM, V11, P659, DOI 10.1016/S1042-3680(18)30091-3; Pollock BE, 2003, INT J RADIAT ONCOL, V55, P1000, DOI 10.1016/S0360-3016(02)04356-0; Pourel N, 2001, RADIOTHER ONCOL, V61, P65, DOI 10.1016/S0167-8140(01)00391-7; Roberti F, 2001, SURG NEUROL, V56, P8, DOI 10.1016/S0090-3019(01)00479-7; Roessler K, 2002, NEUROL RES, V24, P241, DOI 10.1179/016164102101199855; Rosen CL, 2002, ACTA NEUROCHIR, V144, P1157, DOI 10.1007/s00701-002-0965-y; ROTHWELL P, 1995, LANCET, V346, P1623, DOI 10.1016/S0140-6736(95)91953-8; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Roux-Vaillard S, 1999, NEUROCHIRURGIE, V45, P407; Sadetzki S, 2002, J NEUROSURG, V97, P1078, DOI 10.3171/jns.2002.97.5.1078; Sandberg DI, 2001, NEUROSURGERY, V48, P590, DOI 10.1097/00006123-200103000-00027; Schulz S, 2000, CLIN CANCER RES, V6, P1865; SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22; Sindou M, 2001, J CLIN NEUROSCI, V8, P8, DOI 10.1054/jocn.2001.0868; Sindou MP, 1998, NEUROSURGERY, V42, P476, DOI 10.1097/00006123-199803000-00007; Stafford SL, 1998, MAYO CLIN PROC, V73, P936, DOI 10.4065/73.10.936; Stafford SL, 2001, NEUROSURGERY, V49, P1029, DOI 10.1097/00006123-200111000-00001; Strik HM, 2002, IN VIVO, V16, P265; Subach BR, 1998, NEUROSURGERY, V42, P437, DOI 10.1097/00006123-199803000-00001; Thompson LDR, 2003, MODERN PATHOL, V16, P236, DOI 10.1097/01.MP.0000056631.15739.1B; Trofatter J A, 1993, Cell, V75, P826; Turbin RE, 2002, OPHTHALMOLOGY, V109, P890, DOI 10.1016/S0161-6420(02)01017-5; Verheijen FM, 2001, EUR J CANCER, V37, P1488, DOI 10.1016/S0959-8049(01)00146-0; Watson MA, 2002, AM J PATHOL, V161, P665, DOI 10.1016/S0002-9440(10)64222-8; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; Whittle IR, 1998, LANCET, V351, P1014, DOI 10.1016/S0140-6736(97)08295-0; WILSON CB, 1994, J NEUROSURG, V81, P666, DOI 10.3171/jns.1994.81.5.0666; Yashioka H, 1999, CANCER-AM CANCER SOC, V85, P936, DOI 10.1002/(SICI)1097-0142(19990215)85:4<936::AID-CNCR23>3.0.CO;2-J; Zentner J, 1997, J NEUROL NEUROSUR PS, V62, P341, DOI 10.1136/jnnp.62.4.341	110	400	424	0	33	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2004	363	9420					1535	1543		10.1016/S0140-6736(04)16153-9	http://dx.doi.org/10.1016/S0140-6736(04)16153-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135603				2022-12-28	WOS:000221302700023
J	Edwards, PN				Edwards, PN			"A vast machine": Standards as social technology	SCIENCE			English	Editorial Material									Univ Michigan, Sch Informat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Edwards, PN (corresponding author), Univ Michigan, Sch Informat, Ann Arbor, MI 48109 USA.	pne@umich.edu						BARTKY IR, 1989, TECHNOL CULT, V30, P25, DOI 10.2307/3105430; Daniel Howard., 1973, 100 YEARS INT COOPER; Fleming J. R., 1990, METEOROLOGY AM 1800; KARL TR, 1993, J CLIMATE, V6, P1481, DOI [10.1175/1520-0442(1993)006<1481:DCVACN>2.0.CO;2, 10.1175/1520-0442(1993)006&lt;1481:DCVACN&gt;2.0.CO;2]; Maury MF, 1851, EXPLANATIONS SAILING; QUAYLE RG, 1991, B AM METEOROL SOC, V72, P1718, DOI 10.1175/1520-0477(1991)072<1718:EORTCI>2.0.CO;2; SHAW N, 1920, RESEAU MONDIAL 1910; SHAW N, 1939, DRAMA WEATHER	8	27	28	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	2004	304	5672					827	828		10.1126/science.1099290	http://dx.doi.org/10.1126/science.1099290			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131292				2022-12-28	WOS:000221243000026
J	Patel, UD; Hollander, H; Saint, S				Patel, UD; Hollander, H; Saint, S			Index of suspicion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAT-SCRATCH DISEASE; BACILLARY ANGIOMATOSIS; BARTONELLA HENSELAE; UNKNOWN ORIGIN; FEVER; EPIDEMIOLOGY; ROCHALIMAEA; DIAGNOSIS; TESTS		Univ Michigan, Robert Wood Johnson Clin Scholars Program, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Vet Affairs Hlth Serv, Res & Dev Ctr Excellence, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Patel, UD (corresponding author), Univ Michigan, Robert Wood Johnson Clin Scholars Program, Sch Med, Dept Pediat, 6312 Med Sci Bldg 1,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	patelu@umich.edu	Patel, Shraddha/C-9520-2015; Saint, Sanjay/AAF-5126-2019	Patel, Uptal/0000-0002-6905-6649	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER; AHRQ HHS [P20-HS11540] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAL KA, 1994, NEW ENGL J MED, V330, P1509, DOI 10.1056/NEJM199405263302108; Arnow PM, 1997, LANCET, V350, P575, DOI 10.1016/S0140-6736(97)07061-X; Bergmans AMC, 1997, J CLIN MICROBIOL, V35, P1931, DOI 10.1128/JCM.35.8.1931-1937.1997; Cline MS, 1999, TRANSPLANTATION, V67, P296, DOI 10.1097/00007890-199901270-00019; COTELL SL, 1994, ARCH INTERN MED, V154, P524, DOI 10.1001/archinte.154.5.524; Denton MD, 1999, LANCET, V353, P1083, DOI 10.1016/S0140-6736(98)07493-5; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; KIRIAKOS J, 2003, PEDIATR NEPHROL, V18, pC46; Knockaert DC, 2003, J INTERN MED, V253, P263, DOI 10.1046/j.1365-2796.2003.01120.x; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; Pizzo PA, 1999, NEW ENGL J MED, V341, P893, DOI 10.1056/NEJM199909163411207; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; Sander A, 1998, CLIN DIAGN LAB IMMUN, V5, P486, DOI 10.1128/CDLI.5.4.486-490.1998; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; Tappero JW, 1997, NEW ENGL J MED, V337, P1888, DOI 10.1056/NEJM199712253372605; VANDERWOUW PA, 1989, AIDS, V3, P751, DOI 10.1097/00002030-198911000-00011; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	18	9	10	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1990	1995		10.1056/NEJMcps032937	http://dx.doi.org/10.1056/NEJMcps032937			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128900				2022-12-28	WOS:000221218800013
J	Saleh, M; Vaillancourt, JP; Graham, RK; Huyck, M; Srinivasula, SM; Alnemri, ES; Steinberg, MH; Nolan, V; Baldwin, CT; Hotchkiss, RS; Buchman, TG; Zehnbauer, BA; Hayden, MR; Farrer, LA; Roy, S; Nicholson, DW				Saleh, M; Vaillancourt, JP; Graham, RK; Huyck, M; Srinivasula, SM; Alnemri, ES; Steinberg, MH; Nolan, V; Baldwin, CT; Hotchkiss, RS; Buchman, TG; Zehnbauer, BA; Hayden, MR; Farrer, LA; Roy, S; Nicholson, DW			Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms	NATURE			English	Article							KAPPA-B; ACTIVATION; APOPTOSIS; SEPSIS; MUTATIONS; DISEASE; DEATH; BETA; ASC	Caspases mediate essential key proteolytic events in inflammatory cascades and the apoptotic cell death pathway. Human caspases functionally segregate into two distinct subfamilies: those involved in cytokine maturation (caspase-1, -4 and -5) and those involved in cellular apoptosis (caspase-2, -3, -6, -7, -8, -9 and -10)(1,2). Although caspase-12 is phylogenetically related to the cytokine maturation caspases, in mice it has been proposed as a mediator of apoptosis induced by endoplasmic reticulum stress including amyloid-beta cytotoxicity, suggesting that it might contribute to the pathogenesis of Alzheimer's disease(3). Here we show that a single nucleotide polymorphism in caspase-12 in humans results in the synthesis of either a truncated protein (Csp12-S) or a full-length caspase proenzyme (Csp12-L). The read-through single nucleotide polymorphism encoding Csp12-L is confined to populations of African descent and confers hypo-responsiveness to lipopolysaccharide-stimulated cytokine production in ex vivo whole blood, but has no significant effect on apoptotic sensitivity. In a preliminary study, we find that the frequency of the Csp12-L allele is increased in African American individuals with severe sepsis. Thus, Csp12-L attenuates the inflammatory and innate immune response to endotoxins and in doing so may constitute a risk factor for developing sepsis.	Merck Frosst Ctr Therapeut Res, Dept Biochem Mol Biol & Pharmacol, Montreal, PQ H9H 3L1, Canada; Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Genet Program, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Hematol Oncol Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Human Genet, Boston, MA 02118 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Merck & Company; University of British Columbia; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Jefferson University; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Nicholson, DW (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem Mol Biol & Pharmacol, Montreal, PQ H9H 3L1, Canada.	donald_nicholson@merck.com	Farrer, Lindsay/AAS-1035-2020; Alnemri, Emad S/B-4526-2010; Graham, Rona K/R-7358-2018; Hayden, Michael R/D-8581-2011	Graham, Rona K/0000-0003-3722-6241; Hayden, Michael R/0000-0001-5159-1419; Farrer, Lindsay/0000-0001-5533-4225; Baldwin, Clinton/0000-0002-3275-9463; Buchman, Timothy/0000-0001-7350-5921; Saleh, Maya/0000-0003-1538-9146; Steinberg, Martin/0000-0001-8800-8020	NATIONAL CANCER INSTITUTE [ZIABC010629, Z01BC010629] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Chan SL, 2002, NEUROBIOL DIS, V11, P2, DOI 10.1006/nbdi.2002.0542; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Freeman BD, 2002, J MOL DIAGN, V4, P209, DOI 10.1016/S1525-1578(10)60705-2; Green RC, 2002, JAMA-J AM MED ASSOC, V287, P329, DOI 10.1001/jama.287.3.329; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mouw G, 2003, NEUROREPORT, V14, P183, DOI 10.1097/00001756-200302100-00004; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Shibata M, 2003, NEUROSCIENCE, V118, P491, DOI 10.1016/S0306-4522(02)00910-7; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stehlik C, 2003, BIOCHEM J, V373, P101, DOI 10.1042/BJ20030304	18	323	342	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	2004	429	6987					75	79		10.1038/nature02451	http://dx.doi.org/10.1038/nature02451			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129283	Bronze			2022-12-28	WOS:000221222100047
J	Richeldi, L; Ewer, K; Losi, M; Hansell, DM; Roversi, P; Fabbri, LM; Lalvani, A				Richeldi, L; Ewer, K; Losi, M; Hansell, DM; Roversi, P; Fabbri, LM; Lalvani, A			Early diagnosis of subclinical multi drug-resistant tuberculosis	ANNALS OF INTERNAL MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; RAPID DETECTION; INFECTION; ENUMERATION; ASSAY	Background: Tuberculosis control hinges on prompt diagnosis of active cases and screening of contacts by tuberculin skin testing. Rapid blood tests for Mycobacterium tuberculosis infection are a new alternative to the tuberculin skin test, but whether they improve clinical outcomes is unknown. Objective: To describe how a novel T-cell-based test for M. tuberculosis infection helped diagnose tuberculosis in an asymptomatic, immunosuppressed adult with a negative result on a tuberculin skin test. Design: Case report. Setting: Household contact. Patients: Asymptomatic man receiving maintenance azathioprine therapy for Crohn disease whose wife had multidrug-resistant pulmonary tuberculosis. Measurements: Enzyme-linked immunospot (ELISPOT) assay, computed tomography, and bronchoalveolar lavage cultures. Results: The man had a negative tuberculin skin test result and a positive ELISPOT assay result. High-resolution computed tomography of the chest showed consolidation with early cavitation. Bronchoalveolar lavage and culture confirmed multidrug-resistant tuberculosis. Limitations: This single case report is a proof of concept and is not a formal evaluation of clinical utility. Conclusions: A positive ELISPOT assay result helped diagnose subclinical active tuberculosis in an immunosuppressed patient with a false-negative tuberculin skin test result. Large prospective studies that compare benefits and costs of this alternative to tuberculin skin testing are needed.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Univ Modena, I-41100 Modena, Italy; Azienda Osped Policlin Modena, I-41100 Modena, Italy; Royal Brompton Hosp, London SW3 6LY, England	University of Oxford; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; Royal Brompton Hospital	Lalvani, A (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Level 7, Oxford OX3 9DU, England.	ajit.lalvani@ndm.ox.ac.uk	Ewer, Katie J/B-4328-2011; Richeldi, Luca/ABF-2486-2020; Richeldi, Luca/B-6243-2019; Fabbri, Leonardo M/I-4055-2012; Losi, Monica/A-7028-2010	Ewer, Katie J/0000-0001-9827-9836; Richeldi, Luca/0000-0001-8594-1448; Fabbri, Leonardo M/0000-0001-8894-1689; Lalvani, Ajit/0000-0002-2396-246X				Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008; Cohn DL, 2000, AM J RESP CRIT CARE, V161, pS221; Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9; Gardam MA, 2003, LANCET INFECT DIS, V3, P148, DOI 10.1016/S1473-3099(03)00545-0; Jasmer RM, 2002, NEW ENGL J MED, V347, P1860, DOI 10.1056/NEJMcp021045; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081; Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1; Mazurek GH, 2001, JAMA-J AM MED ASSOC, V286, P1740, DOI 10.1001/jama.286.14.1740; Organization WH, 1998, LAB SERVICES TUBERCU; Schluger NW, 2001, AM J RESP CRIT CARE, V164, P2020, DOI 10.1164/ajrccm.164.11.2008100; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993	13	50	54	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	2004	140	9					709	713		10.7326/0003-4819-140-9-200405040-00010	http://dx.doi.org/10.7326/0003-4819-140-9-200405040-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816XR	15126254				2022-12-28	WOS:000221143100004
J	Murphy, NF; MacIntyre, K; Capewell, S; Stewart, S; Pell, J; Chalmers, P; Redpath, A; Frame, S; Boyd, J; McMurray, JJV				Murphy, NF; MacIntyre, K; Capewell, S; Stewart, S; Pell, J; Chalmers, P; Redpath, A; Frame, S; Boyd, J; McMurray, JJV			Hospital discharge rates for suspected acute coronary syndromes between 1990 and 2000: population based analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; CASE-FATALITY RATES; MORTALITY		Western Infirm & Associated Hosp, Dept Cardiol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England; Univ S Australia, Div Hlth Sci, Adelaide, SA 5000, Australia; Greater Glasgow Hlth Board, Glasgow G3 8YU, Lanark, Scotland; Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland	University of Glasgow; University of Liverpool; University of South Australia	McMurray, JJV (corresponding author), Western Infirm & Associated Hosp, Dept Cardiol, Glasgow G12 8QQ, Lanark, Scotland.	j.mcmurrray@bio.gla.ac.uk	mcmurray, John/B-2467-2013; Stewart, Simon/M-3316-2016; Macintyre, Kate/J-7174-2014	mcmurray, John/0000-0002-6317-3975; Stewart, Simon/0000-0001-9032-8998; Macintyre, Kate/0000-0003-2741-0467; Pell, Jill/0000-0002-8898-7035; Boyd, James/0000-0002-8925-8811				Goldberg RJ, 1999, J AM COLL CARDIOL, V33, P1533, DOI 10.1016/S0735-1097(99)00040-6; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; Marques-Vidal P, 2000, HEART, V84, P171, DOI 10.1136/heart.84.2.171; McGovern PG, 2001, CIRCULATION, V104, P19, DOI 10.1161/01.CIR.104.1.19; Rosen M, 2000, J INTERN MED, V248, P159, DOI 10.1046/j.1365-2796.2000.00716.x	5	36	36	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2004	328	7453					1413	1414		10.1136/bmj.38111.650741.F7	http://dx.doi.org/10.1136/bmj.38111.650741.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15155470	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000222114400021
J	Perrett, CM; McBride, SR				Perrett, CM; McBride, SR			Drug points: Teicoplanin induced drug hypersensitivity syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Royal Free Hosp, Dept Dermatol, London NW3 2QG, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	McBride, SR (corresponding author), Royal Free Hosp, Dept Dermatol, London NW3 2QG, England.	sandy.mcbride@rfh.nthames.nhs.uk		McBride, Sandy/0000-0002-8449-1809				DAVEY PG, 1991, J ANTIMICROB CHEMOTH, V27, P69, DOI 10.1093/jac/27.suppl_B.69; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; Sullivan JR, 2001, ARCH DERMATOL, V137, P357	3	20	21	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	2004	328	7451					1292	1292		10.1136/bmj.328.7451.1292	http://dx.doi.org/10.1136/bmj.328.7451.1292			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826PN	15166065	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000221841100020
J	Hungate, BA; Stiling, PD; Dijkstra, P; Johnson, DW; Ketterer, ME; Hymus, GJ; Hinkle, CR; Drake, BG				Hungate, BA; Stiling, PD; Dijkstra, P; Johnson, DW; Ketterer, ME; Hymus, GJ; Hinkle, CR; Drake, BG			CO2 elicits long-term decline in nitrogen fixation	SCIENCE			English	Article							GROWTH		No Arizona Univ, Dept Biol Sci, Flagstaff, AZ 86011 USA; No Arizona Univ, Merriam Powell Ctr Environm Res, Flagstaff, AZ 86011 USA; No Arizona Univ, Dept Chem, Flagstaff, AZ 86011 USA; Univ S Florida, Dept Biol, Tampa, FL 33620 USA; Univ Nevada, Dept Biol, Reno, NV 89557 USA; Smithsonian Environm Res Ctr, Edgewater, MD 21038 USA; Dynamac Corp, Kennedy Space Ctr, FL 32899 USA	Northern Arizona University; Northern Arizona University; Northern Arizona University; State University System of Florida; University of South Florida; Nevada System of Higher Education (NSHE); University of Nevada Reno; Smithsonian Institution; Smithsonian Environmental Research Center; Dynamac Corporation	Hungate, BA (corresponding author), No Arizona Univ, Dept Biol Sci, Box 5640, Flagstaff, AZ 86011 USA.	bruce.hungate@nau.edu	Hungate, Bruce/F-8991-2011	Hungate, Bruce/0000-0002-7337-1887				Gifford RM, 1996, PLANT SOIL, V187, P369, DOI 10.1007/BF00017101; HAFNER H, 1992, FERT RES, V31, P69, DOI 10.1007/BF01064229; Houghton J. T., 2001, CLIMATE CHANGE 2001; POORTER H, 1993, VEGETATIO, V104, P77, DOI 10.1007/BF00048146; Vitousek PM, 2002, BIOGEOCHEMISTRY, V57, P1, DOI 10.1023/A:1015798428743	5	134	143	2	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	2004	304	5675					1291	1291		10.1126/science.1095549	http://dx.doi.org/10.1126/science.1095549			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166370	Green Submitted			2022-12-28	WOS:000221669600044
J	Lough, M				Lough, M			Commentary: "Soft" assessment - an oxymoron?	BRITISH MEDICAL JOURNAL			English	Editorial Material							EDUCATIONAL-MEASUREMENT		NHS Educ Scotland, Glasgow G3 8BW, Lanark, Scotland	NHS Education for Scotland	Lough, M (corresponding author), NHS Educ Scotland, Glasgow G3 8BW, Lanark, Scotland.	murray.lough@nes.scot.nhs.uk						Evans R, 2004, BMJ-BRIT MED J, V328, P1240, DOI 10.1136/bmj.328.7450.1240; KING J, 2002, BMJ-BRIT MED J, V324, pS195; MESSICK S, 1984, J EDUC MEAS, V21, P215, DOI 10.1111/j.1745-3984.1984.tb01030.x; MOSS PA, 1992, REV EDUC RES, V62, P229, DOI 10.3102/00346543062003229; Prescott LE, 2002, MED EDUC, V36, P92, DOI 10.1046/j.1365-2923.2002.01099.x; Van der Vleuten CPM, 1996, ADV HEALTH SCI EDUC, V1, P41, DOI 10.1007/BF00596229	6	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 22	2004	328	7450					1243	1243		10.1136/bmj.328.7450.1243	http://dx.doi.org/10.1136/bmj.328.7450.1243			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824HL	15155503	Green Published			2022-12-28	WOS:000221677200027
J	Richardson, L				Richardson, L			Buying biosafety - Is the price right?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Radcliffe Inst Adv Study, Cambridge, MA 02138 USA		Richardson, L (corresponding author), Radcliffe Inst Adv Study, Cambridge, MA 02138 USA.							*GAO, 2003, GAO03482, P50; *NIAID, NIAID BIOD RES	2	6	6	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2121	2123		10.1056/NEJMp048053	http://dx.doi.org/10.1056/NEJMp048053			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152056	Green Published			2022-12-28	WOS:000221496700002
J	Koman, LA; Smith, BP; Shilt, JS				Koman, LA; Smith, BP; Shilt, JS			Cerebral palsy	LANCET			English	Review							BOTULINUM-TOXIN-A; SELECTIVE DORSAL RHIZOTOMY; QUALITY-OF-LIFE; GROSS MOTOR FUNCTION; NEUROMUSCULAR ELECTRICAL-STIMULATION; HYPERBARIC-OXYGEN THERAPY; DOUBLE-BLIND; UPPER-EXTREMITY; POSTERIOR RHIZOTOMY; CONTROLLED-TRIAL	Cerebral palsy, a range of non-progressive syndromes of posture and motor impairment, is a common cause of disability in childhood. The disorder results from various insults to different areas within the developing nervous system, which partly explains the variability of clinical findings. Management options include physiotherapy, occupational and speech therapy, orthotics, device-assisted modalities, pharmacological intervention, and orthopaedic and neurosurgical procedures. Since 1980, modification of spasticity by means of orally administered drugs, intramuscular chemodenervation agents (alcohol, phenol, botulinum toxin A), intrathecally administered drugs (baclofen), and surgery (neurectomy, rhizotomy) has become more frequent. Family-directed use of holistic approaches for their children with cerebral palsy includes the widespread adoption of complementary and alternative therapies; however, the prevalence of their use and the cost of these options are unknown. Traditional medical techniques (physiotherapy, bracing, and orthopaedic musculoskeletal surgery) remain the mainstay of treatment strategies at this time. This seminar addresses only the musculoskeletal issues associated with cerebral palsy and only indirectly discusses the cognitive, medical, and social issues associated with this diagnosis.	Wake Forest Univ, Bowman Gray Sch Med, Dept Orthopaed Surg, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Koman, LA (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Orthopaed Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.	lakoman@wfubmc.edu						ALBRIGHT AL, 1995, PEDIATR NEUROSURG, V23, P82; Albright AL, 1996, J CHILD NEUROL, V11, pS29, DOI 10.1177/0883073896011001S05; ALMAN BA, 1993, J PEDIATR ORTHOPED, V13, P634; AMON SS, 2001, JAMA-J AM MED ASSOC, V285, P1059; Andreacchio A, 2000, J PEDIATR ORTHOPED, V20, P501, DOI 10.1097/00004694-200007000-00015; Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS30, DOI 10.1053/apmr.2000.20621; Arens LJ, 1997, S AFR MED J, V87, P1001; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Back SA, 2001, J NEUROSCI, V21, P1302; Baker R, 2002, DEV MED CHILD NEUROL, V44, P666, DOI 10.1111/j.1469-8749.2002.tb00268.x; Bakheit AMO, 2001, DEV MED CHILD NEUROL, V43, P234, DOI 10.1017/S0012162201000445; Barry MJ, 1996, J CHILD NEUROL, V11, pS51, DOI 10.1177/0883073896011001S08; Barry MJ, 1999, DEV MED CHILD NEUROL, V41, P404, DOI 10.1017/S0012162299000870; Barwood S, 2000, DEV MED CHILD NEUROL, V42, P116, DOI 10.1017/S0012162200000220; Beals RK, 2001, DEV MED CHILD NEUROL, V43, P802, DOI 10.1017/S0012162201001451; Beckung E, 2002, DEV MED CHILD NEUROL, V44, P309; Bleck E., 1987, ORTHOPAEDIC MANAGEME; Blickstein I, 2002, DEV MED CHILD NEUROL, V44, P352; Bobath B, 1969, Physiotherapy, V55, P18; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Borton DC, 2001, J BONE JOINT SURG BR, V83B, P364, DOI 10.1302/0301-620X.83B3.10827; BOSCARINO LF, 1993, J PEDIATR ORTHOPED, V13, P174; Bower E, 2001, DEV MED CHILD NEUROL, V43, P4, DOI 10.1017/S0012162201000020; BOYCE WF, 1995, PHYS THER, V75, P603, DOI 10.1093/ptj/75.7.603; Boyd RN, 2001, EUR J NEUROL, V8, P109, DOI 10.1046/j.1468-1331.2001.00043.x; Boyd RN, 1999, EUR J NEUROL, V6, pS23, DOI 10.1111/j.1468-1331.1999.tb00031.x; Boyle C A, 1996, MMWR CDC Surveill Summ, V45, P1; BOYLE CA, 1994, PEDIATRICS, V93, P399; Buckon CE, 2001, DEV MED CHILD NEUROL, V43, P371, DOI 10.1017/S0012162201000706; BURKE RE, 1985, NEUROLOGY, V35, P73, DOI 10.1212/WNL.35.1.73; Butler C, 2001, DEV MED CHILD NEUROL, V43, P778, DOI 10.1017/S0012162201001414; Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x; CARMICK J, 1993, PHYS THER, V73, P505, DOI 10.1093/ptj/73.8.505; CARPENTER EB, 1980, DEV MED CHILD NEUROL, V22, P497; CARPENTER EB, 1983, FOOT ANKLE, V4, P164, DOI 10.1177/107110078300400309; *CENTR W HLTH PLAN, 2002, EV CER PALS DAT EP S; Chambers H, 1998, J PEDIATR ORTHOPED, V18, P703, DOI 10.1097/00004694-199811000-00003; Charles J, 2001, Pediatr Phys Ther, V13, P68, DOI 10.1097/00001577-200107000-00003; Chicoine MR, 1997, J NEUROSURG, V86, P34, DOI 10.3171/jns.1997.86.1.0034; Collet JP, 2001, LANCET, V357, P582, DOI 10.1016/S0140-6736(00)04054-X; COOPER J, 1995, J CHILD NEUROL, V10, P300, DOI 10.1177/088307389501000412; Corry IS, 1998, J PEDIATR ORTHOPED, V18, P304, DOI 10.1097/00004694-199805000-00006; Corry IS, 1997, DEV MED CHILD NEUROL, V39, P185; Corry IS, 1995, DEV MED CHILD NEUROL, V37, P20; COSGROVE AP, 1994, DEV MED CHILD NEUROL, V36, P386; Cottalorda J, 1998, INT ORTHOP, V22, P374, DOI 10.1007/s002640050281; Crenshaw S, 2000, J PEDIATR ORTHOPED, V20, P210, DOI 10.1097/00004694-200003000-00015; Crocker MD, 1997, AM J OCCUP THER, V51, P824, DOI 10.5014/ajot.51.10.824; Dabney Kirk W., 1997, Current Opinion in Pediatrics, V9, P81, DOI 10.1097/00008480-199702000-00017; Dali CI, 2002, DEV MED CHILD NEUROL, V44, P364; Daltroy LH, 1998, J PEDIATR ORTHOPED, V18, P561, DOI 10.1097/00004694-199809000-00001; Damiano DL, 2002, DEV MED CHILD NEUROL, V44, P68, DOI 10.1017/S0012162201001682; Dammann O, 2000, CURR OPIN PEDIATR, V12, P99, DOI 10.1097/00008480-200004000-00002; DeLuca PA, 1998, J PEDIATR ORTHOPED, V18, P712, DOI 10.1097/00004694-199811000-00004; DeMatteo C., 1992, QUEST QUALITY UPPER; Desloovere K, 2001, EUR J NEUROL, V8, P75, DOI 10.1046/j.1468-1331.2001.00040.x; Detrembleur C, 2002, MOVEMENT DISORD, V17, P162, DOI 10.1002/mds.1282; DOMAN RJ, 1960, JAMA-J AM MED ASSOC, V174, P257, DOI 10.1001/jama.1960.03030030037007; Doute D A, 1997, Am J Orthop (Belle Mead NJ), V26, P613; DRVARIC DM, 1989, DEV MED CHILD NEUROL, V31, P665; Eklind S, 2001, EUR J NEUROSCI, V13, P1101, DOI 10.1046/j.0953-816x.2001.01474.x; El-Said NS, 2001, J BONE JOINT SURG BR, V83B, P259, DOI 10.1302/0301-620X.83B2.10763; ELMER EB, 1992, J PEDIATR ORTHOPED, V12, P329, DOI 10.1097/01241398-199205000-00009; Essex C, 2003, DEV MED CHILD NEUROL, V45, P213, DOI 10.1017/S0012162203000409; EVANS P, 1985, ARCH DIS CHILD, V60, P940, DOI 10.1136/adc.60.10.940; Fedrizzi E, 2003, DEV MED CHILD NEUROL, V45, P85, DOI 10.1017/S0012162203000173; Fehlings D, 2000, J PEDIATR-US, V137, P331, DOI 10.1067/mpd.2000.108393; FELDMAN AB, 1990, PHYS THER, V70, P602, DOI 10.1093/ptj/70.10.602; FERGUSON RL, 1988, ORTHOP CLIN N AM, V19, P419; FILLER BC, 1976, J BONE JOINT SURG AM, V58, P667, DOI 10.2106/00004623-197658050-00015; Flett P, 2003, J PAEDIATR CHILD H, V39, P6, DOI 10.1046/j.1440-1754.2003.00082.x; Flett PJ, 1999, J PAEDIATR CHILD H, V35, P71, DOI 10.1046/j.1440-1754.1999.00330.x; Flynn John M, 2002, J Am Acad Orthop Surg, V10, P198; Foster-Barber A, 2001, DEV NEUROSCI-BASEL, V23, P213, DOI 10.1159/000046146; FULFORD GE, 1990, CLIN ORTHOP RELAT R, P55; Furlong WJ, 2001, ANN MED, V33, P375, DOI 10.3109/07853890109002092; Gaudet LM, 2001, OBSTET GYNECOL SURV, V56, P433, DOI 10.1097/00006254-200107000-00023; GINSBERG GM, 2002, DEV MED CHILD NE S91, V44, P13; GOLDNER JL, 1988, HAND CLIN, V4, P223; GOLDNER JL, 1990, CLIN ORTHOP RELAT R, V253, P75; Goldstein EM, 2001, J CHILD NEUROL, V16, P16, DOI 10.1177/088307380101600104; Gormley ME, 2001, J CHILD NEUROL, V16, P113, DOI 10.2310/7010.2001.6901; GRAHAM HK, 1988, J BONE JOINT SURG BR, V70, P472, DOI 10.1302/0301-620X.70B3.3372574; Graham HK, 2000, GAIT POSTURE, V11, P67, DOI 10.1016/S0966-6362(99)00054-5; GREEN NE, 1983, J BONE JOINT SURG AM, V65, P748, DOI 10.2106/00004623-198365060-00004; GREENE WB, 1991, J PEDIATR ORTHOPED, V11, P494, DOI 10.1097/01241398-199107000-00014; Gu YD, 1998, CHINESE MED J-PEKING, V111, P874; HAGBERG B, 1993, ACTA PAEDIATR, V82, P387, DOI 10.1111/j.1651-2227.1993.tb12704.x; Hardy P, 2002, DEV MED CHILD NEUROL, V44, P436; Hesse S, 1995, NEUROSCI LETT, V201, P37, DOI 10.1016/0304-3940(94)12124-9; HOFFER MM, 1986, J HAND SURG-AM, V11A, P836, DOI 10.1016/S0363-5023(86)80232-5; HOUSE JH, 1981, J BONE JOINT SURG AM, V63, P216, DOI 10.2106/00004623-198163020-00006; Hutton JL, 2002, ARCH DIS CHILD, V86, P84, DOI 10.1136/adc.86.2.84; Hutzler Y, 1998, DEV MED CHILD NEUROL, V40, P176; INGRAM TTS, 1984, EPIDEMIOLOGY CEREBRA, P1; JOHNSON LM, 1994, DEV MED CHILD NEUROL, V36, P965; Jongerius PH, 2001, EUR J PEDIATR, V160, P509, DOI 10.1007/s004310100784; Kay RM, 2002, J PEDIATR ORTHOPED, V22, P169, DOI 10.1097/00004694-200203000-00006; Kennes J, 2002, DEV MED CHILD NEUROL, V44, P240, DOI 10.1017/S0012162201002018; Ketelaar M, 1998, CLIN REHABIL, V12, P369, DOI 10.1191/026921598673571117; KHALILI ALI A., 1964, ARCH PHYS MED REHABIL, V45, P513; Knox V, 2002, DEV MED CHILD NEUROL, V44, P447; Koman L Andrew, 2003, Paediatr Drugs, V5, P11, DOI 10.2165/00128072-200305010-00002; KOMAN LA, 1993, J PEDIATR ORTHOPED, V13, P489, DOI 10.1097/01241398-199307000-00013; KOMAN LA, 1993, J PEDIATR ORTHOPED, V13, P180; KOMAN LA, 1990, CLIN ORTHOP RELAT R, P62; KOMAN LA, 1994, J PEDIATR ORTHOPED, V14, P299, DOI 10.1097/01241398-199405000-00005; Koman LA, 2001, PEDIATRICS, V108, P1062, DOI 10.1542/peds.108.5.1062; Koman LA, 2000, J PEDIATR ORTHOPED, V20, P108, DOI 10.1097/00004694-200001000-00022; KOMAN LA, 2003, J S ORTHOP ASS, V12, P1; KUBAN KCK, 1994, NEW ENGL J MED, V330, P188, DOI 10.1056/NEJM199401203300308; Landgraf J.M., 1996, CHILD HLTH QUESTIONN; LETTS M, 1992, J PEDIATR ORTHOPED, V12, P470, DOI 10.1097/01241398-199207000-00010; Mackey AH, 2003, DEV MED CHILD NEUROL, V45, P4, DOI 10.1017/S0012162203000021; MADIGAN RR, 1981, SPINE, V6, P583, DOI 10.1097/00007632-198111000-00009; MANSKE PR, 1990, HAND CLIN, V6, P697; Manske PR, 2001, J PEDIATR ORTHOPED, V21, P772, DOI 10.1097/00004694-200111000-00014; Mason C, 1998, Int J Lang Commun Disord, V33 Suppl, P24; MATEV I, 1991, J HAND SURG-BRIT EUR, V16B, P127, DOI 10.1016/0266-7681(91)90160-P; McCarthy ML, 2002, DEV MED CHILD NEUROL, V44, P468; McLaughlin J, 2002, DEV MED CHILD NEUROL, V44, P17, DOI 10.1017/S0012162201001608; Miller A, 1996, J PEDIATR ORTHOPED, V16, P332, DOI 10.1097/01241398-199605000-00007; Miller F, 1997, J PEDIATR ORTHOPED, V17, P603, DOI 10.1097/00004694-199709000-00006; Mittal S, 2002, PEDIATR NEUROSURG, V36, P133, DOI 10.1159/000048368; Montgomery D, 1999, UNDERSEA HYPERBAR M, V26, P235; Mooney JF, 1999, CLIN ORTHOP RELAT R, P48; MOONEY V, 1969, CLIN ORTHOP RELAT R, P122; MOORE TJ, 1991, FOOT ANKLE, V11, P219, DOI 10.1177/107110079101100406; MOSCA VS, 1995, J BONE JOINT SURG AM, V77A, P500, DOI 10.2106/00004623-199504000-00002; MOWERY CA, 1985, J PEDIATR ORTHOPED, V5, P69, DOI 10.1097/01241398-198501000-00012; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; Nelson Karin B., 1999, Current Opinion in Pediatrics, V11, P487, DOI 10.1097/00008480-199912000-00002; Nelson Karin B., 2000, Current Opinion in Neurology, V13, P133, DOI 10.1097/00019052-200004000-00004; Ness JK, 2001, DEV NEUROSCI-BASEL, V23, P203, DOI 10.1159/000046144; Novacheck TF, 2002, J PEDIATR ORTHOPED, V22, P158, DOI 10.1097/00004694-200203000-00004; Nylander G, 1999, J HAND SURG-BRIT EUR, V24B, P719, DOI 10.1054/jhsb.1999.0265; O'Brien CF, 2002, CLIN J PAIN, V18, pS182, DOI 10.1097/00002508-200211001-00011; O'Shea TM, 1998, PEDIATRICS, V101, P642, DOI 10.1542/peds.101.4.642; Olafsson Y, 1999, J PEDIATR ORTHOPED, V19, P376, DOI 10.1097/00004694-199905000-00017; Palisano RJ, 2000, PHYS THER, V80, P974, DOI 10.1093/ptj/80.10.974; PALMER FB, 1988, NEW ENGL J MED, V318, P803, DOI 10.1056/NEJM198803313181302; PANETH N, 1986, PEDIATR ANN, V15, P191, DOI 10.3928/0090-4481-19860301-05; PAPE KE, 1993, J PEDIATR ORTHOPED, V13, P628; PARK TS, 1994, PEDIATR NEUROSURG, V20, P43, DOI 10.1159/000120763; PARK TS, 1992, NEW ENGL J MED, V326, P745; PEACOCK WJ, 1981, S AFR MED J, V60, P849; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; Pierce SR, 2002, ARCH PHYS MED REHAB, V83, P1462, DOI 10.1053/apmr.2002.34832; PINZUR MS, 1991, J HAND SURG-BRIT EUR, V16B, P133, DOI 10.1016/0266-7681(91)90161-G; Polak F, 2002, DEV MED CHILD NEUROL, V44, P551; Reddihough DS, 1998, DEV MED CHILD NEUROL, V40, P763; Reimers J, 1980, Acta Orthop Scand Suppl, V184, P1; RENSHAW TS, 1995, J BONE JOINT SURG AM, V77, P1590, DOI 10.2106/00004623-199510000-00016; Roijen LEG, 2001, DEV MED CHILD NEUROL, V43, P103, DOI 10.1017/S0012162201000172; ROOT L, 1981, J BONE JOINT SURG AM, V63, P767, DOI 10.2106/00004623-198163050-00011; RUMEAUROUQUETTE C, 1992, INT J EPIDEMIOL, V21, P359, DOI 10.1093/ije/21.2.359; RumeauRouquette C, 1997, INT J EPIDEMIOL, V26, P137, DOI 10.1093/ije/26.1.137; Russell DJ, 2000, PHYS THER, V80, P873, DOI 10.1093/ptj/80.9.873; Sanger TD, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.1.e89; Sarwahi V, 2001, J PEDIATR ORTHOPED, V21, P756, DOI 10.1097/00004694-200111000-00010; Scheker LR, 1999, J HAND SURG-BRIT EUR, V24B, P226, DOI 10.1054/jhsb.1998.0002; Schendel D E, 2001, J Am Med Womens Assoc (1972), V56, P105; Schneider JW, 2001, DEV MED CHILD NEUROL, V43, P601, DOI 10.1017/S0012162201001098; Semenova K A, 1997, Neurosci Behav Physiol, V27, P639, DOI 10.1007/BF02461920; Sommerfelt K, 2001, DEV MED CHILD NEUROL, V43, P609, DOI 10.1017/S0012162201001104; Stanley F, 2000, CLIN DEV MED; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; Steinbok P, 1997, DEV MED CHILD NEUROL, V39, P178; Sterba JA, 2002, DEV MED CHILD NEUROL, V44, P301; Stewart K, 2000, Nurs Times, V96, P50; Stiers P, 2002, DEV MED CHILD NEUROL, V44, P370; Strauss D, 1998, DEV MED CHILD NEUROL, V40, P369; STRECKER WB, 1988, J HAND SURG-AM, V13A, P540, DOI 10.1016/S0363-5023(88)80091-1; Sutherland DH, 1999, GAIT POSTURE, V10, P1, DOI 10.1016/S0966-6362(99)00012-0; Szabo R M, 1985, Hand Clin, V1, P525; TARDIEU G, 1972, RECONS SURG, V13, P18; TARDIEU G, 1971, REV NEUROL, V125, P63; TARDIEU G, 1954, REV NEUROL, V91, P143; Taub E, 2001, Curr Atheroscler Rep, V3, P279, DOI 10.1007/s11883-001-0020-0; THOMETZ JG, 1988, J BONE JOINT SURG AM, V70A, P1290, DOI 10.2106/00004623-198870090-00002; Thomson JD, 2001, J PEDIATR ORTHOP B, V10, P6, DOI 10.1097/00009957-200101000-00002; Ubhi T, 2000, ARCH DIS CHILD, V83, P481, DOI 10.1136/adc.83.6.481; Van Heest AE, 1999, J HAND SURG-AM, V24A, P614; Van Heest AE, 1999, J HAND SURG-AM, V24A, P323; VANHEEST AE, 1993, J HAND SURG-AM, V18A, P278, DOI 10.1016/0363-5023(93)90361-6; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Willis JK, 2002, PEDIATRICS, V110, P94, DOI 10.1542/peds.110.1.94; Wissel J, 1999, NEUROPEDIATRICS, V30, P120, DOI 10.1055/s-2007-973475; Wong V, 1998, PEDIATR NEUROL, V18, P124, DOI 10.1016/S0887-8994(97)00164-1; Wright JG, 1996, SURGERY, V119, P241, DOI 10.1016/S0039-6060(96)80107-3	190	319	347	3	86	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	2004	363	9421					1619	1631		10.1016/S0140-6736(04)16207-7	http://dx.doi.org/10.1016/S0140-6736(04)16207-7			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145637				2022-12-28	WOS:000221408800023
J	Walsh, SH				Walsh, SH			The clinician's perspective on electronic health records and how they can affect patient care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MEDICAL-RECORD; INTERVIEW; BARRIERS; DESIGN		Solihull Hosp, Birmingham Heartlands & Solihull NHS Trust, Solihull B91 2JL, W Midlands, England	Heart of England NHS Foundation Trust	Walsh, SH (corresponding author), Solihull Hosp, Birmingham Heartlands & Solihull NHS Trust, Solihull B91 2JL, W Midlands, England.	stephen.walsh@heartsol.wmids.nhs.uk						Aydin C E, 1995, Proc Annu Symp Comput Appl Med Care, P824; Berg M, 1998, INT J MED INFORM, V52, P243, DOI 10.1016/S1386-5056(98)00143-9; Berg M, 1998, METHOD INFORM MED, V37, P294; Brown PJB, 2003, BMJ-BRIT MED J, V326, P1127, DOI 10.1136/bmj.326.7399.1127; Coiera E, 2000, J AM MED INFORM ASSN, V7, P277, DOI 10.1136/jamia.2000.0070277; COIERA E, 1997, GUIDE MED INFORMATIC, P64; de Lusignan S, 2003, METHOD INFORM MED, V42, P416; Dougherty GE, 1999, CAN MED ASSOC J, V160, P345; FRISSE M, 1995, YB MED INFORM, P238; Gadd CS, 2000, J AM MED INFORM ASSN, P275; Gilbert J A, 1998, Health Data Manag, V6, P84; GOSS RM, NOW SOMETHING COMPLE; Greenhalgh T, 1999, BMJ-BRIT MED J, V318, P323, DOI 10.1136/bmj.318.7179.323; Haidet P, 2003, ARCH INTERN MED, V163, P1134, DOI 10.1001/archinte.163.10.1134; Kaplan B, 1994, Top Health Inf Manage, V15, P24; Kay S, 1996, METHOD INFORM MED, V35, P72; McDonald CJ, 1997, J AM MED INFORM ASSN, V4, P213, DOI 10.1136/jamia.1997.0040213; MITCHELL E, 2001, BMJ-BRIT MED J, V322, P1369; Poon AD, 1996, J AM MED INFORM ASSN, V3, P168, DOI 10.1136/jamia.1996.96236285; Powsner SM, 1998, LANCET, V352, P1617, DOI 10.1016/S0140-6736(98)08309-3; Rousseau N, 2003, BMJ-BRIT MED J, V326, P314, DOI 10.1136/bmj.326.7384.314; SOLOMON GL, 1995, J FAM PRACTICE, V41, P241; TANG PC, 1994, J AM MED INFORM ASSN, P575; Tange HJ, 1997, COMPUT METH PROG BIO, V54, P157, DOI 10.1016/S0169-2607(97)00022-9; Trace David, 1993, Journal of Medical Systems, V17, P139, DOI 10.1007/BF00996938; VANBEMMEL J, 1997, HDB MED INFORMATICS, P34; vanGinneken AM, 1996, METHOD INFORM MED, V35, P98; Wright P, 1998, LANCET, V352, P1539, DOI 10.1016/S0140-6736(98)08308-1; Zue V, 1999, SCI AM, P40; NHS PLAN, P48	30	125	133	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2004	328	7449					1184	1187		10.1136/bmj.328.7449.1184	http://dx.doi.org/10.1136/bmj.328.7449.1184			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142929	Green Published			2022-12-28	WOS:000221497500030
J	Accili, D; Arden, KC				Accili, D; Arden, KC			FoxOs at the crossroads of cellular metabolism, differentiation, and transformation	CELL			English	Review							FORKHEAD TRANSCRIPTION FACTOR; LIFE-SPAN; ACTIVATION; MICE; BETA; PROLIFERATION; DEACETYLASE; DOWNSTREAM; EXPRESSION; DISRUPTION	Forkhead transcription factors of the FoxO subfamily are emerging as a shared component among pathways regulating diverse cellular functions, such as differentiation, metabolism, proliferation, and survival. Their transcriptional output is controlled via a two-tiered mechanism of phosphorylation and acetylation. Modest alterations of this balance can result in profound effects. The gamut of phenotypes runs from protection against diabetes and predisposition to neoplasia, conferred by FoxO loss of function, to increased cellular survival and a marked catabolic response associated with gain of function.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Univ Calif San Diego, Ludwig Inst Canc Res, San Diego, CA USA	Columbia University; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Accili, D (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.	da230@columbia.edu	Gimenez, Luis E Diaz/D-9291-2011					Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Finch CE, 2001, ANNU REV GENOM HUM G, V2, P435, DOI 10.1146/annurev.genom.2.1.435; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Leenders H, 2000, EUR J IMMUNOL, V30, P2980, DOI 10.1002/1521-4141(200010)30:10<2980::AID-IMMU2980>3.0.CO;2-9; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; STITT TN, 2004, IN PRESS MOL CELL, V14; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Xia SJJ, 2002, CANCER BIOL THER, V1, P97, DOI 10.4161/cbt.51; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	37	1052	1114	4	87	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	2004	117	4					421	426		10.1016/S0092-8674(04)00452-0	http://dx.doi.org/10.1016/S0092-8674(04)00452-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137936	Bronze			2022-12-28	WOS:000221458000003
J	Avidor-Reiss, T; Maer, AM; Koundakjian, E; Polyanovsky, A; Keil, T; Subramaniam, S; Zuker, CS				Avidor-Reiss, T; Maer, AM; Koundakjian, E; Polyanovsky, A; Keil, T; Subramaniam, S; Zuker, CS			Decoding cilia function: Defining specialized genes required for compartmentalized cilia biogenesis	CELL			English	Article							INTRAFLAGELLAR TRANSPORT; CAENORHABDITIS-ELEGANS; SENSORY CILIA; KINESIN-II; MECHANOSENSORY TRANSDUCTION; DROSOPHILA-MELANOGASTER; PROTEIN; HOMOLOG; FLAGELLA; CLATHRIN	The evolution of the ancestral eukaryotic flagellum is an example of a cellular organelle that became dispensable in some modern eukaryotes while remaining an essential motile and sensory apparatus in others. To help define the repertoire of specialized proteins needed for the formation and function of cilia, we used comparative genomics to analyze the genomes of organisms with prototypical cilia, modified cilia, or no cilia and identified similar to200 genes that are absent in the genomes of nonciliated eukaryotes but are conserved in ciliated organisms. Importantly, over 80% of the known ancestral proteins involved in cilia function are included in this small collection. Using Drosophila as a model system, we then characterized a novel family of proteins (OSEGs: outer segment) essential for ciliogenesis. We show that osegs encode components of a specialized transport pathway unique to the cilia compartment and are related to prototypical intracellular transport proteins.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Max Planck Society	Zuker, CS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.	charles@flyeye.ucsd.edu	Avidor-Reiss, Tomer/AAK-6153-2020	Avidor-Reiss, Tomer/0000-0003-0918-526X; Polyanovsky, Andrey/0000-0002-8116-022X				Andrews J, 2000, GENOME RES, V10, P2030, DOI 10.1101/gr.10.12.2030; Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; BAILEY TL, 1994, ISMB, V2, P28; Barolo S, 2000, CELL, V103, P957, DOI 10.1016/S0092-8674(00)00198-7; BLOODGOOD RA, 1990, CILIARY FLAGELIAR ME; Brazelton WJ, 2001, CURR BIOL, V11, P1591, DOI 10.1016/S0960-9822(01)00485-7; Cavalier-Smith T, 2002, INT J SYST EVOL MICR, V52, P297, DOI 10.1099/00207713-52-2-297; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Cuvillier A, 2000, J CELL SCI, V113, P2065; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Dubruille R, 2002, DEVELOPMENT, V129, P5487, DOI 10.1242/dev.00148; Dwyer ND, 2001, NEURON, V31, P277, DOI 10.1016/S0896-6273(01)00361-0; Eugster A, 2000, EMBO J, V19, P3905, DOI 10.1093/emboj/19.15.3905; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; Fujiwara M, 1999, DEVELOPMENT, V126, P4839; Galindo K, 2001, GENETICS, V159, P1059; Grieder NC, 2000, DEVELOPMENT, V127, P4253; Han YG, 2003, CURR BIOL, V13, P1679, DOI 10.1016/j.cub.2003.08.034; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; KERNAN M, 1994, NEURON, V12, P1195, DOI 10.1016/0896-6273(94)90437-5; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; PatelKing RS, 1997, J CELL BIOL, V137, P1081, DOI 10.1083/jcb.137.5.1081; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pazour GJ, 1999, J CELL BIOL, V144, P473, DOI 10.1083/jcb.144.3.473; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Piperno G, 1997, P NATL ACAD SCI USA, V94, P4457, DOI 10.1073/pnas.94.9.4457; Qin HM, 2001, CURR BIOL, V11, P457, DOI 10.1016/S0960-9822(01)00122-1; Ray K, 1999, J CELL BIOL, V147, P507, DOI 10.1083/jcb.147.3.507; Remm M, 2001, J MOL BIOL, V314, P1041, DOI 10.1006/jmbi.2000.5197; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Signor D, 1999, J CELL BIOL, V147, P519, DOI 10.1083/jcb.147.3.519; SINDEN RE, 1976, PROC R SOC SER B-BIO, V193, P55, DOI 10.1098/rspb.1976.0031; Sleigh M.A., 1974, CILIA FLAGELLA; Stechmann A, 2003, J MOL EVOL, V57, P408, DOI 10.1007/s00239-003-2490-x; Stechmann A, 2002, SCIENCE, V297, P89, DOI 10.1126/science.1071196; Swoboda P, 2000, MOL CELL, V5, P411, DOI 10.1016/S1097-2765(00)80436-0; Tamm Sidney, 1994, Trends in Cell Biology, V4, P305, DOI 10.1016/0962-8924(94)90226-7; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; TOKUYASU KT, 1972, Z ZELLFORSCH MIK ANA, V124, P479, DOI 10.1007/BF00335253; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708	47	400	407	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	2004	117	4					527	539		10.1016/S0092-8674(04)00412-X	http://dx.doi.org/10.1016/S0092-8674(04)00412-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137945	Bronze			2022-12-28	WOS:000221458000012
J	Gorelick, JL				Gorelick, JL			Stretch brachial plexopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									New Haven Neurosurg Associates, New Haven, CT 06510 USA		Gorelick, JL (corresponding author), New Haven Neurosurg Associates, New Haven, CT 06510 USA.								0	1	1	1	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2080	2080		10.1056/NEJMicm970647	http://dx.doi.org/10.1056/NEJMicm970647			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141046				2022-12-28	WOS:000221354000009
J	Jabbour, S				Jabbour, S			Fall of a dictator, failure of ethics	BRITISH MEDICAL JOURNAL			English	Editorial Material									Amer Univ Beirut, Fac Hlth Sci, Beirut, Lebanon; Amer Univ Beirut, Fac Med, Beirut, Lebanon	American University of Beirut; American University of Beirut	Jabbour, S (corresponding author), Amer Univ Beirut, Fac Hlth Sci, Beirut, Lebanon.		Jabbour, Samer/Y-6860-2018	Jabbour, Samer/0000-0002-7150-6856					0	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 10	2004	328	7431					115	115		10.1136/bmj.328.7431.115	http://dx.doi.org/10.1136/bmj.328.7431.115			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MP	15132142	Green Published			2022-12-28	WOS:000187976400048
J	Palle, E; Goode, PR; Montanes-Rodriguez, P; Koonin, SE				Palle, E; Goode, PR; Montanes-Rodriguez, P; Koonin, SE			Changes in Earth's reflectance over the past two decades	SCIENCE			English	Article							GENERAL-CIRCULATION; ALBEDO	We correlate an overlapping period of earthshine measurements of Earth's reflectance (from 1999 through mid-2001) with satellite observations of global cloud properties to construct from the latter a proxy measure of Earth's global shortwave reflectance. This proxy shows a steady decrease in Earth's reflectance from 1984 to 2000, with a strong climatologically significant drop after 1995. From 2001 to 2003, only earthshine data are available, and they indicate a complete reversal of the decline. Understanding how the causes of these decadal changes are apportioned between natural variability, direct forcing, and feedbacks is fundamental to confidently assessing and predicting climate change.	New Jersey Inst Technol, Big Bear Solar Observ, Big Bear City, CA 92314 USA; CALTECH, WK Kellogg Radiat Lab, Pasadena, CA 91125 USA	New Jersey Institute of Technology; California Institute of Technology	Palle, E (corresponding author), New Jersey Inst Technol, Big Bear Solar Observ, 40386 N Shore Lane, Big Bear City, CA 92314 USA.	epb@bbso.njit.edu	Palle, Enric/AAE-4492-2019	Palle, Enric/0000-0003-0987-1593; Montanes Rodriguez, Pilar/0000-0002-6855-9682				Cess RD, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016128; Cess RD, 1996, J GEOPHYS RES-ATMOS, V101, P12791, DOI 10.1029/96JD00822; Chen JY, 2002, SCIENCE, V295, P838, DOI 10.1126/science.1065835; Goode PR, 2001, GEOPHYS RES LETT, V28, P1671, DOI 10.1029/2000GL012580; HOUGHTON JT, 2001, CLIM CHANG 2001 SCI; Lean J, 1997, ANNU REV ASTRON ASTR, V35, P33, DOI 10.1146/annurev.astro.35.1.33; Palle E, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003611; Qiu J, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003610; Rossow WB, 1996, 737 WMOTD; Wang PH, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014264; Wielicki BA, 2002, SCIENCE, V295, P841, DOI 10.1126/science.1065837	11	96	98	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1299	1301		10.1126/science.1094070	http://dx.doi.org/10.1126/science.1094070			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166373	Green Submitted			2022-12-28	WOS:000221669600047
J	Booker, JR; Favetto, A; Pomposiello, MC				Booker, JR; Favetto, A; Pomposiello, MC			Low electrical resistivity associated with plunging of the Nazca flat slab beneath Argentina	NATURE			English	Article							UPPER-MANTLE; CONDUCTIVITY; MELTS; ARC	Beneath much of the Andes, oceanic lithosphere descends eastward into the mantle at an angle of about 30degrees (ref. 1). A partially molten region is thought to form in a wedge between this descending slab and the overlying continental lithosphere as volatiles given off by the slab lower the melting temperature of mantle material(2). This wedge is the ultimate source for magma erupted at the active volcanoes that characterize the Andean margin. But between 28degrees and 33degrees S the subducted Nazca plate appears to be anomalously buoyant(3,4), as it levels out at about 100 km depth and extends nearly horizontally under the continent(1,5,6). Above this 'flat slab', volcanic activity in the main Andean Cordillera terminated about 9 million years ago as the flattening slab presumably squeezed out the mantle wedge(5,6). But it is unknown where slab volatiles go once this happens, and why the flat slab finally rolls over to descend steeply into the mantle 600 km further eastward. Here we present results from a magnetotelluric profile in central Argentina, from which we infer enhanced electrical conductivity along the eastern side of the plunging slab, indicative of the presence of partial melt. This conductivity structure may imply that partial melting occurs to at least 250 km and perhaps to more than 400 km depth, or that melt is supplied from the 410 km discontinuity, consistent with the transition-zone 'water-filter' model of Bercovici and Karato(7).	Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; Inst Geocronol & Geol Isotop, RA-1428 Buenos Aires, DF, Argentina	University of Washington; University of Washington Seattle	Booker, JR (corresponding author), Univ Washington, Dept Earth & Space Sci, Box 351310, Seattle, WA 98195 USA.	booker@ess.washington.edu						[Anonymous], 1999, GEOLOGIA ARGENTINA; Bercovici D, 2003, NATURE, V425, P39, DOI 10.1038/nature01918; Bureau H, 1999, EARTH PLANET SC LETT, V165, P187, DOI 10.1016/S0012-821X(98)00266-0; CAHILL T, 1992, J GEOPHYS RES-SOL EA, V97, P17503, DOI 10.1029/92JB00493; CARTER NL, 1987, TECTONOPHYSICS, V136, P27, DOI 10.1016/0040-1951(87)90333-7; CHAVE AD, 1994, J GEOPHYS RES-SOL EA, V99, P4669, DOI 10.1029/93JB03368; CLOOS M, 1993, GEOL SOC AM BULL, V105, P715, DOI 10.1130/0016-7606(1993)105<0715:LBACOS>2.3.CO;2; James D.E., 1999, SOC EC GEOL SPEC PUB, V7, P1, DOI DOI 10.5382/SP.07.01; Jones AG, 1999, LITHOS, V48, P57, DOI 10.1016/S0024-4937(99)00022-5; JONES AG, 1992, CONTINENTAL LOWER CR, P81; JORDAN TE, 1986, AM J SCI, V286, P737, DOI 10.2475/ajs.286.10.737; Kay SM, 2002, J S AM EARTH SCI, V15, P39; MCGEARY S, 1985, TECTONOPHYSICS, V119, P195, DOI 10.1016/0040-1951(85)90039-3; Norabuena EO, 1999, GEOPHYS RES LETT, V26, P3405, DOI 10.1029/1999GL005394; Park SK, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001899; PEARSON DG, 1994, CONTRIB MINERAL PETR, V115, P449, DOI 10.1007/BF00320978; PEYRONNEAU J, 1989, NATURE, V342, P537, DOI 10.1038/342537a0; Ramos VA, 2002, J S AM EARTH SCI, V15, P59, DOI 10.1016/S0895-9811(02)00006-8; Roberts JJ, 1999, J GEOPHYS RES-SOL EA, V104, P7055, DOI 10.1029/1998JB900111; Rodi W, 2001, GEOPHYSICS, V66, P174, DOI 10.1190/1.1444893; Rogers JJW, 1996, J GEOL, V104, P91, DOI 10.1086/629803; Schilling FR, 1997, PHYS EARTH PLANET IN, V103, P17, DOI 10.1016/S0031-9201(97)00011-3; Ulmer P, 2001, PHYS EARTH PLANET IN, V127, P215, DOI 10.1016/S0031-9201(01)00229-1; Vozoff K., 1991, ELECTROMAGNETIC METH, P641, DOI [10.1190/1.1444178, DOI 10.1190/1.1444178]; WANNAMAKER PE, 1999, 3 DIMENSIONAL ELECTR, P511; WILEY PJ, 1979, AM MINERAL, V64, P469; Williams Q, 2001, ANNU REV EARTH PL SC, V29, P365, DOI 10.1146/annurev.earth.29.1.365; Xu YS, 2000, J GEOPHYS RES-SOL EA, V105, P27865, DOI 10.1029/2000JB900299	28	106	112	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					399	403		10.1038/nature02565	http://dx.doi.org/10.1038/nature02565			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164059				2022-12-28	WOS:000221644600035
J	Crutzen, PJ				Crutzen, PJ			A late change to the programme	NATURE			English	Editorial Material									Max Planck Inst Chem, D-55020 Mainz, Germany; Univ Calif San Diego, Scripps Inst Oceanog, Ctr Atmospher Sci, La Jolla, CA 92093 USA	Max Planck Society; University of California System; University of California San Diego; Scripps Institution of Oceanography	Crutzen, PJ (corresponding author), Max Planck Inst Chem, D-55020 Mainz, Germany.		Crutzen, Paul J/F-6044-2012						0	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	2004	429	6990					349	349		10.1038/429349a	http://dx.doi.org/10.1038/429349a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164041				2022-12-28	WOS:000221644600019
J	Muir, AJ; Bornstein, JD; Killenberg, PG; Fowler, F; Gilliam, J; Harlan, W; Hayes, J; Marcuard, S; McCone, J; Medoff, J; Mertesdorf, J; Newton, D; Pancotto, F; Poleynard, G; Riely, C; Strohecker, J; Werth, T; Williams, D				Muir, AJ; Bornstein, JD; Killenberg, PG; Fowler, F; Gilliam, J; Harlan, W; Hayes, J; Marcuard, S; McCone, J; Medoff, J; Mertesdorf, J; Newton, D; Pancotto, F; Poleynard, G; Riely, C; Strohecker, J; Werth, T; Williams, D		Atlantic Coast Hepatitis Treatment	Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-INFECTION; PLUS RIBAVIRIN; RACIAL-DIFFERENCES; AFRICAN-AMERICANS; INTERFERON-ALPHA; THERAPY; ETHNICITY	BACKGROUND: Several small studies have reported a lower response rate to interferon alfa among black patients with chronic hepatitis C infection than among white patients. The increased prevalence of infection with hepatitis C virus (HCV) genotype 1, which has a lower response rate than other genotypes, has been suggested as the cause. METHODS: We treated 100 black patients and 100 non-Hispanic white patients with chronic hepatitis C with peginterferon alfa-2b and ribavirin for 48 weeks. Enrollment was controlled so that the two groups had similar proportions of patients with genotype 1 infection. The primary end point was a sustained virologic response, which was defined as a negative test for serum HCV RNA six months after the completion of therapy. RESULTS: In both cohorts, 98 percent of patients had genotype 1 infection. The rate of sustained virologic response was higher among non-Hispanic white patients than among black patients (52 percent vs.19 percent, P<0.001). The black patients also had significantly lower rates of virologic response at 12 weeks and at the end of treatment. Multivariable analyses examining sociodemographic and clinical characteristics found that black race was the only variable significantly associated with the difference in response rate. CONCLUSIONS: Black patients with chronic hepatitis C have a lower rate of response to treatment with peginterferon alfa-2b and ribavirin than non-Hispanic white patients, a difference that is not explained by differences in the viral genotype.	Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC 27710 USA; Duke Univ, Duke Clin Res Inst, Durham, NC 27710 USA	Duke University; Duke University	Muir, AJ (corresponding author), Duke Univ, Med Ctr, Div Gastroenterol, Box 3913, Durham, NC 27710 USA.	muir0002@mc.duke.edu						Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Davis GL, 2003, HEPATOLOGY, V38, P645, DOI 10.1053/jhep.2003.50364; De Maria N, 2002, HEPATO-GASTROENTEROL, V49, P788; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Ioannou GN, 2003, HEPATOLOGY, V37, P795, DOI 10.1053/jhep.2003.50147; Kimball P, 2001, J MED VIROL, V65, P510, DOI 10.1002/jmv.2065; Kinzie JL, 2001, J VIRAL HEPATITIS, V8, P264, DOI 10.1046/j.1365-2893.2001.00292.x; Layden-Almer JE, 2003, HEPATOLOGY, V37, P1343, DOI 10.1053/jhep.2003.50217; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; McHutchison JG, 2000, GASTROENTEROLOGY, V119, P1317, DOI 10.1053/gast.2000.19289; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reddy KR, 1999, HEPATOLOGY, V30, P787, DOI 10.1002/hep.510300319; Soza A, 2002, HEPATOLOGY, V36, P1273, DOI 10.1053/jhep.2002.36502; Sugimoto K, 2003, HEPATOLOGY, V37, P590, DOI 10.1053/jhep.2003.50103; Thio CL, 2001, J INFECT DIS, V184, P16, DOI 10.1086/321005; Thomas DL, 2000, JAMA-J AM MED ASSOC, V284, P450, DOI 10.1001/jama.284.4.450; *UN NETW ORG SHAR, 1994, ANN REP US SCI REG T	21	423	439	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2265	2271		10.1056/NEJMoa032502	http://dx.doi.org/10.1056/NEJMoa032502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163776	Bronze			2022-12-28	WOS:000221641900007
J	Howard, SC; Pedrosa, N; Lins, M; Pedrosa, A; Pui, CH; Ribeiro, RC; Pedrosa, F				Howard, SC; Pedrosa, N; Lins, M; Pedrosa, A; Pui, CH; Ribeiro, RC; Pedrosa, F			Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEVELOPING-COUNTRIES; EL SALVADOR; CHILDREN; CANCER; NICARAGUA; THERAPY; TRIALS	Context The cure rate for childhood acute lymphoblastic leukemia (ALL) differs markedly between developed and developing countries. Objective To assess the effect of a multidisciplinary team approach and protocol-based therapy on the event-free survival of children with ALL in an area with limited resources. Design, Population, and Setting A retrospective cohort study at a pediatric hospital in the resource-poor city of Recife, Brazil. We reviewed medical records of the outcomes of 375 children with ALL diagnosed between 1980 and 2002. Eighty-three children were diagnosed in the early period (1980-1989), in the absence of a dedicated pediatric oncology unit, protocol-based therapy, specially trained nurses, 24-hour-on-site physician coverage, and ready access to intensive care. Seventy-eight children were treated (all according to protocol) during the middle period (July 1994 to March 1997). During the recent period (April 1997 to December 2002), 214 children were treated with protocol in a dedicated pediatric oncology unit staffed 24 hours by pediatric oncologists and oncology nurses. Improvements were implemented gradually during the middle period and were completed during the recent period. Main Outcome Measure Event-free survival was estimated by the Kaplan-Meier method. Events included death from toxicity, disease progression or relapse, and abandonment of treatment. Results The 5-year event-free survival improved steadily: 32% (95% Cl, 21% 43%) in the early period, 47% (95% Cl, 36%-58%) in the middle period, and 63% (95% Cl, 55%-71%) in the recent period. The probability of cause-specific treatment failure in the early, middle, and late periods, respectively, within 1 year of diagnosis was 14% vs 3.8% vs 3.3% for relapse; 6.0% vs 12% vs 9.8% for death from infection; 2.4% vs 13% vs 4.2% for death from noninfectious toxicity; and 16% vs 1.3% vs 0.5% for abandonment of therapy. Conclusion Treatment of childhood ALL in a dedicated pediatric oncology unit using a comprehensive multidisciplinary team approach, protocol-based therapy, and local support and funding is associated with improved outcomes in a resource-poor area.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Int Outreach Program, Memphis, TN 38105 USA; Inst Materno Infantil Pernambuco, Recife, PE, Brazil; Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Howard, SC (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	scott.howard@stjude.org	Howard, Scott C/K-3401-2013; Pui, Ching-Hon/N-8076-2018	Howard, Scott C/0000-0003-2244-1686; Pui, Ching-Hon/0000-0003-0303-5658	NCI NIH HHS [CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonilla M, 2000, J PEDIAT HEMATOL ONC, V22, P495, DOI 10.1097/00043426-200011000-00004; Campbell M, 1999, MED PEDIATR ONCOL, V33, P88, DOI 10.1002/(SICI)1096-911X(199908)33:2<88::AID-MPO5>3.0.CO;2-Z; Eden T, 2002, BRIT J HAEMATOL, V118, P945, DOI 10.1046/j.1365-2141.2002.03670.x; Laosombat V, 2002, MED PEDIATR ONCOL, V38, P266, DOI 10.1002/mpo.1321; Masera G, 1998, LANCET, V352, P1923, DOI 10.1016/S0140-6736(98)07077-9; MASERA G, 1993, ANN ONCOL, V4, P37, DOI 10.1093/oxfordjournals.annonc.a058354; Masera G, 1999, ANN ONCOL, V10, P137, DOI 10.1023/A:1008382631875; Metzger ML, 2003, LANCET, V362, P706, DOI 10.1016/S0140-6736(03)14228-6; Pedrosa F, 2000, J PEDIAT HEMATOL ONC, V22, P502, DOI 10.1097/00043426-200011000-00005; Pui CH, 2000, LEUKEMIA, V14, P2286, DOI 10.1038/sj.leu.2401938; Pui CH, 2001, LANCET ONCOL, V2, P597, DOI 10.1016/S1470-2045(01)00516-2; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Pui CH, 2003, INT J HEMATOL, V78, P383, DOI 10.1007/BF02983810; Pui CH, 2003, JAMA-J AM MED ASSOC, V290, P2001, DOI 10.1001/jama.290.15.2001; Ribeiro RC, 2000, LANCET, V356, pS7, DOI 10.1016/S0140-6736(00)91993-7; RiveraLuna R, 1997, ARCH MED RES, V28, P233; Sala A, 2004, CANCER-AM CANCER SOC, V100, P677, DOI 10.1002/cncr.11833; Schrappe M, 2000, LEUKEMIA, V14, P2205, DOI 10.1038/sj.leu.2401973; Schrappe M, 2000, LEUKEMIA, V14, P2193, DOI 10.1038/sj.leu.2401977; Silverman LB, 2001, BLOOD, V97, P1211, DOI 10.1182/blood.V97.5.1211; Spinetta JJ, 2002, MED PEDIATR ONCOL, V38, P114, DOI 10.1002/mpo.1283; *UNICEF, STAT WORLDS CHILDR 2; von Stackelberg A, 1999, EUR J CANCER, V35, P1349, DOI 10.1016/S0959-8049(99)00112-4; Wagner HP, 1997, ANN NY ACAD SCI, V824, P193, DOI 10.1111/j.1749-6632.1997.tb46222.x; Wake DJ, 1998, TROP DOCT, V28, P4, DOI 10.1177/004947559802800104; Wehl G, 1999, MED PEDIATR ONCOL, V32, P336; *WHO, STAT INF; Wilimas JA, 2003, MED PEDIATR ONCOL, V41, P136, DOI 10.1002/mpo.10242; Wilimas JA, 2001, HEMATOL ONCOL CLIN N, V15, P775, DOI 10.1016/S0889-8588(05)70246-X; World Medical Association, DECL HELS	30	221	232	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2004	291	20					2471	2475		10.1001/jama.291.20.2471	http://dx.doi.org/10.1001/jama.291.20.2471			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823HB	15161898	Bronze			2022-12-28	WOS:000221599700030
J	Buchner, T; Berdel, WE; Hiddemann, W				Buchner, T; Berdel, WE; Hiddemann, W			Priming with granulocyte colony-stimulating factor - Relation to high-dose cytarabine in acute myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							CHEMOTHERAPY; REMISSION; TRIAL		Univ Munster, D-48129 Munster, Germany; Univ Munich, D-81377 Munich, Germany	University of Munster; University of Munich	Buchner, T (corresponding author), Univ Munster, D-48129 Munster, Germany.							Bloomfield CD, 1998, CANCER RES, V58, P4173; Buchner T, 2003, J CLIN ONCOL, V21, P4496, DOI 10.1200/JCO.2003.02.133; Burnett AK, 1998, LANCET, V351, P700, DOI 10.1016/S0140-6736(97)09214-3; Lowenberg B, 2003, NEW ENGL J MED, V349, P743, DOI 10.1056/NEJMoa025406	4	26	27	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2215	2216		10.1056/NEJM200405203502124	http://dx.doi.org/10.1056/NEJM200405203502124			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152074	Bronze			2022-12-28	WOS:000221496700040
J	Verrier, ED; Shernan, SK; Taylor, KM; Van de Werf, F; Newman, MF; Chen, JC; Carrier, M; Haverich, A; Malloy, KJ; Adams, PX; Todaro, TG; Mojcik, CF; Rollins, SA; Levy, JH				Verrier, ED; Shernan, SK; Taylor, KM; Van de Werf, F; Newman, MF; Chen, JC; Carrier, M; Haverich, A; Malloy, KJ; Adams, PX; Todaro, TG; Mojcik, CF; Rollins, SA; Levy, JH		PRIMO-CABG Investigators	Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ANGIOPLASTY COMMA TRIAL; INFLAMMATORY RESPONSE; EXTRACORPOREAL-CIRCULATION; ADJUNCTIVE THERAPY; GUARDIAN TRIAL; INHIBITION; ANTIBODY; ACTIVATION; MORTALITY	Context Inflammation and ischemia-reperfusion injury during coronary artery bypass graft (CABG) surgery requiring cardiopulmonary bypass are associated with postoperative myocardial infarction (MI) and mortality. Objective To determine the efficacy and safety of pexelizumab, a C5 complement inhibitor, in reducing perioperative MI and mortality in CABG surgery. Design, Setting, and Participants A randomized, double-blind, placebo-controlled trial, including 3099 patients (greater than or equal to 18 years) undergoing CABG surgery with or without valve surgery at 205 hospitals in North America and Western Europe from January 2002 to February 2003. Interventions Patients were randomly assigned to receive intravenous pexelizumab (2.0 mg/kg bolus plus 0.05 mg/kg per hour for 24 hours; n = 1553) or placebo (n = 1546) 10 minutes before undergoing the procedure. Main Outcome Meaures The primary composite end point was the incidence of death or MI within 30 days of randomization in those undergoing CABG surgery only (n = 2746). Secondary analyses included the intent-to-treat analyses of death or MI composite at days 4 and 30 in all 3099 study patients. Results After 30 days, 134 (9.8%) of 1373 of patients receiving pexelizumab vs 161 (11.8%) of 1359 of patients receiving placebo (relative risk, 0.82; 95% confidence interval, 0.66-1.02; P = .07) died or experienced MI in the CABG surgery only population. In the intent-to-treat analyses, 178 (11.5%) of 1547 patients receiving pexelizumab vs 215 (14.0%) of 1535 receiving placebo died or experienced MI (relative risk, 0.82; 95% confidence interval, 0.68-0.99; P = .03). The trial was not powered to detect a reduction in mortality alone. Conclusions Compared with placebo, pexelizumab was not associated with a significant reduction in the risk of the composite end point of death or MI in 2746 patients who had undergone CABG surgery only but was associated with a statistically significant risk reduction 30 days after the procedure among all 3099 patients undergoing CABG with or without valve surgery.	Univ Washington, Sch Med, Div Cardiothorac Surg, Seattle, WA 98195 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; NHLI Imperial Coll Sch Med, Hammersmith Hosp, London, England; Univ Hosp Gasthuisberg, Louvain, Belgium; Duke Univ, Duke Clin Res Inst, Durham, NC USA; Univ Hawaii, Kaiser Permanente Med Ctr, Honolulu, HI USA; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; Hannover Med Sch, Hannover, Germany; Procter & Gamble Pharmaceut, Cincinnati, OH USA; Alex Pharmaceut, Cheshire, CT USA; Emory Univ Hosp, Atlanta, GA USA	University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Imperial College London; KU Leuven; University Hospital Leuven; Duke University; Kaiser Permanente; University of Hawaii System; Universite de Montreal; Hannover Medical School; Procter & Gamble; Emory University	Verrier, ED (corresponding author), Univ Washington, Sch Med, Div Cardiothorac Surg, 1959 NE Pacific, Seattle, WA 98195 USA.	edver@u.wash.edu	Haverich, Axel/AAC-7552-2022	Van de Werf, Frans/0000-0001-9479-7767				Califf RM, 1998, J AM COLL CARDIOL, V31, P241, DOI 10.1016/S0735-1097(97)00506-8; CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901; Ferguson TB, 2002, ANN THORAC SURG, V73, P480, DOI 10.1016/S0003-4975(01)03339-2; Fitch JCK, 1999, CIRCULATION, V100, P2499, DOI 10.1161/01.CIR.100.25.2499; Gavard JA, 2003, J THORAC CARDIOV SUR, V126, P807, DOI 10.1016/S0022-5223(03)00735-9; GILLINOV AM, 1993, ANN THORAC SURG, V56, P847, DOI 10.1016/0003-4975(93)90342-F; Granger CB, 2003, CIRCULATION, V108, P1184, DOI 10.1161/01.CIR.0000087447.12918.85; Hall RI, 1997, ANESTH ANALG, V85, P766, DOI 10.1097/00000539-199710000-00011; HOMEISTER JW, 1992, CIRC RES, V71, P303, DOI 10.1161/01.RES.71.2.303; KIRKLIN JK, 1983, J THORAC CARDIOV SUR, V86, P845; Kong TQ, 1997, JAMA-J AM MED ASSOC, V277, P461, DOI 10.1001/jama.277.6.461; Levy JH, 2003, ANN THORAC SURG, V75, pS715, DOI 10.1016/S0003-4975(02)04701-X; Mahaffey KW, 2003, CIRCULATION, V108, P1176, DOI 10.1161/01.CIR.0000087404.53661.F8; MATIS LA, 1995, NAT MED, V1, P839, DOI 10.1038/nm0895-839; McCarthy PM, 1999, ANN THORAC SURG, V67, P1268, DOI 10.1016/S0003-4975(99)00136-8; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; Rao V, 2002, J THORAC CARDIOV SUR, V123, P928, DOI 10.1067/mtc.2002.121686; RINDER CS, 1992, BLOOD, V79, P1201; RINDER CS, 1995, J CLIN INVEST, V96, P1564, DOI 10.1172/JCI118195; Royston D, 1996, PERFUSION-UK, V11, P177, DOI 10.1177/026765919601100302; SEGHAYE MC, 1993, J THORAC CARDIOV SUR, V106, P978, DOI 10.1016/S0022-5223(19)33968-6; Shernan SK, 2004, ANN THORAC SURG, V77, P942, DOI 10.1016/j.athoracsur.2003.08.054; Theroux P, 2004, J AM COLL CARDIOL, V43, p287A, DOI 10.1016/S0735-1097(04)91216-8; Theroux P, 2000, CIRCULATION, V102, P3032; Thomas TC, 1996, MOL IMMUNOL, V33, P1389, DOI 10.1016/S0161-5890(96)00078-8; Vakeva AP, 1998, CIRCULATION, V97, P2259, DOI 10.1161/01.CIR.97.22.2259; Van de Werf FJ, 2004, J AM COLL CARDIOL, V43, p474A, DOI 10.1016/S0735-1097(04)92006-2; WACHTFOGEL YT, 1987, BLOOD, V69, P324; Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676	29	143	156	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2004	291	19					2319	2327		10.1001/jama.291.19.2319	http://dx.doi.org/10.1001/jama.291.19.2319			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821JD	15150203	Bronze			2022-12-28	WOS:000221455400019
J	Maile, T; Kwoczynski, S; Katzenberger, RJ; Wassarman, DA; Sauer, F				Maile, T; Kwoczynski, S; Katzenberger, RJ; Wassarman, DA; Sauer, F			TAF1 activates transcription by phosphorylation of serine 33 in histone H2B	SCIENCE			English	Article							CELL-CYCLE PROGRESSION; TAF(II)250; TAILS	Dynamic changes in chromatin structure, induced by posttranslational modification of histones, play a fundamental role in regulating eukaryotic transcription. Here we report that histone H2B is phosphorylated at evolutionarily conserved Ser(33) (H2B-S33) by the carboxyl-terminal kinase domain (CTK) of the Drosophila TFIID subunit TAF1. Phosphorylation of H2B-S33 at the promoter of the cell cycle regulatory gene string and the segmentation gene giant coincides with transcriptional activation. Elimination of TAF1 CTK activity in Drosophila cells and embryos reduces transcriptional activation and phosphorylation of H2B-S33. These data reveal that H2B-S33 is a physiological substrate for the TAF1 CTK and that H2B-S33 phosphorylation is essential for transcriptional activation events that promote cell cycle progression and development.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Calif Riverside, Dept Biochem, Riverside, CA 95121 USA; Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Riverside; Ruprecht Karls University Heidelberg	Wassarman, DA (corresponding author), Univ Wisconsin, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	dawassarman@wisc.edu; frank.sauer@ucr.edu	Maile, Tobias M/A-7805-2016	Maile, Tobias M/0000-0003-0376-8683	NIGMS NIH HHS [GM066204-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066204] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Chen BS, 2002, CURR BIOL, V12, pR620, DOI 10.1016/S0960-9822(02)01134-X; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dunphy EL, 2000, MOL CELL BIOL, V20, P1134, DOI 10.1128/MCB.20.4.1134-1139.2000; ELGIN SCR, 1979, BIOCHEMISTRY-US, V18, P5679, DOI 10.1021/bi00592a025; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Florence B, 2001, FRONT BIOSCI-LANDMRK, V6, pD1008, DOI 10.2741/Florence; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Goll MG, 2002, GENE DEV, V16, P1739, DOI 10.1101/gad.1013902; Hamiche A, 2001, P NATL ACAD SCI USA, V98, P14316, DOI 10.1073/pnas.251421398; ISENBERG I, 1979, ANNU REV BIOCHEM, V48, P159, DOI 10.1146/annurev.bi.48.070179.001111; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martin J, 1999, MOL CELL BIOL, V19, P5548; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Pile LA, 2002, MOL CELL BIOL, V22, P4965, DOI 10.1128/MCB.22.14.4965-4976.2002; Recht J, 1999, EMBO J, V18, P229, DOI 10.1093/emboj/18.1.229; RiveraPomar R, 1996, TRENDS GENET, V12, P478, DOI 10.1016/0168-9525(96)10044-5; Um M, 2001, MOL CELL BIOL, V21, P2435, DOI 10.1128/MCB.21.7.2435-2448.2001; Wassarman DA, 2001, J CELL SCI, V114, P2895; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	28	49	55	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					1010	1014		10.1126/science.1095001	http://dx.doi.org/10.1126/science.1095001			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143281				2022-12-28	WOS:000221383300049
J	Jaffe, W; Meisenheimer, K; Rottgering, HJA; Leinert, C; Richichi, A; Chesneau, O; Fraix-Burnet, D; Glazenborg-Kluttig, A; Granato, GL; Graser, U; Heijligers, B; Kohler, R; Malbet, F; Miley, GK; Paresce, F; Pel, JW; Perrin, G; Przygodda, F; Schoeller, M; Sol, H; Waters, LBFM; Weigelt, G; Woillez, J; de Zeeuw, PT				Jaffe, W; Meisenheimer, K; Rottgering, HJA; Leinert, C; Richichi, A; Chesneau, O; Fraix-Burnet, D; Glazenborg-Kluttig, A; Granato, GL; Graser, U; Heijligers, B; Kohler, R; Malbet, F; Miley, GK; Paresce, F; Pel, JW; Perrin, G; Przygodda, F; Schoeller, M; Sol, H; Waters, LBFM; Weigelt, G; Woillez, J; de Zeeuw, PT			The central dusty torus in the active nucleus of NGC 1068	NATURE			English	Article							GALACTIC NUCLEI; NGC 1068; INFRARED-SPECTRA; SPECTROSCOPY; EMISSION; VLTI	Active galactic nuclei (AGNs) display many energetic phenomena - broad emission lines, X-rays, relativistic jets, radio lobes originating from matter falling onto a supermassive black hole. It is widely accepted that orientation effects play a major role in explaining the observational appearance of AGNs. Seen from certain directions, circum-nuclear dust clouds would block our view of the central powerhouse(1,2). Indirect evidence suggests that the dust clouds form a parsec-sized torus-shaped distribution. This explanation, however, remains unproved, as even the largest telescopes have not been able to resolve the dust structures. Here we report interferometric mid-infrared observations that spatially resolve these structures in the galaxy NGC 1068. The observations reveal warm (320 K) dust in a structure 2.1 parsec thick and 3.4 parsec in diameter, surrounding a smaller hot structure. As such a configuration of dust clouds would collapse in a time much shorter than the active phase of the AGN(3), this observation requires a continual input of kinetic energy to the cloud system from a source coexistent with the AGN.	Leiden Observ, NL-2333 CA Leiden, Netherlands; Max Planck Inst Astron, D-69117 Heidelberg, Germany; European So Observ, D-85748 Garching, Germany; Observ Grenoble, F-38041 Grenoble 9, France; Stichting ASTRON, NL-7990 AA Dwingeloo, Netherlands; Astron Observ Padova, I-35122 Padua, Italy; Univ Groningen, Kapteyn Astron Inst, NL-9700 AV Groningen, Netherlands; Observ Paris, F-92195 Meudon, France; European So Observ, Santiago 19, Chile; Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Katholieke Univ Leuven, Inst Sterrenkunde, B-3001 Heverlee, Belgium; Max Planck Inst Radioastron, D-53121 Bonn, Germany	Leiden University; Leiden University - Excl LUMC; Max Planck Society; European Southern Observatory; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); University of Padua; University of Groningen; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; European Southern Observatory; University of Amsterdam; KU Leuven; Max Planck Society	Jaffe, W (corresponding author), Leiden Observ, Niels Bohrweg 2, NL-2333 CA Leiden, Netherlands.	jaffe@strw.leidenuniv.nl	Fraix-Burnet, Didier/ABF-5745-2020; Malbet, Fabien/ABF-1483-2020; Köhler, Rainer/L-6037-2018	Köhler, Rainer/0000-0002-8955-520X; Perrin, Guy/0000-0003-0680-0167; Granato, Gian Luigi/0000-0002-4480-6909; Fraix-Burnet, Didier/0000-0002-7418-0513; Malbet, Fabien/0000-0002-8029-4226; Schoeller, Markus/0000-0002-5379-1286				ANTONUCCI R, 1993, ANNU REV ASTRON ASTR, V31, P473, DOI 10.1146/annurev.aa.31.090193.002353; ANTONUCCI RRJ, 1985, ASTROPHYS J, V297, P621, DOI 10.1086/163559; BlandHawthorn J, 1997, ASTROPHYS SPACE SCI, V248, P9, DOI 10.1023/A:1000567831370; Bock JJ, 2000, ASTRON J, V120, P2904, DOI 10.1086/316871; Bruhweiler FC, 2001, ASTROPHYS J, V546, P866, DOI 10.1086/318302; Crenshaw DM, 2000, ASTROPHYS J, V532, pL101, DOI 10.1086/312581; EFSTATHIOU A, 1995, MON NOT R ASTRON SOC, V277, P1134, DOI 10.1093/mnras/277.3.1134; Glindemann A, 2003, P SOC PHOTO-OPT INS, V4838, P89, DOI 10.1117/12.458117; Granato GL, 1997, ASTROPHYS J, V486, P147, DOI 10.1086/304502; KEMPER F, UNPUB ASTROPHYS J; KROLIK JH, 1988, ASTROPHYS J, V329, P702, DOI 10.1086/166414; Leinert C, 2003, P SOC PHOTO-OPT INS, V4838, P893, DOI 10.1117/12.457027; Lumsden SL, 1999, MON NOT R ASTRON SOC, V303, P209, DOI 10.1046/j.1365-8711.1999.02074.x; Lutz D, 2000, ASTROPHYS J, V536, P697, DOI 10.1086/308972; Maiolino R, 2001, ASTRON ASTROPHYS, V365, P28, DOI 10.1051/0004-6361:20000177; Muxlow TWB, 1996, MON NOT R ASTRON SOC, V278, P854, DOI 10.1093/mnras/278.3.854; Nenkova M, 2002, ASTROPHYS J, V570, pL9, DOI 10.1086/340857; PIER EA, 1992, ASTROPHYS J, V401, P99, DOI 10.1086/172042; SCHARTMANN M, 2003, THESIS U HEIDELBERG; Speck AK, 2000, ASTRON ASTROPHYS SUP, V146, P437, DOI 10.1051/aas:2000274; URRY CM, 1995, PUBL ASTRON SOC PAC, V107, P803, DOI 10.1086/133630	21	418	420	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	2004	429	6987					47	49		10.1038/nature02531	http://dx.doi.org/10.1038/nature02531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129274				2022-12-28	WOS:000221222100038
J	Mamdani, M; Juurlink, DN; Kopp, A; Naglie, G; Austin, PC; Laupacis, A				Mamdani, M; Juurlink, DN; Kopp, A; Naglie, G; Austin, PC; Laupacis, A			Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; TOXICITY		Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute	Mamdani, M (corresponding author), Inst Clin Evaluat Sci, 2075 Bayview Ave G106, Toronto, ON M4N 3M5, Canada.	muhammad.mamdani@ices.on.ca		Naglie, Gary/0000-0002-6274-0894; Austin, Peter/0000-0003-3337-233X				Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Mamdani M, 2002, BRIT MED J, V325, P624, DOI 10.1136/bmj.325.7365.624; PINDYCK RS, 1998, ECONOMETRIC MODELS E, pCH15; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Williams J. I., 1996, PATTERNS HLTH CARE O, P339	5	67	71	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 12	2004	328	7453					1415	1416		10.1136/bmj.38068.716262.F7	http://dx.doi.org/10.1136/bmj.38068.716262.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15138157	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000222114400022
J	Becker, L; Poreda, RJ; Basu, AR; Pope, KO; Harrison, TM; Nicholson, C; Iasky, R				Becker, L; Poreda, RJ; Basu, AR; Pope, KO; Harrison, TM; Nicholson, C; Iasky, R			Bedout: A possible end-Permian impact crater offshore of Northwestern Australia	SCIENCE			English	Article							CRETACEOUS-TERTIARY BOUNDARY; TRIASSIC BOUNDARY; CHICXULUB IMPACT; FLOOD BASALTS; NOBLE-GASES; BASIN; ANTARCTICA; FULLERENES; EXTINCTION; EVOLUTION	The Bedout High, located on the northwestern continental margin of Australia, has emerged as a prime candidate for an end-Permian impact structure. Seismic imaging, gravity data, and the identification of melt rocks and impact breccias from drill cores located on top of Bedout are consistent with the presence of a buried impact crater. The impact breccias contain nearly pure silica glass ( SiO2), fractured and shock-melted plagioclases, and spherulitic glass. The distribution of glass and shocked minerals over hundreds of meters of core material implies that a melt sheet is present. Available gravity and seismic data suggest that the Bedout High represents the central uplift of a crater similar in size to Chicxulub. A plagioclase separate from the Lagrange-1 exploration well has an Ar/Ar age of 250.1 +/- 4.5 million years. The location, size, and age of the Bedout crater can account for reported occurrences of impact debris in Permian-Triassic boundary sediments worldwide.	Univ Calif Santa Barbara, Dept Geol Sci, Inst Crustal Studies, Santa Barbara, CA 93106 USA; Univ Rochester, Dept Earth & Environm Sci, Rochester, NY 14627 USA; Geo Eco Arc Res, Aquasco, MD 20608 USA; Australian Natl Univ, Canberra, ACT, Australia; Geol Survey Western Australia, Perth, WA 6004, Australia	University of California System; University of California Santa Barbara; University of Rochester; Australian National University; Geological Survey of Western Australia	Becker, L (corresponding author), Univ Calif Santa Barbara, Dept Geol Sci, Inst Crustal Studies, Santa Barbara, CA 93106 USA.	lbecker@crustal.ucsb.edu	Harrison, Timothy M/E-7443-2012					ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; BASU AR, 1993, SCIENCE, V261, P902, DOI 10.1126/science.261.5123.902; Basu AR, 2003, SCIENCE, V302, P1388, DOI 10.1126/science.1090852; Becker L, 2001, SCIENCE, V291, P1530, DOI 10.1126/science.1057243; Becker L, 2000, P NATL ACAD SCI USA, V97, P2979, DOI 10.1073/pnas.050519397; BECKER L, 2002, AM GEOPH UN AGU ABST; Charlton TR, 2001, J ASIAN EARTH SCI, V19, P595, DOI 10.1016/S1367-9120(00)00054-7; Christeson GL, 2001, J GEOPHYS RES-SOL EA, V106, P21751, DOI 10.1029/2001JB000337; Claeys P, 2003, METEORIT PLANET SCI, V38, P1299, DOI 10.1111/j.1945-5100.2003.tb00315.x; COLWELL S, 1994, SEDIMENTARY BASINS W, P757; FRENCH BM, 1998, 594 LPI; Glikson AY, 1999, GEOLOGY, V27, P387, DOI 10.1130/0091-7613(1999)027<0387:OMIACE>2.3.CO;2; GORTER J, 1996, PET EXPLOR SOC AUST, P33; GORTER J, 1998, AUST PET PROD EXPLOR, P159; Graup G, 1999, METEORIT PLANET SCI, V34, P425, DOI 10.1111/j.1945-5100.1999.tb01351.x; *GSWA, 1983, WELL REP GRANG 1 BED; HILDEBRAND AR, 1991, GEOLOGY, V19, P867, DOI 10.1130/0091-7613(1991)019<0867:CCAPCT>2.3.CO;2; HORSTMAN EL, 1984, CANNING BASIN W AUST, P240; IVANOV BA, 2003, LUNAR PLANET SCI, V34, P1338; Izett G. A., 1990, GEOL SOC AM SPEC PAP, V249; JONES AP, 2002, EARTH PLANET SC LETT, V6343, P1; Kaiho K, 2001, GEOLOGY, V29, P815, DOI 10.1130/0091-7613(2001)029<0815:EPCBAB>2.0.CO;2; KRITSKI A, 2000, THESIS U SYDNEY SYDN; KYTE FT, 1995, EARTH PLANET SC LETT, V132, P113, DOI 10.1016/0012-821X(95)00051-D; MELOSH HJ, 2000, CATASTROPHIC EVENTS, P3144; Melosh J, 2001, NATURE, V414, P861, DOI 10.1038/414861a; Miono S, 1996, NUCL INSTRUM METH B, V109, P612, DOI 10.1016/0168-583X(95)00978-7; MIONO S, 1966, NUCL INSTRUM METH B, V150, P516; Morgan J, 1999, GEOLOGY, V27, P407, DOI 10.1130/0091-7613(1999)027<0407:CTTDOA>2.3.CO;2; PETAEV MI, 2004, LUN PLAN SCI C ABSTR, V35, P1216; Pope KO, 2002, GEOLOGY, V30, P99, DOI 10.1130/0091-7613(2002)030<0099:IDNTCO>2.0.CO;2; Poreda RJ, 2003, ASTROBIOLOGY, V3, P75, DOI 10.1089/153110703321632435; PURCELL PG, 1994, SEDIMENTARY BASINS W, P63; PURCELL PG, 1994, SEDIMENTARY BASINS W, P769; Reeckmann S., 1984, CANNING BASIN, P389; Reichow MK, 2002, SCIENCE, V296, P1846, DOI 10.1126/science.1071671; RENNE PR, 1991, SCIENCE, V253, P176, DOI 10.1126/science.253.5016.176; Retallack GJ, 1998, GEOLOGY, V26, P979, DOI 10.1130/0091-7613(1998)026<0979:SFEOIA>2.3.CO;2; SCHURAYTZ BC, 1994, GEOLOGY, V22, P868, DOI 10.1130/0091-7613(1994)022<0868:POIMRA>2.3.CO;2; SHARPTON VL, 1992, NATURE, V359, P819, DOI 10.1038/359819a0; Smit J, 1999, ANNU REV EARTH PL SC, V27, P75, DOI 10.1146/annurev.earth.27.1.75; SMITH SA, 1999, THESIS U ADELAIDE AD; Stu┬ffler D., 1972, FORTSCHRITTE MINERAL, V49, P50; Tsikalas F, 1998, GEOL SOC AM BULL, V110, P537, DOI 10.1130/0016-7606(1998)110<0537:CIAPDA>2.3.CO;2; Tsikalas F, 1998, J GEOPHYS RES-SOL EA, V103, P30469, DOI 10.1029/97JB03389; TSIKALAS F, 1998, J GEOPHYS RES, V103, P30	46	148	174	4	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1469	1476		10.1126/science.1093925	http://dx.doi.org/10.1126/science.1093925			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15143216				2022-12-28	WOS:000221795800034
J	Cobb, BA; Wang, O; Tzianabos, AO; Kasper, DL				Cobb, BA; Wang, O; Tzianabos, AO; Kasper, DL			Polysaccharide processing and presentation by the MHCII pathway	CELL			English	Article							CHRONIC GRANULOMATOUS-DISEASE; HLA-DR MOLECULES; ABSCESS FORMATION; T-CELLS; ANTIGEN PRESENTATION; NITRIC-OXIDE; ZWITTERIONIC POLYSACCHARIDES; CAPSULAR POLYSACCHARIDE; BACTEROIDES-FRAGILIS; CATHEPSIN-S	The adaptive immune system functions through the combined action of antigen-presenting cells (APCs) and T cells. Specifically, class I major histocompatibility complex antigen presentation to CD8(+) T cells is limited to proteosome-generated peptides from intracellular pathogens while the class II (MHCII) endocytic pathway presents only proteolytic peptides from extracellular pathogens to CD4(+) T cells. Carbohydrates have been thought to stimulate immune responses independently of T cells; however, zwitterionic polysaccharides (ZPSs) from the capsules of some bacteria can activate CD4(+) T cells. Here we show that ZPSs are processed to low molecular weight carbohydrates by a nitric oxide-mediated mechanism and presented to T cells through the MHCII endocytic pathway. Furthermore, these carbohydrates bind to MHCII inside APCs for presentation to T cells. Our observations begin to elucidate the mechanisms by which some carbohydrates induce important immunologic responses through T cell activation, suggesting a fundamental shift in the MHCII presentation paradigm.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Kasper, DL (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02215 USA.	dennis_kasper@hms.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039576, R21AI039576, T32AI007061, R01AI052397] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI039576, T32 AI007061, AI52397, AI039576, AI007061, R01 AI039576-08, R01 AI052397] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas A., 2017, CELLULAR MOL IMMUNOL, P281; ACCOLLA RS, 1985, J IMMUNOL, V134, P3265; ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; Bacci S, 1996, J INVEST DERMATOL, V107, P838, DOI 10.1111/1523-1747.ep12330994; Baker CJ, 1999, J INFECT DIS, V179, P142, DOI 10.1086/314574; Brubaker JO, 1999, J IMMUNOL, V162, P2235; Busch R, 1998, J BIOL CHEM, V273, P27557, DOI 10.1074/jbc.273.42.27557; Choi YH, 2002, BIOCHEMISTRY-US, V41, P15144, DOI 10.1021/bi020491v; Chung DR, 2003, J IMMUNOL, V170, P1958, DOI 10.4049/jimmunol.170.4.1958; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5; Edmunds NJ, 2003, J VASC RES, V40, P68, DOI 10.1159/000068941; Forman Henry Jay, 2001, Molecular Aspects of Medicine, V22, P189; Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893; Gauthier L, 1998, P NATL ACAD SCI USA, V95, P11828, DOI 10.1073/pnas.95.20.11828; Kalka-Moll WM, 2000, J IMMUNOL, V164, P719, DOI 10.4049/jimmunol.164.2.719; Kalka-Moll WM, 2002, J IMMUNOL, V169, P6149, DOI 10.4049/jimmunol.169.11.6149; KAPPLER J, 1994, P NATL ACAD SCI USA, V91, P8462, DOI 10.1073/pnas.91.18.8462; Kaspar DL, 1996, J CLIN INVEST, V98, P2308, DOI 10.1172/JCI119042; Koh SD, 2001, J BIOL CHEM, V276, P44338, DOI 10.1074/jbc.M108125200; Krinos CM, 2001, NATURE, V414, P555, DOI 10.1038/35107092; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; PIER GB, 1984, J IMMUNOL, V133, P734; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; Riese RJ, 1998, J CLIN INVEST, V101, P2351, DOI 10.1172/JCI1158; Rotzschke O, 2002, P NATL ACAD SCI USA, V99, P16946, DOI 10.1073/pnas.212643999; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; Schroter CJ, 1999, J IMMUNOL METHODS, V227, P161, DOI 10.1016/S0022-1759(99)00079-4; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Svensson M, 1997, J IMMUNOL, V158, P4229; Tsuji S, 2002, NITRIC OXIDE-BIOL CH, V7, P283, DOI 10.1016/S1089-8603(02)00110-6; Tzianabos AO, 2000, J BIOL CHEM, V275, P6733, DOI 10.1074/jbc.275.10.6733; TZIANABOS AO, 1993, SCIENCE, V262, P416, DOI 10.1126/science.8211161; TZIANABOS AO, 1992, J BIOL CHEM, V267, P18230; TZIANABOS AO, 1994, INFECT IMMUN, V62, P4881, DOI 10.1128/IAI.62.11.4881-4886.1994; Tzianabos AO, 1999, J IMMUNOL, V163, P893; Tzianabos AO, 2002, CURR OPIN MICROBIOL, V5, P92, DOI 10.1016/S1369-5274(02)00292-8; Tzianabos AO, 2001, P NATL ACAD SCI USA, V98, P9365, DOI 10.1073/pnas.161175598; Wang Y, 2000, P NATL ACAD SCI USA, V97, P13478, DOI 10.1073/pnas.97.25.13478; Watts C, 1999, Rev Immunogenet, V1, P60; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; WIMAN K, 1982, BIOCHEMISTRY-US, V21, P5351, DOI 10.1021/bi00264a036	47	264	285	2	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					677	687		10.1016/j.cell.2004.05.001	http://dx.doi.org/10.1016/j.cell.2004.05.001			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163414	Bronze, Green Accepted			2022-12-28	WOS:000221857900013
J	Gardel, ML; Shin, JH; MacKintosh, FC; Mahadevan, L; Matsudaira, P; Weitz, DA				Gardel, ML; Shin, JH; MacKintosh, FC; Mahadevan, L; Matsudaira, P; Weitz, DA			Elastic Behavior of cross-linked and bundled actin networks	SCIENCE			English	Article							MECHANICAL-PROPERTIES; DYNAMICS; VISCOELASTICITY; FILAMENTS; POLYMERS; MODULUS; MOTION; GELS	Networks of cross-linked and bundled actin. laments are ubiquitous in the cellular cytoskeleton, but their elasticity remains poorly understood. We show that these networks exhibit exceptional elastic behavior that reflects the mechanical properties of individual. laments. There are two distinct regimes of elasticity, one reflecting bending of single. laments and a second reflecting stretching of entropic fluctuations of filament length. The mechanical stiffness can vary by several decades with small changes in cross-link concentration, and can increase markedly upon application of external stress. We parameterize the full range of behavior in a state diagram and elucidate its origin with a robust model.	Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; MIT, Dept Mech Engn, Cambridge, MA 02139 USA; MIT, Whitehead Inst Biomed Res, Dept Biol, Cambridge, MA 02142 USA; MIT, Whitehead Inst Biomed Res, Div Biol Engn, Cambridge, MA 02142 USA; Vrije Univ Amsterdam, Div Phys & Astron, Amsterdam, Netherlands	Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Vrije Universiteit Amsterdam	Weitz, DA (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.	weitz@deas.harvard.edu	MacKintosh, Fred C/A-9450-2008; Shin, Jennifer H/C-1647-2011; MacKintosh, Frederick/AAB-9332-2021; Gardel, Margaret/D-1703-2012; Matsudaira, Paul/H-1475-2012	MacKintosh, Fred C/0000-0002-2607-9541; Shin, Jennifer H/0000-0001-8448-6236; MacKintosh, Frederick/0000-0002-2607-9541; Matsudaira, Paul/0000-0002-8399-3276	NIGMS NIH HHS [GM52703] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052703] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1980, VISCOELASTIC PROPERT; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; FIXMAN M, 1973, J CHEM PHYS, V58, P1564, DOI 10.1063/1.1679396; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Head DA, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.108102; Isambert H, 1996, MACROMOLECULES, V29, P1036, DOI 10.1021/ma946418x; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; JANMEY PA, 1990, NATURE, V345, P89, DOI 10.1038/345089a0; Kreis T., 1999, CYTOSKELETAL MOTOR P; Kroy K, 1996, PHYS REV LETT, V77, P306, DOI 10.1103/PhysRevLett.77.306; Landau LD, 1986, THEORY ELASTICITY, DOI 10.1016/C2009-0-25521-8; Lodish H., 1999, MOL CELL BIOL; MACKINTOSH FC, 1995, PHYS REV LETT, V75, P4425, DOI 10.1103/PhysRevLett.75.4425; Morse DC, 1998, MACROMOLECULES, V31, P7044, DOI 10.1021/ma980304u; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RUDDIES R, 1993, EUR BIOPHYS J BIOPHY, V22, P309, DOI 10.1007/BF00213554; Satcher RL, 1996, BIOPHYS J, V71, P109, DOI 10.1016/S0006-3495(96)79206-8; SCHMIDT CF, 1989, MACROMOLECULES, V22, P3638, DOI 10.1021/ma00199a023; SEMENOV AN, 1986, J CHEM SOC FARAD T 2, V82, P317, DOI 10.1039/f29868200317; Sherman MB, 1999, J MOL BIOL, V294, P139, DOI 10.1006/jmbi.1999.3222; Shin J., UNPUB; Shin JH, 2004, J MOL BIOL, V337, P255, DOI 10.1016/j.jmb.2004.01.028; Tempel M, 1996, PHYS REV E, V54, P1802, DOI 10.1103/PhysRevE.54.1802; TILNEY LG, 1975, J CELL BIOL, V64, P289, DOI 10.1083/jcb.64.2.289; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; Wilhelm J, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.108103; Xu JY, 1998, BIOPHYS J, V74, P2731, DOI 10.1016/S0006-3495(98)77979-2; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570	28	927	946	8	274	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1301	1305		10.1126/science.1095087	http://dx.doi.org/10.1126/science.1095087			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166374				2022-12-28	WOS:000221669600048
J	Holland, P				Holland, P			The ups and downs of a sea anemone	SCIENCE			English	Editorial Material									Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Holland, P (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	peter.holland@zoology.oxford.ac.uk						Bonnet C, 1779, OEUVRES HIST NATUREL; Finnerty JR, 2004, SCIENCE, V304, P1335, DOI 10.1126/science.1091946; Hayward DC, 2002, P NATL ACAD SCI USA, V99, P8106, DOI 10.1073/pnas.112021499; HYMAN LH, 1940, INVERTEBRATES PROTOZ; ROKHSAR DS, COMMUNICATION; Yanze N, 2001, DEV BIOL, V236, P89, DOI 10.1006/dbio.2001.0299	6	4	5	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	2004	304	5675					1255	1256		10.1126/science.1099829	http://dx.doi.org/10.1126/science.1099829			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166351				2022-12-28	WOS:000221669600025
J	Wurmser, AE; Palmer, TD; Gage, FH				Wurmser, AE; Palmer, TD; Gage, FH			Cellular interactions in the stem cell niche	SCIENCE			English	Editorial Material							ENDOTHELIAL-CELLS; DIFFERENTIATION; NEUROGENESIS; ANGIOGENESIS; INDUCTION		Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA	Salk Institute; Stanford University	Wurmser, AE (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gage@salk.edu	Palmer, Theo/GSI-6635-2022	Palmer, Theo/0000-0002-6266-1862				Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Mi HY, 2001, J NEUROSCI, V21, P1538, DOI 10.1523/JNEUROSCI.21-05-01538.2001; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a	10	118	133	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1253	+		10.1126/science.1099344	http://dx.doi.org/10.1126/science.1099344			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166350				2022-12-28	WOS:000221669600024
J	Groce, NE; Trasi, R				Groce, NE; Trasi, R			Rape of individuals with disability: AIDS and the folk belief of virgin cleansing	LANCET			English	Editorial Material							SOUTH-AFRICA; ABUSE; WOMEN		Yale Univ, Sch Publ Hlth, Global Hlth Div, New Haven, CT 06520 USA	Yale University	Groce, NE (corresponding author), Yale Univ, Sch Publ Hlth, Global Hlth Div, New Haven, CT 06520 USA.	nora.groce@yale.edu		Groce, Nora/0000-0002-7885-7042				Cambridge P, 1997, DISABIL SOC, V12, P427, DOI 10.1080/09687599727272; DOSSANTOS V, 2004, STATEMENT SEXUAL ABU; Earl-Taylor M, 2002, HIV AIDS STATS VIRGI; Groce NE, 2003, LANCET, V361, P1401, DOI 10.1016/S0140-6736(03)13146-7; Jewkes R, 2002, LANCET, V359, P711, DOI 10.1016/S0140-6736(02)07794-2; Jewkes R, 2002, LANCET, V359, P319, DOI 10.1016/S0140-6736(02)07530-X; *MENT DIS RIGHTS I, 2002, NOT AG HUM RIGHTS PE; Nosek MA, 2001, VIOLENCE AGAINST WOM, V7, P477, DOI 10.1177/10778010122182569; Pitcher GJ, 2002, LANCET, V359, P274, DOI 10.1016/S0140-6736(02)07532-3; Saxton M, 2001, VIOLENCE AGAINST WOM, V7, P393, DOI 10.1177/10778010122182523; SMITH C, 2003, IASSCS C SEX SECR JO; SOBSEY D, 1991, VIOLENCE ABUSE LIVES; *UN INT REG INF NE, 2002, FOC VIRG MYTH HIV AI; Womendez C., 1991, SEX DISABIL, V9, P273, DOI DOI 10.1007/BF01102397; *YAL U WORLD BANK, 2004, HIV AIDS DIS GLOB SU	15	84	84	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	2004	363	9422					1663	1664		10.1016/S0140-6736(04)16288-0	http://dx.doi.org/10.1016/S0140-6736(04)16288-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	822NG	15158626				2022-12-28	WOS:000221546300005
J	Patel, SD; Rajala, MW; Rossetti, L; Scherer, PE; Shapiro, L				Patel, SD; Rajala, MW; Rossetti, L; Scherer, PE; Shapiro, L			Disulfide-dependent multimeric assembly of resistin family hormones	SCIENCE			English	Article							ADIPOSE-TISSUE; INSULIN-RESISTANCE; GLUCOSE-PRODUCTION; PROTEIN ACRP30; ADIPOCYTE; THIAZOLIDINEDIONES; CYSTEINE; MOLECULE; OBESITY; DIFFERENTIATION	Resistin, founding member of the resistin-like molecule (RELM) hormone family, is secreted selectively from adipocytes and induces liver-specific antagonism of insulin action, thus providing a potential molecular link between obesity and diabetes. Crystal structures of resistin and RELMbeta reveal an unusual multimeric structure. Each protomer comprises a carboxy-terminal disulfide-rich beta-sandwich "head" domain and an amino-terminal alpha-helical "tail" segment. The alpha-helical segments associate to form three-stranded coiled coils, and surface-exposed interchain disulfide linkages mediate the formation of tail-to-tail hexamers. Analysis of serum samples shows that resistin circulates in two distinct assembly states, likely corresponding to hexamers and trimers. Infusion of a resistin mutant, lacking the intertrimer disulfide bonds, in pancreatic-insulin clamp studies reveals substantially more potent effects on hepatic insulin sensitivity than those observed with wildtype resistin. This result suggests that processing of the intertrimer disulfide bonds may reflect an obligatory step toward activation.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Endocrinol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY 10032 USA; Columbia Univ, Edward S Harkness Eye Inst, New York, NY 10032 USA	Columbia University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Columbia University; Columbia University	Shapiro, L (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.	lss8@columbia.edu	Scherer, Philipp E/K-7819-2012; Shapiro, Lawrence/AAE-7172-2019	Scherer, Philipp E/0000-0003-0680-3392; Patel, Saurabh/0000-0002-5738-3175				Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Banerjee RR, 2001, J BIOL CHEM, V276, P25970, DOI 10.1074/jbc.M103109200; Beales PE, 2002, DIABETES-METAB RES, V18, P114, DOI 10.1002/dmrr.262; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; FUJITA T, 1983, DIABETES, V32, P804, DOI 10.2337/diabetes.32.9.804; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; Gerstmayer B, 2003, GENOMICS, V81, P588, DOI 10.1016/S0888-7543(03)00070-3; Hauner H, 2002, DIABETES-METAB RES, V18, pS10, DOI 10.1002/dmrr.249; Henry RR, 1997, ENDOCRIN METAB CLIN, V26, P553, DOI 10.1016/S0889-8529(05)70267-X; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Jazet IM, 2003, NETH J MED, V61, P194; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; Rajala MW, 2002, MOL ENDOCRINOL, V16, P1920, DOI 10.1210/me.2002-0048; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; Reilly JJ, 2003, ARCH DIS CHILD, V88, P748, DOI 10.1136/adc.88.9.748; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; *US CENS, BUR CENS 2000 CENS E	32	236	259	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1154	1158		10.1126/science.1093466	http://dx.doi.org/10.1126/science.1093466			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155948				2022-12-28	WOS:000221524500042
J	Lawrence, PA				Lawrence, PA			Last hideout of the unknown?	NATURE			English	Editorial Material							SIZE		MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Lawrence, PA (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	pal@mrc-lmb.cam.ac.uk		Lawrence, Peter/0000-0002-9554-8268				Coen E, 2004, P NATL ACAD SCI USA, V101, P4728, DOI 10.1073/pnas.0306308101; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Day SJ, 2000, DEVELOPMENT, V127, P2977; Hafen E, 2003, PLOS BIOL, V1, P319, DOI 10.1371/journal.pbio.0000086; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; Thompson D. W., 1917, GROWTH FORM	6	13	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 20	2004	429	6989					247	247		10.1038/429247a	http://dx.doi.org/10.1038/429247a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152230				2022-12-28	WOS:000221505900021
J	Sijacic, P; Wang, X; Skirpan, AL; Wang, Y; Dowd, PE; McCubbin, AG; Huang, S; Kao, TH				Sijacic, P; Wang, X; Skirpan, AL; Wang, Y; Dowd, PE; McCubbin, AG; Huang, S; Kao, TH			Identification of the pollen determinant of S-RNase-mediated self-incompatibility	NATURE			English	Article							F-BOX GENE; RECEPTOR-LIKE KINASE; PETUNIA-INFLATA; TRANSCRIPTIONAL ANALYSIS; LOCUS; REJECTION; ANTIRRHINUM; PROTEINS; INTERACTS	Many flowering plants have adopted self-incompatibility mechanisms to prevent inbreeding and promote out-crosses(1). In the Solanaceae, Rosaceae and Scrophulariaceae, two separate genes at the highly polymorphic S-locus control self-incompatibility interactions: the S-RNase gene encodes the pistil determinant and the previously unidentified S-gene encodes the pollen determinant(2-4). S-RNases interact with pollen S-allele products to inhibit the growth of self-pollen tubes in the style. Pollen-expressed F-box genes showing allelic sequence polymorphism have recently been identified near to the S-RNase gene in members of the Rosaceae and Scrophulariaceae(5-8); but until now have not been directly shown to encode the pollen determinant. Here we report the identification and characterization of PiSLF, an S-locus F-box gene of Petunia inflata ( Solanaceae). We show that transformation of S1S1, S1S2 and S2S3 plants with the S-2-allele of PiSLF causes breakdown of their pollen function in self-incompatibility. This breakdown of pollen function is consistent with 'competitive interaction', in which pollen carrying two different pollen S-alleles fails to function in self-incompatibility(1,9,10). We conclude that PiSLF encodes the pollen self-incompatibility determinant.	Penn State Univ, Integrat Biosci Grad Degree Program, Althouse Lab 403, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 403, University Pk, PA 16802 USA; Penn State Univ, Intercoll Grad Program Plant Physiol, Althouse Lab 403, University Pk, PA 16802 USA; Monsanto Co, Mystic Res, Mystic, CT 06355 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Monsanto	Kao, TH (corresponding author), Penn State Univ, Integrat Biosci Grad Degree Program, Althouse Lab 403, University Pk, PA 16802 USA.	txk3@psu.edu	McCubbin, Andrew/B-3178-2013					AI YJ, 1990, SEX PLANT REPROD, V3, P130, DOI 10.1007/BF00198857; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Entani T, 2003, GENES CELLS, V8, P203, DOI 10.1046/j.1365-2443.2003.00626.x; Golz JF, 1999, GENETICS, V152, P1123; Golz JF, 2001, P NATL ACAD SCI USA, V98, P15372, DOI 10.1073/pnas.261571598; HUANG S, 1994, PLANT CELL, V6, P1021, DOI 10.1105/tpc.6.7.1021; KAO TH, 2004, PLANT CELL      0309; Lai Z, 2002, PLANT MOL BIOL, V50, P29, DOI 10.1023/A:1016050018779; LEE HS, 1994, NATURE, V367, P560, DOI 10.1038/367560a0; Luu DT, 2000, NATURE, V407, P649, DOI 10.1038/35036623; Luu DT, 2001, GENETICS, V159, P329; McCubbin AG, 2000, GENOME, V43, P820, DOI 10.1139/gen-43-5-820; MU JH, 1994, PLANT CELL, V6, P709, DOI 10.1105/tpc.6.5.709; MURFETT J, 1994, NATURE, V367, P563, DOI 10.1038/367563a0; Nettancourt, 2001, INCOMPATIBILITY INCO; Qiao H, 2004, PLANT CELL, V16, P582, DOI 10.1105/tpc.017673; Skirpan AL, 2001, PLANT PHYSIOL, V126, P1480, DOI 10.1104/pp.126.4.1480; Ushijima K, 2003, PLANT CELL, V15, P771, DOI 10.1105/tpc.009290; Wang Y, 2003, PLANT MOL BIOL, V53, P565, DOI 10.1023/B:PLAN.0000019068.00034.09; WANG Y, IN PRESS PLANT MOL; Zhou JL, 2003, SEX PLANT REPROD, V16, P165, DOI 10.1007/s00497-003-0185-5	21	302	344	3	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					302	305		10.1038/nature02523	http://dx.doi.org/10.1038/nature02523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152253				2022-12-28	WOS:000221505900044
J	Jenkins, DJA				Jenkins, DJA			Psychological, physiological, and drug interventions for type 2 diabetes	LANCET			English	Editorial Material									St Michaels Hosp, Clin Nutr & Risk Factor Modificat Ctr, Toronto, ON M5C 2T2, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Jenkins, DJA (corresponding author), St Michaels Hosp, Clin Nutr & Risk Factor Modificat Ctr, Toronto, ON M5C 2T2, Canada.	cyril.kendall@utoronto.ca	Jenkins, David JA/A-1992-2009					Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; Miller WR, 1996, ADDICT BEHAV, V21, P835, DOI 10.1016/0306-4603(96)00044-5; Rollnick S, 1995, BEHAV COGN PSYCHOTH, V23, P325, DOI DOI 10.1017/S135246580001643X; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	2004	363	9421					1569	1570		10.1016/S0140-6736(04)16236-3	http://dx.doi.org/10.1016/S0140-6736(04)16236-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145627				2022-12-28	WOS:000221408800004
J	Bliss, T; Schoepfer, R				Bliss, T; Schoepfer, R			Controlling the ups and downs of synaptic strength	SCIENCE			English	Editorial Material							LONG-TERM DEPRESSION; AREA CA1; PLASTICITY; POTENTIATION; HIPPOCAMPUS; INDUCTION; MEMORY; RAT		Natl Inst Med Res, Div Neurophysiol, London NW7 1AA, England; UCL, Dept Pharmacol, London WC1E 6BT, England	MRC National Institute for Medical Research; University of London; University College London	Bliss, T (corresponding author), Natl Inst Med Res, Div Neurophysiol, Mill Hill, London NW7 1AA, England.	tbliss@nimr.mrc.ac.uk						BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Doyere V, 1996, HIPPOCAMPUS, V6, P52, DOI 10.1002/(SICI)1098-1063(1996)6:1<52::AID-HIPO9>3.3.CO;2-Q; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; Hrabetova S, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-12-j0002.2000; HSUI H, 2000, NAT NEUROSCI, V3, P661; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Montgomery JM, 2002, NEURON, V33, P765, DOI 10.1016/S0896-6273(02)00606-2; Paulsen O, 2000, CURR OPIN NEUROBIOL, V10, P172, DOI 10.1016/S0959-4388(00)00076-3; Yang SN, 1999, J NEUROPHYSIOL, V81, P781, DOI 10.1152/jn.1999.81.2.781; Yoshimura Y, 2003, J NEUROSCI, V23, P6557	12	19	20	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	2004	304	5673					973	974		10.1126/science.1098805	http://dx.doi.org/10.1126/science.1098805			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143268				2022-12-28	WOS:000221383300033
J	Lewontin, R				Lewontin, R			In memory of John Maynard Smith (1920-2004)	SCIENCE			English	Biographical-Item									Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA	Harvard University	Lewontin, R (corresponding author), Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA.								0	0	0	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	2004	304	5673					979	979		10.1126/science.1099576	http://dx.doi.org/10.1126/science.1099576			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143272				2022-12-28	WOS:000221383300037
J	Maeda, M; Lu, SJ; Shaulsky, G; Miyazaki, Y; Kuwayama, H; Tanaka, Y; Kuspa, A; Loomis, WF				Maeda, M; Lu, SJ; Shaulsky, G; Miyazaki, Y; Kuwayama, H; Tanaka, Y; Kuspa, A; Loomis, WF			Periodic signaling controlled by an oscillatory circuit that includes protein kinases ERK2 and PKA	SCIENCE			English	Article							DICTYOSTELIUM-DISCOIDEUM; CYCLIC-AMP; CAMP-PHOSPHODIESTERASE; MAP KINASE; CELLS; DIFFERENTIATION; AGGREGATION; ACTIVATION; CYCLASE; RAS	Self-regulating systems often use robust oscillatory circuits. One such system controls the chemotactic signaling mechanism of Dictyostelium, where pulses of adenosine 3', 5'-monophosphate (cAMP) are generated with a periodicity of 7 minutes. We have observed spontaneous oscillations in activation of the mitogen-activated protein (MAP) kinase ERK2 that occur in phase with peaks of cAMP, and we show that ERK2 modulates cAMP levels through the phosphodiesterase RegA. Computer modeling and simulations of the underlying circuit faithfully account for the ability of the cells to spontaneously generate periodic pulses during specific stages of development. Similar oscillatory processes may occur in cells of many different species.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan	University of California System; University of California San Diego; Osaka University; Baylor College of Medicine; Baylor College of Medicine; University of Tsukuba	Loomis, WF (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.	wloomis@ucsd.edu		Shaulsky, Gad/0000-0002-0532-0551; Kuspa, Adam/0000-0002-9156-149X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062350, R01GM052359] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52359, GM62350, R01 GM052359] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; Anjard C, 2001, DEVELOPMENT, V128, P3649; Aubry L, 1999, ANNU REV CELL DEV BI, V15, P469, DOI 10.1146/annurev.cellbio.15.1.469; Aubry L, 1997, J BIOL CHEM, V272, P3883, DOI 10.1074/jbc.272.7.3883; Baillie G, 2001, MOL PHARMACOL, V60, P1100, DOI 10.1124/mol.60.5.1100; Baillie GS, 2000, BRIT J PHARMACOL, V131, P811, DOI 10.1038/sj.bjp.0703636; BEHRENS MM, 1986, BIOCHEM INT, V13, P221; GERISCH G, 1979, J EXP BIOL, V81, P33; GERISCH G, 1975, BIOCHEM BIOPH RES CO, V65, P364, DOI 10.1016/S0006-291X(75)80102-1; Goldbeter A, 2002, NATURE, V420, P238, DOI 10.1038/nature01259; Iranfar N, 2003, EUKARYOT CELL, V2, P664, DOI 10.1128/EC.2.4.664-670.2003; Knetsch MLW, 1996, EMBO J, V15, P3361, DOI 10.1002/j.1460-2075.1996.tb00701.x; Laub MT, 1998, MOL BIOL CELL, V9, P3521, DOI 10.1091/mbc.9.12.3521; Maeda M, 1996, J BIOL CHEM, V271, P3351; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; MARTIEL JL, 1987, BIOPHYS J, V52, P807, DOI 10.1016/S0006-3495(87)83275-7; Mohanty S, 2001, GENE DEV, V15, P1435, DOI 10.1101/gad.871101; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; ROOS W, 1977, NATURE, V266, P259, DOI 10.1038/266259a0; SEGALL JE, 1995, J CELL BIOL, V128, P405, DOI 10.1083/jcb.128.3.405; Shaulsky G, 1998, DEVELOPMENT, V125, P691; TOMCHIK KJ, 1981, SCIENCE, V212, P443, DOI 10.1126/science.6259734; Wang B, 1997, SCIENCE, V277, P251, DOI 10.1126/science.277.5323.251; Wessels DJ, 2000, MOL BIOL CELL, V11, P2803, DOI 10.1091/mbc.11.8.2803	24	125	127	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					875	878		10.1126/science.1094647	http://dx.doi.org/10.1126/science.1094647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131307				2022-12-28	WOS:000221243000045
J	Poon, W				Poon, W			Colloids as big atoms	SCIENCE			English	Editorial Material									Univ Edinburgh, Sch Phys, Edinburgh EH9 3JZ, Midlothian, Scotland	University of Edinburgh	Poon, W (corresponding author), Univ Edinburgh, Sch Phys, Edinburgh EH9 3JZ, Midlothian, Scotland.	w.poon@ed.ac.uk	Poon, Wilson/V-3495-2019	Poon, Wilson/0000-0003-0760-7940				Aarts DGAL, 2004, SCIENCE, V304, P847, DOI 10.1126/science.1097116; Auer S, 2001, NATURE, V409, P1020, DOI 10.1038/35059035; Mora S, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.216101; Pham KN, 2002, SCIENCE, V296, P104, DOI 10.1126/science.1068238; Poon WCK, 2004, MRS BULL, V29, P96, DOI 10.1557/mrs2004.35; Poon WCK, 2002, J PHYS-CONDENS MAT, V14, pR859, DOI 10.1088/0953-8984/14/33/201; Weeks ER, 2000, SCIENCE, V287, P627, DOI 10.1126/science.287.5453.627; Wijting WK, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.196101	8	169	171	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					830	831		10.1126/science.1097964	http://dx.doi.org/10.1126/science.1097964			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131294				2022-12-28	WOS:000221243000028
J	Thompson, RC; Olsen, Y; Mitchell, RP; Davis, A; Rowland, SJ; John, AWG; McGonigle, D; Russell, AE				Thompson, RC; Olsen, Y; Mitchell, RP; Davis, A; Rowland, SJ; John, AWG; McGonigle, D; Russell, AE			Lost at sea: Where is all the plastic?	SCIENCE			English	Article							WATERS		Univ Plymouth, Plymouth PL4 8AA, Devon, England; Sir Alister Hardy Fdn Ocean Sci, Plymouth PL1 2PB, Devon, England; Univ Southampton, Southampton SO17 1BJ, Hants, England	University of Plymouth; University of Southampton	Thompson, RC (corresponding author), Univ Plymouth, Plymouth PL4 8AA, Devon, England.	rcthompson@plymouth.ac.uk	Russell, Andrea/A-9625-2012; Olsen, Ylva S/B-7445-2013; Thompson, Richard C/J-8879-2014; Bond, Alexander L/A-3786-2010; Russell, Andrea E/B-8114-2009	Russell, Andrea/0000-0002-8382-6443; Olsen, Ylva S/0000-0003-4498-7057; Thompson, Richard/0000-0003-2262-6621				CARPENTE.EJ, 1972, SCIENCE, V178, P749, DOI 10.1126/science.178.4062.749; COLTON JB, 1974, SCIENCE, V185, P491, DOI 10.1126/science.185.4150.491; Derraik JGB, 2002, MAR POLLUT BULL, V44, P842, DOI 10.1016/S0025-326X(02)00220-5; GREGORY MR, 1996, MARINE DEBRIS, P48; KLEMCHUK PP, 1990, POLYM DEGRAD STABIL, V27, P183, DOI 10.1016/0141-3910(90)90108-J; RYAN PG, 1993, NATURE, V361, P23, DOI 10.1038/361023a0	6	2764	3036	481	3714	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	2004	304	5672					838	838		10.1126/science.1094559	http://dx.doi.org/10.1126/science.1094559			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131299				2022-12-28	WOS:000221243000033
J	Tocheva, EI; Rosell, FI; Mauk, AG; Murphy, MEP				Tocheva, EI; Rosell, FI; Mauk, AG; Murphy, MEP			Side-on copper-nitrosyl coordination by nitrite reductase	SCIENCE			English	Article							X-RAY-STRUCTURE; ALCALIGENES-FAECALIS S-6; ACHROMOBACTER-CYCLOCLASTES; TYPE-2 COPPER; ACTIVE-SITE; SUBSTRATE-BINDING; DISSIMILATORY NITRITE; OXIDE; COMPLEX; DIOXYGEN	A copper-nitrosyl intermediate forms during the catalytic cycle of nitrite reductase, the enzyme that mediates the committed step in bacterial denitrification. The crystal structure of a type 2 copper-nitrosyl complex of nitrite reductase reveals an unprecedented side-on binding mode in which the nitrogen and oxygen atoms are nearly equidistant from the copper cofactor. Comparison of this structure with a refined nitrite-bound crystal structure explains how coordination can change between copper-oxygen and copper-nitrogen during catalysis. The side-on copper-nitrosyl in nitrite reductase expands the possibilities for nitric oxide interactions in copper proteins such as superoxide dismutase and prions.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Murphy, MEP (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada.	memurphy@interchange.ubc.ca	Murphy, Michael/R-6805-2017	Murphy, Michael/0000-0003-2589-0014				Aboelella NW, 2002, J AM CHEM SOC, V124, P10660, DOI 10.1021/ja027164v; ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Bange HW, 2000, NATURE, V408, P301, DOI 10.1038/35042656; Boulanger MJ, 2003, PROTEIN SCI, V12, P248, DOI 10.1110/ps.0224503; Boulanger MJ, 2001, BIOCHEMISTRY-US, V40, P9132, DOI 10.1021/bi0107400; Boulanger MJ, 2000, J BIOL CHEM, V275, P23957, DOI 10.1074/jbc.M001859200; Carducci MD, 1997, J AM CHEM SOC, V119, P2669, DOI 10.1021/ja9625743; Chen P, 2003, J AM CHEM SOC, V125, P466, DOI 10.1021/ja020969i; DAWSON JH, 1978, P NATL ACAD SCI USA, V75, P4078, DOI 10.1073/pnas.75.9.4078; Dodd FE, 1998, J MOL BIOL, V282, P369, DOI 10.1006/jmbi.1998.2007; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FUJISAWA K, 1994, J AM CHEM SOC, V116, P12079, DOI 10.1021/ja00105a069; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HALFEN JA, 1994, J AM CHEM SOC, V116, P5475, DOI 10.1021/ja00091a064; Hauck R. D., 1981, Ecological Bulletins, P551; HOWES BD, 1994, BIOCHEMISTRY-US, V33, P3171, DOI 10.1021/bi00177a005; HULSE CL, 1989, J AM CHEM SOC, V111, P2322, DOI 10.1021/ja00188a067; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA, P3; JACKSON MA, 1991, FEBS LETT, V291, P41, DOI 10.1016/0014-5793(91)81099-T; Karlsson A, 2003, SCIENCE, V299, P1039, DOI 10.1126/science.1078020; Kataoka K, 2000, J BIOCHEM-TOKYO, V127, P345, DOI 10.1093/oxfordjournals.jbchem.a022613; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; Mani K, 2003, J BIOL CHEM, V278, P38956, DOI 10.1074/jbc.M300394200; MARTIN CT, 1981, BIOCHEMISTRY-US, V20, P5147, DOI 10.1021/bi00521a008; MURPHY MEP, 1995, BIOCHEMISTRY-US, V34, P12107, DOI 10.1021/bi00038a003; Murphy MEP, 1997, J BIOL CHEM, V272, P28455, DOI 10.1074/jbc.272.45.28455; PAUL PP, 1990, J AM CHEM SOC, V112, P2430, DOI 10.1021/ja00162a060; Robertson GP, 2000, SCIENCE, V289, P1922, DOI 10.1126/science.289.5486.1922; RUGGIERO CE, 1993, J AM CHEM SOC, V115, P11285, DOI 10.1021/ja00077a030; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; Strange RW, 1999, J MOL BIOL, V287, P1001, DOI 10.1006/jmbi.1999.2648; STRANGE RW, 1995, NAT STRUCT BIOL, V2, P287, DOI 10.1038/nsb0495-287; VANLEEUWEN FX, 1973, BIOCHIM BIOPHYS ACTA, V315, P200, DOI 10.1016/0005-2744(73)90144-7; Wasser IM, 2002, CHEM REV, V102, P1201, DOI 10.1021/cr0006627; Weichsel A, 2000, NAT STRUCT BIOL, V7, P551, DOI 10.1038/76769; Wijma HJ, 2003, BIOCHEMISTRY-US, V42, P4075, DOI 10.1021/bi027270+; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Wilmot CM, 1999, SCIENCE, V286, P1724, DOI 10.1126/science.286.5445.1724; Zhang HM, 2000, J PHYS CHEM B, V104, P10738, DOI 10.1021/jp000745r; Zhao YW, 2002, BIOCHEMISTRY-US, V41, P7464, DOI 10.1021/bi0256274	41	189	193	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					867	870		10.1126/science.1095109	http://dx.doi.org/10.1126/science.1095109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131305				2022-12-28	WOS:000221243000043
J	Reese, DB				Reese, DB			Cor triatriatum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Winchester Med Ctr, Winchester, VA 22601 USA		Reese, DB (corresponding author), Winchester Med Ctr, Winchester, VA 22601 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1989	1989		10.1056/NEJMicm990415	http://dx.doi.org/10.1056/NEJMicm990415			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128899				2022-12-28	WOS:000221218800011
J	Wachter, RM				Wachter, RM			Hospitalists in the United States - Mission accomplished or work in progress?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wachter, RM (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.							Hoff TH, 2001, ARCH INTERN MED, V161, P851, DOI 10.1001/archinte.161.6.851; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487	2	52	52	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1935	1936		10.1056/NEJMp038201	http://dx.doi.org/10.1056/NEJMp038201			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128892				2022-12-28	WOS:000221218800004
J	Dyer, O				Dyer, O			Journal rejects article after objections from marketing department	BRITISH MEDICAL JOURNAL			English	News Item																			0	13	14	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 31	2004	328	7434					244	244		10.1136/bmj.328.7434.244-b	http://dx.doi.org/10.1136/bmj.328.7434.244-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771LC	15133870				2022-12-28	WOS:000188786000009
J	Evans, WE; Relling, MV				Evans, WE; Relling, MV			Moving towards individualized medicine with pharmacogenomics	NATURE			English	Review							GENE-EXPRESSION; DRUG; MERCAPTOPURINE; DEBRISOQUINE; DEFICIENT	Individuals respond differently to drugs and sometimes the effects are unpredictable. Differences in DNA sequences that alter the expression or function of proteins that are targeted by drugs can contribute significantly to variation in the responses of individuals. Many of the genes examined in early studies were linked to highly penetrant, single-gene traits, but future advances hinge on the more difficult challenge of elucidating multi-gene determinants of drug response. This intersection of genomics and medicine has the potential to yield a new set of molecular diagnostic tools that can be used to individualize and optimize drug therapy.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Tennessee, Coll Pharm, Chicago, IL USA; Univ Tennessee, Coll Med, Chicago, IL USA; Pharmacogenet Anticanc Agents Res Grp, Chicago, IL USA; Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA; Pharmacogenet Anticanc Agents Res Grp, Memphis, TN USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Evans, WE (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	william.evans@stjude.org; mary.relling@stjude.org	Relling, Mary/N-5032-2018; Evans, William E./C-2069-2012	Evans, William E./0000-0002-9333-5322				Abbott A, 2003, NATURE, V425, P760, DOI 10.1038/425760a; Altman RB, 2003, PHARMACOGENETICS, V13, P3, DOI 10.1097/00008571-200301000-00002; Buetow KH, 2001, P NATL ACAD SCI USA, V98, P581, DOI 10.1073/pnas.021506298; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; Cheok MH, 2003, NAT GENET, V34, P85, DOI 10.1038/ng1151; Eccles DM, 2003, LANCET, V361, P178, DOI 10.1016/S0140-6736(03)12213-1; EICHELBAUM M, 1975, N-S ARCH PHARMACOL, V287, pR94; Evans WE, 2004, NAT GENET, V36, P214, DOI 10.1038/ng0304-214; Evans WE, 2001, J CLIN ONCOL, V19, P2293, DOI 10.1200/JCO.2001.19.8.2293; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; EVANS WE, 1991, J PEDIATR-US, V119, P985, DOI 10.1016/S0022-3476(05)83063-X; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Evans WE, 2001, ANNU REV GENOM HUM G, V2, P9, DOI 10.1146/annurev.genom.2.1.9; Goldstein DB, 2003, NAT REV GENET, V4, P937, DOI 10.1038/nrg1229; Golub TR, 2003, NAT MED, V9, P510, DOI 10.1038/nm0503-510; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; Guengerich FP, 1998, DRUG METAB DISPOS, V26, P1175; Holden C, 2003, SCIENCE, V302, P594, DOI 10.1126/science.302.5645.594; INELMANSUNDBERG M, 1999, TRENDS PHARMACOL SCI, V20, P342; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Liotta LA, 2001, JAMA-J AM MED ASSOC, V286, P2211, DOI 10.1001/jama.286.18.2211; MAHGOUB A, 1977, LANCET, V2, P584, DOI 10.1016/S0140-6736(77)91430-1; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Marshall E, 2003, SCIENCE, V302, P588, DOI 10.1126/science.302.5645.588; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Phillips KA, 2001, JAMA-J AM MED ASSOC, V286, P2270, DOI 10.1001/jama.286.18.2270; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; VESELL ES, 1989, PHARMACOL THERAPEUT, V41, P535, DOI 10.1016/0163-7258(89)90130-7; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021	30	513	568	0	141	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					464	468		10.1038/nature02626	http://dx.doi.org/10.1038/nature02626			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164072				2022-12-28	WOS:000221644600049
J	Finke, DL; Denno, RF				Finke, DL; Denno, RF			Predator diversity dampens trophic cascades	NATURE			English	Article							INTRAGUILD PREDATION; SPECIES RICHNESS; FOOD WEBS; ECOSYSTEM PROCESSES; BIODIVERSITY; PRODUCTIVITY; SUPPRESSION; VEGETATION; ECOLOGY	Food web complexity is thought to weaken the strength of terrestrial trophic cascades(1-3) in which strong impacts of natural enemies on herbivores cascade to influence primary production indirectly(4). Predator diversity can enhance food web complexity because predators may feed on each other and on shared prey(5-7). In such cases, theory suggests that the impact of predation on herbivores relaxes and cascading effects on basal resources are dampened(8,9). Despite this view, no empirical studies have explicitly investigated the role of predator diversity in mediating primary productivity in a natural terrestrial system(10,11). Here we compare, in a coastal marsh community, impacts of arthropod predators on herbivores and plant productivity between a simple food web with a single predator species and a complex food web with a diverse predator assemblage. We show that enhancing predator diversity dampens enemy effects on herbivores and weakens trophic cascades. Consequently, changes in diversity at higher trophic levels can significantly alter ecosystem function in natural systems.	Univ Maryland, Dept Entomol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Finke, DL (corresponding author), Univ Maryland, Dept Entomol, College Pk, MD 20742 USA.	dfinke@umd.edu						Cardinale BJ, 2003, ECOL LETT, V6, P857, DOI 10.1046/j.1461-0248.2003.00508.x; Cardinale BJ, 2002, NATURE, V415, P426, DOI 10.1038/415426a; CARPENTER SR, 1985, BIOSCIENCE, V35, P634, DOI 10.2307/1309989; Crooks KR, 1999, NATURE, V400, P563, DOI 10.1038/23028; DENNO RF, IN PRESS ECOL ENTOMO; Downing AL, 2002, NATURE, V416, P837, DOI 10.1038/416837a; Duffy JE, 2003, ECOL LETT, V6, P680, DOI 10.1046/j.1461-0248.2003.00494.x; Finke DL, 2002, ECOLOGY, V83, P643, DOI 10.1890/0012-9658(2002)083[0643:IPDICS]2.0.CO;2; Fraser LH, 1998, OECOLOGIA, V113, P239, DOI 10.1007/s004420050374; Gutierrez JR, 1997, OECOLOGIA, V109, P398, DOI 10.1007/s004420050099; Halaj J, 2001, AM NAT, V157, P262, DOI 10.1086/319190; Hart DR, 2002, J THEOR BIOL, V218, P111, DOI 10.1006/jtbi.2002.3053; Hooper DU, 1997, SCIENCE, V277, P1302, DOI 10.1126/science.277.5330.1302; Jolliffe PA, 2000, J ECOL, V88, P371, DOI 10.1046/j.1365-2745.2000.00470.x; LANGELLOTTO G. A., 2002, THESIS U MARYLAND; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; McCann K, 1998, NATURE, V395, P794, DOI 10.1038/27427; McGradySteed J, 1997, NATURE, V390, P162, DOI 10.1038/36561; MORIN PJ, 1995, ANNU REV ECOL SYST, V26, P505, DOI 10.1146/annurev.es.26.110195.002445; Mulder CPH, 1999, ECOL LETT, V2, P237; Naeem S, 1997, NATURE, V390, P507, DOI 10.1038/37348; Norberg J, 2000, OECOLOGIA, V122, P264, DOI 10.1007/PL00008855; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; Petchey OL, 1999, NATURE, V402, P69, DOI 10.1038/47023; POLIS GA, 1989, ANNU REV ECOL SYST, V20, P297, DOI 10.1146/annurev.es.20.110189.001501; ROSENHEIM JA, 1995, BIOL CONTROL, V5, P303, DOI 10.1006/bcon.1995.1038; Schmitz OJ, 2003, ECOL LETT, V6, P156, DOI 10.1046/j.1461-0248.2003.00412.x; Shurin JB, 2002, ECOL LETT, V5, P785, DOI 10.1046/j.1461-0248.2002.00381.x; STRONG DR, 1992, ECOLOGY, V73, P747, DOI 10.2307/1940154; Tilman D, 2001, SCIENCE, V294, P843, DOI 10.1126/science.1060391	30	408	426	4	295	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	2004	429	6990					407	410		10.1038/nature02554	http://dx.doi.org/10.1038/nature02554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164061				2022-12-28	WOS:000221644600037
J	McElvaney, NG				McElvaney, NG			Smoking ban - Made in Ireland, for home use and for export	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Beaumont Hosp, Royal Coll Surg Ireland, Dept Med, Dublin 9, Ireland	Royal College of Surgeons - Ireland	McElvaney, NG (corresponding author), Beaumont Hosp, Royal Coll Surg Ireland, Dept Med, Dublin 9, Ireland.		McElvaney, Noel/A-6809-2010	mcelvaney, Noel/0000-0002-0152-4370					0	15	16	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2231	2233		10.1056/NEJMp048097	http://dx.doi.org/10.1056/NEJMp048097			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163770	Green Accepted, Green Published			2022-12-28	WOS:000221641900001
J	Kadish, A; Dyer, A; Daubert, JP; Quigg, R; Estes, NAM; Anderson, KP; Calkins, H; Hoch, D; Goldberger, J; Shalaby, A; Sanders, WE; Schaechter, A; Levine, JH				Kadish, A; Dyer, A; Daubert, JP; Quigg, R; Estes, NAM; Anderson, KP; Calkins, H; Hoch, D; Goldberger, J; Shalaby, A; Sanders, WE; Schaechter, A; Levine, JH		DEFINITE Investigators	Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSUSTAINED VENTRICULAR-TACHYCARDIA; SEQUENTIAL CLINICAL-TRIALS; CONGESTIVE-HEART-FAILURE; CARDIOVERTER-DEFIBRILLATOR; SUDDEN-DEATH; MORTALITY; SURVIVAL; CARVEDILOL; PREVENTION; METOPROLOL	BACKGROUND: Patients with nonischemic dilated cardiomyopathy are at substantial risk for sudden death from cardiac causes. However, the value of prophylactic implantation of an implantable cardioverter-defibrillator (ICD) to prevent sudden death in such patients is unknown. METHODS: We enrolled 458 patients with nonischemic dilated cardiomyopathy, a left ventricular ejection fraction of less than 36 percent, and premature ventricular complexes or nonsustained ventricular tachycardia. A total of 229 patients were randomly assigned to receive standard medical therapy, and 229 to receive standard medical therapy plus a single-chamber ICD. RESULTS: Patients were followed for a mean (+/-SD) of 29.0+/-14.4 months. The mean left ventricular ejection fraction was 21 percent. The vast majority of patients were treated with angiotensin-converting-enzyme (ACE) inhibitors (86 percent) and beta-blockers (85 percent). There were 68 deaths: 28 in the ICD group, as compared with 40 in the standard-therapy group (hazard ratio, 0.65; 95 percent confidence interval, 0.40 to 1.06; P=0.08). The mortality rate at two years was 14.1 percent in the standard-therapy group (annual mortality rate, 7 percent) and 7.9 percent in the ICD group. There were 17 sudden deaths from arrhythmia: 3 in the ICD group, as compared with 14 in the standard-therapy group (hazard ratio, 0.20; 95 percent confidence interval, 0.06 to 0.71; P=0.006). CONCLUSIONS: In patients with severe, nonischemic dilated cardiomyopathy who were treated with ACE inhibitors and beta-blockers, the implantation of a cardioverter-defibrillator significantly reduced the risk of sudden death from arrhythmia and was associated with a nonsignificant reduction in the risk of death from any cause.	Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA; Univ N Carolina, Chapel Hill, NC USA; St Francis Hosp, Roslyn, NY USA; Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Univ Rochester, Med Ctr, Rochester, NY 14642 USA; Northwestern Univ, Sch Med, Dept Med, Div Cardiol,Clin Cardiol Trials Off, Chicago, IL 60611 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; University of North Carolina; University of North Carolina Chapel Hill; Marshfield Clinic; Tufts Medical Center; University of Rochester; Northwestern University	Kadish, A (corresponding author), 251 E Huron,Feinberg 8-536, Chicago, IL 60611 USA.	a-kadish@northwestern.edu	Daubert, James P./ABC-1476-2021; Goldberger, Jeffrey J/AAB-3684-2020					Bansch D, 2002, CIRCULATION, V105, P1453, DOI 10.1161/01.CIR.0000012350.99718.AD; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Carson PA, 2000, J AM COLL CARDIOL, V36, P541, DOI 10.1016/S0735-1097(00)00728-2; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; Connolly SJ, 1997, LANCET, V350, P1417; Doval HC, 1996, CIRCULATION, V94, P3198, DOI 10.1161/01.CIR.94.12.3198; Epstein AE, 1996, J AM COLL CARDIOL, V27, P433, DOI 10.1016/0735-1097(95)00482-3; Grimm W, 2002, J AM COLL CARDIOL, V39, P780, DOI 10.1016/S0735-1097(01)01822-8; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; Hjalmarson A, 1999, LANCET, V353, P2001; Kadish A, 2000, PACE, V23, P338, DOI 10.1111/j.1540-8159.2000.tb06759.x; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P321; KIM K, 1990, BIOMETRICS, V46, P81, DOI 10.2307/2531632; KIM K, 1987, BIOMETRIKA, V74, P149, DOI 10.2307/2336029; KIM KM, 1992, STAT MED, V11, P1391, DOI 10.1002/sim.4780111012; Lechat P, 1999, LANCET, V353, P9; Levine JH, 1996, AM HEART J, V131, P59, DOI 10.1016/S0002-8703(96)90051-4; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Poole-Wilson PA, 2003, LANCET, V362, P7, DOI 10.1016/S0140-6736(03)13800-7; Rankovic V, 2002, AM J CARDIOL, V89, P1072, DOI 10.1016/S0002-9149(02)02278-6; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; Strickberger SA, 2003, J AM COLL CARDIOL, V41, P1707, DOI 10.1016/S0735-1097(03)00297-3; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WHITEHEAD J, 1983, BIOMETRICS, V39, P227, DOI 10.2307/2530822	29	1384	1425	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2151	2158		10.1056/NEJMoa033088	http://dx.doi.org/10.1056/NEJMoa033088			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152060	Bronze, Green Published			2022-12-28	WOS:000221496700007
J	Epstein, RM; Alper, BS; Quill, TE				Epstein, RM; Alper, BS; Quill, TE			Communicating evidence for participatory decision making	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOCTOR-PATIENT COMMUNICATION; ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; CANCER-PATIENTS; BREAST-CANCER; HEALTH-CARE; UNCERTAINTY; RISK; RECALL; SATISFACTION	Context Informed patients are more likely to actively participate in their care, make wiser decisions, come to a common understanding with their physicians, and adhere more fully to treatment; however, currently there are no evidence-based guidelines for discussing clinical evidence with patients in the process of making medical decisions. Objective To identify ways to communicate evidence that improve patient understanding, involvement in decisions, and outcomes. Data Sources and Study Selection Systematic review of MEDLINE for the period 1966-2003 and review of reference lists of retrieved articles to identify original research dealing with communication between clinicians and patients and directly addressing methods of presenting clinical evidence to patients. Data Extraction Two investigators and a research assistant screened 367 abstracts and 2 investigators reviewed 51 full-text articles, yielding 8 potentially relevant articles. Data Synthesis Methods for communicating clinical evidence to patients include nonquantitative general terms, numerical translation of clinical evidence, graphical representations, and decision aids. Focus-group data suggest presenting options and/or equipoise before asking patients about preferred decision-making roles or formats for presenting details. Relative risk reductions may be misleading; absolute risk is preferred. Order of information presented and time-frame of outcomes can bias patient understanding. Limited evidence supports use of human stick figure graphics or faces for single probabilities and vertical bar graphs for comparative information. Less-educated and older patients preferred proportions to percentages and did not appreciate confidence intervals. Studies of decision aids rarely addressed patient-physician communication directly. No studies addressed clinical outcomes of discussions of clinical evidence. Conclusions There is a paucity of evidence to guide how physicians can most effectively share clinical evidence with patients facing decisions; however, basing our recommendations largely on related studies and expert opinion, we describe means of accomplishing 5 communication tasks to address in framing and communicating clinical evidence: understanding the patient's (and family members') experience and expectations; building partnership; providing evidence, including a balanced discussion of uncertainties; presenting recommendations informed by clinical judgment and patient preferences; and checking for understanding and agreement.	Univ Rochester, Med Ctr, Dept Family Med, Ctr Improve Commun Hlth Care, Rochester, NY 14620 USA; Univ Rochester, Med Ctr, Dept Internal Med, Rochester, NY 14620 USA; Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA; Univ Missouri, Sch Med, Dept Family & Community Med, Columbia, MO USA; Dynam Med Informat Syst LLC, Columbia, MO USA	University of Rochester; University of Rochester; University of Rochester; University of Missouri System; University of Missouri Columbia	Epstein, RM (corresponding author), Univ Rochester, Med Ctr, Dept Family Med, Ctr Improve Commun Hlth Care, 1381 South Ave, Rochester, NY 14620 USA.	ronald-epstein@urmc.rochester.edu						Balsa AI, 2003, J HEALTH ECON, V22, P89, DOI 10.1016/S0167-6296(02)00098-X; Balsa AI, 2001, J HEALTH ECON, V20, P881, DOI 10.1016/S0167-6296(01)00101-1; BARANDIARAN FA, 1993, GAC SANIT, V7, P27; Bergh KD, 1998, J FAM PRACTICE, V46, P153; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; BOYD NF, 1990, MED DECIS MAKING, V10, P58, DOI 10.1177/0272989X9001000109; Braddock CH, 1997, J GEN INTERN MED, V12, P339, DOI 10.1046/j.1525-1497.1997.00057.x; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; BUDESCU DV, 1990, ORGAN BEHAV HUM DEC, V46, P240, DOI 10.1016/0749-5978(90)90031-4; Chao C, 2003, J CLIN ONCOL, V21, P4299, DOI 10.1200/JCO.2003.06.025; DREYFUS HL, 2001, INTERNET THINKING AC; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; Edwards A, 1999, BRIT MED J, V318, P603; Elit LM, 1996, GYNECOL ONCOL, V62, P329, DOI 10.1006/gyno.1996.0244; Elwyn G, 2000, BRIT J GEN PRACT, V50, P892; Elwyn G, 1999, BRIT MED J, V319, P753, DOI 10.1136/bmj.319.7212.753; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; EPSTEIN RM, 2001, FUNDAMENTALS CLIN PR; FEINSTEIN AR, 1977, CLIN PHARMACOL THER, V21, P482; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; Fisher R., 1991, GETTING YES NEGOTIAT; Ford S, 2003, SOC SCI MED, V56, P589, DOI 10.1016/S0277-9536(02)00056-4; Fox Renee Claire, 1959, EXPT PERILOUS PHYS P; Geddes JR, 2003, LANCET, V361, P653, DOI 10.1016/S0140-6736(03)12599-8; GERRITY MS, 1990, MED CARE, V28, P724, DOI 10.1097/00005650-199008000-00005; Goel V, 2001, MED DECIS MAKING, V21, P1, DOI 10.1177/0272989X0102100101; Hewson MG, 1996, J GEN INTERN MED, V11, P481, DOI 10.1007/BF02599044; James P, 1999, J FAM PRACTICE, V48, P669; Kennedy ADM, 2002, JAMA-J AM MED ASSOC, V288, P2701, DOI 10.1001/jama.288.21.2701; KORSCH BM, 1984, PEDIATRICS, V74, P917; Lang F, 2002, FAM MED, V34, P325; Lang F, 2000, ARCH FAM MED, V9, P222, DOI 10.1001/archfami.9.3.222; LEVINE MN, 1992, ANN INTERN MED, V117, P53, DOI 10.7326/0003-4819-117-1-53; Lloyd AJ, 1999, LANCET, V353, P645, DOI 10.1016/S0140-6736(98)05670-0; Lobb EA, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.5.e56; MALENKA DJ, 1993, J GEN INTERN MED, V8, P543, DOI 10.1007/BF02599636; Man-Son-Hing M, 1999, JAMA-J AM MED ASSOC, V282, P737, DOI 10.1001/jama.282.8.737; MAZUR DJ, 1993, J AM GERIATR SOC, V41, P223, DOI 10.1111/j.1532-5415.1993.tb06696.x; McWhinney I R, 1993, Scand J Prim Health Care, V11, P3, DOI 10.3109/02813439308994894; Molenaar S, 2000, MED DECIS MAKING, V20, P112, DOI 10.1177/0272989X0002000114; NEWELL S, 1995, AUST J PUBLIC HEALTH, V19, P368; OConnor AM, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431, DOI 10.1002/14651858.CD001431]; ONG LML, 1995, SOC SCI MED, V40, P903, DOI 10.1016/0277-9536(94)00155-M; Ong LML, 2000, J CLIN ONCOL, V18, P3052, DOI 10.1200/JCO.2000.18.16.3052; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1993, HUM MED, V9, P109; RANSOHOFF DF, 1976, YALE J BIOL MED, V49, P165; Rost K, 1990, Fam Med, V22, P453; ROTER DL, 1987, MED CARE, V25, P437, DOI 10.1097/00005650-198705000-00007; Sackett D. L., 1997, EVIDENCE BASED MED P; Schapira MM, 2001, MED DECIS MAKING, V21, P459, DOI 10.1177/02729890122062811; Skolbekken JA, 1998, BMJ-BRIT MED J, V316, P1956, DOI 10.1136/bmj.316.7149.1956; Stewart M, 1999, Cancer Prev Control, V3, P25; Stewart M, 1995, MED INTERVIEW, P525; Stewart M, 1995, PATIENT CTR MED TRAN; Suchman A.L., 1998, PARTNERSHIPS HEALTHC; Sullivan M, 2003, SOC SCI MED, V56, P1595, DOI 10.1016/S0277-9536(02)00159-4; SUTHERLAND HJ, 1991, SOC SCI MED, V32, P725, DOI 10.1016/0277-9536(91)90152-3; Sweeney KG, 1998, LANCET, V351, P134, DOI 10.1016/S0140-6736(97)06316-2; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; Volk RJ, 1997, ARCH FAM MED, V6, P72, DOI 10.1001/archfami.6.1.72; WAGNER EH, 1995, MED CARE, V33, P765, DOI 10.1097/00005650-199508000-00002; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; Whelan T, 2003, J NATL CANCER I, V95, P581, DOI 10.1093/jnci/95.8.581; Whitney SN, 2004, ANN INTERN MED, V140, P54, DOI 10.7326/0003-4819-140-1-200401060-00012; Whitney SN, 2003, MED DECIS MAKING, V23, P275, DOI 10.1177/0272989X03256006; WILLAIMS GC, 1997, PARTNERSHIPS POWER P	69	389	399	0	54	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2004	291	19					2359	2366		10.1001/jama.291.19.2359	http://dx.doi.org/10.1001/jama.291.19.2359			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821JD	15150208	Bronze			2022-12-28	WOS:000221455400024
J	Nebeker, JR; Barach, P; Samore, MH				Nebeker, JR; Barach, P; Samore, MH			Clarifying adverse drug events: A clinician's guide to terminology, documentation, and reporting	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICATION ERRORS; DEPARTMENTS; MEDICINE; SAFETY; CARE	Adverse drug events cause substantial morbidity and mortality, yet they remain underappreciated and misunderstood. The terminology to describe errors and patient harm associated with medications causes much confusion. This article uses the case study of a patient with multiple adverse drug events to clarify key terms, such as adverse event, adverse drug reaction, adverse drug event, medication error, and side effect. The case discussion illustrates clinical approaches to analyzing the causal connection between a suspect drug and an adverse event. Examples and rationale for meaningful documentation of adverse drug events are provided, along with an outline of the types of events that should be reported to regulatory agencies.	Salt Lake IDEAS Ctr, Salt Lake City, UT 84148 USA		Nebeker, JR (corresponding author), Salt Lake IDEAS Ctr, GRECC 182,500 Foothill Dr, Salt Lake City, UT 84148 USA.	Jonathan.Nebeker@hsc.utah.edu	Barach, Paul/AAX-5315-2020; Barach, paul/B-9915-2016	Barach, Paul/0000-0002-7906-698X; Barach, paul/0000-0002-7906-698X				Ahmad SR, 2003, J GEN INTERN MED, V18, P57, DOI 10.1046/j.1525-1497.2003.20130.x; Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; [Anonymous], 2003, INT C HARM TECHN REQ; Bates DW, 1996, DRUG SAFETY, V15, P303, DOI 10.2165/00002018-199615050-00001; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; COBERT BL, 2002, PHARMACOVIGILANCE A; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; ENBEKER JR, 2002, J AM MED INFORM AS S, V9, pS80; *EUR AG EV MED PRO, 1995, CLIN SAF DAT MAN DEF; Evans R S, 1992, Proc Annu Symp Comput Appl Med Care, P437; Fattinger K, 2000, BRIT J CLIN PHARMACO, V49, P158, DOI 10.1046/j.1365-2125.2000.00132.x; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gurwitz JH, 2000, AM J MED, V109, P87, DOI 10.1016/S0002-9343(00)00451-4; Hanlon JT, 1997, J AM GERIATR SOC, V45, P945, DOI 10.1111/j.1532-5415.1997.tb02964.x; Hofer T P, 2000, Eff Clin Pract, V3, P261; HURDLE JF, 2003, P AMIA S, P309; JOHNSTONE DM, 1995, AM J HEALTH-SYST PH, V52, P297, DOI 10.1093/ajhp/52.3.297; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; Ladewski LA, 2003, J CLIN ONCOL, V21, P3859, DOI 10.1200/JCO.2003.04.537; LUCAS LM, 1992, WESTERN J MED, V156, P172; Meyboom RHB, 1997, DRUG SAFETY, V17, P374, DOI 10.2165/00002018-199717060-00004; MICHEL DJ, 1986, AM J HOSP PHARM, V43, P1709, DOI 10.1093/ajhp/43.7.1709; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; National Coordinating Council for Medication Error Reporting and Prevention, 1998, WHAT IS MED ERR; Ross SD, 2001, ARCH INTERN MED, V161, P1041, DOI 10.1001/archinte.161.8.1041; SCHAFF T, 1991, NEAR MISS REPORTING; Schlienger RG, 1999, PHARM WORLD SCI, V21, P110, DOI 10.1023/A:1008631926100; Shojania KG, 2002, JAMA-J AM MED ASSOC, V288, P508, DOI 10.1001/jama.288.4.508; Sivaram CA, 1996, JOINT COMM J QUAL IM, V22, P259, DOI 10.1016/S1070-3241(16)30229-2; Tegeder I, 1999, BRIT J CLIN PHARMACO, V47, P557; THATCHER C, 2002, CAN PHARM J, V134, P11; *US FDA, 1992, GUID POSTM REP ADV D; Venulet J, 1996, INT J CLIN PHARM TH, V34, P112; Wood AJJ, 1998, NEW ENGL J MED, V339, P1851, DOI 10.1056/NEJM199812173392512	37	455	471	1	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					795	801		10.7326/0003-4819-140-10-200405180-00009	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148066				2022-12-28	WOS:000221520900004
J	DeWitt, AL; Gunn, SR; Hopkins, P; Streat, S				DeWitt, AL; Gunn, SR; Hopkins, P; Streat, S			Critical care medicine mailing list: growth of an online forum	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATIENT		Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15261 USA; Bartimus Frickleton Robertson & Obetz, Jefferson City, MO 65101 USA; Univ London Imperial Coll Sci Technol & Med, Fac Med, London W12 0NN, England; Auckland City Hosp, Dept Crit Care Med, Auckland 1003, New Zealand	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Imperial College London; Auckland City Hospital	Gunn, SR (corresponding author), Univ Pittsburgh, Med Ctr, Dept Crit Care Med, 646B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	gunnsr@ccm.upmc.edu						Caldicott Committee Department of Health, 1997, REP REV PAT ID INF; Campbell D, 2000, CAN J ANAESTH, V47, P53, DOI 10.1007/BF03020733; Cassell J, 2003, CRIT CARE MED, V31, P1551, DOI 10.1097/00003246-200305000-00039; Crippen D, 1999, CRIT CARE CLIN, V15, P605, DOI 10.1016/S0749-0704(05)70074-9; Crippen Kileullen JK, 2002, 3 PATIENTS INT PERSP; HOPKINS P, 2002, CLIN INTENSIVE CARE, V13, P147; Nagappan R, 2000, CRIT CARE MED, V28, P2116, DOI 10.1097/00003246-200006000-00076; Porayko LD, 1999, CAN J ANAESTH, V46, P529, DOI 10.1007/BF03013542; PORAYKO LD, 1998, EUR J ANAESTH S, V15, P48; 2003, DOCTOR HONG KONG DEA	10	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2004	328	7449					1180	1180		10.1136/bmj.328.7449.1180	http://dx.doi.org/10.1136/bmj.328.7449.1180			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142927	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000221497500028
J	Schlieker, C; Mogk, A; Bukau, B				Schlieker, C; Mogk, A; Bukau, B			A PDZ switch for a cellular stress response	CELL			English	Editorial Material							PROTEASE; CLEAVAGE; DEGS; RSEA	The accumulation of misfolded porins in the periplasm of bacteria triggers a proteolytic cascade, initiated by activation of DegS, a member of the family of HtrA proteases. Activation of DegS ultimately leads to the expression of genes encoding the periplasmic protein folding machinery. A new study now reveals that binding of exposed C-termini of unassembled porins to the PDZ domain of DegS induces structural rearrangements that activate the catalytic site of the protease domain.	Univ Heidelberg, Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Schlieker, C (corresponding author), Univ Heidelberg, Zentrum Mol Biol Heidelberg, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.			Bukau, Bernd/0000-0003-0521-7199				Alba BM, 2002, GENE DEV, V16, P2156, DOI 10.1101/gad.1008902; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Harris BZ, 2001, J CELL SCI, V114, P3219; Kanehara K, 2002, GENE DEV, V16, P2147, DOI 10.1101/gad.1002302; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Wilken C, 2004, CELL, V117, P483, DOI 10.1016/S0092-8674(04)00454-4	9	30	31	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	2004	117	4					417	419		10.1016/S0092-8674(04)00453-2	http://dx.doi.org/10.1016/S0092-8674(04)00453-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137934	Bronze			2022-12-28	WOS:000221458000001
J	Ives, AR; Cardinale, BJ				Ives, AR; Cardinale, BJ			Food-web interactions govern the resistance of communities after non-random extinctions	NATURE			English	Article							DENSITY COMPENSATION; BIODIVERSITY; PRODUCTIVITY; DIVERSITY; POPULATIONS; RESPONSES; DYNAMICS	Growing concern about how loss of biodiversity will affect ecosystems has stimulated numerous studies(1-5). Although most studies have assumed that species go extinct randomly(6-8), species often go extinct in order of their sensitivity to a stress that intensifies through time (such as climate change)(9). Here we show that the consequences of random and ordered extinctions differ. Both depend on food-web interactions that create compensation; that is, the increase of some species when their competitors and/or predators decrease in density due to environmental stress. Compensation makes communities as a whole more resistant to stress by reducing changes in combined species densities. As extinctions progress, the potential for compensation is depleted, and communities become progressively less resistant. For ordered extinctions, however, this depletion is offset and communities retain their resistance, because the surviving species have greater average resistance to the stress. Despite extinctions being ordered, changes in the food web with successive extinctions make it difficult to predict which species will show compensation in the future. This unpredictability argues for 'whole-ecosystem' approaches to biodiversity conservation, as seemingly insignificant species may become important after other species go extinct.	Univ Wisconsin, Dept Zool, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ives, AR (corresponding author), Univ Wisconsin, Dept Zool, Madison, WI 53706 USA.	arives@wisc.edu	Ives, Anthony/A-5698-2008; Cardinale, Bradley J/I-7076-2013	Ives, Anthony/0000-0001-9375-9523; 				CASE TJ, 1981, AM NAT, V118, P920, DOI 10.1086/283885; Chapin FS, 2000, NATURE, V405, P234, DOI 10.1038/35012241; Davis AJ, 1998, NATURE, V391, P783, DOI 10.1038/35842; Diaz S, 2003, TRENDS ECOL EVOL, V18, P140, DOI 10.1016/S0169-5347(03)00007-7; Ehrlich A.H., 1981, EXTINCTION; FROST TM, 1995, LINKING SPECIES & ECOSYSTEMS, P224; Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123; IVES AR, 1995, ECOLOGY, V76, P926, DOI 10.2307/1939357; Ives AR, 1999, ECOLOGY, V80, P1405, DOI 10.1890/0012-9658(1997)080[1405:CIWAZR]2.0.CO;2; Klug JL, 2000, ECOLOGY, V81, P387; Laska MS, 1998, ECOLOGY, V79, P461, DOI 10.2307/176946; MacArthur R.H., 1972, pvii; May R.M., 1974, STABILITY COMPLEXITY; McGrady-Steed J, 2000, ECOLOGY, V81, P361; NAEEM S, 1994, NATURE, V368, P734, DOI 10.1038/368734a0; Naeem S, 1999, NATURE, V401, P653, DOI 10.1038/44297; Ostfeld RS, 2003, ECOLOGY, V84, P1421, DOI 10.1890/02-3125; PAINE RT, 1966, AM NAT, V100, P65, DOI 10.1086/282400; Peres CA, 2000, OECOLOGIA, V122, P175, DOI 10.1007/PL00008845; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; PIMM SL, 1982, FOOD WEBS; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Smith MD, 2003, ECOL LETT, V6, P509, DOI 10.1046/j.1461-0248.2003.00454.x; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397; Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0; Tilman D, 1996, ECOLOGY, V77, P350, DOI 10.2307/2265614; Tilman D, 2001, SCIENCE, V294, P843, DOI 10.1126/science.1060391; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; Wootton JT, 2001, ECOLOGY, V82, P580, DOI 10.2307/2679881; Yodzis P., 1989, INTRO THEORETICAL EC	30	170	174	3	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988					174	177		10.1038/nature02515	http://dx.doi.org/10.1038/nature02515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141210				2022-12-28	WOS:000221356300039
J	Marshall, CB; Fletcher, GL; Davies, PL				Marshall, CB; Fletcher, GL; Davies, PL			Hyperactive antifreeze protein in a fish	NATURE			English	Editorial Material							WINTER FLOUNDER; ICE; POLYPEPTIDES; ADSORPTION		Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Mem Univ Newfoundland, Ctr Ocean Sci, St Johns, NF A1C 5S7, Canada	Queens University - Canada; Memorial University Newfoundland	Marshall, CB (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	daviesp@post.queensu.ca	Marshall, Christopher/K-8943-2019	Marshall, Christopher/0000-0002-7571-5700				DAVIES PL, 1992, GENE, V112, P171, DOI 10.1016/0378-1119(92)90373-W; DUMAN JG, 1974, NATURE, V247, P237, DOI 10.1038/247237a0; Fletcher GL, 2001, ANNU REV PHYSIOL, V63, P359, DOI 10.1146/annurev.physiol.63.1.359; HEW CL, 1986, EUR J BIOCHEM, V160, P267, DOI 10.1111/j.1432-1033.1986.tb09966.x; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; Kuiper MJ, 2003, BIOCHEM BIOPH RES CO, V300, P645, DOI 10.1016/S0006-291X(02)02900-5; SCOTT GK, 1988, J MOL EVOL, V27, P29, DOI 10.1007/BF02099727; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; SLAUGHTER D, 1982, CAN J BIOCHEM CELL B, V60, P824, DOI 10.1139/o82-103; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	10	96	111	3	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988					153	153		10.1038/429153a	http://dx.doi.org/10.1038/429153a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141201	Bronze			2022-12-28	WOS:000221356300028
J	Quill, TE				Quill, TE			Retrospective - Dying and decision making - Evolution of end-of-life options	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; EUTHANASIA		Univ Rochester, Sch Med, Rochester, NY 14627 USA	University of Rochester	Quill, TE (corresponding author), Univ Rochester, Sch Med, Rochester, NY 14627 USA.							Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Sullivan AD, 2001, NEW ENGL J MED, V344, P605, DOI 10.1056/NEJM200102223440811	4	29	29	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2029	2032		10.1056/NEJMp038216	http://dx.doi.org/10.1056/NEJMp038216			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141040				2022-12-28	WOS:000221354000003
J	Glass, RI; Bresee, JS; Parashar, UD; Jiang, BM; Gentsch, J				Glass, RI; Bresee, JS; Parashar, UD; Jiang, BM; Gentsch, J			The future of rotavirus vaccines: a major setback leads to new opportunities	LANCET			English	Editorial Material							ORAL POLIO VACCINE; INTUSSUSCEPTION; INFANTS; ASSOCIATION; PROGRAM; DEATHS; TRENDS		CDCP, Viral Gastroenteritis Sect, Resp & Enter Viruses Branch, Div Viral & Rickettsial Dis, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Glass, RI (corresponding author), CDC, Mailstop G04,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	rglass@cdc.gov						Andrews N, 2001, EUR J EPIDEMIOL, V17, P701, DOI 10.1023/A:1015691619745; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 42 INT C ANT AG CHEM; [Anonymous], 42 INT C ANT AG CHEM; Bresee JS, 1999, VACCINE, V17, P2207, DOI 10.1016/S0264-410X(98)00376-4; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P1007; CHERRY JD, 1989, CONT ISSUES INFECT D, V8, P47; Clark HF, 2003, PEDIATR INFECT DIS J, V22, P914, DOI 10.1097/01.inf.0000091887.48999.77; CLARK HF, 2004, VACCINES, P1327; Ehresman K., 1999, Morbidity and Mortality Weekly Report, V48, P577; Halsey NA, 1998, PEDIATRICS, V102, P1483, DOI 10.1542/peds.102.6.1483; Kramarz P, 2001, PEDIATR INFECT DIS J, V20, P410, DOI 10.1097/00006454-200104000-00008; Melton L, 2000, LANCET, V356, P318, DOI 10.1016/S0140-6736(05)73604-7; Murphy BR, 2003, J INFECT DIS, V187, P1301, DOI 10.1086/367895; Murphy TV, 2003, J INFECT DIS, V187, P1309, DOI 10.1086/374420; Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804; Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562; Parashar UD, 2000, PEDIATRICS, V106, P1413, DOI 10.1542/peds.106.6.1413; Peter G, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e67; Sardinas MAG, 2001, EUR J EPIDEMIOL, V17, P783, DOI 10.1023/A:1015675932509; Simonsen L, 2001, LANCET, V358, P1224, DOI 10.1016/S0140-6736(01)06346-2; STAAT MA, 2002, PED AC SOC M; Tucker AW, 1998, JAMA-J AM MED ASSOC, V279, P1371, DOI 10.1001/jama.279.17.1371; Weijer C, 2000, BRIT MED J, V321, P525, DOI 10.1136/bmj.321.7260.525; *WHO, 1997, REP CONS WORKSH ROT, P24	25	92	96	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2004	363	9420					1547	1550		10.1016/S0140-6736(04)16155-2	http://dx.doi.org/10.1016/S0140-6736(04)16155-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135605				2022-12-28	WOS:000221302700025
J	He, XL; Garcia, KC				He, XL; Garcia, KC			Structure of nerve growth factor complexed with the shared neurotrophin receptor p75	SCIENCE			English	Article							CRYSTAL-STRUCTURE; SIGNAL-TRANSDUCTION; P75(NTR); BINDING; ACTIVATION; SYSTEM	Neurotrophins are secreted growth factors critical for the development and maintenance of the vertebrate nervous system. Neurotrophins activate two types of cell surface receptors, the Trk receptor tyrosine kinases and the shared p75 neurotrophin receptor. We have determined the 2.4 Angstrom crystal structure of the prototypic neurotrophin, nerve growth factor (NGF), complexed with the extracellular domain of p75. Surprisingly, the complex is composed of an NGF homodimer asymmetrically bound to a single p75. p75 binds along the homodimeric interface of NGF, which disables NGF's symmetry-related second p75 binding site through an allosteric conformational change. Thus, neurotrophin signaling through p75 may occur by disassembly of p75 dimers and assembly of asymmetric 2: 1 neurotrophin/p75 complexes, which could potentially engage a Trk receptor to form a trimolecular signaling complex.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University; Stanford University	Garcia, KC (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Fairchild D319,299 Campus Dr, Stanford, CA 94305 USA.	kcgarcia@stanford.edu						BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Boulanger MJ, 2003, MOL CELL, V12, P577, DOI 10.1016/S1097-2765(03)00365-4; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; GROB PM, 1985, J BIOL CHEM, V260, P8044; He XL, 2001, SCIENCE, V293, P1657, DOI 10.1126/science.1062246; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; IBANEZ CF, 1995, TRENDS BIOTECHNOL, V13, P217, DOI 10.1016/S0167-7799(00)88949-0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Li PW, 2001, NAT IMMUNOL, V2, P443, DOI 10.1038/87757; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; Rabizadeh S, 2003, CYTOKINE GROWTH F R, V14, P225, DOI 10.1016/S1359-6101(03)00018-2; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; Wang JJL, 2000, J NEUROSCI RES, V60, P587, DOI 10.1002/(SICI)1097-4547(20000601)60:5<587::AID-JNR3>3.0.CO;2-1; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9	23	218	249	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					870	875		10.1126/science.1095190	http://dx.doi.org/10.1126/science.1095190			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131306				2022-12-28	WOS:000221243000044
J	Christensen, K; Juel, K; Herskind, M; Murray, JC				Christensen, K; Juel, K; Herskind, M; Murray, JC			Long term follow up study of survival associated with cleft lip and palate at birth	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL-MALFORMATIONS; CHILDHOOD-CANCER; RECORD-LINKAGE; RISK; DEFECTS; POPULATION; CHILDREN; INFANTS	Objective To assess the overall and cause specific mortality of people from birth to 55 years with cleft lip and palate. Design Long term follow up study. Setting Danish register of deaths. Participants People born with cleft lip and palate between 1943 and 1987, followed to 1998. Main outcome measures Observed and expected numbers of deaths, summarised as overall and cause specific standardised mortality ratios. Results 5331 people with cleft lip and palate were followed for 170 421 person years. The expected number of deaths was 259, but 402 occurred, corresponding to a standardised mortality ratio of 1.4 (95% confidence interval 1.3 to 1.6) for males and 1.8 (1.5 to 2.1) for females. The increased risk of mortality was nearly constant for the three intervals at follow up: first year of life, 1-17 years, and 18-55 years. The participants had an increased risk of all major causes of death. Conclusions People with cleft lip and palate have increased mortality up to age 55. Children born with cleft lip and palate and possibly other congenital malformations may benefit from specific preventive health measures into and throughout adulthood.	Univ So Denmark, Inst Publ Hlth, Ctr Prevent Congenital Malformat, DK-5000 Odense, Denmark; Natl Inst Publ Hlth, DK-2100 Copenhagen, Denmark; Odense Univ Hosp, Dept Pediat, DK-5000 Odense, Denmark; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA	University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of Iowa	Christensen, K (corresponding author), Univ So Denmark, Inst Publ Hlth, Ctr Prevent Congenital Malformat, DK-5000 Odense, Denmark.	kchristensen@health.sdu.dk	Juel, Knud/C-8916-2013; Christensen, Kaare/C-2360-2009	Christensen, Kaare/0000-0002-5429-5292; Juel, Knud/0000-0002-4134-1173	NIDCR NIH HHS [R01 DE 11948] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011948] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Christensen K, 1999, CLEFT PALATE-CRAN J, V36, P96, DOI 10.1597/1545-1569(1999)036<0096:TCDFCP>2.3.CO;2; CHRISTENSEN K, 1995, NEW ENGL J MED, V333, P161, DOI 10.1056/NEJM199507203330305; Christensen K, 2002, CLEFT PALATE-CRAN J, V39, P392, DOI 10.1597/1545-1569(2002)039<0392:FCAPDA>2.0.CO;2; CHRISTENSEN K, 1994, CLIN GENET, V46, P329; Fogh-Andersen, 1942, INHERITANCE HARELIP; MILI F, 1993, AM J EPIDEMIOL, V137, P629, DOI 10.1093/oxfordjournals.aje.a116720; MILI F, 1993, AM J EPIDEMIOL, V137, P639, DOI 10.1093/oxfordjournals.aje.a116721; Nopoulos P, 2002, GENET MED, V4, P1, DOI 10.1097/00125817-200201000-00001; Ramstad T, 1995, SCAND J PLAST RECONS, V29, P329, DOI 10.3109/02844319509008968; WINDHAM GC, 1985, AM J EPIDEMIOL, V121, P49, DOI 10.1093/oxfordjournals.aje.a113982; ZACK M, 1991, CANCER RES, V51, P3696; Zhu JL, 2002, BRIT J CANCER, V87, P524, DOI 10.1038/sj.bjc.6600488	12	151	156	2	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 12	2004	328	7453					1405	1406		10.1136/bmj.38106.559120.7C	http://dx.doi.org/10.1136/bmj.38106.559120.7C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15145797	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222114400016
J	Kodaira, S; Iidaka, T; Kato, A; Park, JO; Iwasaki, T; Kaneda, Y				Kodaira, S; Iidaka, T; Kato, A; Park, JO; Iwasaki, T; Kaneda, Y			High pore fluid pressure may cause silent slip in the Nankai Trough	SCIENCE			English	Article							1944 TONANKAI EARTHQUAKE; COSEISMIC SLIP; FRICTION LAWS; CENTRAL JAPAN; SUBDUCTION; ZONE	Silent-slip events have been detected at several subduction zones, but the cause of these events is unknown. Using seismic imaging, we detected a cause of the Tokai silent slip, which occurred at a presumed fault zone of a great earthquake. The seismic image that we obtained shows a zone of high pore fluid pressure in the subducted oceanic crust located down-dip of a subducted ridge. We propose that these structures effectively extend a region of conditionally stable slips and consequently generate the silent slip.	Japan Agcy Marine Earth Sci & Technol, Inst Frontier Res Earth Evolut, Kanazawa Ku, Yokohama, Kanagawa 2360001, Japan; Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, Tokyo 1130032, Japan	Japan Agency for Marine-Earth Science & Technology (JAMSTEC); University of Tokyo	Kodaira, S (corresponding author), Japan Agcy Marine Earth Sci & Technol, Inst Frontier Res Earth Evolut, Kanazawa Ku, Showa Machi 3175-25, Yokohama, Kanagawa 2360001, Japan.		Kodaira, Shuichi/G-8746-2016	Kodaira, Shuichi/0000-0002-5774-2561				ANDO M, 1975, TECTONOPHYSICS, V27, P119, DOI 10.1016/0040-1951(75)90102-X; Aoki Y., UNPUB; Baba T, 2002, PHYS EARTH PLANET IN, V132, P59, DOI 10.1016/S0031-9201(02)00044-4; CHRISTENSEN NI, 1984, GEOPHYS J ROY ASTR S, V79, P411, DOI 10.1111/j.1365-246X.1984.tb02232.x; Dessa JX, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002689; DIETERICH J, 1994, J GEOPHYS RES-SOL EA, V99, P2601, DOI 10.1029/93JB02581; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; Hacker BR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001127; Heki K, 2001, GEOPHYS RES LETT, V28, P2313, DOI 10.1029/2000GL012537; HYNDMAN RD, 1995, J GEOPHYS RES-SOL EA, V100, P15373, DOI 10.1029/95JB00153; Iidaka T, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002gl016517; Kamiya S, 2000, GEOPHYS RES LETT, V27, P819, DOI 10.1029/1999GL011080; Kikuchi M, 2003, EARTH PLANETS SPACE, V55, P159, DOI 10.1186/BF03351745; KIMATA F, 2001, EOS, V82, pF266; Kodaira S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016595; Mazzotti S, 2002, MAR GEOL, V187, P63, DOI 10.1016/S0025-3227(02)00245-1; MOLNAR P, 1995, EARTH PLANET SC LETT, V131, P57, DOI 10.1016/0012-821X(94)00253-U; Nakanishi A, 2002, EARTH PLANET SC LETT, V203, P255, DOI 10.1016/S0012-821X(02)00866-X; OKINO K, 1994, J GEOMAGN GEOELECTR, V46, P463, DOI 10.5636/jgg.46.463; Ozawa S, 2002, SCIENCE, V298, P1009, DOI 10.1126/science.1076780; RUINA A, 1983, J GEOPHYS RES, V88, P359, DOI 10.1029/JB088iB12p10359; Sagiya T, 1999, GEOPHYS RES LETT, V26, P2315, DOI 10.1029/1999GL900511; SATO H, 2002, JAP EARTH PLAN SCI J; Scholz CH, 1997, GEOLOGY, V25, P487, DOI 10.1130/0091-7613(1997)025<0487:TEOSSO>2.3.CO;2; Scholz CH, 1998, NATURE, V391, P37, DOI 10.1038/34097; Tanioka Y, 2001, GEOPHYS RES LETT, V28, P1075, DOI 10.1029/2000GL012284; Yamano M, 2003, PHYS CHEM EARTH, V28, P487, DOI 10.1016/S1474-7065(03)00068-8; Yoshida S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017439; Zhang J, 1998, J GEOPHYS RES-SOL EA, V103, P29743, DOI 10.1029/98JB01981	29	349	355	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1295	1298		10.1126/science.1096535	http://dx.doi.org/10.1126/science.1096535			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166372				2022-12-28	WOS:000221669600046
J	Siegel, JS				Siegel, JS			Chemical topology and interlocking molecules	SCIENCE			English	Editorial Material							ACID		Univ Zurich, Inst Organ Chem, CH-8057 Zurich, Switzerland	University of Zurich	Siegel, JS (corresponding author), Univ Zurich, Inst Organ Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	jss@oci.unizh.ch	Siegel, Jay/E-6415-2011	Siegel, Jay/0000-0002-3226-3521				AMMANN M, 2003, POLYM PREPRINTS, V44, P379; Breault GA, 1999, TETRAHEDRON, V55, P5265, DOI 10.1016/S0040-4020(99)00282-3; Chichak KS, 2004, SCIENCE, V304, P1308, DOI 10.1126/science.1096914; Cromwell P, 1998, MATH INTELL, V20, P53; Diederich F., 2000, TEMPLATED ORGANIC SY; DUCHAMP DJ, 1969, ACTA CRYSTALL B-STRU, VB 25, P5, DOI 10.1107/S0567740869001713; ERMER O, 1988, J AM CHEM SOC, V110, P3747, DOI 10.1021/ja00220a005; FRISCH HL, 1961, J AM CHEM SOC, V83, P3789, DOI 10.1021/ja01479a015; Fujita M, 1999, ACCOUNTS CHEM RES, V32, P53, DOI 10.1021/ar9701068; Leigh DA, 2003, NATURE, V424, P174, DOI 10.1038/nature01758; LIANG CZ, 1994, J MATH CHEM, V16, P27, DOI 10.1007/BF01169193; Loren JC, 2003, ANGEW CHEM INT EDIT, V42, P5702, DOI 10.1002/anie.200352562; PEDERSEN CJ, 1967, J AM CHEM SOC, V89, P7017, DOI 10.1021/ja01002a035; Raehm L, 2002, SYNLETT, P1743; Reuter C, 2000, PURE APPL CHEM, V72, P2233, DOI 10.1351/pac200072122233; Sauvage, 1999, MOL CATENANES ROTAXA; SCHILL G, 1971, ORGANIC CHEM SERIES, V22; Seeman NC, 1998, ANGEW CHEM INT EDIT, V37, P3220, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3220::AID-ANIE3220>3.0.CO;2-C; Wang LY, 2004, SCIENCE, V304, P1312, DOI 10.1126/science.1096688; WASSERMAN E, 1960, J AM CHEM SOC, V82, P4433, DOI 10.1021/ja01501a082; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; Wu H, 2000, J AM CHEM SOC, V122, P12691, DOI 10.1021/ja002687t; Yan LZ, 2001, ANGEW CHEM INT EDIT, V40, P3625, DOI 10.1002/1521-3773(20011001)40:19<3625::AID-ANIE3625>3.0.CO;2-Q	23	96	96	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1256	1258		10.1126/science.1099216	http://dx.doi.org/10.1126/science.1099216			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166352				2022-12-28	WOS:000221669600026
J	Ianora, A; Miralto, A; Poulet, SA; Carotenuto, Y; Buttino, I; Romano, G; Casotti, R; Pohnert, G; Wichard, T; Colucci-D'Amato, L; Terrazzano, G; Smetacek, V				Ianora, A; Miralto, A; Poulet, SA; Carotenuto, Y; Buttino, I; Romano, G; Casotti, R; Pohnert, G; Wichard, T; Colucci-D'Amato, L; Terrazzano, G; Smetacek, V			Aldehyde suppression of copepod recruitment in blooms of a ubiquitous planktonic diatom	NATURE			English	Article							CHEMICAL DEFENSE; CALANUS-HELGOLANDICUS; HATCHING SUCCESS; FERTILIZATION; REPRODUCTION; INHIBITION; ECOSYSTEMS; ABUNDANCE; EXTRACTS; CYCLES	The growth cycle in nutrient-rich, aquatic environments starts with a diatom bloom that ends in mass sinking of ungrazed cells and phytodetritus(1). The low grazing pressure on these blooms has been attributed to the inability of overwintering copepod populations to track them temporally(2). We tested an alternative explanation: that dominant diatom species impair the reproductive success of their grazers. We compared larval development of a common overwintering copepod fed on a ubiquitous, early-blooming diatom species with its development when fed on a typical post-bloom dinoflagellate. Development was arrested in all larvae in which both mothers and their larvae were fed the diatom diet. Mortality remained high even if larvae were switched to the dinoflagellate diet. Aldehydes, cleaved from a fatty acid precursor by enzymes activated within seconds after crushing of the cell(3), elicit the teratogenic effect(4). This insidious mechanism, which does not deter the herbivore from feeding but impairs its recruitment, will restrain the cohort size of the next generation of early-rising overwinterers. Such a transgenerational plant-herbivore interaction could explain the recurringly inefficient use of a predictable, potentially valuable food resource-the spring diatom bloom-by marine zooplankton.	Stn Zool A Dohrn, Ecophysiol Lab, I-80121 Naples, Italy; CNRS, Stn Biol Roscoff, F-29682 Roscoff, France; Max Planck Inst Chem Ecol, D-07745 Jena, Germany; CNR, Inst Endocrinol & Expt Oncol, I-80131 Naples, Italy; Univ Naples Federico II, Dept Cellular & Mol Biol & Pathol, I-80131 Naples, Italy; Alfred Wegener Inst Polar & Marine Res, D-27570 Bremerhaven, Germany	Stazione Zoologica Anton Dohrn di Napoli; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Max Planck Society; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Ianora, A (corresponding author), Stn Zool A Dohrn, Ecophysiol Lab, Villa Comunale, I-80121 Naples, Italy.	ianora@szn.it	Casotti, Raffaella/I-9833-2019; Carotenuto, Ylenia/ABG-4872-2021; Casotti, Raffaella/H-1697-2016; Wichard, Thomas/C-2794-2009; Romano, Giovanna/F-4561-2015; Pohnert, Georg/D-3721-2013; Carotenuto, Ylenia/B-5708-2013; Ianora, Adrianna/O-3408-2019; Wichard, Thomas/L-9861-2019; Buttino, Isabella/AAI-3264-2020	Casotti, Raffaella/0000-0002-9876-4601; Carotenuto, Ylenia/0000-0002-7188-9279; Casotti, Raffaella/0000-0002-9876-4601; Wichard, Thomas/0000-0003-0061-4160; Romano, Giovanna/0000-0002-4898-7153; Pohnert, Georg/0000-0003-2351-6336; Carotenuto, Ylenia/0000-0002-7188-9279; Wichard, Thomas/0000-0003-0061-4160; TERRAZZANO, Giuseppe/0000-0003-3556-6891				Adolph S, 2003, TETRAHEDRON, V59, P3003, DOI 10.1016/S0040-4020(03)00382-X; Ban SH, 1997, MAR ECOL PROG SER, V157, P287, DOI 10.3354/meps157287; Caldwell GS, 2003, TOXICON, V42, P301, DOI 10.1016/S0041-0101(03)00147-8; Caldwell GS, 2002, AQUAT TOXICOL, V60, P123, DOI 10.1016/S0166-445X(01)00277-6; CALDWELL GS, 2004, THESIS U NEWCASTLE U; COLEBROOK JM, 1982, J PLANKTON RES, V4, P435, DOI 10.1093/plankt/4.3.435; CUSHING DH, 1975, MASRINE ECOLOGY FISH; d'Ippolito G, 2002, TETRAHEDRON LETT, V43, P6133, DOI 10.1016/S0040-4039(02)01285-6; Hamm CE, 2003, NATURE, V421, P841, DOI 10.1038/nature01416; Ianora A, 2003, PHYCOLOGIA, V42, P351, DOI 10.2216/i0031-8884-42-4-351.1; Irigoien X, 2002, NATURE, V419, P387, DOI 10.1038/nature01055; KLEPPEL GS, 1993, MAR ECOL PROG SER, V99, P183, DOI 10.3354/meps099183; LUO XP, 1995, ANAL BIOCHEM, V228, P294, DOI 10.1006/abio.1995.1353; Mauchline J, 1998, BIOL CALANOID COPEPO; Miralto A, 2003, MAR ECOL PROG SER, V254, P253, DOI 10.3354/meps254253; Miralto A, 1999, NATURE, V402, P173, DOI 10.1038/46023; Pohnert G, 2002, MAR ECOL PROG SER, V245, P33, DOI 10.3354/meps245033; Pohnert G, 2000, ANGEW CHEM INT EDIT, V39, P4352, DOI 10.1002/1521-3773(20001201)39:23<4352::AID-ANIE4352>3.0.CO;2-U; Poulet SA, 1995, MAR ECOL PROG SER, V129, P85, DOI 10.3354/meps129085; Romano G, 2003, J EXP BIOL, V206, P3487, DOI 10.1242/jeb.00580; Smetacek V, 2002, NATURE, V419, P565, DOI 10.1038/419565a; Smetacek V, 2001, NATURE, V411, P745, DOI 10.1038/35081210; SMETACEK VS, 1985, MAR BIOL, V84, P239, DOI 10.1007/BF00392493; TAKAI M, 1992, ACS S SER, V489, P38; Tester P.A., 1991, P 4 INT C COPEPODA K, P603; Tosti E, 2003, MOL REPROD DEV, V66, P72, DOI 10.1002/mrd.10332; Turner JT, 2001, MAR ECOL PROG SER, V220, P187, DOI 10.3354/meps220187; Verity PG, 1996, MAR ECOL PROG SER, V130, P277, DOI 10.3354/meps130277; Weikert H, 2001, J MARINE SYST, V30, P221, DOI 10.1016/S0924-7963(01)00060-4; Wolfe GV, 2000, BIOL BULL-US, V198, P225, DOI 10.2307/1542526; Yoshida T, 2003, NATURE, V424, P303, DOI 10.1038/nature01767	31	327	339	2	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					403	407		10.1038/nature02526	http://dx.doi.org/10.1038/nature02526			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164060				2022-12-28	WOS:000221644600036
J	Andrews, DW; Scott, CB; Sperduto, PW; Flanders, AE; Gaspar, LE; Schell, MC; Werner-Wasik, M; Demas, W; Ryu, J; Bahary, JP; Souhami, L; Rotman, M; Mehta, MP; Curran, WJ				Andrews, DW; Scott, CB; Sperduto, PW; Flanders, AE; Gaspar, LE; Schell, MC; Werner-Wasik, M; Demas, W; Ryu, J; Bahary, JP; Souhami, L; Rotman, M; Mehta, MP; Curran, WJ			Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial	LANCET			English	Article							COST-EFFECTIVENESS; ONCOLOGY-GROUP; RADIOTHERAPY; SURGERY; MANAGEMENT	Background Brain metastases occur in up to 40% of all patients with systemic cancer. We aimed to assess whether stereotactic radiosurgery provided any therapeutic benefit in a randomised multi-institutional trial directed by the Radiation Therapy Oncology Group (RTOG). Methods Patients with one to three newly diagnosed brain metastases were randomly allocated either whole brain radiation therapy (WBRT) or WBRT followed by stereotactic radiosurgery boost. Patients were stratified by number of metastases and status of extracranial disease. Primary outcome was survival; secondary outcomes were tumour response and local rates, overall intracranial recurrence rates, cause of death, and performance measurements. Findings From January, 1996, to June, 2001, we enrolled 333 patients from 55 participating RTOG institutions-167 were assigned WBRT and stereotactic radiosurgery and 164 were allocated WBRT alone. Univariate analysis showed that there was a survival advantage in the WBRT and stereotactic radiosurgery group for patients with a single brain metastasis (median survival time 6.5 vs 4.9 months, p=0.0393). Patients in the stereotactic surgery group were more likely to have a stable or improved Karnofsky Performance Status (KPS) score at 6 months' follow-up than were patients allocated WBRT alone (43% vs 27%, respectively; p=0.03). By multivariate analysis, survival improved in patients with an RPA class 1 (p<0.0001) or a favourable histological status (p=0.0121). Interpretation WBRT and stereotactic boost treatment improved functional autonomy (KPS) for all patients and survival for patients with a single unresectable brain metastasis. WBRT and stereotactic radiosurgery should, therefore, be standard treatment for patients with a single unresectable brain metastasis and considered for patients with two or three brain metastases.	Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA 19107 USA; Thomas Jefferson Univ Hosp, Dept Radiol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ Hosp, Dept Radiat Oncol, Philadelphia, PA 19107 USA; Amer Coll Radiol, Philadelphia, PA USA; Methodist Hosp, Ctr Canc, Minneapolis, MN USA; Univ Rochester, Dept Radiat Oncol, Rochester, NY USA; Summa Hlth Syst, Akron City Hosp, Akron, OH USA; Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA; Univ Colorado, Ctr Canc, Denver, CO 80262 USA; Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada; McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ, Canada; SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA	Jefferson University; Jefferson University; Jefferson University; American College of Radiology; University of Rochester; Summa Health System; University of California System; University of California Davis; University of Colorado System; University of Colorado Denver; Universite de Montreal; McGill University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Wisconsin System; University of Wisconsin Madison	Andrews, DW (corresponding author), Thomas Jefferson Univ, 909 Walnut St,2nd Floor, Philadelphia, PA 19107 USA.	david.andrews@jefferson.edu	Mehta, Minesh P./AAB-8915-2019	Mehta, Minesh P./0000-0002-4812-5713; Sperduto, Paul/0000-0002-4628-7161	NCI NIH HHS [U10 CA32115, U10 CA21661, U10CA37422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037422, U10CA032115, U10CA021661] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKESON P, 1995, ACTA RADIOL, V36, P300, DOI 10.3109/02841859509177639; Auchter RM, 1996, INT J RADIAT ONCOL, V35, P27, DOI 10.1016/S0360-3016(96)85008-5; Bindal AK, 1996, J NEUROSURG, V84, P748, DOI 10.3171/jns.1996.84.5.0748; BORGELT B, 1980, INT J RADIAT ONCOL, V6, P1, DOI 10.1016/0360-3016(80)90195-9; CAIRNCROSS JG, 1980, ANN NEUROL, V7, P529, DOI 10.1002/ana.410070606; COX DR, 1972, J R STAT SOC B, V34, P187; DIENERWEST M, 1989, INT J RADIAT ONCOL, V16, P669, DOI 10.1016/0360-3016(89)90483-5; FLICKINGER JC, 1994, INT J RADIAT ONCOL, V28, P797, DOI 10.1016/0360-3016(94)90098-1; FULLER BG, 1992, INT J RADIAT ONCOL, V23, P413, DOI 10.1016/0360-3016(92)90762-7; Gaspar L, 1997, INT J RADIAT ONCOL, V37, P745, DOI 10.1016/S0360-3016(96)00619-0; Hawighorst H, 1997, MAGN RESON IMAGING, V15, P1121, DOI 10.1016/S0730-725X(97)00178-1; Kondziolka D, 1999, INT J RADIAT ONCOL, V45, P427, DOI 10.1016/S0360-3016(99)00198-4; Larner AJ, 2002, INT J CLIN PRACT, V56, P219; LEKSELL L, 1951, ACTA CHIR SCAND, V102, P316; Lohr F, 2001, SEMIN SURG ONCOL, V20, P50, DOI 10.1002/ssu.1016; MARKS LB, 1991, J NEUROSURG, V75, P177, DOI 10.3171/jns.1991.75.2.0177; Mehta M, 1997, INT J RADIAT ONCOL, V39, P445, DOI 10.1016/S0360-3016(97)00071-0; MEHTA MP, 1992, INT J RADIAT ONCOL, V24, P619, DOI 10.1016/0360-3016(92)90706-N; Mintz AH, 1996, CANCER, V78, P1470, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO;2-X; NOORDIJK EM, 1994, INT J RADIAT ONCOL, V29, P711, DOI 10.1016/0360-3016(94)90558-4; PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802; Proschan MA, 2000, CONTROL CLIN TRIALS, V21, P527, DOI 10.1016/S0197-2456(00)00106-9; ROCK J, 2000, NEUROSURG FOCUS, V9, P1; Sanghavi SN, 2001, INT J RADIAT ONCOL, V51, P426, DOI 10.1016/S0360-3016(01)01622-4; Shaw E, 2000, INT J RADIAT ONCOL, V47, P291, DOI 10.1016/S0360-3016(99)00507-6; Sneed PK, 2002, INT J RADIAT ONCOL, V53, P519, DOI 10.1016/S0360-3016(02)02770-0; Sperduto PW, 1996, INT J RADIAT ONCOL, V36, P511, DOI 10.1016/S0360-3016(96)00347-1; WEISSMAN DE, 1988, J CLIN ONCOL, V6, P543, DOI 10.1200/JCO.1988.6.3.543	28	1744	1823	0	64	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	2004	363	9422					1665	1672		10.1016/S0140-6736(04)16250-8	http://dx.doi.org/10.1016/S0140-6736(04)16250-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158627				2022-12-28	WOS:000221546300006
J	Castle, LA; Siehl, DL; Gorton, R; Patten, PA; Chen, YH; Bertain, S; Cho, HJ; Duck, N; Wong, J; Liu, DL; Lassner, MW				Castle, LA; Siehl, DL; Gorton, R; Patten, PA; Chen, YH; Bertain, S; Cho, HJ; Duck, N; Wong, J; Liu, DL; Lassner, MW			Discovery and directed evolution of a glyphosate tolerance gene	SCIENCE			English	Article							SEROTONIN N-ACETYLTRANSFERASE; HERBICIDE-RESISTANCE; PROTEIN; PLANTS; MECHANISM; RESIDUES	The herbicide glyphosate is effectively detoxified by N-acetylation. We screened a collection of microbial isolates and discovered enzymes exhibiting glyphosate N-acetyltransferase (GAT) activity. Kinetic properties of the discovered enzymes were insufficient to confer glyphosate tolerance to transgenic organisms. Eleven iterations of DNA shuffling improved enzyme efficiency by nearly four orders of magnitude from 0.87 mM(-1) min(-1) to 8320 mM(-1) min(-1). From the fifth iteration and beyond, GAT enzymes conferred increasing glyphosate tolerance to Escherichia coli, Arabidopsis, tobacco, and maize. Glyphosate acetylation provides an alternative strategy for supporting glyphosate use on crops.	Verdia Inc, Redwood City, CA 94063 USA; Maxygen Inc, Redwood City, CA 94063 USA; Pioneer HiBred Int Inc, Johnston, IA 50131 USA	DuPont	Castle, LA (corresponding author), Verdia Inc, Redwood City, CA 94063 USA.	linda.castle@verdiainc.com						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barry G, 1992, CURR TOP PLANT PHYSL, P139; CASTLE L, UNPUB; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; DEBLOCK M, 1987, EMBO J, V6, P2513, DOI 10.1002/j.1460-2075.1987.tb02537.x; Draker KA, 2004, BIOCHEMISTRY-US, V43, P446, DOI 10.1021/bi035667n; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Franz J. E., 1997, GLYPHOSATE UNIQUE GL; GOUGLER JA, 1981, PLANT PHYSIOL, V68, P668, DOI 10.1104/pp.68.3.668; JAMES C, 2003, ISAA BRIEFS, V29; Khalil EM, 1998, J BIOL CHEM, V273, P30321, DOI 10.1074/jbc.273.46.30321; KINSKY SC, 1960, J BIOL CHEM, V235, P94; Ness JE, 2002, NAT BIOTECHNOL, V20, P1251, DOI 10.1038/nbt754; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Padgette Stephen R., 1996, P53; Pline WA, 2002, J AGR FOOD CHEM, V50, P506, DOI 10.1021/jf0110699; Scheibner KA, 2002, J BIOL CHEM, V277, P18118, DOI 10.1074/jbc.M200595200; STALKER DM, 1988, SCIENCE, V242, P419, DOI 10.1126/science.242.4877.419; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; THOMPSON CJ, 1987, EMBO J, V6, P2519, DOI 10.1002/j.1460-2075.1987.tb02538.x; ZHAO ZY, 2004, Patent No. 5981840	21	220	318	1	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	2004	304	5674					1151	1154		10.1126/science.1096770	http://dx.doi.org/10.1126/science.1096770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155947				2022-12-28	WOS:000221524500041
J	Paredes, B; Widera, A; Murg, V; Mandel, O; Folling, S; Cirac, I; Shlyapnikov, GV; Hansch, TW; Bloch, I				Paredes, B; Widera, A; Murg, V; Mandel, O; Folling, S; Cirac, I; Shlyapnikov, GV; Hansch, TW; Bloch, I			Tonks-Girardeau gas of ultracold atoms in an optical lattice	NATURE			English	Article							BOSE-EINSTEIN CONDENSATION; IMPENETRABLE BOSONS; GROUND STATE; TRANSITION; SUPERFLUID; INSULATOR; MOLECULES	Strongly correlated quantum systems are among the most intriguing and fundamental systems in physics. One such example is the Tonks-Girardeau gas(1,2), proposed about 40 years ago, but until now lacking experimental realization; in such a gas, the repulsive interactions between bosonic particles confined to one dimension dominate the physics of the system. In order to minimize their mutual repulsion, the bosons are prevented from occupying the same position in space. This mimics the Pauli exclusion principle for fermions, causing the bosonic particles to exhibit fermionic properties(1,2). However, such bosons do not exhibit completely ideal fermionic ( or bosonic) quantum behaviour; for example, this is reflected in their characteristic momentum distribution(3). Here we report the preparation of a Tonks-Girardeau gas of ultracold rubidium atoms held in a two-dimensional optical lattice formed by two orthogonal standing waves. The addition of a third, shallower lattice potential along the long axis of the quantum gases allows us to enter the Tonks-Girardeau regime by increasing the atoms' effective mass and thereby enhancing the role of interactions. We make a theoretical prediction of the momentum distribution based on an approach in which trapped bosons acquire fermionic properties, finding that it agrees closely with the measured distribution.	Max Planck Inst Quantum Opt, D-85748 Garching, Germany; Univ Munich, Sekt Phys, D-80799 Munich, Germany; Johannes Gutenberg Univ Mainz, Inst Phys, D-55099 Mainz, Germany; Univ Paris 11, Lab Phys Theor & Modeles Stat, F-91405 Orsay, France; Univ Amsterdam, Van der Waals Zeeman Inst, NL-1018 XE Amsterdam, Netherlands	Max Planck Society; University of Munich; Johannes Gutenberg University of Mainz; UDICE-French Research Universities; Universite Paris Saclay; University of Amsterdam	Bloch, I (corresponding author), Max Planck Inst Quantum Opt, D-85748 Garching, Germany.	bloch@uni-mainz.de	Cirac, J. Ignacio/A-9105-2017; Bloch, Immanuel/N-9169-2019; Bloch, Immanuel/G-3174-2010; Widera, Artur/D-1032-2017	Cirac, J. Ignacio/0000-0003-3359-1743; Bloch, Immanuel/0000-0002-0679-4759; Widera, Artur/0000-0002-0338-9969; Folling, Simon/0000-0002-6951-3651				Astrakharchik GE, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.031602; Cazalilla MA, 2004, J PHYS B-AT MOL OPT, V37, pS1, DOI 10.1088/0953-4075/37/7/051; Dunjko V, 2001, PHYS REV LETT, V86, P5413, DOI 10.1103/PhysRevLett.86.5413; FISHER MPA, 1989, PHYS REV B, V40, P546, DOI 10.1063/1.38820; Gangardt DM, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.010401; GIRARDEAU M, 1960, J MATH PHYS, V1, P516, DOI 10.1063/1.1703687; GOERLITZ A, 2001, PHYS REV LETT, V87; Greiner M, 2003, NATURE, V426, P537, DOI 10.1038/nature02199; Greiner M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.160405; Jochim S, 2003, SCIENCE, V302, P2101, DOI 10.1126/science.1093280; Kollath C, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.031601; Korepin V. E., 1993, QUANTUM INVERSE SCAT; LENARD A, 1964, J MATH PHYS, V5, P930, DOI 10.1063/1.1704196; LIEB EH, 1963, PHYS REV, V130, P1605, DOI 10.1103/PhysRev.130.1605; Moritz H, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.250402; Olshanii M, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.090401; Olshanii M, 1998, PHYS REV LETT, V81, P938, DOI 10.1103/PhysRevLett.81.938; Ovchinnikov YB, 1999, PHYS REV LETT, V83, P284, DOI 10.1103/PhysRevLett.83.284; Paredes B, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.150402; Petrov DS, 2000, PHYS REV LETT, V85, P3745, DOI 10.1103/PhysRevLett.85.3745; Regal CA, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.040403; Richard S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.010405; Sachdev S., 1999, QUANTUM PHASE TRANSI; Schreck F, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.080403; Stoferle T, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.130403; TOLRA BL, 2003, OBSERVATION REDUCED; Zwierlein MW, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.250401; [No title captured]	30	1294	1301	7	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					277	281		10.1038/nature02530	http://dx.doi.org/10.1038/nature02530			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152247				2022-12-28	WOS:000221505900037
J	Goldman, DP; Joyce, GF; Escarce, JJ; Pace, JE; Solomon, MD; Laouri, M; Landsman, PB; Teutsch, SM				Goldman, DP; Joyce, GF; Escarce, JJ; Pace, JE; Solomon, MD; Laouri, M; Landsman, PB; Teutsch, SM			Pharmacy benefits and the use of drugs by the chronically ill	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST; IMPACT	Context Many health plans have instituted more cost sharing to discourage use of more expensive pharmaceuticals and to reduce drug spending. Objective To determine how changes in cost sharing affect use of the most commonly used drug classes among the privately insured and the chronically ill. Design, Setting, and Participants Retrospective US study conducted from 1997 to 2000, examining linked pharmacy claims data with health plan benefit designs from 30 employers and 52 health plans. Participants were 528969 privately insured beneficiaries aged 18 to 64 years and enrolled from 1 to 4 years (960791 person-years). Main Outcome Measure Relative change in drug days supplied (per member, per year) when co-payments doubled in a prototypical drug benefit plan. Results Doubling co-payments was associated with reductions in use of 8 therapeutic classes. The largest decreases occurred for nonsteroidal anti-inflammatory drugs (NSAIDs) (45%) and antihistamines (44%). Reductions in overall days supplied of antihyperlipidemics (34%), antiulcerants (33%), antiasthmatics (32%), antihypertensives (26%), antidepressants (26%), and antidiabetics (25%) were also observed. Among patients diagnosed as having a chronic illness and receiving ongoing care, use was less responsive to co-payment changes. Use of antidepressants by depressed patients declined by 8%; use of anti hypertensives by hypertensive patients decreased by 10%. Larger reductions were observed for arthritis patients taking NSAIDs (27%) and allergy patients taking antihistamines (31%). Patients with diabetes reduced their use of antidiabetes drugs by 23%. Conclusions The use of medications such as antihistamines and NSAIDs, which are taken intermittently to treat symptoms, was sensitive to co-payment changes. Other medications-antihypertensive, antiasthmatic, antidepressant, antihyperlipidemic, antiulcerant, and antidiabetic agents-also demonstrated significant price responsiveness. The reduction in use of medications for individuals in ongoing care was more modest. Still, significant increases in co-payments raise concern about adverse health consequences because of the large price effects, especially among diabetic patients.	RAND Corp, Santa Monica, CA 90407 USA; Merck, W Point, PA USA; Calif Healthcare Fdn, Oakland, CA USA	RAND Corporation	Goldman, DP (corresponding author), RAND Corp, 1700 Main St, Santa Monica, CA 90407 USA.	dgoldman@rand.org; gjoyce@rand.org	Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396				Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; HARRIS BL, 1990, MED CARE, V28, P907, DOI 10.1097/00005650-199010000-00005; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; Johnson RE, 1997, HEALTH SERV RES, V32, P103; Joyce GF, 2002, JAMA-J AM MED ASSOC, V288, P1733, DOI 10.1001/jama.288.14.1733; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Law MR, 2002, BMJ-BRIT MED J, V324, P1570, DOI 10.1136/bmj.324.7353.1570; LOHR KN, 1986, MED CARE S, V24, pS39; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; *MED EC CO, 2000, 2000 DRUG TOP RED BO; Motheral B, 2001, MED CARE, V39, P1293, DOI 10.1097/00005650-200112000-00005; Rector TS, 2003, MED CARE, V41, P398, DOI 10.1097/00005650-200303000-00008; REEDER CE, 1985, INQUIRY-J HEALTH CAR, V22, P396; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421	15	419	423	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2004	291	19					2344	2350		10.1001/jama.291.19.2344	http://dx.doi.org/10.1001/jama.291.19.2344			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821JD	15150206	Bronze			2022-12-28	WOS:000221455400022
J	Charap, M				Charap, M			Reducing resident work hours: Unproven assumptions and unforeseen outcomes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University	Charap, M (corresponding author), NYU, Sch Med, Dept Med, 550 1st Ave, New York, NY 10016 USA.							*ACCR COUNC GRAD M, 2002, REP ACGME WORK GROUP; Kohn KT, 2000, ERR IS HUMAN BUILDIN; LUDMERER K, 1999, TIME HEAL, P320; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Philibert I, 2002, JAMA-J AM MED ASSOC, V288, P1112, DOI 10.1001/jama.288.9.1112; Steinbrook R, 2002, NEW ENGL J MED, V347, P1296, DOI 10.1056/NEJMhpr022383; Veasey S, 2002, JAMA-J AM MED ASSOC, V288, P1116, DOI 10.1001/jama.288.9.1116; Weinger MB, 2002, JAMA-J AM MED ASSOC, V287, P955, DOI 10.1001/jama.287.8.955	8	91	91	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					814	815		10.7326/0003-4819-140-10-200405180-00011	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148068				2022-12-28	WOS:000221520900006
J	Cooper, CP; Williams, KN; Carey, KA; Fowler, CS; Frank, M; Gelb, CA				Cooper, CP; Williams, KN; Carey, KA; Fowler, CS; Frank, M; Gelb, CA			Advertising campaign on a major internet search engine to promote colorectal cancer screening	BRITISH MEDICAL JOURNAL			English	Article									Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Yahoo, Atlanta, GA 30327 USA; Ogilvy Publ Relat Worldwide, Washington, DC 20036 USA	Centers for Disease Control & Prevention - USA	Cooper, CP (corresponding author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-55, Atlanta, GA 30341 USA.	ccooper@cdc.gov						Bannan K. J., 2003, BtoB, V88; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P196; Jorgensen CM, 2001, J WOMEN HEALTH GEN-B, V10, P417, DOI 10.1089/152460901300233876; Krishnamurthy S, 2000, MARK MANAG, V9, P34	4	10	10	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 15	2004	328	7449					1179	1180		10.1136/bmj.328.7449.1179	http://dx.doi.org/10.1136/bmj.328.7449.1179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142926	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000221497500027
J	Katikireddi, SV				Katikireddi, SV			HINARI: bridging the global information divide	BRITISH MEDICAL JOURNAL			English	Article							COUNTRIES		Univ Edinburgh, Liverpool L18 9XN, Merseyside, England	University of Edinburgh	Katikireddi, SV (corresponding author), Univ Edinburgh, Liverpool L18 9XN, Merseyside, England.	vkatikireddi@yahoo.co.uk		Katikireddi, Srinivasa/0000-0001-6593-9092				Aronson B, 2004, NEW ENGL J MED, V350, P966, DOI 10.1056/NEJMp048009; Godlee F, 2000, BRIT MED J, V321, P776, DOI 10.1136/bmj.321.7264.776; Pakenham-Walsh N, 2002, QJM-INT J MED, V95, P469, DOI 10.1093/qjmed/95.7.469; PakenhamWalsh N, 1997, BRIT MED J, V314, P90, DOI 10.1136/bmj.314.7074.90	4	55	57	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 15	2004	328	7449					1190	1193		10.1136/bmj.328.7449.1190	http://dx.doi.org/10.1136/bmj.328.7449.1190			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142931	Green Published			2022-12-28	WOS:000221497500032
J	Pringle, E; Bingham, J; Graham, E				Pringle, E; Bingham, J; Graham, E			Progressive binasal hemianopia	LANCET			English	Editorial Material									St Thomas Hosp, Med Eye Unit, London, England; St Thomas Hosp, Dept Genitourinary Med, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Pringle, E (corresponding author), St Thomas Hosp, Med Eye Unit, London, England.	edwardpringle@doctors.org.uk						Drake RL, 1934, ARCH OPHTHALMOL-CHIC, V12, P583, DOI 10.1001/archopht.1934.00830170121016; *HLTH PROT AG, SEX TRANSM INF CONT; Pao D, 2002, DRUGS, V62, P1447, DOI 10.2165/00003495-200262100-00003; Sloan LL, 1938, ARCH OPHTHALMOL-CHIC, V20, P201; Stokes JH, 1945, MODERN CLIN SYPHILOL	5	13	14	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	2004	363	9421					1606	1606		10.1016/S0140-6736(04)16204-1	http://dx.doi.org/10.1016/S0140-6736(04)16204-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145634				2022-12-28	WOS:000221408800011
J	Billker, O; Dechamps, S; Tewari, R; Wenig, G; Franke-Fayard, B; Brinkmann, V				Billker, O; Dechamps, S; Tewari, R; Wenig, G; Franke-Fayard, B; Brinkmann, V			Calcium and a calcium-dependent protein kinase regulate gamete formation and mosquito transmission in a malaria parasite	CELL			English	Article							PLASMODIUM-FALCIPARUM; TOXOPLASMA-GONDII; MONOCLONAL-ANTIBODIES; SEXUAL DEVELOPMENT; XANTHURENIC ACID; GENOME SEQUENCE; HOST-CELLS; BERGHEI; EXFLAGELLATION; GAMETOGENESIS	Transmission of malaria parasites to mosquitoes is initiated by the obligatory sexual reproduction of the parasite within the mosquito bloodmeal. Differentiation of specialized transmission stages, the gametocytes, into male and female gametes is induced by a small mosquito molecule, xanthurenic acid (XA). Using a Plasmodium berghei strain expressing a bioluminescent calcium sensor, we show that XA triggers a rapid rise in cytosolic calcium specifically in gametocytes that is essential for their differentiation into gametes. A member of a family of plant-like calcium dependent protein kinases, CDPK4, is identified as the molecular switch that translates the XA-induced calcium signal into a cellular response by regulating cell cycle progression in the male gametocyte. CDPK4 is shown to be essential for the sexual reproduction and mosquito transmission of P. berghei. This study reveals an unexpected function for a plant-like signaling pathway in cell cycle regulation and life cycle progression of a malaria parasite.	Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AZ, England; Leiden Univ, Med Ctr, Parasitol Lab, NL-2300 RC Leiden, Netherlands; Max Planck Inst Infekt Biol, D-10117 Berlin, Germany	Imperial College London; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Max Planck Society	Billker, O (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AZ, England.	o.billker@imperial.ac.uk	Brinkmann, Volker/A-6015-2009; Tewari, Rita/M-5698-2014	, Blandine/0000-0001-6041-4182; Billker, Oliver/0000-0003-1716-168X; Tewari, Rita/0000-0003-3943-1847	Medical Research Council [G120/746] Funding Source: Medline; MRC [G120/746] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alleva LM, 2001, MOL BIOCHEM PARASIT, V117, P121, DOI 10.1016/S0166-6851(01)00338-3; Aravind L, 2003, CELL, V115, P771, DOI 10.1016/S0092-8674(03)01023-7; Baubet V, 2000, P NATL ACAD SCI USA, V97, P7260, DOI 10.1073/pnas.97.13.7260; Beetsma AL, 1998, EXP PARASITOL, V88, P69, DOI 10.1006/expr.1998.4203; BILKER O, 1997, PARSSITOLOGY, V115, P1; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Dammann C, 2003, PLANT PHYSIOL, V132, P1840, DOI 10.1104/pp.103.020008; DOERIG C, 1995, MOL BIOCHEM PARASIT, V70, P167, DOI 10.1016/0166-6851(95)00033-W; Farber PM, 1997, MOL BIOCHEM PARASIT, V87, P211, DOI 10.1016/S0166-6851(97)00052-2; Farmer PK, 1999, BBA-PROTEIN STRUCT M, V1434, P6, DOI 10.1016/S0167-4838(99)00166-1; FRANKEFAYARD B, 2004, IN PRESS MOL BIOCH P; Gantt S, 2000, INFECT IMMUN, V68, P3667, DOI 10.1128/IAI.68.6.3667-3673.2000; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; Hotta CT, 2000, NAT CELL BIOL, V2, P466, DOI 10.1038/35017112; JANSE CJ, 1986, MOL BIOCHEM PARASIT, V20, P173, DOI 10.1016/0166-6851(86)90029-0; KAWAMOTO F, 1990, MOL BIOCHEM PARASIT, V42, P101, DOI 10.1016/0166-6851(90)90117-5; KAWAMOTO F, 1993, EUR J CELL BIOL, V60, P101; Kieschnick H, 2001, J BIOL CHEM, V276, P12369, DOI 10.1074/jbc.M011045200; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Li JL, 2000, BBA-GENE STRUCT EXPR, V1491, P341, DOI 10.1016/S0167-4781(00)00032-4; Lovett JL, 2003, J CELL SCI, V116, P3009, DOI 10.1242/jcs.00596; LUDWIG AA, 2003, J EXP BOT, V55, P1; MARTIN SK, 1994, J PARASITOL, V80, P371, DOI 10.2307/3283406; Moudy R, 2001, J BIOL CHEM, V276, P41492, DOI 10.1074/jbc.M106154200; Muhia DK, 2001, MOL MICROBIOL, V42, P553, DOI 10.1046/j.1365-2958.2001.02665.x; Romeis T, 2001, EMBO J, V20, P5556, DOI 10.1093/emboj/20.20.5556; SINDEN RE, 1976, PROC R SOC SER B-BIO, V193, P55, DOI 10.1098/rspb.1976.0031; Sinden Robert E, 2002, Methods Mol Med, V72, P25, DOI 10.1385/1-59259-271-6:25; THOMPSON J, 1994, MOL BIOCHEM PARASIT, V68, P189, DOI 10.1016/0166-6851(94)90164-3; Tomas AM, 2001, EMBO J, V20, P3975, DOI 10.1093/emboj/20.15.3975; Tucker WC, 2002, BIOCHEM J, V366, P1, DOI 10.1042/BJ20020776; van Spaendonk RML, 2001, J BIOL CHEM, V276, P22638, DOI 10.1074/jbc.M101234200; WINGER LA, 1988, PARASITE IMMUNOL, V10, P193, DOI 10.1111/j.1365-3024.1988.tb00214.x; WOODS A, 1989, J CELL SCI, V93, P491; ZHAO Y, 1994, MOL BIOCHEM PARASIT, V66, P329, DOI 10.1016/0166-6851(94)90159-7; ZHAO Y, 1994, BIOCHEMISTRY-US, V33, P3714, DOI 10.1021/bi00178a031; ZHAO Y, 1993, J BIOL CHEM, V268, P4347; [No title captured]	41	346	358	0	28	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	2004	117	4					503	514		10.1016/S0092-8674(04)00449-0	http://dx.doi.org/10.1016/S0092-8674(04)00449-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137943	Bronze			2022-12-28	WOS:000221458000010
J	MacDonald, IR; Bohrmann, G; Escobar, E; Abegg, F; Blanchon, P; Blinova, V; Bruckmann, W; Drews, M; Eisenhauer, A; Han, X; Heeschen, K; Meier, F; Mortera, C; Naehr, T; Orcutt, B; Bernard, B; Brooks, J; de Farago, M				MacDonald, IR; Bohrmann, G; Escobar, E; Abegg, F; Blanchon, P; Blinova, V; Bruckmann, W; Drews, M; Eisenhauer, A; Han, X; Heeschen, K; Meier, F; Mortera, C; Naehr, T; Orcutt, B; Bernard, B; Brooks, J; de Farago, M			Asphalt volcanism and chemosynthetic life in the Campeche Knolls, Gulf of Mexico	SCIENCE			English	Article							OIL; SEEPS	In the Campeche Knolls, in the southern Gulf of Mexico, lava-like flows of solidified asphalt cover more than 1 square kilometer of the rim of a dissected salt dome at a depth of 3000 meters below sea level. Chemosynthetic tubeworms and bivalves colonize the sea floor near the asphalt, which chilled and contracted after discharge. The site also includes oil seeps, gas hydrate deposits, locally anoxic sediments, and slabs of authigenic carbonate. Asphalt volcanism creates a habitat for chemosynthetic life that may be widespread at great depth in the Gulf of Mexico.	Texas A&M Univ, Phys & Life Sci Dept, Corpus Christi, TX 78412 USA; Univ Bremen, Fachbereich Geowissensch 5, D-28334 Bremen, Germany; Univ Nacl Autonoma Mexico, Inst Ciencias Mar & Limnol, Mexico City 045510, DF, Mexico; Inst Ciencias Mar & Limnol, Cancun, DF, Mexico; Leibniz Inst Meereswissensch, IFM, GEOMAR, D-24148 Kiel, Germany; State Ocean Adm, Inst Oceanog 2, Zhejiang 310012, Peoples R China; Univ Nacl Autonoma Mexico, Inst Geofis, Mexico City 04510, DF, Mexico; Univ Georgia, Athens, GA 30602 USA; TDI Brooks Int Inc, College Stn, TX 77845 USA; Aurensis SA, Madrid 28003, Spain	Texas A&M University System; University of Bremen; Universidad Nacional Autonoma de Mexico; Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; State Oceanic Administration; Universidad Nacional Autonoma de Mexico; University System of Georgia; University of Georgia	MacDonald, IR (corresponding author), Texas A&M Univ, Phys & Life Sci Dept, 6300 Ocean Dr, Corpus Christi, TX 78412 USA.	imacdonald@falcon.tamucc.edu	Eisenhauer, Anton/K-6454-2012; Han, Xiqiu/AIB-2819-2022; Orcutt, Beth N/A-4051-2011; Bohrmann, Gerhard/D-4474-2017; Naehr, Thomas/C-2958-2008; Blanchon, Paul/B-7720-2009	Han, Xiqiu/0000-0001-9285-0915; Orcutt, Beth N/0000-0002-6233-3578; Bohrmann, Gerhard/0000-0001-9976-4948; Mortera Gutierrez, Carlos Angel Quintil/0000-0002-8522-004X; Brueckmann, Warner/0000-0001-6636-8148; Blanchon, Paul/0000-0002-7792-5808; Escobar Briones, Elva/0000-0002-8485-7495				Aharon P, 2000, GEOCHIM COSMOCHIM AC, V64, P233, DOI 10.1016/S0016-7037(99)00292-6; Bergquist DC, 2003, MAR ECOL-P S Z N I, V24, P31, DOI 10.1046/j.1439-0485.2003.03800.x; BOUMA AH, 1969, T GULF COAST ASS GEO, V19, P115; Bryant W. R., 1991, GULF MEXICO BASIN, P13; COLE GA, 2001, WORLD OIL, P69; EWING TE, 1991, GEOLOGY N AM, VJ, P31, DOI DOI 10.1130/DNAG-GNA-J.31; Grajales-Nishimura JM, 2000, GEOLOGY, V28, P307, DOI 10.1130/0091-7613(2000)028<0307:CITOOR>2.3.CO;2; Homafius J.S., 1999, J GEOPHYS RES, V20, P20; JOYE SB, IN PRESS CHEM GEOL; MacDonald IR, 2003, MAR GEOL, V198, P133, DOI 10.1016/S0025-3227(03)00098-7; MACDONALD IR, 1993, J GEOPHYS RES-OCEANS, V98, P16351, DOI 10.1029/93JC01289; MACGREGOR DS, 1993, MAR PETROL GEOL, V10, P606, DOI 10.1016/0264-8172(93)90063-X; PEQUEGNAT WE, 1978, CONRIB MAR SCI, V22, P63; Sloan E.D., 1998, CLATHRATE HYDRATES N, P705; *TDI BROOKS INT, 2001, 01698 TDI BROOKS INT	15	106	114	3	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	2004	304	5673					999	1002		10.1126/science.1097154	http://dx.doi.org/10.1126/science.1097154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143278				2022-12-28	WOS:000221383300045
J	Chini, R; Hoffmeister, V; Kimeswenger, S; Nielbock, M; Nurnberger, D; Schmidtobreick, L; Sterzik, M				Chini, R; Hoffmeister, V; Kimeswenger, S; Nielbock, M; Nurnberger, D; Schmidtobreick, L; Sterzik, M			The formation of a massive protostar through the disk accretion of gas	NATURE			English	Article							TAURI MAGNETOSPHERIC ACCRETION; EMISSION-LINE DIAGNOSTICS; STAR-FORMATION; STELLAR OBJECTS; YOUNG STARS; REGION	The formation of low-mass stars like our Sun can be explained by the gravitational collapse of a molecular cloud fragment into a protostellar core and the subsequent accretion of gas and dust from the surrounding interstellar medium(1-3). Theoretical considerations suggest that the radiation pressure from the protostar on the in-falling material may prevent the formation of stars above ten solar masses through this mechanism(4), although some calculations have claimed that stars up to 40 solar masses can in principle be formed via accretion through a disk(5-7). Given this uncertainty and the fact that most massive stars are born in dense clusters, it was suggested that high-mass stars are the result of the runaway merging of intermediate-mass stars(8). Here we report observations that clearly show a massive star being born from a large rotating accretion disk. The protostar has already assembled about 20 solar masses, and the accretion process is still going on. The gas reservoir of the circumstellar disk contains at least 100 solar masses of additional gas, providing sufficient fuel for substantial further growth of the forming star.	Ruhr Univ Bochum, Astron Inst, D-44780 Bochum, Germany; Univ Innsbruck, Inst Astrophys, A-6020 Innsbruck, Austria; European So Observ, Santiago 19, Chile	Ruhr University Bochum; University of Innsbruck; European Southern Observatory	Chini, R (corresponding author), Ruhr Univ Bochum, Astron Inst, D-44780 Bochum, Germany.	chini@astro.rub.de	Kimeswenger, of/K-7393-2013; Nielbock, Markus/GRR-3301-2022	Sterzik, Michael F./0000-0002-5784-4437; Nielbock, Markus/0000-0002-1271-1825; Kimeswenger, Stefan/0000-0003-2379-0474; Schmidtobreick, Linda/0000-0002-6713-4754				Bonnell IA, 1998, MON NOT R ASTRON SOC, V298, P93, DOI 10.1046/j.1365-8711.1998.01590.x; Calvet N., 1997, IAU S, V182, P417; Chini R, 1998, ASTRON ASTROPHYS, V329, P161; GEHRZ RD, 1982, ASTROPHYS J, V254, P550, DOI 10.1086/159765; Greenhill LJ, 1998, NATURE, V396, P650, DOI 10.1038/25299; HAMANN F, 1992, ASTROPHYS J SUPPL S, V82, P285, DOI 10.1086/191716; Hanson MM, 1997, ASTROPHYS J, V489, P698, DOI 10.1086/304808; HARTIGAN P, 1995, ASTROPHYS J, V452, P736, DOI 10.1086/176344; HARTMANN L, 1994, ASTROPHYS J, V426, P669, DOI 10.1086/174104; Hofner P, 2001, ASTROPHYS J, V549, P425, DOI 10.1086/319065; Jijina J, 1996, ASTROPHYS J, V462, P874, DOI 10.1086/177201; Larson R. B., 2003, ASP C SER, V287, P65; LARSON RB, 1969, MON NOT R ASTRON SOC, V145, P297, DOI 10.1093/mnras/145.3.297; MARTI J, 1993, ASTROPHYS J, V416, P208, DOI 10.1086/173227; Muzerolle J, 2001, ASTROPHYS J, V550, P944, DOI 10.1086/319779; Muzerolle J, 1998, ASTRON J, V116, P455, DOI 10.1086/300428; NAKANO T, 1995, ASTROPHYS J, V450, P183, DOI 10.1086/176130; Sandell G, 2003, ASTROPHYS J, V590, pL45, DOI 10.1086/376612; Shepherd DS, 2001, SCIENCE, V292, P1513, DOI 10.1126/science.1059475; SHU FH, 1987, ANNU REV ASTRON ASTR, V25, P23, DOI 10.1146/annurev.aa.25.090187.000323; Siebenmorgen R, 2000, ASTRON ASTROPHYS, V364, P625; WOLFIRE MG, 1987, ASTROPHYS J, V319, P850, DOI 10.1086/165503; Yorke HW, 2002, ASTROPHYS J, V569, P846, DOI 10.1086/339264	23	104	104	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	2004	429	6988					155	157		10.1038/nature02507	http://dx.doi.org/10.1038/nature02507			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141204				2022-12-28	WOS:000221356300033
J	Banks, E; Beral, V; Reeves, G; Balkwill, A; Barnes, I				Banks, E; Beral, V; Reeves, G; Balkwill, A; Barnes, I		Million Women Study Collaborators	Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN PLUS PROGESTIN; INITIATIVE RANDOMIZED-TRIAL; BONE-MINERAL DENSITY; REPLACEMENT THERAPY; HIP FRACTURE; RISK; METAANALYSIS; FOREARM; BREAST; CANCER	Context Evidence is limited on the effects of different patterns of use of postmenopausal hormone therapy on fracture incidence and particularly on the effects of ceasing use. Objective To investigate the effect of different patterns of hormone therapy use on fracture incidence. Design, Setting, and Participants Prospective study of 138737 postmenopausal women aged 50 to 69 years recruited from the UK general population in 19961998 (the Million Women Study) and followed up for 1.9 to 3.9 years (average, 2.8 years) for fracture incidence. Main Outcome Measure Adjusted relative risk (RR) for incident fracture (except fracture of the fingers, toes, and ribs) in hormone therapy users compared with never users at baseline. Results A total of 5197 women (3.7%) reported 1 or more fractures, 79% resulting from falls. Current users of hormone therapy at baseline had a significantly reduced incidence of fracture (RR, 0.62; 95% confidence interval [CI], 0.58-0.66; P<.001). This protection was evident soon after hormone therapy began, and the RR decreased with increasing duration of use (P=.001). Among current users at baseline the RR of fracture did not vary significantly according to whether estrogen-only, estrogen-progestin, or other types of hormones were used (RR [95% CI], 0.64 [0.58-0.71], 0.58 [0.53-0.64], and 0.67 [0.56-0.80], respectively; P=19), nor did it vary significantly according to estrogen dose or estrogen or progestin constituents. The RR associated with current use of hormone therapy did not vary significantly according to 11 personal characteristics of study participants, including their age at menopause, body mass index, and physical activity. Past users of hormone therapy at baseline experienced no significant protection against fractures (RR, 1.07; 95% CI, 0.99-1.15); incidence rates returned to those of never-users within about a year of ceasing use. Conclusions All types of hormone therapy studied confer substantial protection against fracture while they are used. This protection appears rapidly after use commences and wears off rapidly after use ceases. The older women are, the greater is their absolute reduction in fracture incidence while using hormone therapy.	Radcliffe Infirm, Epidemiol Unit, Canc Res UK, Oxford OX2 6HE, England; Univ Reading, Sch Appl Stat, Reading, Berks, England	Cancer Research UK; Radcliffe Infirmary; University of Reading	Banks, E (corresponding author), Radcliffe Infirm, Epidemiol Unit, Canc Res UK, Oxford OX2 6HE, England.	emily.banks@anu.edu.au		Balkwill, Angela/0000-0002-6327-6245; Banks, Emily/0000-0002-4617-1302				Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Banks E, 2001, J Epidemiol Biostat, V6, P357; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Honkanen K, 1999, AM J EPIDEMIOL, V150, P511; Keegan THM, 2003, OSTEOPOROSIS INT, V14, P469, DOI 10.1007/s00198-003-1379-2; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; MEHTA D, 1999, BRIT NATL FORMULARY; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; *STAT CORP, 2003, STAT STAT SOFTW REL; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Townsend PP., 1988, HLTH DEPRIVATION INE; Tremollieres FA, 2001, OSTEOPOROSIS INT, V12, P385, DOI 10.1007/s001980170107; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001-5002	22	91	95	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2004	291	18					2212	2220		10.1001/jama.291.18.2212	http://dx.doi.org/10.1001/jama.291.18.2212			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GR	15138243	Bronze			2022-12-28	WOS:000221303500023
J	Kalra, L; Evans, A; Perez, I; Melbourn, A; Patel, A; Knapp, M; Donaldson, N				Kalra, L; Evans, A; Perez, I; Melbourn, A; Patel, A; Knapp, M; Donaldson, N			Training care givers of stroke patients: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SUPPORT; SURVIVORS; IMPACT	Background Informal care givers support disabled stroke patients at home but receive little training for the caregiving role. Objective To evaluate the effectiveness of training care givers in reducing burden of stroke in patients and their care givers. Design A single, blind, randomised controlled trial. Setting Stroke rehabilitation unit. Subjects 300 stroke patients and their care givers. Interventions Training care givers in basic nursing and facilitation of personal care techniques. Main outcome measures Cost to health and social services, caregiving burden, patients' and care givers' functional status (Barthel index, Frenchay activities index), psychological state (hospital anxiety and depression score), quality of life (EuroQol visual analogue scale) and patients' institutionalisation or mortality at one year. Results Patients were comparable for age (median 76 years; interquartile range 70-82 years), sex (53% men), and severity of stroke (median Barthel index 8; interquartile range 4-12). The costs of care over one year for patients whose care givers had received training were significantly lower (pound10133 v pound13794 ($18087 v $24619; C15204 v C20697); P=0.001). Trained care givers experienced less caregiving burden (care giver burden score 32 v 41; P=0.0001), anxiety (anxiety score 3 v 4; P=0.0001) or depression (depression score 2 v 3; P=0.0001) and had a higher quality of life (EuroQol score 80 v 70; P=0.001). Patients' mortality, institutionalisation, and disability were not influenced by caregiver training. However, patients reported less anxiety (3 v 4.5; P<0.0001) and depression (3 v 4; P<0.0001) and better quality of life (65 v 60; P=0.009) in the caregiver training group. Conclusion Training care givers during patients' rehabilitation reduced costs and caregiver burden while improving psychosocial outcomes in care givers and patients at one year.	Guys Kings & St Thomass Sch Med, Dept Med, London SE5 9PJ, England; Kings Coll London, Inst Psychiat, Ctr Econ Mental Hlth, London WC2R 2LS, England; Kings Coll Hosp London, Biostat Unit, Dept Res & Dev, London SE5 9RS, England; Orpington Hosp, Bromley Hosp NHS Trust, Bromley BR6 9JU, England	University of London; King's College London; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital	Kalra, L (corresponding author), Guys Kings & St Thomass Sch Med, Dept Med, London SE5 9PJ, England.	lalit.kalra@kcl.ac.uk	Knapp, Martin RJ/G-3011-2011; Patel, Anita/F-9832-2010	Knapp, Martin/0000-0003-1427-0215; Patel, Anita/0000-0003-0769-1732				ANDERSON CS, 1995, STROKE, V26, P843, DOI 10.1161/01.STR.26.5.843; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BOSANQUET N, 1998, STROKE CARE REDUCING; Dennis M, 1997, BRIT MED J, V314, P1071, DOI 10.1136/bmj.314.7087.1071; Dewey HM, 2002, STROKE, V33, P1028, DOI 10.1161/01.STR.0000013067.24300.B0; Duncan PW, 2000, STROKE, V31, P1429, DOI 10.1161/01.STR.31.6.1429; Forster A, 1996, BRIT MED J, V312, P1642, DOI 10.1136/bmj.312.7047.1642; FORSTER A, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001919; FRIEDLAND JF, 1992, ARCH PHYS MED REHAB, V73, P573; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Higginson IJ, 2001, BRIT MED J, V322, P1297, DOI 10.1136/bmj.322.7297.1297; Kavanagh S, 1999, J PUBLIC HEALTH MED, V21, P385, DOI 10.1093/pubmed/21.4.385; Kerr SM, 2001, CLIN REHABIL, V15, P428, DOI 10.1191/026921501678310234; Low JTS, 1999, SOC SCI MED, V49, P711, DOI 10.1016/S0277-9536(99)00194-X; Mant J, 2000, LANCET, V356, P808, DOI 10.1016/S0140-6736(00)02655-6; Patel A, 2004, BMJ-BRIT MED J, V328, P1102, DOI 10.1136/bmj.328.7448.1102; Persson U, 1990, Int J Technol Assess Health Care, V6, P125; Reimer WJMSO, 1998, STROKE, V29, P1605, DOI 10.1161/01.STR.29.8.1605; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Simon Chantal, 2002, Br J Community Nurs, V7, P292; van den Heuvel ETP, 2001, CLIN REHABIL, V15, P669, DOI 10.1191/0269215501cr446oa; WADE DT, 1986, BRIT MED J, V293, P418, DOI 10.1136/bmj.293.6544.418; Wade DT., 1992, MEASUREMENT NEUROLOG; WELLWOOD I, 1995, AGE AGEING, V24, P519, DOI 10.1093/ageing/24.6.519; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	25	243	249	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	2004	328	7448					1099	1101		10.1136/bmj.328.7448.1099	http://dx.doi.org/10.1136/bmj.328.7448.1099			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130977	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000221281000015
J	Skop, AR; Liu, HB; Yates, J; Meyer, BJ; Heald, R				Skop, AR; Liu, HB; Yates, J; Meyer, BJ; Heald, R			Dissection of the mammalian midbody proteome reveals conserved cytokinesis mechanisms	SCIENCE			English	Article							FUNCTIONAL GENOMIC ANALYSIS; CAENORHABDITIS-ELEGANS; FISSION YEAST; LIPID RAFTS; CELL-DIVISION; HUMAN HOMOLOG; CLEAVAGE; MITOSIS; PROTEINS; EXPRESSION	Cytokinesis is the essential process that partitions cellular contents into daughter cells. To identify and characterize cytokinesis proteins rapidly, we used a functional proteomic and comparative genomic strategy. Midbodies were isolated from mammalian cells, proteins were identified by multidimensional protein identification technology ( MudPIT), and protein function was assessed in Caenorhabditis elegans. Of 172 homologs disrupted by RNA interference, 58% displayed defects in cleavage furrow formation or completion, or germline cytokinesis. Functional dissection of the midbody demonstrated the importance of lipid rafts and vesicle trafficking pathways in cytokinesis, and the utilization of common membrane cytoskeletal components in diverse morphogenetic events in the cleavage furrow, the germline, and neurons.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Scripps Research Institute	Skop, AR (corresponding author), Univ Wisconsin, Dept Genet, Madison, WI 53706 USA.	skop@wisc.edu	Skop, Ahna Renee/X-3305-2019	Skop, Ahna Renee/0000-0003-3522-4939; Heald, Rebecca/0000-0001-6671-6528; Meyer, Barbara/0000-0002-6530-4588	NCRR NIH HHS [P41 RR011823, RR1823] Funding Source: Medline; NIGMS NIH HHS [F32 GM064159-03, F32 GM064159-01, F32 GM64159-01, F32 GM064159-02, F32 GM064159] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM064159] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aumais JP, 2003, J CELL SCI, V116, P1991, DOI 10.1242/jcs.00412; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; BASU J, 1988, BIOCHIM BIOPHYS ACTA, V945, P121, DOI 10.1016/0005-2736(88)90474-9; Bednarek SY, 2002, TRAFFIC, V3, P621, DOI 10.1034/j.1600-0854.2002.30904.x; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; BIELIAVSKY N, 1990, J SUBMICR CYTOL PATH, V22, P445; Brandt R, 2001, CELL TISSUE RES, V305, P255, DOI 10.1007/s004410000334; BRAWLEY SH, 1977, J CELL SCI, V24, P275; Breen EC, 2003, J CELL BIOCHEM, V88, P848, DOI 10.1002/jcb.10398; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chang F, 2001, CELL STRUCT FUNCT, V26, P539, DOI 10.1247/csf.26.539; DAN K, 1990, ANN NY ACAD SCI, V582, P108; EARNSHAW WC, 1991, J CELL SCI, V98, P443; Feng B, 2002, EXP CELL RES, V279, P14, DOI 10.1006/excr.2002.5579; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Flemming W., 1891, ARCH MIKROSK ANAT, V37, P685, DOI [DOI 10.1007/BF02954311, 10.1007/BF02954311]; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Girardot N, 2003, NEUROPATH APPL NEURO, V29, P451, DOI 10.1046/j.1365-2990.2003.00479.x; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Jiang M, 2003, BIOCHEM BIOPH RES CO, V309, P196, DOI 10.1016/S0006-291X(03)01559-6; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; KOCH GLE, 1987, J CELL SCI, V87, P491; Kuwabara PE, 2000, GENE DEV, V14, P1933; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Li N, 2003, PROTEOMICS, V3, P536, DOI 10.1002/pmic.200390067; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; LoTurco JJ, 2003, CEREB CORTEX, V13, P588, DOI 10.1093/cercor/13.6.588; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; Machesky LM, 1998, CURR BIOL, V8, pR202, DOI 10.1016/S0960-9822(98)70125-3; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Matuliene J, 2002, MOL BIOL CELL, V13, P1832, DOI 10.1091/mbc.01-10-0504; Melchionda S, 2001, AM J HUM GENET, V69, P635, DOI 10.1086/323156; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Miller RK, 2000, MOL BIOL CELL, V11, P2949, DOI 10.1091/mbc.11.9.2949; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; MULLINS JM, 1982, J CELL BIOL, V94, P654, DOI 10.1083/jcb.94.3.654; Nebenfuhr A, 2000, PLANT PHYSIOL, V124, P135, DOI 10.1104/pp.124.1.135; Osman MA, 1998, J CELL BIOL, V142, P443, DOI 10.1083/jcb.142.2.443; Paweletz N, 2001, NAT REV MOL CELL BIO, V2, P72, DOI 10.1038/35048077; Peretti D, 2000, J CELL BIOL, V149, P141, DOI 10.1083/jcb.149.1.141; Peyrl A, 2002, ELECTROPHORESIS, V23, P152, DOI 10.1002/1522-2683(200201)23:1<152::AID-ELPS152>3.0.CO;2-T; Piano F, 2000, CURR BIOL, V10, P1619, DOI 10.1016/S0960-9822(00)00869-1; PICKETTHEAPS J, 1981, EUR J CELL BIOL, V25, P150; Rajendran L, 2003, P NATL ACAD SCI USA, V100, P8241, DOI 10.1073/pnas.1331629100; Seidl P, 2002, INT J CANCER, V102, P129, DOI 10.1002/ijc.10675; SELLITTO C, 1988, J CELL BIOL, V106, P431, DOI 10.1083/jcb.106.2.431; Sharp DJ, 1997, J CELL SCI, V110, P2373; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sisson JC, 1999, CELL BIOL INT, V23, P871, DOI 10.1006/cbir.1999.0484; Skop AR, 2001, CURR BIOL, V11, P735, DOI 10.1016/S0960-9822(01)00231-7; Skop AR, 1998, CURR BIOL, V8, P1110, DOI 10.1016/S0960-9822(98)70465-8; Staehlin LA, 1996, CELL, V84, P821, DOI 10.1016/S0092-8674(00)81060-0; Thompson HM, 2002, CURR BIOL, V12, P2111, DOI 10.1016/S0960-9822(02)01390-8; Thurmond DC, 2001, MOL MEMBR BIOL, V18, P237; Velichkova M, 2002, CELL MOTIL CYTOSKEL, V51, P147, DOI 10.1002/cm.10025; Wachtler V, 2003, J CELL SCI, V116, P867, DOI 10.1242/jcs.00299; Walling HW, 1998, J NEUROSCI RES, V54, P301, DOI 10.1002/(SICI)1097-4547(19981101)54:3<301::AID-JNR1>3.0.CO;2-W; Wheatley SP, 2001, EXP CELL RES, V262, P122, DOI 10.1006/excr.2000.5088; Won M, 2001, BIOCHEM BIOPH RES CO, V282, P10, DOI 10.1006/bbrc.2001.4535	66	369	500	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					61	66		10.1126/science.1097931	http://dx.doi.org/10.1126/science.1097931			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15166316	Green Accepted			2022-12-28	WOS:000222386000033
J	Joffe, S; Harrington, DP; George, SL; Emanuel, EJ; Budzinski, LA; Weeks, JC				Joffe, S; Harrington, DP; George, SL; Emanuel, EJ; Budzinski, LA; Weeks, JC			Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; EQUIPOISE; ETHICS; PERSPECTIVE; ONCOLOGY; THERAPY; REASONS; SURGERY	Objective To assess whether publicly funded adult cancer trials satisfy the uncertainty principle, which states that physicians should enrol a patient in a trial only if they are substantially uncertain which of the treatments in the trial is most appropriate for the patient. This principle is violated if trials systematically favour either the experimental or the standard treatment. Design Retrospective cohort study of completed cancer trials, with randomisation as the unit of analysis. Setting Two cooperative research groups in the United States. Studies included 93 phase III randomised trials (103 randomisations) that completed recruitment of patients between 1981 and 1995. Main outcome measures Whether the randomisation favoured the experimental treatment, the standard treatment, or neither treatment; effect size (outcome of the experimental treatment compared with outcome of the standard treatment) for each randomisation. Results Three randomisations (3%) favoured the standard treatment, 70 (68%) found no significant difference between treatments, and 30 (29%) favoured the experimental treatment. The average effect size was 1.20 (95% confidence interval 1.13 to 1.28), reflecting a slight advantage for the experimental treatment. Conclusions In cooperative group trials in adults with cancer, there is a measurable average improvement in disease control associated with assignment to the experimental rather than the standard arm. However, the heterogeneity of outcomes and the small magnitude of the advantage suggest that, as a group, these trials satisfy the uncertainty principle.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Durham, NC 27710 USA; Lesley Coll, Cambridge, MA 02138 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Ctr Stat, Canc & Leukemia Grp B, Durham, NC 27710 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; Harvard University; Dana-Farber Cancer Institute	Joffe, S (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.	steven_joffe@dfci.harvard.edu	Joffe, Steven/H-3941-2019	Joffe, Steven/0000-0002-0667-7384	NATIONAL CANCER INSTITUTE [U10CA033601, K01CA096872, U10CA023318] Funding Source: NIH RePORTER; NCI NIH HHS [CA33601, CA23318, CA96872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alderson P, 1996, J MED ETHICS, V22, P135, DOI 10.1136/jme.22.3.135; Als-Nielsen B, 2003, JAMA-J AM MED ASSOC, V290, P921, DOI 10.1001/jama.290.7.921; Chalmers I, 1997, BRIT MED J, V314, P74, DOI 10.1136/bmj.314.7073.74a; CHLEBOWSKI RT, 1994, J CLIN ONCOL, V12, P1789, DOI 10.1200/JCO.1994.12.9.1789; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; Edwards SJ., 1998, HEALTH TECHNOL ASSES, V2, P1; ENKIN MW, 2000, BMJ-BRIT MED J, V321, P757; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Fried C., 1974, MED EXPT PERSONAL IN; GILBERT JP, 1977, SCIENCE, V198, P684, DOI 10.1126/science.333585; GOTAY CC, 1991, SOC SCI MED, V33, P569, DOI 10.1016/0277-9536(91)90214-W; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; HUNTER CP, 1987, CANCER TREAT REP, V71, P559; Jenkins V, 2000, BRIT J CANCER, V82, P1783, DOI 10.1054/bjoc.2000.1142; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Lee SJ, 2000, STAT SCI, V15, P95; Lilford RJ, 2003, BRIT MED J, V326, P980, DOI 10.1136/bmj.326.7396.980; Machin D, 1997, Clin Oncol (R Coll Radiol), V9, P100; MARQUIS D, 1983, HASTINGS CENT REP, V13, P40, DOI 10.2307/3561721; Miller FG, 2003, HASTINGS CENT REP, V33, P19, DOI 10.2307/3528434; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; TAYLOR KM, 1984, NEW ENGL J MED, V310, P1363, DOI 10.1056/NEJM198405243102106; Ubel PA, 1997, J INVEST MED, V45, P561; Welch HG, 2002, BMJ-BRIT MED J, V324, P1088, DOI 10.1136/bmj.324.7345.1088	24	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	2004	328	7454					1463	1466		10.1136/bmj.38118.685289.55	http://dx.doi.org/10.1136/bmj.38118.685289.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15163611	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000222244600014
J	Lelieveld, J; van Aardenne, J; Fischer, H; de Reus, M; Williams, J; Winkler, P				Lelieveld, J; van Aardenne, J; Fischer, H; de Reus, M; Williams, J; Winkler, P			Increasing ozone over the Atlantic Ocean	SCIENCE			English	Article							TROPICAL TROPOSPHERIC OZONE; CHEMICAL-TRANSPORT MODEL; BOUNDARY-LAYER; SURFACE OZONE; TRENDS; TOMS; STRATOSPHERE; EMISSIONS; PARADOX; OH	Ship-borne ozone (O-3) measurements over the Atlantic Ocean during the period from 1977 to 2002 show that O-3 trends in the northern mid-latitudes are small. In contrast, remarkably large O-3 trends occur at low latitudes and in the Southern Hemisphere, where near-surface O-3 has increased by up to a factor of 2. The likely cause is the substantial increase of anthropogenic emissions of nitrogen oxides (NOx) associated with energy use in Africa, which has added to NOx from biomass burning and natural sources.	Max Planck Inst Chem, Dept Atmospher Chem, D-55218 Mainz, Germany; German Weather Serv, Meteorol Observ, D-82383 Hohenpeissenberg, Germany	Max Planck Society; Deutscher Wetterdienst	Lelieveld, J (corresponding author), Max Planck Inst Chem, Dept Atmospher Chem, D-55218 Mainz, Germany.	lelieveld@mpch-mainz.mpg.de	Williams, Jonathan/K-7686-2017; Lelieveld, Jos/A-1986-2013	Williams, Jonathan/0000-0001-9421-1703; Lelieveld, Jos/0000-0001-6307-3846				BRASSEUR GP, 2003, ATMOSPHERIC CHEM CHA; Brauers T, 2001, J GEOPHYS RES-ATMOS, V106, P7399, DOI 10.1029/2000JD900679; Burkert J, 2001, J GEOPHYS RES-ATMOS, V106, P5457, DOI 10.1029/2000JD900613; Chandra S, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000447; CRUTZEN P, 1973, PURE APPL GEOPHYS, V106, P1385, DOI 10.1007/BF00881092; Duncan BN, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002378; Edwards DP, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002927; Endresen O, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002898; Fiore AM, 1998, J GEOPHYS RES-ATMOS, V103, P1471, DOI 10.1029/97JD03036; Fishman J, 1997, J GEOPHYS RES-ATMOS, V102, P19275, DOI 10.1029/97JD01373; FISHMAN J, 1979, TELLUS, V31, P432, DOI 10.1111/j.2153-3490.1979.tb00922.x; Fusco AC, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002742; HASTENRATH S, 1985, CLIMATE CIRCULATION; Hauglustaine DA, 1998, J GEOPHYS RES-ATMOS, V103, P28291, DOI 10.1029/98JD02398; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; Jenkins GS, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003297; JUNGE CE, 1962, TELLUS, V14, P363, DOI 10.3402/tellusa.v14i4.9563; Lee S, 1998, GEOPHYS RES LETT, V25, P1637, DOI 10.1029/98GL01224; Lelieveld J, 2000, J GEOPHYS RES-ATMOS, V105, P3531, DOI 10.1029/1999JD901011; LIU SC, 1987, J GEOPHYS RES-ATMOS, V92, P4191, DOI 10.1029/JD092iD04p04191; LOGAN JA, 1994, J GEOPHYS RES-ATMOS, V99, P25553, DOI 10.1029/94JD02333; Ma JZ, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001354; Martin RV, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001480; Marufu L, 2000, J GEOPHYS RES-ATMOS, V105, P14513, DOI 10.1029/1999JD901055; Oltmans SJ, 1998, GEOPHYS RES LETT, V25, P139, DOI 10.1029/97GL03505; PEIOXOTO JP, 1992, PHYS CLIMATE; Staehelin J, 2001, REV GEOPHYS, V39, P231, DOI 10.1029/1999RG000059; STAEHELIN J, 1994, ATMOS ENVIRON, V28, P75, DOI 10.1016/1352-2310(94)90024-8; Stohl A, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001396; Thompson AM, 2000, GEOPHYS RES LETT, V27, P3317, DOI 10.1029/1999GL011273; Thompson AM, 1999, J GEOPHYS RES-ATMOS, V104, P26961, DOI 10.1029/1999JD900470; Trainer M, 2000, ATMOS ENVIRON, V34, P2045, DOI 10.1016/S1352-2310(99)00459-8; van Aardenne JA, 2001, GLOBAL BIOGEOCHEM CY, V15, P909, DOI 10.1029/2000GB001265; Wang YH, 1998, J GEOPHYS RES-ATMOS, V103, P31123, DOI 10.1029/1998JD100004; Waugh DW, 2000, GEOPHYS RES LETT, V27, P3857, DOI 10.1029/2000GL012250; WINKLER P, 1988, J ATMOS CHEM, V7, P73, DOI 10.1007/BF00048255; WMO, 2003, SCI ASS OZ DEPL 2002; Ziemke JR, 1998, J GEOPHYS RES-ATMOS, V103, P22115, DOI 10.1029/98JD01567	38	105	106	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1483	1487		10.1126/science.1096777	http://dx.doi.org/10.1126/science.1096777			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15143217				2022-12-28	WOS:000221795800038
J	Banks, E; Reeves, G; Beral, V; Bull, D; Crossley, B; Simmonds, M; Hilton, E; Bailey, S; Barren, N; Briers, P; English, R; Jackson, A; Kutt, E; Lavelle, J; Rockall, L; Wallis, MG; Wilson, M; Patnick, J				Banks, E; Reeves, G; Beral, V; Bull, D; Crossley, B; Simmonds, M; Hilton, E; Bailey, S; Barren, N; Briers, P; English, R; Jackson, A; Kutt, E; Lavelle, J; Rockall, L; Wallis, MG; Wilson, M; Patnick, J			Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the million women study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CANCER		Radcliffe Infirm, Canc Res UK Epidemiol Unit, Oxford OX2 6HE, England; Princess Wales Community Hosp, Breast Screening Serv, Bromsgrove B61 0BB, England; Charing Cross Hosp, W London Breast Screening Serv, London W6 8RF, England; Gloucestershire Breast Screening Serv, Cheltenham GL53 7AS, Glos, England; Churchill Hosp, Oxford Radcliffe Hosp NHS Trust, Breast Care Unit, Oxford OX3 7JH, England; Queen Alexandra Hosp, Patricia Massey Breast Screening Unit, Portsmouth PO6 3LY, Hants, England; Cent Hlth Clin, Avon Breast Screening, Bristol BS2 0JD, Avon, England; Royal Lancaster Infirm, N Lancashire Breast Screening Serv, Lancaster LA1 4GG, England; Worthing Dist Hosp, W Sussex Breast Screening Serv, Worthing BN11 2DH, England; Coventry & Warwick Hosp, Breast Screening Unit, Coventry CV1 4FH, W Midlands, England; Nightingale Ctr, Greater Manchester Breast Screening Serv, Manchester M20 0PT, Lancs, England; NHS Breast Screening Programme, Sheffield S11 9PS, S Yorkshire, England	Cancer Research UK; Radcliffe Infirmary; Imperial College London; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	Banks, E (corresponding author), Radcliffe Infirm, Canc Res UK Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.	emily.banks@anu.edu.au		Banks, Emily/0000-0002-4617-1302				Abbott S, 2002, BJOG-INT J OBSTET GY, V109, P1319; Banks E, 2001, J MED SCREEN, V8, P29, DOI 10.1136/jms.8.1.29; McCann J, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr455; PATNICK J, 2002, 2002 NHS BREAST SCRE; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16	5	23	24	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	2004	328	7451					1291	1292		10.1136/bmj.328.7451.1291	http://dx.doi.org/10.1136/bmj.328.7451.1291			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826PN	15166064	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000221841100019
J	Xu, WH; Zheng, W; Xiang, YB; Ruan, ZM; Cheng, JR; Dai, Q; Gao, YT; Shu, XO				Xu, WH; Zheng, W; Xiang, YB; Ruan, ZM; Cheng, JR; Dai, Q; Gao, YT; Shu, XO			Soya food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; PHYTOESTROGENS; ISOFLAVONES; ASSOCIATION; HORMONES; FIBER	Objective To evaluate the association of intake of soya food, a rich source of phytoestrogens, with the risk of endometrial cancer. Design Population based case-control study, with detailed information on usual soya food intake over the past five years collected by face to face interview using a food frequency questionnaire. Setting Urban Shanghai, China. Participants 832 incident cases of endometrial cancer in women aged 30 to 69 years diagnosed during 1997-2001 and identified from the Shanghai Cancer Registry; 846 control women frequency matched to cases on age and randomly selected from the Shanghai Residential Registry. Main outcome measures Odds ratios for risk of endometrial cancer in women with different intakes of soya foods. Results Regular consumption of soya foods, measured as amount of either soya protein or soya isoflavones, was inversely associated with the risk of endometrial cancer. Compared with women with the lowest quarter of intake, the adjusted odds ratio of endometrial cancer was reduced from 0.93 to 0.85 and 0.67 with increasing quarter of soya protein intake (P for trend 0.01). A similar inverse association was observed for soya isoflavones and soya fibre intake. The inverse association seemed to be more pronounced among women with high body mass index and waist:hip ratio. Conclusion Regular intake of soya foods is associated with a reduced risk of endometrial cancer.	Vanderbilt Univ, Vanderbilt Ctr Hlth Serv Res, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA; Shanghai Canc Inst, Dept Epidemiol, Shanghai 200032, Peoples R China	Vanderbilt University; Shanghai Jiao Tong University	Shu, XO (corresponding author), Vanderbilt Univ, Vanderbilt Ctr Hlth Serv Res, Vanderbilt Ingram Canc Ctr, Dept Med, 6009 Med Ctr E,1215 21st Ave S, Nashville, TN 37232 USA.	Yiao-Ou.Shu@vanderbilt.edu	Zheng, Wei/O-3351-2013; zhang, weihua/GXV-1334-2022; Gao, Yu/HGE-1937-2022	Zheng, Wei/0000-0003-1226-070X; xu, wanghong/0000-0003-2045-2218	NATIONAL CANCER INSTITUTE [R01CA092585] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA92585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLERCREUTZ H, 1991, AM J CLIN NUTR, V54, P1093, DOI 10.1093/ajcn/54.6.1093; Adlercreutz H, 1997, ANN MED, V29, P95, DOI 10.3109/07853899709113696; ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; ALELSON M, 1983, J ENDOCRINOL, V102, P49; AXELSON M, 1984, J ENDOCRINOL, V102, P49, DOI 10.1677/joe.0.1020049; Burton JL, 2002, J CLIN PATHOL, V55, P401, DOI 10.1136/jcp.55.6.401; Chen Z, 1999, NUTR CANCER, V33, P82, DOI 10.1080/01635589909514752; CHEN Z, 1909, NUTR CANC, V33, P2; *CHIN AC MED SCI, 1991, FOOD COMP TABL; Dai Q, 2001, BRIT J CANCER, V85, P372, DOI 10.1054/bjoc.2001.1873; GOLDIN BR, 1982, NEW ENGL J MED, V307, P1542, DOI 10.1056/NEJM198212163072502; Goodman MT, 1997, AM J EPIDEMIOL, V146, P294, DOI 10.1093/oxfordjournals.aje.a009270; Hale GE, 2002, J CLIN ENDOCR METAB, V87, P3, DOI 10.1210/jc.87.1.3; HENDERSON BE, 1982, CANCER RES, V42, P3232; Horn-Ross PL, 2003, J NATL CANCER I, V95, P1158, DOI 10.1093/jnci/djg015; KAKU T, 1993, INT J GYNECOL PATHOL, V12, P297, DOI 10.1097/00004347-199310000-00003; KELLY GE, 1995, P SOC EXP BIOL MED, V208, P40, DOI 10.3181/00379727-208-43829; Kumar NB, 2002, CANCER-AM CANCER SOC, V94, P1166, DOI 10.1002/cncr.10320; MARKIEWICZ L, 1993, J STEROID BIOCHEM, V45, P399, DOI 10.1016/0960-0760(93)90009-L; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; Parkin DM, 1997, CANC INCIDENCE 5 CON, VVII; Potischman N, 1996, JNCI-J NATL CANCER I, V88, P756, DOI 10.1093/jnci/88.11.756; Potischman N, 1996, J NATL CANCER I, V88, P1127, DOI 10.1093/jnci/88.16.1127; ROSE DP, 1990, NUTR CANCER, V13, P1, DOI 10.1080/01635589009514040; Shu XO, 2004, EUR J CLIN NUTR, V58, P17, DOI 10.1038/sj.ejcn.1601738; XIAO OS, 1993, AM J EPIDEMIOL, V137, P155, DOI 10.1093/oxfordjournals.aje.a116655	26	75	86	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	2004	328	7451					1285	1288		10.1136/bmj.38093.646215.AE	http://dx.doi.org/10.1136/bmj.38093.646215.AE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826PN	15136343	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000221841100017
J	Yoo, HY; Kumagai, A; Shevchenko, A; Shevchenko, A; Dunphy, WG				Yoo, HY; Kumagai, A; Shevchenko, A; Shevchenko, A; Dunphy, WG			Adaptation of a DNA replication checkpoint response depends upon inactivation of Claspin by the Polo-like kinase	CELL			English	Article							XENOPUS EGG EXTRACTS; DOUBLE-STRAND BREAK; CELL-FREE-EXTRACTS; DAMAGE CHECKPOINT; CHK1; ATR; ARREST; PHOSPHORYLATION; PROTEIN; MRC1	The checkpoint mediator protein Claspin is essential for the ATR-dependent activation of Chk1 in Xenopus egg extracts containing aphidicolin-induced DNA replication blocks. We show that, during this checkpoint response, Claspin becomes phosphorylated on threonine 906 (T906), which creates a docking site for Plx1, the Xenopus Polo-like kinase. This interaction promotes the phosphorylation of Claspin on a nearby serine (S934) by Plx1. After a prolonged interphase arrest, aphidicolin-treated egg extracts typically undergo adaptation and enter into mitosis despite the presence of incompletely replicated DNA. In this process, Claspin dissociates from chromatin, and Chk1 undergoes inactivation. By contrast, aphidicolin-treated extracts containing mutants of Claspin with alanine substitutions at positions 906 or 934 (T906A or S934A) are unable to undergo adaptation. Under such adaptation-defective conditions, Claspin accumulates on chromatin at high levels, and Chk1 does not decrease in activity. These results indicate that the Plx1-dependent inactivation of Claspin results in termination of a DNA replication checkpoint response.	CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	California Institute of Technology; Max Planck Society	Dunphy, WG (corresponding author), CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA.	dunphy@cco.caltech.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043974, R37GM043974] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43974] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Canman CE, 2003, CURR BIOL, V13, pR488, DOI 10.1016/S0960-9822(03)00410-X; Caspari T, 2002, GENE DEV, V16, P1195, DOI 10.1101/gad.221402; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Liu QH, 2000, GENE DEV, V14, P1448; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Shevchenko A, 2001, ANAL CHEM, V73, P1917, DOI 10.1021/ac0013709; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shevchenko Anna, 2003, Methods Mol Biol, V211, P221; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5	36	178	182	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					575	588		10.1016/S0092-8674(04)00417-9	http://dx.doi.org/10.1016/S0092-8674(04)00417-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163406	Bronze			2022-12-28	WOS:000221857900005
J	Louie, T				Louie, T			Twilight on North Second	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												tedlouie@msn.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2004	291	20					2411	2412		10.1001/jama.291.20.2411	http://dx.doi.org/10.1001/jama.291.20.2411			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823HB	15161874				2022-12-28	WOS:000221599700001
J	Terry, MB; Gammon, MD; Zhang, FF; Tawfik, H; Teitelbaum, SL; Britton, JA; Subbaramaiah, K; Dannenberg, AJ; Neugut, AI				Terry, MB; Gammon, MD; Zhang, FF; Tawfik, H; Teitelbaum, SL; Britton, JA; Subbaramaiah, K; Dannenberg, AJ; Neugut, AI			Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PREVENT COLORECTAL ADENOMAS; RANDOMIZED-TRIAL; CYCLOOXYGENASE-2; METAANALYSIS; AROMATASE; TARGET; TUMOR; STAGE; GENE	Context Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with a decrease in the risk of several cancers, including breast cancer. NSAIDs inhibit cyclooxygenase activity and thereby reduce prostaglandin synthesis; prostaglandins stimulate aromatase gene expression and thereby stimulate estrogen biosynthesis. Given the importance of estrogen in the pathogenesis of breast cancer, the ability of aspirin and other NSAIDs to protect against breast cancer could vary according to hormone receptor status. Objectives To determine the association between the frequency and duration of use of aspirin and other NSAIDs and breast cancer risk and to investigate whether any observed association is more pronounced for women with hormone receptor-positive breast cancers. Design, Setting, and Patients Population-based case-control study of women with breast cancer, including in-person interviews conducted on Long Island, NY, during 1996-1997 (1442 cases and 1420 controls). Main Outcome Measure Incident invasive and in situ breast cancer by aspirin and NSAID use and hormone receptor status. Results Ever use of aspirin or other NSAIDs at least once per week for 6 months or longer was reported in 301 cases (20.9%) and 345 controls (24.3%) (odds ratio [OR], 0.80; 95% confidence interval [Cl], 0.66-0.97 for ever vs nonusers). The inverse association was most pronounced among frequent users (greater than or equal to7 tablets per week) (OR, 0.72; 95% Cl, 0.58-0.90). The results for ibuprofen, which was used by fewer women on a regular basis, were generally weaker (OR, 0.78; 95% Cl, 0.55-1.10 for <3 times per week vs OR, 0.92; 95% Cl, 0.70-1.22 for >= 3 times per week). Use of acetaminophen, an analgesic that does not inhibit prostaglandin synthesis, was not associated with a reduction in the incidence of breast cancer. The reduction in risk with aspirin use was seen among those with hormone receptor-positive tumors (OR, 0.74; 95% Cl, 0.60-0.93) but not for women with hormone receptor-negative tumors (OR, 0.97; 95% Cl, 0.67-1.40). Conclusion These data add to the growing evidence that supports the regular use of aspirin and other NSAIDs (which may operate through inhibition of estrogen biosynthesis) as effective chemopreventive agents for breast cancer.	Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; CUNY Mt Sinai Sch Med, Dept Community Med, New York, NY USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA; Strang Canc Prevent Ctr, New York, NY USA	Columbia University; Columbia University; Columbia University; University of North Carolina; University of North Carolina Chapel Hill; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Cornell University	Neugut, AI (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, 722 W 168th St, New York, NY 10032 USA.	ainq@columbia.edu		Terry, Mary Beth/0000-0002-4106-5033	NATIONAL CANCER INSTITUTE [K07CA090685, K05CA089155, U01CA066572, R01CA089578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA/ES66572, K07 CA90685-02, K05 CA89155, R01 CA89578] Funding Source: Medline; NIEHS NIH HHS [P30 ES10126] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baron JA, 2003, PROG EXP TUMOR RES, V37, P1; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Boolbol SK, 1996, CANCER RES, V56, P2556; Brueggemeier RW, 1999, CANCER LETT, V140, P27, DOI 10.1016/S0304-3835(99)00050-6; CARTER CA, 1983, CANCER RES, V43, P3559; Coogan PF, 1999, PREV MED, V29, P72, DOI 10.1006/pmed.1999.0518; Cotterchio M, 2001, CANCER EPIDEM BIOMAR, V10, P1213; Daniel WW., 1991, BIOSTATISTICS FDN AN; Derry S, 2000, BMJ-BRIT MED J, V321, P1183, DOI 10.1136/bmj.321.7270.1183; Egan KM, 1996, J NATL CANCER I, V88, P988, DOI 10.1093/jnci/88.14.988; Elvin JA, 2000, P NATL ACAD SCI USA, V97, P10288, DOI 10.1073/pnas.180295197; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; Gammon MD, 2002, BREAST CANCER RES TR, V74, P235, DOI 10.1023/A:1016387020854; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Harris RE, 2003, CANCER RES, V63, P6096; HARRIS RE, 1995, PREV MED, V24, P119, DOI 10.1006/pmed.1995.1022; Harris RE, 1996, EPIDEMIOLOGY, V7, P203, DOI 10.1097/00001648-199603000-00017; Harris RE, 1999, ONCOL REP, V6, P71; HOSMER DW, 1989, APPL LOGISTIC REGRES; Howe LR, 2001, ENDOCR-RELAT CANCER, V8, P97, DOI 10.1677/erc.0.0080097; Johnson TW, 2002, CANCER EPIDEM BIOMAR, V11, P1586; Langman MJS, 2000, BRIT MED J, V320, P1642, DOI 10.1136/bmj.320.7250.1642; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; ROSENBERG L, 1995, PREV MED, V24, P107, DOI 10.1006/pmed.1995.1018; Rosenberg L, 1996, J NATL CANCER I, V88, P941, DOI 10.1093/jnci/88.14.941; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Sanmuganathan PS, 2001, HEART, V85, P265, DOI 10.1136/heart.85.3.265; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Sharpe CR, 2000, BRIT J CANCER, V83, P112; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Zhao Y, 1996, ENDOCRINOLOGY, V137, P5739, DOI 10.1210/en.137.12.5739	32	213	224	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2004	291	20					2433	2440		10.1001/jama.291.20.2433	http://dx.doi.org/10.1001/jama.291.20.2433			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823HB	15161893				2022-12-28	WOS:000221599700025
J	Grann, M; Fazel, S				Grann, M; Fazel, S			Substance misuse and violent crime: Swedish population study	BRITISH MEDICAL JOURNAL			English	Article									Karolinska Inst, Ctr Violence Prevent, SE-10435 Stockholm, Sweden; Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England	Karolinska Institutet; University of Oxford	Grann, M (corresponding author), Karolinska Inst, Ctr Violence Prevent, POB 23000, SE-10435 Stockholm, Sweden.	martin.grann@cvp.se	Fazel, Seena/B-5307-2008	Fazel, Seena/0000-0002-5383-5365				Farrell M, 1998, BMJ-BRIT MED J, V316, P1399, DOI 10.1136/bmj.316.7142.1399; Gossop M, 2003, ADDICTION, V98, P291, DOI 10.1046/j.1360-0443.2003.00296.x; GRANN M, 1998, SCANDINAVIAN J FOREN, V3, P78; Rothman K., 1998, MODERN EPIDEMIOLOGY; Steadman HJ, 1998, ARCH GEN PSYCHIAT, V55, P393, DOI 10.1001/archpsyc.55.5.393	5	80	83	1	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 22	2004	328	7450					1233	1234		10.1136/bmj.328.7450.1233	http://dx.doi.org/10.1136/bmj.328.7450.1233			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824HL	15155501	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000221677200019
J	Che, S; Liu, Z; Ohsuna, T; Sakamoto, K; Terasaki, O; Tatsumi, T				Che, S; Liu, Z; Ohsuna, T; Sakamoto, K; Terasaki, O; Tatsumi, T			Synthesis and characterization of chiral mesoporous silica	NATURE			English	Article							CATALYSIS; ZEOLITE	Chirality is widely expressed in organic materials, perhaps most notably in biological molecules such as DNA, and in proteins, owing to the homochirality of their components (D-sugars and L-amino acids). But the occurrence of large-scale chiral pores in inorganic materials is rare(1). Although some progress has been made in strategies to synthesize helical and chiral zeolite-like materials(1-3), the synthesis of enantiomerically pure mesoporous materials is a challenge that remains unsolved(4). Here we report the surfactant-templated synthesis of ordered chiral mesoporous silica, together with a general approach for the structural analysis of chiral mesoporous crystals by electron microscopy. The material that we have synthesized has a twisted hexagonal rodlike morphology, with diameter 130-180 nm and length 1-6 mum. Transmission electron microscopy combined with computer simulations confirm the presence of hexagonally ordered chiral channels of 2.2 nm diameter winding around the central axis of the rods. Our findings could lead to new uses for mesoporous silica and other chiral pore materials in, for example, catalysis and separation media, where both shape selectivity and enantio-selectivity(5) can be applied to the manufacturing of enantiomerically pure chemicals and pharmaceuticals.	Shanghai Jiao Tong Univ, Sch Chem & Chem Technol, Dept Chem, Shanghai 200240, Peoples R China; Bussan Nanotech Res Inst, Tsukuba, Ibaraki 3050074, Japan; Univ Stockholm, Arrhenius Lab, S-10691 Stockholm, Sweden; Ajinomoto Co Inc, AminoSci Lab, Kawasaki, Kanagawa 2108681, Japan; Yokohama Natl Univ, Fac Engn, Div Mat Sci & Chem Engn, JST,CREST, Yokohama, Kanagawa 2408501, Japan	Shanghai Jiao Tong University; Stockholm University; Ajinomoto Co Inc; Japan Science & Technology Agency (JST); Yokohama National University	Che, S (corresponding author), Shanghai Jiao Tong Univ, Sch Chem & Chem Technol, Dept Chem, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.	chesa@sjtu.edu.cn	Liu, Zheng/E-6119-2018; Terasaki, Osamu/Y-1137-2018	Liu, Zheng/0000-0001-9095-7647; Terasaki, Osamu/0000-0001-5803-0817				Acharya D. P, 2003, J OLEO SCI, V52, P407; Baiker A, 1998, CURR OPIN SOLID ST M, V3, P86, DOI 10.1016/S1359-0286(98)80070-3; Che S, 2003, NAT MATER, V2, P801, DOI 10.1038/nmat1022; DAVIS ME, 1993, ACCOUNTS CHEM RES, V26, P111, DOI 10.1021/ar00027a006; Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785; Gier TE, 1998, NATURE, V395, P154, DOI 10.1038/25960; Iwahashi M., 2003, J OLEO SCI, V51, P705; SAKAMOTO K, 1980, B CHEM SOC JPN, V53, P339, DOI 10.1246/bcsj.53.339; Shin HJ, 2001, J AM CHEM SOC, V123, P1246, DOI 10.1021/ja003461t; Tian BZ, 2004, J AM CHEM SOC, V126, P865, DOI 10.1021/ja037877t; TRACEY AS, 1992, J PHYS CHEM-US, V96, P3889, DOI 10.1021/j100188a058; Wang Y, 2003, ANGEW CHEM INT EDIT, V42, P4089, DOI 10.1002/anie.200351643	12	679	707	22	657	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 20	2004	429	6989					281	284		10.1038/nature02529	http://dx.doi.org/10.1038/nature02529			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152248				2022-12-28	WOS:000221505900038
J	Szathmary, E; Hammerstein, P				Szathmary, E; Hammerstein, P			Obituary - John Maynard Smith (1920-2004)	NATURE			English	Biographical-Item									Coll Budapest, Budapest, Hungary; Eotvos Lorand Univ, H-1364 Budapest, Hungary; Humboldt Univ, Inst Theoret Biol, D-10115 Berlin, Germany	Eotvos Lorand University; Humboldt University of Berlin	Szathmary, E (corresponding author), Coll Budapest, Szentharomsag Utca 2, Budapest, Hungary.	szathmary@colbud.hu; p.hammerstein@biologie.hu-berlin.de	Szathmáry, Eörs/A-5007-2011; Szathmary, Eors/AAS-1202-2021	Szathmary, Eors/0000-0001-5227-2997				SMITH J, PUBLICATION LIST	1	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 20	2004	429	6989					258	259		10.1038/429258a	http://dx.doi.org/10.1038/429258a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152239				2022-12-28	WOS:000221505900029
J	Skeff, KM; Ezeji-Okoye, S; Pompei, P; Rockson, S				Skeff, KM; Ezeji-Okoye, S; Pompei, P; Rockson, S			Benefits of resident work hours regulation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PATIENT-CARE; MEDICINE; PROGRAM		Stanford Univ, Med Ctr, Stanford, CA 94305 USA	Stanford University	Skeff, KM (corresponding author), Stanford Univ, Med Ctr, 300 Pasteur Dr,Room S101, Stanford, CA 94305 USA.			rockson, stanley/0000-0003-1253-474X				Baldwin DC, 2003, ACAD MED, V78, P1154, DOI 10.1097/00001888-200311000-00018; Berwick DM, 2003, QUAL SAF HEALTH CARE, V12, P448, DOI 10.1136/qhc.12.6.448; Clever LH, 2002, ANN INTERN MED, V136, P391, DOI 10.7326/0003-4819-136-5-200203050-00012; Cruess RL, 1999, ACAD MED, V74, P878, DOI 10.1097/00001888-199908000-00010; DaRosa DA, 2003, SURGERY, V133, P13, DOI 10.1067/msy.2003.67; GURJALA A, 2001, HRG PUBLICATION, V1570; Johnson T, 2003, ACAD MED, V78, P3, DOI 10.1097/00001888-200301000-00002; LAINE C, 1993, JAMA-J AM MED ASSOC, V269, P374, DOI 10.1001/jama.269.3.374; Lawrence Hal C 3rd, 2003, Curr Womens Health Rep, V3, P487; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; Souba WW, 2002, ACAD MED, V77, P139, DOI 10.1097/00001888-200202000-00008; Whang EE, 2003, J AM COLL SURGEONS, V197, P624, DOI 10.1016/S1072-7515(03)00602-1	14	29	29	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					816	817		10.7326/0003-4819-140-10-200405180-00012	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148069				2022-12-28	WOS:000221520900007
J	Huang, LR; Cox, EC; Austin, RH; Sturm, JC				Huang, LR; Cox, EC; Austin, RH; Sturm, JC			Continuous particle separation through deterministic lateral displacement	SCIENCE			English	Article							FIELD-FLOW FRACTIONATION; SIZE; DIFFUSION; DISPERSION	We report on a microfluidic particle-separation device that makes use of the asymmetric bifurcation of laminar flow around obstacles. A particle chooses its path deterministically on the basis of its size. All particles of a given size follow equivalent migration paths, leading to high resolution. The microspheres of 0.8, 0.9, and 1.0 micrometers that were used to characterize the device were sorted in 40 seconds with a resolution of similar to10 nanometers, which was better than the time and resolution of conventional flow techniques. Bacterial artificial chromosomes could be separated in 10 minutes with a resolution of similar to12%.	Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Princeton Inst Sci & Technol Mat, Dept Phys, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University	Huang, LR (corresponding author), Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA.				NHGRI NIH HHS [HG01506] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001506] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ARIS R, 1956, PROC R SOC LON SER-A, V235, P67, DOI 10.1098/rspa.1956.0065; Baba M, 2003, APPL PHYS LETT, V83, P1468, DOI 10.1063/1.1602555; Berg H. C., 1993, RANDOM WALKS BIOL, p[56, 83]; Blom MT, 2003, ANAL CHEM, V75, P6761, DOI 10.1021/ac034663l; Chou CF, 1999, P NATL ACAD SCI USA, V96, P13762, DOI 10.1073/pnas.96.24.13762; DiMarzio E. A., 1970, MACROMOLECULES, V3, P131; Dupont AL, 2004, J CHROMATOGR A, V1026, P129, DOI 10.1016/j.chroma.2003.11.002; FEYNMAN RP, 1966, FEYNMAN LECT PHYS, V2, pCH41; GIDDINGS JC, 1959, NATURE, V184, P357, DOI 10.1038/184357a0; GIDDINGS JC, 1993, SCIENCE, V260, P1456, DOI 10.1126/science.8502990; Happel J., 1983, LOW REYNOLDS NUMBER; HEFTMANN E, 1983, CHROMATOGRAPHY FUNDA; Huang LR, 2003, ANAL CHEM, V75, P6963, DOI 10.1021/ac0348524; Huang LR, 2002, NAT BIOTECHNOL, V20, P1048, DOI 10.1038/nbt733; Janca J, 2003, J COLLOID INTERF SCI, V260, P317, DOI 10.1016/S0021-9797(02)00216-3; KIM YS, 1995, ANAL CHEM, V67, P784, DOI 10.1021/ac00101a002; Osoegawa K, 2000, GENOME RES, V10, P116; PERKINS TK, 1963, SOC PETROL ENG J, V3, P70, DOI 10.2118/480-PA; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sano T, 2003, APPL PHYS LETT, V83, P4438, DOI 10.1063/1.1629379; SATTELLE DB, 1991, BIOCHEM SOC T, V19, P501, DOI 10.1042/bst0190501; TAYLOR G, 1953, PROC R SOC LON SER-A, V219, P186, DOI 10.1098/rspa.1953.0139; van Oudenaarden A, 1999, SCIENCE, V285, P1046, DOI 10.1126/science.285.5430.1046	24	1195	1323	27	550	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					987	990		10.1126/science.1094567	http://dx.doi.org/10.1126/science.1094567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143275				2022-12-28	WOS:000221383300041
J	Watts, C				Watts, C			The bell tolls for phagosome maturation	SCIENCE			English	Editorial Material							INNATE IMMUNITY; RECEPTOR; PHAGOCYTOSIS; RECOGNITION; INDUCTION; PATHOGENS		Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Watts, C (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	c.watts@dundee.ac.uk		Watts, Colin/0000-0001-6183-2087				Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Fratti RA, 2003, J BIOL CHEM, V278, P46961, DOI 10.1074/jbc.M305225200; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Rosenberger CM, 2003, NAT REV MOL CELL BIO, V4, P385, DOI 10.1038/nrm1104; Shiratsuchi A, 2004, J IMMUNOL, V172, P2039, DOI 10.4049/jimmunol.172.4.2039; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; TOBLAN AA, 2003, J IMMUNOL, V171, P1413; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; WEST M, UNPUB	17	12	13	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	2004	304	5673					976	977		10.1126/science.1098573	http://dx.doi.org/10.1126/science.1098573			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143270				2022-12-28	WOS:000221383300035
J	Bennewith, O; Gunnell, D; Peters, TJ; Hawton, K; House, A				Bennewith, O; Gunnell, D; Peters, TJ; Hawton, K; House, A			Variations in the hospital management of self harm in adults in England: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England; Univ Oxford, Warneford Hosp, Dept Psychiat, Ctr Suicide Res, Oxford OX3 7JX, England; Univ Leeds, Acad Unit Psychiat & Behav Sci, Leeds LS2 9JT, W Yorkshire, England	University of Bristol; University of Bristol; University of Oxford; University of Leeds	Gunnell, D (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	D.J.Gunnell@Bristol.ac.uk	Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470; Peters, Tim/0000-0003-2881-4180; House, Allan/0000-0001-8721-8026				Department of Health, 2002, NAT SUIC PREV STRAT; Gunnell DJ, 1996, J EPIDEMIOL COMMUN H, V50, P24, DOI 10.1136/jech.50.1.24; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Kapur N, 1998, BRIT MED J, V316, P831, DOI 10.1136/bmj.316.7134.831; *ROYAL COLL PSYCH, 1994, GEN HOSP MAN AD SELF	5	70	72	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	2004	328	7448					1108	1109		10.1136/bmj.328.7448.1108	http://dx.doi.org/10.1136/bmj.328.7448.1108			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130979	Green Accepted, Green Published, Green Submitted, Bronze			2022-12-28	WOS:000221281000020
J	Covert, MW; Knight, EM; Reed, JL; Herrgard, MJ; Palsson, BO				Covert, MW; Knight, EM; Reed, JL; Herrgard, MJ; Palsson, BO			Integrating high-throughput and computational data elucidates bacterial networks	NATURE			English	Article							IN-SILICO MODELS; ESCHERICHIA-COLI; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; REGULATORY NETWORK; DISCOVERY; GENOTYPE; ROLES; ARCA; FNR	The flood of high-throughput biological data has led to the expectation that computational ( or in silico) models can be used to direct biological discovery, enabling biologists to reconcile heterogeneous data types, find inconsistencies and systematically generate hypotheses(1-3). Such a process is fundamentally iterative, where each iteration involves making model predictions, obtaining experimental data, reconciling the predicted outcomes with experimental ones, and using discrepancies to update the in silico model. Here we have reconstructed, on the basis of information derived from literature and databases, the first integrated genome-scale computational model of a transcriptional regulatory and metabolic network. The model accounts for 1,010 genes in Escherichia coli, including 104 regulatory genes whose products together with other stimuli regulate the expression of 479 of the 906 genes in the reconstructed metabolic network. This model is able not only to predict the outcomes of high-throughput growth phenotyping and gene expression experiments, but also to indicate knowledge gaps and identify previously unknown components and interactions in the regulatory and metabolic networks. We find that a systems biology approach that combines genome-scale experimentation and computation can systematically generate hypotheses on the basis of disparate data sources.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Palsson, BO (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.	palsson@ucsd.edu	Reed, Jennifer L/E-5137-2011	Reed, Jennifer L/0000-0001-7854-6220; Palsson, Bernhard/0000-0003-2357-6785; Covert, Markus/0000-0002-5993-8912				Bar-Joseph Z, 2003, NAT BIOTECHNOL, V21, P1337, DOI 10.1038/nbt890; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bochner BR, 2003, NAT REV GENET, V4, P309, DOI 10.1038/nrg1046; Burgard AP, 2001, BIOTECHNOL PROGR, V17, P791, DOI 10.1021/bp0100880; Burgard AP, 2001, BIOTECHNOL BIOENG, V74, P364, DOI 10.1002/bit.1127; COMPAN I, 1994, MOL MICROBIOL, V11, P955, DOI 10.1111/j.1365-2958.1994.tb00374.x; Cotter PA, 1997, MOL MICROBIOL, V25, P605, DOI 10.1046/j.1365-2958.1997.5031860.x; Covert MW, 2002, J BIOL CHEM, V277, P28058, DOI 10.1074/jbc.M201691200; Covert MW, 2001, J THEOR BIOL, V213, P73, DOI 10.1006/jtbi.2001.2405; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Forster Jochen, 2003, OMICS A Journal of Integrative Biology, V7, P193, DOI 10.1089/153623103322246584; Glasner JD, 2003, NUCLEIC ACIDS RES, V31, P147, DOI 10.1093/nar/gkg125; Griffin TJ, 2002, MOL CELL PROTEOMICS, V1, P323, DOI 10.1074/mcp.M200001-MCP200; Gutierrez-Rios RM, 2003, GENOME RES, V13, P2435, DOI 10.1101/gr.1387003; Herrgard MJ, 2003, GENOME RES, V13, P2423, DOI 10.1101/gr.1330003; Ideker T, 2001, ANNU REV GENOM HUM G, V2, P343, DOI 10.1146/annurev.genom.2.1.343; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Palsson B, 2000, NAT BIOTECHNOL, V18, P1147, DOI 10.1038/81125; Price ND, 2003, TRENDS BIOTECHNOL, V21, P162, DOI 10.1016/S0167-7799(03)00030-1; Reed JL, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r54; Reed JL, 2003, J BACTERIOL, V185, P2692, DOI 10.1128/JB.185.9.2692-2699.2003; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881	30	582	606	6	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 6	2004	429	6987					92	96		10.1038/nature02456	http://dx.doi.org/10.1038/nature02456			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129285				2022-12-28	WOS:000221222100051
J	Kodambaka, S; Khare, SV; Swiech, W; Ohmori, K; Petrov, I; Greene, JE				Kodambaka, S; Khare, SV; Swiech, W; Ohmori, K; Petrov, I; Greene, JE			Dislocation-driven surface dynamics on solids	NATURE			English	Article							ELECTRON-MICROSCOPE; GROWTH	Dislocations(1) are line defects that bound plastically deformed regions in crystalline solids. Dislocations terminating on the surface of materials can strongly influence nanostructural and interfacial stability, mechanical properties, chemical reactions, transport phenomena, and other surface processes. While most theoretical and experimental studies have focused on dislocation motion in bulk solids under applied stress(2,3) and step formation due to dislocations at surfaces during crystal growth(4-7), very little is known about the effects of dislocations on surface dynamics and morphological evolution. Here we investigate the near-equilibrium dynamics of surface-terminated dislocations using low-energy electron microscopy(8). We observe, in real time, the thermally driven nucleation and shape-preserving growth of spiral steps rotating at constant temperature-dependent angular velocities around cores of dislocations terminating on the (111) surface of TiN in the absence of applied external stress or net mass change. We attribute this phenomenon to point-defect migration from the bulk to the surface along dislocation lines. Our results demonstrate that dislocation-mediated surface roughening can occur even in the absence of deposition or evaporation, and provide fundamental insights into mechanisms controlling nanostructural stability.	Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA; Univ Illinois, Dept Mat Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kodambaka, S (corresponding author), Univ Illinois, Frederick Seitz Mat Res Lab, 104 S Goodwin Ave, Urbana, IL 61801 USA.	kodambak@uiuc.edu	Petrov, Ivan/D-4910-2011; Ohmori, Kenji/M-6291-2014	Petrov, Ivan/0000-0002-2955-4897; Ohmori, Kenji/0000-0002-5312-319X				BARDEEN J, 1952, IMPERFECTIONS NEARLY, pCH10; BAUER E, 1994, REP PROG PHYS, V57, P895, DOI 10.1088/0034-4885/57/9/002; Bulatov V, 1998, NATURE, V391, P669, DOI 10.1038/35577; BURTON WK, 1951, PHILOS T R SOC S-A, V243, P299, DOI 10.1098/rsta.1951.0006; COTTRELL AH, 1953, DISLOCATIONS PLASTIC, pCH1; FRANK FC, 1950, PHYS REV, V79, P722, DOI 10.1103/PhysRev.79.722; Gall D, 2003, J APPL PHYS, V93, P9086, DOI 10.1063/1.1567797; Giesen M, 2001, PROG SURF SCI, V68, P1, DOI 10.1016/S0079-6816(00)00021-6; HULL D, 1984, INTRO DISLOCATIONS, pCH8; INDENBOM VL, 1992, ELASTIC STRAIN FIELD, pCH10; Justo JF, 2001, MAT SCI ENG A-STRUCT, V309, P129, DOI 10.1016/S0921-5093(00)01738-X; Kodambaka S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.176102; Kodambaka S, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.146101; Lagow BW, 2001, MAT SCI ENG A-STRUCT, V309, P445, DOI 10.1016/S0921-5093(00)01699-3; McCarty KF, 2001, NATURE, V412, P622, DOI 10.1038/35088026; Pina CM, 1998, NATURE, V395, P483, DOI 10.1038/26718; SUNDGREN JE, 1986, PHYSICS CHEM PROTECT, P95; Teng HH, 1998, SCIENCE, V282, P724, DOI 10.1126/science.282.5389.724; TROMP RM, 1991, ULTRAMICROSCOPY, V36, P99, DOI 10.1016/0304-3991(91)90141-R; VERMA AR, 1951, NATURE, V167, P939, DOI 10.1038/167939a0; WEERTMAN J, 1964, ELEMENTARY DISLOCATI, pCH6; ZINKEALLMANG M, 1992, SURF SCI REP, V16, P377, DOI 10.1016/0167-5729(92)90006-W	22	34	34	6	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	2004	429	6987					49	52		10.1038/nature02495	http://dx.doi.org/10.1038/nature02495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129275				2022-12-28	WOS:000221222100039
J	Polley, DB; Kvasnak, E; Frostig, RD				Polley, DB; Kvasnak, E; Frostig, RD			Naturalistic experience transforms sensory maps in the adult cortex of caged animals	NATURE			English	Article							DEPENDENT SYNAPTIC PLASTICITY; SOMATOSENSORY CORTEX; BARREL CORTEX; RAT; ORGANIZATION; STIMULATION; MOUSE; SI; ENVIRONMENTS; SUPPRESSION	Much of what is known about the functional organization and plasticity of adult sensory cortex is derived from animals housed in standard laboratory cages(1,2). Here we report that the transfer of adult rats reared in standard laboratory cages to a naturalistic habitat modifies the functional and morphological organization of the facial whisker representation in the somatosensory 'barrel' cortex. Cortical whisker representations, visualized with repeated intrinsic signal optical imaging in the same animals, contracted by 46% after four to six weeks of exposure to the naturalistic habitat. Acute, multi-site extracellular recordings demonstrated suppressed evoked neuronal responses and smaller, sharper constituent receptive fields in the upper cortical layers (II/III), but not in the thalamic recipient layer (IV), of rats with naturalistic experience. Morphological plasticity of the layer IV barrel field was observed, but on a substantially smaller scale than the functional plasticity. Thus, transferring animals to an environment that promotes the expression of natural, innate behaviours induces a large-scale functional refinement of cortical sensory maps.	Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Polley, DB (corresponding author), Univ Calif San Francisco, Keck Ctr Integrat Neurosci, 513 Parnassus Ave, San Francisco, CA 94143 USA.	dpolley@phy.ucsf.edu	Kvasnak, Eugen/B-4207-2018	Kvasnak, Eugen/0000-0001-9855-6362; Polley, Daniel/0000-0002-5120-2409				ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; BEAULIEU C, 1990, DEV BRAIN RES, V53, P71, DOI 10.1016/0165-3806(90)90125-I; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; Brett-Green BA, 2001, J NEUROSCI, V21, P9944, DOI 10.1523/JNEUROSCI.21-24-09944.2001; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Castro-Alamancos MA, 2002, J NEUROSCI, V22, P9651; Castro-Alamancos MA, 2002, J PHYSIOL-LONDON, V541, P319, DOI 10.1113/jphysiol.2002.016857; Chen-Bee CH, 2000, J NEUROSCI METH, V97, P157, DOI 10.1016/S0165-0270(00)00180-1; Coq JO, 1998, EXP BRAIN RES, V121, P191, DOI 10.1007/s002210050452; DIAMOND ME, 1993, P NATL ACAD SCI USA, V90, P2082, DOI 10.1073/pnas.90.5.2082; Fanselow EE, 1999, J NEUROSCI, V19, P7603, DOI 10.1523/JNEUROSCI.19-17-07603.1999; FOX K, 1992, J NEUROSCI, V12, P1826; FOX K, 1994, J NEUROSCI, V14, P7665; Frostig RD, 2002, METH NE FRO NEUROSCI, P21; Glazewski S, 1996, J NEUROPHYSIOL, V75, P1714, DOI 10.1152/jn.1996.75.4.1714; GREEN EJ, 1983, BRAIN RES, V264, P233, DOI 10.1016/0006-8993(83)90821-1; JEANMONOD D, 1981, NEUROSCIENCE, V6, P1503, DOI 10.1016/0306-4522(81)90222-0; KAAS JH, 2000, NEW COGNITIVE NEUROS, P223; Knott GW, 2002, NEURON, V34, P265, DOI 10.1016/S0896-6273(02)00663-3; KOSSUT M, 1988, J NEUROPHYSIOL, V60, P829, DOI 10.1152/jn.1988.60.2.829; LAND PW, 1985, J COMP NEUROL, V238, P225, DOI 10.1002/cne.902380209; Polley DB, 1999, NEURON, V24, P623, DOI 10.1016/S0896-6273(00)81117-4; Prakash N, 1996, NATURE, V381, P702, DOI 10.1038/381702a0; SIMONS DJ, 1987, NATURE, V326, P694, DOI 10.1038/326694a0; Stern EA, 2001, NEURON, V31, P305, DOI 10.1016/S0896-6273(01)00360-9; UYLINGS HBM, 1978, EXP NEUROL, V62, P658, DOI 10.1016/0014-4886(78)90276-5; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; WELKER E, 1992, J NEUROSCI, V12, P153; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; ZARZECKI P, 1993, J NEUROPHYSIOL, V69, P1422, DOI 10.1152/jn.1993.69.5.1422	30	118	123	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 6	2004	429	6987					67	71		10.1038/nature02469	http://dx.doi.org/10.1038/nature02469			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129281				2022-12-28	WOS:000221222100045
J	Staba, SL; Escolar, ML; Poe, M; Kim, Y; Martin, PL; Szabolcs, P; Allison-Thacker, J; Wood, S; Wenger, DA; Rubinstein, P; Hopwood, JJ; Krivit, W; Kurtzberg, J				Staba, SL; Escolar, ML; Poe, M; Kim, Y; Martin, PL; Szabolcs, P; Allison-Thacker, J; Wood, S; Wenger, DA; Rubinstein, P; Hopwood, JJ; Krivit, W; Kurtzberg, J			Cord-blood transplants from unrelated donors in patients with Hurler's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW-TRANSPLANTATION; MUCOPOLYSACCHARIDOSIS TYPE-I; ENZYME-REPLACEMENT THERAPY; CELL TRANSPLANTATION; STORAGE DISEASES; PLACENTAL BLOOD; RECONSTITUTION; ENGRAFTMENT; CHILDREN; DYSPLASIA	BACKGROUND Hurler's syndrome ( the most severe form of mucopolysaccharidosis type I) causes progressive deterioration of the central nervous system and death in childhood. Allogeneic bone marrow transplantation before the age of two years halts disease progression and prolongs life, but many children lack a bone marrow donor. We investigated the feasibility of using cord-blood transplants from unrelated donors and a myeloablative preparative regimen that did not involve total-body irradiation in young children with Hurler's syndrome. METHODS Between December 1995 and October 2002, 20 consecutive children with Hurler's syndrome received busulfan, cyclophosphamide, and antithymocyte globulin before receiving cord-blood transplants from unrelated donors. The children were subsequently evaluated for engraftment, adverse effects, and effects on disease symptoms. RESULTS Cord-blood donors had normal alpha-L-iduronidase activity ( mean number of cells, 10.53 x 10(7) per kilogram of body weight) and were discordant for up to three of six HLA markers. Neutrophil engraftment occurred a median of 24 days after transplantation. Five patients had grade II or grade III acute graft-versus-host disease; none had extensive chronic graft-versus-host disease. Seventeen of the 20 children were alive a median of 905 days after transplantation, with complete donor chimerism and normal peripheral-blood alpha-L-iduronidase activity (event-free survival rate, 85 percent). Transplantation improved neurocognitive performance and decreased somatic features of Hurler's syndrome. CONCLUSIONS Cord blood from unrelated donors appears to be an excellent source of stem cells for transplantation in patients with Hurler's syndrome. Sustained engraftment can be achieved without total-body irradiation. Cord-blood transplantation favorably altered the natural history of Hurler's syndrome and thus may be important to consider in young children with this form of the disease.	Duke Univ, Med Ctr, Pediat Stem Cell Transplant Program, Durham, NC 27710 USA; Univ N Carolina, Sch Med, Frank Porter Graham Child Dev Ctr, Chapel Hill, NC USA; Univ N Carolina, Sch Med, Ctr Dev & Learning, Chapel Hill, NC USA; Emmes Corp, Rockville, MD USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; New York Blood Ctr, Placental Blood Program, New York, NY 10021 USA; Womens & Childrens Hosp, Adelaide, SA, Australia; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Emmes Corporation; Jefferson University; New York Blood Center; Womens & Childrens Hospital Australia; University of Minnesota System; University of Minnesota Twin Cities	Staba, SL (corresponding author), Duke Univ, Med Ctr, Pediat Stem Cell Transplant Program, Box 3350, Durham, NC 27710 USA.	staba001@mc.duke.edu	Escolar, Maria/J-3721-2016; Poe, Michele/K-6615-2012	Poe, Michele/0000-0001-9693-3638				ASHTON LJ, 1992, AM J HUM GENET, V50, P787; Braunlin EA, 2001, AM J CARDIOL, V88, P1075, DOI 10.1016/S0002-9149(01)01999-3; COWAN MJ, 1991, CLIN BIOCHEM, V24, P375, DOI 10.1016/0009-9120(91)80012-R; deCasperi R, 2000, BONE MARROW TRANSPL, V25, P541, DOI 10.1038/sj.bmt.1702185; Fleming D R, 1998, Pediatr Transplant, V2, P299; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O; Guffon N, 1998, J PEDIATR-US, V133, P119, DOI 10.1016/S0022-3476(98)70201-X; Hite SH, 2000, PEDIATR RADIOL, V30, P464, DOI 10.1007/s002470000210; HOBBS JR, 1981, LANCET, V2, P709; Jacobson P, 2001, BONE MARROW TRANSPL, V27, P855, DOI 10.1038/sj.bmt.1703010; Kakavanos R, 2003, LANCET, V361, P1608, DOI 10.1016/S0140-6736(03)13311-9; Kakkis ED, 2001, NEW ENGL J MED, V344, P182, DOI 10.1056/NEJM200101183440304; Krivit W., 1995, Bone Marrow Transplantation, V15, pS182; Krivit W, 1999, Curr Opin Neurol, V12, P167, DOI 10.1097/00019052-199904000-00007; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; Masterson EL, 1996, J PEDIATR ORTHOPED, V16, P731, DOI 10.1097/01241398-199611000-00006; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; Odunusi E, 1999, J PEDIATR ORTHOPED, V19, P270, DOI 10.1097/00004694-199903000-00026; Peters C, 1996, BLOOD, V87, P4894, DOI 10.1182/blood.V87.11.4894.bloodjournal87114894; Peters C, 1998, BLOOD, V91, P2601, DOI 10.1182/blood.V91.7.2601.2601_2601_2608; Peters C, 1998, J PEDIATR-US, V133, P7, DOI 10.1016/S0022-3476(98)70170-2; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; RESNICK JM, 1992, BONE MARROW TRANSPL, V10, P273; RUBINSTEIN P, 1995, P NATL ACAD SCI USA, V92, P10119, DOI 10.1073/pnas.92.22.10119; RUBINSTEIN P, 1993, BLOOD, V81, P1679; SHAPIRO EG, 1995, J INHERIT METAB DIS, V18, P413, DOI 10.1007/BF00710053; SUMMERS CG, 1989, OPHTHALMOLOGY, V96, P977; VINALLONGA X, 1992, PEDIATR CARDIOL, V13, P107, DOI 10.1007/BF00798216; WENGER DA, 1991, TECHNIQUES DIAGNOSTI, P587; Whitley C B, 1986, Birth Defects Orig Artic Ser, V22, P7; WHITLEY CB, 1993, AM J MED GENET, V46, P209, DOI 10.1002/ajmg.1320460222; Wraith JE, 2001, J INHERIT METAB DIS, V24, P245, DOI 10.1023/A:1010379320378	33	340	362	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1960	1969		10.1056/NEJMoa032613	http://dx.doi.org/10.1056/NEJMoa032613			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128896	Green Published			2022-12-28	WOS:000221218800008
J	Quinones, MJ; Hernandez-Pampaloni, M; Schelbert, H; Bulnes-Enriquez, I; Jimenez, X; Hernandez, G; De la Rosa, R; Chon, Y; Yang, HY; Nicholas, SB; Modilevsky, T; Yu, K; Van Herle, K; Castellani, LW; Elashoff, R; Hsueh, WA				Quinones, MJ; Hernandez-Pampaloni, M; Schelbert, H; Bulnes-Enriquez, I; Jimenez, X; Hernandez, G; De la Rosa, R; Chon, Y; Yang, HY; Nicholas, SB; Modilevsky, T; Yu, K; Van Herle, K; Castellani, LW; Elashoff, R; Hsueh, WA			Coronary vasomotor abnormalities in insulin-resistant individuals	ANNALS OF INTERNAL MEDICINE			English	Article							MYOCARDIAL BLOOD-FLOW; NECROSIS-FACTOR-ALPHA; 3RD NATIONAL-HEALTH; ENDOTHELIAL DYSFUNCTION; NITRIC-OXIDE; US ADULTS; N-13 AMMONIA; PLASMA; PREVALENCE; DISEASE	Background: Insulin resistance is a metabolic spectrum that progresses from hyperinsulinemia to the metabolic syndrome, impaired glucose tolerance, and finally type 2 diabetes mellitus. It is unclear when vascular abnormalities begin in this spectrum of metabolic effects. Objective: To evaluate the association of insulin resistance with the presence and reversibility of coronary vasomotor abnormalities in young adults at low cardiovascular risk. Design: Cross-sectional study followed by prospective, open-label treatment study. Setting: University hospital. Patients: 50 insulin-resistant and 22 insulin-sensitive, age-matched Mexican-American participants without glucose intolerance or traditional risk factors for or evidence of coronary artery disease. Intervention: 3 months of thiazolidinedione therapy for 25 insulin-resistant patients. Measurements: Glucose infusion rate in response to insulin infusion was used to define insulin resistance (glucose infusion rate less than or equal to 4.00 mg/kg of body weight per minute [range, 0.90 to 3.96 mg/kg per minute]) and insulin sensitivity (glucose infusion rate greater than or equal to 7.50 mg/kg per minute [range, 7.52 to 13.92 mg/kg per minute]). Myocardial blood flow was measured by using positron emission tomography at rest, during cold pressor test (largely endothelium-dependent), and after dipyridamole administration (largely vascular smooth muscle-dependent). Results: Myocardial blood flow responses to dipyridamole were similar in the insulin-sensitive and insulin-resistant groups. However, myocardial blood flow response to cold pressor test increased by 47.6% from resting values in insulin-sensitive patients and by 14.4% in insulin-resistant patients. During thiazolidinedione therapy in a subgroup of insulin-resistant patients, insulin sensitivity improved, fasting plasma insulin levels decreased, and myocardial blood flow responses to cold pressor test normalized. Limitations: The study was not randomized, and it included only 1 ethnic group. Conclusions: insulin-resistant patients who do not have hypercholesterolemia or hypertension and do not smoke manifest coronary vasomotor abnormalities. Insulin-sensitizing thiazolidinedione therapy normalized these abnormalities. These results suggest an association between insulin resistance and abnormal coronary vasomotor function, a relationship that requires confirmation in larger studies.	Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA; Olive View Univ Calif, Los Angeles Med Ctr, Sylmar, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Hsueh, WA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Cedars Sinai Med Ctr, 900 Vet Ave,Suite 24-130, Los Angeles, CA 90095 USA.	whsueh@mednet.ucla.edu			NHLBI NIH HHS [5PO1HL6003, HL33177] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033177] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amberger A, 1997, CELL STRESS CHAPERON, V2, P94, DOI 10.1379/1466-1268(1997)002<0094:CEOIVE>2.3.CO;2; Arcaro G, 2002, CIRCULATION, V105, P576, DOI 10.1161/hc0502.103333; Balletshofer BM, 2000, CIRCULATION, V101, P1780, DOI 10.1161/01.CIR.101.15.1780; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Bhagat K, 1997, CIRCULATION, V96, P3042, DOI 10.1161/01.CIR.96.9.3042; Borch-Johnsen K, 2001, ARCH INTERN MED, V161, P397, DOI 10.1001/archinte.161.3.397; Caballero AE, 1999, DIABETES, V48, P1856, DOI 10.2337/diabetes.48.9.1856; Calles-Escandon J, 2001, ENDOCR REV, V22, P36, DOI 10.1210/er.22.1.36; Campisi R, 1998, CIRCULATION, V98, P119, DOI 10.1161/01.CIR.98.2.119; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cooke JP, 2000, ARTERIOSCL THROM VAS, V20, P2032, DOI 10.1161/01.ATV.20.9.2032; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DiCarli MF, 1997, NEW ENGL J MED, V336, P1208, DOI 10.1056/NEJM199704243361703; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fonseca VA, 1998, J DIABETES COMPLICAT, V12, P181, DOI 10.1016/S1056-8727(97)00109-8; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gavin JR, 1999, DIABETES CARE, V22, pS5; Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23; Haffner SM, 2000, NEW ENGL J MED, V342, P1040, DOI 10.1056/NEJM200004063421408; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hastie T., 2009, ELEMENTS STAT LEARNI, DOI 10.1007/978-0-387-84858-7_7; Hogikyan RV, 1998, J CLIN ENDOCR METAB, V83, P1946, DOI 10.1210/jc.83.6.1946; Hsueh WA, 1999, AM J CARDIOL, V84, p21J; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; Katsuki A, 2000, DIABETES OBES METAB, V2, P189, DOI 10.1046/j.1463-1326.2000.00072.x; KRIVOKAPICH J, 1989, CIRCULATION, V80, P1328, DOI 10.1161/01.CIR.80.5.1328; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; KUHLE WG, 1992, CIRCULATION, V86, P1004, DOI 10.1161/01.CIR.86.3.1004; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Momose M, 2002, EUR J NUCL MED MOL I, V29, P1675, DOI 10.1007/s00259-002-0977-0; Montagnani M, 2002, J BIOL CHEM, V277, P1794, DOI 10.1074/jbc.M103728200; NABEL EG, 1988, CIRCULATION, V77, P43, DOI 10.1161/01.CIR.77.1.43; Nitenberg A, 2001, DIABETES, V50, P1180, DOI 10.2337/diabetes.50.5.1180; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Palatini P, 1999, AM J HYPERTENS, V12, p3S, DOI 10.1016/S0895-7061(98)00207-6; Parulkar AA, 2001, ANN INTERN MED, V134, P61, DOI 10.7326/0003-4819-134-1-200101020-00014; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899; Steer P, 2002, LIPIDS, V37, P1135, DOI 10.1007/s11745-002-1010-3; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; Stuhlinger MC, 2002, JAMA-J AM MED ASSOC, V287, P1420, DOI 10.1001/jama.287.11.1420; TUZCU EM, 1995, CIRCULATION, V91, P1706, DOI 10.1161/01.CIR.91.6.1706; Warnick G R, 1986, Methods Enzymol, V129, P101; Williams SB, 1996, J AM COLL CARDIOL, V27, P567, DOI 10.1016/0735-1097(95)00522-6; ZEIHER AM, 1991, CIRCULATION, V84, P1984, DOI 10.1161/01.CIR.84.5.1984; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539	52	132	140	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	2004	140	9					700	708		10.7326/0003-4819-140-9-200405040-00009	http://dx.doi.org/10.7326/0003-4819-140-9-200405040-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816XR	15126253				2022-12-28	WOS:000221143100003
J	Kirk, P; Kirk, I; Kristjanson, L				Kirk, P; Kirk, I; Kristjanson, L			What do patients receiving palliative care for cancer and their families want to be told? A Canadian and Australian qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMATION NEEDS; COMMUNICATION	Objective To obtain feedback from patients receiving palliative care and their relatives from various ethnic backgrounds about their experiences of the disclosure process and their satisfaction with information sharing during the illness. Design A qualitative study with semistructured single interviews. Setting Perth, Western Australia, and Winnipeg, Manitoba, Canada. Participants 72 participants registered with palliative care: 21 patient-family dyads in Perth and 14 dyads and 2 patients in Winnipeg. Results Participants described their experiences in great detail. The analysis indicates that in information sharing the process is as important as the content. The timing, management, and delivery of information and perceived attitude of practitioners were critical to the process. This applied to information interactions at all stages of the illness. Main content areas mentioned related to prognosis and hope. Hope can be conveyed in different ways. Secondary information from various sources is accessed and synthesised with the primary information. All patients, regardless of origin, wanted information about their illness and wanted it fully shared with relatives. Almost all patients requested prognostic information, and all family members respected their wishes. Information was perceived as important for patient-family communication. Information needs of patient and family changed and diverged as illness progressed, and communication between them became less verbally explicit. Conclusions Information delivery for patients needs to be individualised with particular attention to process at all stages of illness. Patients and families use secondary sources of information to complement and verify information given by health carers.	Univ Victoria, Isl Med Program, Victoria, BC V8N 1V7, Canada; Univ British Columbia, Isl Med Program, Victoria, BC V8N 1V7, Canada; Victoria Hospice Soc, Victoria, BC V8R 1J8, Canada; Edith Cowan Univ, Sch Nursing & Publ Hlth, Perth, WA 6018, Australia	University of Victoria; University of British Columbia; University of Victoria; Edith Cowan University	Kirk, P (corresponding author), Univ Victoria, Isl Med Program, Victoria, BC V8N 1V7, Canada.	clincoor@uvic.ca						Altheide David L., 1994, HDB QUALITATIVE RES, P485; Baile W F, 2000, Oncologist, V5, P302, DOI 10.1634/theoncologist.5-4-302; Bruera E, 2000, PALLIATIVE MED, V14, P287, DOI 10.1191/026921600674582192; BUTOW PN, 1997, ANN ONCOL, V8, P821; Christakis NicholasA., 1999, DEATH FORETOLD; Code K, 1997, Aust Nurs J, V5, P20; Crawley LM, 2002, ANN INTERN MED, V136, P673, DOI 10.7326/0003-4819-136-9-200205070-00010; Davies E, 2003, SUPPORT CARE CANCER, V11, P21, DOI 10.1007/s00520-002-0392-x; Faulkner Ann, 1994, TALKING CANC PATIENT; Glaser B.G., 1965, AWARENESS DYING; Hinton J, 1999, PALLIATIVE MED, V13, P19, DOI 10.1191/026921699672169546; Kutner JS, 1999, SOC SCI MED, V48, P1341, DOI 10.1016/S0277-9536(98)00453-5; Lincoln Y, 1985, NATURALISTIC ENQUIRY; McIllmurray MB, 2001, EUR J CANCER CARE, V10, P261, DOI 10.1046/j.1365-2354.2001.00280.x; McPherson CJ, 2001, J PUBLIC HEALTH MED, V23, P227, DOI 10.1093/pubmed/23.3.227; Mystakidou Kyriaki, 2002, BMC Palliat Care, V1, P3, DOI 10.1186/1472-684X-1-3; Ptacek JT, 1996, JAMA-J AM MED ASSOC, V276, P496; Rose KE, 1999, J CLIN NURS, V8, P81, DOI 10.1046/j.1365-2702.1999.00214.x; Schouwstra J, 1997, ANN NY ACAD SCI, V809, P422, DOI 10.1111/j.1749-6632.1997.tb48105.x; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; SURBONE A, 1992, JAMA-J AM MED ASSOC, V268, P1661; VACHON MLS, 1995, J PAIN SYMPTOM MANAG, V10, P142, DOI 10.1016/0885-3924(94)00076-W; WEISSMAN AD, 1979, COPING CANC; Wong RKS, 2002, SUPPORT CARE CANCER, V10, P408, DOI 10.1007/s00520-002-0354-3	24	262	266	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	2004	328	7452					1343	1347		10.1136/bmj.38103.423576.55	http://dx.doi.org/10.1136/bmj.38103.423576.55			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15151964	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000221952700016
J	Carlson, CS; Eberle, MA; Kruglyak, L; Nickerson, DA				Carlson, CS; Eberle, MA; Kruglyak, L; Nickerson, DA			Mapping complex disease loci in whole-genome association studies	NATURE			English	Review							SINGLE-NUCLEOTIDE POLYMORPHISMS; GENE-GENE INTERACTION; LINKAGE-DISEQUILIBRIUM; COMMON DISEASE; MYOCARDIAL-INFARCTION; PARAOXONASE ACTIVITY; SEQUENCE VARIATION; VASCULAR-DISEASE; CYSTIC-FIBROSIS; MOLECULAR-BASIS	Identification of the genetic polymorphisms that contribute to susceptibility for common diseases such as type 2 diabetes and schizophrenia will aid in the development of diagnostics and therapeutics. Previous studies have focused on the technique of genetic linkage, but new technologies and experimental resources make whole-genome association studies more feasible. Association studies of this type have good prospects for dissecting the genetics of common disease, but they currently face a number of challenges, including problems with multiple testing and study design, definition of intermediate phenotypes and interaction between polymorphisms.	Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center	Carlson, CS (corresponding author), Univ Washington, Dept Genome Sci, 1705 NE Pacific, Seattle, WA 98195 USA.	csc47@u.washington.edu		Eberle, Michael/0000-0001-8965-1253				ADKINS S, 1993, AM J HUM GENET, V52, P598; Bansal A, 2002, P NATL ACAD SCI USA, V99, P16871, DOI 10.1073/pnas.262671399; Barcellos LF, 2003, J NEUROIMMUNOL, V143, P1, DOI 10.1016/j.jneuroim.2003.08.004; BEGG CB, 1994, CANCER EPIDEM BIOMAR, V3, P173; Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; Bolk S, 2000, P NATL ACAD SCI USA, V97, P268, DOI 10.1073/pnas.97.1.268; Bonner AE, 2003, J MED GENET, V40, P408, DOI 10.1136/jmg.40.6.408; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Brophy VH, 2001, AM J HUM GENET, V68, P1428, DOI 10.1086/320600; Butt C, 2003, BLOOD, V101, P3037, DOI 10.1182/blood-2002-09-2888; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229; Cristea IM, 2004, BLOOD, V103, P3624, DOI 10.1182/blood-2003-09-3295; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Grody WW, 1997, AM J HUM GENET, V60, P935; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Haufroid V, 1998, INT ARCH OCC ENV HEA, V71, P162, DOI 10.1007/s004200050266; HOWELL WM, 1989, ANN RHEUM DIS, V48, P295, DOI 10.1136/ard.48.4.295; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; Jarvik GP, 2000, ARTERIOSCL THROM VAS, V20, P2441, DOI 10.1161/01.ATV.20.11.2441; Jarvik GP, 2003, ARTERIOSCL THROM VAS, V23, P1465, DOI 10.1161/01.ATV.0000081635.96290.D3; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Kammerer S, 2003, P NATL ACAD SCI USA, V100, P4066, DOI 10.1073/pnas.2628028100; Ke XY, 2003, BIOINFORMATICS, V19, P287, DOI 10.1093/bioinformatics/19.2.287; Khoury MJ, 1996, AM J EPIDEMIOL, V144, P207; Kosorok MR, 1996, STAT MED, V15, P449, DOI 10.1002/(SICI)1097-0258(19960315)15:5<449::AID-SIM173>3.0.CO;2-X; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Mohlke KL, 2002, P NATL ACAD SCI USA, V99, P16928, DOI 10.1073/pnas.262661399; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Permutt MA, 2002, DIABETES, V51, pS308, DOI 10.2337/diabetes.51.2007.S308; PIEGORSCH WW, 1994, STAT MED, V13, P153, DOI 10.1002/sim.4780130206; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6; Risch N, 1998, GENOME RES, V8, P1273, DOI 10.1101/gr.8.12.1273; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Risch N, 1997, EPIDEMIOL REV, V19, P24, DOI 10.1093/oxfordjournals.epirev.a017942; Rocchi A, 2003, BRAIN RES BULL, V61, P1, DOI 10.1016/S0361-9230(03)00067-4; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sawcer S, 1997, GENET EPIDEMIOL, V14, P223, DOI 10.1002/(SICI)1098-2272(1997)14:3<223::AID-GEPI1>3.0.CO;2-6; Schork NJ, 2002, AM J HUM GENET, V70, P1480, DOI 10.1086/340788; Schwartz S, 2003, NUCLEIC ACIDS RES, V31, P3518, DOI 10.1093/nar/gkg579; Sham P, 2002, NAT REV GENET, V3, P862, DOI 10.1038/nrg930; Slooter AJC, 1998, ARCH NEUROL-CHICAGO, V55, P964, DOI 10.1001/archneur.55.7.964; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Stram DO, 2003, HUM HERED, V55, P27, DOI 10.1159/000071807; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; TIRET L, 1994, LANCET, V344, P910, DOI 10.1016/S0140-6736(94)92268-3; Weale ME, 2003, AM J HUM GENET, V73, P551, DOI 10.1086/378098; Yang YN, 2003, P NATL ACAD SCI USA, V100, P7225, DOI 10.1073/pnas.1237858100; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28; Zetterberg H, 2003, HUM REPROD, V18, P1948, DOI 10.1093/humrep/deg375; Zhang K, 2002, AM J HUM GENET, V71, P1386, DOI 10.1086/344780; Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270; 2003, J NEUROIMMUNOL, V143, P39	66	451	484	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	2004	429	6990					446	452		10.1038/nature02623	http://dx.doi.org/10.1038/nature02623			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164069				2022-12-28	WOS:000221644600046
J	Jarillo-Herrero, P; Sapmaz, S; Dekker, C; Kouwenhoven, LP; van der Zant, HSJ				Jarillo-Herrero, P; Sapmaz, S; Dekker, C; Kouwenhoven, LP; van der Zant, HSJ			Electron-hole symmetry in a semiconducting carbon nanotube quantum dot	NATURE			English	Article							WIRES	Optical and electronic phenomena in solids arise from the behaviour of electrons and holes ( unoccupied states in a filled electron sea). Electron-hole symmetry can often be invoked as a simplifying description, which states that electrons with energy above the Fermi sea behave the same as holes below the Fermi energy. In semiconductors, however, electron-hole symmetry is generally absent, because the energy-band structure of the conduction band differs from the valence band(1). Here we report on measurements of the discrete, quantized-energy spectrum of electrons and holes in a semiconducting carbon nanotube(2). By applying a voltage to a gate electrode, an individual nanotube is filled controllably with a precise number of either electrons or holes, starting from one. The discrete excitation spectrum for a nanotube with N holes is strikingly similar to the corresponding spectrum for N electrons. This observation of near-perfect electron-hole symmetry(3) demonstrates that a semiconducting nanotube can be free of charged impurities, even in the limit of few electrons or holes. We furthermore find an anomalously small Zeeman spin splitting and an excitation spectrum indicating strong electron-electron interactions.	Delft Univ Technol, Kavli Inst Nanosci, NL-2600 GA Delft, Netherlands; Delft Univ Technol, ERATO, Project Mesoscop Correlat, NL-2600 GA Delft, Netherlands	Delft University of Technology; Delft University of Technology	Jarillo-Herrero, P (corresponding author), Delft Univ Technol, Kavli Inst Nanosci, POB 5046, NL-2600 GA Delft, Netherlands.	Pablo@qt.tn.tudelft.nl	van der Zant, Herre S.J./J-9467-2016	van der Zant, Herre S.J./0000-0002-5385-0282; Dekker, Cees/0000-0001-6273-071X				Ando T, 1998, J PHYS SOC JPN, V67, P1704, DOI 10.1143/JPSJ.67.1704; Ashcroft N.W., 1976, SOLID STATE PHYS; Bachtold A, 2001, SCIENCE, V294, P1317, DOI 10.1126/science.1065824; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; Bronikowski MJ, 2001, J VAC SCI TECHNOL A, V19, P1800, DOI 10.1116/1.1380721; Cobden DH, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.046803; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Fuhrer MS, 2000, SCIENCE, V288, P494, DOI 10.1126/science.288.5465.494; GRABERT H, 1992, SINGLE CHARGE TUNNEL; HAUSLER W, 1993, PHYS REV B, V47, P16353, DOI 10.1103/PhysRevB.47.16353; Heinze S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.106801; Kouwenhoven LP, 2001, REP PROG PHYS, V64, P701, DOI 10.1088/0034-4885/64/6/201; McEuen PL, 1999, PHYS REV LETT, V83, P5098, DOI 10.1103/PhysRevLett.83.5098; Nygard J, 2001, APPL PHYS LETT, V79, P4216, DOI 10.1063/1.1428117; Park H, 2000, NATURE, V407, P57, DOI 10.1038/35024031; Park JW, 2001, APPL PHYS LETT, V79, P1363, DOI 10.1063/1.1396318; Postma HWC, 2000, ADV MATER, V12, P1299, DOI 10.1002/1521-4095(200009)12:17<1299::AID-ADMA1299>3.0.CO;2-O; Postma HWC, 2000, J LOW TEMP PHYS, V118, P495, DOI 10.1023/A:1004618823190; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Wigner E, 1934, PHYS REV, V46, P1002, DOI 10.1103/PhysRev.46.1002	21	185	187	0	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					389	392		10.1038/nature02568	http://dx.doi.org/10.1038/nature02568			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164056	Green Submitted			2022-12-28	WOS:000221644600032
J	Zullig, S; Hengartner, MO				Zullig, S; Hengartner, MO			Tickling macrophages, a serious business	SCIENCE			English	Editorial Material							APOPTOTIC CELLS; ENGULFMENT; DEATH; CLEARANCE; SIGNALS; PROTEIN		Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Zullig, S (corresponding author), Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland.	michael.hengartner@molbio.unizh.ch	Hengartner, Michael O/A-7058-2008; Hengartner, Michael O/E-6235-2011	Hengartner, Michael/0000-0002-7584-596X				Akakura S, 2004, EXP CELL RES, V292, P403, DOI 10.1016/j.yexcr.2003.09.011; Byrne A, 2002, J IMMUNOL, V168, P1968, DOI 10.4049/jimmunol.168.4.1968; Cui P, 2004, EXP CELL RES, V293, P154, DOI 10.1016/j.yexcr.2003.09.023; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Grimsley C, 2003, TRENDS CELL BIOL, V13, P648, DOI 10.1016/j.tcb.2003.10.004; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Hanayama R, 2004, J IMMUNOL, V172, P3876, DOI 10.4049/jimmunol.172.6.3876; Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Somersan S, 2001, J CELL BIOL, V155, P501, DOI 10.1083/jcb.200110066; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417	13	15	15	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1123	1124						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155940				2022-12-28	WOS:000221524500031
J	Han, JS; Szak, ST; Boeke, JD				Han, JS; Szak, ST; Boeke, JD			Transcriptional disruption by the L1 retrotransposon and implications for mammalian transcriptomes	NATURE			English	Article							REVERSE TRANSCRIPTION; ALLELIC VARIATION; ORF1 PROTEIN; LINE-1; RNA; IDENTIFICATION; EXPRESSION; GENE; DNA; SPECIFICITY	LINE-1 (L1) elements are the most abundant autonomous retrotransposons in the human genome, accounting for about 17% of human DNA. The L1 retrotransposon encodes two proteins, open reading frame (ORF)1 and the ORF2 endonuclease/reverse transcriptase. L1 RNA and ORF2 protein are difficult to detect in mammalian cells, even in the context of overexpression systems. Here we show that inserting L1 sequences on a transcript significantly decreases RNA expression and therefore protein expression. This decreased RNA concentration does not result from major effects on the transcription initiation rate or RNA stability. Rather, the poor L1 expression is primarily due to inadequate transcriptional elongation. Because L1 is an abundant and broadly distributed mobile element, the inhibition of transcriptional elongation by L1 might profoundly affect expression of endogenous human genes. We propose a model in which L1 affects gene expression genome-wide by acting as a 'molecular rheostat' of target genes. Bioinformatic data are consistent with the hypothesis that L1 can serve as an evolutionary fine-tuner of the human transcriptome.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, High Throughput Biol Ctr, Baltimore, MD 21205 USA; Biogen Inc, Cambridge, MA 02142 USA	Johns Hopkins University; Johns Hopkins University; Biogen	Boeke, JD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	jboeke@jhmi.edu		Boeke, Jef/0000-0001-5322-4946				Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Bestor TH, 1999, GENETICA, V107, P289, DOI 10.1023/A:1003990818251; Boissinot S, 2000, MOL BIOL EVOL, V17, P915, DOI 10.1093/oxfordjournals.molbev.a026372; Boissinot S, 2001, MOL BIOL EVOL, V18, P926, DOI 10.1093/oxfordjournals.molbev.a003893; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; Burwinkel B, 1998, J MOL BIOL, V277, P513, DOI 10.1006/jmbi.1998.1641; Chavez S, 2001, MOL CELL BIOL, V21, P7054, DOI 10.1128/MCB.21.20.7054-7064.2001; Clements AP, 1998, NUCLEIC ACIDS RES, V26, P3528, DOI 10.1093/nar/26.15.3528; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; Cost GJ, 1998, BIOCHEMISTRY-US, V37, P18081, DOI 10.1021/bi981858s; Cuello P, 1999, EMBO J, V18, P2867, DOI 10.1093/emboj/18.10.2867; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Dieckmann T, 1997, J MOL BIOL, V273, P467, DOI 10.1006/jmbi.1997.1329; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; FENG Q, 1996, THESIS J HOPKINS U; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Goodier JL, 2000, HUM MOL GENET, V9, P653, DOI 10.1093/hmg/9.4.653; Han JS, 2004, NATURE, V429, P314, DOI 10.1038/nature02535; HICKEY DA, 1982, GENETICS, V101, P519; Kolosha VO, 2003, J BIOL CHEM, V278, P8112, DOI 10.1074/jbc.M210487200; Kolosha VO, 1997, P NATL ACAD SCI USA, V94, P10155, DOI 10.1073/pnas.94.19.10155; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Martin SL, 2001, MOL CELL BIOL, V21, P467, DOI 10.1128/MCB.21.2.467-475.2001; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; Miller T, 2000, J BIOL CHEM, V275, P32052, DOI 10.1074/jbc.M005175200; MINAKAMI R, 1992, NUCLEIC ACIDS RES, V20, P3139, DOI 10.1093/nar/20.12.3139; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Oliver JL, 2002, GENE, V300, P117, DOI 10.1016/S0378-1119(02)01034-X; Perepelitsa-Belancio V, 2003, NAT GENET, V35, P363, DOI 10.1038/ng1269; Pickeral OK, 2000, GENOME RES, V10, P411, DOI 10.1101/gr.10.4.411; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; Schwahn U, 1998, NAT GENET, V19, P327, DOI 10.1038/1214; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; Szak ST, 2002, GENOME BIOL, V3; Tang W, 2000, P NATL ACAD SCI USA, V97, P6025, DOI 10.1073/pnas.110139897; Tchenio T, 2000, NUCLEIC ACIDS RES, V28, P411, DOI 10.1093/nar/28.2.411; TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; XU QH, 1994, J BIOL CHEM, V269, P3100; Yajima I, 1999, HUM MOL GENET, V8, P1431, DOI 10.1093/hmg/8.8.1431; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; Yang N, 2003, NUCLEIC ACIDS RES, V31, P4929, DOI 10.1093/nar/gkg663; Zarudnaya MI, 2003, NUCLEIC ACIDS RES, V31, P1375, DOI 10.1093/nar/gkg241	50	365	373	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					268	274		10.1038/nature02536	http://dx.doi.org/10.1038/nature02536			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152245				2022-12-28	WOS:000221505900035
J	Han, JS; Boeke, JD				Han, JS; Boeke, JD			A highly active synthetic mammalian retrotransposon	NATURE			English	Article							HUMAN L1 RETROTRANSPOSITION; LINE-1 RETROTRANSPOSITION; MOUSE LINE-1; IN-VITRO; ENDONUCLEASE; ELEMENT; CELLS	LINE-1 (L1) elements are retrotransposons that comprise large fractions of mammalian genomes(1). Transcription through L1 open reading frames is inefficient owing to an elongation defect(2), inhibiting the robust expression of L1 RNA and proteins, the substrate and enzyme(s) for retrotransposition(3-5). This elongation defect probably controls L1 transposition frequency in mammalian cells. Here we report bypassing this transcriptional defect by synthesizing the open reading frames of L1 from synthetic oligonucleotides, altering 24% of the nucleic acid sequence without changing the amino acid sequence. Such resynthesis led to greatly enhanced steady-state L1 RNA and protein levels. Remarkably, when the synthetic open reading frames were substituted for the wild-type open reading frames in an established retrotransposition assay(4), transposition levels increased more than 200-fold. This indicates that there are probably no large, rigidly conserved cis-acting nucleic acid sequences required for retrotransposition within L1 coding regions. These synthetic retrotransposons are also the most highly active L1 elements known so far and have potential as practical tools for manipulating mammalian genomes.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, High Throughput Biol Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Boeke, JD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	jboeke@jhmi.edu		Boeke, Jef/0000-0001-5322-4946				Boissinot S, 2000, MOL BIOL EVOL, V17, P915, DOI 10.1093/oxfordjournals.molbev.a026372; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; Cost GJ, 1998, BIOCHEMISTRY-US, V37, P18081, DOI 10.1021/bi981858s; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Hamer L, 2001, CURR OPIN CHEM BIOL, V5, P67, DOI 10.1016/S1367-5931(00)00162-9; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; Kolosha VO, 1997, P NATL ACAD SCI USA, V94, P10155, DOI 10.1073/pnas.94.19.10155; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; MARTIN SL, 1995, GENE, V153, P261, DOI 10.1016/0378-1119(94)00785-Q; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Morrish TA, 2002, NAT GENET, V31, P159, DOI 10.1038/ng898; Naas TP, 1998, EMBO J, V17, P590, DOI 10.1093/emboj/17.2.590; Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; Wei W, 2000, ANAL BIOCHEM, V284, P435, DOI 10.1006/abio.2000.4675; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001	23	133	139	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 20	2004	429	6989					314	318		10.1038/nature02535	http://dx.doi.org/10.1038/nature02535			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152256				2022-12-28	WOS:000221505900047
J	Grotenhermen, F				Grotenhermen, F			How to prevent cannabis-induced psychological distress ... in politicians	LANCET			English	Editorial Material							PSYCHOSIS; RISK		Nova Inst GmbH, D-50354 Huerth, Germany		Grotenhermen, F (corresponding author), Nova Inst GmbH, D-50354 Huerth, Germany.	franjo.grotenhermen@nova-institut.de						Arseneault L, 2002, BRIT MED J, V325, P1212, DOI 10.1136/bmj.325.7374.1212; Arseneault L, 2004, BRIT J PSYCHIAT, V184, P110, DOI 10.1192/bjp.184.2.110; BARTHWELL A, 2004, CHICAGO TRIBUNE 0217; Bollinger L, 2002, J DRUG ISSUES, V32, P553, DOI 10.1177/002204260203200214; Grotenhermen F, 2002, CANNABIS CANNABINOID, P233; House of Lords Select Committee on Science and Technology, 1998, CANN SCI MED EV; *WALSH GROUP, FEAS PER DRUGG DRIV; Williams J, 2004, HEALTH ECON, V13, P123, DOI 10.1002/hec.796; WISH ED, 1990, JAMA-J AM MED ASSOC, V264, P2676, DOI 10.1001/jama.264.20.2676; Zammit S, 2002, BRIT MED J, V325, P1199, DOI 10.1136/bmj.325.7374.1199; 2004, PHYS SAY UK CANN REC	11	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	2004	363	9421					1568	1569		10.1016/S0140-6736(04)16235-1	http://dx.doi.org/10.1016/S0140-6736(04)16235-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	820SE	15145626				2022-12-28	WOS:000221408800003
J	Blander, JM; Medzhitov, R				Blander, JM; Medzhitov, R			Regulation of phagosome maturation by signals from Toll-like receptors	SCIENCE			English	Article							LYSOSOMAL MEMBRANE GLYCOPROTEIN; PHAGOCYTOSIS; IDENTIFICATION; MECHANISMS	In higher metazoans, phagocytosis is essential in host defense against microbial pathogens and in clearance of apoptotic cells. Both microbial and apoptotic cells are delivered on a common route from phagosomes to lysosomes for degradation. Here, we found that activation of the Toll-like receptor (TLR) signaling pathway by bacteria, but not apoptotic cells, regulated phagocytosis at multiple steps including internalization and phagosome maturation. Phagocytosis of bacteria was impaired in the absence of TLR signaling. Two modes of phagosome maturation were observed, constitutive and inducible; their differential engagement depended on the ability of the cargo to trigger TLR signaling.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University	Medzhitov, R (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.	ruslan.medzhitov@yale.edu		Blander, Julie Magarian/0000-0001-9207-1700	NIAID NIH HHS [AI46688] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046688, R37AI046688] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; BLANDER JM, UNPUB; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Metchnikoff E., 1905, IMMUNITY INFECT DIS; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Rosenberger CM, 2003, NAT REV MOL CELL BIO, V4, P385, DOI 10.1038/nrm1104; Storrie Brian, 1996, Bioessays, V18, P895, DOI 10.1002/bies.950181108; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Via LE, 1998, J CELL SCI, V111, P897; Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691	22	783	815	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					1014	1018		10.1126/science.1096158	http://dx.doi.org/10.1126/science.1096158			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143282				2022-12-28	WOS:000221383300050
J	Zubavicus, Y; Grunze, M				Zubavicus, Y; Grunze, M			New insights into the structure of water with ultrafast probes	SCIENCE			English	Editorial Material									Heidelberg Univ, Inst Appl Phys Chem, D-69120 Heidelberg, Germany; Univ Maine, Inst Mol Biophys, Bar Harbor, ME 04609 USA	Ruprecht Karls University Heidelberg; University of Maine System; University of Maine Orono	Zubavicus, Y (corresponding author), Heidelberg Univ, Inst Appl Phys Chem, D-69120 Heidelberg, Germany.	michael.grunze@urz.uni-heidelberg.de	Grunze, Michael/O-2912-2019; Grunze, Michael H/H-1600-2013; Zubavichus, Yan/A-3418-2014	Zubavichus, Yan/0000-0003-2266-8944				Ball Philip., 1999, H2O BIOGRAPHY WATER; DOSCH H, 1995, SURF SCI, V327, P145, DOI 10.1016/0039-6028(94)00801-9; Fecko CJ, 2003, SCIENCE, V301, P1698, DOI 10.1126/science.1087251; Guthrie M, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.184110; HELD G, 1994, SURF SCI, V316, P92, DOI 10.1016/0039-6028(94)91131-2; Modig K, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.075502; OHMINE I, 1993, CHEM REV, V93, P2545, DOI 10.1021/cr00023a011; PRATT LR, 2002, CHEM REV, V102; RONTGEN WC, 1892, ANN PHYS, V45, P91, DOI DOI 10.1002/ANDP.18922810108; Ruan CY, 2004, SCIENCE, V304, P80, DOI 10.1126/science.1094818; SOPER A, 2000, CHEM PHYS, V258; Tulk CA, 2002, SCIENCE, V297, P1320, DOI 10.1126/science.1074178; Wernet P, 2004, SCIENCE, V304, P995, DOI 10.1126/science.1096205	13	49	51	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					974	976		10.1126/science.1097848	http://dx.doi.org/10.1126/science.1097848			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143269				2022-12-28	WOS:000221383300034
J	He, WH; Miao, FJP; Lin, DCH; Schwandner, RT; Wang, ZL; Gao, JH; Chen, JL; Tian, H; Ling, L				He, WH; Miao, FJP; Lin, DCH; Schwandner, RT; Wang, ZL; Gao, JH; Chen, JL; Tian, H; Ling, L			Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors	NATURE			English	Article							RENIN-ANGIOTENSIN SYSTEM; PROXIMAL TUBULE; BLOOD-PRESSURE; HYPERTENSION; ACTIVATION; TRANSPORT; DISCOVERY; ASSAY; ALPHA; MICE	The citric acid cycle is central to the regulation of energy homeostasis and cell metabolism(1). Mutations in enzymes that catalyse steps in the citric acid cycle result in human diseases with various clinical presentations(2). The intermediates of the citric acid cycle are present at micromolar concentration in blood and are regulated by respiration, metabolism and renal reabsorption/ extrusion. Here we show that GPR91 (ref. 3), a previously orphan G-protein-coupled receptor (GPCR), functions as a receptor for the citric acid cycle intermediate succinate. We also report that GPR99 (ref. 4), a close relative of GPR91, responds to alpha-ketoglutarate, another intermediate in the citric acid cycle. Thus by acting as ligands for GPCRs, succinate and alpha-ketoglutarate are found to have unexpected signalling functions beyond their traditional roles. Furthermore, we show that succinate increases blood pressure in animals. The succinate-induced hypertensive effect involves the renin - angiotensin system and is abolished in GPR91-deficient mice. Our results indicate a possible role for GPR91 in renovascular hypertension, a disease closely linked to atherosclerosis, diabetes and renal failure(5,6).	Tularik Inc, San Francisco, CA 94080 USA; Tularik GmbH, D-93053 Regensburg, Germany		Ling, L (corresponding author), Tularik Inc, 1120 Vet Blvd, San Francisco, CA 94080 USA.	ling@tularik.com						An SZ, 2001, P NATL ACAD SCI USA, V98, P7576, DOI 10.1073/pnas.131200698; BAUMBACH L, 1976, J PHYSIOL-LONDON, V258, P243, DOI 10.1113/jphysiol.1976.sp011417; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN; Brandish PE, 2003, ANAL BIOCHEM, V313, P311, DOI 10.1016/S0003-2697(02)00630-9; Campean V, 2001, AM J PHYSIOL-RENAL, V281, pF1028, DOI 10.1152/ajprenal.0148.2001; Chuang PT, 2003, GENE DEV, V17, P342, DOI 10.1101/gad.1026303; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; GULLANS SR, 1984, AM J PHYSIOL, V246, pF859, DOI 10.1152/ajprenal.1984.246.6.F859; GULLANS SR, 1988, AM J PHYSIOL, V255, pF1170, DOI 10.1152/ajprenal.1988.255.6.F1170; Gurley SB, 2002, COLD SPRING HARB SYM, V67, P451, DOI 10.1101/sqb.2002.67.451; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; HEMS DA, 1970, BIOCHEM J, V120, P105, DOI 10.1042/bj1200105; Jandeleit-Dahm K, 2002, CURR OPIN NEPHROL HY, V11, P221, DOI 10.1097/00041552-200203000-00014; Krebs H A, 1970, Adv Enzyme Regul, V8, P335, DOI 10.1016/0065-2571(70)90028-2; KREBS HA, 1970, PERSPECT BIOL MED, V14, P154; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Kushnir MM, 2001, CLIN CHEM, V47, P1993; Lavoie JL, 2003, ENDOCRINOLOGY, V144, P2179, DOI 10.1210/en.2003-0150; Lee DK, 2001, GENE, V275, P83, DOI 10.1016/S0378-1119(01)00651-5; MARTIN M, 1989, PFLUG ARCH EUR J PHY, V413, P217, DOI 10.1007/BF00583533; Olin Jeffrey W., 2002, Cardiology Clinics, V20, P547, DOI 10.1016/S0733-8651(02)00091-7; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pan L, 2001, J BIOL CHEM, V276, P45530, DOI 10.1074/jbc.M103010200; Silva APT, 2002, RENAL FAILURE, V24, P275, DOI 10.1081/JDI-120005361; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Sugiyama F, 2002, PHYSIOL GENOMICS, V10, P5, DOI 10.1152/physiolgenomics.00002.2002; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; Wittenberger T, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-17; Wittenberger T, 2001, J MOL BIOL, V307, P799, DOI 10.1006/jmbi.2001.4520; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866	30	606	669	1	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988					188	193		10.1038/nature02488	http://dx.doi.org/10.1038/nature02488			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141213	Bronze			2022-12-28	WOS:000221356300043
J	Sauvan, C; Lalanne, P; Hugonin, JP				Sauvan, C; Lalanne, P; Hugonin, JP			Photonics - Tuning holes in photonic-crystal nanocavities	NATURE			English	Editorial Material							WAVE-GUIDES		CNRS, Inst Opt, Lab Charles Fabry, BP 147, F-91403 Orsay, France; Univ Paris 11, F-91403 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Sauvan, C (corresponding author), CNRS, Inst Opt, Lab Charles Fabry, BP 147, F-91403 Orsay, France.	philippe.lalanne@iota.u-psud.fr	lalanne, philippe/AAE-4888-2020	Sauvan, Christophe/0000-0002-8360-9254				Akahane Y, 2003, NATURE, V425, P944, DOI 10.1038/nature02063; Chutinan A, 2000, PHYS REV B, V62, P4488, DOI 10.1103/PhysRevB.62.4488; Coldren L.A., 1995, DIODE LASERS PHOTONI; Lalanne P, 2004, OPT EXPRESS, V12, P458, DOI 10.1364/OPEX.12.000458; Lalanne P, 2003, IEEE J QUANTUM ELECT, V39, P1430, DOI 10.1109/JQE.2003.818283; Notomi M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.253902; Palamaru M, 2001, APPL PHYS LETT, V78, P1466, DOI 10.1063/1.1354666; Silberstein E, 2001, J OPT SOC AM A, V18, P2865, DOI 10.1364/JOSAA.18.002865; Vuckovic J, 2002, IEEE J QUANTUM ELECT, V38, P850, DOI 10.1109/JQE.2002.1017597	9	15	15	1	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988								10.1038/nature02602	http://dx.doi.org/10.1038/nature02602			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15143766	Bronze			2022-12-28	WOS:000221356300031
J	Gillison, ML; Lowy, DR				Gillison, ML; Lowy, DR			A causal role for human papillomavirus in head and neck cancer	LANCET			English	Editorial Material							SQUAMOUS-CELL CARCINOMAS; ORAL-CANCER; INFECTION; P53; OVEREXPRESSION; P16(INK4A); CAVITY; SUBSET; RISK; DNA		Johns Hopkins Med Inst, Baltimore, MD 21231 USA; NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gillison, ML (corresponding author), Johns Hopkins Med Inst, Baltimore, MD 21231 USA.	gillima@jhmi.edu			NATIONAL CANCER INSTITUTE [Z01BC010579, ZIABC010579] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGUM S, 2003, CLIN CANCER RES, V9, P6469; Fregonesi PAG, 2003, J HISTOCHEM CYTOCHEM, V51, P1291; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Hafkamp HC, 2003, INT J CANCER, V107, P394, DOI 10.1002/ijc.11389; Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg/107, 10.1093/jnci/djg107]; Klussmann JP, 2003, AM J PATHOL, V162, P747, DOI 10.1016/S0002-9440(10)63871-0; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Kutler DI, 2003, J NATL CANCER I, V95, P1718, DOI 10.1093/jnci/djg091; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; Rajkumar T, 2003, EUR J CANCER PREV, V12, P135, DOI 10.1097/00008469-200304000-00007; Schwartz SM, 1998, JNCI-J NATL CANCER I, V90, P1626, DOI 10.1093/jnci/90.21.1626; Schwartz SR, 2001, OTOLARYNG HEAD NECK, V125, P1, DOI 10.1067/mhn.2001.116979; Smith EM, 2004, JNCI-J NATL CANCER I, V96, P449, DOI 10.1093/jnci/djh074; Smith EM, 2004, INT J CANCER, V108, P766, DOI 10.1002/ijc.11633; Summersgill KF, 2000, ORAL SURG ORAL MED O, V90, P334, DOI 10.1067/moe.2000.107359	15	168	173	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2004	363	9420					1488	1489		10.1016/S0140-6736(04)16194-1	http://dx.doi.org/10.1016/S0140-6736(04)16194-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135592				2022-12-28	WOS:000221302700004
J	Hansell, DA; Kadko, D; Bates, NR				Hansell, DA; Kadko, D; Bates, NR			Degradation of terrigenous dissolved organic carbon in the western Arctic Ocean	SCIENCE			English	Article							FRESH-WATER; SEA-ICE; MATTER; RIVER; NUTRIENTS; RA-228	The largest flux of terrigenous organic carbon into the ocean occurs in dissolved form by way of rivers. The fate of this material is enigmatic; there are numerous reports of conservative behavior over continental shelves, but the only knowledge we have about removal is that it occurs on long unknown time scales in the deep ocean. To investigate the removal process, we evaluated terrigenous dissolved organic carbon concentration gradients in the Beaufort Gyre of the western Arctic Ocean, which allowed us to observe the carbon's slow degradation. Using isotopic tracers of water-mass age, we determined that terrigenous dissolved organic carbon is mineralized with a half-life of 7.1 +/- 3.0 years, thus allowing only 21 to 32% of it to be exported to the North Atlantic Ocean.	Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Bermuda Biol Stn Res, Ferry Reach GE01, St Georges, Bermuda	University of Miami	Hansell, DA (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, 4600 Rickenbacker Causeway, Miami, FL 33149 USA.	dhansell@rsmas.miami.edu	Hansell, Dennis A./AAC-1271-2019	Hansell, Dennis A./0000-0001-9275-3445				AAGAARD K, 1989, J GEOPHYS RES-OCEANS, V94, P14485, DOI 10.1029/JC094iC10p14485; Amon RMW, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2002JC001594; Amon RMW, 2003, DEEP-SEA RES PT I, V50, P151, DOI 10.1016/S0967-0637(02)00130-9; AMON RMW, 2003, ARCTIC OCEAN ORGANIC, P83; ANDERSON LG, 2002, BIOGEOCHEMISTRY MARI, P665; BAUCH D, 1995, PROG OCEANOGR, V35, P53, DOI 10.1016/0079-6611(95)00005-2; Benner R, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019251; Cauwet G., 2002, BIOGEOCHEMISTRY MARI, P579, DOI DOI 10.1016/B978-012323841-2/50014-2; Deser C, 2000, J CLIMATE, V13, P617, DOI 10.1175/1520-0442(2000)013<0617:ASIVIT>2.0.CO;2; Dittmar T, 2003, MAR CHEM, V83, P103, DOI 10.1016/S0304-4203(03)00105-1; Droppo IG, 1998, ARCTIC, V51, P155; Fransson A, 2001, CONT SHELF RES, V21, P225, DOI 10.1016/S0278-4343(00)00088-1; GREBMEIER JM, 2003, ARCTIC RES US, V17, P24; Guay CK, 1999, GEOPHYS RES LETT, V26, P1007, DOI 10.1029/1999GL900130; Guay CKH, 2001, J GEOPHYS RES-OCEANS, V106, P11469, DOI 10.1029/2000JC000261; Hedges JI, 1997, ORG GEOCHEM, V27, P195, DOI 10.1016/S0146-6380(97)00066-1; Karcher MJ, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2000JC000530; Kattner G, 1999, MAR CHEM, V65, P25, DOI 10.1016/S0304-4203(99)00008-0; KAUFMAN A, 1973, J GEOPHYS RES, V78, P8827, DOI 10.1029/JC078i036p08827; Lobbes JM, 2000, GEOCHIM COSMOCHIM AC, V64, P2973, DOI 10.1016/S0016-7037(00)00409-9; Macdonald RW, 2002, DEEP-SEA RES PT I, V49, P1769, DOI 10.1016/S0967-0637(02)00097-3; MANTOURA RFC, 1983, GEOCHIM COSMOCHIM AC, V47, P1293, DOI 10.1016/0016-7037(83)90069-8; Opsahl S, 1999, LIMNOL OCEANOGR, V44, P2017, DOI 10.4319/lo.1999.44.8.2017; Opsahl S, 1997, NATURE, V386, P480, DOI 10.1038/386480a0; Peterson BJ, 2002, SCIENCE, V298, P2171, DOI 10.1126/science.1077445; Proshutinsky AY, 1997, J GEOPHYS RES-OCEANS, V102, P12493, DOI 10.1029/97JC00738; Steele M, 1998, J GEOPHYS RES-OCEANS, V103, P10419, DOI 10.1029/98JC00580; VanderLoeff MMR, 1995, DEEP-SEA RES PT II, V42, P1533; Wheeler PA, 1997, DEEP-SEA RES PT II, V44, P1571, DOI 10.1016/S0967-0645(97)00051-9	29	149	156	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					858	861		10.1126/science.1096175	http://dx.doi.org/10.1126/science.1096175			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131302				2022-12-28	WOS:000221243000040
J	Martinon, F; Tschopp, J				Martinon, F; Tschopp, J			Inflammatory caspases: Linking an intracellular innate immune system to autoinflammatory diseases	CELL			English	Review							ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; LEUCINE-RICH REPEAT; FAMILIAL MEDITERRANEAN FEVER; RECRUITMENT DOMAIN PROTEIN; MUCKLE-WELLS-SYNDROME; CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; IL-1-BETA-CONVERTING ENZYME; REGULATES APOPTOSIS	Caspases not only play an essential role during apoptotic cell death, but a subfamily of them-the inflammatory caspases-are associated with immune responses to microbial pathogens. Activation of inflammatory caspases, such as caspase-1 and caspase-5, occurs upon assembly of an intracellular complex, designated the inflammasome. This results in the cleavage and activation of the proinflammatory cytokines IL-1beta and IL-18. Mutations in one of the scaffold proteins of the inflammasome, NALP3/Cryopyrin, are associated with autoinflammatory disorders underscoring the importance of regulating inflammatory caspase activation.	Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne	Tschopp, J (corresponding author), Univ Lausanne, Dept Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	jurg.tschopp@ib.unil.ch	Martinon, Fabio/A-5575-2009	Martinon, Fabio/0000-0002-6969-822X				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Aganna E, 2002, ARTHRITIS RHEUM-US, V46, P2445, DOI 10.1002/art.10509; Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Ahn EY, 2002, INT J CANCER, V100, P445, DOI 10.1002/ijc.10516; Aksentijevich I, 1997, CELL, V90, P797; Albrecht M, 2003, FEBS LETT, V554, P520, DOI 10.1016/S0014-5793(03)01222-5; Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; ARMATO U, 1999, CURR T BIOCHEM RES, V1, P1; AURON PE, 1987, J IMMUNOL, V138, P1447; Bernot A, 1997, NAT GENET, V17, P25; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Boatright KM, 2003, BIOCHEM SOC SYMP, V70, P233, DOI 10.1042/bss0700233; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bouchier-Hayes L, 2001, J BIOL CHEM, V276, P44069, DOI 10.1074/jbc.M107373200; CAMERON P, 1985, J EXP MED, V162, P790, DOI 10.1084/jem.162.3.790; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chae JJ, 2003, MOL CELL, V11, P591, DOI 10.1016/S1097-2765(03)00056-X; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; CHIN J, 1993, J IMMUNOL, V151, P5574; Choi YJ, 2001, J AM SOC NEPHROL, V12, P983, DOI 10.1681/ASN.V125983; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Conway KE, 2000, CANCER RES, V60, P6236; Cuisset L, 1999, AM J HUM GENET, V65, P1054, DOI 10.1086/302589; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; DOWDS TA, 2004, IN PRESS J BIOL CHEM; Druilhe A, 2001, CELL DEATH DIFFER, V8, P649, DOI 10.1038/sj.cdd.4400881; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Fantuzzi G, 2001, ACTA PHYSIOL SCAND, V173, P5, DOI 10.1046/j.1365-201X.2001.00879.x; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Fiorentino L, 2002, J BIOL CHEM, V277, P35333, DOI 10.1074/jbc.M200446200; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Gracie JA, 2003, J LEUKOCYTE BIOL, V73, P213, DOI 10.1189/jlb.0602313; Green DR, 2001, CELL DEATH DIFFER, V8, P549, DOI 10.1038/sj.cdd.4400887; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Hawkins PN, 2004, ARTHRITIS RHEUM-US, V50, P607, DOI 10.1002/art.20033; Hawkins PN, 2003, NEW ENGL J MED, V348, P2583, DOI 10.1056/NEJM200306193482523; Hazan J, 1999, NAT GENET, V23, P296, DOI 10.1038/15472; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Hiller S, 2003, STRUCTURE, V11, P1199, DOI 10.1016/j.str.2003.08.009; Hisahara S, 2001, J EXP MED, V193, P111, DOI 10.1084/jem.193.1.111; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hoffman HM, 2003, HUM GENET, V112, P209, DOI 10.1007/s00439-002-0860-x; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; Holt BF, 2003, CURR OPIN IMMUNOL, V15, P20, DOI 10.1016/S0952-7915(02)00014-6; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hull KM, 2003, CURR OPIN RHEUMATOL, V15, P61, DOI 10.1097/00002281-200301000-00011; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Inohara N, 2001, ONCOGENE, V20, P6473, DOI 10.1038/sj.onc.1204787; Jaroszewski L, 2000, PROTEINS, V39, P197, DOI 10.1002/(SICI)1097-0134(20000515)39:3<197::AID-PROT10>3.0.CO;2-V; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; Krippner-Heidenreich A, 2001, BIOCHEM J, V358, P705, DOI 10.1042/0264-6021:3580705; Krueger JM, 2003, ANN NY ACAD SCI, V992, P9, DOI 10.1111/j.1749-6632.2003.tb03133.x; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Liepinsh E, 2003, J MOL BIOL, V332, P1155, DOI 10.1016/j.jmb.2003.07.007; Lin XY, 2000, J BIOL CHEM, V275, P39920, DOI 10.1074/jbc.M007255200; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Masumoto J, 2003, J BIOL CHEM, V278, P4268, DOI 10.1074/jbc.M203944200; McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c; McDermott MF, 2000, ARTHRITIS RHEUM-US, V43, P2034, DOI 10.1002/1529-0131(200009)43:9<2034::AID-ANR14>3.0.CO;2-J; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Neuwald AF, 1999, GENOME RES, V9, P27; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; O'Connor W, 2003, J IMMUNOL, V171, P6329, DOI 10.4049/jimmunol.171.12.6329; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Pathan N, 2001, J BIOL CHEM, V276, P32220, DOI 10.1074/jbc.M100433200; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Razmara M, 2002, J BIOL CHEM, V277, P13952, DOI 10.1074/jbc.M107811200; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Schumann RR, 1998, BLOOD, V91, P577, DOI 10.1182/blood.V91.2.577.577_577_584; Schwartz S, 1999, CANCER RES, V59, P2995; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shiohara M, 2002, BIOCHEM BIOPH RES CO, V293, P1314, DOI 10.1016/S0006-291X(02)00384-4; Shoham NG, 2003, P NATL ACAD SCI USA, V100, P13501, DOI 10.1073/pnas.2135380100; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Staskawicz BJ, 2001, SCIENCE, V292, P2285, DOI 10.1126/science.1062013; Stehlik C, 2003, BIOCHEM J, V373, P101, DOI 10.1042/BJ20030304; Taylor SL, 2002, GENOMICS, V79, P726, DOI 10.1006/geno.2002.6752; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tong ZB, 2000, NAT GENET, V26, P267, DOI 10.1038/81547; Touitou I, 2001, EUR J HUM GENET, V9, P473, DOI 10.1038/sj.ejhg.5200658; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Verhoef PA, 2003, J IMMUNOL, V170, P5728, DOI 10.4049/jimmunol.170.11.5728; Wang CZ, 1998, J ASIAN NAT PROD RES, V1, P1, DOI 10.1080/10286029808039839; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wewers MD, 1999, J IMMUNOL, V162, P4858; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; ZIP CM, 1993, CLIN EXP DERMATOL, V18, P338, DOI 10.1111/j.1365-2230.1993.tb02212.x; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	126	731	774	1	68	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					561	574		10.1016/j.cell.2004.05.004	http://dx.doi.org/10.1016/j.cell.2004.05.004			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163405	Bronze			2022-12-28	WOS:000221857900004
J	Palmer, M; Bernhardt, E; Chornesky, E; Collins, S; Dobson, A; Duke, C; Gold, B; Jacobson, R; Kingsland, S; Kranz, R; Mappin, M; Martinez, ML; Micheli, F; Morse, J; Pace, M; Pascual, M; Palumbi, S; Reichman, OJ; Simons, A; Townsend, A; Turner, M				Palmer, M; Bernhardt, E; Chornesky, E; Collins, S; Dobson, A; Duke, C; Gold, B; Jacobson, R; Kingsland, S; Kranz, R; Mappin, M; Martinez, ML; Micheli, F; Morse, J; Pace, M; Pascual, M; Palumbi, S; Reichman, OJ; Simons, A; Townsend, A; Turner, M			Ecology for a crowded planet	SCIENCE			English	Editorial Material									Univ Maryland, College Pk, MD 20742 USA; Duke Univ, Durham, NC USA; Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA; Univ New Mexico, Albuquerque, NM 87131 USA; Princeton Univ, Princeton, NJ 08544 USA; Ecol Soc Amer, Washington, DC USA; David & Lucile Packard Fdn, Los Altos, CA USA; US Geol Survey, Columbia, MD USA; Johns Hopkins Univ, Baltimore, MD USA; Univ Calgary, Calgary, AB T2N 1N4, Canada; Inst Ecol, Xalapa, Veracruz, Mexico; Stanford Univ, Pacific Grove, CA USA; Inst Ecosyst Studies, Millbrook, NY 12545 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA; COMPASS, Washington, DC USA; Univ Colorado, Boulder, CO 80309 USA; Univ Wisconsin, Madison, WI USA	University System of Maryland; University of Maryland College Park; Duke University; University of California System; University of California Santa Cruz; University of New Mexico; Princeton University; United States Department of the Interior; United States Geological Survey; Johns Hopkins University; University of Calgary; Instituto de Ecologia - Mexico; Stanford University; Cary Institute of Ecosystem Studies; University of Michigan System; University of Michigan; University of California System; University of California Santa Barbara; University of Colorado System; University of Colorado Boulder; University of Wisconsin System; University of Wisconsin Madison	Palmer, M (corresponding author), Univ Maryland, College Pk, MD 20742 USA.	mpalmer@umd.edu	Collins, Scott L/P-7742-2014; Martinez, M. Luisa/R-4631-2017; Townsend, Alan/AAE-9602-2019; Bernhardt, Emily/B-4541-2010; Bernhardt, Emily S/D-9940-2011; Palmer, Margaret A/F-9648-2013	Collins, Scott L/0000-0002-0193-2892; Martinez, M. Luisa/0000-0002-4469-5284; Bernhardt, Emily S/0000-0003-3031-621X; Palmer, Margaret A/0000-0003-1468-7993; Micheli, Fiorenza/0000-0002-6865-1438; Pace, Michael/0000-0001-5945-6131; Morse, Jennifer/0000-0001-8872-4940				Alberti M, 2003, BIOSCIENCE, V53, P1169, DOI 10.1641/0006-3568(2003)053[1169:IHIEOA]2.0.CO;2; Daily GC, 1997, NATURES SERVICES SOC, DOI DOI 10.12987/9780300188479-039; Font WF, 2003, BIOSCIENCE, V53, P1061, DOI 10.1641/0006-3568(2003)053[1061:TGSOPW]2.0.CO;2; Gleick PH, 2000, WORLDS WATER BIENNIA; Graham DW, 2004, FRONT ECOL ENVIRON, V2, P199, DOI 10.1890/1540-9295(2004)002[0199:DESAOE]2.0.CO;2; Gunderson L., 2002, RESILIENCE BEHAV LAR; LUBCHENCO J, 1991, ECOLOGY, V72, P371, DOI 10.2307/2937183; MARTINEZ ML, 2004, ECOLOGICAL STUDIES S, V171; McMichael AJ, 2003, SCIENCE, V302, P1919; Millennium Ecosystem Assessment, 2003, EC HUM WELL BEING; Palmer MA, 2004, ECOLOGICAL SCI SUSTA; Palumbi SR, 2003, P NATL ACAD SCI USA, V100, P11927, DOI 10.1073/pnas.2335832100; Vitousek PM, 1997, ECOL APPL, V7, P737, DOI 10.2307/2269431	13	318	368	7	176	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1251	1252		10.1126/science.1095780	http://dx.doi.org/10.1126/science.1095780			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166349				2022-12-28	WOS:000221669600023
J	Sobering, AK; Watanabe, R; Romeo, MJ; Yan, BC; Specht, CA; Orlean, P; Riezman, H; Levin, DE				Sobering, AK; Watanabe, R; Romeo, MJ; Yan, BC; Specht, CA; Orlean, P; Riezman, H; Levin, DE			Yeast Ras regulates the complex that catalyzes the first step in GPI-anchor biosynthesis at the ER	CELL			English	Article							PHOSPHATE-MANNOSE SYNTHASE; SACCHAROMYCES-CEREVISIAE; CHITIN SYNTHESIS; ENDOPLASMIC-RETICULUM; CELL-WALL; PROTEINS; GENE; PATHWAYS; CLONING; KINASE	The yeast ERI1 gene encodes a small ER-localized protein that associates in vivo with GTP bound Ras2 in an effector loop-dependent manner. We showed previously that loss of Eri1 function results in hyperactive Ras phenotypes. Here, we demonstrate that Eri1 is a component of the GPl-GlcNAc transferase (GPl-GnT) complex in the ER, which catalyzes transfer of GlcNAc from UDP-GlcNAc to an acceptor phosphatidylinositol, the first step in the production of GPl-anchors for cell surface proteins. We also show that GTP bound Ras2 associates with the GPl-GnT complex in vivo and inhibits its activity, indicating that yeast Ras uses the ER as a signaling platform from which to negatively regulate the GPl-GnT. We propose that diminished GPl-anchor protein production contributes to hyperactive Ras phenotypes.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; Univ Geneva, Dept Biochem Sci 2, CH-1211 Geneva, Switzerland; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Geneva; University of Illinois System; University of Illinois Urbana-Champaign; Boston University	Levin, DE (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.	levin@jhmi.edu		Romeo, Martin/0000-0001-7941-1862; Levin, David/0000-0003-0696-2860; Riezman, Howard/0000-0003-4680-9422; Watanabe, Reika/0000-0002-7427-7702	NCI NIH HHS [5T32CA09110] Funding Source: Medline; NIGMS NIH HHS [GM46220, GM48533, R01 GM067698, GM67698] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067698, R01GM048533, R01GM046220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; Bulik DA, 2003, EUKARYOT CELL, V2, P886, DOI 10.1128/EC.2.5.886-900.2003; CABIB E, 1987, ADV ENZYMOL RAMB, V59, P59; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Gancedo JM, 2001, FEMS MICROBIOL REV, V25, P107, DOI 10.1016/S0168-6445(00)00056-5; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; JOENS EW, 1997, MOL CELLULAR BIOL YE, P363; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; Kostova Z, 2000, BIOCHEM J, V350, P815, DOI 10.1042/0264-6021:3500815; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Maeda Y, 2000, EMBO J, V19, P2475, DOI 10.1093/emboj/19.11.2475; Mosch HU, 1999, MOL BIOL CELL, V10, P1325, DOI 10.1091/mbc.10.5.1325; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; Orlean P., 1997, MOL CELLULAR BIOL YE, P229; Osmond BC, 1999, P NATL ACAD SCI USA, V96, P11206, DOI 10.1073/pnas.96.20.11206; Popolo L, 1999, BBA-GEN SUBJECTS, V1426, P385, DOI 10.1016/S0304-4165(98)00138-X; Romeo MJ, 2002, MOL CELL BIOL, V22, P8165, DOI 10.1128/MCB.22.23.8165-8174.2002; SCHONBACHLER M, 1995, EMBO J, V14, P1637, DOI 10.1002/j.1460-2075.1995.tb07152.x; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sobering AK, 2003, MOL CELL BIOL, V23, P4983, DOI 10.1128/MCB.23.14.4983-4990.2003; Sobering AK, 2002, EUKARYOT CELL, V1, P56, DOI 10.1128/EC.1.1.56-65.2002; Sutterlin C, 1997, J CELL SCI, V110, P2703; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; Valdivieso MH, 2000, J BACTERIOL, V182, P4752, DOI 10.1128/JB.182.17.4752-4757.2000; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Watanabe R, 2000, EMBO J, V19, P4402, DOI 10.1093/emboj/19.16.4402; WATZELE G, 1989, J BIOL CHEM, V264, P8753; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Yan BC, 2001, YEAST, V18, P1383, DOI 10.1002/yea.783	44	52	56	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					637	648		10.1016/j.cell.2004.05.003	http://dx.doi.org/10.1016/j.cell.2004.05.003			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163411	Bronze			2022-12-28	WOS:000221857900010
J	Cheng, PKC; Wong, DA; Tong, LKL; Ip, SM; Lo, ACT; Lau, CS; Yeung, EYH; Lim, WWL				Cheng, PKC; Wong, DA; Tong, LKL; Ip, SM; Lo, ACT; Lau, CS; Yeung, EYH; Lim, WWL			Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome	LANCET			English	Article								Severe acute respiratory syndrome (SARS) is thought to be caused by a novel coronavirus, SARS-associated coronavirus. We studied viral shedding of SARS coronavirus to improve diagnosis and infection control. Reverse-transcriptase PCR was done on 2134 specimens of different types. 355 (45%) specimens of nasopharyngeal aspirates and 150 (28%) of faeces were positive for SARS coronavirus RNA. Positive rates peaked at 6-11 days after onset of illness for nasopharyngeal aspirates (87 of 149 [58%], to 37 of 62 [60%]), and 9-14 days for faeces (15 of 22 [68%], to 26 of 37 [70%]). Overall, peak viral loads were reached at 12-14 days of illness when patients were probably in hospital care, which would explain why hospital workers were prone to infection. Low rate of viral shedding in the first few days of illness meant that early isolation measures would probably be effective.	Publ Hlth Lab Ctr, Govt Virus Unit, Kowloon, Hong Kong, Peoples R China		Lim, WWL (corresponding author), Publ Hlth Lab Ctr, Govt Virus Unit, 382 Nam Cheong St, Kowloon, Hong Kong, Peoples R China.	wllim@pacific.net.hk						Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Tsang OTY, 2003, EMERG INFECT DIS, V9, P1381, DOI 10.3201/eid0911.030400; *WHO, CASE DEF SURV SEV AC; *WHO, SEV AC RESP SYNDR MU	5	223	235	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	2004	363	9422					1699	1700		10.1016/S0140-6736(04)16255-7	http://dx.doi.org/10.1016/S0140-6736(04)16255-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158632	Green Published, Bronze			2022-12-28	WOS:000221546300011
J	Concato, J; Horwitz, RI				Concato, J; Horwitz, RI			Beyond randomised versus observational studies	LANCET			English	Editorial Material							EVIDENCE-BASED MEDICINE; CLINICAL-TRIALS; THERAPY; CANCER		W Haven Vet Affairs Med Ctr, Clin Epidemiol Res Ctr, West Haven, CT USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; Case Western Reserve Univ, Sch Med, Off Dean, Cleveland, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Case Western Reserve University	Concato, J (corresponding author), W Haven Vet Affairs Med Ctr, Clin Epidemiol Res Ctr, West Haven, CT USA.	john.concato@yale.edu						Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; Concato J, 2001, CANCER, V91, P1607, DOI 10.1002/1097-0142(20010415)91:8+<1607::AID-CNCR1174>3.0.CO;2-J; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; FEINSTEIN AR, 1981, JAMA-J AM MED ASSOC, V246, P957, DOI 10.1001/jama.246.9.957; Garbe E, 2004, HUM REPROD, V19, P8, DOI 10.1093/humrep/deh022; Goodman SN, 2002, ANN INTERN MED, V137, P363, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00015; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365; Gunnell D, 2002, INT J EPIDEMIOL, V31, P390, DOI 10.1093/ije/31.2.390; Guyatt GH, 1996, JAMA-J AM MED ASSOC, V275, P1232; Horwitz R I, 1987, Am J Med, V82, P498, DOI 10.1016/0002-9343(87)90450-5; Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185; McKee M, 1999, BMJ-BRIT MED J, V319, P312, DOI 10.1136/bmj.319.7205.312; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; RABENECK L, 1992, ARCH INTERN MED, V152, P507, DOI 10.1001/archinte.152.3.507; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, V2nd, P861	20	107	107	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	2004	363	9422					1660	1661		10.1016/S0140-6736(04)16285-5	http://dx.doi.org/10.1016/S0140-6736(04)16285-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158623				2022-12-28	WOS:000221546300002
J	Hester, JJ; Desch, SJ; Healy, KR; Leshin, LA				Hester, JJ; Desch, SJ; Healy, KR; Leshin, LA			The cradle of the solar system	SCIENCE			English	Editorial Material							YOUNG STELLAR OBJECTS; ORION NEBULA; PHOTOEVAPORATION; CLOUDS; DISKS; BIRTH; M16		Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA; Arizona State Univ, Dept Geol Sci, Tempe, AZ 85387 USA; Arizona State Univ, Ctr Meteorite Studies, Tempe, AZ 85387 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Hester, JJ (corresponding author), Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA.	jhester@asu.edu						Adams FC, 2001, ICARUS, V150, P151, DOI 10.1006/icar.2000.6567; Bally J, 2000, ASTRON J, V119, P2919, DOI 10.1086/301385; Bally J, 1998, ASTRON J, V116, P854, DOI 10.1086/300469; BERTOLDI F, 1990, ASTROPHYS J, V354, P529, DOI 10.1086/168713; HEALY KR, IN PRESS ASTROPHYS J; Hester JJ, 1996, ASTRON J, V111, P2349, DOI 10.1086/117968; HESTER JJ, 1999, BAAS, V31, P932; Johnstone D, 1998, ASTROPHYS J, V499, P758, DOI 10.1086/305658; Lada CJ, 2003, ANNU REV ASTRON ASTR, V41, P57, DOI 10.1146/annurev.astro.41.011802.094844; Sugitani K, 2002, ASTROPHYS J, V565, pL25, DOI 10.1086/339196; Tachibana S, 2003, ASTROPHYS J, V588, pL41, DOI 10.1086/375362	12	81	83	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	2004	304	5674					1116	1117		10.1126/science.1096808	http://dx.doi.org/10.1126/science.1096808			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155936				2022-12-28	WOS:000221524500026
J	Jedicke, R; Nesvorny, D; Whiteley, R; Ivezic, Z; Juric, M				Jedicke, R; Nesvorny, D; Whiteley, R; Ivezic, Z; Juric, M			An age-colour relationship for main-belt S-complex asteroids	NATURE			English	Article							NEAR-EARTH ASTEROIDS; ORDINARY CHONDRITE METEORITES; FAMILIES	Asteroid collisions in the main belt eject fragments that may eventually land on Earth as meteorites(1-3). It has therefore been a long-standing puzzle in planetary science that laboratory spectra of the most populous class of meteorite (ordinary chondrites, OC) do not match the remotely observed surface spectra of their presumed (S-complex) asteroidal parent bodies. One of the proposed solutions to this perplexing observation is that 'space weathering' modifies the exposed planetary surfaces over time through a variety of processes (such as solar and cosmic ray bombardment, micro-meteorite bombardment, and so on). Space weathering has been observed on lunar samples(4), in Earth-based laboratory experiments(5,6), and there is good evidence from spacecraft data that the process is active on asteroid surfaces(7,8). Here, we present a measurement of the rate of space weathering on S-complex main-belt asteroids using a relationship between the ages of asteroid families and their colours(9). Extrapolating this age-colour relationship to very young ages yields a good match to the colour of freshly cut OC meteorite samples, lending strong support to a genetic relationship between them and the S-complex asteroids.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; SW Res Inst, Boulder, CO 80302 USA; USAF, Space & Missile Syst Ctr, Los Angeles AFB, El Segundo, CA 90245 USA; Princeton Univ, Dept Astrophys Sci, Princeton, NJ 08544 USA	University of Hawaii System; United States Department of Defense; United States Air Force; Princeton University	Jedicke, R (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.	jedicke@ifa.hawaii.edu		Jedicke, Robert/0000-0001-7830-028X; Juric, Mario/0000-0003-1996-9252				ADAMS JB, 1971, SCIENCE, V171, P567, DOI 10.1126/science.171.3971.567; Binzel RP, 1996, SCIENCE, V273, P946, DOI 10.1126/science.273.5277.946; Bus SJ, 2002, ICARUS, V158, P106, DOI 10.1006/icar.2002.6857; Chapman CR, 1996, METEORIT PLANET SCI, V31, P699, DOI 10.1111/j.1945-5100.1996.tb02107.x; Clark BE, 2001, METEORIT PLANET SCI, V36, P1617, DOI 10.1111/j.1945-5100.2001.tb01853.x; DEEMING TJ, 1964, MON NOT R ASTRON SOC, V127, P493, DOI 10.1093/mnras/127.6.493; DIMARTINO M, 1995, ASTRON ASTROPHYS, V302, P609; Doressoundiram A, 1998, ICARUS, V131, P15, DOI 10.1006/icar.1997.5852; GAFFEY MJ, 1976, J GEOPHYS RES, V81, P905, DOI 10.1029/JB081i005p00905; GAFFEY MJ, 1993, ICARUS, V106, P573, DOI 10.1006/icar.1993.1194; Gladman BJ, 1997, SCIENCE, V277, P197, DOI 10.1126/science.277.5323.197; Hapke B, 2001, J GEOPHYS RES-PLANET, V106, P10039, DOI 10.1029/2000JE001338; Ivezic Z., 2002, Proceedings of the SPIE - The International Society for Optical Engineering, V4836, P98, DOI 10.1117/12.457304; Ivezic Z, 2002, ASTRON J, V124, P2943, DOI 10.1086/344077; Lazzarin M, 1997, ASTRON ASTROPHYS, V327, P388; MARTI K, 1992, ANNU REV EARTH PL SC, V20, P221, DOI 10.1146/annurev.ea.20.050192.001253; Michel P, 2001, SCIENCE, V294, P1696, DOI 10.1126/science.1065189; Migliorini F, 1997, ICARUS, V128, P104, DOI 10.1006/icar.1997.5679; MILANI A, 1994, ICARUS, V107, P219, DOI 10.1006/icar.1994.1020; Morbidelli A, 2003, ICARUS, V163, P120, DOI 10.1016/S0019-1035(03)00047-2; Moroz LV, 1996, ICARUS, V122, P366, DOI 10.1006/icar.1996.0130; Rabinowitz DL, 1998, ICARUS, V134, P342, DOI 10.1006/icar.1998.5951; Sasaki S, 2001, NATURE, V410, P555, DOI 10.1038/35069013; Sykes MV, 2000, ICARUS, V146, P161, DOI 10.1006/icar.2000.6366; Tedesco EF, 2002, ASTRON J, V123, P1056, DOI 10.1086/338320; Vokrouhlicky D, 2000, NATURE, V407, P606, DOI 10.1038/35036528; WISDOM J, 1985, NATURE, V315, P731, DOI 10.1038/315731a0	27	56	56	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 20	2004	429	6989					275	277		10.1038/nature02578	http://dx.doi.org/10.1038/nature02578			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152246				2022-12-28	WOS:000221505900036
J	Mills, MM; Ridame, C; Davey, M; La Roche, J; Geider, RJ				Mills, MM; Ridame, C; Davey, M; La Roche, J; Geider, RJ			Iron and phosphorus co-limit nitrogen fixation in the eastern tropical North Atlantic	NATURE			English	Article							OCEANIC PRIMARY PRODUCTION; WESTERN MEDITERRANEAN SEA; MARINE CYANOBACTERIUM; TRICHODESMIUM SPP.; PACIFIC-OCEAN; PHYTOPLANKTON; GROWTH; PHOSPHATE; N-2	The role of iron in enhancing phytoplankton productivity in high nutrient, low chlorophyll oceanic regions was demonstrated first through iron-addition bioassay experiments(1) and subsequently confirmed by large-scale iron fertilization experiments(2). Iron supply has been hypothesized to limit nitrogen fixation and hence oceanic primary productivity on geological timescales(3), providing an alternative to phosphorus as the ultimate limiting nutrient(4). Oceanographic observations have been interpreted both to confirm and refute this hypothesis(5,6), but direct experimental evidence is lacking(7). We conducted experiments to test this hypothesis during the Meteor 55 cruise to the tropical North Atlantic. This region is rich in diazotrophs(8) and strongly impacted by Saharan dust input(9). Here we show that community primary productivity was nitrogen-limited, and that nitrogen fixation was co-limited by iron and phosphorus. Saharan dust addition stimulated nitrogen fixation, presumably by supplying both iron and phosphorus(10,11). Our results support the hypothesis that aeolian mineral dust deposition promotes nitrogen fixation in the eastern tropical North Atlantic.	Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England; IFM GEOMAR Leibniz Inst Meereswissensch, D-24105 Kiel, Germany; Marine Biol Assoc UK, Plymouth PL1 2PB, Devon, England	University of Essex; Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; Marine Biological Association United Kingdom	Geider, RJ (corresponding author), Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England.	geider@essex.ac.uk	LaRoche, Julie/A-1109-2010	LaRoche, Julie/0000-0003-4809-6411; Geider, Richard/0000-0003-3276-047X				Ammerman J.W., 2003, EOS T AM GEOPHYS UN, V84, P165, DOI [10.1029/2003-o180001, DOI 10.1029/2003EO180001, 10.1029/2003EO180001]; Berman-Frank I, 2001, LIMNOL OCEANOGR, V46, P1249, DOI 10.4319/lo.2001.46.6.1249; Boyd PW, 2000, NATURE, V407, P695, DOI 10.1038/35037500; Capone DG, 1997, SCIENCE, V276, P1221, DOI 10.1126/science.276.5316.1221; Coale KH, 1996, NATURE, V379, P621, DOI 10.1038/379621a0; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; Gao Y, 2001, GEOPHYS RES LETT, V28, P29, DOI 10.1029/2000GL011926; GLIBERT PM, 1994, APPL ENVIRON MICROB, V60, P3996, DOI 10.1128/AEM.60.11.3996-4000.1994; Graziano LM, 1996, AQUAT MICROB ECOL, V11, P53, DOI 10.3354/ame011053; Gruber N, 1997, GLOBAL BIOGEOCHEM CY, V11, P235, DOI 10.1029/97GB00077; Guieu C, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000582; Karl D, 2002, BIOGEOCHEMISTRY, V57, P47, DOI 10.1023/A:1015798105851; Kustka A, 2003, J PHYCOL, V39, P12, DOI 10.1046/j.1529-8817.2003.01156.x; Kustka AB, 2003, LIMNOL OCEANOGR, V48, P1869, DOI 10.4319/lo.2003.48.5.1869; LOHRENZ SE, 1992, J PLANKTON RES, V14, P201, DOI 10.1093/plankt/14.2.201; Mahowald N, 1999, J GEOPHYS RES-ATMOS, V104, P15895, DOI 10.1029/1999JD900084; MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341a0; Montoya JP, 1996, APPL ENVIRON MICROB, V62, P986, DOI 10.1128/AEM.62.3.986-993.1996; Morel FMM, 2003, SCIENCE, V300, P944, DOI 10.1126/science.1083545; Palinska KA, 2002, MICROBIOL-SGM, V148, P2405, DOI 10.1099/00221287-148-8-2405; REDFIELD AC, 1958, AM SCI, V46, P205; Ridame C, 2002, LIMNOL OCEANOGR, V47, P856, DOI 10.4319/lo.2002.47.3.0856; RUE EL, 1995, MAR CHEM, V50, P117, DOI 10.1016/0304-4203(95)00031-L; Sanudo-Wilhelmy SA, 2001, NATURE, V411, P66, DOI 10.1038/35075041; Tyrrell T, 2003, J PLANKTON RES, V25, P405, DOI 10.1093/plankt/25.4.405; Tyrrell T, 1999, NATURE, V400, P525, DOI 10.1038/22941; WELSCHMEYER N, 1994, LIMNOL OCEANOGR, V38, P1985; Wu JF, 2000, SCIENCE, V289, P759, DOI 10.1126/science.289.5480.759; Wu JF, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2002GB001924; Zehr JP, 2001, NATURE, V412, P635, DOI 10.1038/35088063	30	684	708	8	270	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					292	294		10.1038/nature02550	http://dx.doi.org/10.1038/nature02550			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152251	Green Submitted			2022-12-28	WOS:000221505900041
J	Wilson, JF				Wilson, JF			Finland pioneers international suicide prevention	ANNALS OF INTERNAL MEDICINE			English	Article												jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136					0	9	10	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					853	856		10.7326/0003-4819-140-10-200405180-00037	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00037			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148086				2022-12-28	WOS:000221520900025
J	Al-Ubaydli, M				Al-Ubaydli, M			Handheld computers	BMJ-BRITISH MEDICAL JOURNAL			English	Review									NIH, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA	Al-Ubaydli, M (corresponding author), NIH, Bethesda, MD 20814 USA.	mo@mo.md						Rothschild JM, 2002, J AM MED INFORM ASSN, V9, P223, DOI 10.1197/jamia.M1001	1	23	23	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2004	328	7449					1181	1184		10.1136/bmj.328.7449.1181	http://dx.doi.org/10.1136/bmj.328.7449.1181			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142928	Green Published			2022-12-28	WOS:000221497500029
J	Fernando, B; Savelyich, BSP; Avery, AJ; Sheikh, A; Bainbridge, M; Horsfield, P; Teasdale, S				Fernando, B; Savelyich, BSP; Avery, AJ; Sheikh, A; Bainbridge, M; Horsfield, P; Teasdale, S			Prescribing safety features of general practice computer systems: evaluation using simulated test cases	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England; Univ Edinburgh, GP Sect, Div Community Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Nottingham, PRIMIS, Nottingham NG7 2RD, England	University of Nottingham; University of Edinburgh; University of Nottingham	Avery, AJ (corresponding author), Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England.	tony.avery@nottingham.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056; Avery, Anthony/0000-0001-7591-4438				Avery Anthony J, 2003, Inform Prim Care, V11, P203; Department of Health, 2002, DEL 21 CENT IT SUPP; Magnus D, 2002, J CLIN PHARM THER, V27, P377, DOI 10.1046/j.1365-2710.2002.00434.x; Wilson T, 2002, BRIT MED J, V324, P584, DOI 10.1136/bmj.324.7337.584; YENFU C, 2001, PHARMACOEPIDEM DR S, V10, pS53	5	41	42	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2004	328	7449					1171	1172		10.1136/bmj.328.7449.1171	http://dx.doi.org/10.1136/bmj.328.7449.1171			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142922	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000221497500023
J	Somers, CM; McCarry, BE; Malek, F; Quinn, JS				Somers, CM; McCarry, BE; Malek, F; Quinn, JS			Reduction of particulate air pollution lowers the risk of heritable mutations in mice	SCIENCE			English	Article							AMBIENT AIR; MOUSE; CANCER; ADMISSIONS; RADIATION; INDUCTION; MORTALITY; EXPOSURE; DAMAGE; LOCI	Urban and industrial air pollution can cause elevated heritable mutation rates in birds and rodents. The relative importance of airborne particulate matter versus gas-phase substances in causing these genetic effects under ambient conditions has been unclear. Here we show that high-efficiency particulate-air (HEPA) filtration of ambient air significantly reduced heritable mutation rates at repetitive DNA loci in laboratory mice housed outdoors near a major highway and two integrated steel mills. These findings implicate exposure to airborne particulate matter as a principal factor contributing to elevated mutation rates in sentinel mice and add to accumulating evidence that air pollution may pose genetic risks to humans and wildlife.	McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8S 4K1, Canada; Lakeland Coll, Sch Environm Sci, Vermilion, AB T9X 1K5, Canada	McMaster University; McMaster University	Quinn, JS (corresponding author), McMaster Univ, Dept Biol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	quinn@mcmaster.ca	Malek, Fairouz/E-4410-2018; Somers, Christopher/AAE-6390-2019	Malek, Fairouz/0000-0002-0948-5775; 				Bobak M, 2000, ENVIRON HEALTH PERSP, V108, P173, DOI 10.2307/3454517; Bois P, 1998, GENOMICS, V49, P122, DOI 10.1006/geno.1998.5228; Bostrom CE, 2002, ENVIRON HEALTH PERSP, V110, P451, DOI 10.1289/ehp.02110s3451; Burgaz S, 2002, CHEMOSPHERE, V47, P57, DOI 10.1016/S0045-6535(01)00185-0; BURNETT RT, 1995, AM J EPIDEMIOL, V142, P15, DOI 10.1093/oxfordjournals.aje.a117540; DELFINO RJ, 1994, ENVIRON RES, V67, P1, DOI 10.1006/enrs.1994.1061; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Dubrova YE, 2002, MUTAT RES-FUND MOL M, V499, P143, DOI 10.1016/S0027-5107(01)00284-6; ETTINGER HJ, 1969, AM IND HYG ASSOC J, V30, P20, DOI 10.1080/0002889698506002; GIBBS M, 1993, GENOMICS, V17, P121, DOI 10.1006/geno.1993.1292; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; Krewski D, 2003, J TOXICOL ENV HEAL A, V66, P1507, DOI 10.1080/15287390306424; LEGZDINS AE, 1994, POLYCYCL AROMAT COMP, V5, P157, DOI 10.1080/10406639408015167; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; Palli D, 2001, INT J CANCER, V94, P121, DOI 10.1002/ijc.1433; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Ritz B, 2002, AM J EPIDEMIOL, V155, P17, DOI 10.1093/aje/155.1.17; Selevan SG, 2000, ENVIRON HEALTH PERSP, V108, P887, DOI 10.2307/3434998; Soares SRC, 2003, ENVIRON RES, V92, P191, DOI 10.1016/S0013-9351(02)00061-0; Somers CM, 2002, P NATL ACAD SCI USA, V99, P15904, DOI 10.1073/pnas.252499499; Sorensen M, 2003, CANCER EPIDEM BIOMAR, V12, P191; Vilarino-Guell C, 2003, MUTAT RES-FUND MOL M, V526, P63, DOI 10.1016/S0027-5107(03)00016-2; YAMADA Y, 1984, HEALTH PHYS, V46, P543, DOI 10.1097/00004032-198403000-00005; Yauk CL, 2000, MUTAT RES-FUND MOL M, V452, P211, DOI 10.1016/S0027-5107(00)00093-2; Yauk CL, 1996, P NATL ACAD SCI USA, V93, P12137, DOI 10.1073/pnas.93.22.12137	25	237	252	1	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					1008	1010		10.1126/science.1095815	http://dx.doi.org/10.1126/science.1095815			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143280				2022-12-28	WOS:000221383300048
J	Barnett, HJM				Barnett, HJM			Carotid endarterectomy	LANCET			English	Editorial Material												hjmb@sympatico.ca						Barnett H J M, 2003, Adv Neurol, V92, P319; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; BARNETT HJM, 2003, CMAJ, V166, P1167; EASTCOTT HHG, 1954, LANCET, V2, P994; *EUR CAR SURG TRIA, 1991, LANCET, V347, P1591; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Inzitari D, 2000, NEW ENGL J MED, V342, P1693, DOI 10.1056/NEJM200006083422302; Johnston DCC, 2001, NEUROLOGY, V56, P1009, DOI 10.1212/WNL.56.8.1009; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035	9	32	32	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2004	363	9420					1486	1487		10.1016/S0140-6736(04)16182-5	http://dx.doi.org/10.1016/S0140-6736(04)16182-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135590				2022-12-28	WOS:000221302700002
J	Sadler, L; Saftlas, A; Wang, WQ; Exeter, M; Whittaker, J; McCowan, L				Sadler, L; Saftlas, A; Wang, WQ; Exeter, M; Whittaker, J; McCowan, L			Treatment for cervical intraepithelial neoplasia and risk of preterm delivery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LARGE LOOP EXCISION; 2001 CONSENSUS GUIDELINES; TRANSFORMATION ZONE; UTERINE CERVIX; LASER-SURGERY; CONE BIOPSY; PREGNANCY; CONIZATION; WOMEN; MANAGEMENT	Context It is unclear whether treatments for cervical intraepithelial neoplasia (CIN) increase the subsequent risk of preterm delivery. Most studies have lacked sufficient sample size, mixed heterogeneous subtypes of preterm delivery, and failed to control for confounding factors. Objective To determine whether cervical laser and loop electrosurgical excision procedure (LEEP) treatments increase risk of preterm delivery and its subtypes. Design, Setting, and Participants Retrospective cohort study conducted among women evaluated at a colposcopy clinic serving Auckland, New Zealand (1988-2000), comparing delivery outcomes of untreated women (n =426) and those treated (n = 652) with laser conization, laser ablation, or LEEP. Record linkage using unique health identifiers identified women who had subsequent deliveries. Main Outcome Measures Total preterm delivery and its subtypes, spontaneous labor and premature rupture of membranes before 37 weeks' gestation (pPROM). Results The overall rate of preterm delivery was 13.8%. The rate of pPROM was 6.2 % and the rate of spontaneous preterm delivery was 3.8 %. Analyses showed no significant increase in risk of total preterm delivery (adjusted relative risk [aRR], 1.1; 95% confidence interval [CI], 0.8-1.5) or spontaneous preterm delivery (aRR, 1.3; 95% Cl, 0.7-2.6) for any treatment. Risk of pPROM was significantly increased following treatment with laser conization (aRR, 2.7; 95% Cl, 1.3-5.6) or LEEP (aRR, 1.9; 95% Cl, 1.0-3.8), but not laser ablation (aRR, 1.1; 95% Cl, 0.5-2.4). Moreover, risk of pPROM and total preterm delivery increased significantly with increasing height of tissue removed from the cervix in conization. Women in the highest tertile of cone height (greater than or equal to1.7 cm) had a greater than 3-fold increase in risk of pPROM compared with untreated women (aRR, 3.6; 95% Cl, 1.8-7.5). Conclusions LEEP and laser cone treatments were associated with significantly increased risk of pPROM. Careful consideration should be given to treatment of CIN in women of reproductive age, especially when treatment might reasonably be delayed or targeted to high-risk cases.	Univ Auckland, Natl Womens Hosp, Dept Obstet & Gynaecol, Auckland 1, New Zealand; Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA	University of Auckland; University of Iowa	Sadler, L (corresponding author), Univ Auckland, Natl Womens Hosp, Dept Obstet & Gynaecol, Private Bag 92-189, Auckland 1, New Zealand.	l.sadler@auckland.ac.nz	McCowan, Lesley/C-2215-2009	McCowan, Lesley/0000-0001-9915-7873	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037924] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD37924] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Althuisius SM, 2001, AM J OBSTET GYNECOL, V185, P1106, DOI 10.1067/mob.2001.118655; BLOMFIELD PI, 1993, AM J OBSTET GYNECOL, V169, P620, DOI 10.1016/0002-9378(93)90633-T; Braet P. G., 1994, Journal of Obstetrics and Gynaecology (Abingdon), V14, P79, DOI 10.3109/01443619409030016; BULLER RE, 1982, AM J OBSTET GYNECOL, V142, P506, DOI 10.1016/0002-9378(82)90752-9; Coppell K, 2000, NEW ZEAL MED J, V113, P48; CRAMPTON P, 1998, NZ PUBLIC HLTH REPOR, V5, P81; CRUICKSHANK ME, 1995, BRIT J OBSTET GYNAEC, V102, P467, DOI 10.1111/j.1471-0528.1995.tb11319.x; Drakeley AJ, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003253, DOI 10.1002/14651858.CD003253]; El-Bastawissi AY, 1999, OBSTET GYNECOL, V93, P207, DOI 10.1016/S0029-7844(98)00386-X; Forsmo S, 1996, ACTA OBSTET GYN SCAN, V75, P139, DOI 10.3109/00016349609033306; Gunasekera P. C., 1992, Journal of Obstetrics and Gynaecology (Abingdon), V12, P291, DOI 10.3109/01443619209015508; HAFFENDEN DK, 1993, BRIT J OBSTET GYNAEC, V100, P1059, DOI 10.1111/j.1471-0528.1993.tb15153.x; HAGEN B, 1993, BRIT J OBSTET GYNAEC, V100, P717, DOI 10.1111/j.1471-0528.1993.tb14261.x; JONES JM, 1979, BRIT J OBSTET GYNAEC, V86, P913, DOI 10.1111/j.1471-0528.1979.tb11237.x; KRISTENSEN J, 1993, OBSTET GYNECOL, V81, P1005; LARSSON G, 1982, ACTA OBSTET GYN SCAN, V61, P461, DOI 10.3109/00016348209156591; LEIMAN G, 1980, AM J OBSTET GYNECOL, V136, P14, DOI 10.1016/0002-9378(80)90556-6; LUDVIKSSON K, 1982, EUR J OBSTET GYN R B, V14, P135, DOI 10.1016/0028-2243(82)90088-0; MATHEVET P, 1994, GYNECOL ONCOL, V54, P175, DOI 10.1006/gyno.1994.1189; MOINIAN M, 1982, EUR J OBSTET GYN R B, V14, P135; Paraskevaidis E, 2002, GYNECOL ONCOL, V86, P10, DOI 10.1006/gyno.2002.6650; RAOI L, 1997, OBSTET GYNECOL, V90, P978; RICCIOTTI HA, 1995, INT J GYNECOL OBSTET, V50, P175, DOI 10.1016/0020-7292(95)02432-C; SAGOT P, 1995, EUR J OBSTET GYN R B, V58, P53, DOI 10.1016/0028-2243(94)01986-H; SAUNDERS N, 1986, REPROD PERINAT MED, V6, P121; SAVITZ DA, 1991, AM J OBSTET GYNECOL, V164, P467, DOI 10.1016/S0002-9378(11)80001-3; SOUTTER WP, 1986, COLP GYNECOL LAS SUR, V2, P35; SPITZER M, 1995, OBSTET GYNECOL, V86, P504, DOI 10.1016/0029-7844(95)00237-L; SVARE JA, 1992, EUR J OBSTET GYN R B, V47, P41, DOI 10.1016/0028-2243(92)90212-H; WEBER T, 1979, ACTA OBSTET GYN SCAN, V58, P347, DOI 10.3109/00016347909154594; Wright TC, 2003, AM J OBSTET GYNECOL, V189, P295, DOI 10.1067/mob.2003.633; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120	32	284	309	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2004	291	17					2100	2106		10.1001/jama.291.17.2100	http://dx.doi.org/10.1001/jama.291.17.2100			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JR	15126438	Bronze			2022-12-28	WOS:000221174300027
J	Raser, JM; O'Shea, EK				Raser, JM; O'Shea, EK			Control of stochasticity in eukaryotic gene expression	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PHO5 PROMOTER; NOISE; CHROMATIN; ACTIVATION; NETWORKS; PRODUCT; YEAST; LOCUS	Noise, or random fluctuations, in gene expression may produce variability in cellular behavior. To measure the noise intrinsic to eukaryotic gene expression, we quantified the differences in expression of two alleles in a diploid cell. We found that such noise is gene-specific and not dependent on the regulatory pathway or absolute rate of expression. We propose a model in which the balance between promoter activation and transcription influences the variability in messenger RNA levels. To confirm the predictions of our model, we identified both cis- and trans-acting mutations that alter the noise of gene expression. These mutations suggest that noise is an evolvable trait that can be optimized to balance fidelity and diversity in eukaryotic gene expression.	Univ Calif San Francisco, Dept Biochem & Biophys, Howard Hughes Med Inst, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	O'Shea, EK (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Howard Hughes Med Inst, 600 16th St,Room S472D, San Francisco, CA 94143 USA.	oshea@biochem.ucsf.edu			NIGMS NIH HHS [GM51377, R01 GM051377] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051377] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Arkin A, 1998, GENETICS, V149, P1633; Barbaric S, 2003, MOL CELL BIOL, V23, P3468, DOI 10.1128/MCB.23.10.3468-3476.2003; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Ebbert R, 1999, MOL MICROBIOL, V32, P741, DOI 10.1046/j.1365-2958.1999.01390.x; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; Fraser HB, 2004, PLOS BIOL, V2, P834, DOI 10.1371/journal.pbio.0020137; KO MSH, 1991, J THEOR BIOL, V153, P181, DOI 10.1016/S0022-5193(05)80421-7; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Paulsson J, 2004, NATURE, V427, P415, DOI 10.1038/nature02257; PECCOUD J, 1995, THEOR POPUL BIOL, V48, P222, DOI 10.1006/tpbi.1995.1027; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Schroedinger E., 1944, WHAT IS LIFE; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Swain PS, 2002, P NATL ACAD SCI USA, V99, P12795, DOI 10.1073/pnas.162041399; Thattai M, 2001, P NATL ACAD SCI USA, V98, P8614, DOI 10.1073/pnas.151588598	23	1055	1066	0	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1811	1814		10.1126/science.1098641	http://dx.doi.org/10.1126/science.1098641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15166317	Green Accepted			2022-12-28	WOS:000222089500048
J	Harvey, RF; Lane, JA; Murray, LJ; Harvey, IM; Donovan, JL; Nair, P				Harvey, RF; Lane, JA; Murray, LJ; Harvey, IM; Donovan, JL; Nair, P			Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DUODENAL-ULCER PATIENTS; GASTRIC-ACID-SECRETION; BARRETTS-ESOPHAGUS; CORPUS GASTRITIS; DISEASE; SYMPTOMS; PREVALENCE; POPULATION; ASSOCIATION; COMMUNITY	Objectives To investigate the effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux. Design Cross sectional study, followed by a randomised placebo controlled trial. Setting Seven general practices in Bristol, England. Participants 10 537 people, aged 20-59 years, with and without H pylori infection (determined by the C-13-urea breath test). Main outcome measures Prevalence of heartburn and gastro-oesophageal acid reflux at baseline and two years after treatment to eradicate H pylori infection. Results At baseline, H pylori infection was associated with increased prevalence of heartburn (odds ratio 1.14, 95% confidence interval 1.05 to 1.23) but not reflux (1.05, 0.97 to 1.14). In participants with H pylori infection, active treatment had no effect on the overall prevalence of heartburn (0.99, 0.88 to 1.12) or reflux (1.04, 0.91 to 1.19) and did not improve pre-existing symptoms of heartburn or reflux. Conclusions H pylori infection is associated with a slightly increased prevalence of heartburn but not reflux. Treatment to eradicate H pylori has no net benefit in patients with heartburn or gastro-oesophageal reflux.	N Bristol NHS Trust, Frenchay Hosp, Bristol BS16 1LE, Avon, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT9 5EE, Antrim, North Ireland; Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; Peterborough Dist Gen Hosp, Peterborough, England	North Bristol NHS Trust; University of Bristol; Queens University Belfast; University of East Anglia	Harvey, RF (corresponding author), N Bristol NHS Trust, Frenchay Hosp, Bristol BS16 1LE, Avon, England.	richard.harvey1@virgin.net						Befrits R, 2000, HELICOBACTER, V5, P202, DOI 10.1046/j.1523-5378.2000.00031.x; CALAM J, 1996, CLIN GUIDE HELICOBAC, P39; DominguezMunoz JE, 1997, GUT, V40, P459, DOI 10.1136/gut.40.4.459; El-Serag HB, 1999, GUT, V45, P181, DOI 10.1136/gut.45.2.181; ElOmar EM, 1997, GASTROENTEROLOGY, V113, P15, DOI 10.1016/S0016-5085(97)70075-1; ELOMAR EM, 1995, GASTROENTEROLOGY, V109, P681, DOI 10.1016/0016-5085(95)90374-7; Fallone CA, 2000, AM J GASTROENTEROL, V95, P659, DOI 10.1111/j.1572-0241.2000.01970.x; Hamada H, 2000, ALIMENT PHARM THER, V14, P729; Haruma K, 2000, HELICOBACTER, V5, P24, DOI 10.1046/j.1523-5378.2000.00003.x; Iijima K, 2000, GUT, V46, P20, DOI 10.1136/gut.46.1.20; Koike T, 1999, AM J GASTROENTEROL, V94, P3468, DOI 10.1111/j.1572-0241.1999.01593.x; Koike T, 2001, ALIMENT PHARM THERAP, V15, P813, DOI 10.1046/j.1365-2036.2001.00988.x; Labenz J, 1997, GASTROENTEROLOGY, V112, P1442, DOI 10.1016/S0016-5085(97)70024-6; LABENZ J, 2002, GASTROENTEROLOGY, pW1163; Laine L, 2002, AM J GASTROENTEROL, V97, P2992, DOI 10.1111/j.1572-0241.2002.07116.x; Lane JA, 2002, CONTROL CLIN TRIALS, V23, P321, DOI 10.1016/S0197-2456(01)00208-2; Loffeld RJLF, 2000, DIGESTION, V62, P95, DOI 10.1159/000007801; Manes G, 2001, DIGEST LIVER DIS, V33, P665, DOI 10.1016/S1590-8658(01)80042-6; Moayyedi P, 2000, LANCET, V355, P1665, DOI 10.1016/S0140-6736(00)02236-4; Moayyedi P, 2001, GASTROENTEROLOGY, V121, P1120, DOI 10.1053/gast.2001.29332; Schwizer W, 2001, LANCET, V357, P1738, DOI 10.1016/S0140-6736(00)04894-7; Shirota T, 1999, J GASTROENTEROL, V34, P553, DOI 10.1007/s005350050372; Stuart RC, 2001, GASTROENTEROLOGY, V120, pA48; TARPILA S, 1983, HEPATO-GASTROENTEROL, V30, P198; van Zanten SJO, 2001, DIGEST LIVER DIS, V33, P647, DOI 10.1016/S1590-8658(01)80037-2; Varanasi RV, 1998, HELICOBACTER, V3, P188, DOI 10.1046/j.1523-5378.1998.08001.x; Warburton-Timms VJ, 2001, GUT, V49, P341, DOI 10.1136/gut.49.3.341; Werdmuller BFM, 1997, DIGEST DIS SCI, V42, P103, DOI 10.1023/A:1018841222856; Weston AP, 2000, AM J GASTROENTEROL, V95, P387, DOI 10.1111/j.1572-0241.2000.01758.x; Wildner-Christensen M, 2003, GASTROENTEROLOGY, V125, P372, DOI 10.1016/S0016-5085(03)00897-7; Wu JCY, 2002, ALIMENT PHARM THER, V16, P545, DOI 10.1046/j.1365-2036.2002.01189.x; Yamaji Y, 2001, GUT, V49, P335, DOI 10.1136/gut.49.3.335	32	50	53	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2004	328	7453					1417	1419		10.1136/bmj.38082.626725.EE	http://dx.doi.org/10.1136/bmj.38082.626725.EE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15126313	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000222114400024
J	Murre, C				Murre, C			Reprogramming committed B lineage cells	CELL			English	Editorial Material								It is generally assumed that once a cell commits to a certain lineage it no longer can change its fate. A new study in this issue of Cell (Xie et al., 2004) provides compelling evidence that committed mature B lineage cells can be reprogrammed to become macrophages.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Murre, C (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.							BOYD AW, 1982, NATURE, V297, P691, DOI 10.1038/297691a0; Ikawa T, 2004, IMMUNITY, V20, P349, DOI 10.1016/S1074-7613(04)00049-4; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Singh H, 1996, CURR OPIN IMMUNOL, V8, P160, DOI 10.1016/S0952-7915(96)80053-7; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2	9	2	2	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					556	558		10.1016/j.cell.2004.05.006	http://dx.doi.org/10.1016/j.cell.2004.05.006			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163403	Bronze			2022-12-28	WOS:000221857900002
J	Annas, GJ				Annas, GJ			Forcible medication for courtroom competence - The case of Charles Sell	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				ANNAS GEORGE J., 2004, RIGHTS PATIENTS, P277; ANNAS GJ, 1990, HASTINGS CENT REP, V20, P28, DOI 10.2307/3563158; Cantor NL, 2001, J LAW MED ETHICS, V29, P182; GRISSO T, 1998, ASSESSING COMPETENCE, P27; *INT DUAL LOYALTY, 2003, DUAL LOYALTY HUM RIG; SCHLAFLY P, 2002, EAGLE FORUM     0327; STONE A, 2003, PSYCHIAT TIMES  0901, V1	7	7	7	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2297	2301		10.1056/NEJMlim033389	http://dx.doi.org/10.1056/NEJMlim033389			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163782	Green Published			2022-12-28	WOS:000221641900014
J	Sehorn, MG; Sigurdsson, S; Bussen, W; Unger, VM; Sung, P				Sehorn, MG; Sigurdsson, S; Bussen, W; Unger, VM; Sung, P			Human meiotic recombinase Dmc1 promotes ATP-dependent homologous DNA strand exchange	NATURE			English	Article							REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; COMPLEX-FORMATION; RECA PROTEIN; RAD51; MEIOSIS; HSDMC1; REPAIR; GENES; RING	Homologous recombination is crucial for the repair of DNA breaks and maintenance of genome stability(1-3). In Escherichia coli, homologous recombination is dependent on the RecA protein. In the presence of ATP, RecA mediates the homologous DNA pairing and strand exchange reaction that links recombin-letters ing DNA molecules. DNA joint formation is initiated through the nucleation of RecA onto single-stranded DNA (ssDNA) to form helical nucleoprotein filaments(4-6). Two RecA-like recombinases, Rad51 and Dmc1, exist in eukaryotes(1). Whereas Rad51 is needed for both mitotic and meiotic recombination events, the function of Dmc1 is restricted to meiosis(3,7). Here we examine human Dmc1 protein (hDmc1) for the ability to promote DNA strand exchange, and show that hDmc1 mediates strand exchange between paired DNA substrates over at least several thousand base pairs. DNA strand exchange requires ATP and is strongly dependent on the heterotrimeric ssDNA-binding molecule replication factor A (RPA). We present evidence that hDmc1-mediated DNA recombination initiates through the nucleation of hDmc1 onto ssDNA to form a helical nucleoprotein filament. The DNA strand exchange activity of hDmc1 is probably indispensable for repair of DNA double-strand breaks during meiosis and for maintaining the ploidy of meiotic chromosomes.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	Yale University; University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.	patrick.sung@yale.edu	Sigurdsson, Stefan/L-9820-2015	Sigurdsson, Stefan/0000-0002-5284-0058				Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Eggler AL, 2002, J BIOL CHEM, V277, P39280, DOI 10.1074/jbc.M204328200; Gupta RC, 2001, P NATL ACAD SCI USA, V98, P8433, DOI 10.1073/pnas.121005298; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hong ERL, 2001, J BIOL CHEM, V276, P41906, DOI 10.1074/jbc.M105563200; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; Passy SI, 1999, P NATL ACAD SCI USA, V96, P10684, DOI 10.1073/pnas.96.19.10684; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; YOSHIDA N, 1998, REC RES DEV FERMEN 1, V1, P1; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603	25	141	148	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					433	437		10.1038/nature02563	http://dx.doi.org/10.1038/nature02563			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164066				2022-12-28	WOS:000221644600043
J	Clark, PU; McCabe, AM; Mix, AC; Weaver, AJ				Clark, PU; McCabe, AM; Mix, AC; Weaver, AJ			Rapid rise of sea level 19,000 years ago and its global implications	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; NORTH-ATLANTIC; EQUATORIAL PACIFIC; CLIMATE; ISOTOPE; OCEAN; GREENLAND; EVENTS; DEGLACIATION; RADIOCARBON	Evidence from the Irish Sea basin supports the existence of an abrupt rise in sea level ( meltwater pulse) at 19,000 years before the present ( B. P.). Climate records indicate a large reduction in the strength of North Atlantic Deep Water formation and attendant cooling of the North Atlantic at this time, indicating a source of the meltwater pulse from one or more Northern Hemisphere ice sheets. Warming of the tropical Atlantic and Pacific oceans and the Southern Hemisphere also began at 19,000 years B. P. These responses identify mechanisms responsible for the propagation of deglacial climate signals to the Southern Hemisphere and tropics while maintaining a cold climate in the Northern Hemisphere.	Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA; Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA; Univ Ulster, Sch Environm Studies, Coleraine BT52 1SA, Londonderry, North Ireland; Univ Victoria, Sch Earth & Ocean Sci, Victoria, BC V8W 3P6, Canada	Oregon State University; Oregon State University; Ulster University; University of Victoria	Clark, PU (corresponding author), Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA.	clarkp@geo.oregonstate.edu	Weaver, Andrew J/E-7590-2011	Weaver, Andrew J/0000-0001-8919-3598				Bard E, 2000, SCIENCE, V289, P1321, DOI 10.1126/science.289.5483.1321; Bard E, 1998, RADIOCARBON, V40, P1085, DOI 10.1017/S0033822200019135; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; BERGER WH, 1982, MAR GEOL, V45, P93, DOI 10.1016/0025-3227(82)90182-7; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Bowen DQ, 2002, QUATERNARY SCI REV, V21, P89, DOI 10.1016/S0277-3791(01)00102-0; Crosta X, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2000PA000565; DINKLEMAN MG, 1974, THESIS OREGON STATE; Duplessy JC, 1988, PALEOCEANOGRAPHY, V3, P343, DOI 10.1029/PA003i003p00343; Elliot M, 2001, EARTH PLANET SC LETT, V194, P151, DOI 10.1016/S0012-821X(01)00561-1; Fanning AF, 1997, PALEOCEANOGRAPHY, V12, P307, DOI 10.1029/96PA03726; Feldberg MJ, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2001PA000740; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Gu DF, 1997, SCIENCE, V275, P805, DOI 10.1126/science.275.5301.805; Hanebuth T, 2000, SCIENCE, V288, P1033, DOI 10.1126/science.288.5468.1033; Hillaire-Marcel C, 2001, NATURE, V410, P1073, DOI 10.1038/35074059; Hughen KA, 2000, SCIENCE, V290, P1951, DOI 10.1126/science.290.5498.1951; JOHNSEN SJ, 1972, NATURE, V235, P429, DOI 10.1038/235429a0; Liu ZY, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013938; Manabe S, 1997, PALEOCEANOGRAPHY, V12, P321, DOI 10.1029/96PA03932; McCabe AM, 1998, NATURE, V392, P373, DOI 10.1038/32866; Mix AC, 1999, GEOPH MONOG SERIES, V112, P127; Monnin E, 2001, SCIENCE, V291, P112, DOI 10.1126/science.291.5501.112; Palmer MR, 2003, SCIENCE, V300, P480, DOI 10.1126/science.1080796; Ruhlemann C, 1999, NATURE, V402, P511, DOI 10.1038/990069; Schmittner A, 2003, QUATERNARY SCI REV, V22, P659, DOI 10.1016/S0277-3791(02)00184-1; Schmittner A, 2002, SCIENCE, V295, P1489, DOI 10.1126/science.1066174; Shennan I, 2003, QUATERNARY SCI REV, V22, P1543, DOI 10.1016/S0277-3791(03)00088-X; Sigman DM, 2000, NATURE, V407, P859, DOI 10.1038/35038000; Spero HJ, 2002, SCIENCE, V296, P522, DOI 10.1126/science.1069401; Stocker TF, 1992, PALEOCEANOGRAPHY, V7, P529, DOI 10.1029/92PA01695; Stuiver M, 2000, QUATERNARY RES, V53, P277, DOI 10.1006/qres.2000.2127; TOGGWEILER JR, 1991, J GEOPHYS RES-OCEANS, V96, P20467, DOI 10.1029/91JC02063; Visser K, 2003, NATURE, V421, P152, DOI 10.1038/nature01297; Waelbroeck C, 2001, NATURE, V412, P724, DOI 10.1038/35089060; Weaver AJ, 2003, SCIENCE, V299, P1709, DOI 10.1126/science.1081002; Weaver AJ, 1998, NATURE, V394, P847, DOI 10.1038/29695; Weaver AJ, 1999, GEOPHYS RES LETT, V26, P743, DOI 10.1029/1999GL900102; Yokoyama Y, 2000, NATURE, V406, P713, DOI 10.1038/35021035; Zahn R, 1997, PALEOCEANOGRAPHY, V12, P696, DOI 10.1029/97PA00581	41	221	236	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1141	1144		10.1126/science.1094449	http://dx.doi.org/10.1126/science.1094449			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155944				2022-12-28	WOS:000221524500038
J	Ismail, K; Winkley, K; Rabe-Hesketh, S				Ismail, K; Winkley, K; Rabe-Hesketh, S			Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes	LANCET			English	Article							WEIGHT-LOSS; BEHAVIOR-MODIFICATION; MAJOR DEPRESSION; MELLITUS; NIDDM; EDUCATION; MANAGEMENT; THERAPY; COMPLICATIONS; QUALITY	Background Adherence difficulties and psychological problems are associated with poor glycaemic control in diabetes. We undertook a systematic review and meta-analysis of psychological therapies to assess their effectiveness in improving glycaemic control in type 2 diabetes. Methods We searched MEDLINE, PsychINFO, EMBASE, and the Cochrane Central Register of Controlled Trials up to January, 2003. Eligible studies were randomised controlled trials that involved people with type 2 diabetes and evaluated a psychological therapy (counselling, cognitive behaviour therapy, or psychodynamic therapy) to improve diabetes control. We extracted the number of participants, their age, duration of diabetes, glycaemic control, type of psychological therapy, its mode of delivery, and type of intervention in the control group. The main outcome was long-term glycaemic control measured by percentage of glycated haemoglobin. Blood glucose concentration, weight, and psychological distress were also measured. Pooled standardised effect sizes were calculated. Findings 25 trials were eligible for the review. In 12 trials, the mean percentage glycated haemoglobin was lower in people assigned a psychological intervention than in the control group (usual care, education, waiting list, or attention control); the pooled mean difference was -0.32 (95% CI -0.57 to -0.07) equivalent to an absolute difference of -0.76%. There were non-significant differences in blood glucose concentration (eight trials; -0.11 [-0.65 to 0.42]) and weight gain (nine trials; 0.37 [-0.18 to 0.93]). Psychological distress was significantly lower in the intervention groups (five trials; -0.58 [-0.95 to -0.20]). Interpretation In type 2 diabetes, there are improvements in long-term glycaemic control and psychological distress but not in weight control or blood glucose concentration in people who receive psychological therapies.	Inst Psychiat, Weston Educ Ctr, Acad Dept Psychol Med, London SE5 9RJ, England; Inst Psychiat, Dept Biostat, London SE5 9RJ, England	University of London; King's College London; University of London; King's College London	Ismail, K (corresponding author), Inst Psychiat, Weston Educ Ctr, Acad Dept Psychol Med, 10 Cutcombe Rd, London SE5 9RJ, England.	khalida.ismail@iop.kci.ac.uk	Winkley, Kirsty/AAH-9458-2020; Rabe-Hesketh, Sophia/B-1643-2008	Winkley, Kirsty/0000-0002-1725-6040; Rabe-Hesketh, Sophia/0000-0002-5257-4837; Ismail, Khalida/0000-0001-6084-449X				Aikens JE, 1997, PSYCHOTHER PSYCHOSOM, V66, P302, DOI 10.1159/000289152; AMOS AF, 1997, DIABETIC MED, V14, P7; Beck A.T., 1979, COGNITIVE THERAPY EM; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Boehm S, 1993, Clin Nurs Res, V2, P327, DOI 10.1177/105477389300200308; BRADBURN MJ, 1998, STATA TECHNICAL B, V44, P4; BROWN SA, 1992, RES NURS HEALTH, V15, P409, DOI 10.1002/nur.4770150603; Campbell EM, 1996, DIABETES EDUCATOR, V22, P379, DOI 10.1177/014572179602200412; CAMPBELL LV, 1990, DIABETES CARE, V13, P841, DOI 10.2337/diacare.13.8.841; Churchill R, 2001, Health Technol Assess, V5, P1; CLARK M, IN PRESS BR J HLTH P; de Groot M, 1999, J PSYCHOSOM RES, V46, P425, DOI 10.1016/S0022-3999(99)00014-8; de Groot M, 2001, PSYCHOSOM MED, V63, P619, DOI 10.1097/00006842-200107000-00015; DERAMOMELKUS GA, 1992, DIABETES CARE, V15, P864, DOI 10.2337/diacare.15.7.864; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FAIRBURN C, 1991, ARCH GEN PSYCHIAT, V48, P462; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GAVARD JA, 1993, DIABETES CARE, V16, P1167, DOI 10.2337/diacare.16.8.1167; GRIFFIN S, 1998, ED PSYCHOSOCIAL INTE; HARTWELL SL, 1986, BEHAV THER, V17, P447, DOI 10.1016/S0005-7894(86)80074-0; Hawton KE, 1989, COGNITIVE BEHAV THER; HEITZMANN CA, 1987, J BEHAV MED, V10, P197, DOI 10.1007/BF00846426; Henry JL, 1997, PSYCHOL HEALTH MED, V2, P109; Herpertz S, 2000, INT J EAT DISORDER, V28, P68, DOI 10.1002/(SICI)1098-108X(200007)28:1&lt;68::AID-EAT8&gt;3.0.CO;2-R; HUANG X, 2001, CHIN J CLIN PSYCHOL, V9, P187; ISMAIL K, 2001, COCHRANE LIB; Jablon SL, 1997, APPL PSYCHOPHYS BIOF, V22, P155, DOI 10.1023/A:1026259725197; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jeffery RW, 2000, HEALTH PSYCHOL, V19, P5, DOI 10.1037/0278-6133.19.Suppl1.5; Kenardy J, 2002, DIABETIC MED, V19, P234, DOI 10.1046/j.1464-5491.2002.00679.x; KENARDY J, 1994, DIABETES CARE, V17, P1197, DOI 10.2337/diacare.17.10.1197; Klerman GL, 1984, INTERPERSONAL PSYCHO; LANE JD, 1993, DIABETES CARE, V16, P1087, DOI 10.2337/diacare.16.8.1087; Lustman PJ, 1997, GEN HOSP PSYCHIAT, V19, P138, DOI 10.1016/S0163-8343(96)00170-3; Lustman PJ, 2000, DIABETES CARE, V23, P934, DOI 10.2337/diacare.23.7.934; Lustman PJ, 1998, ANN INTERN MED, V129, P613, DOI 10.7326/0003-4819-129-8-199810150-00005; Malan D. H., 1963, STUDY BRIEF PSYCHOTH, DOI [10.1007/978-1-4613-4395-0, DOI 10.1007/978-1-4613-4395-0]; McKay HG, 2001, DIABETES CARE, V24, P1328, DOI 10.2337/diacare.24.8.1328; MECA J, 1998, REV PSICOL GRAL APLI, V51, P501; Meichenbaum D, 1977, COGNITIVE BEHAV MODI; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; MOOREY S, 1997, ESSENTIALS POSTGRADU, P636; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; ODES M, 1993, PSYCHOL TREATMENT DI; RABKIN SW, 1983, DIABETES CARE, V6, P50, DOI 10.2337/diacare.6.1.50; Ridgeway NA, 1999, SOUTHERN MED J, V92, P667, DOI 10.1097/00007611-199907000-00004; RODRIGUEZ F, 1987, REV ESP COMPORTAMIEN, V5, P233; Rogers C., 1976, CLIENT CTR PSYCHOTHE; SCHULZ K, 1995, JAMA-J AM MED ASSOC, V273, P403; Smith DE, 1997, DIABETES CARE, V20, P52, DOI 10.2337/diacare.20.1.52; Snoek FJ, 2002, DIABETIC MED, V19, P265, DOI 10.1046/j.1464-5491.2002.00678.x; Surwit RS, 2002, DIABETES CARE, V25, P30, DOI 10.2337/diacare.25.1.30; Tsujiuchi T, 2002, DIABETES CARE, V25, P241, DOI 10.2337/diacare.25.1.241; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WHITE N, 1986, DIABETES CARE, V9, P490, DOI 10.2337/diacare.9.5.490; WING RR, 1985, J CONSULT CLIN PSYCH, V53, P111, DOI 10.1037/0022-006X.53.1.111; WING RR, 1991, J CONSULT CLIN PSYCH, V59, P156, DOI 10.1037/0022-006X.59.1.156; Zhu XZ, 2001, CHIN J CLIN PSYCHOL, V9, P170, DOI [10.3969/j.issn.1005-3611.2001.03.004, DOI 10.3969/J.ISSN.1005-3611.2001.03.004]	59	331	341	0	60	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	2004	363	9421					1589	1597		10.1016/S0140-6736(04)16202-8	http://dx.doi.org/10.1016/S0140-6736(04)16202-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	820SE	15145632				2022-12-28	WOS:000221408800009
J	Nelson, H; Sargent, D; Wieand, HS; Fleshman, J; Anvari, M; Stryker, SJ; Beart, RW; Hellinger, M; Flanagan, R; Peters, W; Ota, D; Hellinger, M				Nelson, H; Sargent, D; Wieand, HS; Fleshman, J; Anvari, M; Stryker, SJ; Beart, RW; Hellinger, M; Flanagan, R; Peters, W; Ota, D; Hellinger, M		Clinical Outcomes Surg Therapy Stu	A comparison of laparoscopically assisted and open colectomy for colon cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; CLASSIFICATION; SURGERY	BACKGROUND: Minimally invasive, laparoscopically assisted surgery was first considered in 1990 for patients undergoing colectomy for cancer. Concern that this approach would compromise survival by failing to achieve a proper oncologic resection or adequate staging or by altering patterns of recurrence (based on frequent reports of tumor recurrences within surgical wounds) prompted a controlled trial evaluation. METHODS: We conducted a noninferiority trial at 48 institutions and randomly assigned 872 patients with adenocarcinoma of the colon to undergo open or laparoscopically assisted colectomy performed by credentialed surgeons. The median follow-up was 4.4 years. The primary end point was the time to tumor recurrence. RESULTS: At three years, the rates of recurrence were similar in the two groups -- 16 percent among patients in the group that underwent laparoscopically assisted surgery and 18 percent among patients in the open-colectomy group (two-sided P=0.32; hazard ratio for recurrence, 0.86; 95 percent confidence interval, 0.63 to 1.17). Recurrence rates in surgical wounds were less than 1 percent in both groups (P=0.50). The overall survival rate at three years was also very similar in the two groups (86 percent in the laparoscopic-surgery group and 85 percent in the open-colectomy group; P=0.51; hazard ratio for death in the laparoscopic-surgery group, 0.91; 95 percent confidence interval, 0.68 to 1.21), with no significant difference between groups in the time to recurrence or overall survival for patients with any stage of cancer. Perioperative recovery was faster in the laparoscopic-surgery group than in the open-colectomy group, as reflected by a shorter median hospital stay (five days vs. six days, P<0.001) and briefer use of parenteral narcotics (three days vs. four days, P<0.001) and oral analgesics (one day vs. two days, P=0.02). The rates of intraoperative complications, 30-day postoperative mortality, complications at discharge and 60 days, hospital readmission, and reoperation were very similar between groups. CONCLUSIONS: In this multi-institutional study, the rates of recurrent cancer were similar after laparoscopically assisted colectomy and open colectomy, suggesting that the laparoscopic approach is an acceptable alternative to open surgery for colon cancer.	Mayo Clin & Mayo Fdn, Div Colon & Rectal Surg, NCCTG, Rochester, MN 55905 USA; Washington Univ, Sch Med, RTOG, St Louis, MO USA; McMaster Univ, St Joseph Healthcare, NCIC, CTG, Hamilton, ON, Canada; Northwestern Univ, Feinberg Sch Med, ECOG, RTOG, Chicago, IL 60611 USA; Univ So Calif, Keck Sch Med, SWOG, Los Angeles, CA USA; Univ Miami, Jackson Mem Med Ctr, ECOG, Miami, FL USA; St Joseph Mercy Hosp, NCCTG, Ann Arbor, MI 48104 USA; Boone Hosp Ctr, CALGB, Columbia, MO USA; LDS Hosp, Intermt Hlth Care Canc Serv, RTOG, Salt Lake City, UT USA; Columbia Presbyterian Med Ctr, SWOG, New York, NY USA; Univ Missouri, CALGB, Columbia, MO USA; Midwest Surg PA, SWOG, Wichita, KS USA; Grp Hlth Cooperat Puget Sound, SWOG, Seattle, WA USA; Lahey Clin Fdn, CALGB, Burlington, MA USA; MD Anderson Orlando Canc Ctr, RTOG, Orlando, FL USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Univ Kentucky, SWOG, Lexington, KY USA; Kankenau Hosp, Inst Med Res, NSABP, Wynnewood, PA USA; Ottawa Reg Canc Ctr, NCIC, CTG, Ottawa, ON K1Y 4K7, Canada; Creighton Univ, NCCTG, Omaha, NE 68178 USA; Lehigh Valley Hosp, ECOG, Allentown, PA USA; Cleveland Clin Fdn, SWOG, Cleveland, OH 44195 USA; St Joseph Med Ctr, RTOG, Baltimore, MD USA; Eastern Virginia Med Sch, Norfolk Surg Grp, CALGB, Norfolk, VA 23501 USA; St Lukes Hosp, ECOG, Bethlehem, PA USA; Mercy Hlth Ctr, SWOG, Oklahoma City, OK USA; Mayo Clin, NCCTG, Scottsdale, AZ USA; Massachusetts Gen Hosp, CALGB, Boston, MA 02114 USA; Swedish Med Ctr, ECOG, Englewood, CO USA; Ctr Hosp Univ Quebec, NSABP, Quebec City, PQ, Canada; E Carolina Univ, Brody Sch Med, NSABP, Greenville, NC USA; Mt Sinai Hosp, CALGB, New York, NY 10029 USA; Jefferson Reg Med Ctr, ECOG, Pittsburgh, PA USA; St Joseph Mercy Hosp, NCCTG, Pontiac, MI USA; Abington Mem Hosp, ECOG, Abington, PA 19001 USA; Brigham & Womens Hosp, Boston Med Ctr, CALGB, Boston, MA 02115 USA; Dartmouth Hitchcock Med Ctr, CALGB, Lebanon, NH 03766 USA; Wilford Hall USAF Med Ctr, Wilford Hall, TX USA; Univ Virginia, ECOG, Charlottesville, VA USA; Legacy Hlth Syst, SWOG, Portland, OR USA; Allegheny Gen Hosp, NSABP, Pittsburgh, PA 15212 USA; John Muir Mt Diablo Hlth Syst, Mt Diablo Med Ctr, RTOG, Concord, CA USA; Huntington Mem Hosp, Beverly Hills, CA USA; Kaiser Permanente Med Ctr, NSABP, San Diego, CA USA; Univ Massachusetts, Mem Med Ctr, CALGB, Worcester, MA 01605 USA; Univ Texas, SW Med Ctr, NSABP, Dallas, TX USA; Dana Farber Canc Inst, CALGB, Boston, MA 02115 USA; Univ Pittsburgh, Pittsburgh, PA USA	Mayo Clinic; Washington University (WUSTL); McMaster University; Northwestern University; Feinberg School of Medicine; Southwest Oncology Group; University of Southern California; University of Miami; Saint Joseph Mercy Health System (SJMHS); Intermountain Healthcare; Columbia University; NewYork-Presbyterian Hospital; Southwest Oncology Group; University of Missouri System; University of Missouri Columbia; Southwest Oncology Group; Group Health Cooperative; Southwest Oncology Group; Lahey Hospital & Medical Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health San Antonio; Southwest Oncology Group; University of Kentucky; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; University of Ottawa; Ottawa Hospital Research Institute; Creighton University; Lehigh Valley Hospital; Cleveland Clinic Foundation; Southwest Oncology Group; Eastern Virginia Medical School; Southwest Oncology Group; Mayo Clinic; Mayo Clinic Phoenix; Harvard University; Massachusetts General Hospital; Laval University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; University of North Carolina; East Carolina University; Icahn School of Medicine at Mount Sinai; Jefferson University; Saint Joseph Mercy Health System (SJMHS); Abington Memorial Hospital; Boston Medical Center; Harvard University; Brigham & Women's Hospital; Dartmouth College; United States Department of Defense; United States Air Force; University of Virginia; Legacy Health; Southwest Oncology Group; Allegheny General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; University of Southern California; Huntington Memorial Hospital; Kaiser Permanente; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Dana-Farber Cancer Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Nelson, H (corresponding author), Mayo Clin & Mayo Fdn, Div Colon & Rectal Surg, NCCTG, 200 1st St SW, Rochester, MN 55905 USA.		Anvari, Mehran/AAQ-1738-2021	Anvari, Mehran/0000-0001-7256-5789; Sargent, Daniel/0000-0002-2684-4741	NCI NIH HHS [CA12027, CA21115, U10 CA21661, CA77202, CA65157, CA32102, CA25224, CA31946] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA012027, U10CA031946, U01CA065157, U10CA021661, U10CA032102, U10CA025224, U10CA021115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM SOC COL RECT S, 1994, DIS COLON RECTUM, V37; BERENDS FJ, 1994, LANCET, V344, P58, DOI 10.1016/S0140-6736(94)91079-0; Chapman AE, 2001, ANN SURG, V234, P590, DOI 10.1097/00000658-200111000-00003; CLAVIEN PA, 1992, SURGERY, V111, P518; COX DR, 1972, J R STAT SOC B, V34, P187; FLESHMAN JW, 1996, DIS COLON RECTUM S, V39, P53; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; HOFFMAN GC, 1994, ANN SURG, V219, P732, DOI 10.1097/00000658-199406000-00018; Johnstone PAS, 1996, J CLIN ONCOL, V14, P1950, DOI 10.1200/JCO.1996.14.6.1950; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEATS AS, 1978, ANESTHESIOLOGY, V49, P233, DOI 10.1097/00000542-197810000-00001; Lacy AM, 2002, LANCET, V359, P2224, DOI 10.1016/S0140-6736(02)09290-5; MANTEL N, 1959, J NATL CANCER I, V22, P719; MEYERS WC, 1991, NEW ENGL J MED, V324, P1073; Nelson H, 1995, J Natl Cancer Inst Monogr, P51; PHILLIPS EH, 1992, ANN SURG, V216, P703, DOI 10.1097/00000658-199212000-00015; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Reilly WT, 1996, DIS COLON RECTUM, V39, P200; *SO SURG CLUB, 1991, NEW ENGL J MED, V325, P1517; SOPER NJ, 1994, NEW ENGL J MED, V330, P409, DOI 10.1056/NEJM199402103300608; Stocchi L, 1998, J SURG ONCOL, V68, P255, DOI 10.1002/(SICI)1096-9098(199808)68:4<255::AID-JSO10>3.0.CO;2-Z; Weeks JC, 2002, JAMA-J AM MED ASSOC, V287, P321, DOI 10.1001/jama.287.3.321	22	2626	2695	5	84	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2050	2059						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141043				2022-12-28	WOS:000221354000006
J	Gugenheim, JJ				Gugenheim, JJ			External fixation in orthopedics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DISTRACTION OSTEOGENESIS; MODEL		Texas Orthoped Hosp, Fondren Orthoped Grp LLP, Houston, TX 77030 USA	Texas Orthopedic Hospital	Gugenheim, JJ (corresponding author), Texas Orthoped Hosp, Fondren Orthoped Grp LLP, 7401 S Main St, Houston, TX 77030 USA.	jig@fondren.com						Aldegheri R, 2001, J PEDIATR ORTHOP B, V10, P238, DOI 10.1097/00009957-200107000-00015; Bernardo L M, 2001, Orthop Nurs, V20, P29, DOI 10.1097/00006416-200109000-00007; GDYAKHOVSKY V, 1993, OPERATIVE MANUAL ILI, pR7; GREEN SA, 1991, ORTHOP CLIN N AM, V22, P515; Inoue N, 2002, J ORTHOP RES, V20, P1106, DOI 10.1016/S0736-0266(02)00031-1; Kim IS, 2002, PLAST RECONSTR SURG, V109, P1966, DOI 10.1097/00006534-200205000-00029; Lowenberg DW., 1996, TECH ORTHOP, V11, P210; MARSH JL, 1994, CLIN ORTHOP RELAT R, P139; Mooney J F 3rd, 2001, J South Orthop Assoc, V10, P32; Paley D, 1997, J BONE JOINT SURG AM, V79A, P1464, DOI 10.2106/00004623-199710000-00003; PALEY D, 1988, J PEDIATR ORTHOPED, V8, P73, DOI 10.1097/01241398-198801000-00018; Paley D, 1993, OPERATIVE ORTHOPAEDI, P883; Shimazaki A, 2000, J BONE JOINT SURG BR, V82B, P1077, DOI 10.1302/0301-620X.82B7.9948; Tracy Watson J, 1996, TECH ORTHOP, V11, P150; Tsuchiya H, 2002, J BONE JOINT SURG BR, V84B, P1162, DOI 10.1302/0301-620X.84B8.13330; Wu CC, 2003, J TRAUMA, V54, P1159, DOI 10.1097/01.TA.0000046254.92637.19	16	2	4	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2004	291	17					2122	2124		10.1001/jama.291.17.2122	http://dx.doi.org/10.1001/jama.291.17.2122			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JR	15126441				2022-12-28	WOS:000221174300030
J	Hoerger, TJ; Harris, R; Hicks, KA; Donahue, K; Sorensen, S; Engelgau, M				Hoerger, TJ; Harris, R; Hicks, KA; Donahue, K; Sorensen, S; Engelgau, M			Screening for type 2 diabetes mellitus: A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							LOWER-EXTREMITY AMPUTATION; BLOOD-PRESSURE CONTROL; DIRECT MEDICAL COSTS; MICROVASCULAR COMPLICATIONS; LIFE-STYLE; NIDDM; HYPERTENSION; PREVALENCE; UTILITIES; MORTALITY	Background: No randomized, controlled trial of screening for diabetes has been conducted. in the absence of direct evidence, cost-effectiveness models may provide guidance about preferred screening strategies. Objective: To estimate the incremental cost-effectiveness of 2 diabetes screening strategies: screening targeted to people with hypertension and universal screening. Design: Markov model. Data Sources: United Kingdom Prospective Diabetes Study, Hypertension Optimal Treatment trial, and recent cost data. Target Population: General primary care population in the United States. Time Horizon: Lifetime. Perspective: Health care system. Interventions: Diabetes screening targeted to people with hypertension and universal screening. Outcome Measures: Cost per quality-adjusted life-year (QALY) gained. Costs (in 1997 U.S. dollars) and QALYs discounted at a 3% annual rate. Results of Base-Case Analysis: At all ages, incremental cost-effectiveness ratios were more favorable for screening targeted to people with hypertension than for universal screening. For example, at age 55 years, the cost per QALY for targeted screening compared with no screening was $34 375, whereas the cost per QALY for universal screening compared with targeted screening was $360 966. Screening was more cost-effective for ages 55 to 75 years than for younger ages. Results of Sensitivity Analysis: in single-way and probabilistic sensitivity analyses, findings were robust to therapy costs, screening costs, screening lead time, reduced effectiveness of intensive antihypertensive therapy, and increased relative risk reduction for stroke attributable to intensive hypertension control. Limitations: We did not consider screening targeted to persons with dyslipidemia, and we used studies of people whose diabetes was detected clinically to estimate screening benefits. Conclusions: Diabetes screening targeted to people with hypertension is more cost-effective than universal screening. The most cost-effective strategy is targeted screening at age 55 to 75 years.	Res Triangle Inst, Res Triangle Pk, NC 27709 USA	Research Triangle Institute	Hoerger, TJ (corresponding author), Res Triangle Inst, POB 12194,3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA.	tjh@rti.org	Donahue, Katrina/E-7486-2012	Donahue, Katrina/0000-0003-4075-2875; Hoerger, Thomas/0000-0003-4154-7806; Hicks, Katherine/0000-0002-1058-3401	PHS HHS [200-97-0621, 290-97-0011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM ASS CLIN END, 2002, ENDOCR PRACT S1, V8, P5; *AM DIAB ASS, 2001, DIABETES CARE, V24, pS 21; Brown JB, 1999, ARCH INTERN MED, V159, P1873, DOI 10.1001/archinte.159.16.1873; Caro JJ, 2002, DIABETES CARE, V25, P476, DOI 10.2337/diacare.25.3.476; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DAVIDSON MB, 2001, BMJ US, V1, P297; DONG F, 1997, EC EVALUATION APPROA; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; ECKMAN MH, 1995, JAMA-J AM MED ASSOC, V273, P712, DOI 10.1001/jama.273.9.712; Elliott WJ, 2000, ARCH INTERN MED, V160, P1277, DOI 10.1001/archinte.160.9.1277; Engelgau MM, 1998, JAMA-J AM MED ASSOC, V280, P1757; Engelgau MM, 2000, DIABETES CARE, V23, P1563, DOI 10.2337/diacare.23.10.1563; ENGELGAU MM, 1995, DIABETES CARE, V18, P1606, DOI 10.2337/diacare.18.12.1606; Estacio RO, 2000, DIABETES CARE, V23, pB54; Goyder E, 1998, BMJ-BRIT MED J, V317, P1644, DOI 10.1136/bmj.317.7173.1644; Goyder EC, 2000, DIABETIC MED, V17, P469, DOI 10.1046/j.1464-5491.2000.00308.x; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HARRIS MI, 1994, DIABETES CARE, V17, P440, DOI 10.2337/diacare.17.5.440; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; HARRIS PR, 2003, SYSTEMATIC EVIDENCE, V19; *HLTH CAR FIN ADM, 1998, 1999 MED CAR DIAGN L; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; Hofer TP, 2000, INT J TECHNOL ASSESS, V16, P822, DOI 10.1017/S0266462300102090; Huang ES, 2001, AM J MED, V111, P633, DOI 10.1016/S0002-9343(01)00978-0; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; HUMPHREY LL, 1994, ARCH INTERN MED, V154, P885, DOI 10.1001/archinte.154.8.885; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Marshall KG, 1999, CAN MED ASSOC J, V160, P1592; MOSS SE, 1992, ARCH INTERN MED, V152, P610, DOI 10.1001/archinte.152.3.610; *NAT CTR HLTH STAT, 1997, NHANES 3, V11; Nathan DM, 1996, JAMA-J AM MED ASSOC, V276, P1409; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; O'Brien JA, 1998, DIABETES CARE, V21, P1122, DOI 10.2337/diacare.21.7.1122; *RED BOOK, 1997, 1997 DRUG TOP; REIBER GE, 1995, NIH PUBLICATION, P409; Rolka DB, 2001, DIABETES CARE, V24, P1899, DOI 10.2337/diacare.24.11.1899; Russell MW, 1998, AM J CARDIOL, V81, P1110, DOI 10.1016/S0002-9149(98)00136-2; SACCO RL, 1994, NEUROLOGY, V44, P626, DOI 10.1212/WNL.44.4.626; Schrier RW, 2002, KIDNEY INT, V61, P1086, DOI 10.1046/j.1523-1755.2002.00213.x; Stearne MR, 1998, BMJ-BRIT MED J, V317, P720; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *US PREV SERV TASK, 2003, GUIDE CLIN PREVENTIV, P287; Vijan S, 1997, ANN INTERN MED, V127, P788, DOI 10.7326/0003-4819-127-9-199711010-00003; Wareham NJ, 2001, BMJ-BRIT MED J, V322, P986, DOI 10.1136/bmj.322.7292.986; Wingard DL, 1995, NIH PUBLICATION; WOLF PA, 1992, STROKE, V23, P1551, DOI 10.1161/01.STR.23.11.1551; 1997, RELATIVE VALUE STUDI, pR1	52	112	117	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	2004	140	9					689	699		10.7326/0003-4819-140-9-200405040-00008	http://dx.doi.org/10.7326/0003-4819-140-9-200405040-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816XR	15126252				2022-12-28	WOS:000221143100002
J	Azzouz, M; Ralph, GS; Storkebaum, E; Walmsley, LE; Mitrophanous, KA; Kingsman, SM; Carmeliet, P; Mazarakis, ND				Azzouz, M; Ralph, GS; Storkebaum, E; Walmsley, LE; Mitrophanous, KA; Kingsman, SM; Carmeliet, P; Mazarakis, ND			VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; LENTIVIRAL VECTORS; NERVOUS-SYSTEM; AXONAL-TRANSPORT; GENE-TRANSFER; MICE; DISEASE; EXPRESSION	Amyotrophic lateral sclerosis (ALS) causes adult-onset, progressive motor neuron degeneration in the brain and spinal cord, resulting in paralysis and death three to five years after onset in most patients(1). ALS is still incurable, in part because its complex aetiology remains insufficiently understood. Recent reports have indicated that reduced levels of vascular endothelial growth factor ( VEGF), which is essential in angiogenesis and has also been implicated in neuroprotection(2-4), predispose mice and humans to ALS(5,6). However, the therapeutic potential of VEGF for the treatment of ALS has not previously been assessed. Here we report that a single injection of a VEGF-expressing lentiviral vector into various muscles delayed onset and slowed progression of ALS in mice engineered to overexpress the gene coding for the mutated G93A form of the superoxide dismutase-1 (SOD1(G93A)) (refs 7-10), even when treatment was only initiated at the onset of paralysis. VEGF treatment increased the life expectancy of ALS mice by 30 per cent without causing toxic side effects, thereby achieving one of the most effective therapies reported in the field so far.	Oxford BioMed Plc, Oxford, England; Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven	Azzouz, M (corresponding author), Oxford BioMed Plc, Oxford Sci Pk,Medawar Ctr, Oxford, England.	m.azzouz@oxfordbiomedica.co.uk; n.mazarakis@oxfordbiomedica.co.uk	Carmeliet, Peter/AAQ-5140-2020; Storkebaum, Erik/B-5389-2017; Azzouz, Mimoun/B-3979-2009	Carmeliet, Peter/0000-0001-7961-1821; Storkebaum, Erik/0000-0002-9519-5642; Azzouz, Mimoun/0000-0001-6564-5967; Shaw, Pamela/0000-0002-8925-2567				Azzouz M, 2002, J NEUROSCI, V22, P10302; Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; Bienemann AS, 2003, MOL THER, V7, P588, DOI 10.1016/S1525-0016(03)00069-8; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; DALCANTO MC, 1995, BRAIN RES, V676, P25, DOI 10.1016/0006-8993(95)00063-V; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; LAMBRECHTS D, 2003, NAT GENET, V34, P33; Martin-Rendon E, 2002, MOL THER, V5, P566, DOI 10.1006/mthe.2002.0576; Mazarakis ND, 2001, HUM MOL GENET, V10, P2109, DOI 10.1093/hmg/10.19.2109; MITCHELL JD, 2002, COCHRANE DB SYST REV, V3; Mitrophanous KA, 1999, GENE THER, V6, P1808, DOI 10.1038/sj.gt.3301023; Mohammed SI, 2002, CANCER RES, V62, P356; Mulder D W, 1982, Adv Neurol, V36, P15; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Rohll JB, 2002, METHOD ENZYMOL, V346, P466; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Sagot Y, 1998, J NEUROSCI, V18, P1132; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; Wang LJ, 2002, J NEUROSCI, V22, P6920; Wong LF, 2004, MOL THER, V9, P101, DOI 10.1016/j.ymthe.2003.09.017	27	481	547	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	2004	429	6990					413	417		10.1038/nature02544	http://dx.doi.org/10.1038/nature02544			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164063				2022-12-28	WOS:000221644600039
J	Pantilat, SZ; Steimle, AE				Pantilat, SZ; Steimle, AE			Palliative care for patients with heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED-TRIALS; MEDICARE PATIENTS; ELDERLY-PATIENTS; INCREASED RISK; SUDDEN-DEATH; ANEMIA; LIFE; PREVENTION; MANAGEMENT; MORTALITY	Heart failure accounts for more hospitalizations among Medicare beneficiaries than any other condition. Its symptoms, including shortness of breath, fatigue, and edema, can be frightening and diminish quality of life. Although treatment advances have allowed patients to live longer with a better quality of life, heart failure remains a leading cause of death in the United States. Half of heart failure patients die within 5 years of diagnosis, and for many patients, death is sudden. Given the availability of effective treatments, the prevalence of distressing symptoms, and a persistent high risk of death that may occur suddenly, physicians must simultaneously treat the underlying condition while helping patients plan for future needs and complete advance directives. Using the case of Mr R, a 74-year-old man with heart failure, we illustrate ways that physicians can address these issues to improve the care of patients with heart failure, including symptom management and discussing advance directives, prognosis, and hospice care. By combining optimal medical management with palliative care, physicians can best care for heart failure patients and their families.	Univ Calif San Francisco, Dept Med, Palliat Care Serv, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Hosp Sect, San Francisco, CA 94143 USA; Kaiser Permanente No Calif, Heart Failure Program, Santa Clara, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	Pantilat, SZ (corresponding author), Univ Calif San Francisco, Dept Med, Palliat Care Serv, 521 Parnassus Ave,Suite C-126,Box 0903, San Francisco, CA 94143 USA.	stevep@medicine.ucsf.edu						*AM HEART ASS, 2000, HEART DIS STROK STAT; Anker SD, 1997, CIRCULATION, V96, P526; Beck A, 1997, J AM GERIATR SOC, V45, P543, DOI 10.1111/j.1532-5415.1997.tb03085.x; Berger R, 2002, CIRCULATION, V105, P2392, DOI 10.1161/01.CIR.0000016642.15031.34; Bleumink GS, 2003, DRUGS, V63, P525, DOI 10.2165/00003495-200363060-00001; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; *CAR MAN I KAIS PE, 2002, SUMM EV BAS GUID MAN; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Corvera-Tindel T, 2004, AM HEART J, V147, P339, DOI 10.1016/j.ahj.2003.09.007; COSTANZO MR, 1995, CIRCULATION, V92, P3593, DOI 10.1161/01.CIR.92.12.3593; CROSS KL, 2000, AAHPM B, V1, P6; Dries DL, 2000, J AM COLL CARDIOL, V35, P681, DOI 10.1016/S0735-1097(99)00608-7; ELKAYAM U, 1990, CIRCULATION, V82, P1954, DOI 10.1161/01.CIR.82.6.1954; Ezekowitz JA, 2003, ANN INTERN MED, V138, P445, DOI 10.7326/0003-4819-138-6-200303180-00007; Felker GM, 2003, AM HEART J, V145, pS18, DOI 10.1067/mhj.2003.150; Felker GM, 2003, AM J CARDIOL, V92, P625, DOI 10.1016/S0002-9149(03)00740-9; Field MJ, 1997, APPROACHING DEATH IM; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Heerdink ER, 1998, ARCH INTERN MED, V158, P1108, DOI 10.1001/archinte.158.10.1108; Heidenreich PA, 2002, AM HEART J, V144, P422, DOI 10.1067/mhj.2002.125499; Hjalmarson A, 1999, LANCET, V353, P2001; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; Hunt SA, 2002, J HEART LUNG TRANSPL, V21, P189, DOI 10.1016/S1053-2498(01)00776-8; Jiang W, 2001, ARCH INTERN MED, V161, P1849, DOI 10.1001/archinte.161.15.1849; Johnson MJ, 2002, EUR J HEART FAIL, V4, P753, DOI 10.1016/S1388-9842(02)00158-7; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Kizer JR, 2001, ARCH INTERN MED, V161, P1145, DOI 10.1001/archinte.161.9.1145; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Krumholz HM, 1998, CIRCULATION, V98, P648, DOI 10.1161/01.CIR.98.7.648; Krumholz HM, 2002, J AM COLL CARDIOL, V39, P83, DOI 10.1016/S0735-1097(01)01699-0; La Rovere MT, 2003, CIRCULATION, V107, P565, DOI 10.1161/01.CIR.0000047275.25795.17; Lamont EB, 2003, JAMA-J AM MED ASSOC, V290, P98, DOI 10.1001/jama.290.1.98; Levenson JW, 2000, J AM GERIATR SOC, V48, pS101, DOI 10.1111/j.1532-5415.2000.tb03119.x; *LITTL BROWN MED D, 1994, NOM CRIT DIAGN DIS H; Liu P, 2003, CAN J CARDIOL, V19, P347; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Mancini DM, 2003, CIRCULATION, V107, P294, DOI 10.1161/01.CIR.0000044914.42696.6A; Masoudi FA, 2003, JAMA-J AM MED ASSOC, V290, P81, DOI 10.1001/jama.290.1.81; McAlister FA, 1999, AM HEART J, V138, P87, DOI 10.1016/S0002-8703(99)70251-6; McCarthy M, 1996, J ROY COLL PHYS LOND, V30, P325; MCCORMICK TR, 1995, WESTERN J MED, V163, P236; Mitka M, 2003, JAMA-J AM MED ASSOC, V290, P1835, DOI 10.1001/jama.290.14.1835; Murberg TA, 1999, INT J PSYCHIAT MED, V29, P311, DOI 10.2190/0C1C-A63U-V5XQ-1DAL; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; *NAT HOSP PALL CAR, 1996, MED GUID DET PROGN S; Oliva F, 1999, AM HEART J, V138, P247, DOI 10.1016/S0002-8703(99)70108-0; Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777; Pantilat SZ, 1999, JAMA-J AM MED ASSOC, V282, P171, DOI 10.1001/jama.282.2.171; Pantilat SZ, 1999, WESTERN J MED, V171, P253; Philbin EF, 2000, AM HEART J, V139, P491, DOI 10.1067/mhj.2000.104238; Piepoli MF, 2004, BMJ-BRIT MED J, V328, P189, DOI 10.1136/bmj.37938.645220.EE; Pozehl Bunny, 2003, Prog Cardiovasc Nurs, V18, P177; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; Silverberg DS, 2001, J AM COLL CARDIOL, V37, P1775, DOI 10.1016/S0735-1097(01)01248-7; Sim I, 1997, CIRCULATION, V96, P2823, DOI 10.1161/01.CIR.96.9.2823; Stevenson LW, 2003, CIRCULATION, V108, P492, DOI 10.1161/01.CIR.0000078349.43742.8A; Stevenson WG, 2001, J CARDIOVASC ELECTR, V12, P112, DOI 10.1046/j.1540-8167.2001.00112.x; Szachniewicz J, 2003, INT J CARDIOL, V90, P303, DOI 10.1016/S0167-5273(02)00574-0; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; Torp-Pedersen C, 1999, NEW ENGL J MED, V341, P857, DOI 10.1056/NEJM199909163411201; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Williams SG, 2003, HEART, V89, P1085, DOI 10.1136/heart.89.9.1085; Young JB, 2002, JAMA-J AM MED ASSOC, V287, P1531, DOI 10.1001/jama.287.12.1531; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	69	88	90	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2004	291	20					2476	2482		10.1001/jama.291.20.2476	http://dx.doi.org/10.1001/jama.291.20.2476			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823HB	15161899				2022-12-28	WOS:000221599700031
J	Anand, KJS; Hall, RW; Desai, N; Shephard, B; Bergqvist, LL; Young, TE; Boyle, EM; Carbajal, R; Bhutani, VK; Moore, MB; Kronsberg, SS; Barton, BA				Anand, KJS; Hall, RW; Desai, N; Shephard, B; Bergqvist, LL; Young, TE; Boyle, EM; Carbajal, R; Bhutani, VK; Moore, MB; Kronsberg, SS; Barton, BA		NEOPAIN Trial Investigators Grp	Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial	LANCET			English	Article							INTRA-VENTRICULAR HEMORRHAGE; DOUBLE-BLIND; PERIVENTRICULAR LEUKOMALACIA; NEWBORN-INFANTS; MAJOR SURGERY; PAIN; PHARMACOKINETICS; INFUSION; STRESS; DIAMORPHINE	Background Opioid analgesia is commonly used during neonatal intensive care. We undertook the Neurologic Outcomes and Pre-emptive Analgesia in Neonates (NEOPAIN) trial to investigate whether pre-emptive morphine analgesia decreases the rate of a composite primary outcome of neonatal death, severe intraventricular haemorrhage (IVH), and periventricular leucomalacia (PVL) in preterm neonates. Methods Ventilated preterm neonates (n=898) from 16 centres were randomly assigned masked placebo (n=449) or morphine (n=449) infusions. After a loading dose (100 mug/kg), morphine infusions (23-26 weeks of gestation 10 mug kg(-1) h(-1); 27-29 weeks 20 mug kg(-1) h(-1); 30-32 weeks 30 mug kg(-1) h(-1)) were continued as long as clinically justified (maximum 14 days). Open-label morphine could be given on clinical judgment (placebo group 242/443 [54.6%], morphine group 202/446 [45.3%]). Analyses were by intention to treat. Findings Baseline variables were similar in the randomised groups. The placebo and morphine groups had similar rates of the composite outcome (105/408 [26%] vs 115/419 [27%]), neonatal death (47/449 [11%] vs 58/449 [13%]), severe IVH (46/429 [11%] vs 55/411 [13%]), and PVL (34/367 [9%] vs 27/367 [7%]). For neonates who were not given open-label morphine, rates of the composite outcome (53/225 [24%] vs 27/179 [15%], p=00338) and severe IVH (19/219 [9%] vs 6/189 [3%], p=0.0209) were higher in the morphine group than the placebo group. Placebo-group neonates receiving open-label morphine had worse rates of the composite outcome than those not receiving open-label morphine (78/228 [34%] vs 27/179 [15%], p<0.0001). Morphine-group neonates receiving open-label morphine were more likely to develop severe IVH (36/190 [19%] vs 19/219 [9%], p=0.0024). Interpretation Pre-emptive morphine infusions did not reduce the frequency of severe IVH, PVL, or death in ventilated preterm neonates, but intermittent boluses of open-label morphine were associated with an increased rate of the composite outcome. The morphine doses used in this study decrease clinical signs of pain but can cause significant adverse effects in ventilated preterm neonates.	Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Anesthesiol Neurobiol & Pharmacol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA; Univ Kentucky, Med Ctr, Dept Pediat, Lexington, KY USA; Tufts Univ, Sch Med, Dept Pediat, Boston, MA 02111 USA; Astrid Lindgrens Childrens Hosp, Karolinska Inst, Neonatal Res Unit, Stockholm, Sweden; Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; Wake Med Ctr, Raleigh, NC USA; Univ Edinburgh, Simpson Mem Matern Pavil, Edinburgh, Midlothian, Scotland; Ctr Hosp Poissy St Germain, Serv Pediat & Med Neonatale, Poissy, France; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Penn Hosp, Philadelphia, PA 19107 USA; Maryland Med Res Inst, Baltimore, MD USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Kentucky; Tufts University; Karolinska Institutet; University of North Carolina; University of North Carolina Chapel Hill; University of Edinburgh; Hospital Chi of Poissy Saint Germain; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Anand, KJS (corresponding author), Arkansas Childrens Hosp, S-4417,800 Marshall St, Little Rock, AR 72202 USA.	anandsunny@uams.edu	Anand, Kanwaljeet/B-3287-2014; Boyle, Elaine/I-6298-2018	Anand, Kanwaljeet/0000-0001-6498-1483; Barton, Bruce/0000-0001-7878-8895; Boyle, Elaine/0000-0002-5038-3148	NICHD NIH HHS [HD36484, HD36270] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036484, R01HD036270] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anand KJS, 1998, BIOL NEONATE, V73, P1, DOI 10.1159/000013953; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; BARKER DP, 1995, ARCH DIS CHILD-FETAL, V73, pF22, DOI 10.1136/fn.73.1.F22; BARKER DP, 1995, ARCH DIS CHILD-FETAL, V72, pF47, DOI 10.1136/fn.72.1.F47; Barker DP, 1996, ARCH DIS CHILD-FETAL, V75, pF187, DOI 10.1136/fn.75.3.F187; BARRETT DA, 1991, BRIT J CLIN PHARMACO, V32, P31, DOI 10.1111/j.1365-2125.1991.tb05609.x; Barrett DA, 1996, BRIT J CLIN PHARMACO, V41, P531, DOI 10.1046/j.1365-2125.1996.03539.x; Bass W Thomas, 2002, J Perinatol, V22, P64; Baud O, 1999, NEW ENGL J MED, V341, P1190, DOI 10.1056/NEJM199910143411604; BHAT R, 1992, J PEDIATR-US, V120, P795, DOI 10.1016/S0022-3476(05)80251-3; BHAT R, 1990, J PEDIATR-US, V117, P477, DOI 10.1016/S0022-3476(05)81102-3; Bhutta AT, 2001, PHYSIOL BEHAV, V73, P51, DOI 10.1016/S0031-9384(01)00432-2; Bouwmeester NJ, 2001, BRIT J ANAESTH, V87, P390, DOI 10.1093/bja/87.3.390; Cunningham N, 1999, PAIN FORUM, V8, P110; De Paoli AG, 2003, ARCH DIS CHILD-FETAL, V88, P168; DYKE MP, 1995, J PAEDIATR CHILD H, V31, P176, DOI 10.1111/j.1440-1754.1995.tb00780.x; Goldstein R F, 1991, J Perinatol, V11, P365; GREENOUGH A, 2003, COCHRANE LIB, DOI UNSP CD000456; Grunau RE, 2000, CLIN J PAIN, V16, P37, DOI 10.1097/00002508-200003000-00007; HARTLEY R, 1993, ARCH DIS CHILD-FETAL, V69, P55, DOI 10.1136/adc.69.1_Spec_No.55; Howard V A, 1998, J Pediatr Nurs, V13, P164; Johnston CC, 1997, CLIN J PAIN, V13, P308, DOI 10.1097/00002508-199712000-00008; Kahn DJ, 1998, ARCH PEDIAT ADOL MED, V152, P844; Kennedy KA, 1999, J PEDIATR-US, V134, P127, DOI 10.1016/S0022-3476(99)70399-9; LAZZARA A, 1980, PEDIATRICS, V65, P30; Lemons JA, 2000, PEDIATRICS, V105, P454; Maalouf EF, 2001, PEDIATRICS, V107, P719, DOI 10.1542/peds.107.4.719; McIntosh N, 1997, EUR J PEDIATR, V156, P173, DOI 10.1007/s004310050576; Ment LR, 2002, NEUROLOGY, V58, P1726, DOI 10.1212/WNL.58.12.1726; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Perlman JM, 2000, ARCH PEDIAT ADOL MED, V154, P822, DOI 10.1001/archpedi.154.8.822; POKELA ML, 1994, PEDIATRICS, V93, P379; POKELA ML, 1993, BIOL NEONATE, V64, P360; QUINN MW, 1993, LANCET, V342, P324, DOI 10.1016/0140-6736(93)91472-X; QUINN MW, 1992, EARLY HUM DEV, V30, P241, DOI 10.1016/0378-3782(92)90073-P; Richardson D K, 2001, J Perinatol, V21, P121, DOI 10.1038/sj.jp.7200501; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Sabatino G, 1997, EARLY HUM DEV, V47, P263, DOI 10.1016/S0378-3782(96)01781-1; Scott CS, 1999, J PEDIATR-US, V135, P423, DOI 10.1016/S0022-3476(99)70163-0; Simons SHP, 2003, ARCH PEDIAT ADOL MED, V157, P1058, DOI 10.1001/archpedi.157.11.1058; Simons SHP, 2003, JAMA-J AM MED ASSOC, V290, P2419, DOI 10.1001/jama.290.18.2419; Stevens B J, 1993, J Obstet Gynecol Neonatal Nurs, V22, P531, DOI 10.1111/j.1552-6909.1993.tb01838.x; Vaccarino AL, 1995, PAIN, V63, P385, DOI 10.1016/0304-3959(95)00069-0; van Dijk M, 2002, PAIN, V98, P305, DOI 10.1016/S0304-3959(02)00031-3; Volpe JJ, 1997, CLIN PERINATOL, V24, P567, DOI 10.1016/S0095-5108(18)30159-3; Volpe JJ, 2001, PEDIATR RES, V50, P553, DOI 10.1203/00006450-200111000-00003; Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417; Zahorodny W, 1998, J DEV BEHAV PEDIATR, V19, P89, DOI 10.1097/00004703-199804000-00005	50	334	348	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	2004	363	9422					1673	1682		10.1016/S0140-6736(04)16251-X	http://dx.doi.org/10.1016/S0140-6736(04)16251-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158628				2022-12-28	WOS:000221546300007
J	Richens, J				Richens, J			ABC of sexually transmitted infections - Main presentations of sexually transmitted infections in men	BRITISH MEDICAL JOURNAL			English	Review									UCL Royal Free & Univ Coll Med Sch, London, England	University of London; University College London; UCL Medical School	Richens, J (corresponding author), UCL Royal Free & Univ Coll Med Sch, London, England.	jrichens@gum.ucl.ac.uk	Richens, John/C-1876-2008					Galejs LE, 1999, AM FAM PHYSICIAN, V59, P817; Hook Er., 1999, SEX TRANSM DIS; Krieger John N, 2002, Curr Urol Rep, V3, P301, DOI 10.1007/s11934-002-0054-z; Morton R.S., 1977, GONORRHOEA; Ostrow D., 1983, SEXUALLY TRANSMITTED	5	2	3	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 22	2004	328	7450					1251	1253		10.1136/bmj.328.7450.1251	http://dx.doi.org/10.1136/bmj.328.7450.1251			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824HL	15155507	Green Published			2022-12-28	WOS:000221677200031
J	Macleod, J; Oakes, R; Copello, A; Crome, L; Egger, M; Hickman, M; Oppenkowski, T; Stokes-Lampard, H; Smith, GD				Macleod, J; Oakes, R; Copello, A; Crome, L; Egger, M; Hickman, M; Oppenkowski, T; Stokes-Lampard, H; Smith, GD			Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies	LANCET			English	Review							ADOLESCENT MARIJUANA USE; SUBSTANCE USE; HIGH-SCHOOL; MENDELIAN RANDOMIZATION; MENTAL-HEALTH; PSYCHOSOCIAL ADJUSTMENT; ANTISOCIAL-BEHAVIOR; MILITARY CONSCRIPTS; SUICIDAL BEHAVIORS; SWEDISH CONSCRIPTS	Background Use of illicit drugs, particularly cannabis, by young people is widespread and is associated with several types of psychological and social harm. These relations might not be causal. Causal relations would suggest that recreational drug use is a substantial public health problem. Non-causal relations would suggest that harm-reduction policy based on prevention of drug use is unlikely to produce improvements in public health. Cross-sectional evidence cannot clarify questions of causality; longitudinal or interventional evidence is needed. Past reviews have generally been non-systematic, have often included cross-sectional data, and have underappreciated the extent of methodological problems associated with interpretation. Methods We did a systematic review of general population longitudinal studies reporting associations between illicit drug use by young people and psychosocial harm. Findings We identified 48 relevant studies, of which 16 were of higher quality and provided the most robust evidence. Fairly consistent associations were noted between cannabis use and both lower educational attainment and increased reported use of other illicit drugs. Less consistent associations were noted between cannabis use and both psychological health problems and problematic behaviour. All these associations seemed to be explicable in terms of non-causal mechanisms. Interpretation Available evidence does not strongly support an important causal relation between cannabis use by young people and psychosocial harm, but cannot exclude the possibility that such a relation exists. The lack of evidence of robust causal relations prevents the attribution of public health detriments to illicit drug use. In view of the extent of illicit drug use, better evidence is needed.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Psychol, Birmingham B15 2TT, W Midlands, England; Keele Univ, Acad Psychiat Unit, Stoke On Trent, Staffs, England; Univ Bristol, Dept Social Med, Bristol, Avon, England; Univ Bern, Dept Social & Prevent Med, Bern, Switzerland; Univ London Imperial Coll Sci Technol & Med, Ctr Res Drugs & Hlth Behav Social Sci & Med, London, England	University of Birmingham; University of Birmingham; Keele University; University of Bristol; University of Bern; Imperial College London	Macleod, J (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Primary Care Clin Sci & Learning Ctr Bldg, Birmingham B15 2TT, W Midlands, England.	j.a.macleod@bham.ac.uk	Hickman, Matthew/Y-2400-2019; Davey Smith, George/A-7407-2013	Hickman, Matthew/0000-0001-9864-459X; Davey Smith, George/0000-0002-1407-8314; Copello, Alex/0000-0003-3788-7197; Macleod, John/0000-0001-8202-1144; Egger, Matthias/0000-0001-7462-5132				ANDREASSON S, 1990, SCAND J SOC MED, V18, P9; Andrews JA, 1997, J BEHAV MED, V20, P523, DOI 10.1023/A:1025514423975; ANNIS HM, 1975, CANADIAN COUNSELOR, V9, P155; [Anonymous], 1988, CONSEQUENCES ADOLESC; Anthony JC, 2000, SCIENCE OF SELF-REPORT, P175; ANTHONY JC, 1995, DRUG ALCOHOL DEPEN, V40, P9, DOI 10.1016/0376-8716(95)01194-3; Arseneault L, 2002, BRIT MED J, V325, P1212, DOI 10.1136/bmj.325.7374.1212; Aust R, 2002, PREVALENCE DRUG USE; Bates ME, 1997, ALCOHOL CLIN EXP RES, V21, P944, DOI 10.1097/00000374-199708000-00027; BENSON G, 1985, ACTA PSYCHIAT SCAND, V71, P38, DOI 10.1111/j.1600-0447.1985.tb05049.x; BENSON G, 1984, ACTA PSYCHIAT SCAND, V70, P550, DOI 10.1111/j.1600-0447.1984.tb01248.x; Berkane M., 1997, LATENT VARIABLE MODE; Braun BL, 1997, AM J PUBLIC HEALTH, V87, P629, DOI 10.2105/AJPH.87.4.629; Bray JW, 2000, HEALTH ECON, V9, P9, DOI 10.1002/(SICI)1099-1050(200001)9:1<9::AID-HEC471>3.0.CO;2-Z; Brook DW, 2002, ARCH PEDIAT ADOL MED, V156, P1101, DOI 10.1001/archpedi.156.11.1101; Brook JS, 1999, AM J PUBLIC HEALTH, V89, P1549, DOI 10.2105/AJPH.89.10.1549; Brook JS, 1998, J AM ACAD CHILD PSY, V37, P322, DOI 10.1097/00004583-199803000-00018; Brook JS, 1996, J AM ACAD CHILD PSY, V35, P1584, DOI 10.1097/00004583-199612000-00009; Brook JS, 1999, GENET SOC GEN PSYCH, V125, P193; Brunswick AF, 1999, J ADDICT DIS, V18, P53, DOI 10.1300/J069v18n01_06; BRUNSWICK AF, 1986, AM J PUBLIC HEALTH, V76, P52, DOI 10.2105/AJPH.76.1.52; CHOQUET M, 1988, Psychiatrie and Psychobiologie, V3, P227; Colon HM, 2001, INT J EPIDEMIOL, V30, P1042, DOI 10.1093/ije/30.5.1042; COPELAND L, IN PRESS ARCH INTERN; Costello EJ, 1999, J CLIN CHILD PSYCHOL, V28, P298, DOI 10.1207/S15374424jccp280302; DAVEYSMITH G, 1992, LANCET, V340, P709; Degenhardt L, 2003, DRUG ALCOHOL DEPEN, V71, P37, DOI 10.1016/S0376-8716(03)00064-4; DEGONDA M, 1993, EUR ARCH PSY CLIN N, V243, P95, DOI 10.1007/BF02191571; Dornbusch S.M., 2011, INT J ADOLESCENT MED, V11, P197, DOI [10.1515/IJAMH.1999.11.3-4.197, DOI 10.1515/IJAMH.1999.11.3-4.197]; Duncan SC, 1999, J BEHAV MED, V22, P21, DOI 10.1023/A:1018795417956; Egger M, 1998, BRIT MED J, V316, P140; Ellickson P, 1998, J DRUG ISSUES, V28, P357, DOI 10.1177/002204269802800205; Ellickson PL, 2000, AM J PUBLIC HEALTH, V90, P566, DOI 10.2105/AJPH.90.4.566; EPSTEIN L, 1984, J ADOLESCENT HEALTH, V5, P91, DOI 10.1016/S0197-0070(84)80005-4; FARRELL AD, 1993, J CONSULT CLIN PSYCH, V61, P327, DOI 10.1037/0022-006X.61.2.327; FARRINGTON DP, 1995, J CHILD PSYCHOL PSYC, V36, P929, DOI 10.1111/j.1469-7610.1995.tb01342.x; Fergusson DM, 2002, ADDICTION, V97, P1123, DOI 10.1046/j.1360-0443.2002.00103.x; Fergusson DM, 2000, ADDICTION, V95, P505, DOI 10.1046/j.1360-0443.2000.9545053.x; Fergusson DM, 1996, J ABNORM CHILD PSYCH, V24, P499, DOI 10.1007/BF01441571; Fergusson DM, 1997, ADDICTION, V92, P279; Fergusson DM, 2003, PSYCHOL MED, V33, P15, DOI 10.1017/S0033291702006402; FRIEDMAN AS, 1987, J DRUG EDUC, V17, P233, DOI 10.2190/F7VJ-3MTA-HF62-0DQC; Friedman AS, 1996, J SUBST ABUSE, V8, P379, DOI 10.1016/S0899-3289(96)90001-2; Gadzicki D, 1999, MOL CELL PROBE, V13, P321, DOI 10.1006/mcpr.1999.0249; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; GUY SM, 1993, PSYCHOL HEALTH, V8, P463, DOI 10.1080/08870449308400449; Hall W, 1998, LANCET, V352, P1611, DOI 10.1016/S0140-6736(98)05021-1; HAMMER T, 1992, SCAND J SOC MED, V20, P143, DOI 10.1177/140349489202000303; HANSELL S, 1991, J HEALTH SOC BEHAV, V32, P288, DOI 10.2307/2136809; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HUIZINGA D, 1993, PUBLIC HEALTH REP, V108, P90; Jablensky A, 2000, EUR ARCH PSY CLIN N, V250, P274, DOI 10.1007/s004060070002; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Juon HS, 1997, J CHILD PSYCHOL PSYC, V38, P553, DOI 10.1111/j.1469-7610.1997.tb01542.x; KAESTNER R, 1994, IND LABOR RELAT REV, V47, P454, DOI 10.2307/2524977; KANDEL D, 1995, SOC FORCES, V74, P243, DOI 10.2307/2580631; KANDEL D, 1975, SCIENCE, V190, P912, DOI 10.1126/science.1188374; KAPLAN HB, 1986, J HEALTH SOC BEHAV, V27, P44, DOI 10.2307/2136502; Kendell R, 2003, ADDICTION, V98, P143, DOI 10.1046/j.1360-0443.2003.00273.x; Krohn MD, 1997, J HEALTH SOC BEHAV, V38, P87, DOI 10.2307/2955363; Lenton S, 2001, ADDICTION, V96, P511; LIPKUS IM, 1994, HEALTH PSYCHOL, V13, P149, DOI 10.1037/0278-6133.13.2.149; Luthar SS, 1997, J YOUTH ADOLESCENCE, V26, P353, DOI 10.1007/s10964-005-0007-1; Lynskey MT, 2003, ADDICTION, V98, P685, DOI 10.1046/j.1360-0443.2003.00356.x; Macleod J, 2002, BMJ-BRIT MED J, V324, P1247, DOI 10.1136/bmj.324.7348.1247; Maughan B, 1997, BRIT MED BULL, V53, P156; McGee R, 2000, ADDICTION, V95, P491, DOI 10.1046/j.1360-0443.2000.9544912.x; Morral AR, 2002, ADDICTION, V97, P1493, DOI 10.1046/j.1360-0443.2002.00280.x; Newcomb MD, 1997, J ADDICT DIS, V16, P51, DOI 10.1300/J069v16n01_05; Newcomb MD, 1999, J COMMUNITY PSYCHOL, V27, P405, DOI 10.1002/(SICI)1520-6629(199907)27:4<405::AID-JCOP4>3.0.CO;2-2; NEWCOMB MD, 1993, EXP CLIN PSYCHOPHARM, V1, P241; Patton GC, 1997, PSYCHOL MED, V27, P715, DOI 10.1017/S003329179600462X; Patton GC, 2002, BMJ-BRIT MED J, V325, P1195, DOI 10.1136/bmj.325.7374.1195; Perkonigg A, 1999, ADDICTION, V94, P1663, DOI 10.1046/j.1360-0443.1999.941116635.x; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; Rao U, 2000, J AM ACAD CHILD PSY, V39, P215, DOI 10.1097/00004583-200002000-00022; Resnick MD, 1997, JAMA-J AM MED ASSOC, V278, P823, DOI 10.1001/jama.278.10.823; Ricaurte GA, 2001, LANCET, V358, P1831, DOI 10.1016/S0140-6736(01)06880-5; ROBINS LN, 1978, PSYCHOL MED, V8, P611, DOI 10.1017/S0033291700018821; ROMERO E, 1995, REV PSICOLOGIA SOCIA, V10, P149; SADAVA SW, 1973, PSYCHOL REP, V33, P75, DOI 10.2466/pr0.1973.33.1.75; SANFORD M, 1994, J AM ACAD CHILD PSY, V33, P1036, DOI 10.1097/00004583-199409000-00015; Scheier L M, 1991, J Subst Abuse, V3, P277; SCHULENBERG J, 1994, J HEALTH SOC BEHAV, V35, P45, DOI 10.2307/2137334; Silva P., 1996, CHILD ADULT DUNEDIN; Smith GD, 2004, INT J EPIDEMIOL, V33, P30, DOI 10.1093/ije/dyh132; Smith GD, 2004, QJM-INT J MED, V97, P163, DOI 10.1093/qjmed/hch025; Smith GD, 2002, BMJ-BRIT MED J, V325, P1437; Smith GD, 2001, BRIT MED J, V322, P184, DOI 10.1136/bmj.322.7280.184; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Solowij N., 1998, CANNABIS COGNITIVE F; Stanton B, 1997, ARCH PEDIAT ADOL MED, V151, P398, DOI 10.1001/archpedi.1997.02170410072010; STEIN JA, 1993, J APPL PSYCHOL, V78, P463; STENBACKA M, 1992, SCAND J SOC MED, V20, P94, DOI 10.1177/140349489202000206; Susser E, 2000, PAEDIATR PERINAT EP, V14, P98, DOI 10.1046/j.1365-3016.2000.00249.x; Tubman J G, 1990, J Subst Abuse, V2, P317; van den Bree MBM, 1998, DRUG ALCOHOL DEPEN, V52, P231, DOI 10.1016/S0376-8716(98)00101-X; Weiser M, 2002, AM J MED GENET, V114, P949, DOI 10.1002/ajmg.10647; White D, 1998, ADDICTION, V93, P1475, DOI 10.1046/j.1360-0443.1998.931014754.x; White HR, 1999, DEV PSYCHOPATHOL, V11, P785, DOI 10.1017/S0954579499002321; White HR, 1998, J DRUG ISSUES, V28, P837, DOI 10.1177/002204269802800402; Windle M, 1997, J STUD ALCOHOL, V58, P573, DOI 10.15288/jsa.1997.58.573; Zammit S, 2002, BRIT MED J, V325, P1199, DOI 10.1136/bmj.325.7374.1199; ZARCO IH, 1999, ATEN PRIM, V23, P289	104	416	422	3	96	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	2004	363	9421					1579	1588		10.1016/S0140-6736(04)16200-4	http://dx.doi.org/10.1016/S0140-6736(04)16200-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	820SE	15145631				2022-12-28	WOS:000221408800008
J	Kobayashi, S; Goto-Yamamoto, N; Hirochika, H				Kobayashi, S; Goto-Yamamoto, N; Hirochika, H			Retrotransposon-induced mutations in grape skin color	SCIENCE			English	Article							ANTHOCYANIN BIOSYNTHESIS; GENES		Natl Inst Fruit Tree Sci, Dept Grape & Persimmon Res, Hiroshima 7292494, Japan; Natl Res Inst Brewing, Hiroshima 7390046, Japan; Natl Inst Agrobiol Sci, Dept Mol Genet, Tsukuba, Ibaraki 3058602, Japan	National Agriculture & Food Research Organization - Japan; National Institute of Agrobiological Sciences - Japan	Kobayashi, S (corresponding author), Natl Inst Fruit Tree Sci, Dept Grape & Persimmon Res, Hiroshima 7292494, Japan.	skobaya@affrc.go.jp		KOBAYASHI, SHOZO/0000-0001-6306-9273				Boss PK, 1996, PLANT MOL BIOL, V32, P565, DOI 10.1007/BF00019111; Kobayashi S, 2002, PLANTA, V215, P924, DOI 10.1007/s00425-002-0830-5; KOBAYASHI S, UNPUB; Kumar A, 1999, ANNU REV GENET, V33, P479, DOI 10.1146/annurev.genet.33.1.479; Mullins MG., 1992, BIOL GRAPEVINE BIOL; ROEDER GS, 1980, CELL, V21, P239, DOI 10.1016/0092-8674(80)90131-2	6	656	756	13	181	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					982	982		10.1126/science.1095011	http://dx.doi.org/10.1126/science.1095011			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143274				2022-12-28	WOS:000221383300039
J	Walsh, JME; Pignone, M				Walsh, JME; Pignone, M			Drug treatment of hyperlipidemia in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; PRIMARY PREVENTION; ARTERY-DISEASE; CHOLESTEROL; PRAVASTATIN; ATHEROSCLEROSIS; RISK; SIMVASTATIN	Context Several clinical trials have evaluated the effects of lipid-lowering medications on coronary heart disease (CHD). Many of the trials have not included enough women to allow sex-specific analyses or have not reported results in women separately. Objectives To assess and synthesize the evidence regarding drug treatment of hyperlipidemia for the prevention of CHID events in women and to conduct a meta-analysis of the effect of drug treatment on mortality. Data Sources We searched MEDLINE, the Cochrane Database, and the Database of Abstracts of Reviews of Effectiveness for articles published from 1966 through December 2003. We reviewed reference lists of articles and consulted content experts. Study Selection and Data Extraction Studies of outpatients that had a treatment duration of at least 1 year, assessed the impact of lipid lowering on clinical outcomes, and reported results by sex were included. Outcomes evaluated were total mortality, CHD mortality, nonfatal myocardial infarction, revascularization, and total CHD events. Summary estimates of the relative risks (RRs) with therapy were calculated using a random-effects model for patients with and without a previous history of cardiovascular disease. Data Synthesis Thirteen studies were included. Six trials included a total of 11435 women without cardiovascular disease and assessed the effects of lipid-lowering medications. Lipid lowering did not reduce total mortality (RR, 0.95; 95% confidence interval [CI], 0.62-1.46), CHD mortality (RR, 1.07; 95% CI, 0.47-2.40), nonfatal myocardial infarction (RR, 0.61; 95% CI, 0.22-1.68), revascularization (RR, 0.87; 95% CI, 0.33-2.31), or CHD events (RR, 0.87; 95% CI, 0.69-1.09). However, some analyses were limited by too few CHD events in the available trials. Eight trials included 8272 women with cardiovascular disease and assessed the effects of lipid-lowering medications. Lipid lowering did not reduce total mortality in women with cardiovascular disease (RR, 1.00; 95% CI, 0.77-1.29). However, lipid lowering reduced CHD mortality (RR, 0.74; 95% CI, 0.55-1.00), nonfatal myocardial infarction (RR, 0.71; 95% CI, 0.58-0.87), revascularization (RR, 0.70; 95% CI, 0.55-0.89), and total CHD events (RR, 0.80; CI, 0.71-0.91). Conclusions For women without cardiovascular disease, lipid lowering does not affect total or CHD mortality. Lipid lowering may reduce CHD events, but current evidence is insufficient to determine this conclusively. For women with known cardiovascular disease, treatment of hyperlipidemia is effective in reducing CHD events, CHD mortality, nonfatal myocardial infarction, and revascularization, but it does not affect total mortality.	Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ N Carolina, Div Gen Internal Med, Chapel Hill, NC USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill	Walsh, JME (corresponding author), Womens Hlth Clin Res Ctr, 1635 Divisadero,Suite 600,Campus Box 1793, San Francisco, CA 94115 USA.	jmwalsh@itsa.ucsf.edu		Pignone, Michael/0000-0002-6657-7342	PHS HHS [290-97-0013] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; *AM HEART ASS, WOM COR HEART DIS; *AM HEART ASS, 2002, HEART DIS STROK STAT; [Anonymous], 1993, JAMA, V269, P505; [Anonymous], 1993, Am J Cardiol, V72, P1031; Arntz HR, 2000, AM J CARDIOL, V86, P1293, DOI 10.1016/S0002-9149(00)01230-3; *AS CAR ART PLAQ S, 1992, CONTR CLIN TRIALS, V13, P293; Atkins D, 2000, J Am Med Womens Assoc (1972), V55, P234; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; BYINGTON RP, 1995, AM J CARDIOL, V76, pC54, DOI 10.1016/S0002-9149(99)80471-8; Campeau L, 1999, CIRCULATION, V99, P3241, DOI 10.1161/01.CIR.99.25.3241; Campeau L, 1997, NEW ENGL J MED, V336, P153; Clearfield M, 2001, J WOMEN HEALTH GEN-B, V10, P971, DOI 10.1089/152460901317193549; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2003, LANCET, V361, P2005; D Grady, 2003, PUBLICATION AGENCY H; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; Hague W, 2003, AM HEART J, V145, P643, DOI 10.1067/mhj.2003.1; HALDANE JBS, 1956, ANN HUM GENET, V20, P309; Herd JA, 1997, AM J CARDIOL, V80, P278, DOI 10.1016/S0002-9149(97)00346-9; LaRosa JC, 1997, ARCH INTERN MED, V157, P961, DOI 10.1001/archinte.157.9.961; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; Lewis SJ, 1998, J AM COLL CARDIOL, V32, P140, DOI 10.1016/S0735-1097(98)00202-2; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; Miettinen TA, 1997, CIRCULATION, V96, P4211; *NAT CTR HLTH STAT, 1991, HLTH US 1990; Pedersen TR, 1996, ARCH INTERN MED, V156, P2085, DOI 10.1001/archinte.156.18.2085; PEDERSEN TR, 1994, LANCET, V344, P1383; *PHYS NEWC TYN REG, 1971, BRIT MED J, V4, P767; Pignone M, 2000, BRIT MED J, V321, P983, DOI 10.1136/bmj.321.7267.983; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; Research Committee of the Scottish Society of Physicians, 1971, BMJ-BRIT MED J, V4, P775; Riegger G, 1999, ATHEROSCLEROSIS, V144, P263, DOI 10.1016/S0021-9150(99)00062-3; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sankey SS, 1996, COMMUN STAT SIMULAT, V25, P1031, DOI 10.1080/03610919608813357; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Teo KK, 2000, CIRCULATION, V102, P1748; THOM TJ, 1987, CARDIOVASCULAR DIS M; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tonkin AM, 2000, LANCET, V356, P1871, DOI 10.1016/S0140-6736(00)03257-8; WALSH JME, 1995, JAMA-J AM MED ASSOC, V274, P1152, DOI 10.1001/jama.274.14.1152; White HD, 2000, NEW ENGL J MED, V343, P317, DOI 10.1056/NEJM200008033430502; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	52	183	188	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2004	291	18					2243	2252		10.1001/jama.291.18.2243	http://dx.doi.org/10.1001/jama.291.18.2243			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GR	15138247	Bronze			2022-12-28	WOS:000221303500027
J	Kimberlin, DW; Rouse, DJ				Kimberlin, DW; Rouse, DJ			Genital herpes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX-VIRUS-INFECTION; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ORAL ACYCLOVIR; IMMUNOCOMPETENT PATIENTS; CESAREAN DELIVERY; LATE PREGNANCY; 1ST EPISODE; LARGE-SCALE; SUPPRESSION		Univ Alabama Birmingham, Div Pediat Infect Dis, Dept Pediat, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kimberlin, DW (corresponding author), Univ Alabama Birmingham, Div Pediat Infect Dis, Dept Pediat, 1600 7th Ave S,CHB 303, Birmingham, AL 35233 USA.	dkimberlin@peds.uab.edu			NIAID NIH HHS [N01-AI-62554, N01-AI-15113] Funding Source: Medline; NICHD NIH HHS [1 K24HDO1375-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K24HD001375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI062554, N01AI015113] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACOG, 2000, INT J GYNECOL OBSTET, V68, P165; Alexander L, 2002, J INFECT DIS, V186, pS57, DOI 10.1086/342964; Ashley RL, 2001, SEX TRANSM INFECT, V77, P232, DOI 10.1136/sti.77.4.232; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; Benedetti JK, 1999, ANN INTERN MED, V131, P14, DOI 10.7326/0003-4819-131-1-199907060-00004; BERGER JR, 1991, LANCET, V337, P1360, DOI 10.1016/0140-6736(91)93051-A; Bodsworth NJ, 1997, GENITOURIN MED, V73, P110; Braig S, 2001, EUR J OBSTET GYN R B, V96, P55, DOI 10.1016/S0301-2115(00)00406-1; Brown ZA, 2003, JAMA-J AM MED ASSOC, V289, P203, DOI 10.1001/jama.289.2.203; CARNEY O, 1994, GENITOURIN MED, V70, P40; Centers for Disease Control and Prevention (CDC), 2016, DEV WAT MAN PROGR RE; Chosidow O, 2001, BRIT J DERMATOL, V144, P818, DOI 10.1046/j.1365-2133.2001.04139.x; Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; Corey L, 2000, JAMA-J AM MED ASSOC, V283, P791, DOI 10.1001/jama.283.6.791; Corey L, 1999, SEX TRANSM DIS, V3rd, P285; Diamond C, 1999, SEX TRANSM DIS, V26, P221, DOI 10.1097/00007435-199904000-00007; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; Fife KH, 1997, SEX TRANSM DIS, V24, P481, DOI 10.1097/00007435-199709000-00007; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; KAUFMAN RH, 1973, CANCER RES, V33, P1446; Kimberlin D, 1996, PEDIATR INFECT DIS J, V15, P247, DOI 10.1097/00006454-199603000-00014; Kimberlin David, 2002, International Journal of STD and AIDS, V13, P60; KIMBERLIN DW, 1995, ANTIVIR RES, V26, P423, DOI 10.1016/0166-3542(95)00031-G; Kimberlin DW, 2001, PEDIATRICS, V108, P230, DOI 10.1542/peds.108.2.230; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; Lafferty WE, 2000, J INFECT DIS, V181, P1454, DOI 10.1086/315395; LOVELESS M, 1995, 35 INT C ANT AG CHEM, P181; MERTZ GJ, 1984, JAMA-J AM MED ASSOC, V252, P1147, DOI 10.1001/jama.252.9.1147; Mertz GJ, 1997, ARCH INTERN MED, V157, P343, DOI 10.1001/archinte.157.3.343; MERTZ GJ, 1988, JAMA-J AM MED ASSOC, V260, P201, DOI 10.1001/jama.260.2.201; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297; Patel R, 1997, GENITOURIN MED, V73, P105; Patel R, 2001, INT J STD AIDS, V12, P640, DOI 10.1258/0956462011923859; Prince HE, 2000, J CLIN LAB ANAL, V14, P13, DOI 10.1002/(SICI)1098-2825(2000)14:1<13::AID-JCLA3>3.0.CO;2-C; RATTRAY MC, 1978, BRIT J VENER DIS, V54, P262; Reitano M, 1998, J INFECT DIS, V178, P603, DOI 10.1086/515385; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; Rouse DJ, 2000, AM J OBSTET GYNECOL, V183, P400, DOI 10.1067/mob.2000.105967; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; SACKS SL, 1997, 37 INT C ANT AG CHEM, P227; Schacker T, 1998, JAMA-J AM MED ASSOC, V280, P61, DOI 10.1001/jama.280.1.61; Scott L L, 2002, Infect Dis Obstet Gynecol, V10, P71, DOI 10.1155/S1064744902000054; Scott LL, 1996, OBSTET GYNECOL, V87, P69, DOI 10.1016/0029-7844(95)00357-6; Sheffield JS, 2003, OBSTET GYNECOL, V102, P1396, DOI 10.1016/j.obstetgynecol.2003.08.015; Spruance SL, 1996, ARCH INTERN MED, V156, P1729, DOI 10.1001/archinte.156.15.1729; Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915; Tyring SK, 1998, ARCH DERMATOL, V134, P185, DOI 10.1001/archderm.134.2.185; Wald A, 2000, NEW ENGL J MED, V342, P844, DOI 10.1056/NEJM200003233421203; Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; Wald A, 2001, JAMA-J AM MED ASSOC, V285, P3100, DOI 10.1001/jama.285.24.3100; WALD A, 1998, 38 INT C ANT AG CHEM, P338; Watts DH, 2003, AM J OBSTET GYNECOL, V188, P836, DOI 10.1067/mob.2003.185	55	88	93	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1970	1977		10.1056/NEJMcp023065	http://dx.doi.org/10.1056/NEJMcp023065			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128897				2022-12-28	WOS:000221218800009
J	Verlinsky, Y; Rechitsky, S; Sharapova, T; Morris, R; Taranissi, M; Kuliev, A				Verlinsky, Y; Rechitsky, S; Sharapova, T; Morris, R; Taranissi, M; Kuliev, A			Preimplantation HLA testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSIS; MUTATION	Context Preimplantation genetic diagnosis (PGD) has become an option for couples for whom termination of an affected pregnancy identified by traditional prenatal diagnosis is unacceptable and is applicable to indications beyond those of prenatal diagnosis, such as HLA matching to affected siblings to provide stem cell transplantation. Objective To describe preimplantation HLA typing, not involving identification of a causative gene, for couples who had children with bone marrow disorders at need for HLA-matched stem cell transplantation. Design, Setting, and Participants HLA matching procedures conducted at a single site during 2002-2003 in an in vitro fertilization program for 9 couples with children affected by acute lymphoid leukemia, acute myeloid leukemia, or Diamond-Blackfan anemia requiring HLA-matched stem cell transplantation. In 13 clinical cycles, DNA in single blastomeres removed from 8-cell embryos following in vitro fertilization was analyzed for HLA genes simultaneously with analysis for short tandem repeats in the HLA region to select and transfer only those embryos that were HLA matched to affected siblings. Main Outcome Measures Results of HLA matching and pregnancy outcome. Results As a result of testing a total of 199 embryos, 45 (23%) HLA-matched embryos were selected, of which 28 were transferred in 12 clinical cycles, resulting in 5 singleton pregnancies and birth of 5 HILA-matched healthy children. Conclusion This is the first known experience of preimplantation HLA typing performed without PGD for a causative gene, providing couples with a realistic option of having HLA-matched offspring to serve as potential donors of stem cells for their affected siblings.	Inst Reprod Genet, Chicago, IL 60657 USA; Assisted Reprod & Gynaecol Ctr, London, England		Kuliev, A (corresponding author), Inst Reprod Genet, 2825 N Halsted St, Chicago, IL 60657 USA.	anverkuliev@hotmail.com	Kuliev, Anver/P-5666-2018	Kuliev, Anver/0000-0002-2486-9339				Abou-Sleiman PM, 2002, MOL HUM REPROD, V8, P304, DOI 10.1093/molehr/8.3.304; Adamson GD, 2000, FERTIL STERIL, V74, P641; Damewood MD, 2001, JAMA-J AM MED ASSOC, V285, P3143, DOI 10.1001/jama.285.24.3143; De Boer K, 2000, HUM REPROD, V15, P2673; Edwards R G, 2003, Reprod Biomed Online, V6, P170; Foissac A, 2000, TISSUE ANTIGENS, V55, P477, DOI 10.1034/j.1399-0039.2000.550601.x; *INT WORK GROUP PR, 2001, REPROD BIOMED ONLINE, V3, P49; KULIEV A, 2002, REPROD BIOMED ONLINE, V5, P296; Munne Santiago, 2002, Reprod Biomed Online, V4, P183; Rechitsky S, 1999, J ASSIST REPROD GEN, V16, P192, DOI 10.1023/A:1020312823155; Rechitsky Svetlana, 2002, Reprod Biomed Online, V5, P148; Verlinsky Y, 2003, NEW ENGL J MED, V348, P1449, DOI 10.1056/NEJMoa022652; Verlinsky Y, 2002, JAMA-J AM MED ASSOC, V287, P1018, DOI 10.1001/jama.287.8.1018; Verlinsky Y, 2001, JAMA-J AM MED ASSOC, V285, P3130, DOI 10.1001/jama.285.24.3130; VERLINSKY Y, 2000, ATLAS PREIMPLANTATIO; VERLINSKY Y, IN PRESS FERTIL STER; DIAMOND BLACKFAN ANE; 1998, B WHO, V76, P313	18	114	119	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2004	291	17					2079	2085		10.1001/jama.291.17.2079	http://dx.doi.org/10.1001/jama.291.17.2079			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JR	15126435	Bronze			2022-12-28	WOS:000221174300024
J	Sheikh, A; Natuveli, G; Kai, J; Panesar, SS				Sheikh, A; Natuveli, G; Kai, J; Panesar, SS			Comparison of reporting of ethnicity in US and European randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Edinburgh, Div Community Hlth Sci, GP Sect, Edinburgh EH8 9DX, Midlothian, Scotland; Univ London Imperial Coll Sci Technol & Med, Div Primary Care & Populat Hlth Sci, London, England; Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England	University of Edinburgh; Imperial College London; University of Nottingham	Sheikh, A (corresponding author), Univ Edinburgh, Div Community Hlth Sci, GP Sect, Edinburgh EH8 9DX, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056; Kai, Joe/0000-0001-9040-9384				Corbie-Smith G, 2003, J CLIN EPIDEMIOL, V56, P416, DOI 10.1016/S0895-4356(03)00031-3; Mulrow CD, 1994, COCHRANE LIB; *NIH, 2001, MON ADH NIH POL INCL; *OFF MAN BUDG, 1997, 15 OOMAB OFF MAN BUD	4	39	39	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	2004	329	7457					87	88		10.1136/bmj.38061.593935.F7	http://dx.doi.org/10.1136/bmj.38061.593935.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15138158	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000222645000025
J	Johanek, V; Laurin, M; Grant, AW; Kasemo, B; Henry, CR; Libuda, J				Johanek, V; Laurin, M; Grant, AW; Kasemo, B; Henry, CR; Libuda, J			Fluctuations and bistabilities on catalyst nanoparticles	SCIENCE			English	Article							CO OXIDATION; MODEL CATALYSTS; REACTION-KINETICS; SURFACE-REACTION; TRANSITIONS; HYSTERESIS; CLUSTERS	We show that coverage fluctuations on catalyst particles can drastically alter their macroscopic catalytic behavior. Scrutinizing the occurrence of kinetic bistabilities, it is demonstrated by molecular beam experiments on model catalysts that macroscopically observable bistabilities vanish completely with decreasing particle size, as previously predicted by theory. The effect is attributed to fluctuation-induced transitions between two kinetic reaction regimes, with a transition rate controlled by both particle size and surface defects. These results suggest that fluctuation-induced effects represent a general phenomenon affecting the reaction kinetics on nanostructured surfaces.	Max Planck Gesell, Fritz Haber Inst, D-14195 Berlin, Germany; Chalmers Univ Technol, Dept Appl Phys, S-41296 Gothenburg, Sweden; CNRS, Ctr Rech Mat Condensee & Nanosci, F-13288 Marseille 9, France	Max Planck Society; Fritz Haber Institute of the Max Planck Society; Chalmers University of Technology; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Libuda, J (corresponding author), Max Planck Gesell, Fritz Haber Inst, Faradayweg 4-6, D-14195 Berlin, Germany.	libuda@fhi-berlin.mpg.de	Johánek, Viktor/A-7383-2008; Libuda, Joerg/O-7967-2016	Johánek, Viktor/0000-0002-8833-5870; Libuda, Joerg/0000-0003-4713-5941				Baumer M, 1999, PROG SURF SCI, V61, P127, DOI 10.1016/S0079-6816(99)00012-X; Bell AT, 2003, SCIENCE, V299, P1688, DOI 10.1126/science.1083671; Campbell CT, 2002, SCIENCE, V298, P811, DOI 10.1126/science.1075094; Chakarova R, 1997, SURF SCI, V389, P234, DOI 10.1016/S0039-6028(97)00417-2; Ertl G., 1997, HDB HETEROGENEOUS CA; Freund HJ, 2003, J CATAL, V216, P223, DOI 10.1016/S0021-9517(02)00073-8; Gardiner CW, 1983, SPRINGER SERIES SYNE, V13; Goodman DW, 2003, J CATAL, V216, P213, DOI 10.1016/S0021-9517(02)00112-4; Hansen TW, 2001, SCIENCE, V294, P1508, DOI 10.1126/science.1064399; Heiz U, 1999, J AM CHEM SOC, V121, P3214, DOI 10.1021/ja983616l; Henry CR, 1998, SURF SCI REP, V31, P235; Hoffmann J, 2001, J CATAL, V204, P378, DOI 10.1006/jcat.2001.3374; Hoffmann J, 2002, CHEM PHYS LETT, V354, P403, DOI 10.1016/S0009-2614(02)00151-3; Imbihl R, 2003, NEW J PHYS, V5, DOI 10.1088/1367-2630/5/1/362; IMBIHL R, 1995, CHEM REV, V95, P697, DOI 10.1021/cr00035a012; JAEGER RM, 1993, J ELECTRON SPECTROSC, V64-5, P217, DOI 10.1016/0368-2048(93)80082-W; JAKUBITH S, 1990, PHYS REV LETT, V65, P3013, DOI 10.1103/PhysRevLett.65.3013; Johansson S, 2001, J CATAL, V201, P275, DOI 10.1006/jcat.2001.3261; Libuda J, 2000, REV SCI INSTRUM, V71, P4395, DOI 10.1063/1.1318919; Libuda J, 2002, J PHYS CHEM B, V106, P4901, DOI 10.1021/jp014055e; Liu DJ, 2002, J CHEM PHYS, V117, P7319, DOI 10.1063/1.1507105; Meusel I, 2001, J PHYS CHEM B, V105, P3567, DOI 10.1021/jp003601l; Meusel I, 2001, CATAL LETT, V71, P5, DOI 10.1023/A:1016635804185; Pavlenko N, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.016121; Sachs C, 2001, SCIENCE, V293, P1635, DOI 10.1126/science.1062883; SCHLOGL R, 1993, ANGEW CHEM INT EDIT, V32, P381, DOI 10.1002/anie.199303811; Suchorski Y, 1999, PHYS REV LETT, V82, P1907, DOI 10.1103/PhysRevLett.82.1907; Suchorski Y, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.165417; Topsoe H, 2003, J CATAL, V216, P155, DOI 10.1016/S0021-9517(02)00133-1; Walters L., 1982, CHEM PHYSICS SOLID S, P73; Wehner S, 2003, CHEM PHYS LETT, V370, P126, DOI 10.1016/S0009-2614(03)00059-9; Wintterlin J, 2000, ADV CATAL, V45, P131; Wong K, 1996, FARADAY DISCUSS, V105, P237, DOI 10.1039/fd9960500237; Worz AS, 2003, J AM CHEM SOC, V125, P7964, DOI 10.1021/ja0352247; Zambelli T, 1996, SCIENCE, V273, P1688, DOI 10.1126/science.273.5282.1688; Zhdanov VP, 1997, PHYS REV B, V55, P4105, DOI 10.1103/PhysRevB.55.4105; ZHDANOV VP, 1994, SURF SCI REP, V20, P111, DOI 10.1016/0167-5729(94)90009-4; Zhdanov VP, 2002, SURF SCI, V496, P251, DOI 10.1016/S0039-6028(01)01604-1	38	146	149	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1639	1644		10.1126/science.1097513	http://dx.doi.org/10.1126/science.1097513			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15131265				2022-12-28	WOS:000221934300041
J	Schroter, S; Barratt, H; Smith, J				Schroter, S; Barratt, H; Smith, J			Authors' perceptions of electronic publishing: two cross sectional surveys	BRITISH MEDICAL JOURNAL			English	Article								Objectives To evaluate how acceptable authors find the BMJs current practice of publishing short versions of research articles in the paper journal and a longer version on the web and to determine authors' attitudes towards publishing only abstracts in the paper journal and publishing unedited versions on bmj.com once papers have been accepted for publication. Design Two cross sectional surveys. Setting General medical journal. Participants Survey 1: corresponding authors of a consecutive sample of published BMJ research articles that had undergone the ELPS (electronic long, paper short) process. Survey 2: corresponding authors of consecutive research articles submitted to BMJ. Results Response rates were 90% (104/115) in survey 1 and 75% (213/283) in survey 2. ELPS is largely acceptable to BMJ authors, but there is some concern that electronic information is not permanent and uncertainty about how versions are referenced. While authors who had experienced ELPS reported some problems with editors shortening papers, most were able to rectify these. Overall, 70% thought that the BMJ should continue to use ELPS; 49% thought that publishing just the abstract in the printed journal with the full version only on bmJ.com was unacceptable; and 23% thought it unacceptable to post unedited versions on bmj.com once a paper had been accepted for publication. Conclusions It is acceptable to authors to publish short versions of research articles in the printed version of a general medical journal with longer versions on the website. Authors dislike the idea of publishing only abstracts in the printed journal but are in favour of posting accepted articles on the website ahead of the printed version.	BMJ Editorial Off, London WC1H 9JR, England		Schroter, S (corresponding author), BMJ Editorial Off, BMA House, London WC1H 9JR, England.	sschroter@bmj.com	Schroter, Sara/G-3427-2012	Schroter, Sara/0000-0002-8791-8564				[Anonymous], 1978, MAIL TELEPHONE SURVE; Delamothe T, 1999, BRIT MED J, V318, P888, DOI 10.1136/bmj.318.7188.888; Editor's Choice, 1999, BMJ; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; Mullner M, 2002, BRIT MED J, V325, P456, DOI 10.1136/bmj.325.7362.456; MULLNER M, 2003, EUR J SCI EDIT, V29, P6	6	5	5	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 5	2004	328	7452					1350	1353		10.1136/bmj.38117.624259.55	http://dx.doi.org/10.1136/bmj.38117.624259.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15151965	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000221952700018
J	Finnerty, JR; Pang, K; Burton, P; Paulson, D; Martindale, MQ				Finnerty, JR; Pang, K; Burton, P; Paulson, D; Martindale, MQ			Origins of bilateral symmetry: Hox and dpp expression in a sea anemone	SCIENCE			English	Article							PARAHOX GENES; EVOLUTION; CONSERVATION; HOMEOBOXES	Over 99% of modern animals are members of the evolutionary lineage Bilateria. The evolutionary success of Bilateria is credited partly to the origin of bilateral symmetry. Although animals of the phylum Cnidaria are not within the Bilateria, some representatives, such as the sea anemone Nematostella vectensis, exhibit bilateral symmetry. We show that Nematostella uses homologous genes to achieve bilateral symmetry: Multiple Hox genes are expressed in a staggered fashion along its primary body axis, and the transforming growth factor-beta gene decapentaplegic (dpp) is expressed in an asymmetric fashion about its secondary body axis. These data suggest that bilateral symmetry arose before the evolutionary split of Cnidaria and Bilateria.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Hawaii, Kewalo Marine Lab, Pacific Biomed Res Ctr, Honolulu, HI 96813 USA	Boston University; University of Hawaii System	Finnerty, JR (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	jrf3@bu.edu	Finnerty, John R/B-6564-2011					Banerjee-Basu S, 2001, NUCLEIC ACIDS RES, V29, P3258, DOI 10.1093/nar/29.15.3258; Beklemishev VN., 1969, PRINCIPLES COMP ANAT; Brusca RC, 2003, INVERTEBRATES; Budd GE, 2000, BIOL REV, V75, P253, DOI 10.1017/S000632310000548X; Campbell N. A., 2004, ESSENTIAL BIOL; Carroll S. B., 2001, DNA DIVERSITY MOL GE; Collins AG, 2001, EVOL DEV, V3, P432, DOI 10.1046/j.1525-142X.2001.01048.x; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; Finnerty JR, 1998, CURR OPIN GENET DEV, V8, P681, DOI 10.1016/S0959-437X(98)80037-3; Finnerty JR, 1997, BIOL BULL-US, V193, P62, DOI 10.2307/1542736; Finnerty JR, 1999, EVOL DEV, V1, P16, DOI 10.1046/j.1525-142x.1999.99010.x; Finnerty JR, 2001, AM ZOOL, V41, P608, DOI 10.1668/0003-1569(2001)041[0608:CRISIT]2.0.CO;2; Gauchat D, 2000, P NATL ACAD SCI USA, V97, P4493, DOI 10.1073/pnas.97.9.4493; Glaessner M. F., 1966, Palaeontology, V9, P599; Hadzi J., 1963, EVOLUTION METAZOA; HAECKEL E, 1874, Q J MICROSC SCI, V14, P142; HANSON ED, 1963, LOWER METAZOA, P7; HATSCHEK B, 1891, LEHRBUCH ZOOLOGIE; Hayward DC, 2002, P NATL ACAD SCI USA, V99, P8106, DOI 10.1073/pnas.112021499; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HYMAN LH, 1940, INVERTEBRATES PROTOZ; JAGERSTEN GOSTA, 1955, ZOOL BIDRAG UPPSALA, V30, P321; Johnson GB., 2003, LIVING WORLD; Kourakis MJ, 2000, J EXP ZOOL, V288, P175, DOI 10.1002/1097-010X(20000815)288:2<175::AID-JEZ8>3.0.CO;2-N; Martinez DE, 1998, NATURE, V393, P748, DOI 10.1038/31616; Masuda-Nakagawa LM, 2000, DEV GENES EVOL, V210, P151, DOI 10.1007/s004270050022; Nielsen C, 2012, ANIMAL EVOLUTION: INTERRELATIONSHIPS OF THE LIVING PHYLA, 3RD EDITION, P1; SALVINIPLAWEN LV, 1978, Z ZOOL SYST EVOL, V16, P40; Siewing R., 1980, Zoologische Jahrbuecher Abteilung fuer Anatomie und Ontogenie der Tiere, V103, P439; STEPHENSON TA, 1926, BRIT SEA ANEMONES, V1; Werner B., 1973, Publications Seto Mar Biol Lab, V20, P35; Willmer P., 1990, INVERTEBRATE RELATIO; Yanze N, 2001, DEV BIOL, V236, P89, DOI 10.1006/dbio.2001.0299	33	283	292	2	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1335	1337		10.1126/science.1091946	http://dx.doi.org/10.1126/science.1091946			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15131263				2022-12-28	WOS:000221669600058
J	Watts, C				Watts, C			Class II MHC: Sweetening the peptide only diet?	CELL			English	Editorial Material							STIMULATE T-CELLS; STRUCTURAL BASIS	MHC molecules typically bind peptides to create ligands for the T cell antigen receptor. In this issue of Cell, Cobb et al. (2004) report an unexpected association of class II MHC molecules with processed zwitter-ionic pollysaccharides from pathogenic bacteria. The complexes appear to modulate the T cell dependent pathology of abscess formation.	Univ Dundee, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	University of Dundee	Watts, C (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland.			Watts, Colin/0000-0001-6183-2087				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; Brigl M, 2004, ANNU REV IMMUNOL, V22, P817, DOI 10.1146/annurev.immunol.22.012703.104608; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; Choi YH, 2002, BIOCHEMISTRY-US, V41, P15144, DOI 10.1021/bi020491v; Cobb BA, 2004, CELL, V117, P677, DOI 10.1016/j.cell.2004.05.001; Kalka-Moll WM, 2002, J IMMUNOL, V169, P6149, DOI 10.4049/jimmunol.169.11.6149; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Stingele F, 2004, J IMMUNOL, V172, P1483, DOI 10.4049/jimmunol.172.3.1483; Tzianabos AO, 2002, CURR OPIN MICROBIOL, V5, P92, DOI 10.1016/S1369-5274(02)00292-8; Wang Y, 2000, P NATL ACAD SCI USA, V97, P13478, DOI 10.1073/pnas.97.25.13478	11	1	1	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					558	559		10.1016/j.cell.2004.05.007	http://dx.doi.org/10.1016/j.cell.2004.05.007			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163404	Bronze			2022-12-28	WOS:000221857900003
J	Hur, N; Park, S; Sharma, PA; Ahn, JS; Guha, S; Cheong, SW				Hur, N; Park, S; Sharma, PA; Ahn, JS; Guha, S; Cheong, SW			Electric polarization reversal and memory in a multiferroic material induced by magnetic fields	NATURE			English	Article							PHASE-TRANSITION; CRYSTALS; TBMN2O5; BIFEO3	Ferroelectric and magnetic materials are a time-honoured subject of study and have led to some of the most important technological advances to date. Magnetism and ferroelectricity are involved with local spins and off-centre structural distortions, respectively. These two seemingly unrelated phenomena can coexist in certain unusual materials, termed multiferroics(1-11). Despite the possible coexistence of ferroelectricity and magnetism, a pronounced interplay between these properties has rarely been observed(6,12). This has prevented the realization of multiferroic devices offering such functionality(13). Here, we report a striking interplay between ferroelectricity and magnetism in the multiferroic TbMn2O5, demonstrated by a highly reproducible electric polarization reversal and permanent polarization imprint that are both actuated by an applied magnetic field. Our results point to new device applications such as magnetically recorded ferroelectric memory.	Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Hur, N (corresponding author), Rutgers State Univ, Dept Phys & Astron, POB 849, Piscataway, NJ 08854 USA.	namjung@physics.rutgers.edu	Sharma, Peter A/G-1917-2011; Hur, Namjung/G-3752-2013					ASCHER E, 1966, J APPL PHYS, V37, P1404, DOI 10.1063/1.1708493; Baturov L. N., 1978, Soviet Physics - Solid State, V20, P1300; BATUROV LN, 1978, FIZ TVERD TELA+, V20, P2254; BUISSON G, 1973, PHYS STATUS SOLIDI A, V17, P191, DOI 10.1002/pssa.2210170121; Fiebig M, 2002, NATURE, V419, P818, DOI 10.1038/nature01077; GARDNER PP, 1998, J PHYS C SOLID STATE, V21, P5653; Golovenchits E. I., 1992, Soviet Physics - Solid State, V34, P56; GOSHEN S, 1969, J APPL PHYS, V40, P1590, DOI 10.1063/1.1657785; Hill NA, 2000, J PHYS CHEM B, V104, P6694, DOI [10.1021/jp000114x, 10.1021/jpc00114x]; Inomata A, 1996, J PHYS-CONDENS MAT, V8, P2673, DOI 10.1088/0953-8984/8/15/016; Katsufuji T, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.104419; Kimura T, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.180401; Kimura T, 2003, NATURE, V426, P55, DOI 10.1038/nature02018; Maisonneuve V, 1997, PHYS REV B, V56, P10860, DOI 10.1103/PhysRevB.56.10860; Nakamura H, 1997, FERROELECTRICS, V204, P107, DOI 10.1080/00150199708222192; Ponomarev B. K., 1994, Ferroelectrics, V161, P43, DOI 10.1080/00150199408213350; Popov YF, 2001, LOW TEMP PHYS+, V27, P478, DOI 10.1063/1.1382990; Popov YF, 2000, PHYSICA B, V284, P1402, DOI 10.1016/S0921-4526(99)02565-X; Rivera J.-P., 1994, Ferroelectrics, V161, P165, DOI 10.1080/00150199408213365; SAITO K, 1995, J PHYS-CONDENS MAT, V7, P2855, DOI 10.1088/0953-8984/7/14/022; SAWADA A, 1992, FERROELECTRICS, V137, P297, DOI 10.1080/00150199208015960; SAWADA A, 1975, J PHYS SOC JPN, V38, P1408, DOI 10.1143/JPSJ.38.1408; Schmid H., 1994, Ferroelectrics, V162, P317, DOI 10.1080/00150199408245120; Schmid H., 1974, International Journal of Magnetism, V4, P337; SCOTT JF, 1979, REP PROG PHYS, V12, P1056; Smolenskii G. A., 1982, Soviet Physics - Uspekhi, V25, P475, DOI 10.1070/PU1982v025n07ABEH004570; SMOLENSKII GA, 1963, SOV PHYS JETP-USSR, V16, P622; Wang J, 2003, SCIENCE, V299, P1719, DOI 10.1126/science.1080615	28	1912	1954	16	783	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					392	395		10.1038/nature02572	http://dx.doi.org/10.1038/nature02572			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164057				2022-12-28	WOS:000221644600033
J	Parker, HG; Kim, LV; Sutter, NB; Carlson, S; Lorentzen, TD; Malek, TB; Johnson, GS; DeFrance, HB; Ostrander, EA; Kruglyak, L				Parker, HG; Kim, LV; Sutter, NB; Carlson, S; Lorentzen, TD; Malek, TB; Johnson, GS; DeFrance, HB; Ostrander, EA; Kruglyak, L			Genetic structure of the purebred domestic dog	SCIENCE			English	Article							MULTILOCUS GENOTYPE DATA; POPULATION-STRUCTURE; MICROSATELLITE MARKERS; HUMAN GENOME; BREEDS; DISTANCES; INFERENCE; SEQUENCE; ORIGIN; LOCI	We used molecular markers to study genetic relationships in a diverse collection of 85 domestic dog breeds. Differences among breeds accounted for similar to 30% of genetic variation. Microsatellite genotypes were used to correctly assign 99% of individual dogs to breeds. Phylogenetic analysis separated several breeds with ancient origins from the remaining breeds with modern European origins. We identified four genetic clusters, which predominantly contained breeds with similar geographic origin, morphology, or role in human activities. These results provide a genetic classification of dog breeds and will aid studies of the genetics of phenotypic breed differences.	Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Missouri, Coll Vet Med, Dept Vet Pathobiol, Columbia, MO 65211 USA; Howard Hughes Med Inst, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Missouri System; University of Missouri Columbia; Howard Hughes Medical Institute	Ostrander, EA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, POB 19024,1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA.	eostrand@fhcrc.org	Kim, Lev V./G-7691-2016; Parker, Heidi/C-6954-2008; Carlson, Scott/E-4606-2010; Fiumefreddo, Andrea/T-2977-2019	Carlson, Scott/0000-0003-1996-0012; Ostrander, Elaine/0000-0001-6075-9738; Parker, Heidi G./0000-0002-9707-6380	NATIONAL CANCER INSTITUTE [K05CA090754] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000035] Funding Source: NIH RePORTER; NCI NIH HHS [K05 CA90754] Funding Source: Medline; NHGRI NIH HHS [T32 HG00035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		CAVALLISFORZA LL, 1967, EVOLUTION, V21, P550, DOI 10.1111/j.1558-5646.1967.tb03411.x; CROWLEY J., 1998, COMPLETE DOG BOOK OF; EXCOFFIER L, 1992, GENETICS, V131, P479; Falush D, 2003, GENETICS, V164, P1567; Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857; Fogel B, 1995, ENCY DOG; GOLDSTEIN DB, 1995, GENETICS, V139, P463; Irion DN, 2003, J HERED, V94, P81, DOI 10.1093/jhered/esg004; Koskinen MT, 2003, ANIM GENET, V34, P297, DOI 10.1046/j.1365-2052.2003.01005.x; Laval G, 2000, GENET SEL EVOL, V32, P187, DOI 10.1051/gse:2000113; Leonard JA, 2002, SCIENCE, V298, P1613, DOI 10.1126/science.1076980; MacHugh DE, 1998, ANIM GENET, V29, P333, DOI 10.1046/j.1365-2052.1998.295330.x; Ostrander EA, 2000, GENOME RES, V10, P1271, DOI 10.1101/gr.155900; PAETKAU D, 1995, MOL ECOL, V4, P347, DOI 10.1111/j.1365-294X.1995.tb00227.x; PATTERSON DF, 1988, J AM VET MED ASSOC, V193, P1131; Piazza A., 1994, HIST GEOGRAPHY HUMAN; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Pritchard JK, 2000, GENETICS, V155, P945; Rogers CA, 1995, INT ENCY DOGS; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Rosenberg NA, 2001, GENETICS, V159, P699; Sablin MV, 2002, CURR ANTHROPOL, V43, P795, DOI 10.1086/344372; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Savolainen P, 2002, SCIENCE, V298, P1610, DOI 10.1126/science.1073906; TAJIMA F, 1984, MOL BIOL EVOL, V1, P269; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vila C, 1997, SCIENCE, V276, P1687, DOI 10.1126/science.276.5319.1687; Wilcox B, 1995, ATLAS DOG BREEDS WOR; YAMAZAKI T, 1995, LEGACY DOG ULTIMATE	29	520	545	2	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1160	1164		10.1126/science.1097406	http://dx.doi.org/10.1126/science.1097406			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822FP	15155949				2022-12-28	WOS:000221524500044
J	Gaynes, BN; West, SL; Ford, CA; Frame, P; Klein, J; Lohr, KN				Gaynes, BN; West, SL; Ford, CA; Frame, P; Klein, J; Lohr, KN			Screening for suicide risk in adults: A summary of the evidence for the US preventive services task force	ANNALS OF INTERNAL MEDICINE			English	Article							DELIBERATE SELF-HARM; RANDOMIZED CONTROLLED-TRIAL; BORDERLINE PERSONALITY-DISORDER; PRIMARY-CARE; POISONING PATIENTS; BEHAVIOR-THERAPY; FOLLOW-UP; PARTIAL HOSPITALIZATION; CONTROLLED INTERVENTION; DEPRESSION	Background: Suicide is the 11th leading cause of death and the seventh leading cause of years of potential life lost in the United States. Although suicide is of great public health significance, its clinical management is complicated. Purpose: The authors systematically reviewed the literature to determine whether screening for suicide risk in primary care settings decreases morbidity, mortality, or both. Data Sources: MEDLINE (1966 to 17 October 2002), PsycINFO, Cochrane databases, hand-searched bibliographies, and experts. Study Selection: For screening, only English-language studies performed in primary care settings were examined. For treatment, randomized, controlled trials and cohort studies were included if they were performed in any setting where suicide completions, suicide attempts, or suicidal ideation were reported. Data Extraction: A primary reviewer abstracted data on key variables of study sample, design, and outcomes; a second reviewer checked information accuracy against the original articles. Data Synthesis: No study directly addressed whether screening for suicide in primary care reduces morbidity and mortality. The remainder of the review focused on the questions of reliable screening tests for suicide risk and the effectiveness of interventions to decrease depression, suicidal ideation, and suicide attempts or completion. One screening study provided limited evidence for the accuracy of suicide screening in a primary care setting. Intervention studies provided fair and mixed evidence that treating those at risk for suicide reduces the number of suicide attempts or completions. The evidence suggests mild to moderate improvement for interventions addressing intermediate outcomes such as suicidal ideation, decreased depressive severity, decreased hopelessness, or improved level of function. Conclusion: Because of the complexity of studying the risk for suicide and the paucity of well-designed research studies, only limited evidence guides the primary care clinician's assessment and management of suicide risk.	Tri Cty Family Med, Cohocton, NY USA; Univ Rochester, Rochester, NY 14627 USA; Univ N Carolina, Chapel Hill, NC USA; RTI Int, Res Triangle Pk, NC USA	University of Rochester; University of North Carolina; University of North Carolina Chapel Hill; Research Triangle Institute				Gaynes, Bradley/0000-0002-8283-5030; Lohr, Kathleen/0000-0002-3825-0713	PHS HHS [290-97-0011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLARD R, 1992, SUICIDE LIFE-THREAT, V22, P303; Bateman A, 1999, AM J PSYCHIAT, V156, P1563, DOI 10.1176/ajp.156.10.1563; Bateman A, 2001, AM J PSYCHIAT, V158, P36, DOI 10.1176/appi.ajp.158.1.36; Battaglia J, 1999, INT CLIN PSYCHOPHARM, V14, P361, DOI 10.1097/00004850-199911000-00007; Beck A.T., 1974, DEV SUICIDAL INTENT; BECK AT, 1979, J CONSULT CLIN PSYCH, V47, P343, DOI 10.1037/0022-006X.47.2.343; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bennewith O, 2002, BRIT MED J, V324, P1254, DOI 10.1136/bmj.324.7348.1254; BLUMENTHAL SJ, 1988, MED CLIN N AM, V72, P937, DOI 10.1016/S0025-7125(16)30754-4; Broadhead W E, 1995, Arch Fam Med, V4, P211, DOI 10.1001/archfami.4.3.211; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Bruce M L, 1999, Dialogues Clin Neurosci, V1, P100; CHOWDHURY N, 1973, SOC PSYCHIATR, V8, P67, DOI 10.1007/BF00589238; Coryell W, 2001, ACTA PSYCHIAT SCAND, V104, P193, DOI 10.1034/j.1600-0447.2001.00338.x; CROCKETT AWB, 1987, BRIT MED J, V295, P476, DOI 10.1136/bmj.295.6596.476; Druss B, 2000, ARCH INTERN MED, V160, P1522, DOI 10.1001/archinte.160.10.1522; Evans K, 1999, PSYCHOL MED, V29, P19, DOI 10.1017/S003329179800765X; Evans MO, 1999, BRIT J PSYCHIAT, V175, P23, DOI 10.1192/bjp.175.1.23; GAYNES BN, 2004, SCREENING SUICIDE RI; GIBBONS JS, 1978, BRIT J PSYCHIAT, V133, P111, DOI 10.1192/bjp.133.2.111; Gilbody S, 1997, J ROY COLL PHYS LOND, V31, P171; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; Guthrie E, 2001, BRIT MED J, V323, P135, DOI 10.1136/bmj.323.7305.135; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; HAWTON K, 1981, PSYCHOL MED, V11, P169, DOI 10.1017/S0033291700053381; HAWTON K, 1987, PSYCHOL MED, V17, P751, DOI 10.1017/S0033291700025988; Hawton K, 2000, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001764, 10.1002/14651858.CD001764]; HAWTON K, 2000, DELIBERATE SELF HARM; HIRSCH SR, 1982, J AFFECT DISORDERS, V4, P299, DOI 10.1016/0165-0327(82)90027-1; Hirschfeld RMA, 1997, NEW ENGL J MED, V337, P910, DOI 10.1056/NEJM199709253371307; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Koons CR, 2001, BEHAV THER, V32, P371, DOI 10.1016/S0005-7894(01)80009-5; LIBERMAN RP, 1981, ARCH GEN PSYCHIAT, V38, P1126; LINEHAN MM, 1991, ARCH GEN PSYCHIAT, V48, P1060; Luoma JB, 2002, AM J PSYCHIAT, V159, P909, DOI 10.1176/appi.ajp.159.6.909; Mann JJ, 2002, ANN INTERN MED, V136, P302, DOI 10.7326/0003-4819-136-4-200202190-00010; MCLEAVEY BC, 1994, SUICIDE LIFE-THREAT, V24, P382; MONTGOMERY DB, 1994, EUR ARCH PSY CLIN N, V244, P211, DOI 10.1007/BF02190400; MONTGOMERY S, 1978, BRIT J CLIN PHARMACO, V5, pS77; Montgomery S, 1979, P 10 INT C SUIC PREV, P227; MONTGOMERY SA, 1983, BRIT J CLIN PHARMACO, V15, pS183, DOI 10.1111/j.1365-2125.1983.tb05864.x; MORGAN HG, 1993, BRIT J PSYCHIAT, V163, P111, DOI 10.1192/bjp.163.1.111; Motto JA, 2001, PSYCHIATR SERV, V52, P828, DOI 10.1176/appi.ps.52.6.828; Murphy S L, 2000, Natl Vital Stat Rep, V48, P1; *NAT I MENT HLTH, SUIC FACTS; National Center for Injury Prevention and Control, WISQARS WEB BAS INJ; Office of the Surgeon General, 1999, SURG GEN CALL ACT PR; Olfson M, 1996, J GEN INTERN MED, V11, P447, DOI 10.1007/BF02599038; PATSIOKAS AT, 1985, PSYCHOTHERAPY, V22, P281, DOI 10.1037/h0085507; PIGNONE M, 2001, PUBLICATION; Pignone MP, 2002, ANN INTERN MED, V136, P765, DOI 10.7326/0003-4819-136-10-200205210-00013; Pirkis J, 1998, BRIT J PSYCHIAT, V173, P462, DOI 10.1192/bjp.173.6.462; Raj AJ, 2001, ACTA PSYCHIAT SCAND, V104, P340, DOI 10.1034/j.1600-0447.2001.00075.x; Rihmer Z, 1995, J AFFECT DISORDERS, V35, P147, DOI 10.1016/0165-0327(95)00055-0; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; Rudd MD, 1996, J CONSULT CLIN PSYCH, V64, P179, DOI 10.1037/0022-006X.64.1.179; SALKOVSKIS PM, 1990, BRIT J PSYCHIAT, V157, P871, DOI 10.1192/bjp.157.6.871; Sansone RA, 2000, GEN HOSP PSYCHIAT, V22, P174, DOI 10.1016/S0163-8343(00)00074-8; Schmidtke A, 1996, ACTA PSYCHIAT SCAND, V93, P327, DOI 10.1111/j.1600-0447.1996.tb10656.x; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Tondo L, 2001, ACTA PSYCHIAT SCAND, V104, P163, DOI 10.1034/j.1600-0447.2001.00464.x; Torhorst A, 1987, Crisis, V8, P53; TORHORST A, 1988, CURRENT ISSUES SUICI, P19; Townsend E, 2001, PSYCHOL MED, V31, P979, DOI 10.1017/S0033291701004238; *US DEP HHS PHS, 2001, NAT STRAT SUIC PREV; *US PREV SERV TASK, 1996, SCREENING SUICIDE RI, P547; VanderSande R, 1997, BRIT J PSYCHIAT, V171, P35, DOI 10.1192/bjp.171.1.35; VANHEERINGEN C, 1995, PSYCHOL MED, V25, P963, DOI 10.1017/S0033291700037454; Verkes RJ, 1998, AM J PSYCHIAT, V155, P543, DOI 10.1176/ajp.155.4.543; WATERHOUSE J, 1990, BRIT J PSYCHIAT, V156, P236, DOI 10.1192/bjp.156.2.236; WELU TC, 1977, SUICIDE LIFE-THREAT, V7, P17; Williams JW, 2002, GEN HOSP PSYCHIAT, V24, P225, DOI 10.1016/S0163-8343(02)00195-0; Zametkin AJ, 2001, JAMA-J AM MED ASSOC, V286, P3120, DOI 10.1001/jama.286.24.3120; ZIMMERMAN M, 1995, J GEN INTERN MED, V10, P573, DOI 10.1007/BF02640368	75	226	229	1	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					822	835		10.7326/0003-4819-140-10-200405180-00015	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00015			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	822EX	15148072				2022-12-28	WOS:000221520900010
J	Yancy, WS; Olsen, MK; Guyton, JR; Bakst, RP; Westman, EC				Yancy, WS; Olsen, MK; Guyton, JR; Bakst, RP; Westman, EC			A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOVASCULAR RISK-FACTORS; PLACEBO-CONTROLLED TRIAL; WEIGHT-LOSS; HIGH-PROTEIN; BODY-WEIGHT; LIPOPROTEINS; PREVALENCE; SERUM; METAANALYSIS; RESTRICTION	Background: Low-carbohydrate diets remain popular despite a paucity of scientific evidence on their effectiveness. Objective: To compare the effects of a low-carbohydrate, ketogenic diet program with those of a low-fat, low-cholesterol, reduced-calorie diet. Design: Randomized, controlled trial Setting: Outpatient research clinic. Participants: 120 overweight, hyperlipidemic volunteers from the community. Intervention: Low-carbohydrate diet (initially, <20 g of carbohydrate daily) plus nutritional supplementation, exercise recommendation, and group meetings, or low-fat diet (<30% energy from fat, <300 mg of cholesterol daily, and deficit of 500 to 1000 kcal/d) plus exercise recommendation and group meetings. Measurements: Body weight, body composition, fasting serum lipid levels, and tolerability. Results: A greater proportion of the low-carbohydrate diet group than the low-fat diet group completed the study (76% vs. 57%; P = 0.02). At 24 weeks, weight loss was greater in the low-carbohydrate diet group than in the low-fat diet group (mean change, -12.9% vs. -6.7%; P < 0.001). Patients in both groups lost substantially more fat mass (change, -9.4 kg with the low-carbohydrate diet vs. -4.8 kg with the low-fat diet) than fat-free mass (change, -3.3 kg vs. -2.4 kg, respectively). Compared with recipients of the low-fat diet, recipients of the low-carbohydrate diet had greater decreases in serum triglyceride levels (change, -0.84 mmol/L vs. -0.31 mmol/L [-74.2 mg/dL vs. -27.9 mg/ dL]; P = 0.004) and greater increases in high-density lipoprotein cholesterol levels (0.14 mmol/L vs. -0.04 mmol/L [5.5 mg/dL vs. -1.6 mg/dL]; P < 0.001). Changes in low-density lipoprotein cholesterol level did not differ statistically (0.04 mmol/L [1.6 mg/dL] with the low-carbohydrate diet and -0.19 mmol/L [-7.4 mg/dL] with the low-fat diet; P = 0.2). Minor adverse effects were more frequent in the low-carbohydrate diet group. Limitations: We could not definitively distinguish effects of the low-carbohydrate diet and those of the nutritional supplements provided only to that group. In addition, participants were healthy and were followed for only 24 weeks. These factors limit the generalizability of the study results. Conclusions: Compared with a low-fat diet, a low-carbohydrate diet program had better participant retention and greater weight loss. During active weight loss, serum triglyceride levels decreased more and high-density lipoprotein cholesterol level increased more with the low-carbohydrate diet than with the low-fat diet.	Duke Univ, Med Ctr, Durham, NC 27705 USA; Ctr Hlth Serv Res Primary Care, Dept Vet Affairs Med Ctr, Durham, NC USA	Duke University	Westman, EC (corresponding author), Duke Univ, Med Ctr, Box 50,Suite 200-B Wing,2200 W Main St, Durham, NC 27705 USA.	ewestman@duke.edu	Biguzzi, Felipe A/E-4724-2015	Guyton, John/0000-0003-0224-7923				ARASE K, 1988, AM J PHYSIOL, V255, pR974, DOI 10.1152/ajpregu.1988.255.6.R974; ATKINS RC, 1998, DR ATKINS NEW DIET R; ATKINSON RL, 1985, J AM COLL NUTR, V4, P411, DOI 10.1080/07315724.1985.10720084; Bray GA, 1996, OBES RES, V4, P263, DOI 10.1002/j.1550-8528.1996.tb00544.x; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; CHAIT A, 1992, ADV INTERNAL MED, V37, P249; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; Davidson MH, 1999, JAMA-J AM MED ASSOC, V281, P235, DOI 10.1001/jama.281.3.235; DIGGLE P, 1994, APPL STAT-J ROY ST C, V43, P49; DUYFF RL, 1998, AM DIETETIC ASS COMP; Farmer A., 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.cd003205, DOI 10.1002/14651858.CD003205]; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FLETCHER SW, 1993, ANN INTERN MED, V119, P764, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00026; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; FREE HM, 1958, CLIN CHEM, V4, P323; Golay A, 1996, AM J CLIN NUTR, V63, P174, DOI 10.1093/ajcn/63.2.174; Harper CR, 2001, ARCH INTERN MED, V161, P2185, DOI 10.1001/archinte.161.18.2185; Jeor STS, 2001, CIRCULATION, V104, P1869, DOI 10.1161/hc4001.096152; Johnston CS, 2002, J AM COLL NUTR, V21, P55, DOI 10.1080/07315724.2002.10719194; Langfort J, 1996, J PHYSIOL PHARMACOL, V47, P361; LAROSA JC, 1980, J AM DIET ASSOC, V77, P264; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; *NIH NAT HEART LUN, 2000, NIH PUBL; PHINNEY SD, 1983, METABOLISM, V32, P757, DOI 10.1016/0026-0495(83)90105-1; RABAST U, 1978, NUTR METAB, V22, P269; Reddy ST, 2002, AM J KIDNEY DIS, V40, P265, DOI 10.1053/ajkd.2002.34504; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; Sondike SB, 2003, J PEDIATR-US, V142, P253, DOI 10.1067/mpd.2003.4; Stubbs J, 2000, CRIT REV FOOD SCI, V40, P481, DOI 10.1080/10408690091189248; *US DEP HHS PHS NI, 1994, NIH PUBL; Westman EC, 2002, AM J MED, V113, P30, DOI 10.1016/S0002-9343(02)01129-4; Westman EC, 1999, J CLIN OUTCOMES MANA, V6, P36; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586	37	583	603	7	251	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					769	777		10.7326/0003-4819-140-10-200405180-00006	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148063				2022-12-28	WOS:000221520900001
J	Ralston, JD; Revere, D; Robins, LS; Goldberg, HI				Ralston, JD; Revere, D; Robins, LS; Goldberg, HI			Patients' experience with a diabetes support programme based on an interactive electronic medical record: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED-TRIAL; CHRONIC ILLNESS; CARE; OUTCOMES; MANAGEMENT	Objective To describe the experiences of patients with type 2 diabetes in a web based disease management programme based on an interactive electronic medical record. Design Qualitative analysis of semistructured interviews with patients enrolled in a diabetes care module that included access to their electronic medical record, secure email, ability to upload blood glucose readings, an education site with endorsed content, and an interactive online diary for entering exercise, diet, and medication. Setting Patients' homes in Washington state, United States. Participants Nine participants aged 45-65 completed interviews before and after they used the programme. Results Six themes emerged: feeling that non-acute concerns are uniquely valued; enhanced sense of security about health and health care; frustration with unmet expectations; feeling more able to manage; valuing feedback; and difficulty fitting the programme into activities of daily life. Three themes-valuing non-acute concerns, feeling secure, and unmet expectations-have particular relevance to the design and use of web based tools for care of patients with diabetes and chronic medical conditions. Conclusion Participants' experiences support further study of open access to the electronic medical record and online communication between patients and their care providers. The development of web based disease management programmes should take into account the specific needs and expectations of patients, and patients and providers should have candid discussions about what web based care can and cannot provide.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Group Health Cooperative; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Ralston, JD (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	ralston.j@ghc.org		Revere, Debra/0000-0002-3863-7774	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE010002] Funding Source: NIH RePORTER; BHP HRSA HHS [5-T-32 PE-10002-10] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); BHP HRSA HHS		Aubert RE, 1998, ANN INTERN MED, V129, P605, DOI 10.7326/0003-4819-129-8-199810150-00004; Bell RA, 2002, J GEN INTERN MED, V17, P817, DOI 10.1046/j.1525-1497.2002.10319.x; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Brim J.A., 1974, RES DESIGN ANTHR PAR; Bronson D L, 1978, QRB Qual Rev Bull, V4, P2; BRONSON DL, 1986, J GEN INTERN MED, V1, P34, DOI 10.1007/BF02596322; BRONSON DL, 1986, MED CARE, V24, P332, DOI 10.1097/00005650-198604000-00004; Clever SL, 2002, J GEN INTERN MED, V17, P893, DOI 10.1046/j.1525-1497.2002.20921.x; Denzin Norman, 1998, STRATEGIES QUALITATI; Giorgi A, 1985, PHENOMENOLOGY PSYCHO; Glasgow RE, 2003, PREV MED, V36, P410, DOI 10.1016/S0091-7435(02)00056-7; Goldberg Harold I, 2003, Jt Comm J Qual Saf, V29, P443; Goldberg HI, 1998, LANCET, V351, P1811, DOI 10.1016/S0140-6736(05)78772-9; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; Institute of Medicine, 2001, CROSSING QUALITY CHA; Kawachi I., 2000, SOCIAL EPIDEMIOLOGY; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; Maly RC, 1999, J FAM PRACTICE, V48, P356; Morse J. M., 1995, QUALITATIVE RES METH; Rachmani R, 2002, DIABETIC MED, V19, P385, DOI 10.1046/j.1464-5491.2002.00701.x; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64	22	107	107	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2004	328	7449					1159	1162		10.1136/bmj.328.7449.1159	http://dx.doi.org/10.1136/bmj.328.7449.1159			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142919	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000221497500019
J	Thomas, H; Bozec, Y; Elkalay, K; de Baar, HJW				Thomas, H; Bozec, Y; Elkalay, K; de Baar, HJW			Enhanced open ocean storage of CO2 from shelf sea pumping	SCIENCE			English	Article							GAS-EXCHANGE; CARBON; SINKS; PCO(2)	Seasonal field observations show that the North Sea, a Northern European shelf sea, is highly efficient in pumping carbon dioxide from the atmosphere to the North Atlantic Ocean. The bottom topography-controlled strati. cation separates production and respiration processes in the North Sea, causing a carbon dioxide increase in the subsurface layer that is ultimately exported to the North Atlantic Ocean. Globally extrapolated, the net uptake of carbon dioxide by coastal and marginal seas is about 20% of the world ocean's uptake of anthropogenic carbon dioxide, thus enhancing substantially the open ocean carbon dioxide storage.	Netherlands Inst Sea Res, Dept Marine Chem & Geol, NL-1790 AB Den Burg, Netherlands	Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ)	Thomas, H (corresponding author), Netherlands Inst Sea Res, Dept Marine Chem & Geol, POB 59, NL-1790 AB Den Burg, Netherlands.	hthomas@nioz.nl	Elkalay, khalid/ABT-7140-2022					Borges AV, 1999, J MARINE SYST, V19, P251, DOI 10.1016/S0924-7963(98)00093-1; Borges AV, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2000JC000571; Chen CTA, 2003, GLO CH IGBP, P53; Chen CTA, 1999, J GEOPHYS RES-OCEANS, V104, P20675, DOI 10.1029/1999JC900055; de Haas H, 2002, CONT SHELF RES, V22, P691, DOI 10.1016/S0278-4343(01)00093-0; Gattuso JP, 1998, ANNU REV ECOL SYST, V29, P405, DOI 10.1146/annurev.ecolsys.29.1.405; KEMPE S, 1991, TELLUS B, V43, P224, DOI 10.1034/j.1600-0889.1991.00015.x; Kortzinger A, 1996, MAR CHEM, V52, P133, DOI 10.1016/0304-4203(95)00083-6; Liss P. S., 1986, ROLE AIR SEA EXCHANG, P113, DOI DOI 10.1007/978-94-009-4738-2_5; Liu K.-K., 2000, EOS T AM GEOPHYS UN, V81, P641, DOI [DOI 10.1029/E0081I052P00641-01, 10.1029/EO081i052p00641-01, DOI 10.1029/EO081I052P00641-01]; LIU KK, 2000, CHANGING OCEAN CARBO, P187; Nightingale PD, 2000, GEOPHYS RES LETT, V27, P2117, DOI 10.1029/2000GL011541; Nightingale PD, 2000, GLOBAL BIOGEOCHEM CY, V14, P373, DOI 10.1029/1999GB900091; Osterroht C, 2000, J MARINE SYST, V25, P33, DOI 10.1016/S0924-7963(00)00007-5; OTTO L, 1990, NETH J SEA RES, V26, P161, DOI 10.1016/0077-7579(90)90091-T; Sarmiento JL, 2002, PHYS TODAY, V55, P30, DOI 10.1063/1.1510279; Takahashi T, 2002, DEEP-SEA RES PT II, V49, P1601, DOI 10.1016/S0967-0645(02)00003-6; Thomas H, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017937; Thomas H, 1999, J MARINE SYST, V22, P53, DOI 10.1016/S0924-7963(99)00030-5; Thomas H, 1999, LIMNOL OCEANOGR, V44, P1999, DOI 10.4319/lo.1999.44.8.1999; THOMAS H, IN PRESS CARBON NUTR; THOMAS H, 2002, SHIPBOARD REPORT RV; Tsunogai S, 1999, TELLUS B, V51, P701, DOI 10.1034/j.1600-0889.1999.t01-2-00010.x; WANNINKHOF R, 1992, J GEOPHYS RES-OCEANS, V97, P7373, DOI 10.1029/92JC00188; Wanninkhof R, 1999, GEOPHYS RES LETT, V26, P1889, DOI 10.1029/1999GL900363	25	372	393	17	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					1005	1008		10.1126/science.1095491	http://dx.doi.org/10.1126/science.1095491			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143279	Green Submitted			2022-12-28	WOS:000221383300047
J	Amlashi, SFA; Riffaud, L				Amlashi, SFA; Riffaud, L			Papilledema and spinal cord tumor	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Rennes Univ Hosp, F-35033 Rennes, France	CHU Rennes; Universite de Rennes	Amlashi, SFA (corresponding author), Rennes Univ Hosp, F-35033 Rennes, France.		RIFFAUD, Laurent/ABC-6349-2020	RIFFAUD, Laurent/0000-0003-3570-8132					0	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					E18	E18		10.1056/NEJMicm030102	http://dx.doi.org/10.1056/NEJMicm030102			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141059				2022-12-28	WOS:000221354000010
J	Ballen, KK; Hasserjian, RP				Ballen, KK; Hasserjian, RP			A 31-year-old man with bilateral testicular enlargement - Precursor B-cell lymphoblastic lymphoma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							REMISSION INDUCTION; LEUKEMIA; TRANSPLANTATION; CONSOLIDATION; RELAPSE; REGIMEN; TESTIS; ADULTS; CANCER; TRIAL		Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Ballen, KK (corresponding author), Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.							Armstrong L, 2000, ITS NOT BIKE MY JOUR; Dalle JH, 2001, J CLIN ONCOL, V19, P2397, DOI 10.1200/JCO.2001.19.9.2397; FERRY JA, 1994, AM J SURG PATHOL, V18, P376, DOI 10.1097/00000478-199404000-00006; Hoelzer D, 2002, BLOOD, V99, P4379, DOI 10.1182/blood-2002-01-0110; Kantarjian HM, 2000, J CLIN ONCOL, V18, P547, DOI 10.1200/JCO.2000.18.3.547; Lal A, 1998, J CLIN PATHOL-MOL PA, V51, P277, DOI 10.1136/mp.51.5.277; Larson RA, 1998, BLOOD, V92, P1556; LARSON RA, 1995, BLOOD, V85, P2025, DOI 10.1182/blood.V85.8.2025.bloodjournal8582025; Levine JE, 2003, BLOOD, V101, P2476, DOI 10.1182/blood-2002-05-1483; Lin P, 2000, AM J SURG PATHOL, V24, P1480, DOI 10.1097/00000478-200011000-00003; Millot F, 2001, J CLIN ONCOL, V19, P1935, DOI 10.1200/JCO.2001.19.7.1935; Shahab N, 1999, SEMIN ONCOL, V26, P259; Stirewalt DL, 2003, BIOL BLOOD MARROW TR, V9, P206, DOI 10.1053/bbmt.2003.50025; THRASHER J, 1994, PROBLEMS UROL, V8, P167; TIEDEMANN J, 1992, BRIT MED J, V285, P1614; Vardiman J., 2001, WHO CLASSIFICATION T, V3; Zucca E, 2003, J CLIN ONCOL, V21, P20, DOI 10.1200/JCO.2003.11.141	17	6	6	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2081	2087		10.1056/NEJMcpc049003	http://dx.doi.org/10.1056/NEJMcpc049003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141047				2022-12-28	WOS:000221354000011
J	Cyranoski, D				Cyranoski, D			Will creativity thrive in an island paradise?	NATURE			English	Article																			0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	2004	429	6988					220	221		10.1038/429220a	http://dx.doi.org/10.1038/429220a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141221				2022-12-28	WOS:000221356300051
J	Walburger, A; Koul, A; Ferrari, G; Nguyen, L; Prescianotto-Baschong, C; Huygen, K; Klebl, B; Thompson, C; Bacher, G; Pieters, J				Walburger, A; Koul, A; Ferrari, G; Nguyen, L; Prescianotto-Baschong, C; Huygen, K; Klebl, B; Thompson, C; Bacher, G; Pieters, J			Protein kinase G from pathogenic mycobacteria promotes survival within macrophages	SCIENCE			English	Article							INTRACELLULAR SURVIVAL; PHAGOSOME MATURATION; TUBERCULOSIS PHAGOSOME; EARLY ENDOSOMES; MICE; INHIBITORS; BIOGENESIS; SEQUENCE; ARREST; FUSION	Pathogenic mycobacteria resist lysosomal delivery after uptake into macrophages, allowing them to survive intracellularly. We found that the eukaryotic-like serine/threonine protein kinase G from pathogenic mycobacteria was secreted within macrophage phagosomes, inhibiting phagosome-lysosome fusion and mediating intracellular survival of mycobacteria. Inactivation of protein kinase G by gene disruption or chemical inhibition resulted in lysosomal localization and mycobacterial cell death in infected macrophages. Besides identifying a target for the control of mycobacterial infections, these findings suggest that pathogenic mycobacteria have evolved eukaryotic-like signal transduction mechanisms capable of modulating host cell trafficking pathways.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Axxima Pharmaceut AG, D-81377 Munich, Germany; Inst Pasteur, B-1180 Brussels, Belgium	University of Basel	Pieters, J (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.	jean.pieters@unibas.ch		Pieters, Jean/0000-0002-5284-9757; Nguyen, Liem/0000-0002-1523-1472; Huygen, Kris/0000-0001-7808-0512				Anes E, 2003, NAT CELL BIOL, V5, P793, DOI 10.1038/ncb1036; ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Berthet FX, 1998, SCIENCE, V282, P759, DOI 10.1126/science.282.5389.759; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Clemens DL, 1996, J EXP MED, V184, P1349, DOI 10.1084/jem.184.4.1349; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DENIS M, 1990, J LEUKOCYTE BIOL, V47, P25, DOI 10.1002/jlb.47.1.25; Ferrari G, 1997, J CELL BIOL, V139, P1433, DOI 10.1083/jcb.139.6.1433; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Fratti RA, 2003, P NATL ACAD SCI USA, V100, P5437, DOI 10.1073/pnas.0737613100; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; Hasan Z, 1998, ELECTROPHORESIS, V19, P1179, DOI 10.1002/elps.1150190719; Koul A, 2001, MICROBIOL-SGM, V147, P2307, DOI 10.1099/00221287-147-8-2307; Kuehnel MP, 2001, CELL MICROBIOL, V3, P551, DOI 10.1046/j.1462-5822.2001.00139.x; Leonard CJ, 1998, GENOME RES, V8, P1038, DOI 10.1101/gr.8.10.1038; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ogawara H, 1999, MICROBIOL-UK, V145, P3343, DOI 10.1099/00221287-145-12-3343; Russell DG, 1997, PHILOS T ROY SOC B, V352, P1303, DOI 10.1098/rstb.1997.0114; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Sambandamurthy VK, 2002, NAT MED, V8, P1171, DOI 10.1038/nm765; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shi L, 1998, FEMS MICROBIOL REV, V22, P229, DOI 10.1016/S0168-6445(98)00015-1; Stanley SA, 2003, P NATL ACAD SCI USA, V100, P13001, DOI 10.1073/pnas.2235593100; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; Tailleux L, 2003, J IMMUNOL, V170, P1939, DOI 10.4049/jimmunol.170.4.1939; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326	34	429	459	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1800	1804		10.1126/science.1099384	http://dx.doi.org/10.1126/science.1099384			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15155913				2022-12-28	WOS:000222089500045
J	Schmutz, J; Wheeler, J; Grimwood, J; Dickson, M; Yang, DJ; Caoile, C; Bajorek, E; Black, S; Chan, YM; Denys, M; Escobar, J; Flowers, D; Fotopulos, D; Garcia, C; Gomez, M; Gonzales, E; Haydu, L; Lopez, F; Ramirez, L; Retterer, J; Rodriguez, A; Rogers, S; Salazar, A; Tsai, M; Myers, RM				Schmutz, J; Wheeler, J; Grimwood, J; Dickson, M; Yang, DJ; Caoile, C; Bajorek, E; Black, S; Chan, YM; Denys, M; Escobar, J; Flowers, D; Fotopulos, D; Garcia, C; Gomez, M; Gonzales, E; Haydu, L; Lopez, F; Ramirez, L; Retterer, J; Rodriguez, A; Rogers, S; Salazar, A; Tsai, M; Myers, RM			Quality assessment of the human genome sequency	NATURE			English	Article							DNA-SEQUENCE; CHROMOSOME	As the final sequencing of the human genome has now been completed, we present the results of the largest examination of the quality of the finished DNA sequence. The competed study covers the major contributing sequencing centres and is based on a rigorous combination of laboratory experiments and computational analysis.	Stanford Univ, Sch Med, Dept Genet, Stanford Human Genome Ctr, Palo Alto, CA 94304 USA	Stanford University	Schmutz, J (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford Human Genome Ctr, 975 Calif Ave, Palo Alto, CA 94304 USA.	jeremy@shgc.stanford.edu; myers@shgc.stanford.edu	Grimwood, Jane/ABD-5737-2021; Schmutz, Jeremy/N-3173-2013	Schmutz, Jeremy/0000-0001-8062-9172				Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a; Dunham A, 2004, NATURE, V428, P522, DOI 10.1038/nature02379; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Felsenfeld A, 1999, GENOME RES, V9, P1; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Grimwood J, 2004, NATURE, V428, P529, DOI 10.1038/nature02399; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348; Hillier LW, 2003, NATURE, V424, P157, DOI 10.1038/nature01782; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722	14	117	122	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					365	368		10.1038/nature02390	http://dx.doi.org/10.1038/nature02390			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164052	Bronze			2022-12-28	WOS:000221644600028
J	Syrjala, KL; Langer, SL; Abrams, JR; Storer, B; Sanders, JE; Flowers, MED; Martin, PJ				Syrjala, KL; Langer, SL; Abrams, JR; Storer, B; Sanders, JE; Flowers, MED; Martin, PJ			Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; BONE-MARROW-TRANSPLANTATION; FOLLOW-UP; ADULT RECIPIENTS; HEALTH; REHABILITATION; COMPLICATIONS; SURVIVORS; DISTRESS; DEATHS	Context Hematopoietic cell transplantation (HCT) is an effective and widely used treatment for hematologic malignancies. The rate and predictors of physical and emotional recovery after HCT have not been adequately defined in prospective long-term studies. Objective To examine the course of recovery and return to work after HCT. Design, Setting, and Patients Prospective, longitudinal cohort study at a US academic center specializing in HCT. Function was assessed from pretransplantation to 5-year follow-up for 319 adults who had myeloablative HCT for treatment of leukemia or lymphoma and spoke English. Of the 99 long-term survivors who had no recurrent malignancy, 94 completed 5-year follow-up. Main Outcome Measures Physical limitations, return to work, depression, and distress related to treatment or disease were evaluated before transplantation, at 90 days, and at 1, 3, and 5 years after HCT. Results Physical recovery occurred earlier than psychological or work recovery. Only 21 patients (19%) recovered on all outcomes at 1 year. The proportion without major limitations increased to 63% (n = 57) by 5 years. Among survivors without recurrent malignancy, 84% (n = 74) returned to full-time work by 5 years. Patients with slower physical recovery had higher medical risk and were more depressed before HCT (Pless than or equal to.001). Patients with chronic graft-vs-host disease (P = .01), with less social support before HCT (P = .001), and women (P <.001) were more depressed after transplantation. Transplant-related distress was slower to recover for allogeneic transplant recipients and those with less social support before HCT (P <=.01). Patients who had more experience with cancer treatment before beginning HCT had more rapid recovery from depression (P = .04) and treatment-related distress (P = .009). Conclusions Full recovery after HCT is a 3- to 5-year process. Recovery might be accelerated by more effective interventions to increase work-related capabilities, improve social support, and manage depression.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Syrjala, KL (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D5-220, Seattle, WA 98109 USA.	ksyrjala@fhcrc.org		Langer, Shelby L/0000-0002-6034-1830	NCI NIH HHS [CA 36444, CA 38522, CA 63030, CA78990, CA 18029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA038522, P01CA018029, R01CA078990, R01CA063030] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRYKOWSKI MA, 1995, BONE MARROW TRANSPL, V15, P837; [Anonymous], 1999, Oncology (Williston Park), V13, P113; APPELBAUM FR, 1985, CANCER-AM CANCER SOC, V55, P2202, DOI 10.1002/1097-0142(19850501)55:9+<2202::AID-CNCR2820551424>3.0.CO;2-S; BAKER F, 1994, BONE MARROW TRANSPL, V13, P589; Beck AT, 1987, COGNITIVE THERAPY DE; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Broers S, 2000, J PSYCHOSOM RES, V48, P11, DOI 10.1016/S0022-3999(99)00059-8; Bush NE, 2000, BIOL BLOOD MARROW TR, V6, P576, DOI 10.1016/S1083-8791(00)70067-X; BUSH NE, 1995, SOC SCI MED, V40, P479, DOI 10.1016/0277-9536(94)00153-K; Chiodi S, 2000, BRIT J HAEMATOL, V110, P614, DOI 10.1046/j.1365-2141.2000.02053.x; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; DEEG HJ, 1990, HEMATOL ONCOL CLIN N, V4, P641; Detry JMR, 2001, J CARDIOVASC RISK, V8, P355, DOI 10.1097/00043798-200112000-00004; Diggle P. J., 2003, ANAL LONGITUDINAL DA; Duell T, 1997, ANN INTERN MED, V126, P184, DOI 10.7326/0003-4819-126-3-199702010-00002; DUNKELSCHETTER C, 1984, J SOC ISSUES, V40, P77, DOI 10.1111/j.1540-4560.1984.tb01108.x; Fife BL, 2000, J CLIN ONCOL, V18, P1539, DOI 10.1200/JCO.2000.18.7.1539; Haberman M, 1993, Oncol Nurs Forum, V20, P1545; Heinonen H, 2001, ANN HEMATOL, V80, P137, DOI 10.1007/s002770000249; Hensel M, 2002, ANN ONCOL, V13, P209, DOI 10.1093/annonc/mdf031; Hjermstad MJ, 1999, J CLIN ONCOL, V17, P706, DOI 10.1200/JCO.1999.17.2.706; HOROWITZ MM, 1999, HEMATOPOIETIC CELL T, P12; La Rosa AM, 2001, CLIN INFECT DIS, V32, P871, DOI 10.1086/319352; Lee SJ, 2001, J CLIN ONCOL, V19, P242, DOI 10.1200/JCO.2001.19.1.242; Loberiza FR, 2002, J CLIN ONCOL, V20, P2118, DOI 10.1200/JCO.2002.08.757; McQuellon RP, 1998, BONE MARROW TRANSPL, V21, P477, DOI 10.1038/sj.bmt.1701115; Prieto JM, 1996, BONE MARROW TRANSPL, V17, P1133; Schulz-Kindermann F, 2002, BONE MARROW TRANSPL, V29, P341, DOI 10.1038/sj.bmt.1703385; Socie G, 1999, NEW ENGL J MED, V341, P14, DOI 10.1056/NEJM199907013410103; Socie G, 2001, BLOOD, V98, P3569, DOI 10.1182/blood.V98.13.3569; Socie G, 2001, BRIT J HAEMATOL, V113, P194, DOI 10.1046/j.1365-2141.2001.02678.x; Stern JM, 2001, BIOL BLOOD MARROW TR, V7, P257, DOI 10.1053/bbmt.2001.v7.pm11400947; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; SULLIVAN KM, 1989, ORGAN TRANSPLANTATIO, P91; SYRJALA KL, 1993, BONE MARROW TRANSPL, V11, P319; SYRJALA KL, 1995, PAIN, V61, P69, DOI 10.1016/0304-3959(94)00153-6; VOSE JM, 1992, CANCER, V69, P784, DOI 10.1002/1097-0142(19920201)69:3<784::AID-CNCR2820690328>3.0.CO;2-M; Whooley MA, 2000, NEW ENGL J MED, V343, P1942, DOI 10.1056/NEJM200012283432607; WITHERSPOON RP, 2003, NEW ENGL J MED, V321, P784	39	237	243	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2004	291	19					2335	2343		10.1001/jama.291.19.2335	http://dx.doi.org/10.1001/jama.291.19.2335			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821JD	15150205	Bronze			2022-12-28	WOS:000221455400021
J	Singhal, A; Cole, TJ; Fewtrell, M; Lucas, A				Singhal, A; Cole, TJ; Fewtrell, M; Lucas, A			Breastmilk feeding and lipoprotein profile in adolescents born preterm: follow-up of a prospective randomised study	LANCET			English	Article							SERUM-CHOLESTEROL CONCENTRATION; CARDIOVASCULAR RISK-FACTORS; BIRTH-WEIGHT INFANTS; APOLIPOPROTEIN-A-I; C-REACTIVE PROTEIN; EARLY NUTRITION; BLOOD-PRESSURE; EARLY DETERMINANTS; PLASMA; REDUCTION	Background Breastfeeding is associated with reduced cholesterol concentration later in life, but previous studies have not used random assignment of infant diet with prospective follow-up. We tested the hypothesis that breastmilk feeding benefits the lipoprotein profile in adolescents born preterm, in whom randomisation to different diets at birth is feasible. Methods 926 infants born preterm were randomly assigned in two parallel trials to receive (trial 1) donated banked breastmilk or preterm formula, or (trial 2) standard term formula or preterm formula, as sole diet or as supplements to mother's milk in both trials. We followed up 216 participants at age 13-16 years and measured ratio of low-density to high-density lipoprotein cholesterol (LDL to HDL), ratio of apolipoprotein B to apolipoprotein A-1 (apoB to apoA-1), and concentration of C-reactive protein (CRP; a measure of the inflammatory process associated with atherosclerosis). Results Adolescents who had been randomised to banked breastmilk had a lower CRP concentration (p=0.006) and LDL to HDL ratio (mean difference 0.34 [14% lower], 95% Cl -0.67 to -0.01; p=0.04) than those given preterm formula. A greater proportion of human milk intake in infancy was associated with lower ratios of LDL to HDL (p=0.03) and apoB to apoA-1 (p=0.004)-independent of gestation and potential confounding factors-and with lower CRP concentration (p=0.03). CRP concentration correlated with the two lipoprotein ratios (p<0.0001 and p=0.003, respectively). Interpretation Our data provide experimental evidence for the long-term benefits of breastmilk feeding on the risk of atherosclerosis.	Inst Child Hlth, MRC, Childhood Nutr Res Ctr, London WC1N 1EH, England; Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England	University of London; University College London; University of London; University College London	Singhal, A (corresponding author), Inst Child Hlth, MRC, Childhood Nutr Res Ctr, 30 Guilford St, London WC1N 1EH, England.	a.singhal@ich.ucl.ac.uk	Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200	MRC [G9827821] Funding Source: UKRI; Medical Research Council [G9827821(62595), G9827821] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BERGSTROM E, 1995, ATHEROSCLEROSIS, V117, P1, DOI 10.1016/0021-9150(95)05549-C; CASTELLI WP, 1983, CIRCULATION, V67, P730, DOI 10.1161/01.CIR.67.4.730; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; Finken MJJ, 2003, PEDIATR RES, V53, p32A; FOMON SJ, 1984, PEDIATR RES, V18, P1233, DOI 10.1203/00006450-198412000-00001; FREEDMAN DS, 1986, NEW ENGL J MED, V315, P721, DOI 10.1056/NEJM198609183151202; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GOULD AL, 1995, CIRCULATION, V91, P2274, DOI 10.1161/01.CIR.91.8.2274; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; HAMOSH M, 1988, J PEDIATR GASTR NUTR, V7, P10, DOI 10.1097/00005176-198801000-00004; HEINRICH J, 1995, THROMB HAEMOSTASIS, V73, P374; HODGSON PA, 1976, METABOLISM, V25, P739, DOI 10.1016/0026-0495(76)90145-1; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; KARK JD, 1984, J EPIDEMIOL COMMUN H, V38, P218, DOI 10.1136/jech.38.3.218; KOLACEK S, 1993, ACTA PAEDIATR, V82, P699, DOI 10.1111/j.1651-2227.1993.tb18044.x; Lagrand WK, 1999, CIRCULATION, V100, P96, DOI 10.1161/01.CIR.100.1.96; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEWIS DS, 1986, J CLIN INVEST, V78, P899, DOI 10.1172/JCI112678; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lucas A, 1998, BRIT MED J, V317, P1481, DOI 10.1136/bmj.317.7171.1481; LUCAS A, 1984, ARCH DIS CHILD, V59, P722, DOI 10.1136/adc.59.8.722; LUCAS A, 1994, BRIT MED J, V309, P304, DOI 10.1136/bmj.309.6950.304; MARMOT MG, 1980, J EPIDEMIOL COMMUN H, V34, P164, DOI 10.1136/jech.34.3.164; McGill HC, 1996, NUTR REV, V54, pS31; Mendall MA, 1996, BRIT MED J, V312, P1061; Mott GE, 1996, P SOC EXP BIOL MED, V212, P342, DOI 10.3181/00379727-212-44024; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; Owen CG, 2002, PEDIATRICS, V110, P597, DOI 10.1542/peds.110.3.597; Pettitt DJ, 1997, LANCET, V350, P166, DOI 10.1016/S0140-6736(96)12103-6; Plancoulaine S, 2000, EUR J CLIN NUTR, V54, P114, DOI 10.1038/sj.ejcn.1600904; Ravelli ACJ, 2000, ARCH DIS CHILD, V82, P248, DOI 10.1136/adc.82.3.248; Singhal A, 2003, LANCET, V361, P1089, DOI 10.1016/S0140-6736(03)12895-4; Singhal A, 2002, AM J CLIN NUTR, V75, P993, DOI 10.1093/ajcn/75.6.993; Singhal A, 2001, LANCET, V358, P1159, DOI 10.1016/S0140-6736(01)06276-6; Singhal A, 2001, LANCET, V357, P413, DOI 10.1016/S0140-6736(00)04004-6; Strbak V, 1993, Endocr Regul, V27, P215; Tang JL, 1998, BMJ-BRIT MED J, V316, P1213, DOI 10.1136/bmj.316.7139.1213; von Kries R, 1999, BRIT MED J, V319, P147, DOI 10.1136/bmj.319.7203.147; Walldius G, 2001, LANCET, V358, P2026, DOI 10.1016/S0140-6736(01)07098-2; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968	40	229	241	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	2004	363	9421					1571	1578		10.1016/S0140-6736(04)16198-9	http://dx.doi.org/10.1016/S0140-6736(04)16198-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145629				2022-12-28	WOS:000221408800006
J	McGraw, R				McGraw, R			Humidity, ice, and nitric acid	SCIENCE			English	Letter									Brookhaven Natl Lab, Div Atmospher Sci, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	McGraw, R (corresponding author), Brookhaven Natl Lab, Div Atmospher Sci, Upton, NY 11973 USA.	rlm@bnl.gov							0	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					961	961		10.1126/science.304.5673.961	http://dx.doi.org/10.1126/science.304.5673.961			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143262				2022-12-28	WOS:000221383300024
J	Otto, SP; Nuismer, SL				Otto, SP; Nuismer, SL			Species interactions and the evolution of sex	SCIENCE			English	Article							DISEASE RESISTANCE; MUTATION ACCUMULATION; GENETIC ARCHITECTURE; RED QUEEN; RECOMBINATION; MAINTENANCE; PARASITISM; COEVOLUTION; ARABIDOPSIS; POPULATION	The Red Queen hypothesis posits that sex has evolved in response to the shifting adaptive landscape generated by the evolution of interacting species. Previous studies supporting the Red Queen hypothesis have considered a narrow region of parameter space and only a subset of ecological and genetic interactions. Here, we develop a population genetics model that circumscribes a broad array of ecological and genetic interactions among species and derive the first general analytical conditions for the impact of species interactions on the evolution of sex. Our results show that species interactions typically select against sex. We conclude that, although the Red Queen favors sex under certain circumstances, it alone does not account for the ubiquity of sex.	Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Univ Idaho, Dept Biol Sci, Moscow, ID 83844 USA	University of British Columbia; Idaho; University of Idaho	Otto, SP (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.	otto@zoology.ubc.ca	Otto, Sarah Perin/K-5625-2012	Otto, Sarah Perin/0000-0003-3042-0818	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM065620] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM65620-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON NH, 1995, GENET RES, V65, P123, DOI 10.1017/S0016672300033140; BELL G, 1987, NATURE, V328, P66, DOI 10.1038/328066a0; BELL G, 1982, MASTERPIECE NATURE E; Dybdahl MF, 1998, EVOLUTION, V52, P1057, DOI [10.1111/j.1558-5646.1998.tb01833.x, 10.2307/2411236]; FLOR HH, 1956, ADV GENET, V8, P29, DOI 10.1016/S0065-2660(08)60498-8; HAMILTON WD, 1980, OIKOS, V35, P282, DOI 10.2307/3544435; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; HOWARD RS, 1994, NATURE, V367, P554, DOI 10.1038/367554a0; Howard RS, 1998, EVOLUTION, V52, P604, DOI [10.2307/2411094, 10.1111/j.1558-5646.1998.tb01658.x]; JAENIKE J, 1978, Evolutionary Theory, V3, P191; Kover PX, 2002, P NATL ACAD SCI USA, V99, P11270, DOI 10.1073/pnas.102288999; Kover PX, 2001, MOL ECOL, V10, P1, DOI 10.1046/j.1365-294X.2001.01124.x; LADLE RJ, 1993, P ROY SOC B-BIOL SCI, V253, P155, DOI 10.1098/rspb.1993.0096; LIVELY CM, 1987, NATURE, V328, P519, DOI 10.1038/328519a0; PARKER MA, 1994, EVOL ECOL, V8, P560, DOI 10.1007/BF01238258; Peters AD, 1999, AM NAT, V154, P393, DOI 10.1086/303247; Stahl EA, 1999, NATURE, V400, P667, DOI 10.1038/23260; West SA, 1999, J EVOLUTION BIOL, V12, P1003; Young ND, 2000, CURR OPIN PLANT BIOL, V3, P285, DOI 10.1016/S1369-5266(00)00081-9	19	169	171	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	2004	304	5673					1018	1020		10.1126/science.1094072	http://dx.doi.org/10.1126/science.1094072			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143283				2022-12-28	WOS:000221383300051
J	Cipollone, F; Toniato, E; Martinotti, S; Fazia, M; Iezzi, A; Cuccurullo, C; Pini, B; Ursi, S; Vitullo, G; Averna, M; Arca, M; Montali, A; Campagna, F; Ucchino, S; Spigonardo, F; Taddei, S; Virdis, A; Ciabattoni, G; Notarbartolo, A; Cuccurullo, F; Mezzetti, A				Cipollone, F; Toniato, E; Martinotti, S; Fazia, M; Iezzi, A; Cuccurullo, C; Pini, B; Ursi, S; Vitullo, G; Averna, M; Arca, M; Montali, A; Campagna, F; Ucchino, S; Spigonardo, F; Taddei, S; Virdis, A; Ciabattoni, G; Notarbartolo, A; Cuccurullo, F; Mezzetti, A		INES Study Grp	A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-DENSITY-LIPOPROTEIN; ATHEROSCLEROTIC PLAQUES; THROMBOXANE BIOSYNTHESIS; UNSTABLE ANGINA; INFLAMMATORY RESPONSE; PROSTANOID FORMATION; ASPIRIN; INHIBITION; RISK; PROSTACYCLIN	Context Myocardial infarction (MI) and ischemic stroke are thought to be caused by matrix digestion by metalloproteinases (MMPs) leading to rupture of atherosclerotic plaques. Production of macrophage MMP-2 and MMP-9 is induced by cyclooxygenase 2 (COX-2) and prostaglandin E-2 synthesis. Although COX-2 expression may be genetically determined, the relation between COX-2 polymorphisms and the risk of MI and stroke is unclear. Objective To investigate the relationship between the -765G-->C polymorphism of the COX-2 gene and clinically evident plaque rupture. Design, Setting, and Participants Prospective, matched case-control study conducted between March 2002 and October 2003 among 864 patients with first MI or atherothrombotic ischemic stroke and 864 hospitalized controls. The groups were matched for age, sex, body mass index, smoking, hypertension, hypercholesterolemia, and diabetes. The -765G-->C variant of the COX-2 gene was genotyped by restriction endonuclease digestion of polymerase chain reaction products. Main Outcome Measures Presence of the -765G-->C polymorphism of the COX-2 gene; COX-2, MMP-2, and MMP-9 expression and activity in plaques and in peripheral monocytes; urinary 6-keto PGF(1alpha) (marker of endothelial prostacyclin); and endothelium-dependent and -independent forearm blood flow vasodilation. Results The prevalence of -765GC was 2.41 times higher among controls than among cases (43.3% vs 17.9%; P<.001). The prevalence of -765CC homozygosity was 5.81 times higher (6.4% vs 1.1%; P=.04). Among participants carrying the -765GC and -765CC genotypes, the prevalence ratios for MI or stroke were 0.48 (95% CI, 0.36-0.68) and 0.33 (95% CI, 0.24-0.55), respectively. Expression of COX-2 and MMPs was significantly lower in atherosclerotic plaques from participants carrying the -765C allele, while the -765G&RARR;C polymorphism did not affect endothelial prostacyclin biosynthesis or endothelium-dependent vasodilation in vivo. In subgroup analyses (n=224 cases), serum high-sensitivity C-reactive protein was significantly lower in patients carrying the -765C allele (mean [SD], 0.78 [0.1] vs 2.56 [0.4] mg/L; P=.04). Conclusions We found that the -765G&RARR;C polymorphism of the COX-2 gene is associated with a decreased risk of MI and stroke. Detection of this genotype may be useful for predicting genetic risk of MI and stroke.	G Dannunzio Univ Chieti, Chieti, Italy; G Dannunzio Univ Fdn, Chieti, Italy; Univ Palermo, Palermo, Italy; Univ Roma La Sapienza, Rome, Italy; Univ Pisa, Pisa, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; University of Palermo; Sapienza University Rome; University of Pisa	Mezzetti, A (corresponding author), Nuovo Policlin SS Annunziata, Ctr Reg Prevenz Aterosclerosis, Via Vestini 66, I-66013 Chieti, Italy.	mezzetti@unich.it	Taddei, Stefano/AAB-2828-2019; Averna, Maurizio/U-9527-2017; Cipollone, Francesco/AAC-5698-2022; ARCA, Marcello/AAC-3883-2022; Virdis, Agostino/K-5315-2016	ARCA, Marcello/0000-0003-3786-0883; Cipollone, Francesco/0000-0002-5993-9341; Averna, Maurizio/0000-0003-3558-9209				ANDERSON RN, 1997, MONTHLY VITAL STAT R, V45, P2; Cipollone F, 2004, CIRCULATION, V109, P1482, DOI 10.1161/01.CIR.0000121735.52471.AC; Cipollone F, 2003, CIRCULATION, V107, P1479, DOI 10.1161/01.CIR.0000056530.03783.81; Cipollone F, 2003, CIRCULATION, V108, P1070, DOI 10.1161/01.CIR.0000086014.80477.0D; Cipollone F, 2003, CIRCULATION, V107, P55, DOI 10.1161/01.CIR.0000043260.82447.62; Cipollone F, 2002, ARTERIOSCL THROM VAS, V22, P1516, DOI 10.1161/01.ATV.0000035402.68085.A0; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P246, DOI 10.1161/01.ATV.0000104005.92603.f2; Cipollone F, 1997, CIRCULATION, V96, P1109, DOI 10.1161/01.CIR.96.4.1109; Cipollone F, 2000, CIRCULATION, V102, P1007, DOI 10.1161/01.CIR.102.9.1007; Cullen L, 1998, J PHARMACOL EXP THER, V287, P578; De Caterina R, 2002, CIRCULATION, V106, P2543, DOI 10.1161/01.CIR.0000038500.43292.D7; de Vries HE, 1999, ARTERIOSCL THROM VAS, V19, P638, DOI 10.1161/01.ATV.19.3.638; Eikelboom JW, 2002, CIRCULATION, V105, P1650, DOI 10.1161/01.CIR.0000013777.21160.07; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Goto K, 2000, HYPERTENSION, V36, P581, DOI 10.1161/01.HYP.36.4.581; HOSMER DW, 1989, APPL LOGISTIC REGRES; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; MAENBER ME, 1994, NEW ENGL J MED, V330, P1041; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Papafili A, 2002, ARTERIOSCL THROM VAS, V22, P1631, DOI 10.1161/01.ATV.0000030340.80207.C5; PATRONO C, 1982, J CLIN INVEST, V69, P231, DOI 10.1172/JCI110435; Patrono C, 2001, J CLIN INVEST, V108, P7, DOI 10.1172/JCI13418; Patrono C, 2001, CHEST, V119, p39S, DOI 10.1378/chest.119.1_suppl.39S; Pratico D, 2001, P NATL ACAD SCI USA, V98, P3358, DOI 10.1073/pnas.061607398; RICKER PM, 2000, NEW ENGL J MED, V342, P836; Taddei S, 1998, CIRCULATION, V97, P2222, DOI 10.1161/01.CIR.97.22.2222; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	33	210	229	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2004	291	18					2221	2228		10.1001/jama.291.18.2221	http://dx.doi.org/10.1001/jama.291.18.2221			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GR	15138244	Green Published, hybrid			2022-12-28	WOS:000221303500024
J	Lloyd-Jones, DM; Nam, BH; D'Agostino, RB; Levy, D; Murabito, JM; Wang, TJ; Wilson, PWF; O'Donnell, CJ				Lloyd-Jones, DM; Nam, BH; D'Agostino, RB; Levy, D; Murabito, JM; Wang, TJ; Wilson, PWF; O'Donnell, CJ			Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults - A prospective study of parents and offspring	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; NEWCASTLE FAMILY-HISTORY; MYOCARDIAL-INFARCTION; INDEPENDENT PREDICTOR; HIGH PREVALENCE; ARTERY DISEASE; ACCURACY; DEATH; MEN	Context Whether parental cardiovascular disease confers increased risk independent of other risk factors remains controversial. Prior studies relied on offspring report, without complete validation of parental events. Objective To determine whether parental cardiovascular disease predicts offspring events independent of traditional risk factors, using a prospective design for both parents and offspring, and uniform criteria to validate events. Design Inception cohort study. Setting Framingham Heart Study, a US population-based epidemiologic cohort begun in 1948 with the offspring cohort established in 1971. Participants All Framingham Offspring Study participants (aged greater than or equal to30 years) who were free of cardiovascular disease and both parents in the original Framingham cohort. Main Outcome Measures We examined the association of parental cardiovascular disease with 8-year risk of offspring cardiovascular disease, using pooled logistic regression. Results Among 2302 men and women (mean age, 44 years), 164 men and 79 women had cardiovascular events during follow-up. Compared with participants with no parental cardiovascular disease, those with at least 1 parent with premature cardiovascular disease (onset age <55 years in father, <65 years in mother) had greater risk for events, with age-adjusted odds ratios of 2.6 (95% confidence interval [CI], 1.7-4.1) for men and 2.3 (95% CI, 1.3-4.3) for women. Multivariable adjustment resulted in odds ratios of 2.0 (95% CI, 1.2-3.1) for men and 1.7 (95% CI, 0.9-3.1) for women. Nonpremature parental cardiovascular disease and parental coronary disease were weaker predictors. Addition of parental information aided in discriminating event rates, notably among offspring with intermediate levels of cholesterol and blood pressure, as well as intermediate predicted multivariable risk. Conclusions Using validated events, we found that parental cardiovascular disease independently predicted future offspring events in middle-aged adults. Addition of parental information may help clinicians and patients with primary prevention of cardiovascular disease, when treatment decisions may be difficult in patients at intermediate risk based on levels of single or multiple risk factors. These data also support further research into genetic determinants of cardiovascular risk.	NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA; Northwestern Univ, Dept Prevent Med, Chicago, IL USA; Boston Univ, Dept Epidemiol & Prevent Med, Stat & Consulting Unit, Boston, MA 02215 USA; Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA 02118 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA; NHLBI, Bethesda, MD 20892 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Northwestern University; Feinberg School of Medicine; Northwestern University; Boston University; Boston University; Harvard University; Harvard Medical School; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	O'Donnell, CJ (corresponding author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.	codonnell@nih.gov	Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Lloyd-Jones, Donald M/C-5899-2009; Wilson, Peter W.F./J-2455-2016	Levy, Daniel/0000-0003-1843-8724; Lloyd-Jones, Donald/0000-0003-0847-6110; Murabito, Joanne/0000-0002-0192-7516	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004253] Funding Source: NIH RePORTER	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott RD, 1987, FRAMINGHAM STUDY EPI; Allen JK, 1998, AM HEART J, V135, P428, DOI 10.1016/S0002-8703(98)70318-7; Assmann G, 2002, CIRCULATION, V105, P310, DOI 10.1161/hc0302.102575; BARRETTCONNOR E, 1984, CIRCULATION, V69, P1065, DOI 10.1161/01.CIR.69.6.1065; Becker DM, 1998, AM J CARDIOL, V82, P1046, DOI 10.1016/S0002-9149(98)00553-0; Bensen JT, 1999, GENET EPIDEMIOL, V16, P165, DOI 10.1002/(SICI)1098-2272(1999)16:2<165::AID-GEPI4>3.0.CO;2-H; Bensen JT, 1999, GENET EPIDEMIOL, V17, P141, DOI 10.1002/(SICI)1098-2272(1999)17:2<141::AID-GEPI4>3.0.CO;2-Q; Blumenthal RS, 2003, CIRCULATION, V107, P702, DOI 10.1161/01.CIR.0000048127.93169.88; Califf RM, 1996, J AM COLL CARDIOL, V27, P1007, DOI 10.1016/0735-1097(96)87733-3; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Clarkson P, 1997, CIRCULATION, V96, P3378; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; COLDITZ GA, 1991, AM J CARDIOL, V67, P933, DOI 10.1016/0002-9149(91)90163-F; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; De Backer G, 1999, J CARDIOVASC RISK, V6, P183; Friedlander Y, 1998, CIRCULATION, V97, P155, DOI 10.1161/01.CIR.97.2.155; FRIEDLANDER Y, 1985, BRIT HEART J, V53, P382; Greenland P, 2003, JAMA-J AM MED ASSOC, V290, P891, DOI 10.1001/jama.290.7.891; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Jousilahti P, 1996, J CLIN EPIDEMIOL, V49, P497, DOI 10.1016/0895-4356(95)00581-1; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KEE F, 1993, BRIT MED J, V307, P1528, DOI 10.1136/bmj.307.6918.1528; KHAW KT, 1986, AM J EPIDEMIOL, V123, P59, DOI 10.1093/oxfordjournals.aje.a114224; Khot UN, 2003, JAMA-J AM MED ASSOC, V290, P898, DOI 10.1001/jama.290.7.898; Koenig W, 2004, CIRCULATION, V109, P1349, DOI 10.1161/01.CIR.0000120707.98922.E3; Leander K, 2001, EPIDEMIOLOGY, V12, P215, DOI 10.1097/00001648-200103000-00014; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; Magnus P, 2001, ARCH INTERN MED, V161, P2657, DOI 10.1001/archinte.161.22.2657; Margaglione M, 2000, ARTERIOSCL THROM VAS, V20, P198, DOI 10.1161/01.ATV.20.1.198; Mills JD, 2002, ARTERIOSCL THROM VAS, V22, P704, DOI 10.1161/hq0402.105902; Murabito JM, 2004, ANN INTERN MED, V140, P434, DOI 10.7326/0003-4819-140-6-200403160-00010; MYERS RH, 1990, AM HEART J, V120, P963, DOI 10.1016/0002-8703(90)90216-K; Pankow JS, 1997, THROMB HAEMOSTASIS, V77, P87; PHILLIPS AN, 1988, EUR HEART J, V9, P243, DOI 10.1093/oxfordjournals.eurheartj.a062492; Pohjola-Sintonen S, 1998, EUR HEART J, V19, P235, DOI 10.1053/euhj.1997.0543; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; RONCAGLIONI MC, 1992, CIRCULATION, V85, P2065, DOI 10.1161/01.CIR.85.6.2065; Sdringola S, 2001, CIRCULATION, V103, P496, DOI 10.1161/01.CIR.103.4.496; Sesso HD, 2001, CIRCULATION, V104, P393, DOI 10.1161/hc2901.093115; SHEA S, 1984, J AM COLL CARDIOL, V4, P793, DOI 10.1016/S0735-1097(84)80408-8; SHOLTZ RI, 1975, AM J EPIDEMIOL, V102, P350, DOI 10.1093/oxfordjournals.aje.a112171; Silberberg JS, 1998, AM J EPIDEMIOL, V147, P1123; Silberberg JS, 1998, AM J EPIDEMIOL, V147, P1133; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; THELLE DS, 1979, AM J EPIDEMIOL, V110, P708, DOI 10.1093/oxfordjournals.aje.a112851; van der Meer IM, 2003, ARCH INTERN MED, V163, P1323, DOI 10.1001/archinte.163.11.1323; Wang TJ, 2003, CIRCULATION, V108, P572, DOI 10.1161/01.CIR.0000081764.35431.DE; Watt G, 2000, J EPIDEMIOL COMMUN H, V54, P859, DOI 10.1136/jech.54.11.859; Williams RR, 2001, AM J CARDIOL, V87, P129, DOI 10.1016/S0002-9149(00)01303-5; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	51	493	509	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2004	291	18					2204	2211		10.1001/jama.291.18.2204	http://dx.doi.org/10.1001/jama.291.18.2204			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GR	15138242	Bronze			2022-12-28	WOS:000221303500022
J	Bowley, DMG; Parmar, NK; Boffard, KD				Bowley, DMG; Parmar, NK; Boffard, KD			Burdens of disease in southern Africa	LANCET			English	Editorial Material									Univ Witwatersrand, Sch Med, Dept Surg, Johannesburg, South Africa; Univ London, St Georges Hosp, Sch Med, London, England	University of Witwatersrand; St Georges University London; University of London	Bowley, DMG (corresponding author), Univ Witwatersrand, Sch Med, Dept Surg, Johannesburg, South Africa.		Parmar, Nitish/AAF-1581-2020	Boffard, Kenneth/0000-0002-7159-5414					0	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	2004	363	9420					1508	1508		10.1016/S0140-6736(04)16149-7	http://dx.doi.org/10.1016/S0140-6736(04)16149-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135597				2022-12-28	WOS:000221302700009
J	Melton, L				Melton, L			Proteomics in multiplex	NATURE			English	Article									Novartis Fdn, London, England	Novartis	Melton, L (corresponding author), Novartis Fdn, London, England.								0	81	87	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	2004	429	6987					101	+		10.1038/429101a	http://dx.doi.org/10.1038/429101a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129287	Bronze			2022-12-28	WOS:000221222100052
J	Ozaki, K; Inoue, K; Sato, H; Iida, A; Ohnishi, Y; Sekine, A; Sato, H; Odashiro, K; Nobuyoshi, M; Hori, M; Nakamura, Y; Tanaka, T				Ozaki, K; Inoue, K; Sato, H; Iida, A; Ohnishi, Y; Sekine, A; Sato, H; Odashiro, K; Nobuyoshi, M; Hori, M; Nakamura, Y; Tanaka, T			Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro	NATURE			English	Article							GENE; ATHEROSCLEROSIS; SUSCEPTIBILITY; ASSOCIATION; EXPRESSION; MECHANISMS; DISEASE; SNPS	Myocardial infarction (MI) has become one of the leading causes of death in the world. Its pathogenesis includes chronic formation of plaque inside the vessel wall of the coronary artery and acute rupture of the artery, implicating a number of inflammation-mediating molecules, such as the cytokine lymphotoxin-alpha (LTA)(1). Functional variations in LTA are associated with susceptibility to MI2. Here we show that LTA protein binds to galectin-2, a member of the galactose-binding lectin family(3). Our case - control association study in a Japanese population showed that a single nucleotide polymorphism in LGALS2 encoding galectin-2 is significantly associated with susceptibility to MI. This genetic substitution affects the transcriptional level of galectin-2 in vitro, potentially leading to altered secretion of LTA, which would then affect the degree of inflammation; however, its relevance to other populations remains to be clarified. Smooth muscle cells and macrophages in the human atherosclerotic lesions expressed both galectin-2 and LTA. Our findings thus suggest a link between the LTA cascade and the pathogenesis of MI.	RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Lab Cardiovasc Dis, Tokyo 1088639, Japan; Kokura Mem Hosp, Dept Cardiol, Kitakyushu, Fukuoka 8028555, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Lab Genotyping, Yokohama, Kanagawa 2300045, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo 1088639, Japan	RIKEN; Kokura Memorial Hospital; Osaka University; RIKEN; University of Tokyo	Tanaka, T (corresponding author), RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Lab Cardiovasc Dis, Tokyo 1088639, Japan.	toshitan@ims.u-tokyo.ac.jp	Iida, Aritoshi/CAA-1373-2022; Tanaka, Toshihiro/J-9310-2014	Iida, Aritoshi/0000-0001-7538-1651; Tanaka, Toshihiro/0000-0001-6201-9784; Odashiro, Keita/0000-0003-0347-6330; Ozaki, Kouichi/0000-0003-0028-1570				den Dunnen JT, 2000, HUM MUTAT, V15, P7; GITT MA, 1992, J BIOL CHEM, V267, P10601; Iida A, 2001, J HUM GENET, V46, P668, DOI 10.1007/s100380170019; Liu LB, 2003, J BIOL CHEM, V278, P30157, DOI 10.1074/jbc.M301511200; Minami M, 2001, ARTERIOSCL THROM VAS, V21, P1796, DOI 10.1161/hq1001.096652; Ohnishi Y, 2001, J HUM GENET, V46, P471, DOI 10.1007/s100380170047; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schreyer SA, 2002, J BIOL CHEM, V277, P12364, DOI 10.1074/jbc.M111727200; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Subramanian VS, 2003, J BIOL CHEM, V278, P3976, DOI 10.1074/jbc.M210717200; Yamada R, 2001, AM J HUM GENET, V68, P674, DOI 10.1086/318789	13	189	200	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 6	2004	429	6987					72	75		10.1038/nature02502	http://dx.doi.org/10.1038/nature02502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129282	Bronze			2022-12-28	WOS:000221222100046
J	Turner, L				Turner, L			Has the President's Council on Bioethics missed the boat?	BRITISH MEDICAL JOURNAL			English	Editorial Material									McGill Univ, Biomed Eth Unit, Montreal, PQ, Canada	McGill University	Turner, L (corresponding author), McGill Univ, Biomed Eth Unit, Montreal, PQ, Canada.			Turner, Leigh/0000-0001-7283-6809					0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					629	629		10.1136/bmj.327.7415.629	http://dx.doi.org/10.1136/bmj.327.7415.629			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	15132125	Green Published			2022-12-28	WOS:000185358700060
J	Bentley, DR				Bentley, DR			Genomes for medicine	NATURE			English	Review							DNA-SEQUENCE; REGULATORY NETWORKS; GENE; CHROMOSOME; SUSCEPTIBILITY; PATHOGENESIS; ANNOTATION; REGIONS; BIOLOGY	We have the human genome sequence. It is freely available, accurate and nearly complete. But is the genome ready for medicine? The new resource is already changing genetic research strategies to find information of medical value. Now we need high-quality annotation of all the functionally important sequences and the variations within them that contribute to health and disease. To achieve this, we need more genome sequences, systematic experimental analyses, and extensive information on human phenotypes. Flexible and user-friendly access to well-annotated genomes will create an environment for innovation, and the potential for unlimited use of sequencing in biomedical research and practice.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Wellcome Trust Sanger Institute	Bentley, DR (corresponding author), Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.	drb@sanger.ac.uk						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Aiuti A, 2003, CURR OPIN ALLERGY CL, V3, P461, DOI 10.1097/01.all.0000104453.09202.d5; Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Bar-Joseph Z, 2003, NAT BIOTECHNOL, V21, P1337, DOI 10.1038/nbt890; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Bentley DR, 1996, SCIENCE, V274, P533, DOI 10.1126/science.274.5287.533; Bingley PJ, 2004, BRIT MED J, V328, P322, DOI 10.1136/bmj.328.7435.322; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Collins JE, 2003, GENOME RES, V13, P27, DOI 10.1101/gr.695703; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a; Dowell RD, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-7; Druker BJ, 2003, SEMIN HEMATOL, V40, P50, DOI 10.1053/shem.2003.50000; Dunham A, 2004, NATURE, V428, P522, DOI 10.1038/nature02379; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Georgiou-Karistianis N, 2003, BRAIN RES BULL, V59, P331, DOI 10.1016/S0361-9230(02)00877-8; Golub TR, 2001, CURR OPIN HEMATOL, V8, P252, DOI 10.1097/00062752-200107000-00012; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Grimwood J, 2004, NATURE, V428, P529, DOI 10.1038/nature02399; Guyer M, 1998, GENOME RES, V8, P413; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348; Hillier LW, 2003, NATURE, V424, P157, DOI 10.1038/nature01782; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lehner B, 2002, TRENDS GENET, V18, P63, DOI 10.1016/S0168-9525(02)02598-2; Margulies EH, 2003, GENOME RES, V13, P2507, DOI 10.1101/gr.1602203; Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055; Novik K. L., 2002, Current Issues in Molecular Biology, V4, P111; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; *RAT GEN PROJ SEQ, 1920, NATURE, V428, P493; Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; ROGERS J, IN PRESS COLD SPRING, V68; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Shendure J, 2004, NAT REV GENET, V5, P335, DOI 10.1038/nrg1325; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; SMITH T, IN PRESS TARGETS; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Treasure T, 2004, BMJ-BRIT MED J, V328, P237, DOI 10.1136/bmj.328.7434.237; van Dellen A, 2004, NEUROGENETICS, V5, P9, DOI 10.1007/s10048-003-0169-5; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	60	49	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					440	445		10.1038/nature02622	http://dx.doi.org/10.1038/nature02622			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164068				2022-12-28	WOS:000221644600045
J	Ravakhah, K; Simionescu, R				Ravakhah, K; Simionescu, R			Unusual cystitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cleveland Clin Hlth Syst, Huron Hosp, Cleveland, OH 44112 USA	Cleveland Clinic Foundation	Ravakhah, K (corresponding author), Cleveland Clin Hlth Syst, Huron Hosp, Cleveland, OH 44112 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2280	2280		10.1056/NEJMicm990827	http://dx.doi.org/10.1056/NEJMicm990827			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163778				2022-12-28	WOS:000221641900009
J	Singer, LT; Minnes, S; Short, E; Arendt, R; Farkas, K; Lewis, B; Klein, N; Russ, S; Min, MO; Kirchner, HL				Singer, LT; Minnes, S; Short, E; Arendt, R; Farkas, K; Lewis, B; Klein, N; Russ, S; Min, MO; Kirchner, HL			Cognitive with outcomes of preschool children prenatal cocaine exposure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSYCHOLOGICAL DISTRESS; MECONIUM; INFANTS; GROWTH	Context Because of methodological limitations, the results of the few prospective studies assessing long-term cognitive effects of prenatal cocaine exposure are inconsistent. Objective To assess effects of prenatal cocaine exposure and quality of caregiving environment on 4-year cognitive outcomes. Design Longitudinal, prospective, masked comparison cohort study from birth (September 1994-June 1996) to 4 years. Setting Research laboratory of a US urban county teaching hospital. Participants A total of 415 consecutively enrolled infants identified from a high-risk population screened for drug use through clinical interview, urine, and meconium screens. Ninety-three percent retention for surviving participants at 4 years of age resulted in 376 children (190 cocaine-exposed and 186 nonexposed). Main Outcome Measure The Wechsler Preschool and Primary Scales of Intelligence-Revised. Results After control for covariates, prenatal cocaine exposure was not related to lower full-scale IQ (cocaine exposed [80.7] vs nonexposed [82.9]; P=.09) scores or summary verbal (cocaine exposed [79.9] vs nonexposed [81.9]; P=.11) or performance (cocaine exposed [85.5] vs nonexposed [87.5]; P=.18) IQ scores at age 4 years. However, prenatal cocaine exposure was related to small but significant deficits on several subscales (mean [SE]): visual-spatial skills (cocaine exposed [7.3 (0.22)] vs nonexposed [8.2 (0.22)]; P=.01), general knowledge (cocaine exposed [6.1 (0.18)] vs nonexposed [6.7 (0.17)]; P=.04), and arithmetic skills (cocaine exposed [6.2 (0.20)] vs nonexposed [6.8 (0.20)]; P=.05). Prenatal cocaine exposure was also associated with a lower likelihood of achievement of IQ above normative means (odds ratio, 0.26 [95% confidence interval, 0.10-0.65]; P=.004). The quality of the caregiving environment was the strongest independent predictor of outcomes. Cocaine-exposed children placed in nonrelative foster or adoptive care lived in homes with more stimulating environments and had caregivers with better vocabulary scores, and they attained full-scale and performance IQ scores (83 and 87, respectively) similar to nonexposed children in biological maternal or relative care (full-scale IQ, 82; performance IQ, 88) and higher than cocaine-exposed children in biological maternal or relative care (full-scale IQ, 79; performance IQ, 84). Conclusions Prenatal cocaine exposure was not associated with lower full-scale, verbal, or performance IQ scores but was associated with an increased risk for specific cognitive impairments and lower likelihood of IQ above the normative mean at 4 years. A better home environment was associated with IQ scores for cocaine-exposed children that are similar to scores in nonexposed children.	Case Western Reserve Univ, Sch Med, Dept Gen Med Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Mandel Sch Appl Social Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Psychol, Cleveland, OH 44106 USA; Cleveland State Univ, Dept Educ, Cleveland, OH 44115 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University System of Ohio; Cleveland State University; University System of Ohio; Ohio State University	Singer, LT (corresponding author), Case Western Reserve Univ, Sch Med, Dept Gen Med Sci, Triangle Bldg,11400 Euclid Ave,Suite 250-A, Cleveland, OH 44106 USA.	Lynn.Singer@case.edu	Singer, Lynn/Q-2045-2019	Singer, Lynn/0000-0003-2950-9460; Min, Meeyoung/0000-0003-3584-6690	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007957] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00080] Funding Source: Medline; NIDA NIH HHS [R01 DA007957] Funding Source: Medline; PHS HHS [R01-07259, 07957] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alessandri SM, 1998, DEV PSYCHOL, V34, P565, DOI 10.1037/0012-1649.34.3.565; Appelbaum M, 1999, DEV PSYCHOL, V35, P1297; Arendt R, 1999, PEDIATRICS, V103, P86, DOI 10.1542/peds.103.1.86; Arendt RE, 1999, J DRUG ISSUES, V29, P203, DOI 10.1177/002204269902900203; Bandstra ES, 2001, PEDIATRICS, V108, P1309, DOI 10.1542/peds.108.6.1309; BARBABAN SC, 1997, J NEUROPHYSIOL, V77, P126; Bennett DS, 2002, DEV PSYCHOL, V38, P648, DOI 10.1037//0012-1649.38.5.648; Caldwell B., 1984, HOME OBSERVATION MEA; COLES CD, 1992, NEUROTOXICOL TERATOL, V14, P23, DOI 10.1016/0892-0362(92)90025-6; Derogatis LR., 1992, BRIEF SYMPTOM INVENT; DOWEDWARDS D, 1995, MOTHERS BABIES COCAI, P1; DOWEDWARDS DL, 1993, DEV BRAIN RES, V72, P309, DOI 10.1016/0165-3806(93)90198-J; Dunn L.M., 2007, PEABODY PICTURE VOCA; Eyler FD, 1998, PEDIATRICS, V101, P237, DOI 10.1542/peds.101.2.237; HOBEL CJ, 1973, AM J OBSTET GYNECOL, V117, P1; Hurt H, 2001, J DEV BEHAV PEDIATR, V22, P27, DOI 10.1097/00004703-200102000-00005; Hurt H, 1997, ARCH PEDIAT ADOL MED, V151, P1237, DOI 10.1001/archpedi.1997.02170490063011; HURT H, 1995, J DEV BEHAV PEDIATR, V16, P29, DOI 10.1097/00004703-199502000-00005; Inman-Wood SL, 2000, NEUROTOXICOL TERATOL, V22, P547, DOI 10.1016/S0892-0362(00)00084-2; JACOBSON SH, 1991, POLYM PREPR, V32, P390; Jacobson SW, 1996, J PEDIATR-US, V129, P581, DOI 10.1016/S0022-3476(96)70124-5; KANDEL D, 1998, DRUG ADDICTIONS RES; Koren G, 1998, ANN NY ACAD SCI, V846, P306, DOI 10.1111/j.1749-6632.1998.tb09747.x; Lester BM, 1998, SCIENCE, V282, P633, DOI 10.1126/science.282.5389.633; LEWIS DE, 1994, J TOXICOL-CLIN TOXIC, V32, P697, DOI 10.3109/15563659409017976; Melnick SM, 2001, NEUROTOXICOL TERATOL, V23, P445, DOI 10.1016/S0892-0362(01)00157-X; OSTREA EM, 1989, J PEDIATR-US, V115, P474, DOI 10.1016/S0022-3476(89)80860-1; Richardson GA, 1996, NEUROTOXICOL TERATOL, V18, P627, DOI 10.1016/S0892-0362(96)00121-3; SAMEROFF AJ, 1987, PEDIATRICS, V79, P343; Singer L, 1997, DEV PSYCHOPATHOL, V9, P473, DOI 10.1017/S0954579497001259; Singer LT, 1999, J DRUG ISSUES, V29, P253, DOI 10.1177/002204269902900207; Singer LT, 2000, NEUROTOXICOL TERATOL, V22, P653, DOI 10.1016/S0892-0362(00)00092-1; Singer LT, 2002, NEUROTOXICOL TERATOL, V24, P127, DOI 10.1016/S0892-0362(01)00208-2; SINGER LT, 1991, J PEDIATR-US, V119, P667, DOI 10.1016/S0022-3476(05)82426-6; Singer LT, 2002, JAMA-J AM MED ASSOC, V287, P1952, DOI 10.1001/jama.287.15.1952; Singer LT, 2001, PEDIATRICS, V107, P1057, DOI 10.1542/peds.107.5.1057; SINGER LT, 2001, BIOBEHAVIORAL ASSESS, P15; Smeriglio VL, 1999, CLIN PERINATOL, V26, P1; Snow DM, 2001, NEUROTOXICOL TERATOL, V23, P225, DOI 10.1016/S0892-0362(01)00137-4; THADANI PV, 1995, NIDA RES MONOGRAPH, V158; Van Beveren TT, 2000, AM J HUM BIOL, V12, P417; VOLPE JJ, 1992, NEW ENGL J MED, V327, P399, DOI 10.1056/NEJM199208063270607; Vorhees C., 1986, HDB BEHAV TERATOLOGY, P23; Wechsler D., 1999, WECHSLER PRESCHOOL P; Wechsler D, 1989, WECHSLER ADULT INTEL; WOODS JR, 1987, JAMA-J AM MED ASSOC, V257, P957, DOI 10.1001/jama.257.7.957; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203	47	165	169	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2004	291	20					2448	2456		10.1001/jama.291.20.2448	http://dx.doi.org/10.1001/jama.291.20.2448			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823HB	15161895	Bronze			2022-12-28	WOS:000221599700027
J	Walter, LC; Davidowitz, NP; Heineken, PA; Covinsky, KE				Walter, LC; Davidowitz, NP; Heineken, PA; Covinsky, KE			Pitfalls of converting practice guidelines into quality measures - Lessons learned from a VA performance measure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE QUALITY; COLORECTAL-CANCER; MORTALITY	The Department of Veterans Affairs (VA) manages the largest health care system in the United States, and the Institute of Medicine has recommended that many practices of VA quality measurement be applied to the US health care system as a whole. The VA measures quality of care at all of its sites by assessing adherence rates to performance measures, which generally are derived from evidence-based practice guidelines. Higher adherence rates are used as evidence of better quality of care. However, there are problems with converting practice guidelines, intended to offer guidance to clinicians, into performance measures that are meant to identify poor-quality care. We suggest a more balanced perspective on the use of performance measures to define quality by delineating conceptual problems with the conversion of practice guidelines into quality measures. Focusing on colorectal cancer screening, we use a case study at 1 VA facility to illustrate pitfalls that can cause adherence rates to guideline-based performance measures to be poor indicators of the quality of cancer screening. Pitfalls identified included (1) not properly considering illness severity of the sample population audited for adherence to screening, (2) not distinguishing screening from diagnostic procedures when setting achievable target screening rates, and (3) not accounting for patient preferences or clinician judgment when scoring performance measures. For many patients with severe comorbid illnesses or strong preferences against screening, the risks of colorectal cancer screening outweigh the benefits, and the decision to not screen may reflect good quality of care. Performance measures require more thoughtful specification and interpretation to avoid defining high testing rates as good quality of care regardless of who received the test, why it was performed, or whether the patient wanted it.	Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Walter, LC (corresponding author), Vet Affairs Med Ctr, Div Geriatr, 181G,4150 Clement St, San Francisco, CA 94121 USA.	louisew@itsa.ucsf.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K02HS000006] Funding Source: NIH RePORTER; AHRQ HHS [K02HS00006-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Berg AO, 2002, ANN INTERN MED, V137, P129, DOI 10.7326/0003-4819-137-2-200207160-00014; Casalino LP, 1999, NEW ENGL J MED, V341, P1147, DOI 10.1056/NEJM199910073411511; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Demakis JG, 2000, MED CARE, V38, pS17; *DEP VET AFF OFF I, 2003, 010154488 DEP VET AF; Derose SF, 2003, ANNU REV PUBL HEALTH, V24, P363, DOI 10.1146/annurev.publhealth.24.100901.140847; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; Greer AL, 2002, INT J TECHNOL ASSESS, V18, P747, DOI 10.1017/S0266462302000569; Harris R, 2000, ANN INTERN MED, V132, P732, DOI 10.7326/0003-4819-132-9-200005020-00008; HLATKY MA, 1995, JAMA-J AM MED ASSOC, V273, P1219, DOI 10.1001/jama.273.15.1219; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Jha AK, 2003, NEW ENGL J MED, V348, P2218, DOI 10.1056/NEJMsa021899; Kaufman A, 1996, QRC Advis, V12, P1; Kizer KW, 1999, AM J MED QUAL, V14, P3, DOI 10.1177/106286069901400103; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; *NAT COMM QUAL ASS, 1999, HEDIS 2000 HLTH PLAN; Palmer RH, 1997, ANN INTERN MED, V127, P733, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00059; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Sheldon T, 1998, QUAL HEALTH CARE, V7, pS45; Sox HC, 1998, J GEN INTERN MED, V13, P424, DOI 10.1046/j.1525-1497.1998.00126.x; *US DEP HHS, HLTH PEOPL 2010 LEAD; *VA OFF QUAL PERF, 2002, EXT PEER REV PROGR E; *VA OFF QUAL PERF, 2001, FY 2002 VHA PERF MEA; *VA OFF QUAL PERF, 2003, PERF MEAS; Vijan S, 2000, Eff Clin Pract, V3, P247; Walter LC, 2001, J GEN INTERN MED, V16, P779, DOI 10.1046/j.1525-1497.2001.10113.x; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2750, DOI 10.1001/jama.285.21.2750; Weissman NW, 1999, J EVAL CLIN PRACT, V5, P269, DOI 10.1046/j.1365-2753.1999.00203.x; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WOOLF SH, 1993, ARCH INTERN MED, V153, P2646, DOI 10.1001/archinte.153.23.2646	33	149	149	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2004	291	20					2466	2470		10.1001/jama.291.20.2466	http://dx.doi.org/10.1001/jama.291.20.2466			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823HB	15161897				2022-12-28	WOS:000221599700029
J	Weinreb, RN; Khaw, PT				Weinreb, RN; Khaw, PT			Primary open-angle glaucoma	LANCET			English	Review							NERVE-FIBER LAYER; WAVELENGTH AUTOMATED PERIMETRY; OPTICAL COHERENCE TOMOGRAPHY; RETINAL GANGLION-CELLS; OCULAR HYPERTENSION TREATMENT; SCANNING LASER POLARIMETRY; LATERAL GENICULATE-NUCLEUS; INTRAOCULAR-PRESSURE; INTRAOPERATIVE 5-FLUOROURACIL; PARVOCELLULAR LAYERS	Primary open-angle glaucoma is a progressive optic neuropathy and, perhaps, the most common form of glaucoma. Because the disease is treatable, and because the visual impairment caused by glaucoma is irreversible, early detection is essential. Early diagnosis depends on examination of the optic disc, retinal nerve fibre layer, and visual field. New imaging and psychophysical tests can improve both detection and monitoring of the progression of the disease. Recently completed long-term clinical trials provide convincing evidence that lowering intraocular pressure prevents progression at both the early and late stages of the disease. The degree of protection is related to the degree to which intraocular pressure is lowered. Improvements in therapy consist of more effective and better-tolerated drugs to lower intraocular pressure, and more effective surgical procedures. New treatments to directly treat and protect the retinal ganglion cells that are damaged in glaucoma are also in development.	Univ Calif San Diego, Hamilton Glaucoma Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA; Moorfields Eye Hosp, Glaucoma Unit, London, England; Moorfields Eye Hosp, Ocular Repair & Regenerat Biol Unit, London, England; UCL, Inst Ophthalmol, London, England	University of California System; University of California San Diego; University of California System; University of California San Diego; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London	Weinreb, RN (corresponding author), Univ Calif San Diego, Hamilton Glaucoma Ctr, 9500 Gilman Dr, La Jolla, CA 92093 USA.	weinreb@eyecenter.ucsd.edu		Khaw, Sir Peng Tee/0000-0002-8087-2268	NEI NIH HHS [EY11158, EY05990] Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY011158, R01EY005990] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ACOTT TS, 1989, AM J OPHTHALMOL, V107, P1; Aihara M, 2003, INVEST OPHTH VIS SCI, V44, P4314, DOI 10.1167/iovs.03-0137; Aihara M, 2003, INVEST OPHTH VIS SCI, V44, P1581, DOI 10.1167/iovs.02-0759; AIHARA M, 1983, INVEST OPHTH VIS SCI, V44, P5168; AIHARA M, 2003, INVEST OPHTH VIS SCI, V77, P681; Alward WL, 1998, AM J OPHTHALMOL, V126, P498; Alward WLM, 1998, NEW ENGL J MED, V338, P1022, DOI 10.1056/NEJM199804093381503; *AM AC OPHTH PREF, 2000, PREF PRACT PATT PRIM; [Anonymous], 1995, Am J Ophthalmol, V120, P718; Bellezza AJ, 2003, INVEST OPHTH VIS SCI, V44, P623, DOI 10.1167/iovs.01-1282; Bloom PA, 1997, OPHTHALMOLOGY, V104, P1508, DOI 10.1016/S0161-6420(97)30109-2; Bowd C, 2003, ARCH OPHTHALMOL-CHIC, V121, P961, DOI 10.1001/archopht.121.7.961; Bradley JMB, 2000, INVEST OPHTH VIS SCI, V41, P422; Carassa RG, 2003, OPHTHALMOLOGY, V110, P882, DOI 10.1016/S0161-6420(03)00081-2; Chauhan BC, 2001, ARCH OPHTHALMOL-CHIC, V119, P1492; CHEN CW, 1990, J OCUL PHARMACOL, V6, P175, DOI 10.1089/jop.1990.6.175; Chiselita D, 2001, EYE, V15, P197, DOI 10.1038/eye.2001.60; Clark AF, 2001, FASEB J, V15, P1251, DOI 10.1096/fj.00-0663fje; Crawford MLJ, 2001, INVEST OPHTH VIS SCI, V42, P358; Damji KF, 1999, BRIT J OPHTHALMOL, V83, P718, DOI 10.1136/bjo.83.6.718; Danias J, 2003, INVEST OPHTH VIS SCI, V44, P5151, DOI 10.1167/iovs.02-1101; Diggory P, 1996, BRIT J OPHTHALMOL, V80, P85, DOI 10.1136/bjo.80.1.85; Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012; *ED DOGMA, 2003, TERM GUID GLAUC EUR; Ederer F, 2001, AM J OPHTHALMOL, V132, P311; Edmunds B, 2002, EYE, V16, P297, DOI 10.1038/sj.eye.6700148; Edmunds B, 1999, EYE, V13, P524, DOI 10.1038/eye.1999.131; EGBERT PR, 1993, AM J OPHTHALMOL, V116, P612, DOI 10.1016/S0002-9394(14)73204-0; Einarson TR, 2000, CLIN THER, V22, P1502, DOI 10.1016/S0149-2918(00)83048-9; El Sayyad F, 2000, OPHTHALMOLOGY, V107, P1671, DOI 10.1016/S0161-6420(00)00263-3; Enyedi LB, 2001, J AAPOS, V5, P281, DOI 10.1067/mpa.2001.117571; FECHTNER RD, 1994, SURV OPHTHALMOL, V39, P23, DOI 10.1016/S0039-6257(05)80042-6; Fingert JH, 2002, SURV OPHTHALMOL, V47, P547, DOI 10.1016/S0039-6257(02)00353-3; Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899; Fremont AM, 2003, ARCH OPHTHALMOL-CHIC, V121, P777, DOI 10.1001/archopht.121.6.777; Gaasterland D E, 1992, Trans Am Ophthalmol Soc, V90, P225; GABELT BT, 1989, EXP EYE RES, V49, P389, DOI 10.1016/0014-4835(89)90049-3; Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714; Greenfield DS, 1996, ARCH OPHTHALMOL-CHIC, V114, P943, DOI 10.1001/archopht.1996.01100140151007; Greenfield DS, 2003, ARCH OPHTHALMOL-CHIC, V121, P41; Greenfield DS, 2000, AM J OPHTHALMOL, V129, P715, DOI 10.1016/S0002-9394(00)00353-6; Grierson I, 2002, SURV OPHTHALMOL, V47, pS176, DOI 10.1016/S0039-6257(02)00304-1; Grierson I, 1999, ARCH OPHTHALMOL-CHIC, V117, P394, DOI 10.1001/archopht.117.3.394; Guedes V, 2003, OPHTHALMOLOGY, V110, P177, DOI 10.1016/S0161-6420(02)01564-6; Gupta N, 1997, J GLAUCOMA, V6, P426; Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268; Higginbotham EJ, 1996, OPHTHALMOLOGY, V103, P650, DOI 10.1016/S0161-6420(96)30639-8; Higginbotham EJ, 1998, OPHTHALMOLOGY, V105, P1137; JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P1469, DOI 10.1001/archopht.1993.01090110027013; JAY JL, 1988, BRIT J OPHTHALMOL, V72, P881, DOI 10.1136/bjo.72.12.881; Jia LJ, 2000, INVEST OPHTH VIS SCI, V41, P1380; John SWM, 1999, J GLAUCOMA, V8, P400; Johnstone MA, 1997, AM J OPHTHALMOL, V124, P544, DOI 10.1016/S0002-9394(14)70870-0; Jonescu-Cuypers CP, 2001, OPHTHALMOLOGY, V108, P254, DOI 10.1016/S0161-6420(00)00514-5; Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701; KHAW PT, 2003, OPHTHALMOLOGY PRACTI; Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446; Knighton RW, 1998, INVEST OPHTH VIS SCI, V39, P189; Landers J, 2000, CLIN EXP OPHTHALMOL, V28, P248, DOI 10.1046/j.1442-9071.2000.00318.x; Leske MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P48; Lichter PR, 2001, OPHTHALMOLOGY, V108, P1943, DOI 10.1016/S0161-6420(01)00873-9; Lindsey JD, 2001, ARCH OPHTHALMOL-CHIC, V119, P853; Lipton SA, 2003, SURV OPHTHALMOL, V48, pS38, DOI 10.1016/S0039-6257(03)00008-0; Liu B, 2001, ARCH OPHTHALMOL-CHIC, V119, P240; Mabuchi F, 2003, INVEST OPHTH VIS SCI, V44, P4321, DOI 10.1167/iovs.03-0138; MIGDAL C, 1994, OPHTHALMOLOGY, V101, P1651; Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1; Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184; O'Brart DPS, 2002, BRIT J OPHTHALMOL, V86, P748, DOI 10.1136/bjo.86.7.748; Parrish RK, 2002, ARCH OPHTHALMOL-CHIC, V120, P1204; Parshley DE, 1996, INVEST OPHTH VIS SCI, V37, P795; Pena JDO, 2001, INVEST OPHTH VIS SCI, V42, P2303; Polansky JR, 2000, EYE, V14, P503, DOI 10.1038/eye.2000.137; Polo V, 2002, OPHTHALMOLOGY, V109, P761, DOI 10.1016/S0161-6420(01)01014-4; Quigley HA, 2000, INVEST OPHTH VIS SCI, V41, P3460; Quigley HA, 1997, INVEST OPHTH VIS SCI, V38, P83; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; QUIGLEY HA, 1992, OPHTHALMOLOGY, V99, P19; QUIGLEY HA, 1989, AM J OPHTHALMOL, V107, P453, DOI 10.1016/0002-9394(89)90488-1; Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1; Sample PA, 2000, INVEST OPHTH VIS SCI, V41, P1783; Sample PA, 2000, PROG RETIN EYE RES, V19, P369, DOI 10.1016/S1350-9462(00)00001-X; Schori H, 2001, P NATL ACAD SCI USA, V98, P3398, DOI 10.1073/pnas.041609498; Schulzer M, 1998, AM J OPHTHALMOL, V126, P487; SCHUMAN JS, 1995, ARCH OPHTHALMOL-CHIC, V113, P586, DOI 10.1001/archopht.1995.01100050054031; Schwartz M, 2003, INVEST OPHTH VIS SCI, V44, P1407, DOI 10.1167/iovs.02-0594; SHEFFIELD VC, 1993, NAT GENET, V4, P47, DOI 10.1038/ng0593-47; Singh K, 1997, AM J OPHTHALMOL, V123, P48, DOI 10.1016/S0002-9394(14)70991-2; Siriwardena D, 2002, OPHTHALMOLOGY, V109, P427, DOI 10.1016/S0161-6420(01)00997-6; SMITH MF, 1992, AM J OPHTHALMOL, V114, P737, DOI 10.1016/S0002-9394(14)74053-X; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Tezel G, 1999, ARCH OPHTHALMOL-CHIC, V117, P917; TIELSCH JM, 1991, AM J EPIDEMIOL, V134, P1102, DOI 10.1093/oxfordjournals.aje.a116013; TIELSCH JM, 1994, ARCH OPHTHALMOL-CHIC, V112, P69, DOI 10.1001/archopht.1994.01090130079022; Toris CB, 1999, AM J OPHTHALMOL, V128, P8, DOI 10.1016/S0002-9394(99)00076-8; VILLUMSEN J, 1989, BRIT J OPHTHALMOL, V73, P975, DOI 10.1136/bjo.73.12.975; Wang L, 2002, INVEST OPHTH VIS SCI, V43, P1088; Weber AJ, 2000, INVEST OPHTH VIS SCI, V41, P1370; Weinreb R N, 1995, J Glaucoma, V4, P2; Weinreb RN, 2003, ARCH OPHTHALMOL-CHIC, V121, P218; Weinreb RN, 1998, ARCH OPHTHALMOL-CHIC, V116, P1229, DOI 10.1001/archopht.116.9.1229; Weinreb RN, 2002, SURV OPHTHALMOL, V47, pS53, DOI 10.1016/S0039-6257(02)00306-5; WEINREB RN, 1990, ARCH OPHTHALMOL-CHIC, V108, P557, DOI 10.1001/archopht.1990.01070060105058; Weinreb RN, 1997, INVEST OPHTH VIS SCI, V38, P2772; Weinreb RN, 1999, ARCH OPHTHALMOL-CHIC, V117, P1403, DOI 10.1001/archopht.117.10.1403; WEINREB RN, 1995, GLAUCOMAS, P1575; Weinreb Robert N., 1997, P59; Wells AP, 2003, OPHTHALMOLOGY, V110, P2192, DOI 10.1016/S0161-6420(03)00800-5; Wilson MR, 2003, AM J OPHTHALMOL, V136, P464, DOI 10.1016/S0002-9394(03)00239-3; WISE JB, 1979, ARCH OPHTHALMOL-CHIC, V97, P319, DOI 10.1001/archopht.1979.01020010165017; Wistrand PJ, 1997, SURV OPHTHALMOL, V41, pS129, DOI 10.1016/S0039-6257(97)80020-3; Wolfs RCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1640, DOI 10.1001/archopht.116.12.1640; Yan XM, 2000, ARCH OPHTHALMOL-CHIC, V118, P666, DOI 10.1001/archopht.118.5.666; Yoles E, 1998, ARCH OPHTHALMOL-CHIC, V116, P906, DOI 10.1001/archopht.116.7.906; Yorston D, 2001, BRIT J OPHTHALMOL, V85, P1028, DOI 10.1136/bjo.85.9.1028; Yucel YH, 2003, PROG RETIN EYE RES, V22, P465, DOI 10.1016/S1350-9462(03)00026-0; Yucel YH, 2001, INVEST OPHTH VIS SCI, V42, P3216; Yucel YH, 2000, ARCH OPHTHALMOL-CHIC, V118, P378; Zangwill L M, 2000, Semin Ophthalmol, V15, P206, DOI 10.3109/08820530009037872; Zangwill LM, 2001, ARCH OPHTHALMOL-CHIC, V119, P985, DOI 10.1001/archopht.119.7.985; Zangwill LM, 2000, OPHTHALMOLOGY, V107, P1309, DOI 10.1016/S0161-6420(00)00168-8; Zhou QY, 2002, INVEST OPHTH VIS SCI, V43, P2221; 1998, OPHTHALMOLOGY, V105, P146	124	1326	1372	3	158	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	2004	363	9422					1711	1720		10.1016/S0140-6736(04)16257-0	http://dx.doi.org/10.1016/S0140-6736(04)16257-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158634				2022-12-28	WOS:000221546300021
J	McKinnon, JS; Mori, S; Blackman, BK; David, L; Kingsley, DM; Jamieson, L; Chou, J; Schluter, D				McKinnon, JS; Mori, S; Blackman, BK; David, L; Kingsley, DM; Jamieson, L; Chou, J; Schluter, D			Evidence for ecology's role in speciation	NATURE			English	Article							THREESPINE STICKLEBACKS GASTEROSTEUS; REPRODUCTIVE ISOLATION; NATURAL-SELECTION; PARALLEL SPECIATION; MATE PREFERENCES; ACULEATUS L; EVOLUTION; DIVERGENCE; REINFORCEMENT; POPULATIONS	A principal challenge in testing the role of natural selection in speciation is to connect the build-up of reproductive isolation between populations to divergence of ecologically important traits(1,2). Demonstrations of 'parallel speciation', or assortative mating by selective environment, link ecology and isolation(3-5), but the phenotypic traits mediating isolation have not been confirmed. Here we show that the parallel build-up of mating incompatibilities between stickleback populations can be largely accounted for by assortative mating based on one trait, body size, which evolves predictably according to environment. In addition to documenting the influence of body size on reproductive isolation for stickleback populations spread across the Northern Hemisphere, we have confirmed its importance through a new experimental manipulation. Together, these results suggest that speciation may arise largely as a by-product of ecological differences and divergent selection on a small number of phenotypic traits.	Univ Wisconsin, Whitewater, WI 53190 USA; Gifu Keizai Univ, Biol Lab, Ogaki, Gifu Prefecture 5038550, Japan; HHMI, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Beckman Ctr B300, Stanford, CA 94305 USA; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Ctr Biodivers, Vancouver, BC V6T 1Z4, Canada	University of Wisconsin System; Howard Hughes Medical Institute; Stanford University; University of British Columbia; University of British Columbia	McKinnon, JS (corresponding author), Univ Wisconsin, Whitewater, WI 53190 USA.	mckinnoj@uww.edu	David, Lior/G-8754-2012	David, Lior/0000-0002-6555-0594; Schluter, Dolph/0000-0003-1683-7836; Blackman, Benjamin/0000-0003-4936-6153				Baker J, 1994, EVOLUTIONARY BIOL TH; Bell MA, 2001, GENETICA, V112, P445; Bell Michael A., 1994, P1; Boughman JW, 2001, NATURE, V411, P944, DOI 10.1038/35082064; Buth Donald G., 1994, P61; Colosimo PF, 2004, PLOS BIOL, V2, P635, DOI 10.1371/journal.pbio.0020109; Greenberg AJ, 2003, SCIENCE, V302, P1754, DOI 10.1126/science.1090432; HAGEN DW, 1967, J FISH RES BOARD CAN, V24, P1637, DOI 10.1139/f67-138; Hatfield T, 1997, AM NAT, V149, P1009, DOI 10.1086/286036; HAY DE, 1975, CAN J ZOOL, V53, P441, DOI 10.1139/z75-057; Hendry AP, 2002, EVOLUTION, V56, P1199; Ishikawa M, 2000, BEHAVIOUR, V137, P1065, DOI 10.1163/156853900502439; Luttbeg B, 2001, ETHOLOGY, V107, P545, DOI 10.1046/j.1439-0310.2001.00694.x; McKinnon JS, 1995, ANIM BEHAV, V50, P1645, DOI 10.1016/0003-3472(95)80018-2; McKinnon JS, 2002, TRENDS ECOL EVOL, V17, P480, DOI 10.1016/S0169-5347(02)02579-X; McPhail J.D., 1994, P399; MCPHAIL JD, 1977, HEREDITY, V38, P53, DOI 10.1038/hdy.1977.7; Mooers AO, 1999, AM NAT, V154, P249, DOI 10.1086/303226; Nagel L, 1998, EVOLUTION, V52, P209, DOI 10.1111/j.1558-5646.1998.tb05154.x; Nosil P, 2002, NATURE, V417, P440, DOI 10.1038/417440a; ORTI G, 1994, EVOLUTION, V48, P608, DOI 10.1111/j.1558-5646.1994.tb01348.x; Peichel CL, 2001, NATURE, V414, P901, DOI 10.1038/414901a; Raufaste N, 2001, EVOLUTION, V55, P1703, DOI 10.1111/j.0014-3820.2001.tb00689.x; Rundle HD, 2000, SCIENCE, V287, P306, DOI 10.1126/science.287.5451.306; Rundle HD, 2003, P NATL ACAD SCI USA, V100, P14943, DOI 10.1073/pnas.2036360100; Rundle HD, 1998, EVOLUTION, V52, P200, DOI 10.1111/j.1558-5646.1998.tb05153.x; SCHLUTER D, 1995, AM NAT, V146, P292, DOI 10.1086/285799; Servedio MR, 2001, EVOLUTION, V55, P1909, DOI 10.1111/j.0014-3820.2001.tb01309.x; SNYDER RJ, 1989, CAN J ZOOL, V67, P2448, DOI 10.1139/z89-345; Ziuganov VV, 1995, BEHAVIOUR, V132, P1173, DOI 10.1163/156853995X00513	30	356	370	4	175	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 20	2004	429	6989					294	298		10.1038/nature02556	http://dx.doi.org/10.1038/nature02556			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152252				2022-12-28	WOS:000221505900042
J	Wu, DA; Kanai, R; Shimojo, S				Wu, DA; Kanai, R; Shimojo, S			Steady-state misbinding of colour and motion	NATURE			English	Editorial Material							BINDING; VISION		CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Utrecht, Psychonom Div, Helmholtz Res Inst, NL-3584 CS Utrecht, Netherlands; NTT Corp, Commun Sci Labs, Human & Informat Sci Lab, Kanagawa 2430198, Japan	California Institute of Technology; Utrecht University; Nippon Telegraph & Telephone Corporation	Wu, DA (corresponding author), CALTECH, Div Biol, 139-74, Pasadena, CA 91125 USA.	daw-an@caltech.edu	Kanai, Ryota/A-1191-2007	Wu, Daw-An/0000-0003-4296-3369; Kanai, Ryota/0000-0002-0186-2687				LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; Moutoussis K, 1997, P ROY SOC B-BIOL SCI, V264, P393, DOI 10.1098/rspb.1997.0056; Nishida S, 2002, CURR BIOL, V12, P359, DOI 10.1016/S0960-9822(02)00698-X; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Wolfe JM, 1999, NEURON, V24, P11, DOI 10.1016/S0896-6273(00)80818-1	5	55	56	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					262	262		10.1038/429262a	http://dx.doi.org/10.1038/429262a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152242	Bronze			2022-12-28	WOS:000221505900031
J	Albillos, A; de-La-Hera, A; Alvarez-Mon, M				Albillos, A; de-La-Hera, A; Alvarez-Mon, M			Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites	LANCET			English	Article								Serum lipopolysaccharide-binding protein is increased in a subset of non-infected ascitic cirrhotic patients, a finding previously related to bacterial passage from the gut to the circulation without overt infection. We prospectively analysed the risk factors associated with a first episode of severe bacterial infection in 84 ascitic cirrhotics, followed up for a median of 46 weeks. The cumulative probability. of such infection in patients with raised and normal lipopolysaccharide-binding protein was 32.4% and 8.0% (p=0.004), respectively. Increased lipopolysaccharide-binding protein was the only factor independently associated with severe bacterial infection in a multivariate analysis (relative risk 4.49, 95% CI 1.42-14.1). Monitoring of serum lipopolysaccharide-binding protein could, therefore, help to target cirrhotic patients with ascites for antibiotic prophylaxis.	Univ Alcala De Henares, Dept Med, CSIC,Unidad I&D Asociada, Lab Enfermedades Sistema Inmune & Oncol, Madrid 28871, Spain; Hosp Univ Ramon y Cajal, Serv Gastroenterol, Madrid, Spain; Hosp Univ Principe Asturias, Serv Enfermedades Sistema Inmune & Oncol, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Alcala; Hospital Universitario Ramon y Cajal; Prince of Asturias University Hospital	Albillos, A (corresponding author), Univ Alcala De Henares, Dept Med, CSIC,Unidad I&D Asociada, Lab Enfermedades Sistema Inmune & Oncol, Carretera Madrid Barcelona,KM 33-600, Madrid 28871, Spain.	aalbillosm@meditex.es							0	78	84	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	2004	363	9421					1608	1610		10.1016/S0140-6736(04)16206-5	http://dx.doi.org/10.1016/S0140-6736(04)16206-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145636				2022-12-28	WOS:000221408800013
J	Cyranoski, D; Chou, IH				Cyranoski, D; Chou, IH			Curiosity makes way for capitalism	NATURE			English	Article																			0	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	2004	429	6988					216	219		10.1038/429216a	http://dx.doi.org/10.1038/429216a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141220				2022-12-28	WOS:000221356300050
J	Klass, P				Klass, P			Index case	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Med, Boston, MA 02118 USA; Boston Med Ctr, Boston, MA USA	Boston University; Boston Medical Center	Klass, P (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.							Tanaka M, 2003, JAMA-J AM MED ASSOC, V290, P2968, DOI 10.1001/jama.290.22.2968; 2002, MMWR MORB MORTAL WKL, V51, P73	2	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2023	2026		10.1056/NEJMp038243	http://dx.doi.org/10.1056/NEJMp038243			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141038				2022-12-28	WOS:000221354000001
J	van Meurs, JBJ; Dhonukshe-Rutten, RAM; Pluijm, SMF; van der Klift, M; de Jonge, R; Lindemans, J; de Groot, LCPGM; Hofman, A; Witteman, JCM; van Leeuwen, JPTM; Breteler, MMB; Lips, P; Pols, HAP; Uitterlinden, AG				van Meurs, JBJ; Dhonukshe-Rutten, RAM; Pluijm, SMF; van der Klift, M; de Jonge, R; Lindemans, J; de Groot, LCPGM; Hofman, A; Witteman, JCM; van Leeuwen, JPTM; Breteler, MMB; Lips, P; Pols, HAP; Uitterlinden, AG			Homocysteine levels and the risk of osteoporotic fracture	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; PLASMA HOMOCYSTEINE; WOMEN; DETERMINANTS; DISEASE; MEN; HOMOCYSTINURIA; DEMENTIA; ACID; AGE	BACKGROUND: Very high plasma homocysteine levels are characteristic of homocystinuria, a rare autosomal recessive disease accompanied by the early onset of generalized osteoporosis. We therefore hypothesized that mildly elevated homocysteine levels might be related to age-related osteoporotic fractures. METHODS: We studied the association between circulating homocysteine levels and the risk of incident osteoporotic fracture in 2406 subjects, 55 years of age or older, who participated in two separate prospective, population-based studies. In the Rotterdam Study, there were two independent cohorts: 562 subjects in cohort 1, with a mean follow-up period of 8.1 years; and 553 subjects in cohort 2, with a mean follow-up period of 5.7 years. In the Longitudinal Aging Study Amsterdam, there was a single cohort of 1291 subjects, with a mean follow-up period of 2.7 years. Multivariate Cox proportional-hazards regression models were used for analysis of the risk of fracture, with adjustment for age, sex, body-mass index, and other characteristics that may be associated with the risk of fracture or with increased homocysteine levels. RESULTS: During 11,253 person-years of follow-up, osteoporotic fractures occurred in 191 subjects. The overall multivariable-adjusted relative risk of fracture was 1.4 (95 percent confidence interval, 1.2 to 1.6) for each increase of 1 SD in the natural-log-transformed homocysteine level. The risk was similar in all three cohorts studied, and it was also similar in men and women. A homocysteine level in the highest age-specific quartile was associated with an increase by a factor of 1.9 in the risk of fracture (95 percent confidence interval, 1.4 to 2.6). The associations between homocysteine levels and the risk of fracture appeared to be independent of bone mineral density and other potential risk factors for fracture. CONCLUSIONS: An increased homocysteine level appears to be a strong and independent risk factor for osteoporotic fractures in older men and women.	Erasmus MC, Dept Internal Med, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Clin Chem, NL-3000 DR Rotterdam, Netherlands; Univ Wageningen & Res Ctr, Div Human Nutr, Wageningen, Netherlands; Vrije Univ Amsterdam, Dept Endocrinol, Med Ctr, Amsterdam, Netherlands; Vrije Univ Amsterdam, Inst Res Extramural Med, Med Ctr, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Wageningen University & Research; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	van Meurs, JBJ (corresponding author), Erasmus MC, Dept Internal Med, POB 1738, NL-3000 DR Rotterdam, Netherlands.	j.vanmeurs@erasmusmc.nl	van Leeuwen, Johannes/D-5015-2014; Breteler, Monique M.B./J-5058-2014	van Leeuwen, Johannes/0000-0002-2282-4006; Breteler, Monique M.B./0000-0002-0626-9305; van Meurs, Joyce/0000-0001-6245-2123; de Groot, Lisette/0000-0003-2778-2789				ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; BURGER H, 1994, BONE MINER, V25, P1, DOI 10.1016/S0169-6009(08)80203-6; Caliskan S, 2001, CLIN CHIM ACTA, V309, P53, DOI 10.1016/S0009-8981(01)00529-0; Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140-6736(98)09075-8; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; de Leeuw FE, 2001, J NEUROL NEUROSUR PS, V70, P9, DOI 10.1136/jnnp.70.1.9; DEEG DJH, 1998, AUTONOMY WELL BEING, V2, P9; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; HARPEY JP, 1981, J PEDIATR-US, V98, P275, DOI 10.1016/S0022-3476(81)80660-9; HARRIS ED, 1966, LANCET, V2, P707, DOI 10.1016/S0140-6736(66)92976-X; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; JACKSON SH, 1973, CLIN CHIM ACTA, V45, P215, DOI 10.1016/0009-8981(73)90429-4; KANG AH, 1973, J CLIN INVEST, V52, P2571, DOI 10.1172/JCI107449; Klipstein-Grobusch K, 1998, EUR J CLIN NUTR, V52, P588, DOI 10.1038/sj.ejcn.1600611; Kriegsman DMW, 1996, J CLIN EPIDEMIOL, V49, P1407, DOI 10.1016/S0895-4356(96)00274-0; Lubec B, 1996, BBA-MOL BASIS DIS, V1315, P159, DOI 10.1016/0925-4439(95)00119-0; McKusick V. A., 1966, HERITABLE DISORDERS, P155; Melton LJ, 2003, J BONE MINER RES, V18, P1139, DOI 10.1359/jbmr.2003.18.6.1139; Miyao MK, 2000, J BONE MINER RES, V15, pS459; MUDD SH, 1985, AM J HUM GENET, V37, P1; Ott A, 1998, AM J EPIDEMIOL, V147, P574; Pfeiffer CM, 2000, J NUTR, V130, P2850, DOI 10.1093/jn/130.11.2850; Pluijm SMF, 2001, J BONE MINER RES, V16, P2142, DOI 10.1359/jbmr.2001.16.11.2142; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; Schnyder G, 2001, NEW ENGL J MED, V345, P1593, DOI 10.1056/NEJMoa011364; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; van der Klift M, 2002, CALCIFIED TISSUE INT, V70, P443, DOI 10.1007/s00223-001-2076-9; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd; Zappacosta B, 2002, CLIN CHEM LAB MED, V40, P1139, DOI 10.1515/CCLM.2002.200; 1993, AM J MED S5A, V95, pS1	34	548	563	0	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2033	2041		10.1056/NEJMoa032546	http://dx.doi.org/10.1056/NEJMoa032546			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141041	Green Published			2022-12-28	WOS:000221354000004
J	Aharinejad, S; Taghavi, S; Klepetko, W; Abraham, D				Aharinejad, S; Taghavi, S; Klepetko, W; Abraham, D			Prediction of lung-transplant rejection by hepatocyte growth factor	LANCET			English	Article							SERUM; PURIFICATION; GANCICLOVIR; PROPHYLAXIS; PREVENTION; EXPRESSION; GLOBULIN; INJURY; GENE	Background Graft rejection is a major complication of lung transplantation. No serological marker of rejection is in common use. Hepatocyte growth factor (HGF) is highly expressed in the lung and produced after acute lung injury; serum concentrations increase in inflammatory lung diseases. We investigated whether HGF could be an accurate marker for prediction of lung-graft rejection. Methods Serum concentrations of HGF were measured by ELISA in 109 patients who had undergone lung transplantation (65 for chronic obstructive pulmonary disease; 23 for cystic fibrosis; 21 for idiopathic lung fibrosis), comparing those who had no subsequent events and those with episodes of infection or rejection, as well as in 12 healthy controls. Findings The mean baseline serum HGF concentration was 645 ng/L (SD 259) in controls and 1358 ng/L (603) in the patients before transplantation. After transplantation the mean concentration in patients with no events was 1147 ng/L (510) compared with 1559 ng/L (323) in patients with infection (p=0.001 vs controls; change from pretransplant value not significant). Patients with rejection had significantly higher concentrations than all other groups (3972 ng/L [1463], p<0.0001). Logistic regression identified HGF as a predictor for lung graft rejection (p=0.012). After steroid treatment, HGF concentrations returned almost to the preoperative values within 3 days. Interpretation HGF might be a marker for graft rejection in lung transplantation. A potential link between viral infection, mainly cytomegalovirus, and HGF, however, remains to be investigated.	Med Univ Vienna, Dept Anat, Cardiovasc Res Lab, A-1090 Vienna, Austria; Med Univ Vienna, Dept Cardiothorac Surg, Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Aharinejad, S (corresponding author), Med Univ Vienna, Dept Anat, Cardiovasc Res Lab, Waehringerstr 13, A-1090 Vienna, Austria.	seyedhossein.aharinejad@meduniwien.ac.at		Abraham, Dietmar/0000-0001-6337-0058				Arcasoy SM, 1999, NEW ENGL J MED, V340, P1081, DOI 10.1056/NEJM199904083401406; BANDO K, 1995, J THORAC CARDIOV SUR, V109, P49, DOI 10.1016/S0022-5223(95)70419-1; Bewig B, 1999, CLIN TRANSPLANT, V13, P432, DOI 10.1034/j.1399-0012.1999.130510.x; Bewig B, 1999, TRANSPLANT INT, V12, P266, DOI 10.1007/s001470050221; COOPER JD, 1986, NEW ENGL J MED, V314, P1140; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; El-Gamel A, 1999, J HEART LUNG TRANSPL, V18, P828, DOI 10.1016/S1053-2498(99)00047-9; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GROSSMAN RF, 1990, NEW ENGL J MED, V322, P727, DOI 10.1056/NEJM199003153221104; HALL SM, 1992, AM J RESP CELL MOL, V7, P49, DOI 10.1165/ajrcmb/7.1.49; Hosenpud JD, 1999, J HEART LUNG TRANSPL, V18, P611, DOI 10.1016/S1053-2498(99)00037-6; KHURSHID A, 1998, AM J RESP CRIT CARE, V157, P811; MAEDA J, 1995, AM J RESP CRIT CARE, V152, P1587, DOI 10.1164/ajrccm.152.5.7582299; Mal H, 1998, CHEST, V113, P645, DOI 10.1378/chest.113.3.645; MATSUMOTO K, 1992, P NATL ACAD SCI USA, V89, P3800, DOI 10.1073/pnas.89.9.3800; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; PATTERSON GA, 1995, CURRENT TOPICS GEN T, V3, P363; Ross DJ, 1999, J HEART LUNG TRANSPL, V18, P627, DOI 10.1016/S1053-2498(99)00007-8; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; Valantine HA, 2001, TRANSPLANTATION, V72, P1647, DOI 10.1097/00007890-200111270-00012; Weill D, 2003, AM J TRANSPLANT, V3, P492, DOI 10.1034/j.1600-6143.2003.00074.x; WILLIAMS TJ, 1995, CURRENT TOPICS GEN T, V3, P501; YANAGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P802, DOI 10.1016/0006-291X(92)91803-X; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; Yoshimura R, 2000, TRANSPLANT P, V32, P2073, DOI 10.1016/S0041-1345(00)01573-6; Yoshimura R, 2002, TRANSPLANT INT, V15, P156, DOI 10.1007/s00147-002-0391-3; Yousem SA, 1996, J HEART LUNG TRANSPL, V15, P1	28	24	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2004	363	9420					1503	1508		10.1016/S0140-6736(04)16148-5	http://dx.doi.org/10.1016/S0140-6736(04)16148-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GK	15135596				2022-12-28	WOS:000221302700008
J	Garnero, EJ				Garnero, EJ			A new paradigm for Earth's core-mantle boundary	SCIENCE			English	Editorial Material							CONSTRAINTS; TOP		Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Garnero, EJ (corresponding author), Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA.	garnero@asu.edu						*AM GEOPH UN, 2003, M AM GEOPH UN 8 12 D; Buffett BA, 2000, SCIENCE, V290, P1338, DOI 10.1126/science.290.5495.1338; LAY T, IN PRESS PHYS EARTH; Masters G., 2000, EARTHS DEEP INTERIOR, V117, P63, DOI DOI 10.1029/GM117P0063; McNamara AK, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001970; Montelli R, 2004, SCIENCE, V303, P338, DOI 10.1126/science.1092485; Moore MM, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002546; Murakami M, 2004, SCIENCE, V304, P855, DOI 10.1126/science.1095932; Ni SD, 2003, PHYS EARTH PLANET IN, V140, P243, DOI 10.1016/j.pepi.2003.07.011; Niu FL, 2001, GEOPHYS RES LETT, V28, P3557, DOI 10.1029/2001GL013270; Olson P, 2003, FL MEC ASTR, V11, P1; Rondenay S, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2003JB002518; Rost S, 2001, SCIENCE, V294, P1911, DOI 10.1126/science.1065617; Tackley PJ, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000167; 2004, S STUD EARTHS DEEP I; 2003, PHYS EARTH PLANET IN, V140, P1	16	65	73	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					834	836		10.1126/science.1097849	http://dx.doi.org/10.1126/science.1097849			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131297				2022-12-28	WOS:000221243000031
J	Serizawa, T; Hamada, K; Akashi, M				Serizawa, T; Hamada, K; Akashi, M			Polymerization within a molecular-scale stereoregular template	NATURE			English	Article							ISOTACTIC POLY(METHYL METHACRYLATE); RADICAL POLYMERIZATION; METHYL-METHACRYLATE; STEREOCOMPLEX; SUBSTRATE; ACID)	Enzymes efficiently synthesize biopolymers by organizing monomer units within regularly structured molecular-scale spaces and exploiting weak non-covalent interactions, such as hydrogen bonds, to control the polymerization(1) process. This 'template' approach is both attractive and challenging for synthetic polymer synthesis, where structurally regulated molecular-scale spaces could in principle provide solid-phase reaction sites for precision polymerization. Previously, free-radical polymerization of methyl methacrylate in solutions containing stereoregular isotactic ( it) or syndiotactic (st) poly( methyl methacrylate) ( PMMA) has been shown to result in template synthesis(2,3) of the opposite PMMA based on stereocomplex formation(4,5) with van der Waals interactions. However, using the structure of a solid to determine the stereochemical structure of a polymer has not been satisfactorily achieved(6). Here we show that macromolecularly porous ultrathin films, fabricated by a single assembly step, can be used for the highly efficient stereoregular template polymerization of methacrylates through stereocomplex formation. This reaction mould accurately transfers its structural properties of stereo-regularity, molecular weight and organization within the template to the new polymer.	Kagoshima Univ, Grad Sch Sci & Engn, Dept Nanostruct & Adv Mat, Kagoshima 8900065, Japan	Kagoshima University	Akashi, M (corresponding author), Osaka Univ, Grad Sch Engn, Dept Mol Chem, 2-1 Yamada Oka, Suita, Osaka 5650871, Japan.	akashi@chem.eng.osaka-u.ac.jp	Serizawa, Takeshi/S-7133-2018	Serizawa, Takeshi/0000-0002-4867-8625				ALBERTS B, 2003, ESSENTIAL CELL BIOL; BUTER R, 1973, J POLYM SCI POL CHEM, V11, P1003, DOI 10.1002/pol.1973.170110507; BUTER R, 1972, J POLYM SCI A1, V10, P1031, DOI 10.1002/pol.1972.150100408; BUTER R, 1973, J POLYM SCI POL CHEM, V11, P1013, DOI 10.1002/pol.1973.170110508; Caruso F, 1998, SCIENCE, V282, P1111, DOI 10.1126/science.282.5391.1111; Decher G., 2003, MULTILAYER THIN FILM, P1; Hamada K, 2001, LANGMUIR, V17, P5513, DOI 10.1021/la0101898; LOHMEYER JHG, 1975, POLYM LETT ED, V13, P725; LOHMEYER JHGM, 1980, J MACROMOL SCI CHEM, VA14, P945, DOI 10.1080/00222338008068122; LOHMEYER JHGM, 1978, POLYMER, V19, P1171, DOI 10.1016/0032-3861(78)90066-6; SCHOMAKER E, 1989, MACROMOLECULES, V22, P3337, DOI 10.1021/ma00198a025; Serizawa T, 2000, LANGMUIR, V16, P7112, DOI 10.1021/la000241k; Serizawa T, 2003, ANGEW CHEM INT EDIT, V42, P1118, DOI 10.1002/anie.200390294; Serizawa T, 2000, J AM CHEM SOC, V122, P1891, DOI 10.1021/ja9913535; SPEVACEK J, 1987, ADV COLLOID INTERFAC, V27, P81, DOI 10.1016/0001-8686(87)85010-8	15	148	149	4	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 6	2004	429	6987					52	55		10.1038/nature02525	http://dx.doi.org/10.1038/nature02525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	818CB	15129276				2022-12-28	WOS:000221222100040
J	Dobson, CM				Dobson, CM			In the footsteps of alchemists	SCIENCE			English	Editorial Material							ALZHEIMERS-DISEASE; PEPTIDE		Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Cambridge	Dobson, CM (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cmd44@cam.ac.uk						Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Dalton R, 2004, NATURE, V427, P5, DOI 10.1038/427005b; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dumoulin M, 2003, NATURE, V424, P783, DOI 10.1038/nature01870; Ghani AC, 2003, P ROY SOC B-BIOL SCI, V270, P689, DOI 10.1098/rspb.2002.2313; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; May BCH, 2003, P NATL ACAD SCI USA, V100, P3416, DOI 10.1073/pnas.2627988100; Merikangas KR, 2003, SCIENCE, V302, P599, DOI 10.1126/science.1091468; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Pepys MB, 2002, NATURE, V417, P254, DOI 10.1038/417254a; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Vassar R, 2002, ADV DRUG DELIVER REV, V54, P1589, DOI 10.1016/S0169-409X(02)00157-6	16	61	63	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	2004	304	5675					1259	+		10.1126/science.1093078	http://dx.doi.org/10.1126/science.1093078			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166354				2022-12-28	WOS:000221669600028
J	Egger, G; Liang, GN; Aparicio, A; Jones, PA				Egger, G; Liang, GN; Aparicio, A; Jones, PA			Epigenetics in human disease and prospects for epigenetic therapy	NATURE			English	Review							H3 LYSINE-9 METHYLATION; HISTONE DEACETYLASE INHIBITION; BINDING PROTEIN MECP2; CANCER-CELL-LINES; DNA METHYLATION; X-CHROMOSOME; SILENCED GENES; AGENT 5-AZA-2'-DEOXYCYTIDINE; HEMATOPOIETIC MALIGNANCIES; COLORECTAL-CANCER	Epigenetic mechanisms, which involve DNA and histone modifications, result in the heritable silencing of genes without a change in their coding sequence. The study of human disease has focused on genetic mechanisms, but disruption of the balance of epigenetic networks can cause several major pathologies, including cancer, syndromes involving chromosomal instabilities, and mental retardation. The development of new diagnostic tools might reveal other diseases that are caused by epigenetic alterations. Great potential lies in the development of 'epigenetic therapies'-several inhibitors of enzymes controlling epigenetic modifications, specifically DNA methyltransferases and histone deacetylases, have shown promising anti-tumorigenic effects for some malignancies.	Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Urol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Egger, G (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, 1441 Eastlake Ave,Room 8302L, Los Angeles, CA 90089 USA.	jones_p@ccnt.hsc.usc.edu	Egger, Gerda/B-7177-2013	Liang, Gangning/0000-0001-8664-922X; Egger, Gerda/0000-0003-2489-155X				Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Ausio J, 2003, CLIN GENET, V64, P83, DOI 10.1034/j.1399-0004.2003.00124.x; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Beaudet AL, 2002, AM J HUM GENET, V70, P1389, DOI 10.1086/340969; Belinsky SA, 2003, CANCER RES, V63, P7089; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CARR BI, 1988, BRIT J CANCER, V57, P395, DOI 10.1038/bjc.1988.89; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; CONSTANTINIDES PG, 1977, NATURE, V267, P364, DOI 10.1038/267364a0; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8; El-Osta A, 2000, GENE EXPRESSION, V9, P63; Esteller M, 2001, CANCER RES, V61, P3225; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; Fang MZ, 2003, CANCER RES, V63, P7563; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Gazzoli I, 2002, CANCER RES, V62, P3925; Gibbons RJ, 2000, AM J MED GENET, V97, P204, DOI 10.1002/1096-8628(200023)97:3<204::AID-AJMG1038>3.0.CO;2-X; GINDER GD, 1984, P NATL ACAD SCI-BIOL, V81, P3954, DOI 10.1073/pnas.81.13.3954; Goldstone AP, 2004, TRENDS ENDOCRIN MET, V15, P12, DOI 10.1016/j.tem.2003.11.003; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; JAHANGEER S, 1982, BIOCHEM BIOPH RES CO, V108, P1434, DOI 10.1016/S0006-291X(82)80067-3; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; JONES A, 1967, ECON BOT, V21, P163, DOI 10.1007/BF02897864; Jones  LK, 2002, BRIT J HAEMATOL, V118, P714, DOI 10.1046/j.1365-2141.2002.03586.x; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kane MF, 1997, CANCER RES, V57, P808; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Klose R, 2003, SCIENCE, V302, P793, DOI 10.1126/science.1091762; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Liang G, 2002, CANCER RES, V62, P961; Lin XH, 2001, CANCER RES, V61, P8611; Lubbert M, 2001, BRIT J HAEMATOL, V114, P349, DOI 10.1046/j.1365-2141.2001.02933.x; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Malagnac F, 2002, EMBO J, V21, P6842, DOI 10.1093/emboj/cdf687; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nguyen CT, 2002, CANCER RES, V62, P6456; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Oostra BA, 2002, CYTOGENET GENOME RES, V99, P257, DOI 10.1159/000071602; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Peterson EJ, 2003, CANCER RES, V63, P6579; Pina IC, 2003, J ORG CHEM, V68, P3866, DOI 10.1021/jo034248t; Plumb JA, 2000, CANCER RES, V60, P6039; Richardson BC, 2002, J NUTR, V132, p2401S, DOI 10.1093/jn/132.8.2401S; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Rougeulle C, 2002, TRENDS GENET, V18, P434, DOI 10.1016/S0168-9525(02)02749-X; Sato N, 2003, CANCER RES, V63, P4158; Saunthararajah Y, 2003, BLOOD, V102, P3865, DOI 10.1182/blood-2003-05-1738; Soejima H, 2004, ONCOGENE, V23, P4380, DOI 10.1038/sj.onc.1207576; Soppe WJJ, 2002, EMBO J, V21, P6549, DOI 10.1093/emboj/cdf657; SORM F, 1964, EXPERIENTIA, V20, P202, DOI 10.1007/BF02135399; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tariq M, 2003, P NATL ACAD SCI USA, V100, P8823, DOI 10.1073/pnas.1432939100; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; WEBER J, 1994, CANCER RES, V54, P1766; WILSON VL, 1983, SCIENCE, V220, P1054; WOLF SF, 1982, NATURE, V295, P667, DOI 10.1038/295667a0; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469; Yang AS, 2003, SCIENCE, V302; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zhou L, 2002, J MOL BIOL, V321, P591, DOI 10.1016/S0022-2836(02)00676-9; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	95	2233	2403	18	800	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					457	463		10.1038/nature02625	http://dx.doi.org/10.1038/nature02625			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	823WN	15164071				2022-12-28	WOS:000221644600048
J	Thompson, IM; Pauler, DK; Goodman, PJ; Tangen, CM; Lucia, MS; Parnes, HL; Minasian, LM; Ford, LG; Lippman, SM; Crawford, ED; Crowley, JJ; Coltman, CA				Thompson, IM; Pauler, DK; Goodman, PJ; Tangen, CM; Lucia, MS; Parnes, HL; Minasian, LM; Ford, LG; Lippman, SM; Crawford, ED; Crowley, JJ; Coltman, CA			Prevalence of prostate cancer among men with a prostate-specific antigen level <= 4.0 ng per milliliter	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACID-PHOSPHATASE; PREVENTION TRIAL; ULTRASOUND; MARKERS; DIAGNOSIS; CARCINOMA; MORTALITY; BIOPSY; SERUM	BACKGROUND: The optimal upper limit of the normal range for prostate-specific antigen (PSA) is unknown. We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less. METHODS: Of 18,882 men enrolled in the prevention trial, 9459 were randomly assigned to receive placebo and had an annual measurement of PSA and a digital rectal examination. Among these 9459 men, 2950 men never had a PSA level of more than 4.0 ng per milliliter or an abnormal digital rectal examination, had a final PSA determination, and underwent a prostate biopsy after being in the study for seven years. RESULTS: Among the 2950 men (age range, 62 to 91 years), prostate cancer was diagnosed in 449 (15.2 percent); 67 of these 449 cancers (14.9 percent) had a Gleason score of 7 or higher. The prevalence of prostate cancer was 6.6 percent among men with a PSA level of up to 0.5 ng per milliliter, 10.1 percent among those with values of 0.6 to 1.0 ng per milliliter, 17.0 percent among those with values of 1.1 to 2.0 ng per milliliter, 23.9 percent among those with values of 2.1 to 3.0 ng per milliliter, and 26.9 percent among those with values of 3.1 to 4.0 ng per milliliter. The prevalence of high-grade cancers increased from 12.5 percent of cancers associated with a PSA level of 0.5 ng per milliliter or less to 25.0 percent of cancers associated with a PSA level of 3.1 to 4.0 ng per milliliter. CONCLUSIONS: Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less -- levels generally thought to be in the normal range.	SW Oncol Grp SWOG 9217, Operat Off, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, Div Urol, San Antonio, TX 78284 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; NCI, Div Canc Prevent, Bethesda, MD 20892 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Canc Res & Biostat, Seattle, WA USA	Southwest Oncology Group; University of Texas System; University of Texas Health San Antonio; Fred Hutchinson Cancer Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center; Cancer Research & Biostatistics	Thompson, IM (corresponding author), SW Oncol Grp SWOG 9217, Operat Off, 14980 Omicron Dr, San Antonio, TX 78245 USA.			Ankerst, Donna/0000-0003-4229-2462	NATIONAL CANCER INSTITUTE [U10CA035178, U10CA045808, U10CA037429] Funding Source: NIH RePORTER; NCI NIH HHS [CA37429, CA35178, CA45808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen PC, 1998, JAMA-J AM MED ASSOC, V280, P975, DOI 10.1001/jama.280.11.975; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; Brawley O W, 1998, Semin Urol Oncol, V16, P187; CATALONA WJ, 1994, J UROLOGY, V152, P2037, DOI 10.1016/S0022-5347(17)32300-5; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1991, NEW ENGL J MED, V325, P1324; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; DeAntoni EP, 1996, UROLOGY, V48, P234, DOI 10.1016/S0090-4295(96)00091-X; FERRO MA, 1987, BRIT J UROL, V60, P69, DOI 10.1111/j.1464-410X.1987.tb09137.x; Gohagan JK, 2000, CONTROL CLIN TRIALS, V21, p251S, DOI 10.1016/S0197-2456(00)00097-0; Krumholtz JS, 2002, UROLOGY, V60, P469, DOI 10.1016/S0090-4295(02)01875-7; KURIYAMA M, 1980, CANCER RES, V40, P4568; KURIYAMA M, 1982, J NATL CANCER I, V68, P99; Labrie F, 1999, PROSTATE, V38, P83, DOI 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B; LEE F, 1985, PROSTATE, V7, P117, DOI 10.1002/pros.2990070202; Levine MA, 1998, J UROLOGY, V159, P471, DOI 10.1016/S0022-5347(01)63951-X; LIEDTKE RJ, 1984, CLIN CHEM, V30, P649; Oliver S, 2000, LANCET, V355, P1788, DOI 10.1016/S0140-6736(00)02269-8; Oliver SE, 2000, LANCET, V356, P1278; Pauler DK, 2002, CONTROL CLIN TRIALS, V23, P675, DOI 10.1016/S0197-2456(02)00231-3; Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054; PONTES JE, 1982, J UROLOGY, V128, P1216, DOI 10.1016/S0022-5347(17)53431-X; Punglia RS, 2003, NEW ENGL J MED, V349, P335, DOI 10.1056/NEJMoa021659; RAGDE H, 1988, UROLOGY, V32, P503, DOI 10.1016/S0090-4295(98)90029-2; RUEBUSH TK, 1979, J UROLOGY, V122, P492, DOI 10.1016/S0022-5347(17)56477-0; SEAMONDS B, 1986, UROLOGY, V28, P472, DOI 10.1016/0090-4295(86)90146-9; Shibata A, 1998, J NATL CANCER I, V90, P1230, DOI 10.1093/jnci/90.16.1230; THOMPSON IM, 1984, J UROLOGY, V132, P690, DOI 10.1016/S0022-5347(17)49828-4; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Thompson IM, 2003, WORLD J UROL, V21, P28, DOI 10.1007/s00345-002-0315-y; WANG MC, 1979, INVEST UROL, V17, P159; YANG N, 1984, CLIN CHEM, V30, P1057	32	1657	1755	0	116	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2239	2246		10.1056/NEJMoa031918	http://dx.doi.org/10.1056/NEJMoa031918			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163773				2022-12-28	WOS:000221641900004
J	Polderman, KH; Girbes, ARJ				Polderman, KH; Girbes, ARJ			Drug intervention trials in sepsis: divergent results	LANCET			English	Review							ACTIVATED PROTEIN-C; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ANTITHROMBIN-III; MONOCLONAL-ANTIBODY; UNITED-STATES; SEPTIC SHOCK; APACHE-II; MULTICENTER; EPIDEMIOLOGY		Vrije Univ Amsterdam Med Ctr, Dept Intens Care, NL-1000 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Polderman, KH (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Intens Care, POB 7057, NL-1000 MB Amsterdam, Netherlands.	k.polderman@tip.nl	Polderman, Kees H/K-3623-2012					Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238; Alberti C, 2002, INTENS CARE MED, V28, P108, DOI 10.1007/s00134-001-1143-z; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Angus DC, 2003, JAMA-J AM MED ASSOC, V290, P256, DOI 10.1001/jama.290.2.256; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Cohen J, 1996, CRIT CARE MED, V24, P1431, DOI 10.1097/00003246-199609000-00002; Eichacker PQ, 2003, CRIT CARE MED, V31, pS94, DOI 10.1097/00003246-200301001-00013; Eisele B, 1998, INTENS CARE MED, V24, P663, DOI 10.1007/s001340050642; FOURRIER F, 1993, CHEST, V104, P882, DOI 10.1378/chest.104.3.882; Garnacho-Montero J, 2003, CRIT CARE MED, V31, P2742, DOI 10.1097/01.CCM.0000098031.24329.10; Girbes ARJ, 2003, J THROMB HAEMOST, V1, P2469, DOI 10.1111/j.1538-7836.2003.00486.x; Manns BJ, 2002, NEW ENGL J MED, V347, P993, DOI 10.1056/NEJMsa020969; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001; Opal S, 2004, CRIT CARE MED, V32, P332, DOI 10.1097/01.CCM.0000108867.87890.6D; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pocock S, 1999, LANCET, V353, P943, DOI 10.1016/S0140-6736(98)00379-1; Polderman KH, 1999, LANCET, V353, P380, DOI 10.1016/S0140-6736(05)74953-9; Polderman KH, 2001, ANAESTHESIA, V56, P47, DOI 10.1046/j.1365-2044.2001.01763.x; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Tarnow-Mordi WO, 2000, LANCET, V356, P185, DOI 10.1016/S0140-6736(00)02478-8; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869; Wheatley K, 2003, CONTROL CLIN TRIALS, V24, P66, DOI 10.1016/S0197-2456(02)00273-8; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	24	76	92	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	2004	363	9422					1721	1723		10.1016/S0140-6736(04)16259-4	http://dx.doi.org/10.1016/S0140-6736(04)16259-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158636				2022-12-28	WOS:000221546300022
J	Tulic, MK; Fiset, PO; Manoukian, JJ; Frenkiel, S; Lavigne, F; Eidelman, DH; Hamid, Q				Tulic, MK; Fiset, PO; Manoukian, JJ; Frenkiel, S; Lavigne, F; Eidelman, DH; Hamid, Q			Role of toll-like receptor 4 in protection by bacterial lipopolysaccharide in the nasal mucosa of atopic children but not adults	LANCET			English	Article							T-CELL PROLIFERATION; AIRWAY HYPERREACTIVITY; IMMUNE-RESPONSES; DOWN-REGULATION; MESSENGER-RNA; CUTTING EDGE; HAY-FEVER; EXPRESSION; ENDOTOXIN; ASTHMA	Background Exposure to bacterial products in early life could protect against development of atopy. We examined the effect of bacterial lipopolysaccharide on allergic inflammation and expression of cytokines and lipopolysaccharide receptor (toll-like receptor 4; TLR4) in nasal mucosa of 15 atopic children and ten atopic adults. Methods Explanted mucosa was cultured with allergen with or without lipopolysaccharide (0.1 mg/L) for 24 h. Immunocytochemistry and in-situ hybridisation were used to phenotype the cells and cytokines. Findings In explants from atopic children, lipopolysaccharide prevented allergen-induced T-helper type 2 (Th2) inflammation and upregulated Th1 cytokine reactivity and expression. These effects were blocked by antibody to interleukin 10. In children but not in adults, lipopolysaccharide caused increases of three times in T-cell reactivity, five times in T-cell proliferation, and four times in expression of interleukin 10 compared with mucosa stimulated with allergen alone. This difference in response was mirrored by lipopolysaccharide-induced increases in TLR4 reactivity in children but not adults. TLR4 receptor was expressed by CD3-positive T cells, and TLR4-positive cells contained interleukin 10. Lipopolysaccharide increased expression of cells positive for both CD3 and TLR4; both TLR4 and interleukin 10; and both CD4 and CD25. Interpretation Lipopolysaccharide inhibits allergic inflammation in nasal mucosa of atopic children by skewing local immune responses from Th2 to Th1 and upregulating production of interleukin 10. These effects are mediated by TLR4. Our results emphasise an important difference between adults and children in their ability to respond to bacterial products. These differences could have a role in normal maturation of the immune system.	McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada; McGill Univ, Ctr Hlth, Dept Otolaryngol, Montreal, PQ, Canada; Univ Montreal, Ctr Hosp, Montreal, PQ, Canada; Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada; Inst ORL Montreal, Montreal, PQ, Canada	McGill University; McGill University; McGill University; Universite de Montreal; Universite de Montreal	Tulic, MK (corresponding author), Telethon Inst Child Hlth Res, Div Cell Biol, 100 Roberts Rd, Perth, WA 6008, Australia.	merit@ichr.uwa.edu.au	Tulic, Meri K/ABB-5138-2020; Tulic, Meri/P-6613-2016	Tulic, Meri K/0000-0002-2661-2369; Tulic, Meri/0000-0002-2661-2369				Annacker O, 2001, J IMMUNOL, V166, P3008, DOI 10.4049/jimmunol.166.5.3008; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Braun-Fahrlander C.H., 1996, EPIDEMIOLOGY, V7, pS47, DOI [10.1097/00001648-199607001-00115, DOI 10.1097/00001648-199607001-00115]; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; COHEN L, 1995, J IMMUNOL, V155, P5337; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Dabbagh K, 2002, J IMMUNOL, V168, P4524, DOI 10.4049/jimmunol.168.9.4524; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fiset PO, 2003, J ALLERGY CLIN IMMUN, V111, P580, DOI 10.1067/mai.2003.179; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; GIAID A, 1993, LANCET, V341, P1550; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; HOMUNG V, 2002, J IMMUNOL, V168, P4531; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; MALEFYT RD, 1991, J EXP MED, V174, P915; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; Rassa JC, 2002, P NATL ACAD SCI USA, V99, P2281, DOI 10.1073/pnas.042355399; Renshaw M, 2002, J IMMUNOL, V169, P4697, DOI 10.4049/jimmunol.169.9.4697; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981, DOI 10.1164/ajrccm/140.4.981; Schwartz DA, 2001, J ENDOTOXIN RES, V7, P389, DOI 10.1179/096805101101532972; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Tulic MK, 2002, J ALLERGY CLIN IMMUN, V110, P771, DOI 10.1067/mai.2002.128857; Tulic MK, 2002, INT ARCH ALLERGY IMM, V129, P119, DOI 10.1159/000065881; Tulic MK, 2001, AM J RESP CELL MOL, V24, P640, DOI 10.1165/ajrcmb.24.5.4265; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; YSSEL H, 1992, J IMMUNOL, V149, P2378	33	73	78	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	2004	363	9422					1689	1697		10.1016/S0140-6736(04)16253-3	http://dx.doi.org/10.1016/S0140-6736(04)16253-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158630				2022-12-28	WOS:000221546300009
J	Camille, N; Coricelli, G; Sallet, J; Pradat-Diehl, P; Duhamel, JR; Sirigu, A				Camille, N; Coricelli, G; Sallet, J; Pradat-Diehl, P; Duhamel, JR; Sirigu, A			The involvement of the orbitofrontal cortex in the experience of regret	SCIENCE			English	Article							DECISION-MAKING; EMOTION; REWARD; CONSEQUENCES; UNCERTAINTY; CHOICE	Facing the consequence of a decision we made can trigger emotions like satisfaction, relief, or regret, which reflect our assessment of what was gained as compared to what would have been gained by making a different decision. These emotions are mediated by a cognitive process known as counterfactual thinking. By manipulating a simple gambling task, we characterized a subject's choices in terms of their anticipated and actual emotional impact. Normal subjects reported emotional responses consistent with counterfactual thinking; they chose to minimize future regret and learned from their emotional experience. Patients with orbitofrontal cortical lesions, however, did not report regret or anticipate negative consequences of their choices. The orbitofrontal cortex has a fundamental role in mediating the experience of regret.	CNRS, Inst Cognit Sci, F-69675 Bron, France; Univ Siena, Dept Econ, I-53100 Siena, Italy; Hop La Pitie Salpetriere, Serv Med Phys & Readaptat, F-75013 Paris, France	Centre National de la Recherche Scientifique (CNRS); University of Siena; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Sirigu, A (corresponding author), CNRS, Inst Cognit Sci, 67 Blvd Pinel, F-69675 Bron, France.	sirigu@isc.cnrs.fr	, sallet/H-9761-2019; Duhamel, Jean-René/M-4723-2017; Sirigu, Angela/L-4683-2017	, sallet/0000-0002-7878-0209; Duhamel, Jean-René/0000-0003-0210-1027; 				Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BELL DE, 1982, OPER RES, V30, P961, DOI 10.1287/opre.30.5.961; Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8; Byrne RMJ, 2002, TRENDS COGN SCI, V6, P426, DOI 10.1016/S1364-6613(02)01974-5; Dolan RJ, 2002, SCIENCE, V298, P1191, DOI 10.1126/science.1076358; Elliott R, 2003, J NEUROSCI, V23, P303; FRIJDA NH, 1989, J PERS SOC PSYCHOL, V57, P212, DOI 10.1037/0022-3514.57.2.212; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; KAHNEMAN D, 1986, PSYCHOL REV, V93, P136, DOI 10.1037/0033-295X.93.2.136; LOOMES G, 1982, ECON J, V92, P805, DOI 10.2307/2232669; Mellers B, 1999, J EXP PSYCHOL GEN, V128, P332, DOI 10.1037/0096-3445.128.3.332; Roese Neal J., 1995, WHAT MIGHT HAVE BEEN; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; Tremblay L, 1999, NATURE, V398, P704, DOI 10.1038/19525; Zeelenberg M, 1996, ORGAN BEHAV HUM DEC, V65, P148, DOI 10.1006/obhd.1996.0013; Zeelenberg M, 2000, COGNITION EMOTION, V14, P521, DOI 10.1080/026999300402781; Zeelenberg M., 2004, PSYCHOL COUNTERFACTU	19	425	441	5	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	2004	304	5674					1167	1170		10.1126/science.1094550	http://dx.doi.org/10.1126/science.1094550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	822FP	15155951				2022-12-28	WOS:000221524500046
J	Stern, L; Iqbal, N; Seshadri, P; Chicano, KL; Daily, DA; McGrory, J; Williams, M; Gracely, EJ; Samaha, FF				Stern, L; Iqbal, N; Seshadri, P; Chicano, KL; Daily, DA; McGrory, J; Williams, M; Gracely, EJ; Samaha, FF			The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: One-year follow-up of a randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-FAT DIET; CHOLESTEROL; NUTRITION; PLASMA	Background: A previous paper reported the 6-month comparison of weight loss and metabolic changes in obese adults randomly assigned to either a low-carbohydrate diet or a conventional weight loss diet. Objective: To review the 1-year outcomes between these diets. Design: Randomized trial. Setting: Philadelphia Veterans Affairs Medical Center. Participants: 132 obese adults with a body mass index of 35 kg/m(2) or greater; 83% had diabetes or the metabolic syndrome. Intervention: Participants received counseling to either restrict carbohydrate intake to <30 g per day (low-carbohydrate diet) or to restrict caloric intake by 500 calories per day with <30% of calories from fat (conventional diet). Measurements: Changes in weight, lipid levels, glycemic control, and insulin sensitivity. Results: By 1 year, mean (+/-SD) weight change for persons on the low-carbohydrate diet was -5.1 +/- 8.7 kg compared with -3.1 +/- 8.4 kg for persons on the conventional diet. Differences between groups were not significant (-1.9 kg [95% CI, -4.9 to 1.0 kg]; P = 0.20). For persons on the low-carbohydrate diet, triglyceride levels decreased more (P = 0.044) and high-density lipoprotein cholesterol levels decreased less (P = 0.025). As seen in the small group of persons with diabetes (n = 54) and after adjustment for covariates, hemoglobin A(1c) levels improved more for persons on the low-carbohydrate diet. These more favorable metabolic responses to a low-carbohydrate diet remained significant after adjustment for weight loss differences. Changes in other lipids or insulin sensitivity did not differ between groups. Limitations: These findings are limited by a high dropout rate (34%) and by suboptimal dietary adherence of the enrolled persons. Conclusion: Participants on a low-carbohydrate diet had more favorable overall outcomes at 1 year than did those on a conventional diet. Weight loss was similar between groups, but effects on atherogenic dyslipidemia and glycemic control were still more favorable with a low-carbohydrate diet after adjustment for differences in weight loss.	Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Drexel University	Samaha, FF (corresponding author), Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, 8th Floor,MC 111C,Univ & Woodland Ave, Philadelphia, PA 19104 USA.	rick.samaha@med.va.gov	Gracely, Ed/B-7188-2014	Gracely, Ed/0000-0002-8344-3223				ATKINS RC, 1998, DR ATKINS NEW DIET R; Bonow RO, 2003, NEW ENGL J MED, V348, P2057, DOI 10.1056/NEJMp030053; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GARG A, 1992, DIABETES, V41, P1278, DOI 10.2337/diabetes.41.10.1278; Golay A, 1996, INT J OBESITY, V20, P1067; Hatahet W, 2003, J NUTR, V133, P689, DOI 10.1093/jn/133.3.689; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; LEWIS SB, 1977, AM J CLIN NUTR, V30, P160, DOI 10.1093/ajcn/30.2.160; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; National Heart Lung and Blood Institute, 1998, NIH PUBL, V98-4083; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Twisk JWR, 2003, APPL LONGITUDINAL DA; 2002, CONSUMER REPORTS, P26	19	567	585	1	77	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					778	785		10.7326/0003-4819-140-10-200405180-00007	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148064				2022-12-28	WOS:000221520900002
J	Geppert, J				Geppert, J			Yes, survive I did...	LANCET			English	Editorial Material												judithgeppert@hotmail.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	2004	363	9421					1632	1632		10.1016/S0140-6736(04)16208-9	http://dx.doi.org/10.1016/S0140-6736(04)16208-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145638				2022-12-28	WOS:000221408800024
J	Paillaud, JL; Harbuzaru, B; Patarin, J; Bats, N				Paillaud, JL; Harbuzaru, B; Patarin, J; Bats, N			Extra-large-pore zeolites with two-dimensional channels formed by 14 and 12 rings	SCIENCE			English	Article							PURE POLYMORPH-C; HIGH-SILICA; SUBSTITUTION; LOCATION; UNITS; GE	Stable zeolites that have larger pore apertures and a three-dimensional pore topology are of interest because they could be used to adsorb larger molecules, particularly for application in oil re. ning. Several large-pore zeolitic materials with channels formed by openings of more than 12 rings are known, but all of them have a one-dimensional channel system that limits their use in catalysis. We report the synthesis and some characterizations of IM-12, a thermally stable germanium-containing zeolite that contains the first two-dimensional channel system with extra-large pores formed by 14- and 12-ring channels.	Univ Haute Alsace, Ecole Natl Super Mulhouse, CNRS, UMR 7016,Lab Mat Mineraux, F-68093 Mulhouse, France; IFP Lyon, Inst Francais Petr, F-69390 Vernaison, France	Centre National de la Recherche Scientifique (CNRS); Universites de Strasbourg Etablissements Associes; Universite de Haute-Alsace (UHA); IFP Energies Nouvelles	Paillaud, JL (corresponding author), Univ Haute Alsace, Ecole Natl Super Mulhouse, CNRS, UMR 7016,Lab Mat Mineraux, 3 Rue Alfred Werner, F-68093 Mulhouse, France.	jl.paillaud@uha.fr	Bats, Nicolas/A-2241-2009	bogdan, harbuzaru/0000-0001-9063-1874				Aubert E, 2002, J PHYS CHEM B, V106, P1110, DOI 10.1021/jp012231d; Blasco T, 2002, J PHYS CHEM B, V106, P2634, DOI 10.1021/jp013302b; Burton A, 2003, CHEM-EUR J, V9, P5737, DOI 10.1002/chem.200305238; CAULLET P, 1991, EUR J SOL STATE INOR, V28, P345; Corma A, 2001, ANGEW CHEM INT EDIT, V40, P2277, DOI 10.1002/1521-3773(20010618)40:12<2277::AID-ANIE2277>3.0.CO;2-O; Corma A, 2002, NATURE, V418, P514, DOI 10.1038/nature00924; Corma A, 2003, ANGEW CHEM INT EDIT, V42, P1156, DOI 10.1002/anie.200390304; Corma A, 2003, NAT MATER, V2, P493, DOI 10.1038/nmat921; Corma A, 2003, CHEM COMMUN, P1050, DOI 10.1039/b212477g; Corma A, 2001, CHEM COMMUN, P1486, DOI 10.1039/b104114m; Flanigen E. M., 1978, U. S. Patent, Patent No. [4, 073,865, 4073865]; Freyhardt CC, 1996, NATURE, V381, P295, DOI 10.1038/381295a0; Guth J.L., 1986, STUDIES SURFACE SCI, V28, P121, DOI [10.1016/S0167-2991, DOI 10.1016/S0167-2991]; O'Keeffe M, 1999, CHEM-EUR J, V5, P2796, DOI 10.1002/(SICI)1521-3765(19991001)5:10<2796::AID-CHEM2796>3.3.CO;2-Y; PATARIN J, 2002, HDB POROUS SOLIDS, V2, P815; Strohmaier KG, 2003, J AM CHEM SOC, V125, P16035, DOI 10.1021/ja0371653; Vidal-Moya JA, 2003, CHEM MATER, V15, P3961, DOI 10.1021/cm034515b; Wang YX, 2003, SOLID STATE SCI, V5, P1421, DOI 10.1016/j.solidstatesciences.2003.09.003; Yoshikawa M, 1998, J PHYS CHEM B, V102, P7139, DOI 10.1021/jp982169t	19	249	261	5	155	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					990	992		10.1126/science.1098242	http://dx.doi.org/10.1126/science.1098242			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15143276				2022-12-28	WOS:000221383300042
J	McLean, RR; Jacques, PF; Selhub, J; Tucker, KL; Samelson, EJ; Broe, KE; Hannan, MT; Cupples, LA; Kiel, DP				McLean, RR; Jacques, PF; Selhub, J; Tucker, KL; Samelson, EJ; Broe, KE; Hannan, MT; Cupples, LA; Kiel, DP			Homocysteine as a predictive factor for hip fracture in older persons	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; METHYLENETETRAHYDROFOLATE-REDUCTASE; RISK FACTOR; OSTEOPOROTIC FRACTURES; PLASMA HOMOCYSTEINE; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; ALZHEIMERS-DISEASE; PERNICIOUS-ANEMIA; UNITED-STATES	BACKGROUND: The increased prevalence of osteoporosis among people with homocystinuria suggests that a high serum homocysteine concentration may weaken bone by interfering with collagen cross-linking, thereby increasing the risk of osteoporotic fracture. We examined the association between the total homocysteine concentration and the risk of hip fracture in men and women enrolled in the Framingham Study. METHODS: We studied 825 men and 1174 women, ranging in age from 59 to 91 years, from whom blood samples had been obtained between 1979 and 1982 to measure plasma total homocysteine. The participants in our study were followed from the time that the sample was obtained through June 1998 for incident hip fracture. Sex-specific, age-adjusted incidence rates of hip fracture were calculated for quartiles of total homocysteine concentrations. Cox proportional-hazards regression was used to calculate hazard ratios for quartiles of homocysteine values. RESULTS: The mean (+/-SD) plasma total homocysteine concentration was 13.4+/-9.1 micromol per liter in men and 12.1+/-5.3 micromol per liter in women. The median duration of follow-up was 12.3 years for men and 15.0 years for women. There were 41 hip fractures among men and 146 among women. The age-adjusted incidence rates per 1000 person-years for hip fracture, from the lowest to the highest quartile for total homocysteine, were 1.96 (95 percent confidence interval, 0.52 to 3.41), 3.24 (0.97 to 5.52), 4.43 (1.80 to 7.07), and 8.14 (4.20 to 12.08) for men and 9.42 (5.72 to 13.12), 7.01 (4.29 to 9.72), 9.58 (6.42 to 12.74), and 16.57 (11.84 to 21.30) for women. Men and women in the highest quartile had a greater risk of hip fracture than those in the lowest quartile - the risk was almost four times as high for men and 1.9 times as high for women. CONCLUSIONS: These findings suggest that the homocysteine concentration, which is easily modifiable by means of dietary intervention, is an important risk factor for hip fracture in older persons.	Hebrew Rehabil Ctr Aged, Res & Training Inst, Boston, MA 02131 USA; Tufts Univ, Jean Mayer Dept Agr Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Boston Univ, Sch Publ Hlth, Dept Biostat, Div Aging, Boston, MA USA	Tufts University; Boston University	McLean, RR (corresponding author), Framingham Study, 73 Mt Wayte Ave, Framingham, MA 01702 USA.	rmclean@mail.hrca.harvard.edu	Tucker, Katherine L/A-4545-2010	Kiel, Douglas/0000-0001-8474-0310; Hannan, Marian/0000-0002-9586-6928; Cupples, L. Adrienne/0000-0003-0273-7965; Tucker, Katherine/0000-0001-7640-662X; Samelson, Elizabeth/0000-0003-1086-1560	NHLBI NIH HHS [N01-HC-25195, HL54776] Funding Source: Medline; NIAMS NIH HHS [R01 AR/AG 41398] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041398] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abrahamsen B, 2003, J BONE MINER RES, V18, P723, DOI 10.1359/jbmr.2003.18.4.723; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BROWNER WS, 1991, LANCET, V338, P1470, DOI 10.1016/0140-6736(91)92782-W; Browner WS, 1996, ARCH INTERN MED, V156, P1521, DOI 10.1001/archinte.156.14.1521; Clarke R, 2001, J CARDIOVASC RISK, V8, P363, DOI 10.1097/00043798-200112000-00005; Clarke R, 2002, INT J EPIDEMIOL, V31, P70, DOI 10.1093/ije/31.1.70; Cooper Cyrus, 1997, American Journal of Medicine, V103, p12S, DOI 10.1016/S0002-9343(97)90022-X; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dhonukshe-Rutten RAM, 2003, J NUTR, V133, P801, DOI 10.1093/jn/133.3.801; EASTELL R, 1992, CLIN SCI, V82, P681, DOI 10.1042/cs0820681; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Food and Drug Administration, 1996, FED REGISTER, V61, P8781; GOERSS JB, 1992, J BONE MINER RES, V7, P573; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; GOYETTE P, 1994, NAT GENET, V7, P551, DOI 10.1038/ng0894-551a; GRIECO AJ, 1977, AM J MED SCI, V273, P120, DOI 10.1097/00000441-197703000-00001; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Jacques PF, 1996, CIRCULATION, V93, P7, DOI 10.1161/01.CIR.93.1.7; JETTE AM, 1988, J CLIN EPIDEMIOL, V41, P719, DOI 10.1016/0895-4356(88)90157-6; Johnson MA, 2003, AM J CLIN NUTR, V77, P211, DOI 10.1093/ajcn/77.1.211; Jorgensen HL, 2002, CALCIFIED TISSUE INT, V71, P386, DOI 10.1007/s00223-001-2126-3; KANG AH, 1973, J CLIN INVEST, V52, P2571, DOI 10.1172/JCI107449; KANNEL WB, 1988, NIH PUBLICATION; KIEL DP, 1990, AM J EPIDEMIOL, V132, P675, DOI 10.1093/oxfordjournals.aje.a115709; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; Lubec B, 1996, BBA-MOL BASIS DIS, V1315, P159, DOI 10.1016/0925-4439(95)00119-0; Masse PG, 2003, BMC MUSCULOSKEL DIS, V4, DOI 10.1186/1471-2474-4-2; MCKUSICK VA, 1966, HERITABLE DISORDERS, P150; McLean RR, 2004, J BONE MINER RES, V19, P410, DOI 10.1359/JBMR.0301261; Miyao M, 2000, CALCIFIED TISSUE INT, V66, P190, DOI 10.1007/s002230010038; MORREELS CL, 1968, RADIOLOGY, V90, P1150, DOI 10.1148/90.6.1150; MUDD SH, 1985, AM J HUM GENET, V37, P1; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; Nurk E, 2001, J NUTR, V131, P1214, DOI 10.1093/jn/131.4.1214; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; UELAND PM, 1993, CLIN CHEM, V39, P1764	41	422	440	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2042	2049		10.1056/NEJMoa032739	http://dx.doi.org/10.1056/NEJMoa032739			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141042				2022-12-28	WOS:000221354000005
J	Walther, P; Pan, JW; Aspelmeyer, M; Ursin, R; Gasparoni, S; Zeilinger, A				Walther, P; Pan, JW; Aspelmeyer, M; Ursin, R; Gasparoni, S; Zeilinger, A			De Broglie wavelength of a non-local four-photon state	NATURE			English	Article							INTERFEROMETER; INTERFERENCE; ENTANGLEMENT; 2-PHOTON; LIMIT; CONVERSION; PAIRS	Superposition is one of the most distinctive features of quantum theory and has been demonstrated in numerous single-particle interference experiments(1-4). Quantum entanglement(5), the coherent superposition of states in multi-particle systems, yields more complex phenomena(6,7). One important type of multi-particle experiment uses path-entangled number states, which exhibit pure higher-order interference and the potential for applications in metrology and imaging(8); these include quantum interferometry and spectroscopy with phase sensitivity at the Heisenberg limit(9-12), or quantum lithography beyond the classical diffraction limit(13). It has been generally understood(14) that in optical implementations of such schemes, lower-order interference effects always decrease the overall performance at higher particle numbers. Such experiments have therefore been limited to two photons(15-18). Here we overcome this limitation, demonstrating a four-photon interferometer based on linear optics. We observe interference fringes with a periodicity of one-quarter of the single-photon wavelength, confirming the presence of a four-particle mode-entangled state. We anticipate that this scheme should be extendable to arbitrary photon numbers, holding promise for realizable applications with entanglement-enhanced performance.	Univ Vienna, Inst Expt Phys, A-1090 Vienna, Austria; Austrian Acad Sci, Inst Quantenopt & Quanteninformat, A-1090 Vienna, Austria	University of Vienna; Austrian Academy of Sciences	Zeilinger, A (corresponding author), Univ Vienna, Inst Expt Phys, Boltzmanngasse 5, A-1090 Vienna, Austria.	zeilinger-office@quantum.at	Ursin, Rupert/E-9548-2012; Pan, Jian-Wei/A-2332-2010; Walther, Philip/D-6346-2018; Zeilinger, Anton/A-1170-2011; Walther, Philip/O-2993-2019; Aspelmeyer, Markus/C-4098-2017	Ursin, Rupert/0000-0002-9403-269X; Pan, Jian-Wei/0000-0002-6100-5142; Walther, Philip/0000-0002-4964-817X; Walther, Philip/0000-0002-4964-817X; Aspelmeyer, Markus/0000-0003-4499-7335				Arndt M, 1999, NATURE, V401, P680, DOI 10.1038/44348; Bollinger JJ, 1996, PHYS REV A, V54, pR4649, DOI 10.1103/PhysRevA.54.R4649; Boto AN, 2000, PHYS REV LETT, V85, P2733, DOI 10.1103/PhysRevLett.85.2733; DESTEUERNAGEL O, 2002, PHYS REV A, V65; Edamatsu K, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.213601; Fonseca EJS, 1999, PHYS REV LETT, V82, P2868, DOI 10.1103/PhysRevLett.82.2868; Gerry CC, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.063814; GREENBERGER DM, 1993, PHYS TODAY, V46, P22, DOI 10.1063/1.881360; HOLLAND MJ, 1993, PHYS REV LETT, V71, P1355, DOI 10.1103/PhysRevLett.71.1355; HONG CK, 1987, PHYS REV LETT, V59, P2044, DOI 10.1103/PhysRevLett.59.2044; Horne M. A., 1985, S F MODERN PHYSICS, P435; JACOBSON J, 1995, PHYS REV LETT, V74, P4835, DOI 10.1103/PhysRevLett.74.4835; Kok P, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.052104; Kok P, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.063407; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; Lamas-Linares A, 2001, NATURE, V412, P887, DOI 10.1038/35091014; LEE H, 2002, P 6 INT C QUANT COMM, P223; MARTON L, 1953, PHYS REV, V90, P490, DOI 10.1103/PhysRev.90.490; OU ZY, 1990, PHYS REV A, V42, P2957, DOI 10.1103/PhysRevA.42.2957; Ou ZY, 1997, PHYS REV A, V55, P2598, DOI 10.1103/PhysRevA.55.2598; OU ZY, 1988, PHYS REV LETT, V61, P50, DOI 10.1103/PhysRevLett.61.50; OU ZY, 1990, PHYS REV A, V41, P566, DOI 10.1103/PhysRevA.41.566; Pan JW, 2003, NATURE, V423, P417, DOI 10.1038/nature01623; RARITY JG, 1990, PHYS REV LETT, V65, P1348, DOI 10.1103/PhysRevLett.65.1348; RAUCH H, 1974, PHYS LETT A, VA 47, P369, DOI 10.1016/0375-9601(74)90132-7; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P844, DOI 10.1007/BF01491987; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P807, DOI 10.1007/BF01491891; Schroedinger E., 1935, NATURWISSENSCHAFTEN, V23, P823, DOI [DOI 10.1007/BF01491914, 10.1007/BF01491914]; SHIH YH, 1988, PHYS REV LETT, V61, P2921, DOI 10.1103/PhysRevLett.61.2921; Simon C, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.257901; Weinfurter H, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.010102; YURKE B, 1986, PHYS REV LETT, V56, P1515, DOI 10.1103/PhysRevLett.56.1515	33	397	404	5	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988					158	161		10.1038/nature02552	http://dx.doi.org/10.1038/nature02552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141205	Green Submitted			2022-12-28	WOS:000221356300034
J	Earnshaw, JJ; Shaw, E; Whyman, MR; Poskitt, KR; Heather, BP				Earnshaw, JJ; Shaw, E; Whyman, MR; Poskitt, KR; Heather, BP			Screening for abdominal aortic aneurysms in men	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY-RATE; TRIAL		Gloucestershire Royal Hosp, Gloucester GL1 3NN, England; Cheltenham Gen Hosp, Cheltenham, Glos, England	Gloucestershire Royal Hospital; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital	Earnshaw, JJ (corresponding author), Gloucestershire Royal Hosp, Gloucester GL1 3NN, England.	Earnshaw@rudford.demon.co.uk						Ashton HA, 2002, LANCET, V360, P1531, DOI 10.1016/S0140-6736(02)11522-4; Ashton HA, 2002, BMJ-BRIT MED J, V325, P1135; Beard JD, 2003, BRIT J SURG, V90, P515, DOI 10.1002/bjs.4140; Best VA, 2003, BRIT J SURG, V90, P1510, DOI 10.1002/bjs.4342; Bown MJ, 2002, BRIT J SURG, V89, P34; Brady AR, 2002, NEW ENGL J MED, V346, P1445; Crow P, 2001, BRIT J SURG, V88, P941, DOI 10.1046/j.0007-1323.2001.01822.x; Gray JAM, 2003, BRIT J SURG, V90, P1165; Greenhalgh RM, 2002, BMJ-BRIT MED J, V325, P1123, DOI 10.1136/bmj.325.7373.1123; Heather BP, 2000, BRIT J SURG, V87, P750, DOI 10.1046/j.1365-2168.2000.01476.x; Hinchliffe RJ, 2003, EUR J VASC ENDOVASC, V25, P191, DOI 10.1053/ejvs.2002.1846; Irvine CD, 2000, EUR J VASC ENDOVASC, V20, P374, DOI 10.1053/ejvs.2000.1187; Jamrozik K, 2000, MED J AUSTRALIA, V173, P345, DOI 10.5694/j.1326-5377.2000.tb125684.x; Lindholt JS, 2002, EUR J VASC ENDOVASC, V23, P55, DOI 10.1053/ejvs.2001.1534; McCarthy RJ, 2003, BRIT J SURG, V90, P821, DOI 10.1002/bjs.4216; Michaels JA, 2003, BRIT J SURG, V90, P827, DOI 10.1002/bjs.4310; Office of Population Census and Surveys, 1995, MORT STAT CAUS ENGL; Prytherch DR, 2001, EUR J VASC ENDOVASC, V21, P477, DOI 10.1053/ejvs.2001.1369; Scott RAP, 2002, BRIT J SURG, V89, P283, DOI 10.1046/j.0007-1323.2001.02014.x; Thompson MM, 2003, BRIT J SURG, V90, P897, DOI 10.1002/bjs.4280; UK National Screening Committee, CRIT APPR VIAB EFF A; Vardulaki KA, 2002, BRIT J SURG, V89, P861, DOI 10.1046/j.1365-2168.2002.02133.x; *VASC SURG SOC GRE, NAT VASC DAT REP 200; Veith Frank J, 2003, Semin Vasc Surg, V16, P171, DOI 10.1016/S0895-7967(03)00003-6; WILSON JMG, 1968, 34 WORLD HLTH AUTH	25	46	47	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	2004	328	7448					1122	1124		10.1136/bmj.328.7448.1122	http://dx.doi.org/10.1136/bmj.328.7448.1122			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130983	Green Published			2022-12-28	WOS:000221281000026
J	Bernier, J; Domenge, C; Ozsahin, M; Matuszewska, K; Lefebvre, JL; Greiner, RH; Giralt, J; Maingon, P; Rolland, F; Bolla, M; Cognetti, F; Bourhis, J; Kirkpatrick, A; van Glabbeke, M				Bernier, J; Domenge, C; Ozsahin, M; Matuszewska, K; Lefebvre, JL; Greiner, RH; Giralt, J; Maingon, P; Rolland, F; Bolla, M; Cognetti, F; Bourhis, J; Kirkpatrick, A; van Glabbeke, M		European Org Res Treatment Canc	Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL-CARCINOMA; WEEKLY CISPLATIN INFUSION; THERAPY-ONCOLOGY-GROUP; ADJUVANT CHEMOTHERAPY; RADIATION-THERAPY; RANDOMIZED-TRIAL; NODE METASTASIS; FINAL REPORT; RADIOTHERAPY; SURGERY	BACKGROUND We compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage III or IV head and neck cancer. METHODS After undergoing surgery with curative intent, 167 patients were randomly assigned to receive radiotherapy alone ( 66 Gy over a period of 6 1/2 weeks) and 167 to receive the same radiotherapy regimen combined with 100 mg of cisplatin per square meter of body-surface area on days 1, 22, and 43 of the radiotherapy regimen. RESULTS After a median follow-up of 60 months, the rate of progression-free survival was significantly higher in the combined-therapy group than in the group given radiotherapy alone (P = 0.04 by the log-rank test; hazard ratio for disease progression, 0.75; 95 percent confidence interval, 0.56 to 0.99), with 5-year Kaplan-Meier estimates of progression-free survival of 47 percent and 36 percent, respectively. The overall survival rate was also significantly higher in the combined-therapy group than in the radiotherapy group (P = 0.02 by the log-rank test; hazard ratio for death, 0.70; 95 percent confidence interval, 0.52 to 0.95), with five-year Kaplan-Meier estimates of overall survival of 53 percent and 40 percent, respectively. The cumulative incidence of local or regional relapses was significantly lower in the combined-therapy group (P = 0.007). The estimated five-year cumulative incidence of local or regional relapses ( considering death from other causes as a competing risk) was 31 percent after radiotherapy and 18 percent after combined therapy. Severe ( grade 3 or higher) adverse effects were more frequent after combined therapy ( 41 percent) than after radiotherapy ( 21 percent, P = 0.001); the types of severe mucosal adverse effects were similar in the two groups, as was the incidence of late adverse effects. CONCLUSIONS Postoperative concurrent administration of high-dose cisplatin with radiotherapy is more efficacious than radiotherapy alone in patients with locally advanced head and neck cancer and does not cause an undue number of late complications.	San Giovanni Hosp, Oncol Inst So Switzerland, Dept Radiooncol, CH-6504 Bellinzona, Switzerland; Inst Gustave Roussy, Dept Radiooncol, Villejuif, France; CHU Vaudois, Dept Radiooncol, CH-1011 Lausanne, Switzerland; Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland; Ctr Oscar Lambret, Dept Ear Nose & Throat, F-59020 Lille, France; Univ Bern, Inselspital, Dept Radiooncol, CH-3010 Bern, Switzerland; Hosp Gen Valle Hebron, Dept Radiooncol, Barcelona, Spain; Ctr GF Leclerc, Dept Radiooncol, Dijon, France; Ctr R Gauducheau, Dept Radiooncol, St Herblain, France; Ctr Hosp Univ A Michallon, Dept Radiooncol, Grenoble, France; Ist Regina Elena, I-00161 Rome, Italy; European Org Res & Treatment Canc Data Ctr, Brussels, Belgium	Institute of Oncology Research (IOR); Regional Hospital of Bellinzona & Valleys, San Giovanni; UNICANCER; Gustave Roussy; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Fahrenheit Universities; Medical University Gdansk; UNICANCER; Centre Oscar Lambret; University of Bern; University Hospital of Bern; Hospital Universitari Vall d'Hebron; UNICANCER; Centre Georges-Francois Leclerc; CHU Grenoble Alpes; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; European Organisation for Research & Treatment of Cancer	Bernier, J (corresponding author), San Giovanni Hosp, Oncol Inst So Switzerland, Dept Radiooncol, CH-6504 Bellinzona, Switzerland.	jacques.bernier@hcuge.ch	Bernier, Jacques/AAE-7248-2020; de Sagredo, Jordi Giralt López/J-1873-2018; Cognetti, Francesco/AAC-2637-2019	Bernier, Jacques/0000-0002-0138-9906; de Sagredo, Jordi Giralt López/0000-0002-1840-5159; Bourhis, Jean/0000-0001-5162-1171; ROLLAND, FREDERIC/0000-0001-6957-0894; Domenge, Christian/0000-0002-9597-4697; Cognetti, Francesco/0000-0001-8498-151X	NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER; NCI NIH HHS [5U10 CA11488-30, 5U10 CA11488-31, 5U10 CA11488-32, 5U10 CA11488-33, 5U10 CA11488-4, 5U10 CA11488-5, 5U10 CA11488-6, 5U10 CA11488-7, 5U10 CA11488-8, 5U10 CA11488-9, 5U10 CA11488-21, 5U10 CA11488-20, 5U10 CA11488-2, 5U10 CA11488-19, 5U10 CA11488-18, 5U10 CA11488-17, 5U10 CA11488-22, 5U10 CA11488-23, 5U10 CA11488-16, 5U10 CA11488-24, 5U10 CA11488-25, 5U10 CA11488-15, 5U10 CA11488-26, 5U10 CA11488-14, 5U10 CA11488-27, 5U10 CA11488-28, 5U10 CA11488-13, 5U10 CA11488-12, 5U10 CA11488-11, 5U10 CA11488-10, 5U10 CA11488-1, 5U10 CA11488, 5U10 CA11488-29, 5U10 CA11488-3] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelstein DJ, 2000, J CLIN ONCOL, V18, P2032, DOI 10.1200/JCO.2000.18.10.2032; ALSARRAF M, 1987, CANCER-AM CANCER SOC, V59, P259, DOI 10.1002/1097-0142(19870115)59:2<259::AID-CNCR2820590214>3.0.CO;2-1; Bachaud JM, 1996, INT J RADIAT ONCOL, V36, P999, DOI 10.1016/S0360-3016(96)00430-0; BACHAUD JM, 1991, INT J RADIAT ONCOL, V20, P243, DOI 10.1016/0360-3016(91)90098-O; BARKLEY HT, 1972, AM J SURG, V124, P462, DOI 10.1016/0002-9610(72)90067-0; BERNIER J, 2002, ANN ONCOL, V13, P9; Brizel DM, 1998, NEW ENGL J MED, V338, P1798, DOI 10.1056/NEJM199806183382503; CACHIN Y, 1975, CANCER TREAT REV, V2, P177, DOI 10.1016/S0305-7372(75)80002-8; Calais G, 1999, J NATL CANCER I, V91, P2081, DOI 10.1093/jnci/91.24.2081; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; FLETCHER GH, 1970, RADIOLOGY, V95, P185, DOI 10.1148/95.1.185; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; HAFFTY BG, 1993, INT J RADIAT ONCOL, V27, P241, DOI 10.1016/0360-3016(93)90234-M; HUANG AT, 1984, ANN SURG, V200, P195, DOI 10.1097/00000658-198408000-00013; JACOBS C, 1990, J CLIN ONCOL, V8, P838, DOI 10.1200/JCO.1990.8.5.838; JACOBS JR, 1989, AM J CLIN ONCOL-CANC, V12, P185, DOI 10.1097/00000421-198906000-00001; Jassem J, 1995, CANCER TREAT REV, V21, P447, DOI 10.1016/0305-7372(95)90029-2; JOHNSON JT, 1987, J CLIN ONCOL, V5, P456, DOI 10.1200/JCO.1987.5.3.456; JOHNSON JT, 1981, ARCH OTOLARYNGOL, V107, P725; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRAMER S, 1987, HEAD NECK SURG, V10, P19, DOI 10.1002/hed.2890100105; LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705, DOI 10.1016/0360-3016(92)90642-U; Merlano M, 1996, J NATL CANCER I, V88, P583, DOI 10.1093/jnci/88.9.583; PETERS LJ, 1993, INT J RADIAT ONCOL, V26, P3, DOI 10.1016/0360-3016(93)90167-T; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; ROBBINS KT, 1991, ARCH OTOLARYNGOL, V117, P601; ROSSI A, 1988, J CLIN ONCOL, V6, P1401, DOI 10.1200/JCO.1988.6.9.1401; SNOW GB, 1982, CLIN OTOLARYNGOL, V7, P185, DOI 10.1111/j.1365-2273.1982.tb01581.x; Spiessl B, 1989, TNM ATLAS ILLUSTRATE; STELL PM, 1990, BRIT J CANCER, V61, P779, DOI 10.1038/bjc.1990.175; Szpirglas H, 1978, Recent Results Cancer Res, V68, P309; TUPCHONG L, 1991, INT J RADIAT ONCOL, V20, P21, DOI 10.1016/0360-3016(91)90133-O; VIKRAM B, 1984, HEAD NECK SURG, V6, P720, DOI 10.1002/hed.2890060303; Wendt TG, 1998, J CLIN ONCOL, V16, P1318, DOI 10.1200/JCO.1998.16.4.1318	34	2078	2123	1	49	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1945	1952		10.1056/NEJMoa032641	http://dx.doi.org/10.1056/NEJMoa032641			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128894				2022-12-28	WOS:000221218800006
J	Girardi, M; Heald, PW; Wilson, LD				Girardi, M; Heald, PW; Wilson, LD			Medical progress - The pathogenesis of mycosis fungoides	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							T-CELL LYMPHOMA; POLYMERASE-CHAIN-REACTION; SEZARY-SYNDROME PATIENTS; TREATMENT-OF-CANCER; LONG-TERM SURVIVAL; CUTANEOUS-LYMPHOMAS; PERIPHERAL-BLOOD; DENDRITIC CELLS; EXTRACORPOREAL PHOTOCHEMOTHERAPY; HISTOLOGIC CRITERIA		Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA	Yale University; Yale University	Wilson, LD (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, HRT 136,333 Cedar St, New Haven, CT 06520 USA.	lynn.wilson@yale.edu		Girardi, Michael/0000-0003-1887-9343				BAGOT M, 1992, J AM ACAD DERMATOL, V27, P589, DOI 10.1016/0190-9622(92)70227-7; Bagot M, 2001, ANN NY ACAD SCI, V941, P31; BENHATTAR J, 1995, DIAGN MOL PATHOL, V4, P108, DOI 10.1097/00019606-199506000-00006; Berger CL, 2001, ANN NY ACAD SCI, V941, P106; BERGER CL, 1979, BLOOD, V53, P642; Berger CL, 2001, INT J CANCER, V91, P438, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1073>3.0.CO;2-R; Berger CL, 2002, BLOOD, V99, P2929, DOI 10.1182/blood.V99.8.2929.h8002929_2929_2939; Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056; BUNN PA, 1979, CANCER TREAT REP, V63, P725; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Cheng SX, 2001, ARCH DERMATOL, V137, P649; Demierre MF, 2003, HEMATOL ONCOL CLIN N, V17, P1485, DOI 10.1016/S0889-8588(03)00111-4; Dereure O, 2002, J INVEST DERMATOL, V118, P949, DOI 10.1046/j.1523-1747.2002.01794.x; Diamandidou E, 1998, BLOOD, V92, P1150, DOI 10.1182/blood.V92.4.1150.416k04_1150_1159; Dietz SB, 1996, J CUTAN PATHOL, V23, P312, DOI 10.1111/j.1600-0560.1996.tb01303.x; Duvic M, 2001, J CLIN ONCOL, V19, P2456, DOI 10.1200/JCO.2001.19.9.2456; Duvic M, 2003, J AM ACAD DERMATOL, V49, P35, DOI 10.1067/mjd.2003.449; Duvic M, 2001, ARCH DERMATOL, V137, P581; EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603; EKKENK MW, 2003, BLOOD, V102, P2213; Eriksen KW, 2001, LEUKEMIA, V15, P787, DOI 10.1038/sj.leu.2402093; Ferenczi K, 2003, ARCH DERMATOL, V139, P909, DOI 10.1001/archderm.139.7.909; Ferenczi K, 2002, J INVEST DERMATOL, V119, P1405, DOI 10.1046/j.1523-1747.2002.19610.x; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Fraser-Andrews EA, 2001, CANCER, V92, P1745, DOI 10.1002/1097-0142(20011001)92:7<1745::AID-CNCR1689>3.0.CO;2-0; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; Gellrich S, 2000, J INVEST DERMATOL, V115, P620, DOI 10.1046/j.1523-1747.2000.00980.x; Girardi M, 2002, TECHNOL CANCER RES T, V1, P65, DOI 10.1177/153303460200100109; Glusac EJ, 1999, DERMATOL CLIN, V17, P601, DOI 10.1016/S0733-8635(05)70110-8; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; HEALD P, 1994, ARCH DERMATOL, V130, P198, DOI 10.1001/archderm.130.2.198; HEALD P, 1992, J AM ACAD DERMATOL, V27, P427, DOI 10.1016/0190-9622(92)70212-X; Heald P, 2001, ANN NY ACAD SCI, V941, P155; HEALD PW, 1993, J INVEST DERMATOL, V101, P222, DOI 10.1111/1523-1747.ep12364814; Herne KL, 2003, BLOOD, V101, P2132, DOI 10.1182/blood-2002-07-2247; HOPPE RT, 1995, J AM ACAD DERMATOL, V32, P448, DOI 10.1016/0190-9622(95)90067-5; Hwang S T, 2001, Adv Dermatol, V17, P211; Hwang ST, 2001, J INVEST DERMATOL, V116, P466, DOI 10.1046/j.1523-1747.2001.01282.x; Jones D, 2001, AM J CLIN PATHOL, V115, P885; Jones GW, 2002, J AM ACAD DERMATOL, V47, P364, DOI 10.1067/mjd.2002.123482; JONES GW, 1995, HEMATOL ONCOL CLIN N, V9, P1057, DOI 10.1016/S0889-8588(18)30058-3; Kakinuma T, 2003, J AM ACAD DERMATOL, V48, P23, DOI 10.1067/mjd.2003.132; Kallinich T, 2003, J INVEST DERMATOL, V121, P1045, DOI 10.1046/j.1523-1747.2003.12555.x; KANTOR AF, 1989, CANCER, V63, P1612, DOI 10.1002/1097-0142(19890415)63:8<1612::AID-CNCR2820630828>3.0.CO;2-C; Kari L, 2003, J EXP MED, V197, P1477, DOI 10.1084/jem.20021726; Kieffer JD, 2001, BIOCHEM BIOPH RES CO, V285, P577, DOI 10.1006/bbrc.2001.5230; Kim YH, 2003, ARCH DERMATOL, V139, P857, DOI 10.1001/archderm.139.7.857; Latkowski JA, 2003, FITZPATRICKS DERMATO, V2, P1537; Liu V, 2002, ADV ANAT PATHOL, V9, P79, DOI 10.1097/00125480-200203000-00001; Lu D, 2003, J CUTAN PATHOL, V30, P222; Lu D, 2002, J CUTAN PATHOL, V29, P465, DOI 10.1034/j.1600-0560.2002.290804.x; Lu D, 2001, AM J CLIN PATHOL, V115, P413; Mao X, 2002, BRIT J DERMATOL, V147, P464, DOI 10.1046/j.1365-2133.2002.04966.x; NAGATANI T, 1990, CANCER-AM CANCER SOC, V66, P2380, DOI 10.1002/1097-0142(19901201)66:11<2380::AID-CNCR2820661122>3.0.CO;2-H; Neish Carol, 1994, Journal of Dermatological Science, V8, P11, DOI 10.1016/0923-1811(94)90315-8; Ni X, 2001, CLIN CANCER RES, V7, P2682; Nielsen M, 2002, BLOOD, V99, P973, DOI 10.1182/blood.V99.3.973; Olsen E, 2001, J CLIN ONCOL, V19, P376, DOI 10.1200/JCO.2001.19.2.376; OLSEN EA, 1995, HEMATOL ONCOL CLIN N, V9, P1089, DOI 10.1016/S0889-8588(18)30060-1; Papadavid E, 2003, BRIT J DERMATOL, V148, P709, DOI 10.1046/j.1365-2133.2003.05224.x; PICKER LJ, 1990, AM J PATHOL, V136, P1053; Quiros PA, 1996, CANCER, V77, P1912; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; Robert C, 1999, NEW ENGL J MED, V341, P1817, DOI 10.1056/NEJM199912093412407; SAED G, 1994, J INVEST DERMATOL, V103, P29, DOI 10.1111/1523-1747.ep12388985; Sander CA, 2001, CLIN LYMPHOMA, V2, P86, DOI 10.3816/CLM.2001.n.014; Santucci M, 2003, CANCER, V97, P610, DOI 10.1002/cncr.11107; SANTUCCI M, 1994, DERMATOL CLIN, V12, P323, DOI 10.1016/S0733-8635(18)30180-3; Sanz MA, 1998, NEW ENGL J MED, V338, P393; Scala E, 2002, J INVEST DERMATOL, V119, P193, DOI 10.1046/j.1523-1747.2002.18194.x; Scarisbrick JJ, 2003, J INVEST DERMATOL, V121, P894, DOI 10.1046/j.1523-1747.2003.12496.x; Schechner JS, 1999, LAB INVEST, V79, P601; Smith Benjamin D, 2003, Oncology (Williston Park), V17, P1419; Suarez-Varela MMM, 2000, DERMATOLOGY, V201, P21, DOI 10.1159/000018423; Suchin KR, 2002, ARCH DERMATOL, V138, P1054, DOI 10.1001/archderm.138.8.1054; Toro JR, 2003, BLOOD, V101, P3407, DOI 10.1182/blood-2002-05-1597; Usener D, 2003, J INVEST DERMATOL, V121, P198, DOI 10.1046/j.1523-1747.2003.12318.x; van Doorn R, 2002, CANCER RES, V62, P5389; Vega F, 2002, BLOOD, V100, P3369, DOI 10.1182/blood.V100.9.3369; Vonderheid EC, 2002, J AM ACAD DERMATOL, V46, P95, DOI 10.1067/mjd.2002.118538; Vonderheid EC, 1998, J AM ACAD DERMATOL, V38, P207, DOI 10.1016/S0190-9622(98)70597-3; VOWELS BR, 1992, J INVEST DERMATOL, V99, P90, DOI 10.1111/1523-1747.ep12611877; WEINSTOCK MA, 1988, JAMA-J AM MED ASSOC, V260, P42, DOI 10.1001/jama.260.1.42; Weinstock MA, 1999, AM J PUBLIC HEALTH, V89, P1240, DOI 10.2105/AJPH.89.8.1240; Whittaker S, 2001, ANN NY ACAD SCI, V941, P39; Willemze R, 1997, BLOOD, V90, P354; Winter D, 2003, J IMMUNOL, V171, P2714, DOI 10.4049/jimmunol.171.5.2714; WOOD GS, 1994, J INVEST DERMATOL, V103, P34, DOI 10.1111/1523-1747.ep12389114; Yawalkar N, 2003, BLOOD, V102, P4059, DOI 10.1182/blood-2003-04-1044; Yazdi AS, 2003, J CUTAN PATHOL, V30, P486, DOI 10.1034/j.1600-0560.2003.00099.x; Zackheim HS, 1999, J AM ACAD DERMATOL, V40, P418, DOI 10.1016/S0190-9622(99)70491-3; Zhang CL, 2002, CLIN CANCER RES, V8, P1234	92	264	278	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2004	350	19					1978	1988		10.1056/NEJMra032810	http://dx.doi.org/10.1056/NEJMra032810			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818AU	15128898				2022-12-28	WOS:000221218800010
J	Rubie, DC; Gessmann, CK; Frost, DJ				Rubie, DC; Gessmann, CK; Frost, DJ			Partitioning of oxygen during core formation on the Earth and Mars	NATURE			English	Article							SNC METEORITES; HIGH-PRESSURE; TEMPERATURE; MANTLE; SILICATE; GPA; CONSTRAINTS; FUGACITY; ELEMENTS; NICKEL	Core formation on the Earth and Mars involved the physical separation of metal and silicate, most probably in deep magma oceans(1-4). Although core-formation models explain many aspects of mantle geochemistry, they have not accounted for the large differences observed between the compositions of the mantles of the Earth (similar to8 wt% FeO) and Mars (similar to18 wt% FeO) or the smaller mass fraction of the martian core(5-7). Here we explain these differences as a consequence of the solubility of oxygen in liquid iron-alloy increasing with increasing temperature. We assume that the Earth and Mars both accreted from oxidized chondritic material. In a terrestrial magma ocean, 1,200 - 2,000 km deep, high temperatures resulted in the extraction of FeO from the silicate magma ocean owing to high solubility of oxygen in the metal. Lower temperatures of a martian magma ocean resulted in little or no extraction of FeO from the mantle, which thus remains FeO-rich. The FeO extracted from the Earth's magma ocean may have contributed to chemical heterogeneities in the lowermost mantle(8), a FeO-rich D" layer(9) and the light element budget of the core(10,11).	Univ Bayreuth, Bayer Geoinst, D-95444 Bayreuth, Germany	University of Bayreuth	Rubie, DC (corresponding author), Univ Bayreuth, Bayer Geoinst, D-95444 Bayreuth, Germany.	dave.rubie@uni-bayreuth.de	Frost, Daniel J/B-7526-2016	Frost, Daniel J/0000-0002-4443-8149				ANDERSON DL, 1989, THEORY EARTH; Bouhifd MA, 2003, EARTH PLANET SC LETT, V209, P245, DOI 10.1016/S0012-821X(03)00076-1; Chabot NL, 2003, GEOCHIM COSMOCHIM AC, V67, P2077, DOI [10.1016/S0016-7037(02)01272-3, 10.1016/S0016-7037(02)012723]; CHASE MW, 1985, J PHYS CHEM REF DATA, V14, P1; DREIBUS G, 1985, METEORITICS, V20, P367; FEI YW, 1994, SCIENCE, V266, P1678, DOI 10.1126/science.266.5191.1678; Garnero EJ, 1998, GEODYNAMICS-US, V28, P319; Gessmann CK, 2000, EARTH PLANET SC LETT, V184, P95, DOI 10.1016/S0012-821X(00)00323-X; Gessmann CK, 1998, GEOCHIM COSMOCHIM AC, V62, P867, DOI 10.1016/S0016-7037(98)00023-4; Herzberg C, 1996, J GEOPHYS RES-SOL EA, V101, P8271, DOI 10.1029/96JB00170; Hillgren V.J., 2000, ORIGIN EARTH MOON PP, P245, DOI DOI 10.2307/J.CTV1V7ZDRP.20; KATO T, 1989, PHYS CHEM MINER, V16, P524, DOI 10.1007/BF00202207; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; Li J, 1996, NATURE, V381, P686, DOI 10.1038/381686a0; Li J, 2001, GEOPHYS RES LETT, V28, P81, DOI 10.1029/2000GL012114; Li J, 2001, GEOCHIM COSMOCHIM AC, V65, P1821, DOI 10.1016/S0016-7037(00)00613-X; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; Melosh H.J., 1990, ORIGIN EARTH, P69; O'Neill H.S.C., 1998, EARTHS MANTLE COMPOS, P3; O'Neill HS, 1998, J GEOPHYS RES-SOL EA, V103, P12239, DOI 10.1029/97JB02601; OHTANI E, 1983, PHYS EARTH PLANET IN, V33, P12, DOI 10.1016/0031-9201(83)90003-1; POIRIER JP, 1994, PHYS EARTH PLANET IN, V85, P319, DOI 10.1016/0031-9201(94)90120-1; Righter K, 1998, GEOCHIM COSMOCHIM AC, V62, P2167, DOI 10.1016/S0016-7037(98)00132-X; Righter K, 1997, PHYS EARTH PLANET IN, V100, P115, DOI 10.1016/S0031-9201(96)03235-9; Rubie DC, 2003, EARTH PLANET SC LETT, V205, P239, DOI 10.1016/S0012-821X(02)01044-0; Stevenson DJ., 1990, ORIGIN EARTH, P231; Sundman B., 1991, J PHASE EQUILIBRIA, V12, P127, DOI [10.1007/BF02645709, DOI 10.1007/BF02645709]; Tronnes RG, 2000, LITHOS, V53, P233, DOI 10.1016/S0024-4937(00)00027-X; Tronnes RG, 2002, EARTH PLANET SC LETT, V197, P117, DOI 10.1016/S0012-821X(02)00466-1	30	126	130	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	2004	429	6987					58	61		10.1038/nature02473	http://dx.doi.org/10.1038/nature02473			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818CB	15129278				2022-12-28	WOS:000221222100042
J	Yu, L; Alva, A; Su, H; Dutt, P; Freundt, E; Welsh, S; Baehrecke, EH; Lenardo, MJ				Yu, L; Alva, A; Su, H; Dutt, P; Freundt, E; Welsh, S; Baehrecke, EH; Lenardo, MJ			Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8	SCIENCE			English	Article							DOMAIN KINASE RIP; INDUCED APOPTOSIS; NECROSIS; PROTEIN; MECHANISMS; BECLIN-1; TUMORIGENESIS; DEGRADATION; APG7P/CVT2P; INHIBITION	Caspases play a central role in apoptosis, a well-studied pathway of programmed cell death. Other programs of death potentially involving necrosis and autophagy may exist, but their relation to apoptosis and mechanisms of regulation remains unclear. We de. ne a new molecular pathway in which activation of the receptor-interacting protein (a serine-threonine kinase) and Jun amino-terminal kinase induced cell death with the morphology of autophagy. Autophagic death required the genes ATG7 and beclin 1 and was induced by caspase-8 inhibition. Clinical therapies involving caspase inhibitors may arrest apoptosis but also have the unanticipated effect of promoting autophagic cell death.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; Univ Maryland, Inst Biotechnol, Ctr Biosyst Res, College Pk, MD 20742 USA; Univ Oxford, Weatherall Inst Mol Med, Oxford OX39D, England	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University System of Maryland; University of Maryland Baltimore; University of Maryland College Park; University of Oxford	Lenardo, MJ (corresponding author), NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA.	lenardo@nih.gov	Su, Helen C/H-9541-2015	Su, Helen C/0000-0002-5582-9110	NIGMS NIH HHS [GM59136] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM059136, R01GM059136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Gorski SM, 2003, CURR BIOL, V13, P358, DOI 10.1016/S0960-9822(03)00082-4; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Nicholson DW, 2003, SCIENCE, V299, P214, DOI 10.1126/science.1081274; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Yu Lili, UNPUB; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	28	1047	1103	1	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1500	1502		10.1126/science.1096645	http://dx.doi.org/10.1126/science.1096645			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15131264				2022-12-28	WOS:000221795800044
J	Xie, HF; Ye, M; Feng, R; Graf, T				Xie, HF; Ye, M; Feng, R; Graf, T			Stepwise reprogramming of B cells into macrophages	CELL			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; BINDING PROTEIN ALPHA; LINEAGE COMMITMENT; C/EBP-BETA; TRANSCRIPTION FACTORS; DEFICIENT MICE; SINGLE CELLS; PROGENITORS; EXPRESSION	Starting with multipotent progenitors, hematopoietic lineages are specified by lineage-restricted transcription factors. The transcription factors that determine the decision between lymphoid and myeloid cell fates, and the underlying mechanisms, remain largely unknown. Here, we report that enforced expression of C/EBPalpha. and C/EBPbeta in differentiated B cells leads to their rapid and efficient reprogramming into macrophages. C/EBPs induce these changes by inhibiting the B cell commitment transcription factor Pax5, leading to the downregulation of its target CD19, and synergizing with endogenous PU.1, an ETS family factor, leading to the upregulation of its target Mac-1 and other myeloid markers. The two processes can be uncoupled, since, in PU.1-deficient pre-B cells, C/EBPs induce CD19 downregulation but not Mac-1 activation. Our observations indicate that C/EBPalpha and beta remodel the transcription network of B cells into that of macrophages through a series of parallel and sequential changes that require endogenous PU.1.	Albert Einstein Coll Med, Ctr Canc Res, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Graf, T (corresponding author), Albert Einstein Coll Med, Ctr Canc Res, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	graf@aecom.yu.edu	Graf, Thomas/B-4252-2015; Wilson, Matthew H/K-3193-2013	Graf, Thomas/0000-0003-2774-4117; 	NATIONAL CANCER INSTITUTE [R01CA089590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043881] Funding Source: NIH RePORTER; NCI NIH HHS [T01 CA89590-01] Funding Source: Medline; NINDS NIH HHS [R01 NS43881-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Akashi K, 2000, CURR OPIN IMMUNOL, V12, P144, DOI 10.1016/S0952-7915(99)00064-3; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Chen XN, 1997, BLOOD, V90, P156; Chevillard C, 2002, J IMMUNOL, V168, P5659, DOI 10.4049/jimmunol.168.11.5659; COOPER CL, 1994, J IMMUNOL, V153, P5049; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; EHLICH A, 1994, CURR BIOL, V4, P573, DOI 10.1016/S0960-9822(00)00129-9; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; Hardy RR, 2003, CURR OPIN IMMUNOL, V15, P158, DOI 10.1016/S0952-7915(03)00012-8; Heavey B, 2003, EMBO J, V22, P3887, DOI 10.1093/emboj/cdg380; Heyworth C, 2002, EMBO J, V21, P3770, DOI 10.1093/emboj/cdf368; Hume DA, 2002, J LEUKOCYTE BIOL, V72, P621; Iwasaki H, 2003, IMMUNITY, V19, P451, DOI 10.1016/S1074-7613(03)00242-5; Iwasaki-Arai J, 2003, J EXP MED, V197, P1311, DOI 10.1084/jem.20021843; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Katsura Y, 2002, NAT REV IMMUNOL, V2, P127, DOI 10.1038/nri721; Kee BL, 2001, CURR OPIN IMMUNOL, V13, P180, DOI 10.1016/S0952-7915(00)00202-8; King AG, 2002, P NATL ACAD SCI USA, V99, P4508, DOI 10.1073/pnas.072087899; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Kuppers R, 2002, ANN ONCOL, V13, P11, DOI 10.1093/annonc/13.S1.11; Mikkola I, 2002, SCIENCE, V297, P110, DOI 10.1126/science.1067518; MIRRO J, 1986, BLOOD, V68, P597; Nerlov C, 1998, GENE DEV, V12, P2413, DOI 10.1101/gad.12.15.2413; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; TENBOEKEL E, 1995, INT IMMUNOL, V7, P1013; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Warren LA, 2003, CURR OPIN IMMUNOL, V15, P166, DOI 10.1016/S0952-7915(03)00011-6; Ye M, 2003, IMMUNITY, V19, P689, DOI 10.1016/S1074-7613(03)00299-1; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	46	701	746	0	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2004	117	5					663	676		10.1016/S0092-8674(04)00419-2	http://dx.doi.org/10.1016/S0092-8674(04)00419-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	826VP	15163413	Bronze			2022-12-28	WOS:000221857900012
J	Saikawa, Y; Hashimoto, K; Nakata, M; Yoshihara, M; Nagai, K; Ida, M; Komiya, T				Saikawa, Y; Hashimoto, K; Nakata, M; Yoshihara, M; Nagai, K; Ida, M; Komiya, T			Pigment chemistry: The red sweat of the hippopotamus	NATURE			English	Editorial Material									Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan	Keio University	Saikawa, Y (corresponding author), Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan.	kimikoh@mb.kyoto-phu.ac.jp	Nakata, Masaya/C-4916-2014					Eltringham S. K, 1999, HIPPAS, P8	1	57	58	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	2004	429	6990					363	363		10.1038/429363a	http://dx.doi.org/10.1038/429363a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	823WN	15164051	Bronze			2022-12-28	WOS:000221644600027
J	Taylor-Robinson, A				Taylor-Robinson, A			In-vitro model offers insight into the pathophysiology of severe malaria	LANCET			English	Editorial Material							RED-BLOOD-CELL; PLASMODIUM-FALCIPARUM; FLOW		Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Taylor-Robinson, A (corresponding author), Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England.	a.w.taylor-robinson@leeds.ac.uk	Taylor-Robinson, Andrew/R-2805-2019	Taylor-Robinson, Andrew/0000-0001-7342-8348				Clark IA, 2003, PHARMACOL THERAPEUT, V99, P221, DOI 10.1016/S0163-7258(03)00060-3; Cooke BM, 2001, ADV PARASIT, V50, P1, DOI 10.1016/S0065-308X(01)50029-9; Cooke Brian M, 2002, Methods Mol Med, V72, P561, DOI 10.1385/1-59259-271-6:561; Dondorp AM, 2000, PARASITOL TODAY, V16, P228, DOI 10.1016/S0169-4758(00)01666-5; Gifford SC, 2003, BIOPHYS J, V84, P623, DOI 10.1016/S0006-3495(03)74882-6; Grau GE, 2003, J INFECT DIS, V187, P461, DOI 10.1086/367960; Shelby JP, 2003, P NATL ACAD SCI USA, V100, P14618, DOI 10.1073/pnas.2433968100; Shelby JP, 2003, ANAL CHEM, V75, P1387, DOI 10.1021/ac026275+; Sherman IW, 2003, MICROBES INFECT, V5, P897, DOI 10.1016/S1286-4579(03)00162-X; Trager W, 1997, INT J PARASITOL, V27, P989, DOI 10.1016/S0020-7519(97)00080-5	10	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	2004	363	9422					1661	1663		10.1016/S0140-6736(04)16286-7	http://dx.doi.org/10.1016/S0140-6736(04)16286-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158624				2022-12-28	WOS:000221546300003
J	Ma, JB; Ye, KQ; Patel, DJ				Ma, JB; Ye, KQ; Patel, DJ			Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain	NATURE			English	Article							HUMAN-CELLS; SIRNAS; INITIATION; SYSTEM	Short RNAs mediate gene silencing, a process associated with virus resistance, developmental control and heterochromatin formation in eukaryotes(1-5). RNA silencing is initiated through Dicer-mediated processing of double-stranded RNA into small interfering RNA (siRNA)(6,7). The siRNA guide strand associates with the Argonaute protein in silencing effector complexes, recognizes complementary sequences and targets them for silencing(8-11). The PAZ domain is an RNA-binding module found in Argonaute and some Dicer proteins and its structure has been determined in the free state(12-14). Here, we report the 2.6 Angstrom crystal structure of the PAZ domain from human Argonaute eIF2c1 bound to both ends of a 9-mer siRNA-like duplex. In a sequence-independent manner, PAZ anchors the 2-nucleotide 3' overhang of the siRNA-like duplex within a highly conserved binding pocket, and secures the duplex by binding the 7-nucleotide phosphodiester backbone of the overhang-containing strand and capping the 5'-terminal residue of the complementary strand. On the basis of the structure and on binding assays, we propose that PAZ might serve as an siRNA-end-binding module for siRNA transfer in the RNA silencing pathway, and as an anchoring site for the 3' end of guide RNA within silencing effector complexes.	Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Patel, DJ (corresponding author), Mem Sloan Kettering Canc Ctr, Struct Biol Program, 1275 York Ave, New York, NY 10021 USA.	pateld@mskcc.org			NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068776] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline; NIAID NIH HHS [R01 AI068776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amarzguioui M, 2003, NUCLEIC ACIDS RES, V31, P589, DOI 10.1093/nar/gkg147; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P2705, DOI 10.1093/nar/gkg393; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Harborth J, 2003, ANTISENSE NUCLEIC A, V13, P83, DOI 10.1089/108729003321629638; Hohjoh H, 2002, FEBS LETT, V521, P195, DOI 10.1016/S0014-5793(02)02860-0; Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Katsamba PS, 2002, METHODS, V26, P95, DOI 10.1016/S1046-2023(02)00012-9; Lingel A, 2003, NATURE, V426, P465, DOI 10.1038/nature02123; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SONG JJ, 1932, NAT STRUCT BIOL, V10, P1026; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; Voinnet O, 2001, TRENDS GENET, V17, P449, DOI 10.1016/S0168-9525(01)02367-8; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Yan KS, 2003, NATURE, V426, P469, DOI 10.1038/nature02129	30	524	592	4	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	2004	429	6989					318	322		10.1038/nature02519	http://dx.doi.org/10.1038/nature02519			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152257	Green Accepted			2022-12-28	WOS:000221505900048
J	Mueller, K; Hough, SE; Bilham, R				Mueller, K; Hough, SE; Bilham, R			Analysing the 1811-1812 New Madrid earthquakes with recent instrumentally recorded aftershocks	NATURE			English	Article							CENTRAL UNITED-STATES; SEISMIC ZONE; MAGNITUDE; INTENSITIES; FAULT	Although dynamic stress changes associated with the passage of seismic waves are thought to trigger earthquakes at great distances, more than 60 per cent of all aftershocks appear to be triggered by static stress changes within two rupture lengths of a mainshock(1-5). The observed distribution of aftershocks may thus be used to infer details of mainshock rupture geometry(6). Aftershocks following large mid-continental earthquakes, where background stressing rates are low, are known to persist for centuries(7,8), and models based on rate-and-state friction laws provide theoretical support for this inference(9). Most past studies of the New Madrid earthquake sequence have indeed assumed ongoing microseismicity to be a continuing aftershock sequence(10-12). Here we use instrumentally recorded aftershock locations and models of elastic stress change to develop a kinematically consistent rupture scenario for three of the four largest earthquakes of the 1811-1812 New Madrid sequence. Our results suggest that these three events occurred on two contiguous faults, producing lobes of increased stress near fault intersections and end points, in areas where present-day microearthquakes have been hitherto interpreted as evidence of primary mainshock rupture. We infer that the remaining New Madrid mainshock may have occurred more than 200 km north of this region in the Wabash Valley of southern Indiana and Illinois-an area that contains abundant modern microseismicity, and where substantial liquefaction was documented by historic accounts. Our results suggest that future large mid-plate earthquake sequences may extend over a much broader region than previously suspected.	Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; US Geol Survey, Pasadena, CA 91030 USA; Univ Colorado, CIRES, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; United States Department of the Interior; United States Geological Survey; University of Colorado System; University of Colorado Boulder	Mueller, K (corresponding author), Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA.	Karl.Mueller@colorado.edu		Bilham, Roger/0000-0002-5547-4102				Al-Shukri, 2002, SEISMOL RES LETT, V73, P751, DOI DOI 10.1785/GSSRL.73.5.751; Bakun WH, 1997, B SEISMOL SOC AM, V87, P1502; Baldwin J. N., 2002, SEISMOL RES LETT, V73, P393, DOI [10.1785/gssrl.73.3.393, DOI 10.1785/GSSRL.73.3.393]; BERRY DL, 1908, ILLINOIS STATE HIST, V12, P74; DAS S, 1981, B SEISMOL SOC AM, V71, P1669; DIETERICH J, 1994, J GEOPHYS RES-SOL EA, V99, P2601, DOI 10.1029/93JB02581; Ebel J. E., 2000, SEISMOL RES LETT, V71, P283, DOI [DOI 10.1785/GSSRL.71.2.283, 10.1785/gssrl.71.2.283]; Gan W, 2001, GEOPHYS RES LETT, V28, P3733, DOI 10.1029/2001GL013266; GOMBERG J, 1994, J GEOPHYS RES-SOL EA, V99, P20299, DOI 10.1029/94JB00039; Guccione MJ, 2000, GEOL SOC AM BULL, V112, P579, DOI 10.1130/0016-7606(2000)112<579:OAAOTM>2.0.CO;2; Guccione MJ, 2002, GEOMORPHOLOGY, V43, P313, DOI 10.1016/S0169-555X(01)00145-3; Hough SE, 2002, B SEISMOL SOC AM, V92, P3259, DOI 10.1785/0120010226; Hough SE, 2001, B SEISMOL SOC AM, V91, P1574, DOI 10.1785/0120000259; Hough SE, 2000, J GEOPHYS RES-SOL EA, V105, P23839, DOI 10.1029/2000JB900110; Johnston AC, 1996, GEOPHYS J INT, V126, P314, DOI 10.1111/j.1365-246X.1996.tb05294.x; Johnston AC, 1996, ANNU REV EARTH PL SC, V24, P339, DOI 10.1146/annurev.earth.24.1.339; Kelson KI, 1996, J GEOPHYS RES-SOL EA, V101, P6151, DOI 10.1029/95JB01815; Kilb D, 2000, NATURE, V408, P570, DOI 10.1038/35046046; Mueller K, 2001, B SEISMOL SOC AM, V91, P1563, DOI 10.1785/0120000276; NUTTLI OW, 1973, B SEISMOL SOC AM, V63, P227; Odum JK, 1998, GEOL SOC AM BULL, V110, P149, DOI 10.1130/0016-7606(1998)110<0149:NSSMFD>2.3.CO;2; REASENBERG PA, 1989, SCIENCE, V243, P1173, DOI 10.1126/science.243.4895.1173; Seeber L, 2000, NATURE, V407, P69, DOI 10.1038/35024055; STAUDER W, 1970, B SEISMOL SOC AM, V60, P973; Toda S, 1998, J GEOPHYS RES-SOL EA, V103, P24543, DOI 10.1029/98JB00765; Tuttle MP, 2001, J SEISMOL, V5, P361, DOI 10.1023/A:1011423525258; Van Arsdale R. B., 1995, SEISMOL RES LETT, V66, P57, DOI [10.1785/gssrl.66.5.57, DOI 10.1785/GSSRL.66.5.57]	27	56	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 20	2004	429	6989					284	288		10.1038/nature02557	http://dx.doi.org/10.1038/nature02557			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822AO	15152249				2022-12-28	WOS:000221505900039
J	Coche, E; Prat, J; Clause, D				Coche, E; Prat, J; Clause, D			Cystic bronchiectasis	LANCET			English	Editorial Material									Univ Catholique Louvain, Clin Univ St Luc, Dept Radiol, B-1200 Brussels, Belgium; Univ Catholique Louvain, Clin Univ St Luc, Dept Pneumol, B-1200 Brussels, Belgium	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Coche, E (corresponding author), Univ Catholique Louvain, Clin Univ St Luc, Dept Radiol, B-1200 Brussels, Belgium.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	2004	363	9421					1578	1578		10.1016/S0140-6736(04)16199-0	http://dx.doi.org/10.1016/S0140-6736(04)16199-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145630				2022-12-28	WOS:000221408800007
J	Sermon, K; Van Steirteghem, A; Liebaers, I				Sermon, K; Van Steirteghem, A; Liebaers, I			Preimplantation genetic diagnosis	LANCET			English	Review							COMPARATIVE GENOMIC HYBRIDIZATION; POLYMERASE-CHAIN-REACTION; SPINAL MUSCULAR-ATROPHY; IN-SITU HYBRIDIZATION; CLEAVAGE-STAGE EMBRYOS; POLAR BODY ANALYSIS; SICKLE-CELL-ANEMIA; FRAGILE-X-SYNDROME; REAL-TIME PCR; CYSTIC-FIBROSIS	Preimplantation genetic diagnosis (PGD) was introduced at the beginning of the 1990s as an alternative to prenatal diagnosis, to prevent termination of pregnancy in couples with a high risk for offspring affected by a sex-linked genetic disease. At that time, embryos obtained in vitro were tested to ascertain their sex, and only female embryos were transferred. Since then, techniques for genetic analysis at the single-cell level, involving assessment of first and second polar bodies from oocytes or blastomeres from cleavage-stage embryos, have evolved. Fluorescence in-situ hybridisation (FISH) has been introduced for the analysis of chromosomes and PCR for the analysis of genes in cases of monogenic diseases. In-vitro culture of embryos has also improved through the use of sequential media. Here, we provide an overview of indications for, and techniques used in, PGD, and discuss results obtained with the technique and outcomes of pregnancies. A brief review of new technologies is also included.	Free Univ Brussels, Univ Hosp & Med Sch, Ctr Med Genet, Brussels, Belgium; Free Univ Brussels, Univ Hosp & Med Sch, Ctr Reprod Med, Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Sermon, K (corresponding author), Free Univ Brussels, Akad Ziekenhuis, Ctr Med Genet, Laarbeeklaan 101, B-1090 Brussels, Belgium.	Karen.sermon@az.vub.ac.be		Sermon, Karen/0000-0002-2311-9034				Ao A, 1998, J ASSIST REPROD GEN, V15, P140, DOI 10.1023/A:1023008921386; Apessos A, 2001, PRENATAL DIAG, V21, P504, DOI 10.1002/pd.111; Blaszczyk A, 1998, J ASSIST REPROD GEN, V15, P281, DOI 10.1023/A:1022540410290; Boada M, 1998, J ASSIST REPROD GEN, V15, P302, DOI 10.1023/A:1022548612107; BOUE A, 1985, ADV HUM GENET, V14, P1; Conn CM, 1998, HUM GENET, V102, P117, DOI 10.1007/s004390050663; Coonen E, 2000, MOL HUM REPROD, V6, P199, DOI 10.1093/molehr/6.3.199; COUTELLE C, 1989, BRIT MED J, V299, P22, DOI 10.1136/bmj.299.6690.22; De Rycke M, 2001, PRENATAL DIAG, V21, P214, DOI 10.1002/1097-0223(200103)21:3<214::AID-PD51>3.0.CO;2-4; De Vos A, 2003, MOL HUM REPROD, V9, P429, DOI 10.1093/molehr/gag054; De Vos A, 2001, PRENATAL DIAG, V21, P767, DOI 10.1002/pd.172; de Wert G, 2003, REPROD MED MOL CELLU, P645; DELHANTY JDA, 1993, HUM MOL GENET, V2, P1183, DOI 10.1093/hmg/2.8.1183; Dreesen JCFM, 2000, MOL HUM REPROD, V6, P391, DOI 10.1093/molehr/6.5.391; Dreesen JCFM, 1998, MOL HUM REPROD, V4, P881, DOI 10.1093/molehr/4.9.881; Eftedal I, 2001, MOL HUM REPROD, V7, P307, DOI 10.1093/molehr/7.3.307; Evsikov S, 2000, FERTIL STERIL, V74, P672, DOI 10.1016/S0015-0282(00)01513-2; Fallon L, 1999, NEUROLOGY, V53, P1087, DOI 10.1212/WNL.53.5.1087; Fiorentino F, 2003, MOL HUM REPROD, V9, P399, DOI 10.1093/molehr/gag046; Georgiou I, 2001, HUM GENET, V108, P494, DOI 10.1007/s004390100534; Gianaroli L, 2002, HUM REPROD, V17, P3201, DOI 10.1093/humrep/17.12.3201; Girardet A, 2003, MOL HUM REPROD, V9, P111, DOI 10.1093/molehr/gag014; Goossens V, 2003, MOL HUM REPROD, V9, P559, DOI 10.1093/molehr/gag065; Goossens V, 2000, PRENATAL DIAG, V20, P571, DOI 10.1002/1097-0223(200007)20:7<571::AID-PD879>3.0.CO;2-N; GRIFFIN DK, 1992, HUM GENET, V89, P18, DOI 10.1007/BF00207035; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HARPER JC, 1994, HUM REPROD, V9, P721, DOI 10.1093/oxfordjournals.humrep.a138577; Harper JC, 2002, PRENATAL DIAG, V22, P525, DOI 10.1002/pd.394; Harton GL, 1996, MOL HUM REPROD, V2, P713, DOI 10.1093/molehr/2.9.713; HOLDING C, 1989, LANCET, V2, P532; Hussey ND, 2002, MOL HUM REPROD, V8, P1136, DOI 10.1093/molehr/8.12.1136; Hussey ND, 1999, MOL HUM REPROD, V5, P1089, DOI 10.1093/molehr/5.11.1089; Inzunza J, 1998, PRENATAL DIAG, V18, P1381, DOI 10.1002/(SICI)1097-0223(199812)18:13<1381::AID-PD495>3.0.CO;2-N; Iwarsson E, 2000, PRENATAL DIAG, V20, P1038, DOI 10.1002/1097-0223(200012)20:13<1038::AID-PD976>3.3.CO;2-#; Jericho H, 2003, HUM REPROD, V18, P568, DOI 10.1093/humrep/deg106; Joris H, 1999, HUM REPROD, V14, P2833, DOI 10.1093/humrep/14.11.2833; Kanavakis E, 1999, PRENATAL DIAG, V19, P1217, DOI 10.1002/(SICI)1097-0223(199912)19:13<1217::AID-PD723>3.0.CO;2-2; Kuliev A, 1999, J ASSIST REPROD GEN, V16, P207, DOI 10.1023/A:1020316924064; Kuliev Anver, 2003, Reprod Biomed Online, V6, P54; Kurg A, 2000, GENET TEST, V4, P1, DOI 10.1089/109065700316408; Lee M, 2000, FERTIL STERIL, V73, P645, DOI 10.1016/S0015-0282(99)00571-3; Liebaers I, 1998, HUM REPROD, V13, P186, DOI 10.1093/humrep/13.suppl_1.186; Lissens W, 1997, HUM REPROD, V12, P1756, DOI 10.1093/humrep/12.8.1756; LIU J, 1994, JAMA-J AM MED ASSOC, V272, P23; Magli MC, 1999, HUM REPROD, V14, P770, DOI 10.1093/humrep/14.3.770; Malpani A, 2002, Reprod Biomed Online, V4, P16; Marquez C, 2000, Reprod Biomed Online, V1, P17; Moutou C, 2003, HUM REPROD, V18, P509, DOI 10.1093/humrep/deg123; Moutou C, 2002, EUR J HUM GENET, V10, P231, DOI 10.1038/sj.ejhg.5200794; Moutou C, 1999, PRENATAL DIAG, V19, P1248, DOI 10.1002/(SICI)1097-0223(199912)19:13<1248::AID-PD737>3.0.CO;2-G; Moutou C, 2001, PRENATAL DIAG, V21, P498, DOI 10.1002/pd.110; Munne S, 1999, HUM REPROD, V14, P2191, DOI 10.1093/humrep/14.9.2191; MUNNE S, 1993, HUM REPROD, V8, P2185, DOI 10.1093/oxfordjournals.humrep.a138001; Munne S, 1998, PRENATAL DIAG, V18, P1459, DOI 10.1002/(SICI)1097-0223(199812)18:13<1459::AID-PD514>3.0.CO;2-V; Munne S, 2002, FERTIL STERIL, V78, P234, DOI 10.1016/S0015-0282(02)03239-9; Munne S, 2000, FERTIL STERIL, V73, P1209, DOI 10.1016/S0015-0282(00)00495-7; MUNNE S, 2003, REPROD BIOMED ONLINE, V4, P223; Pehlivan T, 2003, Reprod Biomed Online, V6, P232; PELLESTOR F, 1994, MOL REPROD DEV, V39, P141, DOI 10.1002/mrd.1080390204; Pennings G, 2002, PRENATAL DIAG, V22, P1123, DOI 10.1002/pd.499; Pennings G, 2002, HUM REPROD, V17, P534, DOI 10.1093/humrep/17.3.534; Pickering S, 2003, FERTIL STERIL, V79, P81, DOI 10.1016/S0015-0282(02)04540-5; Pierce KE, 2000, MOL HUM REPROD, V6, P1155, DOI 10.1093/molehr/6.12.1155; Piyamongkol W, 2001, PRENATAL DIAG, V21, P223, DOI 10.1002/1097-0223(200103)21:3<223::AID-PD52>3.0.CO;2-3; Ray PF, 2003, HUM REPROD, V18, P463, DOI 10.1093/humrep/deg063; Ray PF, 2000, PRENATAL DIAG, V20, P1048, DOI 10.1002/1097-0223(200012)20:13<1048::AID-PD975>3.0.CO;2-8; Ray PF, 2001, MOL HUM REPROD, V7, P489, DOI 10.1093/molehr/7.5.489; Rechitsky S, 2003, Reprod Biomed Online, V6, P488; Rechitsky S, 1999, J ASSIST REPROD GEN, V16, P192, DOI 10.1023/A:1020312823155; Rechitsky Svetlana, 2002, Reprod Biomed Online, V5, P148; Rice JE, 2002, PRENATAL DIAG, V22, P1130, DOI 10.1002/pd.500; Robertson JA, 2003, HUM REPROD, V18, P465, DOI 10.1093/humrep/deg100; Rubio C, 2003, HUM REPROD, V18, P182, DOI 10.1093/humrep/deg015; Sermon K, 2000, MOL HUM REPROD, V6, P1165, DOI 10.1093/molehr/6.12.1165; Sermon K, 2002, HUM REPROD, V17, P233; Sermon K, 2002, EUR J HUM GENET, V10, P591, DOI 10.1038/sj.ejhg.5200865; Sermon K, 2002, HUM REPROD UPDATE, V8, P11, DOI 10.1093/humupd/8.1.11; Sermon K, 2001, MOL CELL ENDOCRINOL, V183, pS77, DOI 10.1016/S0303-7207(01)00572-X; Sermon K, 1998, PRENATAL DIAG, V18, P1427, DOI 10.1002/(SICI)1097-0223(199812)18:13<1427::AID-PD493>3.0.CO;2-3; Sermon K, 1999, PRENATAL DIAG, V19, P1223, DOI 10.1002/(SICI)1097-0223(199912)19:13<1223::AID-PD724>3.3.CO;2-S; Sermon K, 1999, FERTIL STERIL, V71, P163, DOI 10.1016/S0015-0282(98)00412-9; Shenfield F, 2003, HUM REPROD, V18, P649, DOI 10.1093/humrep/deg110; Staessen C, 1999, MOL HUM REPROD, V5, P382, DOI 10.1093/molehr/5.4.382; Stern H., 2002, PRENAT DIAGN, V22, P303; Strom CM, 1998, MOL HUM REPROD, V4, P351, DOI 10.1093/molehr/4.4.351; Strom CM, 1998, AM J OBSTET GYNECOL, V178, P1298, DOI 10.1016/S0002-9378(98)70336-9; Strom CM, 2000, PEDIATRICS, V106, P650, DOI 10.1542/peds.106.4.650; Syvanen AC, 1999, HUM MUTAT, V13, P1; Szuhai K, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e13; Thornton KL, 2000, OBSTET GYN CLIN N AM, V27, P517, DOI 10.1016/S0889-8545(05)70152-2; Van Assche E, 1999, MOL HUM REPROD, V5, P682, DOI 10.1093/molehr/5.7.682; Van de Velde H, 2000, PRENATAL DIAG, V20, P1030, DOI 10.1002/1097-0223(200012)20:13<1030::AID-PD977>3.0.CO;2-D; Van de Velde H, 1999, MOL HUM REPROD, V5, P691, DOI 10.1093/molehr/5.7.691; Veiga A, 1997, ZYGOTE, V5, P351, DOI 10.1017/S0967199400003920; VERHEYEN G, 2003, HUM REPROD S1, V18; Verlinsky Y, 2002, JAMA-J AM MED ASSOC, V287, P1018, DOI 10.1001/jama.287.8.1018; Verlinsky Y, 2001, JAMA-J AM MED ASSOC, V285, P3130, DOI 10.1001/jama.285.24.3130; VERLINSKY Y, 1992, PRENATAL DIAG, V12, P103, DOI 10.1002/pd.1970120205; Verlinsky Y, 1999, J ASSIST REPROD GEN, V16, P165, DOI 10.1023/A:1020304621338; Voullaire L, 2000, HUM GENET, V106, P210, DOI 10.1007/s004390051030; Vrettou C, 2002, MOL HUM REPROD, V8, P880, DOI 10.1093/molehr/8.9.880; Vrettou C, 1999, PRENATAL DIAG, V19, P1209, DOI 10.1002/(SICI)1097-0223(199912)19:13<1209::AID-PD722>3.3.CO;2-Y; Wells D, 2000, MOL HUM REPROD, V6, P1055, DOI 10.1093/molehr/6.11.1055; Wells D, 2003, BIOESSAYS, V25, P289, DOI 10.1002/bies.10232; Wells D, 2002, FERTIL STERIL, V78, P543, DOI 10.1016/S0015-0282(02)03271-5; Wilton L, 2001, NEW ENGL J MED, V345, P1537, DOI 10.1056/NEJMoa011052; WILTON L, 2002, PRENAT DIAGN, V22, P312; Xu KP, 1999, JAMA-J AM MED ASSOC, V281, P1701, DOI 10.1001/jama.281.18.1701; ZENZES MT, 1992, HUM GENET, V88, P367, DOI 10.1007/BF00215667; 2001, REPROD BIOMED ONLINE, V3, P49	111	251	269	1	81	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	2004	363	9421					1633	1641		10.1016/S0140-6736(04)16209-0	http://dx.doi.org/10.1016/S0140-6736(04)16209-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145639				2022-12-28	WOS:000221408800025
J	Singhal, A; Lucas, A				Singhal, A; Lucas, A			Early origins of cardiovascular disease: is there a unifying hypothesis?	LANCET			English	Editorial Material							CATCH-UP GROWTH; DEPENDENT DIABETES-MELLITUS; GESTATIONAL-AGE INFANTS; CORONARY-HEART-DISEASE; LOW-BIRTH-WEIGHT; INSULIN-RESISTANCE; CHILDHOOD GROWTH; EARLY NUTRITION; BLOOD-PRESSURE; CHOLESTEROL		Inst Child Hlth, MRC, Childhood Nutr Res Ctr, London WC1N 1EH, England	University of London; University College London	Singhal, A (corresponding author), Inst Child Hlth, MRC, Childhood Nutr Res Ctr, 30 Guilford St, London WC1N 1EH, England.	a.singhal@ich.ucl.ac.uk						BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Cianfarani S, 1999, ARCH DIS CHILD-FETAL, V81, pF71, DOI 10.1136/fn.81.1.F71; COLLE E, 1976, PEDIATRICS, V57, P363; DEIBER M, 1989, J CLIN ENDOCR METAB, V68, P232, DOI 10.1210/jcem-68-1-232; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; Finken MJJ, 2003, PEDIATR RES, V53, p32A; Forsen T, 2000, ANN INTERN MED, V133, P176, DOI 10.7326/0003-4819-133-3-200008010-00008; Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4; HAHN P, 1984, J NUTR, V114, P1231, DOI 10.1093/jn/114.7.1231; KARLBERG J, 1995, PEDIATR RES, V38, P733, DOI 10.1203/00006450-199511000-00017; Law CM, 2002, ARCH DIS CHILD-FETAL, V86, pF7, DOI 10.1136/fn.86.1.F7; LUCAS A, 1991, CIBA F SYMP, V156, P38; Martin RM, 2003, AM J CLIN NUTR, V77, P1489, DOI 10.1093/ajcn/77.6.1489; MCCANCE RA, 1962, LANCET, V2, P671; Metcalfe NB, 2001, TRENDS ECOL EVOL, V16, P254, DOI 10.1016/S0169-5347(01)02124-3; Ong KKL, 2000, BRIT MED J, V320, P967, DOI 10.1136/bmj.320.7240.967; Ong KKL, 2002, PEDIATR RES, V52, P863, DOI 10.1203/00006450-200212000-00009; OUNSTED MK, 1985, ARCH DIS CHILD, V60, P631, DOI 10.1136/adc.60.7.631; Owen CG, 2002, PEDIATRICS, V110, P597, DOI 10.1542/peds.110.3.597; Pettitt DJ, 1997, LANCET, V350, P166, DOI 10.1016/S0140-6736(96)12103-6; PLAGEMANN A, 1992, EXP CLIN ENDOCRINOL, V99, P154, DOI 10.1055/s-0029-1211159; Plagemann A, 2002, DIABETES CARE, V25, P16, DOI 10.2337/diacare.25.1.16; Roth GS, 2000, EUR J CLIN NUTR, V54, pS15, DOI 10.1038/sj.ejcn.1601020; Singhal A, 2004, CIRCULATION, V109, P1108, DOI 10.1161/01.CIR.0000118500.23649.DF; Singhal A, 2003, LANCET, V361, P1089, DOI 10.1016/S0140-6736(03)12895-4; Singhal A, 2002, AM J CLIN NUTR, V75, P993, DOI 10.1093/ajcn/75.6.993; Singhal A, 2001, LANCET, V358, P1159, DOI 10.1016/S0140-6736(01)06276-6; Singhal A, 2001, LANCET, V357, P413, DOI 10.1016/S0140-6736(00)04004-6; Singhal A, 2004, LANCET, V363, P1571, DOI 10.1016/S0140-6736(04)16198-9; Stern MP, 1996, ANN INTERN MED, V124, P110, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00006; Stettler N, 2002, PEDIATRICS, V109, P194, DOI 10.1542/peds.109.2.194; Victora CG, 2001, INT J EPIDEMIOL, V30, P1325, DOI 10.1093/ije/30.6.1325; von Kries R, 1999, BRIT MED J, V319, P147, DOI 10.1136/bmj.319.7203.147; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21	35	548	571	0	35	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	2004	363	9421					1642	1645		10.1016/S0140-6736(04)16210-7	http://dx.doi.org/10.1016/S0140-6736(04)16210-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	820SE	15145640				2022-12-28	WOS:000221408800026
J	DeLoache, JS; Uttal, D; Rosengren, KS				DeLoache, JS; Uttal, D; Rosengren, KS			Scale errors offer evidence for a perception-action dissociation early in life	SCIENCE			English	Article							SYSTEMS; OBJECTS; INFANCY	We report a perception-action dissociation in the behavior of normally developing young children. In adults and older children, the perception of an object and the organization of actions on it are seamlessly integrated. However, as documented here, 18- to 30-month-old children sometimes fail to use information about object size and make serious attempts to perform impossible actions on miniature objects. They try, for example, to sit in a dollhouse chair or to get into a small toy car. We interpret scale errors as reflecting problems with inhibitory control and with the integration of visual information for perception and action.	Univ Virginia, Dept Psychol, Charlottesville, VA 22904 USA; Northwestern Univ, Dept Psychol, Evanston, IL 60208 USA; Univ Illinois, Dept Psychol, Champaign, IL 61820 USA	University of Virginia; Northwestern University; University of Illinois System; University of Illinois Urbana-Champaign	DeLoache, JS (corresponding author), Univ Virginia, Dept Psychol, Charlottesville, VA 22904 USA.	jdeloache@virginia.edu		Rosengren, Karl/0000-0003-1448-1282	NICHD NIH HHS [5 T32 HD007323-18, HD-25271] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025271, T32HD007323, R01HD025271] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barsalou LW, 2003, TRENDS COGN SCI, V7, P84, DOI 10.1016/S1364-6613(02)00029-3; Bertenthal BI, 1996, ANNU REV PSYCHOL, V47, P431, DOI 10.1146/annurev.psych.47.1.431; Creem SH, 2001, ACTA PSYCHOL, V107, P43, DOI 10.1016/S0001-6918(01)00021-X; David Milner A, 1995, MAG VISUAL BRAIN ACT; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI [10.1093/acprof:oso/9780195134971.003.0029, DOI 10.1093/ACPROF:OSO/9780195134971.003.0029, /10.1093/acprof:oso/9780195134971.003.0029]; Glenberg AM, 1997, BEHAV BRAIN SCI, V20, P1, DOI 10.1017/S0140525X97470012; Glover S, 2002, TRENDS COGN SCI, V6, P288, DOI 10.1016/S1364-6613(02)01920-4; GLOVER S, IN PRESS BEHAV BRAIN; GOODALE MA, 2000, NEW COGNITIVE NEUROS, P365; Leslie AM, 1998, TRENDS COGN SCI, V2, P10, DOI 10.1016/S1364-6613(97)01113-3; Mareschal D, 2003, COGNITION, V88, P259, DOI 10.1016/S0010-0277(03)00039-8; Newman C, 2001, DEV PSYCHOL, V37, P561, DOI 10.1037//0012-1649.37.4.561; Thelen E, 2000, INFANCY, V1, P3, DOI 10.1207/S15327078IN0101_02; Tucker M, 2001, VIS COGN, V8, P769, DOI 10.1080/13506280042000144; VISHTON PM, 2003, BIENN M SOC RES CHIL; von Hofsten C, 1998, COGNITION, V67, P255, DOI 10.1016/S0010-0277(98)00029-8; Zelazo PD, 1998, CURR DIR PSYCHOL SCI, V7, P121, DOI 10.1111/1467-8721.ep10774761	17	104	105	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	2004	304	5673					1027	1029		10.1126/science.1093567	http://dx.doi.org/10.1126/science.1093567			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	820IV	15143286				2022-12-28	WOS:000221383300054
J	Wilken, C; Kitzing, K; Kurzbauer, R; Ehrmann, M; Clausen, T				Wilken, C; Kitzing, K; Kurzbauer, R; Ehrmann, M; Clausen, T			Crystal structure of the DegS stress sensor: How a PDZ domain recognizes misfolded protein and activates a protease	CELL			English	Article							ESCHERICHIA-COLI SIGMA(E); HEAT-SHOCK RESPONSE; SERINE-PROTEASE; EXTRACYTOPLASMIC STRESS; HTRA FAMILY; TRANSCRIPTION-FACTOR; QUALITY-CONTROL; RSEA; MITOCHONDRIAL; APOPTOSIS	Gram-negative bacteria respond to misfolded proteins in the cell envelope with the sigmaE-driven expression of periplasmic proteases/chaperones. Activation of sigmaE is controlled by a proteolytic cascade that is initiated by the DegS protease. DegS senses misfolded protein in the periplasm, undergoes autoactivation, and cleaves the antisigma factor RseA. Here, we present the crystal structures of three distinct states of DegS from E. coli. DegS alone exists in a catalytically inactive form. Binding of stress-signaling peptides to its PDZ domain induces a series of conformational changes that activates protease function. Backsoaking of crystals containing the DegS-activator complex revealed the presence of an active/inactive hybrid structure and demonstrated the reversibility of activation. Taken together, the structural data illustrate in molecular detail how DegS acts as a periplasmic stress sensor. Our results suggest a novel regulatory role for PDZ domains and unveil novel mechanism of reversible protease activation.	Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria; Cardiff Univ, Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Cardiff University	Clausen, T (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	clausen@imp.univie.ac.at	Ehrmann, Michael/A-7307-2012	Ehrmann, Michael/0000-0002-1927-260X; Clausen, Tim/0000-0003-1582-6924				Ades SE, 1999, GENE DEV, V13, P2449, DOI 10.1101/gad.13.18.2449; Ades SE, 2003, J BACTERIOL, V185, P2512, DOI 10.1128/JB.185.8.2512-2519.2003; Alba BM, 2002, GENE DEV, V16, P2156, DOI 10.1101/gad.1008902; Alba BM, 2001, MOL MICROBIOL, V40, P1323, DOI 10.1046/j.1365-2958.2001.02475.x; Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Campbell EA, 2003, MOL CELL, V11, P1067, DOI 10.1016/S1097-2765(03)00148-5; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Collaborative Comuptational Project 4, 2002, ACTA CRYSTALLOGR D, V58, P1897; DeLasPenas A, 1997, MOL MICROBIOL, V24, P373, DOI 10.1046/j.1365-2958.1997.3611718.x; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Friedrich R, 2003, NATURE, V425, P535, DOI 10.1038/nature01962; Harris BZ, 2001, J CELL SCI, V114, P3219; HARRIS BZ, 1996, J CELL SCI, V863, P341; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hengge R, 2003, MOL MICROBIOL, V49, P1451, DOI 10.1046/j.1365-2958.2003.03693.x; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Jones CH, 2002, J BACTERIOL, V184, P5762, DOI 10.1128/JB.184.20.5762-5771.2002; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanehara K, 2002, GENE DEV, V16, P2147, DOI 10.1101/gad.1002302; Kim DY, 2003, J BIOL CHEM, V278, P6543, DOI 10.1074/jbc.M208148200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Liao DI, 2000, NAT STRUCT BIOL, V7, P749, DOI 10.1038/78973; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; Nie GY, 2003, MOL HUM REPROD, V9, P279, DOI 10.1093/molehr/gag036; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Raivio TL, 2001, ANNU REV MICROBIOL, V55, P591, DOI 10.1146/annurev.micro.55.1.591; ROUVIERE PE, 1995, EMBO J, V14, P1032, DOI 10.1002/j.1460-2075.1995.tb07084.x; Shridhar V, 2002, CANCER RES, V62, P262; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Young JC, 2003, CELL, V113, P1, DOI 10.1016/S0092-8674(03)00192-2	51	229	234	2	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	2004	117	4					483	494		10.1016/S0092-8674(04)00454-4	http://dx.doi.org/10.1016/S0092-8674(04)00454-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821KB	15137941	Bronze			2022-12-28	WOS:000221458000008
J	Eubank, S; Guclu, H; Kumar, VSA; Marathe, MV; Srinivasan, A; Toroczkai, Z; Wang, N				Eubank, S; Guclu, H; Kumar, VSA; Marathe, MV; Srinivasan, A; Toroczkai, Z; Wang, N			Modelling disease outbreaks in realistic urban social networks	NATURE			English	Article							SMALLPOX; TRANSMISSION; SPREAD; ATTACK	Most mathematical models for the spread of disease use differential equations based on uniformmixing assumptions(1) or ad hoc models for the contact process(2-4). Here we explore the use of dynamic bipartite graphs to model the physical contact patterns that result from movements of individuals between specific locations. The graphs are generated by large-scale individual-based urban traffic simulations built on actual census, land-use and population-mobility data. We find that the contact network among people is a strongly connected small-world-like(5) graph with a well-defined scale for the degree distribution. However, the locations graph is scale-free(6), which allows highly efficient outbreak detection by placing sensors in the hubs of the locations network. Within this large-scale simulation framework, we then analyse the relative merits of several proposed mitigation strategies for smallpox spread. Our results suggest that outbreaks can be contained by a strategy of targeted vaccination combined with early detection without resorting to mass vaccination of a population.	Los Alamos Natl Lab, Basic & Appl Simulat Sci Grp, Los Alamos, NM 87545 USA; Rensselaer Polytech Inst, Dept Phys Appl Phys & Astron, Troy, NY 12180 USA; Univ Maryland, Dept Comp Sci, College Pk, MD 20742 USA; Univ Maryland, Inst Adv Comp Studies, College Pk, MD 20742 USA; Los Alamos Natl Lab, Ctr Nonlinear Studies, Los Alamos, NM 87545 USA; Los Alamos Natl Lab, Complex Syst Grp, Los Alamos, NM 87545 USA; Univ Maryland, Dept Comp Sci, College Pk, MD 20742 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Rensselaer Polytechnic Institute; University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; University System of Maryland; University of Maryland College Park	Eubank, S (corresponding author), Los Alamos Natl Lab, Basic & Appl Simulat Sci Grp, MS M997, Los Alamos, NM 87545 USA.	eubank@lanl.gov	Eubank, Stephen/AAD-5089-2021; Toroczkai, Zoltan/AAC-8446-2019; Toroczkai, Zoltan/A-3421-2008; Guclu, Hasan/B-7080-2008; Eubank, Stephen/D-7497-2011	Toroczkai, Zoltan/0000-0002-6602-2849; Toroczkai, Zoltan/0000-0002-6602-2849; Guclu, Hasan/0000-0003-3582-9460; Eubank, Stephen/0000-0002-7177-309X; Vullikanti, Anil Kumar/0000-0002-8597-6197				Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; BARRETT CL, 2000, LAUR001725 LOS AL NA; Callaway DS, 2000, PHYS REV LETT, V85, P5468, DOI 10.1103/PhysRevLett.85.5468; Chowell G, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.066102; Cohen R, 2001, PHYS REV LETT, V86, P3682, DOI 10.1103/PhysRevLett.86.3682; Dorogovtsev SN, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.066122; Eichner M, 2003, AM J EPIDEMIOL, V158, P110, DOI 10.1093/aje/kwg103; EUBANK S, 2002, P 2002 ACM S APPL CO, P139; EUBANK S, 2004, P 15 ACM SIAM S DISC, P711; Ferguson NM, 2003, NATURE, V425, P681, DOI 10.1038/nature02007; Halloran ME, 2002, SCIENCE, V298, P1428, DOI 10.1126/science.1074674; Jezek Z, 1988, HUMAN MONKEYPOX; Jin EM, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.046132; Kaplan EH, 2002, P NATL ACAD SCI USA, V99, P10935, DOI 10.1073/pnas.162282799; Keeling MJ, 1999, P ROY SOC B-BIOL SCI, V266, P859, DOI 10.1098/rspb.1999.0716; Keeling MJ, 2000, J THEOR BIOL, V203, P51, DOI 10.1006/jtbi.1999.1064; Kretzschmar M, 1996, MATH BIOSCI, V133, P165, DOI 10.1016/0025-5564(95)00093-3; Lloyd AL, 2001, SCIENCE, V292, P1316, DOI 10.1126/science.1061076; Neff JM, 2002, JAMA-J AM MED ASSOC, V288, P1901, DOI 10.1001/jama.288.15.1901; Newman MEJ, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.026121; Newman MEJ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.208701; Pastor-Satorras R, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.036104; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Szabo G, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.056102; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; ZWINGLE E, 2002, NATL GEOGR, V202, P70	28	1226	1276	11	305	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	2004	429	6988					180	184		10.1038/nature02541	http://dx.doi.org/10.1038/nature02541			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141212				2022-12-28	WOS:000221356300041
J	Yanagida, M				Yanagida, M			Heads and tails - How a visit to the home of structural biology inspired a young scientist.	NATURE			English	Editorial Material									Kyoto Univ, Grad Sch Biostudies, Kyoto 6068501, Japan	Kyoto University	Yanagida, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Yoshida Honmachi, Kyoto 6068501, Japan.								0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	2004	429	6988					135	135		10.1038/429135a	http://dx.doi.org/10.1038/429135a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819ZU	15141191	Bronze			2022-12-28	WOS:000221356300020
J	Frankland, PW; Bontempi, B; Talton, LE; Kaczmarek, L; Silva, AJ				Frankland, PW; Bontempi, B; Talton, LE; Kaczmarek, L; Silva, AJ			The involvement of the anterior cingulate cortex in remote contextual fear memory	SCIENCE			English	Article							TIME-DEPENDENT REORGANIZATION; RETROGRADE-AMNESIA; ZIF268 EXPRESSION; PREFRONTAL CORTEX; HIPPOCAMPUS; PLASTICITY; NEOCORTEX; STORAGE; COGNITION; RETRIEVAL	Although the molecular, cellular, and systems mechanisms required for initial memory processing have been intensively investigated, those underlying permanent memory storage remain elusive. We present neuroanatomical, pharmacological, and genetic results demonstrating that the anterior cingulate cortex plays a critical role in remote memory for contextual fear conditioning. Imaging of activity-dependent genes shows that the anterior cingulate is activated by remote memory and that this activation is impaired by a null alpha-CaMKII mutation that blocks remote memory. Accordingly, reversible inactivation of this structure in normal mice disrupts remote memory without affecting recent memory.	Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; Hosp Sick Children, Dept Integrat Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Cognit Neurosci Lab, CNRS, UMR 5106, F-33405 Talence, France; M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Centre National de la Recherche Scientifique (CNRS); Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Silva, AJ (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, 695 Charles Young Dr, Los Angeles, CA 90095 USA.	silvaa@mednet.ucla.edu	Silva, Alcino/ABD-7684-2021; Kaczmarek, Leszek/AHA-0076-2022; Kaczmarek, Leszek/B-6171-2008	Silva, Alcino/0000-0002-1587-4558; Kaczmarek, Leszek/0000-0002-7207-3490; Kaczmarek, Leszek/0000-0002-7207-3490; Silva, Alcino/0000-0001-5525-0494				Anagnostaras SG, 2001, HIPPOCAMPUS, V11, P8; Anagnostaras SG, 1999, J NEUROSCI, V19, P1106; Anagnostaras SG, 2000, LEARN MEMORY, V7, P58, DOI 10.1101/lm.7.1.58; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bontempi B, 1999, NATURE, V400, P671, DOI 10.1038/23270; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Carter CS, 1999, REV NEUROSCIENCE, V10, P49; Cui ZZ, 2004, NEURON, V41, P781, DOI 10.1016/S0896-6273(04)00072-8; Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050; Fanselow MS, 2003, ANN NY ACAD SCI, V985, P125; Frankland PW, 2001, NATURE, V411, P309, DOI 10.1038/35077089; Hall J, 2001, J NEUROSCI, V21, P2186, DOI 10.1523/JNEUROSCI.21-06-02186.2001; Hoffman KL, 2002, SCIENCE, V297, P2070, DOI 10.1126/science.1073538; KACZMAREK L, 2002, HDB CHEM NEUROANATOM, P370; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LASHLEY KS, 1950, SYM SOC EXP BIOL, V4, P454; Louie K, 2001, NEURON, V29, P145, DOI 10.1016/S0896-6273(01)00186-6; Manns JR, 2003, NEURON, V38, P127, DOI 10.1016/S0896-6273(03)00146-6; MARR D, 1970, PROC R SOC SER B-BIO, V176, P161, DOI 10.1098/rspb.1970.0040; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Robbins TW, 2000, PROG BRAIN RES, V126, P469; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; Takehara K, 2003, J NEUROSCI, V23, P9897; Thomas KL, 2002, EUR J NEUROSCI, V16, P1789, DOI 10.1046/j.1460-9568.2002.02247.x; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	28	673	686	0	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					881	883		10.1126/science.1094804	http://dx.doi.org/10.1126/science.1094804			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131309				2022-12-28	WOS:000221243000047
J	Harvey, RJ; Depner, UB; Wassle, H; Ahmadi, S; Heindl, C; Reinold, H; Smart, TG; Harvey, K; Schutz, B; Abo-Salem, OM; Zimmer, A; Poisbeau, P; Welzl, H; Wolfer, DP; Betz, H; Zeilhofer, HU; Muller, U				Harvey, RJ; Depner, UB; Wassle, H; Ahmadi, S; Heindl, C; Reinold, H; Smart, TG; Harvey, K; Schutz, B; Abo-Salem, OM; Zimmer, A; Poisbeau, P; Welzl, H; Wolfer, DP; Betz, H; Zeilhofer, HU; Muller, U			GlyR alpha 3: An essential target for spinal PGE(2)-mediated inflammatory pain sensitization	SCIENCE			English	Article							INHIBITORY GLYCINE RECEPTOR; DORSAL HORN NEURONS; PROSTAGLANDIN E-2; SUBUNIT; MOUSE; RAT; CORD; LOCALIZATION; HYPERALGESIA; MUTATION	Prostaglandin E-2 (PGE(2)) is a crucial mediator of inflammatory pain sensitization. Here, we demonstrate that inhibition of a specific glycine receptor subtype (GlyR alpha3) by PGE(2)-induced receptor phosphorylation underlies central inflammatory pain sensitization. We show that GlyR alpha3 is distinctly expressed in superficial layers of the spinal cord dorsal horn. Mice deficient in GlyR alpha3 not only lack the inhibition of glycinergic neurotransmission by PGE(2) seen in wildtype mice but also show a reduction in pain sensitization induced by spinal PGE(2) injection or peripheral inflammation. Thus, GlyR alpha3 may provide a previously unrecognized molecular target in pain therapy.	Max Planck Inst Hirnforsch, Neurochem Abt, D-60528 Frankfurt, Germany; Univ London, Sch Pharm, Dept Pharmacol, London WC1N 1AX, England; Univ Erlangen Nurnberg, Inst Expt & Klin Pharmakol & Toxikol, D-91054 Erlangen, Germany; Max Planck Inst Hirnforsch, Abt Neuroanat, D-60528 Frankfurt, Germany; UCL, Dept Pharmacol, London WC1E 6BT, England; Univ Klinikum Bonn, Inst Mol Neurobiol, D-53105 Bonn, Germany; Univ Strasbourg 1, Lab Neurophysiol Cellulaire & Integree, CNRS, UMR 7519, F-67084 Strasbourg, France; Univ Zurich Irchel, Inst Anat, Abt Neuroanat & Verhalten, CH-8057 Zurich, Switzerland	Max Planck Society; University of London; University College London; University of London School of Pharmacy; University of Erlangen Nuremberg; Max Planck Society; University of London; University College London; University of Bonn; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Zurich	Betz, H (corresponding author), Max Planck Inst Hirnforsch, Neurochem Abt, D-60528 Frankfurt, Germany.	neurochemie@mpih-frankfurt.mpg.de; umueller@mpih-frankfurt.mpg.de	Schütz, Burkhard/AAA-8078-2019; Harvey, Robert/D-3994-2016; Abo-Salem, Prof, Dr. Osama Mohamed/AAA-8284-2022; Zeilhofer, Hanns Ulrich/A-4600-2008; Wolfer, David P/B-3293-2016; Heindl-Erdmann, Cornelia/F-4809-2018; Zimmer, Andreas/B-8357-2009	Schütz, Burkhard/0000-0003-4473-1959; Harvey, Robert/0000-0001-5956-6664; Abo-Salem, Prof, Dr. Osama Mohamed/0000-0002-6087-5867; Zeilhofer, Hanns Ulrich/0000-0001-6954-4629; Wolfer, David P/0000-0002-5957-1401; Poisbeau, Pierrick/0000-0002-6089-9201				Ahmadi S, 2002, NAT NEUROSCI, V5, P34, DOI 10.1038/nn778; Baba H, 2001, J NEUROSCI, V21, P1750, DOI 10.1523/JNEUROSCI.21-05-01750.2001; BECKER CM, 1988, EMBO J, V7, P3717, DOI 10.1002/j.1460-2075.1988.tb03255.x; Beiche F, 1996, FEBS LETT, V390, P165, DOI 10.1016/0014-5793(96)00604-7; BUCKWALTER MS, 1994, HUM MOL GENET, V3, P2025, DOI 10.1093/hmg/3.11.2025; Cossart R, 2001, NAT NEUROSCI, V4, P52, DOI 10.1038/82900; DOHERTY NS, 1987, BRIT J PHARMACOL, V91, P39, DOI 10.1111/j.1476-5381.1987.tb08981.x; Doubell TP, 1999, TXB PAIN, V4, P165; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Guhring H, 2000, J NEUROSCI, V20, P6714, DOI 10.1523/JNEUROSCI.20-17-06714.2000; Haverkamp S, 2003, J COMP NEUROL, V465, P524, DOI 10.1002/cne.10852; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; KUHSE J, 1990, J BIOL CHEM, V265, P22317; Maihofner C, 2000, NEUROSCIENCE, V101, P1093, DOI 10.1016/S0306-4522(00)00361-4; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MALOSIO ML, 1991, J BIOL CHEM, V266, P2048; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Nikolic Z, 1998, J BIOL CHEM, V273, P19708, DOI 10.1074/jbc.273.31.19708; RYAN SG, 1994, NAT GENET, V7, P131, DOI 10.1038/ng0694-131; Samad TA, 2002, TRENDS MOL MED, V8, P390, DOI 10.1016/S1471-4914(02)02383-3; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; SCHRODER S, 1991, BIOCHEMISTRY-US, V30, P42, DOI 10.1021/bi00215a007; Turnbach ME, 2002, PAIN, V97, P127, DOI 10.1016/S0304-3959(02)00012-X; Vanegas HN, 2001, PROG NEUROBIOL, V64, P327, DOI 10.1016/S0301-0082(00)00063-0; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	26	458	474	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	2004	304	5672					884	887		10.1126/science.1094925	http://dx.doi.org/10.1126/science.1094925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	818KC	15131310	Green Accepted			2022-12-28	WOS:000221243000048
J	Higashi, T; Shekelle, PG; Solomon, DH; Knight, EL; Roth, C; Chang, JT; Kamberg, CJ; MaClean, CH; Young, RT; Adams, J; Reuben, DB; Avorn, J; Wenger, NS				Higashi, T; Shekelle, PG; Solomon, DH; Knight, EL; Roth, C; Chang, JT; Kamberg, CJ; MaClean, CH; Young, RT; Adams, J; Reuben, DB; Avorn, J; Wenger, NS			The quality of pharmacologic care for vulnerable older patients	ANNALS OF INTERNAL MEDICINE			English	Article							INAPPROPRIATE MEDICATION USE; ACUTE MYOCARDIAL-INFARCTION; ADVERSE DRUG-REACTIONS; EXPLICIT CRITERIA; ELDERLY-PATIENTS; CLINICAL-TRIALS; BEERS CRITERIA; HEART-FAILURE; HEALTH-CARE; COMMUNITY	Background: Although pharmacotherapy is critical to the medical care of older patients, medications can have considerable toxicity in this age group. To date, research has focused on inappropriate prescribing and policy efforts have aimed at access, but no comprehensive measurement of the quality of pharmacologic management using explicit criteria has been performed. Objective: To evaluate the broad range of pharmacologic care processes for vulnerable older patients. Design: Observational cohort study. Setting: 2 managed care organizations enrolling older persons. Patients: community-dwelling high-risk patients 65 years of age or older continuously enrolled in the managed care organizations from 1 July 1998 to 31 July 1999. Measurements: Patients' receipt of care as specified in 43 quality indicators covering 4 domains of pharmacologic care: 1) prescribing indicated medications; 2) avoiding inappropriate medications; 3) education, continuity, and documentation; and 4) medication monitoring. Results: Of 475 vulnerable older patients, 372 (78%) consented to participate and had medical records that could be abstracted.The percentage of appropriate pharmacologic management ranged from 10% for documentation of risks of nonsteroidal anti-inflammatory drugs to 100% for avoiding short-acting calcium-channel blockers in patients with heart failure and avoiding beta-blockers in patients with asthma. Pass rates for quality indicators in the "avoiding inappropriate medications" domain (97% [95% Cl, 96% to 98%]) were significantly higher than pass rates for "prescribing indicated medications" (50% [Cl, 45% to 55%]); "education, continuity, and documentation" (81% [Cl, 79% to 84%]); and "medication monitoring" (64% [Cl, 60% to 68%]). Limitations: Fewer than 10 patients were eligible for many of the quality indicators measured, and the generalizabiIity of these findings in 2 managed care organizations to the general geriatric population is uncertain. Conclusions: Failures to prescribe indicated medications, monitor medications appropriately, document necessary information, educate patients, and maintain continuity are more common prescribing problems than use of inappropriate drugs in older patients.	Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA 90095 USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90095 USA; RAND Hlth, Washington, DC USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; RAND Corporation; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Higashi, T (corresponding author), Univ Calif Los Angeles, Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90095 USA.		Chang, John T./L-7840-2019		BHP HRSA HHS [PE-19001] Funding Source: Medline	BHP HRSA HHS		*AG HEALTHC RES QU, 1996, HLTH CAR US AM 1996; [Anonymous], 2001, ANN INTERN MED, V135, P653, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00004; [Anonymous], 2000, MED EXP PAN SURV 200; Aparasu RR, 2000, ANN PHARMACOTHER, V34, P338, DOI 10.1345/aph.19006; Aparasu RR, 1997, ANN PHARMACOTHER, V31, P823, DOI 10.1177/106002809703100702; Aparasu RR, 1999, AM J HEALTH-SYST PH, V56, P433, DOI 10.1093/ajhp/56.5.433; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; CHRISCHILLES EA, 1992, ANN INTERN MED, V117, P634, DOI 10.7326/0003-4819-117-8-634; *CTR MED MED SERV, 2002, MED CURR BEN SURV; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; FINK A, 1987, JAMA-J AM MED ASSOC, V258, P1905, DOI 10.1001/jama.258.14.1905; Fitzgerald LS, 1997, ANN PHARMACOTHER, V31, P543, DOI 10.1177/106002809703100503; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Hanlon JT, 2000, PHARMACOTHERAPY, V20, P575, DOI 10.1592/phco.20.6.575.35163; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Hanlon JT, 1997, J AM GERIATR SOC, V45, P945, DOI 10.1111/j.1532-5415.1997.tb02964.x; Havranek EP, 1998, ARCH INTERN MED, V158, P2024, DOI 10.1001/archinte.158.18.2024; Heiat A, 2002, ARCH INTERN MED, V162, P1682, DOI 10.1001/archinte.162.15.1682; Hunt D, 2001, ANN INTERN MED, V134, P931, DOI 10.7326/0003-4819-134-10-200105150-00007; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KANE RL, 1994, ESSENTIALS CLIN GERI; Kuperman G J, 2001, Jt Comm J Qual Improv, V27, P509; LASCHOBER MA, 2002, HLTH AFF MILWOOD; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Luck J, 2000, AM J MED, V108, P642, DOI 10.1016/S0002-9343(00)00363-6; MILLER DK, 1995, J AM GERIATR SOC, V43, P60, DOI 10.1111/j.1532-5415.1995.tb06244.x; Monane M, 1998, JAMA-J AM MED ASSOC, V280, P1249, DOI 10.1001/jama.280.14.1249; Primatesta P, 2000, BMJ-BRIT MED J, V321, P1322, DOI 10.1136/bmj.321.7272.1322; RAO JNK, 1981, J AM STAT ASSOC, V76, P221, DOI 10.2307/2287815; RATNER J, 1995, PUBLICATION US GAO; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Rochon PA, 1999, JAMA-J AM MED ASSOC, V282, P113, DOI 10.1001/jama.282.2.113; Saliba D, 2001, J AM GERIATR SOC, V49, P1691, DOI 10.1046/j.1532-5415.2001.49281.x; SCHNEIDER JK, 1992, AM J HOSP PHARM, V49, P90, DOI 10.1093/ajhp/49.1.90; Sloss EM, 2000, J AM GERIATR SOC, V48, P363, DOI 10.1111/j.1532-5415.2000.tb04691.x; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; TAMBLYN RM, 1994, CAN MED ASSOC J, V150, P1801; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; Tseng CW, 2003, JAMA-J AM MED ASSOC, V290, P222, DOI 10.1001/jama.290.2.222; Wenger NS, 2003, ANN INTERN MED, V139, P740, DOI 10.7326/0003-4819-139-9-200311040-00008; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; Zhan Chunliu, 2001, JAMA (Journal of the American Medical Association), V286, P2823	45	151	155	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	2004	140	9					714	720		10.7326/0003-4819-140-9-200405040-00011	http://dx.doi.org/10.7326/0003-4819-140-9-200405040-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816XR	15126255				2022-12-28	WOS:000221143100005
J	Humphrey, LL; Teutsch, S; Johnson, M				Humphrey, LL; Teutsch, S; Johnson, M			Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: An update for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							SUSTAINED-RELEASE BUPROPION; NEOPLASM RESEARCH-PROJECT; DOSE SPIRAL CT; BRONCHOGENIC-CARCINOMA; SMOKING-CESSATION; FOLLOW-UP; NEW-YORK; CONTROLLED-TRIAL; SURGICAL RESECTION; PULMONARY NODULES	Background: Lung cancer is the leading cause of cancer-related death in the United States and worldwide. No major professional organizations, including the U.S. Preventive Services Task Force (USPSTF), currently recommend screening for lung cancer. Purpose: To examine the evidence evaluating screening for lung cancer with chest radiography, sputum cytologic examination, and low-dose computed tomography (CT) to aid the USPSTF in updating its recommendation on lung cancer screening. Data Sources: MEDLINE, the Cochrane Library, reviews, editorials, and experts. Study Selection: Studies that evaluated mass screening programs for lung cancer involving the tests of interest were selected. All studies were reviewed, but only studies with control groups were rated in quality since these would most directly influence the USPSTF screening recommendation. Data Extraction: Data were abstracted to data collection forms. Studies were graded according to criteria developed by the USPSTF. Data Synthesis: None of the 6 randomized trials of screening for lung cancer with chest radiography alone or in combination with sputum cytologic examination showed benefit among those screened. All studies were limited because some level of screening occurred in the control population. Five case-control studies from Japan suggested benefit to both high- and low-risk men and women. All studies were limited by potential healthy screenee bias. Six cohort studies showed that when CT was used to screen for lung cancer, lung cancer was diagnosed at an earlier stage than in usual clinical care. However, these studies did not have control groups, making mortality evaluation difficult. In addition, the studies demonstrated a high rate of false-positive findings. Conclusions: current data do not support screening for lung cancer with any method. These data, however, are also insufficient to conclude that screening does not work, particularly in women. Two randomized trials of screening with chest radiography or low-dose CT are currently under way and will better inform lung cancer screening decisions.	Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA; Merck & Co Inc, West Point, PA USA; Univ Med & Dent New Jersey, Sch Med, Newark, NJ 07103 USA	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; VA Portland Health Care System; Merck & Company; Rutgers State University New Brunswick; Rutgers State University Medical Center	Humphrey, LL (corresponding author), Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Portland, OR 97201 USA.				PHS HHS [290-97-0018] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM CANC SOC, 2003, CANC FACTS FIG; American Cancer Society, 2000, CANC FACTS FIG; AUSTIN JHM, 1992, RADIOLOGY, V182, P115, DOI 10.1148/radiology.182.1.1727272; Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306; BAKER RR, 1979, J THORAC CARDIOV SUR, V78, P876; Battafarano RJ, 2002, J THORAC CARDIOV SUR, V123, P280, DOI 10.1067/mtc.2002.119338; BERLIN NI, 1984, AM REV RESPIR DIS, V130, P545; Bernard A, 2001, EUR J CARDIO-THORAC, V20, P344, DOI 10.1016/S1010-7940(01)00788-6; Bernard A, 1996, ANN THORAC SURG, V61, P202, DOI 10.1016/0003-4975(95)01014-9; Black WC, 2000, J NATL CANCER I, V92, P1280, DOI 10.1093/jnci/92.16.1280; Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167; BRETT GZ, 1969, BRIT MED J, V4, P260, DOI 10.1136/bmj.4.5678.260; BRETT GZ, 1968, THORAX, V23, P414, DOI 10.1136/thx.23.4.414; Burns DM, 2000, CANCER, V89, P2506, DOI 10.1002/1097-0142(20001201)89:11+<2506::AID-CNCR33>3.3.CO;2-#; COLE P, 1980, JNCI-J NATL CANCER I, V64, P1263; Cotran RS, 1994, ROBBINS PATHOLOGIC B; DALES LG, 1979, J CHRON DIS, V32, P385, DOI 10.1016/0021-9681(79)90080-8; DAVILA DG, 1993, MAYO CLIN PROC, V68, P170, DOI 10.1016/S0025-6196(12)60166-9; DESLAURIERS J, 1994, CHEST, V106, pS329, DOI 10.1378/chest.106.6.329S; Diederich S, 2002, RADIOLOGY, V222, P773, DOI 10.1148/radiol.2223010490; Diederich S, 2000, CANCER, V89, P2457, DOI 10.1002/1097-0142(20001201)89:11+<2457::AID-CNCR22>3.0.CO;2-7; EBELING K, 1987, INT J CANCER, V40, P141, DOI 10.1002/ijc.2910400202; Fang DK, 2001, ANN THORAC SURG, V72, P1155, DOI 10.1016/S0003-4975(01)02932-0; FLEHINGER BJ, 1992, CHEST, V101, P1013, DOI 10.1378/chest.101.4.1013; FLEHINGER BJ, 1993, CANCER, V72, P1573, DOI 10.1002/1097-0142(19930901)72:5<1573::AID-CNCR2820720514>3.0.CO;2-9; FLEHINGER BJ, 1984, AM REV RESPIR DIS, V130, P555; FLETCHER RH, 1996, CLIN EPIDEMIOLOGY ES, P128; Fong KM, 1999, J THORAC CARDIOV SUR, V118, P1136, DOI 10.1016/S0022-5223(99)70121-2; FONTANA RS, 1986, J OCCUP ENVIRON MED, V28, P746, DOI 10.1097/00043764-198608000-00038; FONTANA RS, 1991, CANCER-AM CANCER SOC, V67, P1155, DOI 10.1002/1097-0142(19910215)67:4+<1155::AID-CNCR2820671509>3.0.CO;2-0; FONTANA RS, 1975, CHEST, V67, P511, DOI 10.1378/chest.67.5.511; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; FRIEDMAN GD, 1986, J CHRON DIS, V39, P453, DOI 10.1016/0021-9681(86)90112-8; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; Gazdar AF, 1999, JNCI-J NATL CANCER I, V91, P299, DOI 10.1093/jnci/91.4.299; Gohagan JK, 2000, CONTROL CLIN TRIALS, V21, p251S, DOI 10.1016/S0197-2456(00)00097-0; Greenwald HP, 1998, AM J PUBLIC HEALTH, V88, P1681, DOI 10.2105/AJPH.88.11.1681; HALPERN MT, 1993, JNCI-J NATL CANCER I, V85, P457, DOI 10.1093/jnci/85.6.457; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; HAYATA Y, 1982, RECENT RES CANCER, V82, P163; HEELAN RT, 1984, RADIOLOGY, V151, P289, DOI 10.1148/radiology.151.2.6324279; Henschke CI, 2001, ANN NY ACAD SCI, V952, P124, DOI 10.1111/j.1749-6632.2001.tb02733.x; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Hole DJ, 1996, BRIT MED J, V313, P711; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; Jett JR, 2001, AM J RESP CRIT CARE, V163, P812, DOI 10.1164/ajrccm.163.4.16342a; JETT JR, 1993, MAYO CLIN PROC, V68, P603, DOI 10.1016/S0025-6196(12)60376-0; Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903; Keller SM, 2000, ANN THORAC SURG, V70, P358, DOI 10.1016/S0003-4975(00)01673-8; KUBIK A, 1986, CANCER-AM CANCER SOC, V57, P2427, DOI 10.1002/1097-0142(19860615)57:12<2427::AID-CNCR2820571230>3.0.CO;2-M; KUBIK A, 1990, INT J CANCER, V45, P26, DOI 10.1002/ijc.2910450107; Kubik AK, 2000, CANCER, V89, P2363, DOI 10.1002/1097-0142(20001201)89:11+<2363::AID-CNCR9>3.0.CO;2-W; LEVIN ML, 1982, RECENT RES CANCER, V82, P138; LILIENFE.A, 1966, CANCER RES, V26, P2083; Lindgren A, 1993, Qual Assur Health Care, V5, P303; Mahadevia PJ, 2003, JAMA-J AM MED ASSOC, V289, P313, DOI 10.1001/jama.289.3.313; MANSER R, 2001, COCHRANE DATABASE SY; MAO L, 1994, CANCER RES, V54, P1634; Marcus PM, 1999, J MED SCREEN, V6, P47, DOI 10.1136/jms.6.1.47; MARTINI N, 1986, CHEST, V89, pS325, DOI 10.1378/chest.89.4_Supplement.325S; MCDUFFIE HH, 1991, J CLIN EPIDEMIOL, V44, P537, DOI 10.1016/0895-4356(91)90217-W; MCFARLANE MJ, 1986, CHEST, V90, P520, DOI 10.1378/chest.90.4.520; MELAMED M, 1977, CANCER, V39, P369, DOI 10.1002/1097-0142(197702)39:2<369::AID-CNCR2820390202>3.0.CO;2-I; MELAMED MR, 1984, CHEST, V86, P44, DOI 10.1378/chest.86.1.44; Melamed MR, 2000, CANCER, V89, P2356, DOI 10.1002/1097-0142(20001201)89:11+<2356::AID-CNCR8>3.3.CO;2-Q; MOSS SM, 1991, INT J EPIDEMIOL, V20, P1, DOI 10.1093/ije/20.1.1; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; MUHM JR, 1983, RADIOLOGY, V148, P609, DOI 10.1148/radiology.148.3.6308709; MULSHINE JL, 1989, J NATL CANCER I, V81, P900, DOI 10.1093/jnci/81.12.900; Myrdal G, 2001, EUR J CARDIO-THORAC, V20, P694, DOI 10.1016/S1010-7940(01)00875-2; NASH FA, 1968, BRIT MED J, V2, P715, DOI 10.1136/bmj.2.5607.715; Nawa T, 2002, CHEST, V122, P15, DOI 10.1378/chest.122.1.15; Nesbitt JC, 1997, CANC MED; Nishii K, 2001, LUNG CANCER, V34, P325, DOI 10.1016/S0169-5002(01)00270-7; *NLST, 2002, NAT I HLTH; Okamoto N, 1999, LUNG CANCER-J IASLC, V25, P77, DOI 10.1016/S0169-5002(99)00046-X; OSANN KE, 1991, CANCER RES, V51, P4893; OSANN KE, 1993, INT J CANCER, V54, P44, DOI 10.1002/ijc.2910540108; Ostroff JS, 2001, PREV MED, V33, P613, DOI 10.1006/pmed.2001.0935; Palmisano WA, 2000, CANCER RES, V60, P5954; Patz EF, 2000, NEW ENGL J MED, V343, P1627, DOI 10.1056/NEJM200011303432208; Pigula FA, 1996, ANN THORAC SURG, V61, P174, DOI 10.1016/0003-4975(95)00828-4; Prorok PC, 2000, CONTROL CLIN TRIALS, V21, p273S, DOI 10.1016/S0197-2456(00)00098-2; Quekel LGBA, 1999, CHEST, V115, P720, DOI 10.1378/chest.115.3.720; Rizvi N, 1999, LANCET, V353, P1897, DOI 10.1016/S0140-6736(99)00014-8; ROMANO PS, 1992, CHEST, V101, P1332, DOI 10.1378/chest.101.5.1332; Sagawa M, 2001, CANCER, V92, P588, DOI 10.1002/1097-0142(20010801)92:3<588::AID-CNCR1358>3.0.CO;2-8; SANDERSON D, 1982, RECENT RES CANCER, V82, P179; Schmuecking MW, 2000, RADIOLOGY, V217, P469; Snijder RJ, 1998, ANN THORAC SURG, V65, P212, DOI 10.1016/S0003-4975(97)01114-4; Sobue T, 2002, J CLIN ONCOL, V20, P911, DOI 10.1200/JCO.2002.20.4.911; SOBUE T, 1992, CANCER, V69, P685, DOI 10.1002/1097-0142(19920201)69:3<685::AID-CNCR2820690315>3.0.CO;2-W; Sobue T, 2000, CANCER, V89, P2392, DOI 10.1002/1097-0142(20001201)89:11+<2392::AID-CNCR13>3.0.CO;2-J; Sone S, 2001, BRIT J CANCER, V84, P25, DOI 10.1054/bjoc.2000.1531; Sone S, 1998, LANCET, V351, P1242, DOI 10.1016/S0140-6736(97)08229-9; STITIK FP, 1978, RADIOL CLIN N AM, V16, P347; Strauss G M, 1999, Surg Oncol Clin N Am, V8, P747; STRAUSS GM, 1998, TXB PULM DIS; Swensen SJ, 2003, RADIOLOGY, V226, P756, DOI 10.1148/radiol.2263020036; Swensen SJ, 2002, AM J RESP CRIT CARE, V165, P508, DOI 10.1164/ajrccm.165.4.2107006; TAYLOR WF, 1972, CANCER, V30, P1344, DOI 10.1002/1097-0142(197211)30:5<1344::AID-CNCR2820300530>3.0.CO;2-6; TAYLOR WF, 1981, CANCER, V47, P1114, DOI 10.1002/1097-0142(19810301)47:5+<1114::AID-CNCR2820471309>3.0.CO;2-N; TOCKMAN M, 1986, CHEST, V89, pS325; TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512; Tockman MS, 1997, MAYO CLIN PROC, V72, P788, DOI 10.1016/S0025-6196(11)63601-X; Tong LZ, 1996, CANCER, V78, P1004, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1004::AID-CNCR10>3.0.CO;2-6; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; TRICHOPOULOS D, 1992, JAMA-J AM MED ASSOC, V268, P1697, DOI 10.1001/jama.268.13.1697; Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605; Tsukada H, 2001, BRIT J CANCER, V85, P1326, DOI 10.1054/bjoc.2001.2060; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Vaporciyan AA, 2002, ANN THORAC SURG, V73, P420, DOI 10.1016/S0003-4975(01)03443-9; WEISS NS, 1994, EPIDEMIOL REV, V16, P102, DOI 10.1093/oxfordjournals.epirev.a036136; WEISS NS, 1992, AM J EPIDEMIOL, V135, P817, DOI 10.1093/oxfordjournals.aje.a116368; WEISS W, 1974, ARCH INTERN MED, V134, P306; WEISS W, 1971, J AMER MED ASSOC, V216, P2119, DOI 10.1001/jama.216.13.2119; WILDE J, 1989, EUR RESPIR J, V2, P656; WOOLNER LB, 1981, MAYO CLIN PROC, V56, P544; Yoshino I, 2002, SURGERY, V131, pS242, DOI 10.1067/msy.2002.119796; Zang EA, 1996, JNCI-J NATL CANCER I, V88, P183, DOI 10.1093/jnci/88.3-4.183; 1990, CA CANC J CLIN, V40, P77; 2001, MMWR MORB MORTAL WKL, V50, P869	124	148	156	1	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	2004	140	9					740	753		10.7326/0003-4819-140-9-200405040-00015	http://dx.doi.org/10.7326/0003-4819-140-9-200405040-00015			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816XR	15126259				2022-12-28	WOS:000221143100009
J	Mills, JL; Signore, CC				Mills, JL; Signore, CC			Folic acid and the prevention of neural-tube defects	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							FORTIFICATION		NICHHD, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mills, JL (corresponding author), NICHHD, Bethesda, MD 20892 USA.			Mills, James/0000-0003-4496-332X; Gregory, Jesse/0000-0002-9976-2085				DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; Mills JL, 2003, AM J CLIN NUTR, V77, P1474, DOI 10.1093/ajcn/77.6.1474; Mills JL, 2001, JAMA-J AM MED ASSOC, V285, P3022, DOI 10.1001/jama.285.23.3022; Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565; Wald NJ, 2004, NEW ENGL J MED, V350, P101, DOI 10.1056/NEJMp038186	5	16	16	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2209	2210						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152070				2022-12-28	WOS:000221496700029
J	Hill, J				Hill, J			Physical activity and obesity	LANCET			English	Editorial Material									Univ Colorado, Hlth Sci Ctr, Ctr Human Nutr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hill, J (corresponding author), Univ Colorado, Hlth Sci Ctr, Ctr Human Nutr, 4200 E 9th Ave, Denver, CO 80262 USA.	james.hill@uchsc.edu						Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Peters J C, 2002, Obes Rev, V3, P69, DOI 10.1046/j.1467-789X.2002.00059.x; Saris W H M, 2003, Obes Rev, V4, P101, DOI 10.1046/j.1467-789X.2003.00101.x; AM MOVE	4	30	31	1	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	2004	363	9404					182	182		10.1016/S0140-6736(03)15368-8	http://dx.doi.org/10.1016/S0140-6736(03)15368-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	15194273				2022-12-28	WOS:000188243900004
